<SEC-DOCUMENT>0001136261-22-000210.txt : 20220510
<SEC-HEADER>0001136261-22-000210.hdr.sgml : 20220510
<ACCEPTANCE-DATETIME>20220510161715
ACCESSION NUMBER:		0001136261-22-000210
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		66
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220510
DATE AS OF CHANGE:		20220510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SEELOS THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001017491
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870449967
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22245
		FILM NUMBER:		22909880

	BUSINESS ADDRESS:	
		STREET 1:		300 PARK AVENUE
		STREET 2:		2ND FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
		BUSINESS PHONE:		(646) 293-2100

	MAIL ADDRESS:	
		STREET 1:		300 PARK AVENUE
		STREET 2:		2ND FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	APRICUS BIOSCIENCES, INC.
		DATE OF NAME CHANGE:	20100914

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NEXMED INC
		DATE OF NAME CHANGE:	19970311
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>body10-q.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:SEEL="http://seelostx.com/20220331">
<!-- saved from url=(0022)http://internet.e-mail -->
<!-- saved from url=(0022)http://internet.e-mail -->
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_034_SEEL_seelostx.com_20220331 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20220101_20220331 -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DEntityCentralIndexKey_0001017491 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DDocumentFiscalYearFocus_2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_052_edei%2D%2DCurrentFiscalYearEndDate_12%2D31 -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DDocumentFiscalPeriodFocus_Q1 -->
<!-- Field: Set; Name: xdx; ID: xdx_07A_XDX_seelos.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06E_Years_0_utr%2D%2DY -->
<body>
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:EntityCentralIndexKey">0001017491</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate">12-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
  <ix:nonFraction name="SEEL:LicensesPayable" contextRef="AsOf2022-03-31" id="xdx2ixbrl0074" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2022-03-31" id="xdx2ixbrl0080" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2022-03-31" id="xdx2ixbrl0098" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2021-12-31" id="xdx2ixbrl0099" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SEEL:GainLossInFairValueOfConvertibleNotes" contextRef="From2021-01-012021-03-31" id="xdx2ixbrl0173" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0198" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0200" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0203" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0205" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0209" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0211" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0215" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0216" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0232" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0234" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0237" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0239" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0243" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0245" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0251" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0257" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0261" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0262" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SEEL:GainLossInFairValueOfConvertibleNotes" contextRef="From2021-01-012021-03-31" id="xdx2ixbrl0288" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2022-01-01to2022-03-31" id="xdx2ixbrl0290" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLossOnDerivative" contextRef="From2021-01-012021-03-31" id="xdx2ixbrl0306" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2022-01-01to2022-03-31" id="xdx2ixbrl0317" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-01-01to2022-03-31" id="xdx2ixbrl0320" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2022-01-01to2022-03-31" id="xdx2ixbrl0323" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaid" contextRef="From2022-01-01to2022-03-31" id="xdx2ixbrl0350" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaid" contextRef="From2021-01-012021-03-31" id="xdx2ixbrl0351" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SEEL:ReclassOfWarrantLiabilitiesRelatedToSeriesWarrantsExercisedForCash" contextRef="From2022-01-01to2022-03-31" id="xdx2ixbrl0356" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CapitalLeaseObligationsIncurred" contextRef="From2022-01-01to2022-03-31" id="xdx2ixbrl0359" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-03-31_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl0405" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0429" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0431" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_LongTermDebtMember" id="xdx2ixbrl0435" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_LongTermDebtMember" id="xdx2ixbrl0436" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember" id="xdx2ixbrl0440" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember" id="xdx2ixbrl0442" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0447" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0448" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0453" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0454" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_LongTermDebtMember" id="xdx2ixbrl0457" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_LongTermDebtMember" id="xdx2ixbrl0458" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" id="xdx2ixbrl0462" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" id="xdx2ixbrl0463" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember" id="xdx2ixbrl0465" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember" id="xdx2ixbrl0466" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0470" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_LongTermDebtMember" id="xdx2ixbrl0482" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_LongTermDebtMember" id="xdx2ixbrl0483" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-01-012022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" id="xdx2ixbrl0496" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-01-012021-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" id="xdx2ixbrl0498" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" id="xdx2ixbrl0519" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccruedInsuranceCurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl0581" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SEEL:NumberofWarrantsIssuedDuringPeriod" contextRef="From2022-01-012022-03-31_custom_WarrantDerivativeFinancialInstrumentsMember" id="xdx2ixbrl0670" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SEEL:ClassOfWarrantOrRightIssuedExercisePriceOfWarrantsOrRights" contextRef="From2022-01-012022-03-31_custom_WarrantDerivativeFinancialInstrumentsMember" id="xdx2ixbrl0672" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SEEL:NumberofWarrantsExercisedDuringPeriod" contextRef="From2022-01-012022-03-31_custom_WarrantDerivativeFinancialInstrumentsMember" id="xdx2ixbrl0674" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SEEL:ClassOfWarrantOrRightExercisedExercisePriceOfWarrantsOrRights" contextRef="From2022-01-012022-03-31_custom_WarrantDerivativeFinancialInstrumentsMember" id="xdx2ixbrl0676" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SEEL:NumberofWarrantsCancelledDuringPeriod" contextRef="From2022-01-012022-03-31_custom_WarrantDerivativeFinancialInstrumentsMember" id="xdx2ixbrl0678" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SEEL:ClassOfWarrantOrRightCancelledExercisePriceOfWarrantsOrRights" contextRef="From2022-01-012022-03-31_custom_WarrantDerivativeFinancialInstrumentsMember" id="xdx2ixbrl0680" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember654123531" id="xdx2ixbrl0744" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-01-012021-03-31_us-gaap_EmployeeStockOptionMember654123812" id="xdx2ixbrl0746" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember654123531" id="xdx2ixbrl0774" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="seel-20220331.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-01-01to2022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-012021-05-31_custom_May242021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SEEL:May242021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-05-01</xbrli:startDate>
        <xbrli:endDate>2021-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-24_custom_May242021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SEEL:May242021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-01-31_custom_January282021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SEEL:January282021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-28_custom_January282021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SEEL:January282021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_ConvertibleDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_ConvertibleDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-01-31_custom_IXLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:IXLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_LongTermDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_WarrantMember654115578">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_LongTermDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_LongTermDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_LongTermDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_LongTermDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_LongTermDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_LongTermDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_LongTermDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_LongTermDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember_us-gaap_LongTermDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_LongTermDebtMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_LongTermDebtMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_LongTermDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_LongTermDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_LongTermDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_LongTermDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_LongTermDebtMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_LongTermDebtMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_LongTermDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_LongTermDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_May242021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SEEL:May242021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_January282021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SEEL:January282021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-012021-11-30_custom_IXLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:IXLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-01</xbrli:startDate>
        <xbrli:endDate>2021-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-012021-12-31_custom_IXLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:IXLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-012019-08-31_custom_WegLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:WegLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-01-31_custom_WegLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:WegLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-01-31_custom_WegLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:WegLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-01-31_custom_WegLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:WegLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_WegLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:WegLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-012021-11-30_custom_November2021LindSecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SEEL:November2021LindSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-01</xbrli:startDate>
        <xbrli:endDate>2021-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-012022-11-30_custom_FirstAnniversaryOfNovember2021LindSecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SEEL:FirstAnniversaryOfNovember2021LindSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-01</xbrli:startDate>
        <xbrli:endDate>2022-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-232024-11-23_custom_August232022ThruMaturityNovember2021LindSecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SEEL:August232022ThruMaturityNovember2021LindSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-23</xbrli:startDate>
        <xbrli:endDate>2024-11-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-232024-11-24_custom_AmortizeNovember2021LindSecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SEEL:AmortizeNovember2021LindSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-23</xbrli:startDate>
        <xbrli:endDate>2024-11-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-12-012021-12-31_custom_December2021SPAsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SEEL:December2021SPAsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-12-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-02_custom_December2021SPAsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SEEL:December2021SPAsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_December2021SPAsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SEEL:December2021SPAsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_December2021SPAsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SEEL:December2021SPAsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_December2021SPAsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SEEL:December2021SPAsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-012020-12-31_custom_LindSecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SEEL:LindSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-012020-12-31_custom_December17SPAsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SEEL:December17SPAsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-12-012021-12-31_custom_December17SPAsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SEEL:December17SPAsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-12-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_December17SPAsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SEEL:December17SPAsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-09-012020-09-30_custom_September2020WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SEEL:September2020WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-09-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-09-012020-09-30_custom_September2020WarrantsMember654121703">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SEEL:September2020WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-09-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-04_custom_September2020WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SEEL:September2020WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-09-30_custom_September2020WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SEEL:September2020WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_September2020WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SEEL:September2020WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_September2020WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SEEL:September2020WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_September2020WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SEEL:September2020WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_September2020WarrantsMember654121843">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SEEL:September2020WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-012019-08-31_custom_August2019WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SEEL:August2019WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-012019-08-31_custom_August232019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SEEL:August232019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_August2019WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SEEL:August2019WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_August2019WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SEEL:August2019WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_August2019WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SEEL:August2019WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_August2019WarrantsMember654121984">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SEEL:August2019WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-09-30_custom_SeriesAWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SEEL:SeriesAWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_SeriesAWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SEEL:SeriesAWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_SeriesAWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SEEL:SeriesAWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_SeriesAWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SEEL:SeriesAWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_WarrantDerivativeFinancialInstrumentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">SEEL:WarrantDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_WarrantDerivativeFinancialInstrumentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">SEEL:WarrantDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_WarrantDerivativeFinancialInstrumentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">SEEL:WarrantDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember654123531">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-01-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-05-012020-05-31_custom_EmployeeStockPurchasePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SEEL:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-05-01</xbrli:startDate>
        <xbrli:endDate>2020-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-05-15_custom_EmployeeStockPurchasePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SEEL:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-05-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-01-31_custom_EmployeeStockPurchasePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SEEL:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_EmployeeStockPurchasePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SEEL:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_InducementPlanof2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SEEL:InducementPlanof2019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_InducementPlanof2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SEEL:InducementPlanof2019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_IncentiveStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SEEL:IncentiveStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_NonQualifiedStockOptionsToEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SEEL:NonQualifiedStockOptionsToEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_NonQualifiedStockOptionsToNonEmployeeDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SEEL:NonQualifiedStockOptionsToNonEmployeeDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_EmployeeStockOptionMember654123812">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_PerformanceSharesMember_custom_PSUtoExecutivesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SEEL:PSUtoExecutivesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_PerformanceSharesMember_custom_PSUtoExecutivesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SEEL:PSUtoExecutivesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_PerformanceSharesMember_custom_PSUtoExecutivesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SEEL:PSUtoExecutivesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_March2019LeaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">SEEL:March2019LeaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_March2021LeaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">SEEL:March2021LeaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_March2021LeaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">SEEL:March2021LeaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_March2021LeaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">SEEL:March2021LeaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-04-29_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-04-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-04-30_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-04-30_custom_AssetsfromVyeraPharmaceuticalsMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:AssetsfromVyeraPharmaceuticalsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-07-11_custom_AssetsfromVyeraPharmaceuticalsMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:AssetsfromVyeraPharmaceuticalsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-07-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Years">
      <xbrli:measure>utr:Y</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<!-- Field: Rule-Page --><div style="margin-top: 1pt; margin-bottom: 1pt; width: 100%">&#160;</div>

<div style="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><div style="border-top: Black 0.5pt solid; font-size: 1pt"></div></div><!-- Field: /Rule-Page -->
<!-- Field: Rule-Page --><div style="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><div style="border-top: Black 0.5pt solid; font-size: 1pt"></div></div><!-- Field: /Rule-Page -->



<p style="font: 11pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 6pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0 67.15pt 0 4.5pt; text-align: center"><b>UNITED <span style="letter-spacing: -0.5pt">STATES</span></b></p>

<p style="font: 18pt/20.35pt Times New Roman, Times, Serif; margin: 0 67.15pt 0 4.5pt; text-align: center"><b>SECURITIES AND EXCHANGE
COMMISSION</b></p>

<p style="font: 12pt/13.45pt Times New Roman, Times, Serif; margin: 0 67.15pt 0 4.5pt; text-align: center"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 6pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0 67.15pt 0 4.5pt; text-align: center"><b>FORM <span id="xdx_900_edei--DocumentType_c20220101__20220331_zePRfOOtUeG4"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0 67.15pt 0 4.5pt; text-align: center"><b>&#160;</b></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left">(Mark One)</p>

<p style="font: 12pt/12pt Times New Roman, Times, Serif; margin: 0 0 0 39pt; text-indent: -30pt"><span style="font-family: Segoe UI Symbol"><span id="xdx_90E_edei--DocumentQuarterlyReport_c20220101__20220331_zNhzIeItGFNa"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span></span>
<span style="letter-spacing: -0.2pt"><b>QUARTERLY </b></span><b><span style="letter-spacing: -0.15pt">REPORT </span>PURSUANT <span style="letter-spacing: -0.15pt">TO
</span>SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="font: 6pt Times New Roman, Times, Serif; margin: 0 0 0 30pt"><b>&#160;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 30pt; text-align: center"><b>For the quarterly period ended <span id="xdx_903_edei--DocumentPeriodEndDate_c20220101__20220331_z4MziZ49aC0j"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">March 31, 2022</ix:nonNumeric></span></b></p>

<p style="font: 6pt Times New Roman, Times, Serif; margin: 0 0 0 30pt; text-align: center"><b>&#160;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>OR</b></p>

<p style="font: 6pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 12pt/12pt Times New Roman, Times, Serif; margin: 0 0 0 39pt; text-indent: -30pt"><span style="font-family: Segoe UI Symbol"><span id="xdx_900_edei--DocumentTransitionReport_c20220101__20220331_zNWjlr68ZYc9"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span>
</span> <b>TRANSITION <span style="letter-spacing: -0.1pt">REPORT </span>PURSUANT <span style="letter-spacing: -0.15pt">TO </span>SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="font: 6pt/12pt Times New Roman, Times, Serif; margin: 0 0 0 39pt; text-indent: -30pt"><b>&#160;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 30pt; text-align: center"><b>For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to </b></p>

<p style="font: 6pt Times New Roman, Times, Serif; margin: 0 0 0 30pt"><b>&#160;</b></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Commission File Number <span style="text-decoration: underline"><span id="xdx_90C_edei--EntityFileNumber_c20220101__20220331_zNSgVTMobQEl"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:EntityFileNumber">000-22245</ix:nonNumeric></span></span></p>

<p style="font: 6pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 24pt/26.35pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="xdx_900_edei--EntityRegistrantName_c20220101__20220331_zTRhCqG5VZpl"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:EntityRegistrantName">SEELOS THERAPEUTICS, INC.</ix:nonNumeric></span></b></p>

<p style="font: bold 10pt/10.25pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact Name of Registrant as Specified
in Its Charter)</p>

<p style="font: 6pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font: 11pt Times New Roman, Times, Serif; width: 52%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_902_edei--EntityIncorporationStateCountryCode_c20220101__20220331_zVy6AW6Xibua"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="font: 11pt Times New Roman, Times, Serif; width: 48%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_906_edei--EntityTaxIdentificationNumber_c20220101__20220331_zW2JO2bkm8bg"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:EntityTaxIdentificationNumber">87-0449967</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 11pt/8pt Times New Roman, Times, Serif; padding-right: -0.35pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 8pt"><b>(State
    or Other Jurisdiction of Incorporation or Organization)</b></span></td>
    <td style="font: 11pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 8pt"><b>(I.R.S.
    Employer Identification No.)</b></span></td></tr>
  </table>
<p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: bold 10pt/11.5pt Times New Roman, Times, Serif; margin: 4.6pt 0 0; text-align: center"><span id="xdx_900_edei--EntityAddressAddressLine1_c20220101__20220331_zArLne7swFn8"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:EntityAddressAddressLine1">300 Park Avenue</ix:nonNumeric></span>, <span id="xdx_90A_edei--EntityAddressAddressLine2_c20220101__20220331_zA34RElBeMm2"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:EntityAddressAddressLine2">2nd Floor</ix:nonNumeric></span>, <span id="xdx_901_edei--EntityAddressCityOrTown_c20220101__20220331_zdJSvWjitxLd"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:EntityAddressCityOrTown">New
York</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressStateOrProvince_c20220101__20220331_zSUOnuCThaj1"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric></span> <span id="xdx_907_edei--EntityAddressPostalZipCode_c20220101__20220331_z3k2YYSdaFak"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:EntityAddressPostalZipCode">10022</ix:nonNumeric></span></p>

<p style="font: 8pt/9.2pt Times New Roman, Times, Serif; margin: 0 0.05pt 0 0; text-align: center"><b>(Address of Principal Executive
Offices) (Zip Code)</b></p>

<p style="font: bold 10pt/11.5pt Times New Roman, Times, Serif; margin: 5.9pt 0 0; text-align: center"><span id="xdx_901_edei--CityAreaCode_c20220101__20220331_z7PisgDFyaAe"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:CityAreaCode">(646)</ix:nonNumeric></span> <span id="xdx_904_edei--LocalPhoneNumber_c20220101__20220331_zDabzzMAIYUc"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:LocalPhoneNumber">293-2100</ix:nonNumeric></span></p>

<p style="font: 8pt/9.2pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(Registrant&#8217;s telephone number, including
area code)</b></p>

<p style="font: bold 10pt/11.5pt Times New Roman, Times, Serif; margin: 4.6pt 0 0; text-align: center">&#160;</p>

<p style="font: 8pt/9.2pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(Former name, former address and former fiscal
year, if changed since last report)</b></p>

<p style="font: 8pt/9.2pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 4.55pt 0 0 6pt; text-align: center"><b>Securities registered pursuant to Section
12(b) of the Act</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 40%; padding-top: 4.55pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><b>Title of Each Class</b></td>
    <td style="width: 17%; padding-top: 4.55pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><b>Trading Symbol</b></td>
    <td style="width: 43%; padding-top: 4.55pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><b>Name of Each Exchange
    on Which Registered</b></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 4.55pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span id="xdx_90D_edei--Security12bTitle_c20220101__20220331_zKVxxThbrZKe"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:Security12bTitle">Common Stock, par value $0.001 per
    share</ix:nonNumeric></span></td>
    <td style="padding-top: 4.55pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span id="xdx_909_edei--TradingSymbol_c20220101__20220331_zeW6jEJTV2hc"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:TradingSymbol">SEEL</ix:nonNumeric></span></td>
    <td style="padding-top: 4.55pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span id="xdx_90B_edei--SecurityExchangeName_c20220101__20220331_zqri7i6SNqgj"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 4.55pt 0 0 6pt">&#160;</p>

<p style="font: 10pt/103% Times New Roman, Times, Serif; margin: 0 5.9pt 0 6pt; text-align: justify">Indicate by check mark whether the
registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. <span style="letter-spacing: -0.35pt"><span id="xdx_905_edei--EntityCurrentReportingStatus_c20220101__20220331_zhGRVLmXtUJ6"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> </span><span style="font: 12pt/103% Segoe UI Symbol">&#9746;</span>
<span style="letter-spacing: -0.05pt">No </span><span style="font: 12pt/103% Segoe UI Symbol">&#9744;</span></p>

<p style="font: 6pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/103% Times New Roman, Times, Serif; margin: 0 5.85pt 0 6pt; text-align: justify">Indicate by check mark whether the
registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;
232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
<span style="letter-spacing: -0.35pt"><span id="xdx_903_edei--EntityInteractiveDataCurrent_c20220101__20220331_z2TmoIUAKoz9"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> </span><span style="font: 12pt/103% Segoe UI Symbol">&#9746;</span>
<span style="letter-spacing: -0.05pt">No </span><span style="font: 12pt/103% Segoe UI Symbol">&#9744;</span></p>

<p style="font: 6pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/103% Times New Roman, Times, Serif; margin: 0 5.85pt 0 6pt; text-align: justify">Indicate by check mark whether the
registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth
company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221;
and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act:</p>

<p style="font: 6pt/103% Times New Roman, Times, Serif; margin: 0 5.85pt 0 6pt; text-align: justify">&#160;</p>

<p style="font: 10pt/103% Times New Roman, Times, Serif; margin: 0 5.85pt 0 6pt; text-align: justify">Large accelerated filer <span style="font: 12pt/103% Segoe UI Symbol">&#9744;</span> Accelerated
filer <span style="font: 12pt/103% Segoe UI Symbol">&#9744;</span>  <span id="xdx_90C_edei--EntityFilerCategory_c20220101__20220331_zS0nyXRlD3Q3"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span> <span style="font: 12pt/103% Segoe UI Symbol"> &#9746;</span>  Smaller
reporting company  <span style="font-family: Segoe UI Symbol"><span id="xdx_904_edei--EntitySmallBusiness_c20220101__20220331_zyKcDMoGBWTh"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span> Emerging growth company  <span style="font-family: Segoe UI Symbol"><span id="xdx_90C_edei--EntityEmergingGrowthCompany_c20220101__20220331_zOteJgpicJIe"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>


<p style="font: 10pt/103% Times New Roman, Times, Serif; margin: 0 5.85pt 0 6pt; text-align: justify">&#160;</p>



<p style="font: 10pt/103% Times New Roman, Times, Serif; margin: 0 0 0 6pt">If an emerging growth company, indicate by check mark if
the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <span style="font: 12pt/103% Segoe UI Symbol"><span id="xdx_90D_edei--EntityEmergingGrowthCompany_c20220101__20220331_zEDc0pSd6gIl"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 6pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt">Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Exchange Act). <span style="letter-spacing: -0.35pt">Yes </span><span style="font: 12pt Segoe UI Symbol">&#9744;</span>
<span style="letter-spacing: -0.05pt"><span id="xdx_90E_edei--EntityShellCompany_c20220101__20220331_zNTVriWWHGTd"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span> </span><span style="font: 12pt Segoe UI Symbol">&#9746;</span></p>

<p style="font: 6pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt">As of April 28, 2022,
<span id="xdx_90C_edei--EntityCommonStockSharesOutstanding_iI_c20220428_zqiRE0Xj3Xbb"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2022-04-28" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">106,090,773</ix:nonFraction></span> shares of the common stock, par value $0.001, of the registrant were outstanding.</p>

<p style="font: 6pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 3pt Times New Roman, Times, Serif; margin: 0.05pt 0 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><div style="border-top: Black 0.5pt solid; font-size: 1pt"></div></div><!-- Field: /Rule-Page -->
<!-- Field: Rule-Page --><div style="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><div style="border-top: Black 0.5pt solid; font-size: 1pt"></div></div><!-- Field: /Rule-Page -->


<p style="font: 3pt Times New Roman, Times, Serif; margin: 0.05pt 0 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 5.5pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 1 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%"></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 12.5pt Times New Roman, Times, Serif; margin: 0.4pt 0 0">&#160;</p>

<p style="font: bold 10pt/11.5pt Times New Roman, Times, Serif; margin: 4.6pt 0 0; text-align: center">Table of Contents</p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 11%; padding-right: 5.4pt; padding-left: 5.4pt"></td>
    <td style="width: 81%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 9pt"><b>PART I.</b></span></td>
    <td style="width: 8%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 9pt"><b>PAGE</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 9pt"><a href="#a_001">ITEM 1</a>.</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 9pt">FINANCIAL STATEMENTS (UNAUDITED)</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 9pt">1</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"></td></tr>
  <tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 9pt"><a href="#a_002">ITEM 2</a>.</span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 9pt">MANAGEMENT&#8217;S DISCUSSION
    AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 9pt">19</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 9pt"><a href="#a_003">ITEM 3</a>.</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 9pt">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT
    MARKET RISK</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 9pt">28</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 9pt"><a href="#a_004">ITEM 4</a>.</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 9pt">CONTROLS AND PROCEDURES</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 9pt">28</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 9pt"><b>PART II.</b></span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 9pt"><a href="#a_005">ITEM 1</a>.</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 9pt">LEGAL PROCEEDINGS</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 9pt">29</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 9pt"><a href="#a_006">ITEM 1A</a>.</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 9pt">RISK FACTORS</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 9pt">29</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 9pt"><a href="#a_007">ITEM 2</a>.</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 9pt">UNREGISTERED SALES OF EQUITY SECURITIES AND USE
    OF PROCEEDS</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 9pt">61</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 9pt"><a href="#a_008">ITEM 3</a>.</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 9pt">DEFAULTS UPON SENIOR SECURITIES</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 9pt">61</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 9pt"><a href="#a_009">ITEM 4</a></span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 9pt">MINE SAFETY DISCLOSURES</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 9pt">61</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 9pt"><a href="#a_010">ITEM 5</a>.</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 9pt">OTHER INFORMATION</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 9pt">61</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 9pt"><a href="#a_011">ITEM 6</a>.</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 9pt">EXHIBITS</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 9pt">61</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 9pt"><a href="#a_012">SIGNATURES</a></span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 9pt">66</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"></td></tr>
  </table>
<p style="font: 10pt/173% Times New Roman, Times, Serif; margin: 0; text-indent: 81pt"></p>
<p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt/173% Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><i>&#160;</i></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="font-size: 9pt; text-align: center; width: 100%">&#160;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->i<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 4.6pt 0.05pt 0 0; text-align: center">PART I.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0.15pt 0 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.5pt"><b><span id="a_001"></span>ITEM 1. FINANCIAL STATEMENTS</b></p>

<p style="font: 13pt Times New Roman, Times, Serif; margin: 0.55pt 0 0"><b>&#160;</b></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Seelos Therapeutics, Inc. and Subsidiaries</b></p>

<p style="font: bold 10pt/103% Times New Roman, Times, Serif; margin: 0; text-align: center">Condensed Consolidated Balance
Sheets</p>

<p style="font: bold 10pt/103% Times New Roman, Times, Serif; margin: 0; text-align: center">(In thousands, except share and per share
data)</p>

<p style="font: bold 10pt/103% Times New Roman, Times, Serif; margin: 0; text-align: center">(Unaudited)</p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt/103% Times New Roman, Times, Serif; margin: 0 172.15pt 0 172.25pt; text-align: center"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0.05pt 0 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0.05pt 0 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<table border="0" cellpadding="0" cellspacing="0" id="xdx_30E_111_pn3n3_zfXqpNQWTkml" summary="xdx: Statement - Condensed Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: middle; background-color: white; width: 66%"></td>
    <td style="vertical-align: middle; background-color: white; width: 1%"></td>
    <td style="vertical-align: bottom; width: 1%"></td>
    <td id="xdx_490_20220331_z7ToZ3VAGWr3" style="font-weight: bold; vertical-align: top; text-align: center; background-color: white; width: 15%">March
    31,</td>
    <td style="vertical-align: bottom; width: 1%"></td>
    <td style="vertical-align: bottom; width: 1%"></td>
    <td id="xdx_49F_20211231_z0DrsG6FdQZk" style="font-weight: bold; vertical-align: bottom; text-align: center; background-color: white; width: 15%">December 31,</td></tr>
  <tr>
    <td style="vertical-align: middle; background-color: white"></td>
    <td style="vertical-align: middle; background-color: white"></td>
    <td style="vertical-align: bottom"></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white">2022</td>
    <td style="vertical-align: bottom"></td>
    <td style="vertical-align: bottom"></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white">2021</td></tr>
  <tr id="xdx_40C_eus-gaap--AssetsAbstract_iB_z9wioUcTNWw6">
    <td style="font-weight: bold; vertical-align: middle; background-color: white">Assets</td>
    <td style="font-weight: bold; vertical-align: middle; background-color: white"></td>
    <td style="vertical-align: bottom"></td>
    <td style="vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; background-color: white"></td>
    <td style="vertical-align: middle; background-color: white"></td>
    <td style="vertical-align: bottom"></td>
    <td style="vertical-align: middle; border-top-color: Black; border-top-width: 1pt; background-color: white"></td></tr>
  <tr id="xdx_409_eus-gaap--AssetsCurrentAbstract_iB_zppNRc48tux9" style="vertical-align: middle; background-color: white">
    <td style="font-weight: bold">Current assets</td>
    <td style="font-weight: bold"></td>
    <td></td>
    <td></td>
    <td></td>
    <td></td>
    <td></td></tr>
  <tr id="xdx_406_eus-gaap--Cash_i01I_maACzYR4_zSNexQyMoCw1" style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt; text-align: left">Cash</td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">61,772</ix:nonFraction></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">78,734</ix:nonFraction></td></tr>
  <tr id="xdx_40C_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i01I_maACzYR4_zXJ1DSiHx4Uj" style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt; text-align: left">Prepaid expenses and other current assets</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,895</ix:nonFraction></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,727</ix:nonFraction></td></tr>
  <tr id="xdx_401_eus-gaap--AssetsCurrent_i02TI_maAzJVm_mtACzYR4_z9gdcAAV4bee" style="vertical-align: middle; background-color: white">
    <td style="text-indent: 20pt; font-weight: bold">Total current assets</td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">70,667</ix:nonFraction></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">83,461</ix:nonFraction></td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseRightOfUseAsset_iI_maAzJVm_zfp18XzSDWI3" style="vertical-align: middle; background-color: white">
    <td style="text-align: left">Operating lease right-of-use asset</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26</ix:nonFraction></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">39</ix:nonFraction></td></tr>
  <tr id="xdx_408_eus-gaap--Assets_i02TI_mtAzJVm_zXyjsthKEnYj" style="vertical-align: middle; background-color: white">
    <td style="font-weight: bold">Total assets</td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">70,693</ix:nonFraction></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">83,500</ix:nonFraction></td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td></tr>
  <tr style="vertical-align: middle">
    <td style="font-weight: bold; background-color: white">&#160;</td>
    <td style="font-weight: bold; text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="font-weight: bold; text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right; background-color: white">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zFVG0EC1znmi" style="vertical-align: middle">
    <td style="font-weight: bold; background-color: white">Liabilities and stockholders&#8217; equity</td>
    <td style="font-weight: bold; text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right"></td>
    <td style="font-weight: bold; text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesCurrentAbstract_iB_zzTAaSNSTYJk" style="vertical-align: middle">
    <td style="font-weight: bold; background-color: white">Current liabilities</td>
    <td style="font-weight: bold; text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right"></td>
    <td style="font-weight: bold; text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td></tr>
  <tr id="xdx_40D_eus-gaap--AccountsPayableCurrent_i01I_maLCzG0S_zkSizpPHqzJ2" style="vertical-align: middle">
    <td style="text-indent: 10pt; background-color: white">Accounts payable</td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white">$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,127</ix:nonFraction></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white">$</td>
    <td style="text-align: right; background-color: white"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,693</ix:nonFraction></td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_i01I_maLCzG0S_zS8f0WmSJbzf" style="vertical-align: middle">
    <td style="text-indent: 10pt; background-color: white">Accrued expenses</td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,549</ix:nonFraction></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,728</ix:nonFraction></td></tr>
  <tr id="xdx_400_ecustom--LicensesPayable_i01I_maLCzG0S_z1cmdOmpYELk" style="vertical-align: middle">
    <td style="text-indent: 10pt">Licenses payable</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0074">-</span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><ix:nonFraction name="SEEL:LicensesPayable" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">200</ix:nonFraction></td></tr>
  <tr id="xdx_40C_eus-gaap--ConvertibleSubordinatedDebtCurrent_i01I_maLCzG0S_za9YMu5iK3Wg" style="vertical-align: middle">
    <td style="text-indent: 10pt">Short-term portion of convertible notes payable, at fair value</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ConvertibleSubordinatedDebtCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,238</ix:nonFraction></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ConvertibleSubordinatedDebtCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,030</ix:nonFraction></td></tr>
  <tr id="xdx_40D_eus-gaap--DerivativeLiabilities_i01I_maLCzG0S_zwn30X5Nlvs4" style="vertical-align: middle">
    <td style="text-indent: 10pt">Derivative liability</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0080">-</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,174</ix:nonFraction></td></tr>
  <tr id="xdx_405_eus-gaap--DerivativeLiabilitiesCurrent_i01I_maLCzG0S_zrEK2Xfv9QP7" style="vertical-align: middle">
    <td style="text-indent: 10pt">Warrant liabilities, at fair value</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">190</ix:nonFraction></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">424</ix:nonFraction></td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityCurrent_i01I_maLCzG0S_zTLg914QBI25" style="vertical-align: middle">
    <td style="text-indent: 10pt">Operating lease liability</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26</ix:nonFraction></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">38</ix:nonFraction></td></tr>
  <tr id="xdx_401_eus-gaap--LiabilitiesCurrent_i02TI_mtLCzG0S_maLzMwu_zR8OXhSLy2c6" style="vertical-align: middle">
    <td style="text-indent: 20pt; font-weight: bold">Total current liabilities</td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,130</ix:nonFraction></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,287</ix:nonFraction></td></tr>
  <tr style="vertical-align: middle">
    <td style="font-weight: bold"></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td></tr>
  <tr style="vertical-align: middle">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: middle">
    <td></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td></tr>
  <tr id="xdx_402_eus-gaap--ConvertibleSubordinatedDebtNoncurrent_iI_maLzMwu_zuYjWYv7sG46" style="vertical-align: middle">
    <td>Convertible notes payable, at fair value</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ConvertibleSubordinatedDebtNoncurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,926</ix:nonFraction></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ConvertibleSubordinatedDebtNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,890</ix:nonFraction></td></tr>
  <tr id="xdx_404_eus-gaap--Liabilities_i02I_maLASEzqE4_mtLzMwu_zFC9RVo7ZmM3" style="vertical-align: middle">
    <td style="text-indent: 20pt; font-weight: bold">Total liabilities</td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25,056</ix:nonFraction></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26,177</ix:nonFraction></td></tr>
  <tr style="vertical-align: middle">
    <td></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td></tr>
  <tr style="vertical-align: middle">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="visibility: hidden; vertical-align: middle; text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="visibility: hidden; vertical-align: middle; text-align: right">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CommitmentsAndContingencies_iI_zZC8wt13ZoT2" style="vertical-align: middle">
    <td>Commitments and contingencies (note 12)</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="visibility: hidden; vertical-align: middle; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0098">-</span></td>

    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="visibility: hidden; vertical-align: middle; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0099">-</span></td></tr>
  <tr style="vertical-align: middle">
    <td style="text-indent: 0pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--StockholdersEquityAbstract_iB_zDDkEcusPBNd" style="vertical-align: middle">
    <td style="text-indent: 0pt; font-weight: bold">Stockholders&#8217; equity</td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td></tr>
  <tr style="vertical-align: middle">
    <td style="text-indent: 10pt">Preferred stock, $<span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pip0_c20220331_zJKkNvxoP5Xi" title="Preferred stock, per value (in usd per share)"><span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pip0_c20211231_zTwbmCxrAzji"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value,
    <span id="xdx_900_eus-gaap--PreferredStockSharesAuthorized_iI_pip0_c20220331_z1wtQgxn2GM9" title="Preferred stock, authorized (in shares)">
    <span id="xdx_900_eus-gaap--PreferredStockSharesAuthorized_iI_pip0_c20211231_zNk5gClhXbld" title="Preferred stock, authorized (in shares)"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span> </span>shares
    authorized, <span id="xdx_901_eus-gaap--PreferredStockSharesIssued_iI_do_c20220331_z8Zh1V7Wjpd1"><span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_do_c20211231_zzqiMQjwR5Ca" title="Preferred stock, issued (in shares)"><span id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20220331_zlX9G2SYp8V9" title="Preferred stock, issued (in shares)"><span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20211231_zupirOlYmiLf" title="Preferred stock, outstanding (in shares)"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-03-31" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-03-31" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span>
    shares<br />&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; issued or outstanding as of March 31, 2022 and December 31, 2021</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="vertical-align: bottom; text-align: right">-</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="vertical-align: bottom; text-align: right">-</td></tr>
  <tr id="xdx_409_eus-gaap--CommonStockValue_i01I_maSEzZnz_zUVquiwaPJuh" style="vertical-align: middle">
    <td style="text-indent: 10pt">Common stock, $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20220331_z2Qs3HtAObX7" title="Common stock, par value (in usd per share)"><span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pii_c20201231_zl1vJ7fAFthc" title="Common stock, par value (in usd per share)"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_pp0p0_c20220331_zbpeYZ6Zan38" title="Common stock, authorized (in shares)"><span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_pp0p0_c20210331_zJQGXa6jRM04"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">240,000,000</ix:nonFraction></ix:nonFraction></span></span> shares
    authorized,<br /><span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_pip0_c20220331_zGeuEz3Fgyb1" title="Common stock, issued (in shares)"><span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_pp0p0_c20220331_zNOynzE92zv7" title="Common stock, outstanding (in shares)">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">105,590,773</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_pp0p0_c20211231_zpPBoiG8IhTi" title="Common stock, issued (in shares)"><span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_pp0p0_c20211231_zTiWiChc84m4" title="Common stock, outstanding (in shares)"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">105,500,445</ix:nonFraction></ix:nonFraction></span></span> issued and outstanding
    as of<br />&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;March 31, 2022 and December 31, 2021, respectively</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">105</ix:nonFraction></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">105</ix:nonFraction></td></tr>
  <tr id="xdx_403_eus-gaap--AdditionalPaidInCapitalCommonStock_i01I_maSEzZnz_z07KBOuAWaSg" style="vertical-align: middle">
    <td style="text-indent: 10pt">Additional paid-in-capital</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">200,743</ix:nonFraction></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">198,428</ix:nonFraction></td></tr>
  <tr id="xdx_407_eus-gaap--RetainedEarningsAccumulatedDeficit_i01NI_pn3n3_di_maSEzZnz_zxyYlEISuRcf" style="vertical-align: middle">
    <td style="text-indent: 10pt">Accumulated deficit</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">155,211</ix:nonFraction>)</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">141,210</ix:nonFraction>)</td></tr>
  <tr id="xdx_406_eus-gaap--StockholdersEquity_i02TI_mtSEzZnz_maLASEzqE4_zKxfxdrjzyv" style="vertical-align: middle">
    <td style="text-indent: 20pt; font-weight: bold">Total stockholders&#8217; equity</td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">45,637</ix:nonFraction></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">57,323</ix:nonFraction></td></tr>
  <tr id="xdx_40E_eus-gaap--LiabilitiesAndStockholdersEquity_i02TI_mtLASEzqE4_zB03iIij8cK4" style="vertical-align: middle">
    <td style="font-weight: bold; background-color: white">Total liabilities and stockholders&#8217; equity</td>
    <td style="font-weight: bold; text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white">$</td>
    <td style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 1pt"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">70,693</ix:nonFraction></td>
    <td style="font-weight: bold; text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white">$</td>
    <td style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 1pt; background-color: white"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">83,500</ix:nonFraction></td></tr>
  </table>

<p style="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying notes are an integral part of these
unaudited condensed consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>


<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="font-size: 9pt; text-align: center; width: 100%">&#160;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->



<p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Seelos Therapeutics, Inc. and Subsidiaries</b></p>

<p style="font: bold 10pt/103% Times New Roman, Times, Serif; margin: 0; text-align: center">Condensed Consolidated Statements of Operations
and Comprehensive Loss</p>

<p style="font: bold 10pt/103% Times New Roman, Times, Serif; margin: 0; text-align: center">For the Three Months Ended March 31, 2022 and 2021</p>

<p style="font: bold 10pt/103% Times New Roman, Times, Serif; margin: 0; text-align: center">(In thousands, except share and per share
data)</p>

<p style="font: bold 10pt/103% Times New Roman, Times, Serif; margin: 0; text-align: center">(Unaudited)</p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" id="xdx_306_113_pn3n3_zyNYGihXiiC1" summary="xdx: Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: middle">
    <td style="vertical-align: middle; text-align: left">&#160;</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td id="xdx_491_20220101__20220331_zC1lI4OeFoj1" style="vertical-align: top; text-align: center"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td id="xdx_495_20210101__20210331_ztglYWZJLKi7" style="vertical-align: top; text-align: center"></td></tr>
  <tr>
    <td style="vertical-align: middle"></td>
    <td style="vertical-align: middle"></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: bottom"></td>
    <td colspan="4" style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Three
Months Ended March 31,</p></td></tr>
  <tr>
    <td style="vertical-align: middle; width: 64%"></td>
    <td style="vertical-align: middle; text-align: right; width: 1%"></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: bottom; text-align: right; width: 2%"></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; width: 15%">2022</td>
    <td style="vertical-align: middle; text-align: right; width: 1%"></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: bottom; text-align: right; width: 2%"></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; width: 15%">2021</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingExpensesAbstract_iB_z2qN9R4D0Xm5" style="vertical-align: middle">
    <td style="font-weight: bold">Operating expense</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="border-top-color: Black; border-top-width: 1pt"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="border-top-color: Black; border-top-width: 1pt"></td></tr>
  <tr id="xdx_407_eus-gaap--ResearchAndDevelopmentExpense_i01_maOEzp2P_zPkpP0yDJsff" style="vertical-align: middle">
    <td style="text-indent: 10pt; text-align: left">Research and development</td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,009</ix:nonFraction></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,112</ix:nonFraction></td></tr>
  <tr id="xdx_402_eus-gaap--GeneralAndAdministrativeExpense_i01_maOEzp2P_zzDqITPUE1Kb" style="vertical-align: middle">
    <td style="text-indent: 10pt; text-align: left">General and administrative</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,001</ix:nonFraction></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,500</ix:nonFraction></td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingExpenses_i02T_mtOEzp2P_msOILzQ93_z5YQGayKTlG2" style="vertical-align: middle">
    <td style="text-indent: 20pt; font-weight: bold; text-align: left">Total operating expense</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,010</ix:nonFraction></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,612</ix:nonFraction></td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingIncomeLoss_iT_mtOILzQ93_maNILzVt0_maNILzPx1_zoARbHk1paY" style="vertical-align: middle">
    <td style="font-weight: bold">Loss from operations</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right; border-top-color: Black; border-top-width: 1pt">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">14,010</ix:nonFraction>)</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right; border-top-color: Black; border-top-width: 1pt">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">16,612</ix:nonFraction>)</td></tr>
  <tr style="vertical-align: middle">
    <td style="font-weight: bold">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_z6BDpatWVred" style="vertical-align: middle">
    <td style="font-weight: bold">Other income (expense)</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td></tr>
  <tr id="xdx_400_eus-gaap--InterestIncomeDomesticDeposits_i01_maNIEz3eF_z6JWMnOujpG9" style="vertical-align: middle">
    <td style="text-indent: 10pt; text-align: left">Interest income</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeDomesticDeposits" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26</ix:nonFraction></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeDomesticDeposits" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19</ix:nonFraction></td></tr>
  <tr id="xdx_404_eus-gaap--InterestExpense_i01N_di_msNIEz3eF_zC5Olpb5Hz48" style="vertical-align: middle">
    <td style="text-indent: 10pt; text-align: left">Interest expense</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction>)</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">990</ix:nonFraction>)</td></tr>
  <tr id="xdx_408_ecustom--GainLossInFairValueOfConvertibleNotes_i01_z1H1aMkDUoP4" style="vertical-align: middle">
    <td style="text-indent: 10pt; text-align: left">Change in fair value of convertible notes</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="SEEL:GainLossInFairValueOfConvertibleNotes" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">244</ix:nonFraction>)</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0173">-</span></td></tr>
  <tr id="xdx_408_eus-gaap--OtherNonoperatingIncomeExpense_i01_maNIEz3eF_zNuMFYanVs43" style="vertical-align: middle">
    <td style="text-indent: 10pt; text-align: left">Change in fair value of warrant liabilities</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">234</ix:nonFraction></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,533</ix:nonFraction>)</td></tr>
  <tr id="xdx_40D_eus-gaap--NonoperatingIncomeExpense_i02T_mtNIEz3eF_maNILzPx1_zxOskUg9ycKg" style="vertical-align: middle">
    <td style="text-indent: 20pt; font-weight: bold; text-align: left">Total other income (expense)</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,504</ix:nonFraction>)</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_i02T_mtNILzPx1_zZf71aNWZY99" style="vertical-align: middle">
    <td style="text-indent: 20pt; font-weight: bold; text-align: left">Net loss and comprehensive loss</td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="border-bottom: Black 1pt solid; text-align: right; border-top-color: Black; border-top-width: 1pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">14,001</ix:nonFraction>)</td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="border-bottom: Black 1pt solid; text-align: right; border-top-color: Black; border-top-width: 1pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">19,116</ix:nonFraction>)</td></tr>
  <tr>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: bottom"></td>
    <td style="vertical-align: middle; text-align: right"></td>
    <td style="vertical-align: middle; text-align: right"></td>
    <td style="border-top: Black 2pt double; vertical-align: middle; text-align: right"></td>
    <td style="vertical-align: middle; text-align: right"></td>
    <td style="vertical-align: middle; text-align: right"></td>
    <td style="border-top: Black 2pt double; vertical-align: middle; text-align: right"></td></tr>
  <tr style="vertical-align: middle">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: middle">
    <td style="text-align: left">Net loss per share basic and diluted</td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="border-bottom: Black 2pt double; text-align: right"><span id="xdx_90E_eus-gaap--EarningsPerShareBasic_pid_c20220101__20220331_zUEeniyY2Yh3"><span id="xdx_906_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20220331_zH0pS5W92wbi">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.13</ix:nonFraction></ix:nonFraction>)</span></span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="border-bottom: Black 2pt double; text-align: right"><span id="xdx_905_eus-gaap--EarningsPerShareBasic_pid_c20210101__20210331_zCYbq0Fu4Dg3"><span id="xdx_905_eus-gaap--EarningsPerShareDiluted_pid_c20210101__20210331_zKzlWFuVWX8l">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.28</ix:nonFraction></ix:nonFraction>)</span></span></td></tr>
  <tr style="vertical-align: middle">
    <td></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td></tr>
  <tr style="vertical-align: middle">
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td></tr>
  <tr>
    <td style="vertical-align: middle">&#160;</td>
    <td style="vertical-align: middle; text-align: right">&#160;</td>
    <td style="vertical-align: middle; text-align: right">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: middle; text-align: right">&#160;</td>
    <td style="vertical-align: middle; text-align: right">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
  <tr>
    <td style="vertical-align: middle">Weighted-average common shares outstanding<br />&#160;&#160;&#160;&#160;basic and diluted</td>
    <td style="vertical-align: middle; text-align: right"></td>
    <td style="vertical-align: middle; text-align: right"></td>
    <td style="border-bottom: Black 2pt double; vertical-align: bottom; text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pip0_c20220101__20220331_zjd7NnZvT15d"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pip0_c20220101__20220331_zXNwCM9n6NWc"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">105,529,772</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="vertical-align: middle; text-align: right"></td>
    <td style="vertical-align: middle; text-align: right"></td>
    <td style="border-bottom: Black 2pt double; vertical-align: bottom; text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pip0_c20210101__20210331_zOMTQMBJoyvf"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pip0_c20210101__20210331_zMcVBsqSc5Mh"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">69,053,332</ix:nonFraction></ix:nonFraction></span></span></td></tr>
  </table>

<p style="font: 9pt Sans-Serif; margin: 7.7pt 0 0; color: Red"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 7.7pt 0 0 63.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 7.7pt 0 0 63.95pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 7.7pt 0 0 63.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 7.7pt 0 0 63.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 7.7pt 0 0 63.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 7.7pt 0 0 63.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 7.7pt 0 0 63.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 7.7pt 0 0; text-align: center">The accompanying notes are an integral part
of these unaudited condensed consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 7.7pt 0 0; text-align: center"></p>


<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="font-size: 9pt; text-align: center; width: 100%">&#160;2</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<p style="font: bold 10pt/103% Times New Roman, Times, Serif; margin: 0; text-align: center">Seelos Therapeutics, Inc. and Subsidiaries</p>

<p style="font: bold 10pt/103% Times New Roman, Times, Serif; margin: 0.5pt 1pt 0 0; text-align: center">Condensed Consolidated Statements
of Changes in Stockholders&#8217; Equity (Deficit)</p>

<p style="font: bold 10pt/103% Times New Roman, Times, Serif; margin: 0.5pt 1pt 0 0; text-align: center">For the Three Months Ended
March 31, 2022 and 2021</p>

<p style="font: bold 10pt/103% Times New Roman, Times, Serif; margin: 0.5pt 1pt 0 0; text-align: center">(In thousands, except share data)</p>

<p style="font: bold 10pt/103% Times New Roman, Times, Serif; margin: 0.5pt 1pt 0 0; text-align: center">(Unaudited)</p>

<p style="font: bold 10pt/103% Times New Roman, Times, Serif; margin: 0.5pt 1pt 0 0; text-align: center"></p>

<p style="font: bold 9pt/103% Sans-Serif; margin: 0.5pt 1pt 0 0; text-align: left; color: Red">&#160;</p>

<p style="font: bold 9pt/103% Sans-Serif; margin: 0.5pt 1pt 0 0; text-align: left; color: Red"><span style="font-size: 9pt"></span></p>

<p style="font: bold 9pt/103% Sans-Serif; margin: 0.5pt 1pt 0 0; text-align: left; color: Red"><span style="font-size: 9pt"></span></p>

<table border="0" cellpadding="0" cellspacing="0" id="xdx_301_114_pn3n3_zuu0U8dbepDe" summary="xdx: Statement - Condensed Consolidated Statements of Changes in Stockholders&apos; Equity (Deficit)" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: middle; text-align: left; background-color: white; width: 49%"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: middle; text-align: right; background-color: white; width: 1%"><span style="font-size: 9pt"></span></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center; width: 10%"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: middle; text-align: right; width: 1%"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: bottom; text-align: right; width: 1%"><span style="font-size: 9pt"></span></td>
    <td id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zuQl2op9gyn5" style="font-weight: bold; vertical-align: middle; text-align: center; width: 5%"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: middle; text-align: right; width: 1%"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: bottom; text-align: right; width: 1%"><span style="font-size: 9pt"></span></td>
    <td id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zjYIRP83idk6" style="font-weight: bold; vertical-align: middle; text-align: center; width: 8%"><span style="font-size: 9pt">Additional</span></td>
    <td style="vertical-align: middle; text-align: right; width: 1%"><span style="font-size: 9pt"></span></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center; width: 1%"><span style="font-size: 9pt"></span></td>
    <td id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zL1faOdyW618" style="font-weight: bold; vertical-align: middle; text-align: center; width: 9%"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: middle; text-align: right; width: 1%"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: bottom; text-align: right; width: 1%"><span style="font-size: 9pt"></span></td>
    <td id="xdx_4BE_z2lCe5t2f29c" style="font-weight: bold; vertical-align: middle; text-align: center; width: 10%"><span style="font-size: 9pt">Total</span></td></tr>
  <tr>
    <td style="vertical-align: middle; text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: middle; text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td colspan="4" style="border-bottom: Black 1.5pt solid; font-weight: bold; vertical-align: middle; text-align: center"><span style="font-size: 9pt">Common
    Stock</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center"><span style="font-size: 9pt">Paid-In</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center"><span style="font-size: 9pt">Accumulated</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center"><span style="font-size: 9pt">Stockholders'</span></td></tr>
  <tr>
    <td style="vertical-align: middle; text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: middle; text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center"><span style="font-size: 9pt">(Shares)</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center"><span style="font-size: 9pt">(Amount)</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center"><span style="font-size: 9pt">Capital</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: bottom; text-align: center"><span style="font-size: 9pt">Deficit</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white"><span style="font-size: 9pt">Equity</span></td></tr>
  <tr id="xdx_43B_c20220101__20220331_eus-gaap--StockholdersEquity_iS_zIW7ABy83sgh" style="background-color: white">
    <td style="font-weight: bold; vertical-align: middle"><span style="font-size: 9pt">Balance as of December 31, 2021</span></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: right"><span style="font-size: 9pt"></span></td>
    <td id="xdx_98C_eus-gaap--CommonStockSharesOutstanding_iS_pp0p0_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0697hDWgzIh" style="vertical-align: middle; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">105,500,445</ix:nonFraction></span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt">$</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">105</ix:nonFraction></span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt">$</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">198,428</ix:nonFraction></span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">141,210</ix:nonFraction>)</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt">$</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">57,323</ix:nonFraction></span></td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zC8v6pEc0ZE8" style="vertical-align: middle">
    <td style="background-color: white"><span style="font-size: 9pt">Stock-based compensation expense</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">-</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0198">-</span></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,232</ix:nonFraction></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0200">-</span></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,232</ix:nonFraction></td></tr>
  <tr style="vertical-align: middle">
    <td><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"></td></tr>
  <tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_iP3us-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zBOY5kwt8x63" style="vertical-align: middle">
    <td>Issuance of common stock, options exercised</td>
    <td style="text-align: right">&#160;</td>
    <td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iP3us-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_pp0p0_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpSCYANf2kfb" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">6,250</ix:nonFraction></td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0203">-</span></td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8</ix:nonFraction></td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0205">-</span></td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8</ix:nonFraction></td></tr>
  <tr id="xdx_40E_eus-gaap--StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_zaEQ5MqBf2m1" style="vertical-align: middle">
    <td>Issuance of common stock, ESPP</td>
    <td style="text-align: right">&#160;</td>
    <td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_pp0p0_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9vlpqRhlCfg" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">84,078</ix:nonFraction></td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0209">-</span></td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">75</ix:nonFraction></td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0211">-</span></td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">75</ix:nonFraction></td></tr>
  <tr style="vertical-align: middle">
    <td><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"></td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_zkogTv5LJ9Y8" style="vertical-align: middle">
    <td style="background-color: white"><span style="font-size: 9pt">Net loss</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right; background-color: white"><span style="font-size: 9pt">-</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right; background-color: white"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0215">-</span></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right; background-color: white"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0216">-</span></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">14,001</ix:nonFraction>)</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">14,001</ix:nonFraction>)</span></td></tr>
  <tr id="xdx_430_c20220101__20220331_eus-gaap--StockholdersEquity_iE_zHijbIFzw1wb" style="vertical-align: middle">
    <td style="font-weight: bold; background-color: white"><span style="font-size: 9pt">Balance as of March 31, 2022</span></td>
    <td style="font-weight: bold; text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td id="xdx_98D_eus-gaap--CommonStockSharesOutstanding_iE_pp0p0_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3bQanwAukAc" style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 1pt; background-color: white"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">105,590,773</ix:nonFraction></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">$</span></td>
    <td style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 1pt; background-color: white"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">105</ix:nonFraction></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">$</span></td>
    <td style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 1pt; background-color: white"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">200,743</ix:nonFraction></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">$</span></td>
    <td style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 1pt"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">155,211</ix:nonFraction>)</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">$</span></td>
    <td style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 1pt"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">45,637</ix:nonFraction></span></td></tr>
  </table>
<p style="font: bold 9pt/103% Sans-Serif; margin: 0.5pt 1pt 0 0; text-align: left; color: Red"><b>&#160;</b></p>

<p style="font: bold 10pt/103% Times New Roman, Times, Serif; margin: 0.5pt 1pt 0 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: middle; text-align: left; width: 49%"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: middle; text-align: right; width: 1%"><span style="font-size: 9pt"></span></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center; width: 10%"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: middle; text-align: right; width: 1%"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: bottom; text-align: right; width: 1%"><span style="font-size: 9pt"></span></td>
    <td id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_z6oL0cmgMgxd" style="font-weight: bold; vertical-align: middle; text-align: center; width: 5%"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: middle; text-align: right; width: 1%"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: bottom; text-align: right; width: 1%"><span style="font-size: 9pt"></span></td>
    <td id="xdx_4B1_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zn7UCNE1CLqe" style="font-weight: bold; vertical-align: middle; text-align: center; width: 8%"><span style="font-size: 9pt">Additional</span></td>
    <td style="vertical-align: middle; text-align: right; width: 1%"><span style="font-size: 9pt"></span></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center; width: 1%"><span style="font-size: 9pt"></span></td>
    <td id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zLKaYQ9foDb7" style="font-weight: bold; vertical-align: middle; text-align: center; width: 9%"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: middle; text-align: right; width: 1%"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: bottom; text-align: right; width: 1%"><span style="font-size: 9pt"></span></td>
    <td id="xdx_4BF_zngW6zMuQSVg" style="font-weight: bold; vertical-align: middle; text-align: center; width: 10%"><span style="font-size: 9pt">Total</span></td></tr>
  <tr>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt"></span></td>
    <td colspan="4" style="border-bottom: Black 1.5pt solid; font-weight: bold; vertical-align: middle; text-align: center"><span style="font-size: 9pt">Common
    Stock</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center"><span style="font-size: 9pt">Paid-In</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center"><span style="font-size: 9pt">Accumulated</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center"><span style="font-size: 9pt">Stockholders'</span></td></tr>
  <tr>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center"><span style="font-size: 9pt">(Shares)</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center"><span style="font-size: 9pt">(Amount)</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center"><span style="font-size: 9pt">Capital</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: bottom; text-align: center"><span style="font-size: 9pt">Deficit</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white"><span style="font-size: 9pt">Equity</span></td></tr>
  <tr id="xdx_438_c20210101__20210331_eus-gaap--StockholdersEquity_iS_zIUFuSHSx4gh" style="background-color: white">
    <td style="font-weight: bold; vertical-align: middle"><span style="font-size: 9pt">Balance as of December 31, 2020</span></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: right"><span style="font-size: 9pt"></span></td>
    <td id="xdx_983_eus-gaap--CommonStockSharesOutstanding_iS_pp0p0_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zd2q9UWAS1wj" style="vertical-align: middle; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">54,535,891</ix:nonFraction></span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt">$</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">54</ix:nonFraction></span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt">$</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">77,680</ix:nonFraction></span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">75,162</ix:nonFraction>)</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt">$</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,572</ix:nonFraction></span></td></tr>
  <tr id="xdx_40F_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zRGoba0kJ9i" style="vertical-align: middle; background-color: white">
    <td><span style="font-size: 9pt">Stock-based compensation expense</span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt">-</span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0232">-</span></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">705</ix:nonFraction></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0234">-</span></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">705</ix:nonFraction></span></td></tr>
  <tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_iP3us-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zVnRwKZNrg4c" style="vertical-align: middle; background-color: white">
    <td><span style="font-size: 9pt">Issuance of common stock, options exercised</span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iP3us-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_pp0p0_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zeuVGxGEpBxb" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">29,999</ix:nonFraction></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0237">-</span></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">65</ix:nonFraction></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0239">-</span></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">65</ix:nonFraction></span></td></tr>
  <tr id="xdx_40E_eus-gaap--StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_zTXy5MtAUX2b" style="vertical-align: middle; background-color: white">
    <td><span style="font-size: 9pt">Issuance of common stock, ESPP</span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_pp0p0_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDNP8cGaRgCl" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">40,518</ix:nonFraction></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0243">-</span></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30</ix:nonFraction></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0245">-</span></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30</ix:nonFraction></span></td></tr>
  <tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_z0TllZ0hT3T3" style="vertical-align: middle; background-color: white">
    <td><span style="font-size: 9pt">Warrants exercised for cash</span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_iP3us-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_pp0p0_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpMzp6ldaYl4" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">6,146,125</ix:nonFraction></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6</ix:nonFraction></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,017</ix:nonFraction></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0251">-</span></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,023</ix:nonFraction></span></td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zf1tt6SQIyOl" style="vertical-align: middle; background-color: white">
    <td><span style="font-size: 9pt">Issuance of common stock, net of issuance costs</span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0p0_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDwkiG56631k" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">17,530,488</ix:nonFraction></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18</ix:nonFraction></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">33,463</ix:nonFraction></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0257">-</span></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">33,481</ix:nonFraction></span></td></tr>
    <tr id="xdx_40C_eus-gaap--NetIncomeLoss_z79L0j7jojm5" style="vertical-align: middle; background-color: white">
    <td><span style="font-size: 9pt">Net loss</span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">-</span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0261">-</span></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0262">-</span></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">19,116</ix:nonFraction>)</span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">19,116</ix:nonFraction>)</span></td></tr>
  <tr id="xdx_43D_c20210101__20210331_eus-gaap--StockholdersEquity_iE_z4AUlbv7yzd7" style="vertical-align: middle">
    <td style="font-weight: bold; background-color: white"><span style="font-size: 9pt">Balance as of March 31,
    2021</span></td>
    <td style="font-weight: bold; text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td id="xdx_98B_eus-gaap--CommonStockSharesOutstanding_iE_pp0p0_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHPCTWszvBx9" style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 1pt"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">78,283,021</ix:nonFraction></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt">$</span></td>
    <td style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 1pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">78</ix:nonFraction></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt">$</span></td>
    <td style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 1pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">118,960</ix:nonFraction></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt">$</span></td>
    <td style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 1pt"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">94,278</ix:nonFraction>)</span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt">$</span></td>
    <td style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 1pt"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24,760</ix:nonFraction></span></td></tr>
  </table>
<p style="font: 14pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 4.6pt 0 0 64.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 4.6pt 0 0 64.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 4.6pt 0 0 64.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 4.6pt 0 0 64.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 4.6pt 0 0 64.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 4.6pt 0 0 64.95pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 4.6pt 0 0 64.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 4.6pt 0 0 64.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 4.6pt 0 0; text-align: center">The accompanying notes are an integral part
of these unaudited condensed consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 4.6pt 0 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 4.6pt 0 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 4.6pt 0 0; text-align: center"></p>


<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="font-size: 9pt; text-align: center; width: 100%">&#160;3</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<p style="font: bold 10pt/103% Times New Roman, Times, Serif; margin: 0; text-align: left">&#160;</p>

<p style="font: bold 10pt/103% Times New Roman, Times, Serif; margin: 0; text-align: center">Seelos Therapeutics, Inc. and Subsidiaries</p>

<p style="font: 10pt/103% Times New Roman, Times, Serif; margin: 0.45pt 2pt 0 0; text-align: center"><b>Condensed Consolidated Statements
of Cash Flows</b></p>

<p style="font: 10pt/103% Times New Roman, Times, Serif; margin: 0.45pt 2pt 0 0; text-align: center"><b>For the Three Months Ended March 31, 2022 and 2021</b></p>

<p style="font: 10pt/103% Times New Roman, Times, Serif; margin: 0.45pt 2pt 0 0; text-align: center"><b>(In thousands)</b></p>

<p style="font: 10pt/103% Times New Roman, Times, Serif; margin: 0.45pt 2pt 0 0; text-align: center"><b>(Unaudited)</b></p>

<p style="font: 11.5pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"><b>&#160;</b></p>

<table border="0" cellpadding="0" cellspacing="0" id="xdx_304_112_pn3n3_zDYbK7IGewsl" summary="xdx: Statement - Condensed Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: middle; background-color: white">
    <td></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"></td>
    <td id="xdx_497_20220101__20220331_zH1aMHd1rwv" style="vertical-align: top; text-align: center; border-top-color: Black; border-top-width: 2pt"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td id="xdx_498_20210101__20210331_zHw3UgIYpYQc" style="vertical-align: top; text-align: center; border-top-color: Black; border-top-width: 2pt"></td></tr>
  <tr>
    <td style="vertical-align: middle; background-color: white"></td>
    <td style="vertical-align: middle; background-color: white"></td>
    <td style="vertical-align: bottom"></td>
    <td colspan="4" style="font-weight: bold; vertical-align: middle; text-align: center; background-color: white"><p style="margin-top: 0; margin-bottom: 0">Three Months Ended</p></td></tr>
  <tr>
    <td style="vertical-align: middle; background-color: white"></td>
    <td style="vertical-align: middle; background-color: white"></td>
    <td style="vertical-align: bottom"></td>
    <td colspan="4" style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white">March
    31,</td></tr>
  <tr>
    <td style="vertical-align: middle; background-color: white; width: 70%"></td>
    <td style="vertical-align: middle; text-align: right; background-color: white; width: 1%"></td>
    <td style="vertical-align: bottom; text-align: right; width: 1%"></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; background-color: white; width: 13%">2022</td>
    <td style="vertical-align: middle; text-align: right; background-color: white; width: 1%"></td>
    <td style="vertical-align: bottom; text-align: right; width: 1%"></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; background-color: white; width: 13%">2021</td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zfFjzPMXk2vg" style="vertical-align: middle; background-color: white">
    <td style="font-weight: bold">Cash flows from operating activities</td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="border-top-color: Black; border-top-width: 1pt"></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="border-top-color: Black; border-top-width: 1pt"></td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_i01_zqgTOrOXwEJ1" style="vertical-align: middle">
    <td style="text-indent: 10pt; text-align: left; background-color: white">Net loss</td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white">$</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">14,001</ix:nonFraction>)</td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white">$</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">19,116</ix:nonFraction>)</td></tr>
  <tr id="xdx_40B_eus-gaap--AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_ztiRLAoPWQ63" style="vertical-align: middle">
    <td style="text-indent: 10pt; font-weight: bold; text-align: left; background-color: white">Adjustments to reconcile net loss to net cash used in operating activities</td>
    <td style="font-weight: bold; text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right"></td>
    <td style="font-weight: bold; text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right"></td></tr>
  <tr id="xdx_403_eus-gaap--ShareBasedCompensation_i02_zDC4uDzbnF31" style="vertical-align: middle">
    <td style="text-indent: 20pt; text-align: left; background-color: white">Stock-based compensation expense</td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,232</ix:nonFraction></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">705</ix:nonFraction></td></tr>
  <tr id="xdx_407_eus-gaap--FairValueAdjustmentOfWarrants_i02_zM2tHfO37HC5" style="vertical-align: middle">
    <td style="text-indent: 20pt; text-align: left">Change in fair value of warrant liability</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">234</ix:nonFraction>)</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,533</ix:nonFraction></td></tr>
  <tr id="xdx_40D_ecustom--GainLossInFairValueOfConvertibleNotes_i02N_di_z4d41wmQHDZe" style="vertical-align: middle">
    <td style="text-indent: 20pt; text-align: left">Change in fair value of convertible notes payable</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="SEEL:GainLossInFairValueOfConvertibleNotes" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">244</ix:nonFraction></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0288">-</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AmortizationOfDebtDiscountPremium_i02_zXXCi2c7UP" style="vertical-align: middle">
    <td style="text-indent: 20pt; text-align: left">Amortization of debt discount</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0290">-</span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">986</ix:nonFraction></td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B_zrSBdKuaJPD8" style="vertical-align: middle">
    <td style="text-indent: 10pt; font-weight: bold; text-align: left">Changes in operating assets and liabilities</td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i02_zwmddgZuYS1c" style="vertical-align: middle">
    <td style="text-indent: 20pt; text-align: left">Prepaid expenses and other current assets</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,168</ix:nonFraction>)</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">777</ix:nonFraction>)</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInAccountsPayable_i02_zRjWzhVsCzP9" style="vertical-align: middle">
    <td style="text-indent: 20pt; text-align: left">Accounts payable</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">434</ix:nonFraction></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">259</ix:nonFraction>)</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i02_zrtZRknJri79" style="vertical-align: middle">
    <td style="text-indent: 20pt; text-align: left; background-color: white">Accrued expenses</td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">178</ix:nonFraction>)</td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">199</ix:nonFraction>)</td></tr>
  <tr id="xdx_40C_eus-gaap--DerivativeLossOnDerivative_i01N_di_zyojQl3mC9Ng" style="vertical-align: middle">
    <td style="text-indent: 20pt; text-align: left; background-color: white">Derivative liability</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:DerivativeLossOnDerivative" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,174</ix:nonFraction>)</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0306">-</span></td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInOtherAccruedLiabilities_i02_zDODPA9h06Ji" style="vertical-align: middle">
    <td style="text-indent: 20pt; text-align: left">Licenses payable</td>
    <td style="text-align: right"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">200</ix:nonFraction>)</td>
    <td style="text-align: right"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,875</ix:nonFraction></td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i03T_zUbF3X3hdQn5" style="vertical-align: middle">
    <td style="text-indent: 30pt; font-weight: bold; text-align: left; background-color: white">Net cash used in operating activities</td>
    <td style="font-weight: bold; text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">17,045</ix:nonFraction>)</td>
    <td style="font-weight: bold; text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,252</ix:nonFraction>)</td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="font-weight: bold; text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zm0IZJ1RUL23" style="vertical-align: middle; background-color: white">
    <td style="font-weight: bold; text-align: left">Cash flows provided by financing activities</td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td></tr>
  <tr id="xdx_401_eus-gaap--RepaymentsOfNotesPayable_iN_di_msNCPBUzrV8_zHRxxjz4NZWl" style="vertical-align: middle">
    <td style="text-indent: 10pt; text-align: left; background-color: white">Payment of convertible note</td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0317">-</span></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,167</ix:nonFraction>)</td></tr>
  <tr id="xdx_400_eus-gaap--ProceedsFromIssuanceOfCommonStock_maNCPBUzrV8_zQD5y9EhguCh" style="vertical-align: middle">
    <td style="text-indent: 10pt; text-align: left; background-color: white">Proceeds from issuance of common stock, net of issuance costs</td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0320">-</span></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">33,481</ix:nonFraction></td></tr>
  <tr id="xdx_403_eus-gaap--ProceedsFromWarrantExercises_maNCPBUzrV8_zbrkvFcic1Sj" style="vertical-align: middle">
    <td style="text-indent: 10pt; text-align: left; background-color: white">Proceeds from exercise of warrants</td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0323">-</span></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,868</ix:nonFraction></td></tr>
  <tr id="xdx_40A_eus-gaap--ProceedsFromStockOptionsExercised_maNCPBUzrV8_zJrEaSlOR8Z2" style="vertical-align: middle">
    <td style="text-indent: 10pt; text-align: left; background-color: white">Proceeds from exercise of options</td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8</ix:nonFraction></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">65</ix:nonFraction></td></tr>
  <tr id="xdx_400_eus-gaap--ProceedsFromStockPlans_maNCPBUzrV8_zA2IybkxeC8j" style="vertical-align: middle">
    <td style="text-indent: 10pt; text-align: left; background-color: white">Proceeds from sales of common stock under ESPP</td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockPlans" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">75</ix:nonFraction></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockPlans" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30</ix:nonFraction></td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i03_mtNCPBUzrV8_maCCERCzfGQ_z4wND7E9c0Sl" style="vertical-align: middle; background-color: white">
    <td style="text-indent: 30pt; font-weight: bold; text-align: left">Net cash provided by financing activities</td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="border-bottom: Black 1pt solid; text-align: right; border-top-color: Black; border-top-width: 1pt"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">83</ix:nonFraction></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="border-bottom: Black 1pt solid; text-align: right; border-top-color: Black; border-top-width: 1pt"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">34,277</ix:nonFraction></td></tr>
  <tr id="xdx_409_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_i03_mtCCERCzfGQ_zHLR7WOFfb4b" style="vertical-align: middle; background-color: white">
    <td>Net increase (decrease) in cash</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">16,962</ix:nonFraction>)</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,025</ix:nonFraction></td></tr>
  <tr id="xdx_409_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iS_zj9eaAwnb2X8" style="vertical-align: middle; background-color: white">
    <td style="font-weight: bold; text-align: left">Cash, beginning of period</td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">78,734</ix:nonFraction></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,662</ix:nonFraction></td></tr>
  <tr id="xdx_409_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iE_zWeXOdTWHIf2" style="vertical-align: middle; background-color: white">
    <td style="font-weight: bold">Cash, end of period</td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">61,772</ix:nonFraction></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">38,687</ix:nonFraction></td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right; border-top-color: Black; border-top-width: 2pt"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right; border-top-color: Black; border-top-width: 2pt"></td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--SupplementalCashFlowInformationAbstract_iB_ziYJR0v5o9Ak" style="vertical-align: middle; background-color: white">
    <td><b>Supplemental disclosure of cash flow information</b>:</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td></tr>
  <tr id="xdx_402_eus-gaap--InterestPaidNet_i01_zXup1UJY9lg9" style="vertical-align: middle">
    <td style="text-indent: 10pt; text-align: left; background-color: white">Cash paid for interest</td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white">$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white">$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxesPaid_i01_zQVZD3DUFHQk" style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt; text-align: left">Cash paid for income taxes</td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0350">-</span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0351">-</span></td></tr>
  <tr id="xdx_408_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_z3YSTLCVxtC2" style="vertical-align: middle; background-color: white">
    <td><b>Non-cash investing and financing activities:</b></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td></tr>
  <tr id="xdx_403_ecustom--ReclassOfWarrantLiabilitiesRelatedToSeriesWarrantsExercisedForCash_i01_z2wzeG88WOXg" style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt; text-align: left">Reclass of warrant liabilities related to Series A warrants exercised for cash</td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0356">-</span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="text-align: right"><ix:nonFraction name="SEEL:ReclassOfWarrantLiabilitiesRelatedToSeriesWarrantsExercisedForCash" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,155</ix:nonFraction></td></tr>
  <tr id="xdx_409_eus-gaap--CapitalLeaseObligationsIncurred_i01_zTQPeDSSSLIg" style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt; text-align: left">Right-of-use assets obtained in exchange for operating lease liabilities</td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0359">-</span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CapitalLeaseObligationsIncurred" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">74</ix:nonFraction></td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt; text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 1.9pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 1.9pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 1.9pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 1.9pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 1.9pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 1.9pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 1.9pt 0 0; text-align: center">The accompanying notes are an integral part
of these unaudited condensed consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 1.9pt 0 0; text-align: center"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>


<!-- Field: Page; Sequence: 7 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="font-size: 9pt; text-align: center; width: 100%">&#160;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Seelos Therapeutics, Inc. and Subsidiaries</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: center">Notes to Condensed Consolidated Financial
Statements</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: center">(Unaudited)</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 116.25pt; text-align: left">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_809_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z7EGwvIUIQ98" style="font: 11pt Times New Roman, Times, Serif; margin: 0 142.6pt 0 5pt; text-align: justify; text-indent: 0in"><span style="font-size: 10pt; letter-spacing: -0.8pt"><b></b></span><b><span style="font: 7pt Times New Roman, Times, Serif; letter-spacing: -0.8pt">
</span><span style="font-size: 10pt">1. Organization and Description of Business</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 142.6pt 0 5pt; text-align: justify; text-indent: 0in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 5pt">Seelos Therapeutics, Inc. (together with its subsidiaries,
the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company focused on achieving efficient development of products that address
significant unmet needs in Central Nervous System (&#8220;CNS&#8221;) disorders and other rare disorders. The Company&#8217;s lead programs
are SLS-002 for the potential treatment of acute suicidal ideation and behavior in patients with major depressive disorder (&#8220;ASIB
in MDD&#8221;) and SLS-005 for the potential treatment of Amyotrophic Lateral Sclerosis (&#8220;ALS&#8221;) and Spinocerebellar Ataxia
(&#8220;SCA&#8221;). SLS-005 for the potential treatment of Sanfilippo Syndrome currently requires additional natural history data, which
is being considered. Additionally, the Company is developing several preclinical programs, most of which have well-defined mechanisms
of action, including: SLS-004, SLS-006, SLS-007 for the potential treatment of Parkinson&#8217;s Disease (&#8220;PD&#8221;) and SLS-008,
which is being developed for the potential treatment of an undisclosed indication, but may also be targeted at chronic inflammation in
asthma and orphan indications such as pediatric esophagitis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 142.6pt 0 5pt; text-align: justify; text-indent: 0in"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock"><p id="xdx_800_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zUlIFHdf9E01" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify">2.
Liquidity and Going Concern</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 6.85pt 0 5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt">The accompanying condensed consolidated unaudited financial statements
have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and
settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects
on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty
related to its ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt">The Company has generated limited revenues, has incurred operating
losses since inception, and expects to continue to incur significant operating losses for the foreseeable future and may never become
profitable. As of March 31, 2022, the Company had $<span id="xdx_904_eus-gaap--Cash_iI_pn5n6_c20220331_zQZBKEv6Qhy9" title="Cash"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">61.8</ix:nonFraction></span> million in cash and an accumulated deficit of $<span id="xdx_904_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_pn5n6_c20220331_zaykptp0g0i7" title="Accumlated deficit"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">155.2</ix:nonFraction></span> million. The Company has historically
funded its operations through the issuance of convertible notes (see Note 9), the sale of common stock (see Note 6) and exercises of
warrants (see Note 10).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">On May 24, 2021, the Company completed an underwritten
public offering, pursuant to which the Company sold <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20210501__20210531__us-gaap--StatementClassOfStockAxis__custom--May242021Member_z6pU7T7uL1nb" title="Number of shares of common stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-05-012021-05-31_custom_May242021Member" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">22,258,066</ix:nonFraction></span>
shares of its common stock, at a price to the public of $<span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_pp2p0_uUSDPShares_c20210524__us-gaap--StatementClassOfStockAxis__custom--May242021Member_zPIih6iQzU53" title="Shares Issued, Price Per Share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2021-05-24_custom_May242021Member" format="ixt:numdotdecimal" decimals="2" scale="0" unitRef="USDPShares">3.10</ix:nonFraction></span>
per share, which included the exercise in full by the underwriter of its option to purchase up to 2,903,226 additional shares of
common stock. The net proceeds to the Company from the offering were approximately $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20210501__20210531__us-gaap--StatementClassOfStockAxis__custom--May242021Member_znvCOQEUOEA3" title="Cash received from stock sale"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-05-012021-05-31_custom_May242021Member" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">64.5</ix:nonFraction></span>
million, after deducting underwriting discounts and commissions and other offering costs. The Company used
$<span id="xdx_90B_ecustom--OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes_pn5n6_c20210501__20210531__us-gaap--StatementClassOfStockAxis__custom--May242021Member_z3cGiDLwmfm4" title="Offering proceeds used to partially repay certain convertible promissory notes"><ix:nonFraction name="SEEL:OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes" contextRef="From2021-05-012021-05-31_custom_May242021Member" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.3</ix:nonFraction></span>
million of the net proceeds from the offering for the partial repayment of certain outstanding convertible promissory notes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">On January 28, 2021, the Company completed an underwritten
public offering, pursuant to which the Company sold <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20210101__20210131__us-gaap--StatementClassOfStockAxis__custom--January282021Member_zSk5mfKSduR5" title="Number of shares of common stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-01-31_custom_January282021Member" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">17,530,488</ix:nonFraction></span>
shares of its common stock, at a price to the public of $<span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_pp2p0_uUSDPShares_c20210128__us-gaap--StatementClassOfStockAxis__custom--January282021Member_zeNhjQ7tklc2" title="Shares Issued, Price Per Share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2021-01-28_custom_January282021Member" format="ixt:numdotdecimal" decimals="2" scale="0" unitRef="USDPShares">2.05</ix:nonFraction></span>
per share, which included the exercise in full by the underwriter of its option to purchase up to 2,286,585 additional shares of
common stock. The net proceeds to the Company from the offering were approximately $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20210101__20210131__us-gaap--StatementClassOfStockAxis__custom--January282021Member_zXbrplIummQc" title="Cash received from stock sale"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-01-31_custom_January282021Member" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">33.5</ix:nonFraction></span>
million, after deducting underwriting discounts, commissions and other offering costs. The
Company used $<span id="xdx_903_ecustom--OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes_pn5n6_c20210101__20210131__us-gaap--StatementClassOfStockAxis__custom--January282021Member_zeWIkGFTOzUa" title="Offering proceeds used to partially repay certain convertible promissory notes"><ix:nonFraction name="SEEL:OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes" contextRef="From2021-01-012021-01-31_custom_January282021Member" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.8</ix:nonFraction></span>
million of the net proceeds from the offering for the partial repayment of certain outstanding convertible promissory notes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">The Company currently has an effective shelf registration statement
on Form S-3 filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;). The Company may use the shelf registration statement
on Form S-3 to offer from time to time any combination of debt securities, common and preferred stock and warrants. As of March 31, 2022,
the Company had approximately $<span id="xdx_90B_ecustom--FinancingAvailableUnderFormS3ShelfRegistrationStatement_iI_pn5n6_c20220331_zpgalEltyrXk"><ix:nonFraction name="SEEL:FinancingAvailableUnderFormS3ShelfRegistrationStatement" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">95.1</ix:nonFraction></span> million available under its Form S-3 shelf registration statement. The Company also has the ability
to raise funds through other means, such as through the filing of a registration statement on Form S-1 or in private placements. The rules
and regulations of the SEC or any other regulatory agencies may restrict the Company&#8217;s ability to conduct certain types of financing
activities or may affect the timing of and amounts it can raise by undertaking such activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">The Company evaluated whether there
are any conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern
within one year beyond the filing of this Quarterly Report on Form 10-Q. Based on such evaluation and the Company&#8217;s current plans
(including the ongoing clinical programs for SLS-002, SLS-005, and other product candidates), which are subject to change, management
believes that the Company&#8217;s existing cash and cash equivalents as of March 31, 2022 are not sufficient to satisfy its operating
cash needs for the year after the filing of this Quarterly Report on Form 10-Q.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="font-size: 9pt; text-align: center; width: 100%">&#160;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify">The Company&#8217;s future liquidity and capital
funding requirements will depend on numerous factors, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23pt"></td><td style="width: 18pt"><span style="font-size: 10pt; letter-spacing: -0.7pt">&#8226;</span></td><td><span style="font-size: 10pt">its ability to raise additional funds to finance its operations;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23pt"></td><td style="width: 18pt"><span style="font-size: 10pt; letter-spacing: -0.7pt">&#8226;</span></td><td><span style="font-size: 10pt">its ability to maintain compliance with the listing requirements of the Nasdaq Capital Market;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23pt"></td><td style="width: 18pt"><span style="font-size: 10pt; letter-spacing: -0.7pt">&#8226;</span></td><td><span style="font-size: 10pt">the outcome, costs and timing of clinical trial results for the Company&#8217;s current or future product
candidates;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23pt"></td><td style="width: 18pt"><span style="font-size: 10pt; letter-spacing: -0.7pt">&#8226;</span></td><td><span style="font-size: 10pt">potential litigation expenses;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23pt"></td><td style="width: 18pt"><span style="font-size: 10pt; letter-spacing: -0.7pt">&#8226;</span></td><td><span style="font-size: 10pt">the emergence and effect of competing or complementary products or product candidates;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23pt"></td><td style="width: 18pt"><span style="font-size: 10pt; letter-spacing: -0.7pt">&#8226;</span></td><td style="padding-right: 5.85pt"><span style="font-size: 10pt">its ability to maintain, expand and defend the scope of its intellectual
property portfolio, including the amount and timing of any payments the Company may be required to make, or that it may receive, in connection
with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23pt"></td><td style="width: 18pt"><span style="font-size: 10pt; letter-spacing: -0.7pt">&#8226;</span></td><td style="padding-right: 5.85pt"><span style="font-size: 10pt">its ability to retain its current employees and the need and ability to
hire additional management and scientific and medical personnel;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23pt"></td><td style="width: 18pt"><span style="font-size: 10pt; letter-spacing: -0.7pt">&#8226;</span></td><td><span style="font-size: 10pt">the terms and timing of any collaborative, licensing or other arrangements that it has or may establish;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23pt"></td><td style="width: 18pt"><span style="font-size: 10pt; letter-spacing: -0.7pt">&#8226;</span></td><td><span style="font-size: 10pt">the trading price of its common stock; and</span></td></tr></table>


<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23pt"></td><td style="width: 18pt"><span style="font-size: 10pt; letter-spacing: -0.7pt">&#8226;</span></td><td><span style="font-size: 10pt">its ability to increase the number of authorized shares outstanding to facilitate future financing events.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 11.85pt 0 5pt; text-align: justify"><span style="background-color: white">The
Company may raise substantial additional funds, and if it does so, it may do so through one or more of the following: issuance of additional
debt or equity and/or the completion of a licensing or other commercial transaction for one or more of the Company&#8217;s product candidates.
If the Company is unable to maintain sufficient financial resources, its business, financial condition and results of operations will
be materially and adversely affected. This could affect future development and business activities and potential future clinical studies
and/or other future ventures. Failure to obtain additional equity or debt financing will have a material, adverse impact on the Company&#8217;s
business operations. There can be no assurance that the Company will be able to obtain the needed financing on acceptable terms or at
all. Additionally, equity or convertible debt financings will likely have a dilutive effect on the holdings of the Company&#8217;s existing
stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 11.85pt 0 5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 11.85pt 0 5pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_80D_eus-gaap--SignificantAccountingPoliciesTextBlock_zuGSr9jROLy8" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: left">3. Significant Accounting Policies</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: left">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zp2emxigUS7i" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify; text-indent: -0.5pt"><b><i>Basis of Presentation
</i></b></p>

<p style="font: 13.5pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify; text-indent: -0.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 5pt">The accompanying unaudited interim condensed consolidated financial
statements should be read in conjunction with the audited financial statements and notes thereto as of and for the year ended December
31, 2021 included in the Company&#8217;s Annual Report on Form 10-K (the &#8220;Annual Report&#8221;) filed with the SEC on March 4, 2022.
The accompanying financial statements have been prepared by the Company in accordance with United States generally accepted accounting
principles (&#8220;U.S. GAAP&#8221;) for interim financial information and in accordance with the instructions to Form 10-Q and Article
10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in
accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, the accompanying unaudited condensed consolidated
financial statements for the periods presented reflect all adjustments, consisting of only normal, recurring adjustments, necessary to
fairly state the Company&#8217;s financial position, results of operations and cash flows. The December 31, 2021 condensed consolidated
balance sheet was derived from audited financial statements, but it does not include all U.S. GAAP disclosures. The unaudited condensed
consolidated financial statements for the interim periods are not necessarily indicative of results for the full year. The preparation
of these unaudited condensed consolidated financial statements requires the Company to make estimates and judgments that affect the amounts
reported in the financial statements and the accompanying notes. The Company&#8217;s actual results may differ from these estimates under
different assumptions or conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>



</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_848_eus-gaap--UseOfEstimates_zsG5uQdUXm5h" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify; text-indent: -0.5pt"><b><i>Use of Estimates</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt">The preparation of financial statements in conformity with U.S. GAAP requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets
and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant
estimates in the Company&#8217;s financial statements relate to the valuation of warrants, valuation of convertible notes payable, and
the valuation of stock options. These estimates and assumptions are based on current facts, historical experience and various other factors
believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values
of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially
and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s
future results of operations will be affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="font-size: 9pt; text-align: center; width: 100%">&#160;6</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"><span style="font-weight: normal">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_840_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zjtmXpmZ5WGe" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: left"><i>Fair Value Measurements</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">The Company
follows the accounting guidance in the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;)
Topic 820, Fair Value Measurements and Disclosures (&#8220;ASC 820&#8221;), for its fair value measurements of financial assets and liabilities
measured at fair value on a recurring basis. Under this accounting guidance, fair value is defined as an exit price, representing the
amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at
the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants
would use in pricing an asset or a liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">The accounting
guidance requires fair value measurements be classified and disclosed in one of the following three categories:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">Level 1: Quoted
prices in active markets for identical assets or liabilities. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">Level 2: Observable
inputs other than Level 1 prices, for similar assets or liabilities that are directly or indirectly observable in the marketplace.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">Level 3: Unobservable
inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing
models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires
significant judgment or estimation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">The fair value
hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring
fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is
significant to the fair value measurement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify; text-indent: -0.5pt"><b><i>Fair Value Option</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">As permitted
under FASB ASC Topic 825, Financial Instruments (&#8220;ASC 825&#8221;), the Company elected the fair value option to account for its
November 2021 and December 2021 convertible notes (collectively, the &#8220;2021 Convertible Notes&#8221;). In accordance with ASC 825,
the Company records these convertible notes at fair value with changes in fair value recorded in the Consolidated Statement of Operations
and Comprehensive Loss. As a result of applying the fair value option, direct costs and fees related to the convertible notes were expensed
as incurred and were not deferred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_84B_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zylUSVrXTDr3" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"><i>Stock-based Compensation</i></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="font-weight: normal"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"><span style="font-weight: normal">The Company
expenses stock-based compensation to employees, non-employees and board members over the requisite service period based on the estimated
grant-date fair value of the awards and forfeitures rates. The Company accounts for forfeitures as they occur. Stock-based awards with
graded-vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion
of the award. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions
used in calculating the fair value of stock-based awards represent management&#8217;s best estimates and involve inherent uncertainties
and the application of management&#8217;s judgment. All stock-based compensation costs are recorded in general and administrative or research
and development costs in the statements of operations based upon the underlying individual&#8217;s role at the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="font-weight: normal">Performance
share awards are initially valued based on the Company&#8217;s closing stock price on the date of grant. The number of performance share
awards that vest will be determined based on the achievement of specified performance milestones by the end of the performance period.
Compensation expense for performance awards is recognized over the service period and will vary based on remeasurement during the performance
period. If achievement of the performance milestone is not probable of achievement during the performance period, compensation expense
is reversed.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="font-weight: normal"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_zJOg7I8WZ1Vg" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>Net Loss Per Share</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Basic loss per share is computed by dividing net loss applicable
to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share
includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, warrants, performance-based
restricted stock unit awards and stock options that would result in the issuance of incremental shares of common stock. In computing the
basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both
calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 11 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="font-size: 9pt; text-align: center; width: 100%">&#160;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>


<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zKQMCpo58Tdj" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">The following potentially dilutive securities outstanding for
the three months ended March 31, 2022 and 2021 have been excluded from the computation of diluted weighted average shares outstanding,
as they would be anti-dilutive (in thousands):</p>

<p id="xdx_8BF_z66xDxRI5f8d" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; display: none">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: middle"></td>
    <td style="vertical-align: bottom; text-align: right"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center"></td>
    <td colspan="4" style="font-weight: bold; vertical-align: middle; text-align: center">Three Months</td></tr>
  <tr>
    <td style="vertical-align: middle"></td>
    <td style="vertical-align: bottom; text-align: right"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center"></td>
    <td colspan="4" style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center">Ended March
    31,</td></tr>
  <tr>
    <td style="vertical-align: middle; width: 62%"></td>
    <td style="vertical-align: bottom; text-align: right; width: 2%"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center; width: 2%"></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; width: 15%">2022</td>
    <td style="vertical-align: bottom; text-align: right; width: 2%"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center; width: 2%"></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; width: 15%">2021</td></tr>
  <tr style="vertical-align: middle">
    <td>Outstanding stock options</td>
    <td></td>
    <td style="text-align: right"></td>
    <td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zCScnnyODifk" title="Outstanding stock options" style="text-align: right; border-top-color: Black; border-top-width: 1pt"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="3" unitRef="Shares">10,299</ix:nonFraction></td>
    <td></td>
    <td style="text-align: right"></td>
    <td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zsdriRbP2xd" title="Outstanding stock options" style="text-align: right; border-top-color: Black; border-top-width: 1pt"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="3" unitRef="Shares">7,204</ix:nonFraction></td></tr>
  <tr style="vertical-align: middle">
    <td>Restricted stock units</td>
    <td></td>
    <td style="text-align: right"></td>
    <td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zrW6jSAzEgae" title="Restricted stock units" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0405">-</span></td>
    <td></td>
    <td style="text-align: right"></td>
    <td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zqlk7NWOoQwk" title="Restricted stock units" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-03-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" scale="3" unitRef="Shares">2,400</ix:nonFraction></td></tr>
  <tr style="vertical-align: middle">
    <td>Outstanding warrants</td>
    <td></td>
    <td style="text-align: right"></td>
    <td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zIvMtG3p7Qs6" title="Outstanding warrants" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-03-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="3" unitRef="Shares">2,635</ix:nonFraction></td>
    <td></td>
    <td style="text-align: right"></td>
    <td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zQSQ9Fb0Dxvj" title="Outstanding Warrants" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-03-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="3" unitRef="Shares">3,920</ix:nonFraction></td></tr>
  <tr style="vertical-align: middle">
    <td>Convertible debt</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_z5VuN4C7Qug9" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-03-31_us-gaap_ConvertibleDebtSecuritiesMember" format="ixt:numdotdecimal" decimals="INF" scale="3" unitRef="Shares">3,704</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zUWQoM64cIZd" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-03-31_us-gaap_ConvertibleDebtSecuritiesMember" format="ixt:numdotdecimal" decimals="INF" scale="3" unitRef="Shares">5,326</ix:nonFraction></td></tr>
  <tr>
    <td style="vertical-align: middle"></td>
    <td style="vertical-align: middle; text-align: right"></td>
    <td style="vertical-align: middle; text-align: right"></td>
    <td style="vertical-align: bottom; text-align: right"></td>
    <td style="vertical-align: middle; text-align: right"></td>
    <td style="vertical-align: middle; text-align: right"></td>
    <td style="vertical-align: bottom; text-align: right"></td></tr>
  <tr>
    <td style="vertical-align: middle"></td>
    <td style="vertical-align: bottom; text-align: right"></td>
    <td style="vertical-align: middle; text-align: right"></td>
    <td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_i01_pin3_c20220101__20220331_zIrNJ5WBdVL7" title="Antidilutive securities excluded" style="border-top: Black 1pt solid; border-bottom: Black 2pt double; vertical-align: middle; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="3" unitRef="Shares">16,638</ix:nonFraction></td>
    <td style="vertical-align: bottom; text-align: right"></td>
    <td style="vertical-align: middle; text-align: right"></td>
    <td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_i01_pin3_c20210101__20210331_zKMlPxi5SVke" title="Antidilutive securities excluded" style="border-top: Black 1pt solid; border-bottom: Black 2pt double; vertical-align: middle; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="INF" scale="3" unitRef="Shares">18,850</ix:nonFraction></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zKZPpjg80Pv8" style="font: 9pt Sans-Serif; margin: 0 0 0 4.5pt; color: Red"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Amounts in the table reflect the common stock equivalents of
the noted instruments.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: left">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zrTAZ4Okgtok" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left">Recent Accounting Pronouncements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: justify"><span style="font-weight: normal"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">In August 2020, the FASB issued Accounting Standards Update
(&#8220;ASU&#8221;) No. 2020-06: Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging
&#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an
Entity&#8217;s Own Equity (&#8220;ASU 2020-06&#8221;). This standard simplifies the accounting for convertible debt instruments by
removing the separation models for convertible debt with a cash conversion feature, as well as convertible instruments with a
beneficial conversion feature. As a result, entities will account for a convertible debt instrument wholly as debt, unless certain
other conditions are met. The elimination of these models will reduce non-cash interest expense for entities that have issued a
convertible instrument that was within the scope of those models before the adoption of ASU 2020-06. Additionally, ASU 2020-06
requires the application of the if-converted method for calculating diluted earnings per share and precludes the use of the treasury
stock method for certain debt instruments. The provisions of ASU 2020-06 are applicable for the Company beginning after January 1,
2024, with early adoption permitted, and an entity should adopt the provisions at the beginning of its annual fiscal year. The
Company does not expect the adoption of ASU 2020-06 to have an impact on its consolidated financial statements and related
disclosures.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: justify"></p>

</ix:nonNumeric><p id="xdx_850_z7BVrm2KkeWk" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="font-weight: normal">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:FairValueDisclosuresTextBlock"><p id="xdx_808_eus-gaap--FairValueDisclosuresTextBlock_ztlU5aWE8O6h" style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>4. Fair Value Measurement</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">The
following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring
basis and indicate the level of the fair value hierarchy utilized to determine such fair values. There were
<span id="xdx_90B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_do_c20220101__20220331_zjJpAFcFuyTb"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2022-01-01to2022-03-31" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></span>
transfers between fair value measurement levels during the three months ended March 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"><p id="xdx_899_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zmwG4olT1Kz1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">The Company&#8217;s financial assets and liabilities measured at fair value
at March 31, 2022 and December 31, 2021 are as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; background-color: white"><span id="xdx_8BE_zLdsggSUjfL6" style="display: none">Schedule of Fair Value Hierarchy Assets and Liabilities</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; background-color: white"></p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: middle; background-color: white">
    <td style="font-weight: bold; width: 44%"></td>
    <td style="font-weight: bold; text-align: right; width: 2%"></td>
    <td style="font-weight: bold; text-align: right; width: 2%"></td>
    <td style="font-weight: bold; text-align: center; width: 10%"></td>
    <td style="font-weight: bold; text-align: right; width: 2%"></td>
    <td style="font-weight: bold; text-align: right; width: 2%"></td>
    <td style="font-weight: bold; text-align: center; width: 10%"></td>
    <td style="font-weight: bold; text-align: right; width: 2%"></td>
    <td style="font-weight: bold; text-align: right; width: 2%"></td>
    <td style="font-weight: bold; text-align: center; width: 10%"></td>
    <td style="font-weight: bold; text-align: right; width: 2%"></td>
    <td style="font-weight: bold; text-align: right; width: 2%"></td>
    <td style="font-weight: bold; text-align: center; width: 10%"></td></tr>
</table>


<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"></td>
    <td style="vertical-align: bottom; text-align: right"></td>
    <td colspan="10" style="font-weight: bold; vertical-align: middle; text-align: center; background-color: white">Fair Value Measurements</td></tr>
  <tr>
    <td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"></td>
    <td style="vertical-align: bottom; text-align: right"></td>
    <td colspan="10" style="font-weight: bold; vertical-align: middle; text-align: center; background-color: white">as of March 31, 2022</td></tr>
  <tr>
    <td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: right; background-color: white; width: 44%"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white; width: 2%"></td>
    <td style="vertical-align: bottom; text-align: right; width: 2%"></td>
    <td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 10%">(Level 1)</td>
    <td style="vertical-align: middle; text-align: right; background-color: white; width: 2%"></td>
    <td style="vertical-align: bottom; text-align: right; width: 2%"></td>
    <td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 10%">(Level 2)</td>
    <td style="vertical-align: middle; text-align: right; background-color: white; width: 2%"></td>
    <td style="vertical-align: bottom; text-align: right; width: 2%"></td>
    <td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 10%">(Level 3)</td>
    <td style="vertical-align: middle; text-align: right; background-color: white; width: 2%"></td>
    <td style="vertical-align: bottom; text-align: right; width: 2%"></td>
    <td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 10%">Total</td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="font-weight: bold"><span id="xdx_900_eus-gaap--AssetsAbstract_iB_c20220101__20220331_ziSTSyBoNVWc">Assets</span>:</td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="font-weight: bold; text-align: center"></td>
    <td style="font-weight: bold; text-align: center"></td>
    <td style="text-align: right"></td>
    <td style="font-weight: bold; text-align: center"></td>
    <td style="font-weight: bold; text-align: center"></td>
    <td style="text-align: right"></td>
    <td style="font-weight: bold; text-align: center"></td>
    <td style="font-weight: bold; text-align: center"></td>
    <td style="text-align: right"></td>
    <td style="font-weight: bold; text-align: center"></td>
    <td style="font-weight: bold; text-align: center"></td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt">Cash</td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td id="xdx_980_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zMqtLMj6TFSi" title="Cash" style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">61,772</ix:nonFraction></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td id="xdx_988_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zz24VxuSoM5a" title="Cash" style="border-bottom: Black 2pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0429">-</span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td id="xdx_98C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zaL1DaIgI1v5" title="Cash" style="border-bottom: Black 2pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0431">-</span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td id="xdx_986_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20220331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zFAa9NtOhvN6" title="Cash" style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-03-31_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">61,772</ix:nonFraction></td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="font-weight: bold"><span id="xdx_90D_eus-gaap--LiabilitiesAbstract_iB_c20220101__20220331_zSJ30OFb8PIk">Liabilities</span>:</td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="font-weight: bold; text-align: center"></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="font-weight: bold; text-align: center"></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="font-weight: bold; text-align: center"></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="font-weight: bold; text-align: center"></td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt">Convertible notes payable, at fair value</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_980_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zjsKM8XNM0Fg" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0435">-</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_986_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zdXWGeQSnKdk" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0436">-</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_98C_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_z9av2YuWif5f" style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_LongTermDebtMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,164</ix:nonFraction></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_981_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zA9bPAF27hee" style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2022-03-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_LongTermDebtMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,164</ix:nonFraction></td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt">Warrant liabilities, at fair value</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td id="xdx_988_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zAX0BuuWs5Zi" title="Warrant liabilities, at fair value" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0440">-</span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td id="xdx_98D_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zDx7tAT4Cpg3" title="Warrant liabilities, at fair value" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0442">-</span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td id="xdx_989_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zRHvxSJNbD8c" title="Warrant liabilities, at fair value" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">190</ix:nonFraction></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td id="xdx_987_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zGE4pbeM8qeg" title="Warrant liabilities, at fair value" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2022-03-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">190</ix:nonFraction></td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_98C_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zflU3SniAtPg" style="border-bottom: Black 2pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0447">-</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_98F_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z6tMvCVtLyXf" style="border-bottom: Black 2pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0448">-</span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td id="xdx_984_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zQlhU1IQidSc" style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,354</ix:nonFraction></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_987_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zcBb6lxtsIDc" style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2022-03-31_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,354</ix:nonFraction></td></tr>

  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="font-size: 9pt; text-align: center; width: 100%">&#160;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; background-color: white"></p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: middle; background-color: white">
    <td style="font-weight: bold; width: 44%"></td>
    <td style="font-weight: bold; text-align: right; width: 2%"></td>
    <td style="font-weight: bold; text-align: right; width: 2%"></td>
    <td style="font-weight: bold; text-align: center; width: 10%"></td>
    <td style="font-weight: bold; text-align: right; width: 2%"></td>
    <td style="font-weight: bold; text-align: right; width: 2%"></td>
    <td style="font-weight: bold; text-align: center; width: 10%"></td>
    <td style="font-weight: bold; text-align: right; width: 2%"></td>
    <td style="font-weight: bold; text-align: right; width: 2%"></td>
    <td style="font-weight: bold; text-align: center; width: 10%"></td>
    <td style="font-weight: bold; text-align: right; width: 2%"></td>
    <td style="font-weight: bold; text-align: right; width: 2%"></td>
    <td style="font-weight: bold; text-align: center; width: 10%"></td></tr>
</table>


<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"></td>
    <td style="vertical-align: bottom; text-align: right"></td>
    <td colspan="10" style="font-weight: bold; vertical-align: middle; text-align: center; background-color: white">Fair Value Measurements</td></tr>
  <tr>
    <td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"></td>
    <td style="vertical-align: bottom; text-align: right"></td>
    <td colspan="10" style="font-weight: bold; vertical-align: middle; text-align: center; background-color: white">as of December 31, 2021</td></tr>
  <tr>
    <td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: right; background-color: white; width: 44%"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white; width: 1%"></td>
    <td style="vertical-align: bottom; text-align: right; width: 1%"></td>
    <td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 12%">(Level 1)</td>
    <td style="vertical-align: middle; text-align: right; background-color: white; width: 1%"></td>
    <td style="vertical-align: bottom; text-align: right; width: 1%"></td>
    <td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 12%">(Level 2)</td>
    <td style="vertical-align: middle; text-align: right; background-color: white; width: 1%"></td>
    <td style="vertical-align: bottom; text-align: right; width: 1%"></td>
    <td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 12%">(Level 3)</td>
    <td style="vertical-align: middle; text-align: right; background-color: white; width: 1%"></td>
    <td style="vertical-align: bottom; text-align: right; width: 1%"></td>
    <td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 12%">Total</td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="font-weight: bold"><span id="xdx_90C_eus-gaap--AssetsAbstract_iB_c20210101__20211231_z1NdZhfsyYU6">Assets</span>:</td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="font-weight: bold; text-align: center"></td>
    <td style="font-weight: bold; text-align: center"></td>
    <td style="text-align: right"></td>
    <td style="font-weight: bold; text-align: center"></td>
    <td style="font-weight: bold; text-align: center"></td>
    <td style="text-align: right"></td>
    <td style="font-weight: bold; text-align: center"></td>
    <td style="font-weight: bold; text-align: center"></td>
    <td style="text-align: right"></td>
    <td style="font-weight: bold; text-align: center"></td>
    <td style="font-weight: bold; text-align: center"></td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt">Cash</td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td id="xdx_980_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zphNLgkyaaSg" style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">78,734</ix:nonFraction></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td id="xdx_98E_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zTrI2Jcn3cac" style="border-bottom: Black 2pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0453">-</span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td id="xdx_984_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z0vhW9igOboi" style="border-bottom: Black 2pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0454">-</span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td id="xdx_981_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zZ0sFf2PIsVd" style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">78,734</ix:nonFraction></td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="font-weight: bold"><span id="xdx_90E_eus-gaap--LiabilitiesAbstract_iB_c20210101__20211231_zqbnatmsvCN5">Liabilities</span>:</td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="font-weight: bold; text-align: center"></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="font-weight: bold; text-align: center"></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="font-weight: bold; text-align: center"></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="font-weight: bold; text-align: center"></td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt">Convertible notes payable, at fair value</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_982_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_z1Dji7GN6VXc" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0457">-</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_986_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zZc1eDPalm1i" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0458">-</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_98E_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_z6iymzVEu8el" style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_LongTermDebtMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18,920</ix:nonFraction></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_984_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zMlyQogvhvz5" style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2021-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_LongTermDebtMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18,920</ix:nonFraction></td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt">Derivative liability, at fair value</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td id="xdx_982_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zB0e9XsEXIV7" style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,174</ix:nonFraction></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td id="xdx_98C_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_z3vyQwT75uk1" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0462">-</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td id="xdx_98B_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zBPGwAQ3cEei" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0463">-</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td id="xdx_98A_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zai4h0Tys5Ud" style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2021-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,174</ix:nonFraction></td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt">Warrant liabilities, at fair value</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td id="xdx_984_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zZKHP2KXgNKf" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0465">-</span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td id="xdx_98B_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zpHSbRNVJiJi" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0466">-</span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td id="xdx_98F_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_z2rtoturi0K1" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">424</ix:nonFraction></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td id="xdx_982_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zW1Y23DafrH3" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2021-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">424</ix:nonFraction></td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_986_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zkxlXzVGYAY6" style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,174</ix:nonFraction></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_987_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zYs6Is3hVU9l" style="border-bottom: Black 2pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0470">-</span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td id="xdx_980_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zDyahd65sJWd" style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,344</ix:nonFraction></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_988_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zwS6h5ca1G24" style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2021-12-31_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20,518</ix:nonFraction></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0"></p>

<p style="font: 9pt Sans-Serif; margin: 0 0 0 4.5pt; background-color: white; color: Red"></p>



<p style="margin-top: 0; margin-bottom: 0"></p>

<p style="font: 9pt Sans-Serif; margin: 0 0 0 4.5pt; background-color: white; color: Red"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="font-weight: normal">&#160;</span></p>


</ix:nonNumeric><p id="xdx_8AD_zWf1Uyzwva4e" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="background-color: white">The fair
value of the Company&#8217;s money market funds is based on quoted active market prices for the funds and is determined using the market
approach.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company measures the 2021 Convertible Notes
and warrant liabilities <span style="background-color: white">at fair value based on significant inputs not observable in the market,
which causes them to be classified as a Level&#160;3 measurement within the fair value hierarchy.&#160;</span>These valuations use assumptions
and estimates the Company believes would be made by a market participant in making the same valuation. The Company assesses these assumptions
and estimates on&#160;an&#160;on-going&#160;basis as additional data impacting the assumptions and estimates are obtained. Changes in
the fair value of the convertible notes payable and warrant liabilities related to updated assumptions and estimates are recognized within
the Consolidated Statements of Operations and Comprehensive Loss.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The fair value of the convertible notes payable and warrant
liabilities may change significantly as additional data is obtained, impacting the Company&#8217;s assumptions regarding probabilities
of outcomes used to estimate the fair value of the liabilities. The estimates of fair value may not be indicative of the amounts that
could be realized in a current market exchange. Accordingly, the use of different market assumptions and/or different valuation techniques
may have a material effect on the estimated fair value amounts, and such changes could materially impact the Company&#8217;s results
of operations in future periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>Derivative Liability</i></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The derivative liability represents the fair value of the &#8220;Shortfall
Amount&#8221; provision provided for in the license agreement with iX Biopharma Europe Limited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">At issuance, the fair value of the embedded derivative was estimated
by using a Monte Carlo simulation model. As of December 31, 2021, the Company determined it was probable it would settle the Shortfall
Amount in cash and estimated the fair value based on a probability weighted market approach. The Company paid the Shortfall Amount of
$<span id="xdx_902_ecustom--NonrefundableCashPayment_pn5n6_c20220101__20220131__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_zGsQjw9Csvmh"><ix:nonFraction name="SEEL:NonrefundableCashPayment" contextRef="From2022-01-012022-01-31_custom_IXLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.2</ix:nonFraction></span> million in cash in January 2022.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>2021 Convertible Notes</i></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<ix:nonNumeric contextRef="From2022-01-012022-03-31_us-gaap_LongTermDebtMember" escape="true" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"><p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zobZdwvz86B2" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The
2021 Convertible Notes are valued using a Monte Carlo simulation model. The following assumptions were used in determining the fair
value of the 2021 Convertible Notes as of March 31, 2022 and December 31, 2021:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_8B1_ziFuTHcOTBZ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none">Summary of Fair Value Measurements Convertible Notes Valuation
Assumptions</p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 56%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: center; width: 19%">Three Months Ended</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: right; width: 1%">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: right; width: 2%">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: center; width: 19%">Year Ended</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">March 31, 2022</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">December 31, 2021</td></tr>
  <tr style="vertical-align: middle">
    <td style="background-color: white">Risk-free interest rate</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="font-size: 9pt; text-align: center"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_uPure_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_z5HpRHX11Yob"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember_us-gaap_LongTermDebtMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Pure">2.45</ix:nonFraction></span>%</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: center; border-top-color: Black; border-top-width: 1pt; background-color: white"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_uPure_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MinimumMember_zZeGHvgGJ9s4"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_LongTermDebtMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Pure">0.90</ix:nonFraction></span>% - <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_uPure_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MaximumMember_z37XKizL0Gw7"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_LongTermDebtMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Pure">0.95</ix:nonFraction></span>%</td></tr>
  <tr style="vertical-align: middle">
    <td style="background-color: white">Volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="font-size: 9pt; text-align: center"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pin2_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zacDLrQ4GKdg"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember_us-gaap_LongTermDebtMember" format="ixt:numdotdecimal" decimals="INF" scale="2" unitRef="Pure">105</ix:nonFraction></span>%</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: center; background-color: white"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pin2_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MinimumMember_zg5wBGRG8c44"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_LongTermDebtMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="2" unitRef="Pure">113</ix:nonFraction></span>% - <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pin2_uPure_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MaximumMember_zErzf8T2zyUi"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_LongTermDebtMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="2" unitRef="Pure">114</ix:nonFraction></span>%</td></tr>
  <tr style="vertical-align: middle">
    <td style="background-color: white">Dividend yield</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="font-size: 9pt; text-align: center"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zW1WNfLtpRW5"><span style="-sec-ix-hidden: xdx2ixbrl0482">-</span></span>%</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center; background-color: white"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_ziWfoJRwIme7"><span style="-sec-ix-hidden: xdx2ixbrl0483">-</span></span>%</td></tr>
  <tr style="vertical-align: middle">
    <td style="background-color: white">Contractual term (years)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zWmphv1myut4" style="font-size: 9pt; text-align: center"><ix:nonNumeric contextRef="From2022-01-012022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_LongTermDebtMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">2.7</ix:nonNumeric></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zmlt9elrKnbd" style="vertical-align: bottom; text-align: center; background-color: white"><ix:nonNumeric contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_LongTermDebtMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">3.0</ix:nonNumeric></td></tr>
  <tr style="vertical-align: middle">
    <td style="background-color: white">Stock price</td>
    <td>&#160;</td>
    <td style="text-align: right">$</td>
    <td style="font-size: 9pt; text-align: center"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_uUSDPShares_c20220331__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_z3skXZj1r90j"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2022-03-31_us-gaap_LongTermDebtMember" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">0.84</ix:nonFraction></span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td style="vertical-align: bottom; text-align: center; background-color: white"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_uUSDPShares_c20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MinimumMember_zljLj7MQFzwe"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2021-12-31_us-gaap_LongTermDebtMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">1.74</ix:nonFraction></span> - <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_uUSDPShares_c20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MaximumMember_z3kkv8fM9Zpa"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2021-12-31_us-gaap_LongTermDebtMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">1.95</ix:nonFraction></span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zrGUII808ble" style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 18 --><div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="font-size: 9pt; text-align: center; width: 100%">9</td></tr></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>





<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0; text-align: left"></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>Warrant Liabilities</i></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The common stock warrant liabilities were recorded at fair value using
the Black-Scholes option pricing model. &#160;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"></p>

<ix:nonNumeric contextRef="From2022-01-012022-03-31_us-gaap_WarrantMember654115578" escape="true" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"><p id="xdx_899_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zO2vSCDX6qTh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-weight: normal"><span style="background-color: white">The
following assumptions were used in determining the fair value of the warrant liabilities valued using the Black-Scholes option
pricing model for the three months ended March 31, 2022 and 2021.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-weight: normal"><span style="background-color: white">&#160;</span></span></p>

<p id="xdx_8BD_zAZ6sU0ZV6p3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal"><span style="display: none; background-color: white">Summary
of Fair Value Measurements Warrant Valuation Assumptions</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">&#160;</span></p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
  <tr style="vertical-align: middle">
    <td style="width: 55%">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: right; width: 1%">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: right; width: 1%">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: center; width: 19%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 20%">&#160;</td></tr>
  <tr style="vertical-align: middle">
    <td></td>
    <td style="font-size: 9pt; font-weight: bold; text-align: right"></td>
    <td style="font-size: 9pt; font-weight: bold; text-align: right"></td>
    <td colspan="4" style="font-size: 9pt; font-weight: bold; text-align: center">Three Months  Ended March  31,</td></tr>
  <tr style="vertical-align: middle">
    <td></td>
    <td style="font-size: 9pt; font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">2022</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><b>2021</b></td></tr>
  <tr style="vertical-align: middle">
    <td>Risk-free interest rate</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_uPure_c20220101__20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zOk0436sECG2" style="text-align: center; border-top-color: Black; border-top-width: 1pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-01-012022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.96</ix:nonFraction>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_uPure_c20210101__20210331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zQXop3eyrI2k" style="text-align: center; border-top-color: Black; border-top-width: 1pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-01-012021-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.32</ix:nonFraction>%</td>
    </tr>
  <tr style="vertical-align: middle">
    <td>Volatility</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pin2_uPure_c20220101__20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zFQkpDdm9Xka" style="text-align: center"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-01-012022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Pure">103.30</ix:nonFraction>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pin2_uPure_c20210101__20210331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_z8fdFMccT2S2" style="text-align: center"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-01-012021-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Pure">120.91</ix:nonFraction>%</td>
    </tr>
  <tr style="vertical-align: middle">
    <td><p style="margin-top: 0; margin-bottom: 0">Dividend yield</p></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: center"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20220101__20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zz7ilyPOnhdg" title="Dividend yield (in percent)"><span style="-sec-ix-hidden: xdx2ixbrl0496">-</span></span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20210101__20210331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zSAF5OZBaWde" title="Dividend yield (in percent)"><span style="-sec-ix-hidden: xdx2ixbrl0498">-</span></span>%</td>
    </tr>
  <tr style="vertical-align: middle">
    <td>Expected term (years)</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zcrDiuC8yDRb" style="text-align: center"><ix:nonNumeric contextRef="From2022-01-012022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">1.82</ix:nonNumeric></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zAFqHOxghGpf" style="text-align: center"><ix:nonNumeric contextRef="From2021-01-012021-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">2.82</ix:nonNumeric></td>
    </tr>
  <tr style="vertical-align: middle">
    <td>Weighted-average fair value</td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220101__20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zEZJzyd9xHx3" style="text-align: center"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.63</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20210101__20210331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zr76QnsGRBn5" style="text-align: center"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2021-01-012021-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.76</ix:nonFraction></td>
    </tr>
  </table>

<p style="font: bold 9pt Sans-Serif; margin: 0 0 0 6pt; text-align: left; color: Red"></p>

</ix:nonNumeric><p id="xdx_8A1_zU3M9zd0geK3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left">&#160;</p>






<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"><p id="xdx_895_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zCPml5pFNX89" style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">The
following table is a reconciliation for the common stock warrant liabilities and convertible notes measured at
fair value using Level 3 unobservable inputs (in thousands):&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="font-weight: normal; background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-weight: normal; background-color: white">&#160;</span></p>

<p id="xdx_8BF_z141aSNXGWG7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="display: none; font-weight: normal; background-color: white; font-style: normal">Schedule of Fair Value Level 3 Reconciliation</span></p>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify">&#160;</p>



<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: right; width: 65%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; width: 7%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; width: 6%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; width: 13%"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt"><b>Warrant</b></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt"><b>Derivative</b></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt"><b>Convertible notes,</b></span></td></tr>
  <tr>
    <td style="vertical-align: middle"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; vertical-align: bottom; text-align: center"><span style="font-size: 9pt">liabilities</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; vertical-align: bottom; text-align: center"><span style="font-size: 9pt">liability</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; vertical-align: bottom; text-align: center"><span style="font-size: 9pt">at
    fair value</span></td></tr>
  <tr style="vertical-align: middle">
    <td style="font-weight: bold"><span style="font-size: 9pt">Balance as of December 31, 2020</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">$</span></td>
    <td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zZ5N7YCQckUf" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,062</ix:nonFraction></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td></tr>
  <tr style="vertical-align: middle">
    <td><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;Warrant liability reclassified to stockholders' equity</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"><span id="xdx_90B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zy3q2RQ3tfl9">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,155</ix:nonFraction>)</span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td></tr>
  <tr style="vertical-align: middle">
    <td><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;Issuance of convertible notes, at fair value</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span id="xdx_903_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2l9ITqAdDS3"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_LongTermDebtMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,150</ix:nonFraction></span></span></td></tr>
  <tr style="vertical-align: middle">
    <td><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;Issuance of derivative liability</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span id="xdx_909_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zeSjkKoJkkxe"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" contextRef="From2021-01-012021-12-31_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">805</ix:nonFraction></span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td></tr>
  <tr style="vertical-align: middle">
    <td><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;Change in fair value measurement of derivative liability</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span id="xdx_90E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zsnriOmehMg3"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="From2021-01-012021-12-31_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">369</ix:nonFraction></span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td></tr>
  <tr style="vertical-align: middle">
    <td><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;Change in fair value measurement of convertible notes</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span id="xdx_900_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z1bOcwLgc6ni">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_LongTermDebtMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">230</ix:nonFraction>)</span></span></td></tr>
  <tr style="vertical-align: middle">
    <td><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;Change in fair value measurement of warrant liability</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right; background-color: white"><span style="font-size: 9pt"><span id="xdx_90A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z9ZMDiklTg95"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">517</ix:nonFraction></span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td></tr>
  <tr>
    <td style="font-weight: bold; vertical-align: middle"><span style="font-size: 9pt">Balance as of December 31, 2021</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt">$</span></td>
    <td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zZOckZD8d9d6" style="vertical-align: middle; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">424</ix:nonFraction></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt">$</span></td>
    <td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zqO3PH8nHf3a" style="vertical-align: middle; text-align: right"><span style="font-size: 9pt">&#160;<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,174</ix:nonFraction></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt">$</span></td>
    <td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zzTtUmRpTS0k" style="vertical-align: middle; text-align: right"><span style="font-size: 9pt">&#160;<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_LongTermDebtMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18,920</ix:nonFraction></span></td></tr>
  <tr style="vertical-align: middle">
    <td><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;Settlement of derivative liability</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span id="xdx_905_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_i01N_pn3n3_di_c20220101__20220331__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwCetRrRSAH2">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" contextRef="From2022-01-012022-03-31_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,174</ix:nonFraction>)</span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td></tr>
  <tr style="vertical-align: middle">
    <td><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;Change in fair value measurement of convertible notes</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span id="xdx_90E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_i01_pn3n3_c20220101__20220331__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zhaQF9ZHYUVb"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="From2022-01-012022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_LongTermDebtMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">244</ix:nonFraction></span></span></td></tr>
  <tr style="vertical-align: middle">
    <td><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;Change in fair value measurement of warrant liability</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right; background-color: white"><span style="font-size: 9pt"><span id="xdx_908_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_i01_pn3n3_c20220101__20220331__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zLeLqN2kvjGc">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="From2022-01-012022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">234</ix:nonFraction>)</span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td></tr>
  <tr>
    <td style="font-weight: bold; vertical-align: middle"><span style="font-size: 9pt">Balance as of March 31, 2022</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt">$</span></td>
    <td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zBuArDbAc7Ek" style="border-bottom: Black 3pt double; vertical-align: middle; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">190</ix:nonFraction></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt">$</span></td>
    <td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_z1bamG3QqGxf" style="border-bottom: Black 3pt double; vertical-align: middle; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0519">&#160;</span>-</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt">$</span></td>
    <td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_z07O5qVN9v76" style="border-bottom: Black 3pt double; vertical-align: middle; text-align: right"><span style="font-size: 9pt">&#160;<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_LongTermDebtMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,164</ix:nonFraction></span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zTkGNxX2rtf6" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify">&#160;</p>
<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><span style="background-color: white">For the three months ended
March 31, 2022 and the year ended December 31, 2021, the changes in fair value of the convertible notes, derivative liability and
warrant liability primarily resulted from the volatility of the Company&#8217;s common stock. </span></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:OtherCurrentAssetsTextBlock"><p id="xdx_807_eus-gaap--OtherCurrentAssetsTextBlock_zxTYFBXSMjbi" style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>5. Prepaid Expenses and Other Current Assets</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"><p id="xdx_894_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_z2quCZanxsAd" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Prepaid expenses and other current assets are comprised of the following
(in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_8BB_zFwXqZpjjEH5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none">Schedule of Prepaid Expenses and Other Current Assets</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 85%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: middle">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">&#160;</td>
    <td id="xdx_492_20220331_zUJOJOzjr6L3" style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">&#160;</td>
    <td id="xdx_495_20211231_z0xE0sLPmIEi" style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: middle">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">March 31,</td>
    <td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">December 31,</td></tr>
  <tr>
    <td style="vertical-align: middle">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">2022</td>
    <td style="vertical-align: middle">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">2021</td></tr>
  <tr id="xdx_403_eus-gaap--PrepaidInsurance_iI_pn3n3_maPEAOAzj4M_zj6iYj33ahr1" style="vertical-align: middle">
    <td style="width: 66%">Prepaid insurance</td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; text-align: right; width: 1%">$</td>
    <td style="text-align: right; background-color: white; width: 15%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">787</ix:nonFraction></td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; text-align: right; width: 1%">$</td>
    <td style="text-align: right; width: 15%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">59</ix:nonFraction></td></tr>
  <tr id="xdx_407_ecustom--PrepaidClinicalCosts_iI_pn3n3_maPEAOAzj4M_zosvL0eg1Rc9" style="vertical-align: middle">
    <td>Prepaid clinical costs</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: right; background-color: white">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="SEEL:PrepaidClinicalCosts" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,694</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: right">&#160;</td>
    <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="SEEL:PrepaidClinicalCosts" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,481</ix:nonFraction></td></tr>
  <tr id="xdx_405_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3n3_maPEAOAzj4M_zDuzsVMSYJ83">
    <td style="vertical-align: middle">Other</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: middle; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: middle; text-align: right; background-color: white">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">414</ix:nonFraction></td>
    <td style="vertical-align: middle">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: top; text-align: right">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: middle; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">187</ix:nonFraction></td></tr>
  <tr id="xdx_401_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i01TI_pn3n3_maACzKPF_maACzYR4_mtPEAOAzj4M_zuIdy9vqOoKd" style="vertical-align: middle">
    <td style="padding-left: 24px; text-align: left">Prepaid expenses and other current assets</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2pt double; vertical-align: top; text-align: right">$</td>
    <td style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 1pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,895</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2pt double; vertical-align: top; text-align: right">$</td>
    <td style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 1pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,727</ix:nonFraction></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A9_z5E5zcgHzLMl" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:BusinessCombinationDisclosureTextBlock"><p id="xdx_808_eus-gaap--BusinessCombinationDisclosureTextBlock_zWRxfvxCmEWd" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">6. Common Stock Offerings</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Public Offerings</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On May 24, 2021, the Company completed an underwritten public
offering, pursuant to which the Company sold <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--May242021Member_zPVRgA5RMaM1" title="Number of shares of common stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-12-31_custom_May242021Member" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">22,258,066</ix:nonFraction></span> shares of its common stock, at a price to the public of $<span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_pp2p0_uUSDPShares_c20210524__us-gaap--StatementClassOfStockAxis__custom--May242021Member_zkYUNTkLxcd1" title="Shares Issued, Price Per Share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2021-05-24_custom_May242021Member" format="ixt:numdotdecimal" decimals="2" scale="0" unitRef="USDPShares">3.10</ix:nonFraction></span> per share, which
included the exercise in full by the underwriter of its option to purchase up to 2,903,226 additional shares of common stock. The net
proceeds to the Company from the offering were approximately $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--May242021Member_zhylCscaQiz" title="Cash received from stock sale"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_custom_May242021Member" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">64.5</ix:nonFraction></span> million, after deducting underwriting discounts, commissions and
other offering expenses. The Company used $<span id="xdx_90E_ecustom--OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes_pn5n6_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--May242021Member_zbSSnmJkeCOh" title="Offering proceeds used to partially repay certain convertible promissory notes"><ix:nonFraction name="SEEL:OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes" contextRef="From2021-01-012021-12-31_custom_May242021Member" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.3</ix:nonFraction></span> million of the net proceeds from the offering for the partial repayment
of certain outstanding convertible promissory notes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="font-size: 9pt; text-align: center; width: 100%">&#160;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On January 28, 2021, the Company completed an underwritten public
offering, pursuant to which the Company sold <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--January282021Member_ziiVbkN1rM35"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-12-31_custom_January282021Member" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">17,530,488</ix:nonFraction>
</span>shares of its common stock, at a price to the public of $<span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_pp2p0_uUSDPShares_c20210128__us-gaap--StatementClassOfStockAxis__custom--January282021Member_zhwuTBDaRzq1"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2021-01-28_custom_January282021Member" format="ixt:numdotdecimal" decimals="2" scale="0" unitRef="USDPShares">2.05</ix:nonFraction>
</span>per share, which included the exercise in full by the underwriter of its option to purchase up to 2,286,585 additional shares
of common stock. The net proceeds to the Company from the offering were approximately $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--January282021Member_z86SClZKrcwl"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_custom_January282021Member" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">33.5</ix:nonFraction>
</span>million, after deducting underwriting discounts, commissions and other offering expenses. The Company used $<span id="xdx_907_ecustom--OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes_pn5n6_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--January282021Member_z7HAPFqbneJ7"><ix:nonFraction name="SEEL:OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes" contextRef="From2021-01-012021-12-31_custom_January282021Member" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.8</ix:nonFraction>
</span>million of the net proceeds from the offering for the partial repayment of certain outstanding convertible promissory notes.&#160;</p>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Stock Purchase Agreement with iX Biopharma Europe Limited</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On November 24, 2021, the Company entered in an exclusive license agreement
and stock purchase agreement (the &#8220;iXBEL Stock Purchase Agreement&#8221;) with iX Biopharma Europe Limited (&#8220;iXBEL&#8221;).
As consideration for the license under the license agreement, the Company paid iXBEL an upfront fee of $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20211101__20211130__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_zbhykfLuIVV3"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-11-012021-11-30_custom_IXLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">9.0</ix:nonFraction></span> million, comprised of $<span id="xdx_904_ecustom--NonrefundableCashPayment_pn5n6_c20211101__20211130__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_zmPI9QRGhjX2"><ix:nonFraction name="SEEL:NonrefundableCashPayment" contextRef="From2021-11-012021-11-30_custom_IXLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.5</ix:nonFraction></span>
million in cash and <span id="xdx_901_ecustom--Issuanceofcommonstockforlicenseacquiredshares_pip0_c20211101__20211130__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_zW4EhQQTZYA3"><ix:nonFraction name="SEEL:Issuanceofcommonstockforlicenseacquiredshares" contextRef="From2021-11-012021-11-30_custom_IXLicenseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">2,570,266</ix:nonFraction></span> restricted shares of the Company&#8217;s common stock. Pursuant to the iXBEL Stock Purchase Agreement, the
Company agreed to reimburse iXBEL for the difference in value (the &#8220;Shortfall Amount&#8221;) in the event the aggregate value of
the <span id="xdx_901_ecustom--Issuanceofcommonstockforlicenseacquiredshares_pip0_c20211101__20211130__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_znU54BEBumsl"><ix:nonFraction name="SEEL:Issuanceofcommonstockforlicenseacquiredshares" contextRef="From2021-11-012021-11-30_custom_IXLicenseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">2,570,266</ix:nonFraction></span> shares of the Company&#8217;s common stock at the time of registration and issuance was less than $<span id="xdx_90D_ecustom--MinimumStockValueOfSharesIssued_pn5n6_c20211101__20211130__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_zpmu58Wkjku9"><ix:nonFraction name="SEEL:MinimumStockValueOfSharesIssued" contextRef="From2021-11-012021-11-30_custom_IXLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.5</ix:nonFraction></span> million. The initial
fair value of this Shortfall Amount was $<span id="xdx_909_ecustom--InitialStockValuationShortfallFrom5.5MillionValue_pn5n6_c20211101__20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_z326PtoKuTtb"><ix:nonFraction name="SEEL:InitialStockValuationShortfallFrom5.5MillionValue" contextRef="From2021-11-012021-12-31_custom_IXLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.8</ix:nonFraction></span> million and in January 2022, the Company settled the Shortfall Amount by the payment of $<span id="xdx_906_ecustom--NonrefundableCashPayment_pn5n6_c20220101__20220131__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_zwDR1YtqtHq3"><ix:nonFraction name="SEEL:NonrefundableCashPayment" contextRef="From2022-01-012022-01-31_custom_IXLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.2</ix:nonFraction></span>
million in cash to iXBEL. The change in fair value of the Shortfall Amount is included in Change in fair value of derivative liability
on the Condensed Consolidated Statement of Operations and Comprehensive Loss (see Note 4).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"><p id="xdx_80D_eus-gaap--ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_zdB1HoTH1FWd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>7. License Agreements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Specific information pertaining to each of the Company&#8217;s
significant license agreements is discussed in its audited financial statements included in the Annual Report for the years ended December
31, 2021 and 2020, including their nature and purpose, the significant rights and obligations of the parties, and specific accounting
policy elections. The following represents updates for the three months ended March 31, 2022, if applicable, to the Company&#8217;s significant
license agreements:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Acquisition of Assets from Phoenixus AG f/k/a Vyera Pharmaceuticals,
AG and Turing Pharmaceuticals AG (&#8220;Vyera&#8221;)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">See Note 13 for a subsequent event related to the Vyera Purchase
Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Acquisition of License from Stuart
Weg, MD</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_907_eus-gaap--BusinessCombinationSeparatelyRecognizedTransactionsDescription_c20190801__20190831__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--WegLicenseAgreementMember_zlZ8kLOosFO2"><ix:nonNumeric contextRef="From2019-08-012019-08-31_custom_WegLicenseAgreementMember" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsDescription">On
August 29, 2019, the Company entered into an amended and restated exclusive license agreement with Stuart Weg, M.D. (the &#8220;Weg License
Agreement&#8221;), pursuant to which the Company was granted an exclusive worldwide license to certain intellectual property and regulatory
materials related to SLS-002. Under the terms of the Weg License Agreement, the Company paid an upfront license fee of $75,000 upon execution
of the agreement. The Company agreed to pay additional consideration to Dr. Weg as follows: (i) $0.1 million on January 2, 2020, (ii)
$0.125 million on January 2, 2021, and (iii) in the event the FDA has not approved an NDA for a product containing ketamine in any dosage
on or before December 31, 2021, $</ix:nonNumeric></span><span id="xdx_905_ecustom--NonrefundableCashPayment_pn5n6_c20220101__20220131__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--WegLicenseAgreementMember_zGva1W1wyXU"><ix:nonFraction name="SEEL:NonrefundableCashPayment" contextRef="From2022-01-012022-01-31_custom_WegLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction>
</span>million
on January 2, 2022. The Company paid the required $<span id="xdx_90E_ecustom--NonrefundableCashPayment_pn5n6_c20200101__20200131__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--WegLicenseAgreementMember_zL51DBdLIJ7i"><ix:nonFraction name="SEEL:NonrefundableCashPayment" contextRef="From2020-01-012020-01-31_custom_WegLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction>
</span>million
on January 2, 2020,  $<span id="xdx_90A_ecustom--NonrefundableCashPayment_pp3n6_c20210101__20210131__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--WegLicenseAgreementMember_zMzcpsO2NU67"><ix:nonFraction name="SEEL:NonrefundableCashPayment" contextRef="From2021-01-012021-01-31_custom_WegLicenseAgreementMember" format="ixt:numdotdecimal" decimals="3" scale="6" unitRef="USD">0.125</ix:nonFraction>
</span>million
on January 2, 2021 and $<span id="xdx_901_ecustom--NonrefundableCashPayment_pn5n6_c20220101__20220131__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--WegLicenseAgreementMember_zh1yTMG0Ikdc"><ix:nonFraction name="SEEL:NonrefundableCashPayment" contextRef="From2022-01-012022-01-31_custom_WegLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction>
</span>million
on January 2, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">The remaining potential regulatory and commercial milestones
are not yet considered probable, and <span id="xdx_900_eus-gaap--AssetAcquisitionContingentConsiderationLiabilityCurrent_iI_pip0_do_c20220331__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--WegLicenseAgreementMember_z7ouc9W71hJb"><ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent" contextRef="AsOf2022-03-31_custom_WegLicenseAgreementMember" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></span> other milestone payments have been accrued at March 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"><p id="xdx_80E_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zIsKhPRNio92" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>8. Accrued Expenses</b></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zLbnzvITG1p5" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Accrued expenses are comprised of the following (in
thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin-right: 0; margin-left: 0"><span><span id="xdx_8BD_z6KWwFfJHuHk">Schedule of Accrued Liabilities</span></span></p>




<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_49A_20220331_zwICjhlV6239" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_490_20211231_zmD5DtFUaTSf" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><b>March 31,</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><b>December 31,</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 64%">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 2%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 15%; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 2%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 15%; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td></tr>
  <tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCzZt1_ziFqceZp8kCd" style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Professional fees</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">190</ix:nonFraction>&#160;</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">181</ix:nonFraction>&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCzZt1_zct9paxXbfkh" style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Personnel related</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">332</ix:nonFraction>&#160;</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,303</ix:nonFraction>&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--OutsideResearchAndDevelopmentServicesCurrent_iI_pn3n3_zFJGLg2nsUn5" style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Outside research and development services</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="SEEL:OutsideResearchAndDevelopmentServicesCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,387</ix:nonFraction>&#160;</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="SEEL:OutsideResearchAndDevelopmentServicesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,219</ix:nonFraction>&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AccruedInsuranceCurrent_iI_pn3n3_zfpu6qZ5A2Kg" style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Insurance</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AccruedInsuranceCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">580</ix:nonFraction>&#160;</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-<span style="-sec-ix-hidden: xdx2ixbrl0581">&#160;</span></span></td></tr>
  <tr id="xdx_40B_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzZt1_zVwREZNxc5Fc" style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Other</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">60</ix:nonFraction>&#160;</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25</ix:nonFraction>&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzZt1_ztGJO0fQsEb3" style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;&#160;&#160;&#160; Accrued expenses, net</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,549</ix:nonFraction>&#160;</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,728</ix:nonFraction>&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zJtCCx3fxOm9" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="font-size: 9pt; text-align: center; width: 100%">&#160;11</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify"><b><i>&#160;</i></b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_808_eus-gaap--DebtDisclosureTextBlock_zLtfGH8Xgij3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>9. Debt</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"></p><p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>Convertible Notes</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>November 2021 and December 2021 Convertible Notes and Private Placement</i></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_904_eus-gaap--LongTermDebtDescription_c20211101__20211130__us-gaap--DebtInstrumentAxis__custom--November2021LindSecuritiesPurchaseAgreementMember_zfcTsRffSNl3"><ix:nonNumeric contextRef="From2021-11-012021-11-30_custom_November2021LindSecuritiesPurchaseAgreementMember" name="us-gaap:LongTermDebtDescription">On November 23, 2021, the Company entered into a Securities Purchase Agreement
(the &#8220;2021 Lind Securities Purchase Agreement&#8221;) with Lind Global Asset Management V, LLC (&#8220;Lind V&#8221;) pursuant
to which, among other things, on November 23, 2021 (the &#8220;Closing Date&#8221;), the Company issued and sold to Lind V, in a private
placement transaction (the &#8220;Private Placement&#8221;), in exchange for the payment by Lind V of $20.0 million, (i) a convertible
promissory note (the &#8220;2021 Note&#8221;) in an aggregate principal amount of $22.0 million (the &#8220;Principal Amount&#8221;),
which will bear no interest until the first anniversary of the issuance of the 2021 Note and will thereafter bear interest at a rate
of 5% per annum, and mature on November 23, 2024 (the &#8220;Maturity Date&#8221;), and (ii) 534,759 shares of Company common stock.</ix:nonNumeric></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_904_eus-gaap--LongTermDebtDescription_c20221101__20221130__us-gaap--DebtInstrumentAxis__custom--FirstAnniversaryOfNovember2021LindSecuritiesPurchaseAgreementMember_zEV0cSbbk5d6"><ix:nonNumeric contextRef="From2022-11-012022-11-30_custom_FirstAnniversaryOfNovember2021LindSecuritiesPurchaseAgreementMember" name="us-gaap:LongTermDebtDescription">At the first anniversary of the Closing Date, the Company shall
have the option, at its sole discretion, to issue to Lind V a convertible promissory note (the &#8220;Second Note&#8221;) in the principal
amount of $11.0 million in exchange for the payment by Lind V of $10.0 million. At the earlier of (i) the two-year anniversary of the
Closing Date, or (ii) the successful readout for SLS-005 in ALS, and subject to the mutual agreement of the Company and Lind V, the Company
shall issue to Lind V a convertible promissory note (the &#8220;Third Note&#8221;) in the principal amount of $11.0 million in exchange
for the payment by Lind V of $10.0 million. In the event of the filing of a new drug application with the U.S. Food &amp; Drug Administration
for either SLS-002 or SLS-005, and subject to the mutual agreement of the Company and Lind V, the Company shall issue to Lind V a convertible
promissory note (the &#8220;Fourth Note&#8221;) in the principal amount of $11.0 million in exchange for the payment by Lind V of $10.0
million. The Second Note, the Third Note and the Fourth Note, if issued, would be in substantially the same form as the 2021 Note.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_90C_eus-gaap--LongTermDebtDescription_c20220823__20241123__us-gaap--DebtInstrumentAxis__custom--August232022ThruMaturityNovember2021LindSecuritiesPurchaseAgreementMember_zE0qTVToKwsc"><ix:nonNumeric contextRef="From2022-08-232024-11-23_custom_August232022ThruMaturityNovember2021LindSecuritiesPurchaseAgreementMember" name="us-gaap:LongTermDebtDescription">At any time following August 23, 2022, from time to time and before the
Maturity Date, Lind V shall have the option to convert any portion of the then-outstanding Principal Amount of the 2021 Note into shares
of Common Stock at a price per share of $6.00, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar
transactions (the &#8220;Conversion Price&#8221;). At any time prior August 23, 2022, the Company shall have the right to prepay, in whole
or in part (exercisable by the Company at any time or from time to time during such period), up to an aggregate of $14.7 million of the
outstanding Principal Amount of the 2021 Note with no penalty. If the Company does not prepay any amounts of the 2021 Note prior to August
23, 2022 then, commencing August 23, 2022, the Company shall have the right to prepay, in whole or in part (exercisable by the Company
at any time or from time to time prior to the Maturity Date), up to the full remaining Principal Amount of the 2021 Note with no penalty;
however, if the Company exercises such prepayment right, Lind V will have the option to convert up to thirty-three and one-third percent
(33 1/3%) of the amount that the Company elects to prepay at the Conversion Price. If the Company prepays any amounts of the 2021 Note
prior to August 23, 2022 then, commencing November 23, 2022, the Company shall not have the right to prepay any amounts of the 2021 Note
between August 23, 2022 to November 23, 2022 and, commencing November 23, 2022, the Company shall have the right to prepay, in whole or
in part (exercisable by the Company at any time or from time to time prior to the Maturity Date) up to the full remaining Principal Amount
of the 2021 Note with no penalty; however, if the Company exercises such prepayment right, Lind V will have the option to convert up to
thirty-three and one-third percent (33 1/3%) of the amount that the Company elects to prepay at the Conversion Price.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Subject to certain exceptions, the Company will be required to direct proceeds
from any subsequent debt financings (including subordinated debt, convertible debt or mandatorily redeemable preferred stock but other
than purchase money debt or capital lease obligations or other indebtedness incurred in the ordinary course of business) to repay the
2021 Notes, unless waived by Lind V in advance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_90A_eus-gaap--LongTermDebtDescription_c20221123__20241124__us-gaap--DebtInstrumentAxis__custom--AmortizeNovember2021LindSecuritiesPurchaseAgreementMember_zJDYkPnrmip5"><ix:nonNumeric contextRef="From2022-11-232024-11-24_custom_AmortizeNovember2021LindSecuritiesPurchaseAgreementMember" name="us-gaap:LongTermDebtDescription">Beginning on November 23, 2022, the 2021 Note will amortize in twenty-four
monthly installments equal to the quotient of (i) the then-outstanding Principal Amount of the 2021 Note, divided by (ii) the number of
months remaining until the Maturity Date. All amortization payments shall be payable, at the Company&#8217;s sole option, in cash, shares
of Common Stock or a combination of both. In addition, commencing on the last business day of the first month following November 23, 2022,
the Company will pay, on a monthly basis, all interest that has accrued and remains unpaid on the then-outstanding Principal Amount of
the 2021 Note. Any portion of an amortization payment or interest payment that is paid in shares of Common Stock shall be priced at 90%
of the average of the five lowest daily volume weighted average prices of the Common Stock during the 20 trading days prior to the date
of issuance of the shares. If, after the first amortization payment, the Company elects to make any amortization payments in cash, the
Company shall pay a 5% premium on each cash payment. In conjunction with the 2021 Lind Securities Purchase Agreement and the 2021 Note,
on the Closing Date, the Company and Lind V entered into a security agreement, which provides Lind V with a first priority lien on the
Company&#8217;s assets and properties.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="font-size: 9pt; text-align: center; width: 100%">&#160;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_90F_eus-gaap--LongTermDebtDescription_c20211201__20211231__us-gaap--DebtInstrumentAxis__custom--December2021SPAsMember_zJXT89faIVld"><ix:nonNumeric contextRef="From2021-12-012021-12-31_custom_December2021SPAsMember" name="us-gaap:LongTermDebtDescription">On December 2, 2021, the Company entered into two separate securities purchase
agreements with certain accredited investors on substantially the same terms as the 2021 Lind Securities Purchase Agreement, pursuant
to which the Company sold, in private placement transactions, in exchange for the payment by the accredited investors of an aggregate
of $201,534, (i) convertible promissory notes in an aggregate principal amount of $221,688, which will bear no interest and mature on
December 2, 2024, and (ii) an aggregate of 5,388 shares of its common stock. These notes have substantially the same terms as the 2021
Note.</ix:nonNumeric></span></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">During the year ended December 31, 2021, the Company received
aggregate gross proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromConvertibleDebt_pn5n6_c20211201__20211231__us-gaap--DebtInstrumentAxis__custom--December2021SPAsMember_zwqXfHkzQ9i7"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2021-12-012021-12-31_custom_December2021SPAsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">20.2</ix:nonFraction></span>
million from the convertible note offerings. The Company elected to account for these notes under the fair value option. At time of
issuance, the Company recorded a liability of $<span id="xdx_90F_eus-gaap--ConvertibleSubordinatedDebt_iI_pn5n6_c20211202__us-gaap--DebtInstrumentAxis__custom--December2021SPAsMember_z9w6y8VcH4hc"><ix:nonFraction name="us-gaap:ConvertibleSubordinatedDebt" contextRef="AsOf2021-12-02_custom_December2021SPAsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">19.2</ix:nonFraction></span>
million, which was determined to be the fair value at time of issuance. As of December 31, 2021, the Company recognized a $<span id="xdx_90A_ecustom--GainLossInFairValueOfConvertibleNotes_pn5n6_c20211201__20211231__us-gaap--DebtInstrumentAxis__custom--December2021SPAsMember_zRSD8v8CC3y9"><ix:nonFraction name="SEEL:GainLossInFairValueOfConvertibleNotes" contextRef="From2021-12-012021-12-31_custom_December2021SPAsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span>
million gain on change in fair value of convertible notes, recognizing a total convertible note liability of $<span id="xdx_907_eus-gaap--ConvertibleSubordinatedDebt_iI_pn5n6_c20211231__us-gaap--DebtInstrumentAxis__custom--December2021SPAsMember_zVMjFwqdvbzl"><ix:nonFraction name="us-gaap:ConvertibleSubordinatedDebt" contextRef="AsOf2021-12-31_custom_December2021SPAsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">18.9</ix:nonFraction></span>
million. During the three months ended March 31, 2022, the Company recognized a
$<span id="xdx_90C_ecustom--GainLossInFairValueOfConvertibleNotes_pn5n6_c20220101__20220331__us-gaap--DebtInstrumentAxis__custom--December2021SPAsMember_zq7yOD8Ou9V3"><ix:nonFraction name="SEEL:GainLossInFairValueOfConvertibleNotes" contextRef="From2022-01-012022-03-31_custom_December2021SPAsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million loss on change in fair value of convertible notes, recognizing a total convertible note liability of $<span id="xdx_90B_eus-gaap--LongTermDebtFairValue_iI_pn5n6_c20220331__us-gaap--DebtInstrumentAxis__custom--December2021SPAsMember_zxYdvSHkg5w4"><ix:nonFraction name="us-gaap:LongTermDebtFairValue" contextRef="AsOf2022-03-31_custom_December2021SPAsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">19.2</ix:nonFraction></span> million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of March 31, 2022, the principal contractual balance
of the convertible notes totaled $<span id="xdx_907_eus-gaap--ConvertibleNotesPayable_iI_pn5n6_c20220331__us-gaap--DebtInstrumentAxis__custom--December2021SPAsMember_zUMGnrQcH5Hh"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2022-03-31_custom_December2021SPAsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">22.2</ix:nonFraction></span> million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>December 2020 Convertible Note and Private Placement</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 20pt; text-indent: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><span id="xdx_901_eus-gaap--LongTermDebtDescription_c20201201__20201231__us-gaap--DebtInstrumentAxis__custom--LindSecuritiesPurchaseAgreementMember_zM4f5isFyqNg"><ix:nonNumeric contextRef="From2020-12-012020-12-31_custom_LindSecuritiesPurchaseAgreementMember" name="us-gaap:LongTermDebtDescription">On
December 11, 2020, the Company entered into a Securities Purchase Agreement (the &#8220;2020 Lind Securities Purchase
Agreement&#8221;) with Lind Global Asset Management II, LLC (the &#8220;Investor&#8221;) pursuant to which, among other things, on
December 11, 2020, the Company issued and sold to the Investor, in a private placement transaction, in exchange for the payment by
the Investor of $10,000,000, (1) a convertible promissory note (the &#8220;2020 Note&#8221;) in an aggregate principal amount of
$12,000,000 (the &#8220;Principal Amount&#8221;), which did not bear interest and was to mature on December 11, 2022 (the
&#8220;Maturity Date&#8221;), and (2) 975,000 shares of the Company&#8217;s common stock. At any time following June 11, 2021, and
from time to time before the Maturity Date, the Investor had the option to convert any portion of the then-outstanding Principal
Amount of the Note into shares of common stock at a price per share of $1.60, subject to adjustment for stock splits, reverse stock
splits, stock dividends and similar transactions. Prior to June 11, 2021, the Company had the right to prepay up to sixty-six and
two-thirds percent (66 2/3%) of the then-outstanding Principal Amount of the 2020 Note with no penalty. Subject to certain
exceptions, the Company was required to direct proceeds from any subsequent debt financings (including subordinated debt,
convertible debt or mandatorily redeemable preferred stock but other than purchase money debt or capital lease obligations or other
indebtedness incurred in the ordinary course of business) to repay the 2020 Note, unless waived by the Investor in advance. The 2020
Note began amortizing in June 2021 and was to amortize in eighteen monthly installments equal to the quotient of (i) the
then-outstanding Principal Amount of the 2020 Note, divided by (ii) the number of months remaining until the Maturity Date. All
amortization payments were to be payable solely in cash, plus a 2% premium. During the first half of 2021, the Company made certain
repayments on the outstanding principal balance of the convertible notes. On June 14, 2021, the Company and the Investor entered
into an Acknowledgment and Termination Agreement, pursuant to which the Company agreed to issue to the Investor an aggregate of
406,250 additional shares of its common stock (the &#8220;Lind Shares&#8221;) and to pay the Investor the remaining principal amount
of $790,804 (the &#8220;Final Payment&#8221;) in full satisfaction of the Company&#8217;s  remaining obligations to the Investor
under the 2020 Note. The Company issued the Lind Shares and made the Final Payment to the Investor, and the 2020 Lind Securities
Purchase Agreement and the 2020 Note terminated, effective June 15, 2021.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_902_eus-gaap--LongTermDebtDescription_c20201201__20201231__us-gaap--DebtInstrumentAxis__custom--December17SPAsMember_zNaztLWBB4i4"><ix:nonNumeric contextRef="From2020-12-012020-12-31_custom_December17SPAsMember" name="us-gaap:LongTermDebtDescription">On December 17, 2020, the Company entered into three separate securities
purchase agreements with certain accredited investors on substantially the same terms as the Lind Securities Purchase Agreement (the &#8220;December
17 SPAs&#8221;), pursuant to which the Company sold, in private placement transactions, in exchange for the payment by the accredited
investors of an aggregate of $1,138,023, (1) convertible promissory notes (the &#8220;December 17 Notes&#8221;) in an aggregate principal
amount of $1,365,628, which did not bear interest and were to mature on December 17, 2022, and (2) an aggregate of 110,956 shares of its
common stock. On December 18, 2020, the Company entered into an additional securities purchase agreement with
an accredited investor on substantially the same terms as the Lind Securities Purchase Agreement (the &#8220;December 18 SPA&#8221; and,
together with the December 17 SPAs, the &#34;Subsequent Securities Purchase Agreements&#34;), pursuant to which the Company sold, in
a private placement transaction, in exchange for the payment by the accredited investor of $269,373, (1) a convertible promissory note
in an aggregate principal amount of $323,247, which did not bear interest and was to mature on December 18, 2022 (the &#8220;December
18 Note&#8221; and, together with the December 17 Notes, the &#8220;Subsequent Notes&#8221;), and (2) 26,263 shares of the Company&#8217;s
common stock. The Subsequent Securities Purchase Agreements had substantially the same terms as the Lind Securities Purchase Agreement,
and the Subsequent Notes had substantially the same terms as the Note. During the first half of 2021, the Company made certain repayments
on the outstanding principal balance of the convertible notes. On July 7, 2021, the Company and the holder of the December 18 Note (the
&#8220;December 18 Note Holder&#8221;) entered into an Acknowledgement and Termination Agreement, pursuant to which: (i) the December
18 Note Holder agreed to return to the Company $42,777 in cash (the &#8220;Repayment&#8221;) previously paid by the Company to the December
18 Note Holder as a payment against the Company&#8217;s obligations under the December 18 Note, and (ii) the Company agreed to issue to
the December 18 Note Holder an aggregate of 43,664 additional shares of its common stock (the &#8220;December 18 Note Shares&#8221;) in
full satisfaction of the Company&#8217;s remaining obligations to the December 18 Note Holder under the December 18 Note. The December 18 Note Holder
paid the Company the Repayment and the Company issued the December Note Shares, and the December 18 SPA and the December 18 Note terminated,
effective July 7, 2021.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="font-size: 9pt; text-align: center; width: 100%">&#160;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company received aggregate net proceeds of $10.9 million from
the convertible note offering, net of $0.5 million of issuance costs. The total gross proceeds were allocated to the convertible notes
and common stock issued under the agreements based on their relative fair values. Due to the principal payments made during the year,
the Company remeasured the beneficial conversion feature discount at each payment date and recorded a loss on extinguishment of debt
of approximately $1.0 million during the year ended December 31, 2021 as well as a reduction in additional paid-in capital of $1.5 million
as of December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">During the year ended December 31, 2021,
the Company paid approximately $<span id="xdx_905_eus-gaap--RepaymentsOfConvertibleDebt_pn5n6_c20211201__20211231__us-gaap--DebtInstrumentAxis__custom--December17SPAsMember_zBKJoERIgJc5"><ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="From2021-12-012021-12-31_custom_December17SPAsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">13.6</ix:nonFraction></span> million in principal payments on the outstanding convertible notes and issued an aggregate of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pip0_c20211201__20211231__us-gaap--DebtInstrumentAxis__custom--December17SPAsMember_z4zmjDAAiCB7"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2021-12-012021-12-31_custom_December17SPAsMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">475,315</ix:nonFraction></span>
shares of its common stock upon conversion of the convertible notes, and <span id="xdx_90F_eus-gaap--LongTermDebt_iI_dn_c20211231__us-gaap--DebtInstrumentAxis__custom--December17SPAsMember_z5ixQC4kG0Q3"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="AsOf2021-12-31_custom_December17SPAsMember" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">none</ix:nonFraction></span> of the 2020 convertible notes remain outstanding as of December
31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 0; background-color: white">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_80C_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zxvBJE321Eaa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>10. Stockholders&#8217; Equity</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Preferred Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company is authorized to issue <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_pip0_c20220331_zofzEj2Uaoak" title="Preferred stock, authorized (in shares)"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">10,000,000</ix:nonFraction></span> shares of preferred
stock, par value $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pip0_c20220331_zs7lLNcS5yD2" title="Preferred stock, per value (in usd per share)"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.001</ix:nonFraction></span>. <span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20220331_zZaGp0Oct1Ej" title="Preferred stock, outstanding (in shares)"><span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20211231_zfGV5eNrFRGl" title="Preferred stock, outstanding (in shares)"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-03-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">No</ix:nonFraction></ix:nonFraction></span></span> shares of preferred stock were outstanding as of March 31, 2022 or December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company has authorized <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_pp0p0_c20220331_zQX2U7gbKoAc" title="Common stock, authorized (in shares)"><span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_pp0p0_c20211231_zcwqnL9otRod"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">240,000,000</ix:nonFraction></ix:nonFraction></span></span> shares of common stock as of March 31, 2022 and December 31, 2021. <span id="xdx_908_eus-gaap--CommonStockVotingRights_c20220101__20220331_zrNC2Xv2lvob" title="Common stock voting right"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="us-gaap:CommonStockVotingRights">Each share of common stock is entitled to
one voting right</ix:nonNumeric></span>. Common stock owners are entitled to dividends when funds are legally available and declared by the Board of
Directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify; text-indent: -0.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify; text-indent: -0.5pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>September 2020 Warrants</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20200901__20200930__us-gaap--ClassOfWarrantOrRightAxis__custom--September2020WarrantsMember_zKPp0HrdPCD2" title="Warrant description"> <ix:nonNumeric contextRef="From2020-09-012020-09-30_custom_September2020WarrantsMember" name="us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees">On September 4, 2020, the Company entered into a securities purchase agreement
with certain institutional investors pursuant to which the Company issued and sold an aggregate of 8,865,000 shares of common stock in
a registered direct offering and issued warrants to purchase up to 6,648,750 shares of common stock in a concurrent private placement
(the &#8220;September 2020 Warrants&#8221;). The September 2020 Warrants are initially exercisable for
<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20200901__20200930__us-gaap--StatementClassOfStockAxis__custom--September2020WarrantsMember_zx2PxpEuEDol" title="Number of shares of common stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-09-012020-09-30_custom_September2020WarrantsMember654121703" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">6,648,750</ix:nonFraction></span> shares of common stock at an exercise price per share equal to $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20200904__us-gaap--ClassOfWarrantOrRightAxis__custom--September2020WarrantsMember_zVxOUsZ4SiWb"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-09-04_custom_September2020WarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.84</ix:nonFraction></span>. The September 2020 Warrants became exercisable beginning
on <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20210101__20210930__us-gaap--ClassOfWarrantOrRightAxis__custom--September2020WarrantsMember_z0AFn5jPTCFb" title="Date on which warrants became exercisable"><ix:nonNumeric contextRef="From2021-01-012021-09-30_custom_September2020WarrantsMember" format="ixt:datemonthdayyearen" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">March 9, 2021</ix:nonNumeric></span> and will expire on March 9, 2026.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">During the three months ended March 31, 2022 and 2021, September 2020
Warrants were exercised for <span id="xdx_900_ecustom--NumberofWarrantsExercisedDuringPeriod_pip0_uShares_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--September2020WarrantsMember_z89QZtTqhhT3"><ix:nonFraction name="SEEL:NumberofWarrantsExercisedDuringPeriod" contextRef="From2022-01-012022-03-31_custom_September2020WarrantsMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">0</ix:nonFraction></span> and <span id="xdx_900_ecustom--NumberofWarrantsExercisedDuringPeriod_pn5n6_uShares_c20210101__20210331__us-gaap--ClassOfWarrantOrRightAxis__custom--September2020WarrantsMember_z6S3SLFSX7ok" title="Number of warrants exercised"><ix:nonFraction name="SEEL:NumberofWarrantsExercisedDuringPeriod" contextRef="From2021-01-012021-03-31_custom_September2020WarrantsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="Shares">4.7</ix:nonFraction></span>
million shares of common stock, respectively, for approximately $<span id="xdx_904_eus-gaap--ProceedsFromWarrantExercises_pp0p0_uUSD_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--September2020WarrantsMember_zX5GqS2Y2ra8"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2022-01-012022-03-31_custom_September2020WarrantsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_90F_eus-gaap--ProceedsFromWarrantExercises_pn5n6_uUSD_c20210101__20210331__us-gaap--ClassOfWarrantOrRightAxis__custom--September2020WarrantsMember_zLEyWQ58N3Dd" title="Proceeds from exercise of warrants"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2021-01-012021-03-31_custom_September2020WarrantsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.9</ix:nonFraction></span>
million, respectively. As of March 31, 2022, September 2020 Warrants exercisable for <span id="xdx_901_ecustom--WarrantsExercisable_iI_pip0_c20220331__us-gaap--StatementClassOfStockAxis__custom--September2020WarrantsMember_z5BldYmwOLN4" title="Warrants exercisable as of March 31, 2022"><ix:nonFraction name="SEEL:WarrantsExercisable" contextRef="AsOf2022-03-31_custom_September2020WarrantsMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">1.0</ix:nonFraction> million</span>
shares of common stock remain outstanding at an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--September2020WarrantsMember_zjMomzuXBcq8"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-03-31_custom_September2020WarrantsMember654121843" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.84</ix:nonFraction> </span>per
share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>August 2019 Warrants</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20190801__20190831__us-gaap--ClassOfWarrantOrRightAxis__custom--August2019WarrantsMember_z4gydDtfCY6a" title="Warrant description"><ix:nonNumeric contextRef="From2019-08-012019-08-31_custom_August2019WarrantsMember" name="us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees">On August 23, 2019, the Company entered into a securities
purchase agreement with certain institutional investors pursuant to which the Company issued and sold an aggregate of <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20190801__20190831__us-gaap--StatementClassOfStockAxis__custom--August232019Member_zhtMha9qEnSe" title="Number of shares of common stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2019-08-012019-08-31_custom_August232019Member" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">4,475,000</ix:nonFraction></span> shares
of common stock in a registered direct offering and issued warrants to purchase up to 2,237,500 shares of common stock in a concurrent
private placement (the &#8220;August 2019 Warrants&#8221;). The August 2019 Warrants were initially exercisable for 2,237,500 shares of
common stock at an exercise price per share equal to $1.78. The August 2019 Warrants became exercisable beginning on <span id="xdx_903_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--August2019WarrantsMember_zEZJfToIzTLf" title="Date on which warrants became exercisable"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_August2019WarrantsMember" format="ixt:datemonthdayyearen" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">February 27, 2020</ix:nonNumeric></span>
and will expire on August 28, 2023.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">During the three months ended March 31, 2022 and 2021, August 2019
Warrants for <span id="xdx_903_ecustom--NumberofWarrantsExercisedDuringPeriod_pip0_uShares_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--August2019WarrantsMember_zxOn2jkWOai5"><ix:nonFraction name="SEEL:NumberofWarrantsExercisedDuringPeriod" contextRef="From2022-01-012022-03-31_custom_August2019WarrantsMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">0</ix:nonFraction></span> and <span id="xdx_901_ecustom--NumberofWarrantsExercisedDuringPeriod_pin6_uShares_c20210101__20210331__us-gaap--ClassOfWarrantOrRightAxis__custom--August2019WarrantsMember_z7sq2VrYAiU4" title="Number of warrants exercised"><ix:nonFraction name="SEEL:NumberofWarrantsExercisedDuringPeriod" contextRef="From2021-01-012021-03-31_custom_August2019WarrantsMember" format="ixt:numdotdecimal" decimals="INF" scale="6" unitRef="Shares">1.0</ix:nonFraction></span>
million shares of common stock were exercised for approximately $<span id="xdx_90E_eus-gaap--ProceedsFromWarrantExercises_pip0_uUSD_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--August2019WarrantsMember_zKPDOYffFBM6"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2022-01-012022-03-31_custom_August2019WarrantsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--ProceedsFromWarrantExercises_pin6_uUSD_c20210101__20210331__us-gaap--ClassOfWarrantOrRightAxis__custom--August2019WarrantsMember_zt8cfvIKzRyc" title="Proceeds from exercise of warrants"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2021-01-012021-03-31_custom_August2019WarrantsMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">1.8</ix:nonFraction></span>
million, respectively. As of March 31, 2022, August 2019 Warrants exercisable for <span id="xdx_906_ecustom--WarrantsExercisable_iI_pip0_c20220331__us-gaap--StatementClassOfStockAxis__custom--August2019WarrantsMember_zaOf3Z0WsHpa" title="Warrants exercisable as of June 30, 2021"><ix:nonFraction name="SEEL:WarrantsExercisable" contextRef="AsOf2022-03-31_custom_August2019WarrantsMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">900,000</ix:nonFraction></span>
shares of common stock remain outstanding at an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--August2019WarrantsMember_zPuFwVKpImsg"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-03-31_custom_August2019WarrantsMember654121984" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.78</ix:nonFraction> </span>per
share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="font-size: 9pt; text-align: center; width: 100%">&#160;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Series A Warrants</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20210101__20210930__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zEpmqsmW0VWe" title="Warrant description">
<ix:nonNumeric contextRef="From2021-01-012021-09-30_custom_SeriesAWarrantsMember" name="us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees">On January 24, 2019, STI and the Company closed a private placement with certain accredited investors pursuant to which, among other
things, the Company issued warrants representing the right to acquire 1,463,519 shares of common stock (the &#8220;Series A
Warrants&#8221;). The Series A Warrants were initially exercisable for 1,463,519 shares of common stock at an exercise price per
share equal to $4.15, which was adjusted several times pursuant to the terms thereof to 3,629,023 shares of common stock at an
exercise price per share equal to $0.2957 per share. The most recent adjustment to the exercise price (from $0.60 to $0.2957 per
share) occurred during the three months ended September 30, 2020 as a result of the announcement of the registered direct offering
of 8,865,000 shares of common stock in September 2020. The Series A Warrants were immediately exercisable upon issuance and will expire
on January 31, 2024.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt">During the three months ended March 31, 2022 and 2021,
Series A Warrants for <span id="xdx_901_ecustom--NumberofWarrantsExercisedDuringPeriod_pip0_uShares_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zc2QaF5zrXrj" style="background-color: White"><ix:nonFraction name="SEEL:NumberofWarrantsExercisedDuringPeriod" contextRef="From2022-01-012022-03-31_custom_SeriesAWarrantsMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">0</ix:nonFraction> </span><span style="background-color: White">and <span id="xdx_90D_ecustom--NumberofWarrantsExercisedDuringPeriod_pn5n6_uShares_c20210101__20210331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zMIEgJBHlSb6"><ix:nonFraction name="SEEL:NumberofWarrantsExercisedDuringPeriod" contextRef="From2021-01-012021-03-31_custom_SeriesAWarrantsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="Shares">0.5</ix:nonFraction>
million </span></span><span style="background-color: White">shares of common stock, respectively, were exercised for approximately
$<span id="xdx_903_eus-gaap--ProceedsFromWarrantExercises_pip0_uUSD_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zHamcJ2uo7e8"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2022-01-012022-03-31_custom_SeriesAWarrantsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction> </span></span><span style="background-color: White">and
$<span id="xdx_906_eus-gaap--ProceedsFromWarrantExercises_pn5n6_uUSD_c20210101__20210331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zMLeTA3ZyDXa"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2021-01-012021-03-31_custom_SeriesAWarrantsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction> </span></span><span style="background-color: White">million,
respectively. As of March 31, 2022, Series A Warrants exercisable for <span id="xdx_906_ecustom--WarrantsExercisable_iI_pn5n6_uShares_c20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_z8ygjdaLViFj"><ix:nonFraction name="SEEL:WarrantsExercisable" contextRef="AsOf2022-03-31_custom_SeriesAWarrantsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="Shares">0.3</ix:nonFraction> </span></span><span style="background-color: White">million
shares of common stock remain outstanding at an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_z3YW3fGFwEAk"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-03-31_custom_SeriesAWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.2957</ix:nonFraction> </span></span><span style="background-color: White">per
share</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zJmTqFB9NdR" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt">A summary of warrant activity during the three months ended March 31, 2022 is as follows (share amounts in thousands):</p>

<p id="xdx_8B7_zAzfrCVOkjad" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; display: none">Summary of Warrant Activity</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt">&#160;</p>

<p style="font: 9pt Sans-Serif; margin: 0 0 0 5pt; color: Red"><b>&#160;</b></p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: middle; width: 52%"></td>
    <td style="vertical-align: middle; width: 1%"></td>
    <td style="font-weight: bold; vertical-align: middle; width: 12%"></td>
    <td style="font-weight: bold; vertical-align: middle; width: 1%"></td>
    <td style="vertical-align: bottom; text-align: right; width: 1%"></td>
    <td style="vertical-align: bottom; text-align: right; width: 14%"></td>
    <td style="vertical-align: bottom; text-align: right; width: 1%"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center; width: 18%">Weighted-</td></tr>
  <tr>
    <td style="vertical-align: middle"></td>
    <td style="vertical-align: middle"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center"></td>
    <td style="vertical-align: bottom; text-align: right"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Weighted-</td>
    <td style="vertical-align: bottom; text-align: right"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Average</td></tr>
  <tr>
    <td style="vertical-align: middle"></td>
    <td style="vertical-align: middle"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center"></td>
    <td style="vertical-align: bottom; text-align: right"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Average</td>
    <td style="vertical-align: bottom; text-align: right"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Remaining</td></tr>
  <tr>
    <td style="vertical-align: middle"></td>
    <td style="vertical-align: middle"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center"></td>
    <td style="vertical-align: bottom; text-align: right"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Exercise</td>
    <td style="vertical-align: bottom; text-align: right"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Contractual Life</td></tr>
  <tr>
    <td style="vertical-align: middle"></td>
    <td style="vertical-align: middle"></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: bottom; text-align: center">Warrants</td>
    <td style="font-weight: bold; vertical-align: bottom; text-align: center"></td>
    <td style="vertical-align: bottom; text-align: right"></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center">Price</td>
    <td style="vertical-align: bottom; text-align: right"></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center">(in years)</td></tr>
  <tr style="vertical-align: middle">
    <td>Outstanding as of December 31, 2021</td>
    <td></td>
    <td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pin3_c20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zVsegwJaPjd9" title="Outstanding as of December 31, 2021" style="text-align: right; border-top-color: Black; border-top-width: 1pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2021-12-31_custom_WarrantDerivativeFinancialInstrumentsMember" format="ixt:numdotdecimal" decimals="INF" scale="3" unitRef="Shares">2,635</ix:nonFraction></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pp2p0_uUSDPShares_c20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zk5wu7yMDzS4" title="Outstanding as of December 31, 2020, weighted-average exercise price (in usd per share)" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-12-31_custom_WarrantDerivativeFinancialInstrumentsMember" format="ixt:numdotdecimal" decimals="2" scale="0" unitRef="USDPShares">4.29</ix:nonFraction></td>
    <td style="text-align: right"></td>
    <td id="xdx_98A_ecustom--ClassOfWarrantOrRightOutstandingWeightedAverageRemaingContractualLife_dtY_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zBqZIHnvaY05" title="Warrants outstanding as of December 31, 2020, weighted-average remaing contractual life (in years)" style="text-align: right"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_WarrantDerivativeFinancialInstrumentsMember" format="ixt-sec:duryear" name="SEEL:ClassOfWarrantOrRightOutstandingWeightedAverageRemaingContractualLife">2.4</ix:nonNumeric></td></tr>
  <tr style="vertical-align: middle">
    <td style="text-align: left">Issued</td>
    <td style="text-align: left"></td>
    <td id="xdx_98A_ecustom--NumberofWarrantsIssuedDuringPeriod_i01_pin3_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zkbEChDK2uW6" title="Issued" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0670">-</span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td id="xdx_984_ecustom--ClassOfWarrantOrRightIssuedExercisePriceOfWarrantsOrRights_i01_pp0p0_uUSDPShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zFkmle9m8kN3" title="Issued, warrant exercise price" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0672">-</span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td></tr>
  <tr style="vertical-align: middle">
    <td style="text-align: left">Exercised</td>
    <td style="text-align: left"></td>
    <td id="xdx_98C_ecustom--NumberofWarrantsExercisedDuringPeriod_i01_pin3_uShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zi5sOrJmTFnk" title="Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0674">-</span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td id="xdx_989_ecustom--ClassOfWarrantOrRightExercisedExercisePriceOfWarrantsOrRights_i01_pp2p0_uUSDPShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zfLLDTtuHlrf" title="Exercised, exercise price of warrants" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0676">-</span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td></tr>
  <tr style="vertical-align: middle">
    <td style="text-align: left">Cancelled</td>
    <td style="text-align: left"></td>
    <td id="xdx_98F_ecustom--NumberofWarrantsCancelledDuringPeriod_i01_pin3_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zGfA4SCT2qse" title="Cancelled" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0678">-</span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td id="xdx_98D_ecustom--ClassOfWarrantOrRightCancelledExercisePriceOfWarrantsOrRights_i01_pp0p0_uUSDPShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zgm33G3iBXg3" title="Cancelled, exercise price of warrants" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0680">-</span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td></tr>
  <tr style="vertical-align: middle">
    <td>Outstanding as of March 31, 2022</td>
    <td></td>
    <td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_pin3_c20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zBwytxpqO65h" title="Outstanding as of March 31, 2022" style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-03-31_custom_WarrantDerivativeFinancialInstrumentsMember" format="ixt:numdotdecimal" decimals="INF" scale="3" unitRef="Shares">2,635</ix:nonFraction></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_pp2p0_uUSDPShares_c20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zKOF7jshxCng" title="Outstanding as of June 30, 2021, weighted-average exercise price (in usd per share)" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-03-31_custom_WarrantDerivativeFinancialInstrumentsMember" format="ixt:numdotdecimal" decimals="2" scale="0" unitRef="USDPShares">4.29</ix:nonFraction></td>
    <td style="text-align: right"></td>
    <td id="xdx_98A_ecustom--ClassOfWarrantOrRightOutstandingEndOfPeriodWeightedAverageRemaingContractualLife_dtY_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zGziPPGfTX45" title="Warrants outstanding as of June 30, 2021, weighted-average remaing contractual life (in years)" style="text-align: right"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_WarrantDerivativeFinancialInstrumentsMember" format="ixt-sec:duryear" name="SEEL:ClassOfWarrantOrRightOutstandingEndOfPeriodWeightedAverageRemaingContractualLife">2.2</ix:nonNumeric></td></tr>
  <tr style="vertical-align: middle">
    <td>Exercisable as of March 31, 2022</td>
    <td></td>
    <td id="xdx_986_ecustom--WarrantsExercisable_iI_pin3_uShares_c20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zwWZsRDjN16d" title="Warrants exercisable as of March 31, 2022" style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="SEEL:WarrantsExercisable" contextRef="AsOf2022-03-31_custom_WarrantDerivativeFinancialInstrumentsMember" format="ixt:numdotdecimal" decimals="INF" scale="3" unitRef="Shares">2,635</ix:nonFraction></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td id="xdx_980_ecustom--ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights1_iI_pp2p0_uUSDPShares_c20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_ziAsCKdFiqkc" title="Exercisable, weighted-average exercise price (in usd per share)" style="text-align: right"><ix:nonFraction name="SEEL:ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-03-31_custom_WarrantDerivativeFinancialInstrumentsMember" format="ixt:numdotdecimal" decimals="2" scale="0" unitRef="USDPShares">4.29</ix:nonFraction></td>
    <td style="text-align: right"></td>
    <td id="xdx_98F_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageRemaingContractualLife_dtY_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zGBpwIuIP0Ue" title="Warrants exercisable as of June 30, 2021, weighted-average remaing contractual life (in years)" style="text-align: right"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_WarrantDerivativeFinancialInstrumentsMember" format="ixt-sec:duryear" name="SEEL:ClassOfWarrantOrRightExercisableWeightedAverageRemaingContractualLife">2.2</ix:nonNumeric></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AA_zJWRWtXJbfXh" style="font: 9pt Sans-Serif; margin: 0 0 0 5pt; color: Red"><b>&#160;</b></p>

<p style="font: 9pt Sans-Serif; margin: 0 0 0 5pt; color: Red"><b>&#160;</b></p>

<p style="font: 9pt Sans-Serif; margin: 0 0 0 5pt; color: Red"></p>

<p style="font: 10pt/103% Times New Roman, Times, Serif; margin: 0">The Series A Warrants were recognized as a liability at
their fair value upon issuance. The warrant liability is remeasured to the then fair value prior to their exercise or at period end for
warrants that are unexercised and the gain or loss recognized in earnings during the period.</p>

<p style="font: 10pt/103% Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/103% Times New Roman, Times, Serif; margin: 0 1.3pt 0 5pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_803_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zPxW4MSS64y6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>11. Stock-based Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zT8H60SUTzZ8"><ix:nonNumeric contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember654123531" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">The
Company has the Seelos Therapeutics, Inc. Amended and Restated 2012 Stock Long Term Incentive Plan (the &#8220;2012 Plan&#8221;), which
provides for the issuance of incentive and non-incentive stock options, restricted and unrestricted stock awards, stock unit awards and
stock appreciation rights. Options and restricted stock units granted generally vest over a period of one to four years and have a maximum
term of ten years from the date of grant. The 2012 Plan provides that an additional number of shares will automatically be added annually
to the shares authorized for issuance under the 2012 Plan on January 1st of each year commencing on January 1, 2020 and ending on (and
including) January 1, 2029. The number of shares added each year will be equal to the lesser of (a) 4% of the number of shares of common
stock issued and outstanding on a fully-diluted basis as of the close of business on the immediately preceding December 31, and (b) a
number of shares of common stock set by the Company&#8217;s board of directors on or prior to each such January 1. On January 1, 2022,
in accordance with the foregoing, an aggregate of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pn5n6_c20220101__20220131__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4ao9xz93Cyi"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2022-01-012022-01-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="Shares">4,713,637</ix:nonFraction></span> shares of common stock were added to shares authorized for issuance under
the 2012 Plan. As of March 31, 2022, an aggregate of</ix:nonNumeric> </span><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pip0_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zdQ2Sv48gtEa"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2022-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">15,817,818</ix:nonFraction>
shares of common stock were authorized under the 2012 Plan, of which </span><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pin6_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjKFhUvns2bc"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2022-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="6" unitRef="Shares">5.5</ix:nonFraction>
million shares of common stock were available for future grants. No further awards may be issued under the Seelos Therapeutics, Inc. 2016
Equity Incentive Plan (the &#34;2016 Plan&#34;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="font-size: 9pt; text-align: center; width: 100%">&#160;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20200501__20200531__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zUp64cWhap45"><ix:nonNumeric contextRef="From2020-05-012020-05-31_custom_EmployeeStockPurchasePlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">On May 15, 2020, the
Company&#8217;s stockholders approved the Company's 2020 Employee Stock Purchase Plan (the "ESPP"),
whereby qualified employees are allowed to purchase limited amounts of the Company&#8217;s common stock at the lesser of
<span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pip2_dp_uPure_c20200501__20200531__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zoJp2tYn9H46"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="From2020-05-012020-05-31_custom_EmployeeStockPurchasePlanMember" format="ixt:numdotdecimal" decimals="INF" scale="-4" unitRef="Pure">85</ix:nonFraction></span>% of the market price at the beginning or end of the offering period. The
stockholders have authorized an initial amount of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pn5n6_c20200515__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zkHegzw9MvS3"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2020-05-15_custom_EmployeeStockPurchasePlanMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="Shares">1.0</ix:nonFraction></span> million shares for purchase by employees under the ESPP. The ESPP provides
that an additional number of shares will automatically be added annually to the shares authorized for issuance under the ESPP on
January 1st of each year commencing on January 1, 2021 and ending on (and including) January 1, 2030, which amount shall be equal to
the lesser of (i) 1% of the number of shares of the Company's common stock issued and outstanding on the immediately preceding
December 31, and (ii) a number of shares of common stock set by the Company&#8217;s Board of Directors or the Compensation
Committee of the Board of Directors (the &#8220;Compensation Committee&#8221;) of the Company on
or prior to each such January 1. On January 1, 2022, the Company added <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pn5n6_c20220101__20220131__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zGH7iOhmSb3k"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2022-01-012022-01-31_custom_EmployeeStockPurchasePlanMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="Shares">1,055,004</ix:nonFraction></span> shares for purchase by employees under the ESPP.
During the three months ended March 31, 2022, the Company sold <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_pip0_c20220101__20220331__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zJcZe4FXSN0g"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="From2022-01-012022-03-31_custom_EmployeeStockPurchasePlanMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">84,078</ix:nonFraction></span> shares of common
stock under the ESPP. The compensation costs are calculated as the fair value of the <span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceDiscountOfCommonStockPercent_pip2_dp_uPure_c20220101__20220331__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zFStwj24HRXj" title="Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price Discount of Common Stock, Percent"><ix:nonFraction name="SEEL:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceDiscountOfCommonStockPercent" contextRef="From2022-01-012022-03-31_custom_EmployeeStockPurchasePlanMember" format="ixt:numdotdecimal" decimals="INF" scale="-4" unitRef="Pure">15</ix:nonFraction></span>% discount from market price and were
approximately $<span id="xdx_903_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220331__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_z1KoSrVpTl92"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-03-31_custom_EmployeeStockPurchasePlanMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">17,000</ix:nonFraction></span> for the three months ended March 31, 2022.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><span style="background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220101__20220331__us-gaap--AwardTypeAxis__custom--InducementPlanof2019Member_zawA1s8R4qkl" title="Description of share-based compensation arrangement by share-based payment award"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_InducementPlanof2019Member" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">On July 28, 2019, the Compensation Committee of the Board of Directors (the &#8220;Compensation
Committee&#8221;) of the Company adopted the Seelos Therapeutics, Inc. 2019 Inducement Plan (the &#8220;2019 Inducement Plan&#8221;),
which became effective on August 12, 2019. The 2019 Inducement Plan provides for the grant of equity-based awards in the form of stock
options, stock appreciation rights, restricted stock, unrestricted stock, stock units, including restricted stock units, performance units
and cash awards, solely to prospective employees of the Company or an affiliate of the Company provided that certain criteria are met.
Awards under the 2019 Inducement Plan may only be granted to an individual, as a material inducement to such individual to enter into
employment with the Company, who (i) has not previously been an employee or director of the Company or (ii) is rehired following a bona
fide period of non-employment with the Company. The maximum number of shares available for grant under the 2019 Inducement Plan is <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pip0_c20220331__us-gaap--AwardTypeAxis__custom--InducementPlanof2019Member_zvhJBfnRuq66"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2022-03-31_custom_InducementPlanof2019Member" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">1,000,000</ix:nonFraction></span>
shares of the Company&#8217;s common stock. The 2019 Inducement Plan is administered by the Compensation Committee and expires on August 12, 2029.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Stock options</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">During the three months ended March 31, 2022, the Company granted
<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0p0_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__custom--IncentiveStockOptionMember_zVVs6dAihFWk" title="Options granted in period"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-01-012022-03-31_custom_IncentiveStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">560,605</ix:nonFraction></span> incentive stock options and <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0p0_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__custom--NonQualifiedStockOptionsToEmployeesMember_znr2Krc0UUKa" title="Options granted in period"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-01-012022-03-31_custom_NonQualifiedStockOptionsToEmployeesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">2,299,395</ix:nonFraction></span> non-qualified stock options to employees with a weighted average exercise price per share
of $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2p0_uUSDPShares_c20220101__20220331__us-gaap--AwardTypeAxis__custom--IncentiveStockOptionMember_zOl2BrWfHUKl" title="Weighted-average exercise price per share granted in period"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-03-31_custom_IncentiveStockOptionMember" format="ixt:numdotdecimal" decimals="2" scale="0" unitRef="USDPShares">1.46</ix:nonFraction></span> and a <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_pp0p0_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__custom--IncentiveStockOptionMember_zaImMXrXhdOl" title="Term of option grant"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_IncentiveStockOptionMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">10</ix:nonNumeric></span>-year term, subject to the terms and conditions of the 2012 Plan above. The stock options are subject to time vesting
requirements. The stock options granted to employees vest <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pip2_c20220101__20220331__us-gaap--AwardTypeAxis__custom--IncentiveStockOptionMember_zx9Dyvwck5pa" title="Vesting percentage on the first anniversary"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="From2022-01-012022-03-31_custom_IncentiveStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25</ix:nonFraction></span>% on the first anniversary of the grant and monthly thereafter over the next
three years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">During the three months ended March 31, 2022, the
Company also granted <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0p0_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__custom--NonQualifiedStockOptionsToNonEmployeeDirectorsMember_z1Zwg0sFYz99"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-01-012022-03-31_custom_NonQualifiedStockOptionsToNonEmployeeDirectorsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">140,000</ix:nonFraction> </span>non-qualified
stock options to non-employee directors with a weighted average exercise price per share of $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2p0_uUSDPShares_c20220101__20220331__us-gaap--AwardTypeAxis__custom--NonQualifiedStockOptionsToNonEmployeeDirectorsMember_zp3VakZFQ9F"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-03-31_custom_NonQualifiedStockOptionsToNonEmployeeDirectorsMember" format="ixt:numdotdecimal" decimals="2" scale="0" unitRef="USDPShares">1.56</ix:nonFraction> </span>and
a <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_pp0p0_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__custom--NonQualifiedStockOptionsToNonEmployeeDirectorsMember_zFaVzYOqJVUa"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_NonQualifiedStockOptionsToNonEmployeeDirectorsMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">10</ix:nonNumeric></span>-year
term, subject to the terms and conditions of the 2012 Plan above. The stock options granted to non-employee directors vest monthly over the
<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_pp0p0_dtM_c20220101__20220331__us-gaap--AwardTypeAxis__custom--NonQualifiedStockOptionsToNonEmployeeDirectorsMember_zxzxaNj5aR9k"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_NonQualifiedStockOptionsToNonEmployeeDirectorsMember" format="ixt-sec:durmonth" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">12</ix:nonNumeric></span> months following the grant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The fair value of stock option grants are estimated on the date
of grant using the Black-Scholes option-pricing model. The Company was historically a private company and lacked sufficient company-specific
historical and implied volatility information. Therefore, it estimates its expected stock volatility based on a weighted average blend
of the historical volatility of a publicly traded set of peer companies, as well as its own historical volatility. Additionally, due to
an insufficient history with respect to stock option activity and post-vesting cancellations, the expected term assumption for employee
grants is based on a permitted simplified method, which is based on the vesting period and contractual term for each tranche of awards.
The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect for time periods approximately equal
to the expected term of the award. Expected dividend yield is zero based on the fact that the Company has never paid cash dividends and
does not expect to pay any cash dividends in the foreseeable future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">During the three months ended March 31, 2022, <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pip0_c20220101__20220331_ztCw3kiZyTyi" title="Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">6,250</ix:nonFraction></span> stock options were exercised
and <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_pip0_do_c20220101__20220331_zkHYkvCv4GW4"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2022-01-01to2022-03-31" format="ixt-sec:numwordsen" decimals="INF" scale="0" unitRef="Shares">no</ix:nonFraction></span> options were  forfeited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zXhvmmQk8jQ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following assumptions were used in determining the fair value
of the stock options granted during the three months ended March 31, 2022 and 2021:</p>

<p id="xdx_8BF_zXfcPsXzw2Jd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; display: none">Schedule of Valuation Assumptions for Stock Options</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 9pt Sans-Serif; margin: 0 0 0 4.5pt; text-align: center; color: Red"><b>&#160;</b></p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: middle">
    <td></td>
    <td style="font-size: 9pt; font-weight: bold; text-align: right"></td>
    <td style="font-size: 9pt; font-weight: bold; text-align: right"></td>
    <td colspan="4" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">Three Months Ended</td></tr>
  <tr style="vertical-align: middle">
    <td style="width: 56%"></td>
    <td style="font-size: 9pt; font-weight: bold; text-align: right; width: 1%"></td>
    <td style="text-align: right; width: 2%"></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center; width: 19%">March 31, 2022</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center; width: 19%">March 31, 2021</td></tr>
  <tr style="vertical-align: middle">
    <td>Risk-free interest rate</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: center; border-top-color: Black; border-top-width: 1pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjtVcCqUpHQ1" title="Risk-free interest rate, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember654123531" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">1.5</ix:nonFraction></span>%
    - <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYRJR2d5QdVk" title="Risk-free interest rate, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember654123531" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">1.6</ix:nonFraction></span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center; vertical-align: middle"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zzOjUAmjsxFc" title="Risk-free interest rate, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2021-01-012021-03-31_us-gaap_EmployeeStockOptionMember654123812" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.5</ix:nonFraction></span>%
    - <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgvlFJ1D99X1" title="Risk-free interest rate, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2021-01-012021-03-31_us-gaap_EmployeeStockOptionMember654123812" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.9</ix:nonFraction></span>%</td></tr>
  <tr style="vertical-align: middle">
    <td>Volatility</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: center"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip2_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztiOBv52Qkt2" title="Volatility, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember654123531" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">113</ix:nonFraction></span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center; vertical-align: middle"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pip2_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zHkgqet06Yf6" title="Volatility, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="From2021-01-012021-03-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">120</ix:nonFraction></span>%-<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pip2_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zOpmEyP1jL0f" title="Volatility, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="From2021-01-012021-03-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">125</ix:nonFraction></span>%</td></tr>
  <tr style="vertical-align: middle">
    <td>Dividend yield</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: center"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEwBPf3fS8Bg" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0744">-</span></span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zeyq7EuVL3tf" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0746">-</span></span>%</td></tr>
  <tr style="vertical-align: middle">
    <td>Expected term (years)</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: center"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zQuqEZf1Nqbg" title="Expected term (in years)"><ix:nonNumeric contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5</ix:nonNumeric></span>
    - <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zuyt1YNTp7zd" title="Expected term (in years)"><ix:nonNumeric contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zd2w1SirpE4l" title="Expected term (in years)"><ix:nonNumeric contextRef="From2021-01-012021-03-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5</ix:nonNumeric></span>
    - <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zEq8Wb9zgTbh" title="Expected term (in years)"><ix:nonNumeric contextRef="From2021-01-012021-03-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: middle">
    <td>Weighted-average fair value</td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pp2p0_uUSDPShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zSTQ5fbDjrb1" title="Weighted average fair value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="2" scale="0" unitRef="USDPShares">1.24</ix:nonFraction>
    - <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pp2p0_uUSDPShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zVxJYCH0CCqe"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="2" scale="0" unitRef="USDPShares">1.27</ix:nonFraction></span></span></td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: middle">$</td>
    <td style="text-align: center; vertical-align: middle"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pp2p0_uUSDPShares_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUyqXX23Gjzl"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2021-01-012021-03-31_us-gaap_EmployeeStockOptionMember654123812" format="ixt:numdotdecimal" decimals="2" scale="0" unitRef="USDPShares">3.62</ix:nonFraction></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
</ix:nonNumeric><p id="xdx_8A8_zYZBcd45wDAk" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="font-size: 9pt; text-align: center; width: 100%">&#160;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zHoecFH9CL2f" style="font: 10pt Times New Roman, Times, Serif; margin: 0">A summary of stock option activity during the three months ended
March 31, 2022 is as follows (share amounts in thousands):</p>

<p id="xdx_8B1_z61dgi5nD0Y" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; display: none">Summary of Stock Option Activity</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: middle; width: 50%"></td>
    <td style="vertical-align: middle; width: 1%"></td>
    <td style="font-weight: bold; vertical-align: middle; width: 10%"></td>
    <td style="vertical-align: middle; width: 1%"></td>
    <td style="vertical-align: bottom; text-align: right; width: 1%"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center; width: 10%"></td>
    <td style="vertical-align: middle; width: 1%"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center; width: 14%">Weighted-</td>
    <td style="vertical-align: middle; width: 1%"></td>
    <td style="vertical-align: bottom; text-align: right; width: 1%"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center; width: 10%"></td></tr>
  <tr>
    <td style="vertical-align: middle"></td>
    <td style="vertical-align: middle"></td>
    <td style="font-weight: bold; vertical-align: middle"></td>
    <td style="vertical-align: middle"></td>
    <td style="vertical-align: bottom; text-align: right"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Weighted-</td>
    <td style="vertical-align: middle"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Average</td>
    <td style="vertical-align: middle"></td>
    <td style="vertical-align: bottom; text-align: right"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Total</td></tr>
  <tr>
    <td style="vertical-align: middle"></td>
    <td style="vertical-align: middle"></td>
    <td style="font-weight: bold; vertical-align: middle"></td>
    <td style="vertical-align: middle"></td>
    <td style="vertical-align: bottom; text-align: right"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Average</td>
    <td style="vertical-align: middle"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Remaining</td>
    <td style="vertical-align: middle"></td>
    <td style="vertical-align: bottom; text-align: right"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Aggregate</td></tr>
  <tr>
    <td style="vertical-align: middle"></td>
    <td style="vertical-align: middle"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Stock</td>
    <td style="vertical-align: middle"></td>
    <td style="vertical-align: bottom; text-align: right"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Exercise</td>
    <td style="vertical-align: middle"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Contractual</td>
    <td style="vertical-align: middle"></td>
    <td style="vertical-align: bottom; text-align: right"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Intrinsic</td></tr>
  <tr>
    <td style="vertical-align: middle"></td>
    <td style="vertical-align: middle"></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: bottom; text-align: center">Options</td>
    <td style="vertical-align: middle"></td>
    <td style="vertical-align: bottom; text-align: right"></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center">Price</td>
    <td style="vertical-align: middle"></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center">Life (in years)</td>
    <td style="vertical-align: middle"></td>
    <td style="vertical-align: bottom; text-align: right"></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center">Value</td></tr>
  <tr style="vertical-align: middle">
    <td>Outstanding as of December 31, 2021</td>
    <td></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pin3_uShares_c20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z8DRlDoteBmd" title="Outstanding as of December 31, 2020" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="3" unitRef="Shares">7,306</ix:nonFraction></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2p0_uUSDPShares_c20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNRFCa6nzHZd" title="Outstanding, beginning of period (USD per share)" style="text-align: right; border-top-color: Black; border-top-width: 1pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="2" scale="0" unitRef="USDPShares">2.60</ix:nonFraction></td>
    <td></td>
    <td style="text-align: right; border-top-color: Black; border-top-width: 1pt"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td></tr>
  <tr style="vertical-align: middle">
    <td>Granted</td>
    <td></td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pin3_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjcI84J2YaBi" title="Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember654123531" format="ixt:numdotdecimal" decimals="INF" scale="3" unitRef="Shares">3,000</ix:nonFraction></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2p0_uUSDPShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ziUtgz9WNN99" title="Granted in period (USD per share)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember654123531" format="ixt:numdotdecimal" decimals="2" scale="0" unitRef="USDPShares">1.47</ix:nonFraction></td>
    <td></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td></tr>
  <tr style="vertical-align: middle">
    <td>Exercised</td>
    <td></td>
    <td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pin3_di_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUYz51vmAwA8" title="Exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember654123531" format="ixt:numdotdecimal" decimals="INF" scale="3" unitRef="Shares">6</ix:nonFraction>)</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmPS2631gQh6" title="Exercised in period (USD per share)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember654123531" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">1.06</ix:nonFraction></td>
    <td></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td></tr>
  <tr style="vertical-align: middle">
    <td style="text-align: left">Cancelled</td>
    <td style="text-align: left"></td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pin3_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zR6cDFUfPZ4f" title="Cancelled" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0774">-</span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_d0_uUSDPShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjgUGQ9a3OD9" title="Cancelled (USD per share)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember654123531" format="ixt:zerodash" decimals="INF" scale="0" sign="-" unitRef="USDPShares">-</ix:nonFraction></td>
    <td></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td></tr>
  <tr style="vertical-align: middle">
    <td>Outstanding as of March 31, 2022</td>
    <td></td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pin3_uShares_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zuKMgdCfnJY4" title="Outstanding as of March 31, 2022" style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="3" unitRef="Shares">10,300</ix:nonFraction></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pp2p0_uUSDPShares_c20220331_z3GPMX9yPIuc" title="Outstanding, end of period (USD per share)" style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="2" scale="0" unitRef="USDPShares">2.27</ix:nonFraction></td>
    <td></td>
    <td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zne43COO2mHl" title="Outstanding - weighted-average remaining contractual life (in years)" style="text-align: right"><ix:nonNumeric contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember654123531" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.7</ix:nonNumeric></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_uUSD_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zFOhlb7tS3V3" title="Total aggregate intrinsic value shares outstanding" style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2022-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,894</ix:nonFraction></td></tr>
  <tr style="vertical-align: middle">
    <td>Vested and expected to vest as of March 31, 2022</td>
    <td></td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pin3_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zabB3u9YKS3b" title="Vested and expected to vest, end of period (shares)" style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2022-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="3" unitRef="Shares">10,300</ix:nonFraction></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pp2p0_d0_uUSDPShares_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1gIUcwcNnGd" title="Vested and expected to vest stock, end of period (USD per share)" style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="2" scale="0" unitRef="USDPShares">2.27</ix:nonFraction></td>
    <td></td>
    <td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zeDcxxvpPvAk" title="Weighted-average remaining contractual life (in years) of vested and expected to vest stock options" style="text-align: right"><ix:nonNumeric contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember654123531" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">8.7</ix:nonNumeric></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_pn3n3_uUSD_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYGOnPpxeAr9" title="Total aggregate intrinsic value of vested or expected to vest stock options" style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="AsOf2022-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,894</ix:nonFraction></td></tr>
  <tr style="vertical-align: middle">
    <td>Exercisable as of March 31, 2022</td>
    <td></td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pin3_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1xJhUmnf5ve" title="Exercisable, end of period (shares)" style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="3" unitRef="Shares">3,085</ix:nonFraction></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pp2p0_d0_uUSDPShares_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zT2olXBumqNh" title="Exercisable, end of period (USD per share)" style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="2" scale="0" unitRef="USDPShares">3.00</ix:nonFraction></td>
    <td></td>
    <td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjVD2HF0t2Be" title="Weighted-average remaining contractual life (in years) of exercisable stock options" style="text-align: right"><ix:nonNumeric contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember654123531" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">8.1</ix:nonNumeric></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_uUSD_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQC6bN4xDEB3" title="Total aggregate intrinsic value of exercisable stock options" style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2022-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,894</ix:nonFraction></td></tr>
  </table>

<p style="font: 9pt Sans-Serif; margin: 0"></p>

</ix:nonNumeric><p id="xdx_8AF_zcrDRY3Pdsx" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The intrinsic value of options exercised during the three months ended
March 31, 2022 and 2021 was $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pn5n6_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaEw0FmMIJl3"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember654123531" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million and $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zj1hJ44u2uX6"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="From2021-01-012021-03-31_us-gaap_EmployeeStockOptionMember654123812" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>, respectively. As of March 31, 2022, unrecognized stock-option compensation expense of
$<span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zLYM7LhCg7Tk"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2022-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10.2</ix:nonFraction></span> million is expected to be realized over a weighted-average period of <span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_pid_dtY_uYears_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQ3ID0rWSzO"><ix:nonNumeric contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember654123531" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">2.6</ix:nonNumeric></span> years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Performance Stock Award</i></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_pip0_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__us-gaap--PlanNameAxis__custom--PSUtoExecutivesMember_znt4Em1nKwp8"><ix:nonNumeric contextRef="From2021-01-012021-12-31_us-gaap_PerformanceSharesMember_custom_PSUtoExecutivesMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">During the year
ended December 31, 2021, the Company&#8217;s Board of Directors awarded a performance stock unit award to the Company&#8217;s Chief Executive
Officer for <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pp0p0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__us-gaap--PlanNameAxis__custom--PSUtoExecutivesMember_zcXiSQnQOTTa"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2021-01-012021-12-31_us-gaap_PerformanceSharesMember_custom_PSUtoExecutivesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">2,400,000</ix:nonFraction></span> shares of common stock, with a grant date fair value of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pp2p0_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__us-gaap--PlanNameAxis__custom--PSUtoExecutivesMember_zlAQCD3CEaqi"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2021-01-012021-12-31_us-gaap_PerformanceSharesMember_custom_PSUtoExecutivesMember" format="ixt:numdotdecimal" decimals="2" scale="0" unitRef="USDPShares">4.31</ix:nonFraction></span> per unit. Vesting of this award was subject to the
Company achieving certain performance criteria established at the grant date and the individual fulfilling a service condition (continued
employment). As of December 31, 2021, all performance stock unit awards were unvested and three of the five performance conditions had
been satisfied. The Company recognized stock-based compensation related to this award of $<span id="xdx_904_eus-gaap--ShareBasedCompensation_pn5n6_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__us-gaap--PlanNameAxis__custom--PSUtoExecutivesMember_zIRnh2jKais5"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-12-31_us-gaap_PerformanceSharesMember_custom_PSUtoExecutivesMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.9</ix:nonFraction></span> million during the fourth quarter of 2021,
which was recorded in general and administrative expense. During the three months ended March 31, 2022, the Company and its Chief Executive
Officer entered into an agreement to cancel the performance stock unit award for no consideration. In connection with the cancellation
of the award, no replacement awards were granted or authorized. At the time of cancellation, the Company recognized the remaining compensation
expense of the three achieved milestones of $<span id="xdx_902_eus-gaap--ShareBasedCompensation_pn5n6_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__us-gaap--PlanNameAxis__custom--PSUtoExecutivesMember_zHyonyr7eJYh"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-03-31_us-gaap_PerformanceSharesMember_custom_PSUtoExecutivesMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.3</ix:nonFraction></span> million. The two remaining milestones were not deemed probable of achievement at the
time of cancellation, and <span id="xdx_907_ecustom--SharebasedPaymentArrangementNonvestedAndCanceledAwardExcludingOptionCostNotYetRecognizedAmount_iI_pn5n6_do_c20220331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__us-gaap--PlanNameAxis__custom--PSUtoExecutivesMember_z1LdYCnnz1ge" title="Share-Based Payment Arrangement, Nonvested and Canceled  Award, Excluding Option, Cost Not yet Recognized, Amount"><ix:nonFraction name="SEEL:SharebasedPaymentArrangementNonvestedAndCanceledAwardExcludingOptionCostNotYetRecognizedAmount" contextRef="AsOf2022-03-31_us-gaap_PerformanceSharesMember_custom_PSUtoExecutivesMember" format="ixt-sec:numwordsen" decimals="-5" scale="6" unitRef="USD">no</ix:nonFraction></span> compensation cost related to these milestones was recognized.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><p id="xdx_89C_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zKedatNYpX1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes the total stock-based compensation
expense resulting from share-based awards recorded in the Company&#8217;s condensed consolidated statements of operations (in thousands):</p>

<p id="xdx_8B8_zeKdjKdluhy2" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; display: none">Schedule of Stock-Based Compensation Expense</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: middle; background-color: white"></td>
    <td style="vertical-align: middle; background-color: white"></td>
    <td style="vertical-align: bottom; text-align: right"></td>
    <td colspan="4" style="font-weight: bold; vertical-align: middle; text-align: center; background-color: white">Three Months Ended</td>
    </tr>
  <tr>
    <td style="vertical-align: middle; background-color: white"></td>
    <td style="vertical-align: middle; background-color: white"></td>
    <td style="vertical-align: bottom; text-align: right"></td>
    <td colspan="4" style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white">March
    31,</td>
    </tr>
  <tr>
    <td style="vertical-align: middle; background-color: white; width: 64%"></td>
    <td style="vertical-align: middle; background-color: white; width: 2%"></td>
    <td style="vertical-align: bottom; text-align: right; width: 2%"></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; background-color: white; width: 14%">2022</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; background-color: white; width: 2%"></td>
    <td style="vertical-align: middle; border-top-color: Black; border-top-width: 1pt; background-color: white; width: 2%"></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; background-color: white; width: 14%">2021</td>
    </tr>
  <tr style="vertical-align: middle">
    <td style="background-color: white">Research and development</td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right">$</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20220101__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zXHbP0LPHD75" title="Stock-based compensation expense" style="text-align: right; border-top-color: Black; border-top-width: 1pt"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-03-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">229</ix:nonFraction></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right">$</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensation_pn3n3_c20210101__20210331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zumQzKkXYS4" title="Stock-based compensation expense" style="text-align: right; border-top-color: Black; border-top-width: 1pt"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-03-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">136</ix:nonFraction></td>
    </tr>
  <tr style="vertical-align: middle">
    <td style="background-color: white">General and administrative</td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right"></td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensation_pn3n3_c20220101__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zrYJ3d2q7vEb" title="Stock-based compensation expense" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-03-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,003</ix:nonFraction></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right"></td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensation_pn3n3_c20210101__20210331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zoTjvJL1STs" title="Stock-based compensation expense" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-03-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">569</ix:nonFraction></td>
    </tr>
  <tr style="vertical-align: middle">
    <td style="text-align: left; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white">$</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensation_pn3n3_c20220101__20220331_z581oqWEPrX7" title="Stock-based compensation expense" style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 1pt; background-color: white"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,232</ix:nonFraction></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white">$</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensation_pn3n3_c20210101__20210331_zkwVMYZ826Tj" title="Stock-based compensation expense" style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 1pt"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">705</ix:nonFraction></td>
    </tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_z8btxmdDkg6j" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_806_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_znk0rKaHgAr3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>12. Commitments and Contingencies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Leases</i></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> <span id="xdx_901_eus-gaap--LesseeOperatingLeaseDescription_c20220101__20220331__us-gaap--LeaseContractualTermAxis__custom--March2019LeaseMember_zriNh3bpV4uf"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_March2019LeaseMember" name="us-gaap:LesseeOperatingLeaseDescription">In March 2019, the Company entered into a nine-month
office space rental agreement for its headquarters in New York, New York expiring November 2019. In November 2019, the Company renewed
this rental agreement for an additional twelve-months for a base rent of approximately $9,000 per month. In November 2020, the Company
renewed this rental agreement for an additional twelve-months for a base rent of approximately $3,800 per month. In March 2021, the Company
was notified that the counterparty&#8217;s right to occupy the space at 300 Park Avenue, New York, NY was terminated, and the Company
was required to vacate by March 26, 2021. The Company vacated the premises and has advised the counterparty that the counterparty is
in breach of this rental agreement and therefore, the Company has no further obligations thereunder.</ix:nonNumeric></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="font-size: 9pt; text-align: center; width: 100%">&#160;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_90A_eus-gaap--LesseeOperatingLeaseDescription_c20220101__20220331__us-gaap--LeaseContractualTermAxis__custom--March2021LeaseMember_ziUcNfJIbdQb" title="Operating lease description"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_March2021LeaseMember" name="us-gaap:LesseeOperatingLeaseDescription">In
March 2021, the Company entered into an eighteen-month office space rental agreement for its headquarters at 300 Park Avenue, New
York, NY, expiring July 2022. The rental agreement contains a base rent of approximately $4,000 per month. <span id="xdx_90F_eus-gaap--LesseeOperatingLeaseOptionToExtend_c20220101__20220331__us-gaap--LeaseContractualTermAxis__custom--March2021LeaseMember_zWmTXmfaFl1g" title="Option to extend"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_March2021LeaseMember" name="us-gaap:LesseeOperatingLeaseOptionToExtend">This
agreement includes one or more renewal options.</ix:nonNumeric></span> At March 31, 2022, the Company has right-of-use
assets of $<span id="xdx_901_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20220331__us-gaap--LeaseContractualTermAxis__custom--March2021LeaseMember_zQC2hitgpqf" title="Operating lease right-of-use asset"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-03-31_custom_March2021LeaseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">26,000</ix:nonFraction></span> and a total lease liability for operating leases of $<span id="xdx_90F_eus-gaap--OperatingLeaseLiability_iI_pp0p0_c20220331__us-gaap--LeaseContractualTermAxis__custom--March2021LeaseMember_ze3OVgtIekhd" title="Operating lease liabilities"><span id="xdx_90D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20220331__us-gaap--LeaseContractualTermAxis__custom--March2021LeaseMember_zVlDaNdhQ1x9" title="Operating lease liabilities - current"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2022-03-31_custom_March2021LeaseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-03-31_custom_March2021LeaseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">26,000</ix:nonFraction></ix:nonFraction></span></span>, of which all
is included in current lease liabilities.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span title="Operating lease description">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Upon the commencement of the 300 Park Avenue,
New York, NY office space in March 2021, in exchange for the new operating lease liability, the Company recognized a right-of-use asset
of $<span id="xdx_90D_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20210331__us-gaap--LeaseContractualTermAxis__custom--March2021LeaseMember_zTvUV6UY4vjc"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-03-31_custom_March2021LeaseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">74,000</ix:nonFraction></span>. As March 31, 2022, the weighted-average remaining lease term of the operating lease is <span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_pp0p0_dtY_c20220331_zVN3OsRf62Xa"><ix:nonNumeric contextRef="AsOf2022-03-31" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">0.5</ix:nonNumeric></span> years, and the weighted-average
discount rate is <span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pp0p0_uPure_c20220331_zN4GUt3lI1R"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Pure">8.0</ix:nonFraction></span>%.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_zXhLn9nS7Ama" style="font: 10pt Times New Roman, Times, Serif; margin: 0">At March 31, 2022, future minimum lease payments for operating
leases with non-cancelable terms of more than one year were as follows (in thousands):</p>

<p id="xdx_8BF_z1KRk18BYi8c" style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; display: none">Schedule of future minimum operating lease payments</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 79%"></td>
    <td style="width: 2%"></td>
    <td style="width: 2%"></td>
    <td id="xdx_498_20220331_zXO3vxfsGvva" style="font-weight: bold; text-align: center; width: 17%">Operating</td></tr>
  <tr style="vertical-align: bottom">
    <td></td>
    <td></td>
    <td></td>
    <td style="border-bottom: Black 0.5pt solid; font-weight: bold; text-align: center">Leases</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_maLOLLPz53j_zrpgG7zHWwA3" style="vertical-align: bottom">
    <td>Remaining Period Ended December 31, 2022</td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27</ix:nonFraction></td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_i01TI_pn3n3_mtLOLLPz53j_zQwz4jjjjnJc" style="vertical-align: bottom">
    <td style="text-indent: 10pt">Total</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="border-top: Black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27</ix:nonFraction></td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_i01NI_pn3n3_di_maOLLzeMS_zz6HdRwECwrl" style="vertical-align: bottom">
    <td>Less present value discount</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction>)</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_mtOLLzeMS_zuijHUAWEMd6" style="vertical-align: bottom">
    <td>Operating lease liabilities</td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="border-top: Black 0.5pt solid; border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26</ix:nonFraction></td></tr>
  </table>

<p style="font: 9pt Sans-Serif; margin: 0 5.85pt 0 5pt; text-align: left; color: Red"></p>

</ix:nonNumeric><p id="xdx_8A6_zLVHyMAiaLE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">For each of the three months ended March 31, 2022 and 2021, rent expense
totaled <span style="background-color: White">$<span id="xdx_902_eus-gaap--OperatingLeaseExpense_pn5n6_c20210101__20210331_zTnyklpw4w2g"><span id="xdx_90B_eus-gaap--OperatingLeaseExpense_pn5n6_c20220101__20220331_z8svIwns85J2"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></ix:nonFraction></span>
</span></span><span style="background-color: White">million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="background-color: White">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Contractual Commitments</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company has entered into long-term agreements with certain
manufacturers and suppliers that require it to make contractual payment to these organizations. The Company expects to enter into additional
collaborative research, contract research, manufacturing, and supplier agreements in the future, which may require up-front payments and
long-term commitments of cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Litigation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of March 31, 2022, there was no material litigation against
or involving the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_803_eus-gaap--SubsequentEventsTextBlock_zcuUSist3ril" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>13. Subsequent
Events</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_90F_eus-gaap--BusinessCombinationSeparatelyRecognizedTransactionsDescription_c20220401__20220429__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zT3AHb1H6LVe"><ix:nonNumeric contextRef="From2022-04-012022-04-29_us-gaap_SubsequentEventMember" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsDescription">On April 8, 2022,
Seelos Corporation (&#8220;STI&#8221;), a wholly-owned subsidiary of the Company, and Phoenixus AG f/k/a Vyera Pharmaceuticals AG (&#8220;Vyera&#8221;),
entered into an amendment (the &#8220;Amendment&#8221;) to the Asset Purchase Agreement by and between STI and Vyera, dated March 6, 2018
(as amended by a first amendment thereto entered into on May 18, 2018, a second amendment thereto entered into on December 31, 2018, a
third amendment thereto entered into on October 15, 2019 and a fourth amendment thereto entered into on February 15, 2021, the &#8220;Vyera
Purchase Agreement&#8221;). Pursuant to the Vyera Purchase Agreement, STI acquired the assets and liabilities of Vyera related to a product
candidate currently referred to as SLS-002 (intranasal ketamine) (the &#8220;Vyera Assets&#8221;) and agreed, among other things, to make
certain development and commercialization milestone payments and royalty payments related to the Vyera Assets (the &#8220;Milestone and
Royalty Payment Obligations&#8221;) and further agreed that in the event that the Company sold, directly or indirectly, all or substantially
all of the Vyera Assets to a third party, then the Company would pay Vyera an amount equal to 4% of the net proceeds actually received
by the Company as an upfront payment in such sale (the &#8220;Change of Control Payment Obligation&#8221;).</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_902_eus-gaap--SubsequentEventDescription_c20220401__20220430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z2aZd5GJHmra"><ix:nonNumeric contextRef="From2022-04-012022-04-30_us-gaap_SubsequentEventMember" name="us-gaap:SubsequentEventDescription">Pursuant
to the Vyera Purchase Agreement, as amended by the Amendment, STI agreed to (i) make a cash payment to Vyera in the aggregate amount
of $<span id="xdx_90C_ecustom--CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement_pn5n6_c20220401__20220430__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zdTkXpwtEtlb"><ix:nonFraction name="SEEL:CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement" contextRef="From2022-04-012022-04-30_custom_AssetsfromVyeraPharmaceuticalsMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.0</ix:nonFraction></span>
million on or before April 8, 2022; (ii) issue to Vyera on or before April 11, 2022 <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20220401__20220430__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zfEH9dWjQrk4"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-04-012022-04-30_custom_AssetsfromVyeraPharmaceuticalsMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">500,000</ix:nonFraction></span>
shares of the Company&#8217;s common stock, (the &#8220;Initial Shares&#8221;); (iii) issue to Vyera on or before July 11, 2022 an
additional <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20220701__20220711__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zaysRv0Dcs62"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-07-012022-07-11_custom_AssetsfromVyeraPharmaceuticalsMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">500,000</ix:nonFraction></span>
shares of the Company&#8217;s common stock (as adjusted for stock splits, stock dividends, combinations, recapitalizations and the
like) (the &#8220;July 2022 Shares&#8221;); and (iv) issue to Vyera on or before January 11, 2023 an additional number of shares of
the Company&#8217;s common stock equal to $1.0 million divided by the volume weighted average closing price of the Company&#8217;s
common stock for the ten consecutive trading days ending on the fifth trading day prior to the applicable date of issuance of the
shares of the Company&#8217;s common stock (the &#8220;January 2023 Shares&#8221;, and together with the Cash Payment, the Initial
Shares and the July 2022 Shares, &#8220;Final Payments&#8221;). In consideration for the Final Payments, all of STI&#8217;s
contingent payment obligations under the Vyera Purchase Agreement, including the Milestone and Royalty Payment Obligations and the
Change of Control Payment Obligation, as well as all commercialization covenants of STI under the Vyera Purchase Agreement, will
terminate in full upon the date that all of the Final Payments have been made.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company paid
the $<span id="xdx_901_ecustom--CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement_pn5n6_c20220401__20220430__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z5kGY96KKRRh"><ix:nonFraction name="SEEL:CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement" contextRef="From2022-04-012022-04-30_custom_AssetsfromVyeraPharmaceuticalsMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.0</ix:nonFraction></span> million cash payment and issued the <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20220401__20220430__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zDHHdb34L2Mg"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-04-012022-04-30_custom_AssetsfromVyeraPharmaceuticalsMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">500,000</ix:nonFraction></span> Initial Shares to Vyera in April 2022.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><p id="xdx_81B_zvPSRr1dRnP9" style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt">&#160;</p>

<!-- Field: Page; Sequence: 23 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="font-size: 9pt; text-align: center; width: 100%">&#160;
    <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<table cellpadding="0" cellspacing="0" style="font: bold 10pt/103% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 5.05pt"></td><td style="width: 53.9pt"><span id="a_002"></span>ITEM 2.</td><td style="text-align: left; padding-right: 5.5pt">MANAGEMENT&#8217;S DISCUSSION AND <span style="letter-spacing: -0.2pt">ANALYSIS </span>OF
FINANCIAL CONDITION AND <span style="letter-spacing: -0.2pt">RESULTS</span> OF OPERATIONS</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify"><b>Disclosures Regarding Forward-Looking Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt">The following should be read in conjunction with the unaudited
condensed consolidated financial statements and the related notes that appear elsewhere in this report as well as in conjunction with
the Risk Factors section and in our Annual Report on Form 10- K for the year ended December 31, 2021 as filed with the United States Securities
and Exchange Commission (&#8220;SEC&#8221;) on March <span style="letter-spacing: -0.15pt">4</span>, 2022 (the &#8220;Form 10-K&#8221;).
This report and the Form 10-K include forward-looking statements made based on current management expectations pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995, as amended.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt">This report includes &#8220;forward-looking statements&#8221;
within the meaning of Section&#160;21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Those statements
include statements regarding the intent, belief or current expectations of Seelos Therapeutics, Inc. and its subsidiaries (&#8220;we,&#8221;
&#8220;us,&#8221; &#8220;our,&#8221; the &#8220;Company&#8221; or &#8220;Seelos&#8221;) and our management team. Any such forward-looking
statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ materially from
those projected in the forward-looking statements. These risks and uncertainties include but are not limited to those risks and uncertainties
set forth in Part II, Item&#160;1A of this report.&#160;In light of the significant risks and uncertainties inherent in the forward-looking
statements included in this report, the inclusion of such statements should not be regarded as a representation by us or any other person
that our objectives and plans will be achieved. Further, these forward-looking statements reflect our view only as of the date of this
report. Except as required by law, we undertake no obligations to update any forward-looking statements and we disclaim any intent to
update forward-looking statements after the date of this report to reflect subsequent developments. Accordingly, you should also carefully
consider the factors set forth in other reports or documents that we file from time to time with the SEC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt">We have common law trademark rights in the unregistered marks
&#8220;Seelos Therapeutics, Inc.,&#8221; &#8220;Seelos,&#8221; and the Seelos logo in certain jurisdictions. Solely for convenience, trademarks
and tradenames referred to in this Quarterly Report on Form 10-Q appear without the <sup>&#174;</sup> and <sup>&#8482;</sup> symbols, but
those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights
or that the applicable owner will not assert its rights, to these trademarks and tradenames.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify"><b>Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt">We are a clinical-stage biopharmaceutical company focused
on achieving efficient development of products that address significant unmet needs in Central Nervous System (&#34;CNS&#34;) disorders
and other rare disorders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 5pt"><b>Recent Developments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 5pt"><b>Impact of COVID-19</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 5pt">&#160;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 5pt">In March 2020, we began taking
precautionary measures to protect the health and safety of our employees and contractors and further assessing the actual and potential
impact of the coronavirus (&#8220;COVID-19&#8221;) pandemic on our business, financial condition and operations. COVID-19 infections have
been reported throughout the United States, along with other jurisdictions in which our suppliers, partners and collaborators operate.
In addition, COVID-19 has caused disruption and volatility in the global capital markets, and has led to an economic slowdown. Certain
national, provincial, state and local governmental authorities have issued proclamations and/or directives aimed at minimizing the spread
of COVID-19 and additional, more restrictive proclamations and/or directives may be issued in the future. Before the COVID-19 outbreak,
most of our employees worked remotely. Up until the fourth quarter of 2021, we had not experienced any significant delays with our past
or ongoing clinical trials for SLS-002, or our start up activities for clinical trials for SLS-005. Beginning in the fourth quarter of
2021 and through the issuance of this report, we have experienced a slowdown in patient enrollment primarily due to staffing issues at
our study sites related to the spike in COVID-19 cases due to the Omicron variant. However, the pandemic has not materially affected our
liquidity as we maintain our resources in the form of cash.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="font-size: 9pt; text-align: center; width: 100%">&#160;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>



<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 5pt">&#160;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">&#160;In addition, although we do not currently expect
the preventative measures taken to date to have a material adverse impact on our business for the second quarter of 2022, the
continued impact of the COVID-19 pandemic on our business, financial condition and results of operations is unknown and will depend
on future developments and risks, which are highly uncertain and cannot be predicted. These developments and risks include, among
others, the duration and severity of the COVID-19 pandemic, the emergence or spread of new COVID-19 variants, the impact on the
capital markets, the impact on our partners and the regulatory agencies that oversee our sector and any additional preventative and
protective actions that governmental authorities, or we, may implement, any of which may result in an extended period of business
disruption, including potential delays in commencing future clinical trials, or in completing enrollment for any clinical trials we
may commence or in the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or other regulatory agencies conducting in-person
inspections or accommodations for alternatives to in-person inspections. Any resulting financial impact cannot be reasonably
estimated at this time, but the COVID-19 pandemic may force us to make adjustments to our business, our plans and our timeline for
developing assets, including our programs. In addition, the pandemic is currently not anticipated to have a material adverse impact
on our business, financial condition and results of operations, including our ability to raise additional capital, although, if the
pandemic continues at its current rate into the third quarter of 2022, it could have a material adverse impact on our business. See
Part I, Item 1A, Risk Factors, for an additional discussion of risks related to COVID-19.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 5pt"><b>Business Update</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 5pt"><b>&#160;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt">Our business model is to advance multiple late-stage therapeutic
candidates with proven mechanisms of action that address large markets with unmet medical needs and for which there is a strong economic
and scientific rationale for development.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt">&#160;</p>

<p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Our product development pipeline is as follows:</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 15%; text-align: center"><span style="font-size: 10pt"><b>Product</b></span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 28%; text-align: center"><span style="font-size: 10pt"><b>Indication</b></span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 12%; text-align: center"><span style="font-size: 10pt"><b>Development
    Phase</b></span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 42%; text-align: center"><span style="font-size: 10pt"><b>Development
    Status</b></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
  <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">SLS-002<br />
  Intranasal Racemic Ketamine</span></td>
  <td><span style="font-size: 10pt">&#160;<br />
  &#160;</span></td>
  <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Acute Suicidal Ideation and Behavior (ASIB) in Major
  Depressive Disorder (MDD)</span></td>
  <td><span style="font-size: 10pt">&#160; &#160;</span></td>
  <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Phase II<br />
  &#160;</span></td>
  <td><span style="font-size: 10pt">&#160;<br />
  &#160;</span></td>
  <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Completed open-label patient enrollment and announced
  the initial topline data from Part 1 of the proof-of-concept study on May 17, 2021 and initiated enrollment of Part 2 of a registration
  directed study&#160;</span></td>
</tr>
<tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">SLS-005</span></p>
                                   <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">IV Trehalose</span></p></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Amyotrophic Lateral Sclerosis (ALS)</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Phase II/III</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">On February 28, 2022, we announced dosing of the first participants
in the registrational study; enrollment ongoing</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">&#160;Spinocerebellar Ataxia (SCA)</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">Phase IIb/III</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-size: 10pt">Startup activities ongoing; enrollment of our
    first participants expected in the second quarter of 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Sanfilippo Syndrome</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Phase II</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Obtaining natural history data</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">SLS-004</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Parkinson's Disease (PD)</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Pre-IND</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Preclinical studies ongoing</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Gene Therapy</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">SLS-006</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Parkinson's Disease (PD)</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Phase II/III</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Not in active development; considering next steps</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Partial Dopamine Agonist</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">SLS-007</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Parkinson's Disease (PD)</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Pre-IND</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Preclinical study ongoing</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Peptide Inhibitor</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt"><b>Lead Programs</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt">&#160;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt">Our lead programs are currently SLS-002 for the potential
treatment of Acute Suicidal Ideation and Behavior (&#8220;ASIB&#8221;) in patients with Major Depressive Disorder (&#8220;MDD&#8221;)
and SLS-005 for the potential treatment of Amyotrophic Lateral Sclerosis (&#8220;ALS&#8221;) and Spinocerebellar Ataxia (&#8220;SCA&#8221;).
SLS-005 for the potential treatment of Sanfilippo Syndrome currently requires additional natural history data, which is being considered.&#160;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt"></p>

<!-- Field: Page; Sequence: 25 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">20</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt">&#160;</p>


<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt"><b><span style="text-decoration: underline">SLS-002</span></b>&#160;is intranasal racemic ketamine
with two investigational new drug applications (&#8220;INDs&#8221;). The lead program is focused on the treatment of ASIB in MDD. SLS-002
was originally derived from a Javelin Pharmaceuticals, Inc./Hospira, Inc. program with 16 clinical studies involving approximately 500
subjects. SLS-002 addresses an unmet need for an efficacious drug to treat suicidality in the United States. Traditionally, anti-depressants
have been used in this setting but many of the existing treatments are known to contribute to an increased risk of suicidal thoughts in
some circumstances, and if and when they are effective, it often takes weeks for the full therapeutic effect to be manifested. We believe
there is a large opportunity in the United States and European markets for products in this space. Based on information gathered from
the databases of the Agency for Healthcare Research and Quality, there were approximately 1,000,000 visits to emergency rooms for suicide
attempts in 2013 in the United States alone. Experimental studies suggest ketamine has the potential to be a rapid, effective treatment
for refractory depression and suicidality.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt">&#160;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt">The clinical development program for SLS-002 includes
two parallel healthy volunteer studies (Phase I). We announced interim data from our Phase I study of SLS-002 during the quarterly period
ended March 31, 2020. As a result, in March 2020, we completed a Type C meeting with the FDA and received guidance to conduct a Phase
II proof of concept (&#8220;PoC&#8221;) study of SLS-002 for ASIB in patients with MDD, to support the further clinical development of
this product candidate, together with nonclinical data under development.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt">&#160;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt">As a result of the Type C meeting and the Fast Track designation
for SLS-002 for the treatment of ASIB in patients with MDD, we believe we are well positioned to pursue the FDA's expedited programs for
drug development and review.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt">&#160;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt">On June 23, 2020, we announced the final safety data from
our Phase I pharmacokinetics/pharmacodynamics study of intranasal racemic ketamine (SLS-002) as well as the planned design of a Phase
II double blind, placebo-controlled PoC study for ASIB in subjects with MDD. We initiated this PoC study in two parts: Part 1 was an open-label
study of 17 subjects, and is being followed by Part 2, which is a double blind, placebo-controlled study of approximately 120 subjects.
On January 15, 2021, we announced dosing of the first subjects in Part 1 of the PoC study. On March 5, 2021, we announced the completion
of open-label enrollment of subjects in Part 1 of the PoC study. On May 17, 2021, we announced positive topline data from Part 1 of the
POC study, the open-label cohort, of our study of SLS-002 (intranasal racemic ketamine), demonstrating a significant treatment effect
and a well-tolerated safety profile for ASIB in patients with MDD. This study enrolled 17 subjects diagnosed with MDD requiring psychiatric
hospitalization due to significant risk of suicide with a baseline score of &#8805; 28 points on the Montgomery-&#197;sberg Depression Rating
Scale (&#34;MADRS&#34;), a score of 5 or 6 on MADRS Item-10, a score of &#8805; 15 points on the Sheehan-Suicidality Tracking Scale (S-STS)
total score and a history of previous suicide attempt(s), as confirmed on the Columbia Suicide Severity Rating Scale (C-SSRS) with a history
of at least one actual attempt, or if the attempt was interrupted or aborted, is judged to have been serious in intent. SLS-002 demonstrated
a 76.5% response rate (response meaning 50% reduction from baseline) in the primary endpoint on MADRS twenty-four hours after first dose,
with a mean reduction in total score from 39.4 to 14.5 points.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt">&#160;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt">On July 6, 2021, we announced dosing of the first subject
in Part 2 of the planned registration directed study. Based on feedback from a Type C meeting with the FDA in June 2021, we are planning
to increase the subjects in Part 2 to increase the sample size and power to support a potential marketing application.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt"><b>&#160;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt"><b><span style="text-decoration: underline">SLS-005</span></b> is IV trehalose, a protein stabilizer
that crosses the blood-brain-barrier and activates autophagy and the lysosomal pathway. Based on preclinical and in vitro studies, there
is a sound scientific rationale for developing trehalose for the treatment of ALS, SCA and other indications such as Sanfilippo Syndrome.
Trehalose is a low molecular weight disaccharide (0.342 kDa) that protects against pathological processes in cells. It has been shown
to penetrate muscle and cross the blood-brain-barrier. In animal models of several diseases associated with abnormal cellular protein
aggregation, it has been shown to reduce pathological aggregation of misfolded proteins as well as to activate autophagy pathways through
the activation of Transcription Factor EB (&#34;TFEB&#34;), a key factor in lysosomal and autophagy gene expression. Activation of TFEB
is an emerging therapeutic target for a number of diseases with pathologic accumulation of storage material.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 30 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">21</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt">Trehalose 90.5 mg/mL IV solution has demonstrated promising
clinical potential in prior Phase II clinical development for oculopharyngeal muscular dystrophy (&#34;OPMD&#34;) and spinocerebellar
ataxia type 3 (&#34;SCA3&#34;), also known as Machado Joseph disease, with no significant safety signals to date and encouraging efficacy
results. Pathological accumulation of protein aggregates within cells, whether in the CNS or in muscle, eventually leads to loss of function
and ultimately cell death. Prior preclinical studies indicate that this platform has the potential to prevent mutant protein aggregation
in other devastating PolyA/PolyQ diseases.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt">&#160;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt">We own three United States patents for parenteral administration
of trehalose for patients with OPMD and SCA3, all of which are expected to expire in 2034. In addition, Orphan Drug Designation (&#34;ODD&#34;)
for OPMD and SCA3 has been secured in the United States and in the European Union (&#34;EU&#34;). In February 2019, we assumed a collaborative
agreement, turned subsequently into a research grant, with Team Sanfilippo Foundation (&#8220;TSF&#8221;), a nonprofit medical research
foundation founded by parents of children with Sanfilippo Syndrome. On April 30, 2020, we were granted ODD for SLS-005 in Sanfilippo Syndrome
from the FDA. SLS-005 was previously granted ODD from the FDA and European Medicines Agency for SCA3 and OPMD as well as Fast Track designation
for OPMD. On August 25, 2020, we were issued U.S. patent number 10,751,353 titled &#34;COMPOSITIONS AND METHODS FOR TREATING AN AGGREGATION
DISEASE OR DISORDER&#34; which relates to trehalose (SLS-005). The issued patent covers the method of use for trehalose (SLS-005) formulation
for treating a disease or disorder selected from any one of the following: spinal and bulbar muscular atrophy, dentatombral-pallidoluysian
atrophy, Pick's disease, corticobasal degeneration, progressive supranuclear palsy, frontotemporal dementia or parkinsonism linked to
chromosome 17. On May 15, 2020, we were granted Rare Pediatric Disease Designation (&#34;RPDD&#34;) for SLS-005 in Sanfilippo Syndrome
from the FDA. RPDD is an incentive program created under the Federal Food, Drug, and Cosmetic Act to encourage the development of new
therapies for the prevention and treatment of certain rare pediatric diseases. On May 27, 2021, we announced that we were granted ODD
for SLS-005 in ALS from the European Medicines Agency. In December 2020, we announced the selection of SLS-005 for the Healey ALS platform
trial led by Harvard Medical School, Massachusetts. The Healey ALS platform trial is designed to study multiple potential treatments for
ALS simultaneously. The platform trial model aims to greatly accelerate the study access, reduce costs and shorten development timelines.
On February 28, 2022, we announced the dosing of the first participants in the Healey ALS platform trial. In November 2021, we announced
the FDA acceptance of an IND and grant of Fast Track designation for SLS-005 for the treatment of SCA. Start-up activities are underway
and we expect to enroll our first participants in the second quarter of 2022.<span id="a_Hlk78899226"></span></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt">&#160;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt">Additionally, we are developing several preclinical programs,
most of which have well-defined mechanisms of action, including SLS-004, licensed from Duke University, and SLS-007, licensed from The
Regents of the University of California, for the potential treatment of Parkinson&#8217;s Disease (&#8220;PD&#8221;), SLS-008, targeted
at chronic inflammation in asthma, atopic dermatitis and orphan indications such as pediatric esophagitis, SLS-010 in narcolepsy and related
disorders and SLS-012, an injectable therapy for post-operative pain management.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt">&#160;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt"><b>Strategy and Ongoing Programs</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt">&#160;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt"><b><span style="text-decoration: underline">SLS-002:</span></b> The clinical development program
for SLS-002 includes two parallel healthy volunteer studies (Phase I). Following these Phase I studies, we completed a Type C meeting
with the FDA in March 2020 and received guidance to conduct a Phase II PoC study of SLS-002 for ASIB in subjects with MDD. We released
topline data for Part 1 of our open-label study on May 17, 2021. We initiated enrollment in Part 2 of the registration directed study
on July 6, 2021.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt">&#160;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt"><b><span style="text-decoration: underline">SLS-005</span></b> is undergoing startup activities
for clinical studies in ALS and SCA. In December 2020, we announced the selection of SLS-005 for the Healey ALS platform trial led by
Harvard Medical School, Massachusetts. The Healey ALS platform trial is designed to study multiple potential treatments for ALS simultaneously.
The platform trial model aims to greatly accelerate the study access, reduce costs, and shorten development timelines. On February 28,
2022, we announced dosing of the first participants in the Healey ALS platform trial. In November 2021, we announced the FDA acceptance
of an IND and grant of Fast Track designation for SLS-005 for the treatment of SCA. We have begun the start-up activities for a Phase
IIb/III study for SCA and expect to enroll our first participants in the second quarter of 2022. We are continuing to consider trials
in Sanfilippo Syndrome and are seeking more natural history data based on the guidance from regulatory agencies.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt">&#160;</p>

<!-- Field: Page; Sequence: 30 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">22</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt"><b><span style="text-decoration: underline">SLS-004</span></b> is an all-in-one lentiviral vector,
targeted for gene editing through DNA methylation within intron 1 of the synuclein alpha (&#34;SNCA&#34;) gene responsible for expressing
alpha-synuclein protein. SLS-004, when delivered to dopaminergic neurons derived from human induced pluripotent stem cells of a PD patient,
modified the expression on alpha-synuclein (&#34;&#945;-synuclein&#34;) and exhibited reversal of the disease-related cellular-phenotype
characteristics of the neurons. The role of mutated SNCA in PD pathogenesis and the need to maintain the normal physiological levels
of &#945;-synuclein protein emphasize the yet unmet need to develop new therapeutic strategies, such as SLS-004, targeting the regulatory
mechanism of &#945;-synuclein expression. On May 28, 2020, we announced the initiation of a preclinical study of SLS-004 in PD through
an all-in-one lentiviral vector targeting the SNCA gene. We are constructing a bimodular viral system harboring an endogenous &#945;-synuclein
transgene and inducible regulated repressive CRISPR/Cas9-unit to achieve constitutive activation and inducible suppression of PD-related
pathologies. On July 7, 2021, we announced positive in vivo data demonstrating down-regulation of SNCA mRNA and protein expression under
this study.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt"><b>&#160;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt"><b><span style="text-decoration: underline">SLS-006</span></b>&#160;is a true partial dopamine
agonist, originally developed by Wyeth Pharmaceuticals, Inc., with previous clinical studies on 340 subjects in various Phase I and Phase
II studies. It is a potent D2/D3 agonist/antagonist that has shown promising efficacy with statistical significance in Phase II studies
in early-stage PD patients and an attractive safety profile. Moreover, it has also shown synergistic effect with reduced doses of L-DOPA.
Currently, this program is not in active development and we are considering the
next steps.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt">&#160;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt"><b><span style="text-decoration: underline">SLS-007</span></b> is a rationally designed peptide-based
approach, targeting the nonamyloid component core (&#34;NACore&#34;) of &#945;-synuclein to inhibit the protein from aggregation. Recent
in vitro and cell culture research has shown that SLS-007 has the ability to stop the propagation and seeding of &#945;-synuclein aggregates.
We will evaluate the potential for in vivo delivery of SLS-007 in a PD transgenic mice model. The goal will be to establish in vivo pharmacokinetics/pharmacodynamics
and target engagement parameters of SLS-007, a family of anti-&#945;-synuclein peptidic inhibitors. On June 25, 2020, we announced the
initiation of a preclinical study of SLS-007 in PD delivered through an adeno associated viral (&#34;AAV&#34;) vector targeting the
non-amyloid component core of &#945;-synuclein. We have initiated an in vivo preclinical study of SLS-007 in rodents to assess the ability
of two specific novel peptides, S62 and S71, delivered via AAV1/2 viral vector, to protect dopaminergic function in the preformed &#945;-synuclein
fibril rodent model of PD. Production of AAV1/2 vectors encoding each of the two novel peptides incorporating hemagglutinin tags has already
been completed. This preclinical study is designed to establish the in vivo pharmacokinetic and pharmacodynamic profiles and target engagement
parameters of SLS-007.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt"><b>&#160;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt">We intend to become a leading biopharmaceutical company
focused on neurological and psychiatric disorders, including orphan indications. Our business strategy includes:</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 11pt/120% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td style="padding-right: 1pt"><span style="font-size: 10pt">advancing SLS-002 in ASIB in MDD and post-traumatic stress disorder; </span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt/120% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td style="padding-right: 1pt"><span style="font-size: 10pt">advancing SLS-004 in PD;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt/120% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td style="padding-right: 1pt"><span style="font-size: 10pt">advancing SLS-005 in ALS, SCA and Sanfilippo Syndrome;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt/120% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td style="padding-right: 1pt"><span style="font-size: 10pt">advancing SLS-007 in PD as a monotherapy; and</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt/120% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td style="padding-right: 1pt"><span style="font-size: 10pt">acquiring synergistic assets in the CNS therapy space through licensing and
partnerships.</span></td></tr></table>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt">&#160;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt">We also have two legacy product candidates: a product
candidate in the United States for the treatment of erectile dysfunction, which we in-licensed from Warner Chilcott Company, Inc., now
a subsidiary of Allergan plc; and a product candidate which has completed a Phase IIa clinical trial for the treatment of Raynaud&#8217;s
Phenomenon, secondary to scleroderma, for which we own worldwide rights.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 30 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">23</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify">Recent Developments</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: justify; background-color: white">On April 8, 2022,
Seelos Corporation (&#8220;STI&#8221;), our wholly-owned subsidiary, and Phoenixus AG f/k/a Vyera Pharmaceuticals AG (&#8220;Vyera&#8221;)
entered into an amendment (the &#8220;Amendment&#8221;) to the Asset Purchase Agreement by and between STI and Vyera, dated March 6, 2018
(as amended by a first amendment thereto entered into on May 18, 2018, a second amendment thereto entered into on December 31, 2018, a
third amendment thereto entered into on October 15, 2019 and a fourth amendment thereto entered into on February 15, 2021, the &#8220;Vyera
Purchase Agreement&#8221;). Pursuant to the Vyera Purchase Agreement, STI acquired the assets and liabilities of Vyera related to a product
candidate currently referred to as SLS-002 (intranasal ketamine) (the &#8220;Vyera Assets&#8221;) and agreed, among other things, to make
certain development and commercialization milestone payments and royalty payments related to the Vyera Assets (the &#8220;Milestone and
Royalty Payment Obligations&#8221;) and further agreed that in the event that we sold, directly or indirectly, all or substantially all
of the Vyera Assets to a third party, then we would pay Vyera an amount equal to 4% of the net proceeds actually received by us as an
upfront payment in such sale (the &#8220;Change of Control Payment Obligation&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: justify; background-color: white">Pursuant to the
Vyera Purchase Agreement, as amended by the Amendment, STI agreed to (i) make a cash payment to Vyera in the aggregate amount of $4.0
million on or before April 8, 2022; (ii) issue to Vyera on or before April 11, 2022 500,000 shares of our common stock (the &#8220;Initial
Shares&#8221;); (iii) issue to Vyera on or before July 11, 2022 an additional 500,000 shares of our common stock (as adjusted for stock
splits, stock dividends, combinations, recapitalizations and the like) (the &#8220;July 2022 Shares&#8221;); and (iv) issue to Vyera on
or before January 11, 2023 an additional number of shares of our common stock equal to $1.0 million divided by the volume weighted average
closing price of our common stock for the ten consecutive trading days ending on the fifth trading day prior to the applicable date of
issuance of the shares of our common stock (the &#8220;January 2023 Shares&#8221;, and together with the Cash Payment, the Initial Shares
and the July 2022 Shares, &#8220;Final Payments&#8221;). In consideration for the Final Payments, all of STI&#8217;s contingent payment
obligations under the Vyera Purchase Agreement, including the Milestone and Royalty Payment Obligations and the Change of Control Payment
Obligation, as well as all commercialization covenants of STI under the Vyera Purchase Agreement, will terminate in full upon the date
that all of the Final Payments have been made.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: justify; background-color: white">We paid the $4.0
million cash payment and issued the 500,000 Initial Shares to Vyera in April 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 0; text-align: justify"><b>&#160;</b></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify">Liquidity,
Capital Resources and Financial Condition</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify">Liquidity</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 6.85pt 0 5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">We have generated limited revenues, incurred operating losses
since inception, and we expect to continue to incur significant operating losses for the foreseeable future and may never become profitable.
As of March 31, 2022, we had $61.8 million in cash and an accumulated deficit of $155.2 million. We have historically funded our operations
through the issuance of convertible notes (the &#8220;Notes&#8221;) (see Note 9 to our condensed consolidated financial statements), the
sale of common stock (see Note 6 to our condensed consolidated financial statements) and the exercise of warrants (see Note 10 to our
condensed consolidated financial statements).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">On November 23, 2021, we entered into a Securities Purchase Agreement
(the &#8220;Securities Purchase Agreement&#8221;) with Lind Global Asset Management V, LLC (&#8220;Lind V&#8221;) pursuant to which, among
other things, on November 23, 2021 (the &#8220;Closing Date&#8221;), we issued and sold to Lind V, in a private placement transaction
(the &#8220;Private Placement&#8221;), in exchange for the payment by Lind V of $20.0 million, (1) a convertible promissory note (the
&#8220;2021 Note&#8221;) in an aggregate principal amount of $22.0 million (the &#8220;Principal Amount&#8221;), which will bear no interest
until the first anniversary of the issuance of the First Note and will thereafter bear interest at a rate of 5% per annum, and mature
on November 23, 2024 (the &#8220;Maturity Date&#8221;), and (2) 534,759 shares (the &#8220;2021 Closing Shares&#8221;) of our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">At the first anniversary of the Closing Date, we shall have the
option, at our sole discretion, to issue to Lind V a convertible promissory note (the &#8220;Second Note&#8221;) in the principal amount
of $11.0 million in exchange for the payment by Lind V of $10.0 million. At the earlier of (i) the two-year anniversary of the Closing
Date, or (ii) the successful readout for SLS-005 in ALS, and subject to the mutual agreement of us and Lind V, we shall issue to Lind
V a convertible promissory note (the &#8220;Third Note&#8221;) in the principal amount of $11.0 million in exchange for the payment by
Lind V of $10.0 million. In the event of the filing of a new drug application with the FDA for either SLS-002 or SLS-005, and subject
to the mutual agreement of us and Lind V, we shall issue to Lind a convertible promissory note (the &#8220;Fourth Note&#8221;) in the
principal amount of $11.0 million in exchange for the payment by Lind V of $10.0 million. The Second Note, the Third Note and the Fourth
Note, if issued, would be in substantially the same form as the 2021 Note. See Note 9 to our condensed consolidated financial statements
for further discussion.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 30 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">24</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">On December 2, 2021, we entered into two separate securities
purchase agreements with certain accredited investors on substantially the same terms as the Securities Purchase Agreement, pursuant to
which we sold, in private placement transactions, in exchange for the payment by the accredited investors of an aggregate of $201,534,
(i) convertible promissory notes (the &#8220;December 2021 Notes&#8221;) in an aggregate principal amount of $221,688, which will bear
no interest and mature on December 2, 2024, and (ii) an aggregate of 5,388 shares of our common stock. The December 2021 Notes have substantially
the same terms as the 2021 Note.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">On May 24, 2021, we completed an underwritten public offering
pursuant to which we sold 22,258,066 shares of our common stock at a price to the public of $3.10 per share, which included the exercise
in full by the underwriter of its option to purchase up to 2,903,226 additional shares of common stock. The net proceeds to us from the
offering were $64.5 million, after deducting underwriting discounts and commissions and other offering expenses payable by us (see Note
6 to our condensed consolidated financial statements).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">On January 28, 2021, we completed an underwritten public offering
pursuant to which we sold 17,530,488 shares of our common stock at a price to the public of $2.05 per share, which included the exercise
in full by the underwriter of its option to purchase up to 2,286,585 additional shares of common stock. The net proceeds to us from the
offering were $33.5 million, after deducting underwriting discounts and commissions and other offering expenses payable by us (see Note
6 to our condensed consolidated financial statements).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">We expect to use the net proceeds from the above transactions
primarily for general corporate purposes, which may include financing our normal business operations, developing new or existing product
candidates and funding capital expenditures, acquisitions and investments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">We currently have an effective shelf registration statement on
Form S-3 filed with the SEC. As of March 31, 2022, we had approximately $95.1 million available under our Form S-3 shelf registration
statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">We evaluated whether there are any conditions and events, considered
in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year beyond the filing of this
Quarterly Report on Form 10-Q. Based on such evaluation and our current plans (including the ongoing clinical programs for SLS-002, SLS-005,
and other product candidates), which are subject to change, management believes that our existing cash and cash equivalents as of March
31, 2022 are not sufficient to satisfy our operating cash needs for the year after the filing of this Quarterly Report on Form 10-Q.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">The accompanying unaudited condensed consolidated financial statements
have been prepared assuming we will continue to operate as a going concern, which contemplates the realization of assets and settlement
of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability
and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to our ability
to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Our future liquidity and capital funding requirements will depend
on numerous factors, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23pt"></td><td style="width: 18pt"><span style="letter-spacing: -0.7pt">&#8226;</span></td><td>our ability to raise additional funds to finance our operations;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23pt"></td><td style="width: 18pt"><span style="letter-spacing: -0.7pt">&#8226;</span></td><td>our ability to maintain compliance with the listing requirements of The Nasdaq Capital Market;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23pt"></td><td style="width: 18pt"><span style="letter-spacing: -0.7pt">&#8226;</span></td><td>the outcome, costs and timing of any clinical trial results for our current or future product candidates;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23pt"></td><td style="width: 18pt"><span style="letter-spacing: -0.7pt">&#8226;</span></td><td>potential litigation expenses;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23pt"></td><td style="width: 18pt"><span style="letter-spacing: -0.7pt">&#8226;</span></td><td>the emergence and effect of competing or complementary products or product candidates;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23pt"></td><td style="width: 18pt"><span style="letter-spacing: -0.7pt">&#8226;</span></td><td>our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any
payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement
of any patents or other intellectual property rights;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23pt"></td><td style="width: 18pt"><span style="letter-spacing: -0.7pt">&#8226;</span></td><td>our ability to retain our current employees and the need and ability to hire additional management and scientific and medical personnel;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23pt"></td><td style="width: 18pt"><span style="letter-spacing: -0.7pt">&#8226;</span></td><td>the terms and timing of any collaborative, licensing or other arrangements that we have or may establish;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23pt"></td><td style="width: 18pt"><span style="letter-spacing: -0.7pt">&#8226;</span></td><td>the trading price of our common stock; and</td></tr></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23pt"></td><td style="width: 18pt"><span style="letter-spacing: -0.7pt">&#8226;</span></td><td>our ability to increase the number of authorized shares outstanding to facilitate future financing events.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 30 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">25</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">We may need to raise substantial additional funds, and if we
do so, we may do so through one or more of the following: issuance of additional debt, equity, or both and/or the completion of a licensing
or other commercial transaction for one or more of our product candidates. If we are unable to maintain sufficient financial resources,
our business, financial condition and results of operations will be materially and adversely affected. This could adversely affect future
development and business activities, operations and business plans, such as future clinical studies and/or other future ventures. There
can be no assurance that we will be able to obtain the needed financing on acceptable terms or at all. Additionally, equity or convertible
debt financings may have a dilutive effect on the holdings of our existing stockholders. No assurances can be given that we will be able
to obtain additional financing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify">Critical
Accounting Estimates and Policies</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt">The preparation of financial statements in accordance with
United States generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that
affect the amounts reported in our unaudited condensed consolidated financial statements and accompanying notes. Management bases its
estimates on historical experience, market and other conditions, and various other assumptions it believes to be reasonable. Although
these estimates are based on management&#8217;s best knowledge of current events and actions that may impact us in the future, the estimation
process is, by its nature, uncertain given that estimates depend on events over which we may not have control. If market and other conditions
change from those that we anticipate, our unaudited condensed consolidated financial statements may be materially affected. In addition,
if our assumptions change, we may need to revise our estimates, or take other corrective actions, either of which may also have a material
effect in our unaudited condensed consolidated financial statements. We review our estimates, judgments, and assumptions used in our accounting
practices periodically and reflect the effects of revisions in the period in which they are deemed to be necessary. We believe that these
estimates are reasonable; however, our actual results may differ from these estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt">Our critical accounting policies and estimates are discussed
in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and there have been no material changes to such policies
or estimates during the three months ended March 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify">Recent Accounting Pronouncements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 33.25pt 0 5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 33.25pt 0 5pt">Please refer to the notes to the unaudited condensed
consolidated financial statements for a discussion of recent accounting pronouncements.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify">Comparison of the Three Months Ended
March 31, 2022 and 2021</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify">Operating Expense</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify">Operating expense was as follows (in thousands,
except percentages):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="3" style="font-weight: bold; vertical-align: middle; text-align: center; background-color: white">Three Months Ended March 31,</td></tr>
  <tr>
    <td style="vertical-align: middle">&#160;</td>
    <td style="vertical-align: middle">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="4" style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center">Three Months Ended March 31,</td>
    <td style="font-weight: bold; vertical-align: middle">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center">2022 vs 2021</td></tr>
  <tr>
    <td style="vertical-align: middle; width: 45%">&#160;</td>
    <td style="vertical-align: middle; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; width: 12%">2022</td>
    <td style="vertical-align: middle; border-top-color: Black; border-top-width: 1pt; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; width: 12%">2021</td>
    <td style="vertical-align: middle; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; width: 12%">$&#160;&#160;&#160;&#160;&#160;Change</td>
    <td style="vertical-align: middle; border-top-color: Black; border-top-width: 1pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; width: 12%">%&#160;&#160;&#160;Change</td></tr>
  <tr>
    <td style="vertical-align: middle">Operating expense</td>
    <td style="vertical-align: middle; text-align: right">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: middle; border-top-color: Black; border-top-width: 1pt">&#160;</td>
    <td style="vertical-align: middle; text-align: right">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: middle; border-top-color: Black; border-top-width: 1pt">&#160;</td>
    <td style="vertical-align: middle; background-color: white">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: middle; border-top-color: Black; border-top-width: 1pt; background-color: white">&#160;</td>
    <td style="vertical-align: middle; background-color: white">&#160;</td>
    <td style="vertical-align: middle; border-top-color: Black; border-top-width: 1pt; background-color: white">&#160;</td></tr>
  <tr style="vertical-align: middle">
    <td style="text-align: left">&#160;&#160;&#160;&#160;&#160;Research and development</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right; background-color: white">$</td>
    <td style="text-align: right; background-color: white">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;10,009</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right; background-color: white">$</td>
    <td style="text-align: right; background-color: white">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;14,112</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right; background-color: white">$</td>
    <td style="text-align: right; background-color: white">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(4,103)</td>
    <td style="background-color: white">&#160;</td>
    <td style="text-align: right; background-color: white">-29%</td></tr>
  <tr style="vertical-align: middle">
    <td>&#160;&#160;&#160;&#160;&#160;General and administrative</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right; background-color: white">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;4,001</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right; background-color: white">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2,500</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right; background-color: white">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,501</td>
    <td style="background-color: white">&#160;</td>
    <td style="text-align: right; background-color: white">60%</td></tr>
  <tr style="vertical-align: middle">
    <td>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total operating expense</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 3pt double; text-align: right; background-color: white">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;14,010</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right; background-color: white">$</td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 3pt double; text-align: right; background-color: white">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;16,612</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right; background-color: white">$</td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 3pt double; text-align: right; background-color: white">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2,602)</td>
    <td style="background-color: white">&#160;</td>
    <td style="text-align: right; background-color: white">-16%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify">&#160;&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left">Research and Development Expenses</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5.05pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify">Research and development expenses were as
follows (in thousands, except percentages):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="3" style="font-weight: bold; vertical-align: middle; text-align: center; background-color: white">Three Months Ended March 31,</td></tr>
  <tr>
    <td style="vertical-align: middle">&#160;</td>
    <td style="vertical-align: middle">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="4" style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center">Three Months Ended March 31,</td>
    <td style="font-weight: bold; vertical-align: middle">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center">2022 vs 2021</td></tr>
  <tr style="vertical-align: middle">
    <td style="width: 45%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="background-color: white; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; border-top-color: Black; border-top-width: 1pt; width: 12%">2022</td>
    <td style="background-color: white; width: 1%">&#160;</td>
    <td style="background-color: white; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; border-top-color: Black; border-top-width: 1pt; width: 12%">2021</td>
    <td style="width: 1%">&#160;</td>
    <td style="background-color: white; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; border-top-color: Black; border-top-width: 1pt; width: 12%">$&#160;&#160;&#160;&#160;&#160;Change</td>
    <td style="border-top-color: Black; border-top-width: 1pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; border-top-color: Black; border-top-width: 1pt; width: 12%">%&#160;&#160;&#160;Change</td></tr>
  <tr style="vertical-align: middle">
    <td style="background-color: white">Research and development expenses</td>
    <td style="background-color: white">&#160;</td>
    <td style="background-color: white">&#160;</td>
    <td style="border-top-color: Black; border-top-width: 1pt; background-color: white">&#160;</td>
    <td style="background-color: white">&#160;</td>
    <td style="background-color: white">&#160;</td>
    <td style="border-top-color: Black; border-top-width: 1pt; background-color: white">&#160;</td>
    <td style="background-color: white">&#160;</td>
    <td style="background-color: white">&#160;</td>
    <td style="border-top-color: Black; border-top-width: 1pt">&#160;</td>
    <td>&#160;</td>
    <td style="border-top-color: Black; border-top-width: 1pt">&#160;</td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="text-align: left">&#160;&#160;&#160;&#160;&#160;License payments</td>
    <td style="text-align: left">&#160;</td>
    <td>$</td>
    <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td>
    <td style="text-align: left">&#160;</td>
    <td>$</td>
    <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;9,000</td>
    <td style="text-align: left">&#160;</td>
    <td>$</td>
    <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(9,000)</td>
    <td>&#160;</td>
    <td style="text-align: right">-100%</td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="text-align: left">&#160;&#160;&#160;&#160;&#160;Clinical trial expenses</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5,951</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2,781</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3,170</td>
    <td>&#160;</td>
    <td style="text-align: right">114%</td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="text-align: left">&#160;&#160;&#160;&#160;&#160;Manufacturing expenses</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2,323</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,022</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,301</td>
    <td>&#160;</td>
    <td style="text-align: right">127%</td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="text-align: left">&#160;&#160;&#160;&#160;&#160;Employee compensation</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;957</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;690</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;267</td>
    <td>&#160;</td>
    <td style="text-align: right">39%</td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="text-align: left">&#160;&#160;&#160;&#160;&#160;Contract consulting expenses</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;559</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;432</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;127</td>
    <td>&#160;</td>
    <td style="text-align: right">29%</td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="text-align: left">&#160;&#160;&#160;&#160;&#160;Other research and development expenses</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;219</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;187</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;32</td>
    <td>&#160;</td>
    <td style="text-align: right">17%</td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="text-align: left">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total research and development expenses</td>
    <td style="text-align: left">&#160;</td>
    <td>$</td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;10,009</td>
    <td style="text-align: left">&#160;</td>
    <td>$</td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;14,112</td>
    <td style="text-align: left">&#160;</td>
    <td>$</td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(4,103)</td>
    <td>&#160;</td>
    <td style="text-align: right">-29%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 30 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">26</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5.05pt">Research and development (&#8220;R&amp;D&#8221;)
costs are expensed as they are incurred and include the cost of compensation and related expenses, as well as expenses for third
parties who conduct R&amp;D on our behalf. The $4.1 million decrease in R&amp;D expense during the three months ended March 31,
2022, as compared to the same period in 2021, resulted primarily from a decrease of $9.0 million in license payments pursuant to the
Vyera Purchase Agreement in the first quarter of 2021, offset by increases
in clinical trial costs of approximately $3.2 million, manufacturing expenses of approximately $1.3 million and employee
compensation expenses of approximately $267,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5.05pt; text-align: justify; text-indent: 31pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5.05pt; text-align: justify; text-indent: -0.55pt"><b><i>General
and Administrative Expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5.05pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5.05pt">General and administrative (&#8220;G&amp;A&#8221;) costs
include expenses for personnel, finance, legal, business development and investor relations. G&amp;A expenses increased by $1.5 million
during the three months ended March 31, 2022, as compared to the same period in 2021. This increase was primarily due to an increase of
$1.4 million for stock compensation expense, primarily related to the cancellation of performance-based restricted stock units in the
first quarter of 2022, as well as an increase of $403,000 in personnel costs due to increased staffing during the three months ended March
31, 2022. These increases were partially offset by decreases in costs including but not limited to, external investor relations costs
of approximately $330,000 during the three months ended March 31, 2022.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify">Other Income and Expense</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.05pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.05pt; text-align: justify">Other income and expense were as follows
(in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.05pt; text-align: justify">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: middle">&#160;</td>
    <td style="vertical-align: middle">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="4" style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center">Three Months Ended March 31,</td>
    <td style="font-weight: bold; vertical-align: middle">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: middle">
    <td style="width: 52%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="background-color: white; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; border-top-color: Black; border-top-width: 1pt; width: 14%">2022</td>
    <td style="background-color: white; width: 1%">&#160;</td>
    <td style="border-top-color: Black; border-top-width: 1pt; background-color: white; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; border-top-color: Black; border-top-width: 1pt; width: 14%">2021</td>
    <td style="width: 1%">&#160;</td>
    <td style="background-color: white; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 14%">$&#160;&#160;&#160;&#160;&#160;Change</td></tr>
  <tr style="vertical-align: middle">
    <td style="background-color: white">Other income (expense)</td>
    <td style="background-color: white">&#160;</td>
    <td style="background-color: white">&#160;</td>
    <td style="border-top-color: Black; border-top-width: 1pt; background-color: white">&#160;</td>
    <td style="background-color: white">&#160;</td>
    <td style="background-color: white">&#160;</td>
    <td style="border-top-color: Black; border-top-width: 1pt; background-color: white">&#160;</td>
    <td style="background-color: white">&#160;</td>
    <td style="background-color: white">&#160;</td>
    <td style="border-top-color: Black; border-top-width: 1pt">&#160;</td></tr>
  <tr style="vertical-align: middle">
    <td style="text-align: left; background-color: white">&#160;&#160;&#160;&#160;&#160;Interest income</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right; background-color: white">$</td>
    <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;26</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right; background-color: white">$</td>
    <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;19</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right; background-color: white">$</td>
    <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;7</td></tr>
  <tr style="vertical-align: middle">
    <td style="text-align: left; background-color: white">&#160;&#160;&#160;&#160;&#160;Interest expense</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(7)</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(990)</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;983</td></tr>
  <tr style="vertical-align: middle">
    <td style="text-align: left; background-color: white">&#160;&#160;&#160;&#160;&#160;Change in fair value of convertible notes</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(244)</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(244)</td></tr>
  <tr style="vertical-align: middle">
    <td style="text-align: left; background-color: white">&#160;&#160;&#160;&#160;&#160;Change in fair value of warrant liabilities</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;234</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1,533)</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,767</td></tr>
  <tr style="vertical-align: middle">
    <td style="text-align: left; background-color: white">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total other income (expense)</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right; background-color: white">$</td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;9</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right; background-color: white">$</td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2,504)</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right; background-color: white">$</td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2,513</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>Interest Income</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Interest income was $26,000 and $19,000 for the three months
ended March 31, 2022 and 2021, respectively. The increase in interest income primarily related to the higher average cash balances during
the three months ended March 31, 2022 compared to the three months ended March 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>Interest Expense</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Interest expense was $7,000 and $990,000 for the three months
ended March 31, 2022 and 2021, respectively. This decrease in interest expense was due to our repayment of the December 2020 convertible
notes during 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>Change in Fair Value of Convertible Notes</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-indent: 31.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Change in fair value of convertible notes was $0.2 million and
$0 for the three months ended March 31, 2022 and 2021, respectively. This change was due to our 2021 convertible notes issued in November
2021 and December 2021, which have been accounted for under the fair value option and are revalued at each reporting period, with changes
in fair value reflected in earnings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>Change in Fair Value of Warrant Liability</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-indent: 31.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">The fair value of warrant liability was $190,000 at March 31,
2022. For the three months ended March 31, 2022, the change in fair value of warrant liabilities was $234,000, which income was due to
revaluation of the Series A Warrants during such period. For the three months ended March 31, 2021, the change in fair value of warrant
liabilities was $1.5 million, which expense was due to the revaluation of the Series A Warrants during such period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 30 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">27</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify">Cash Flow Summary</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt">The following table summarizes selected items in our unaudited
condensed consolidated statements of cash flows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: middle; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="font-weight: bold; text-align: center">&#160;</td>
    <td colspan="4" style="font-weight: bold; text-align: center">Three Months Ended</td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="font-weight: bold; text-align: center">&#160;</td>
    <td colspan="4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td></tr>
  <tr>
    <td style="vertical-align: middle; background-color: white; width: 60%">&#160;</td>
    <td style="vertical-align: middle; background-color: white; width: 2%">&#160;</td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; background-color: white; width: 16%">2022</td>
    <td style="vertical-align: middle; text-align: right; background-color: white; width: 2%">&#160;</td>
    <td style="vertical-align: bottom; text-align: right; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; background-color: white; width: 16%">2021</td></tr>
  <tr style="vertical-align: middle">
    <td>Net cash (used in) provided by operations</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="font-weight: bold; text-align: right; background-color: white">&#160;</td>
    <td style="font-weight: bold; text-align: center; background-color: white">&#160;</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="font-weight: bold; text-align: right; background-color: white">&#160;</td>
    <td style="font-weight: bold; text-align: center; background-color: white">&#160;</td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="text-align: left">&#160;&#160;&#160;&#160;&#160;Net cash used in operating activities</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(17,045)</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(11,252)</td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="text-align: left">&#160;&#160;&#160;&#160;&#160;Net cash provided by financing activities</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;83</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: Black 0.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;34,277</td></tr>
  <tr style="vertical-align: middle">
    <td>Net increase (decrease) in cash</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right; background-color: white">$</td>
    <td style="border-bottom: Black 2pt double; text-align: right; background-color: white">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(16,962)</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: right; background-color: white">$</td>
    <td style="border-bottom: Black 2pt double; text-align: right; background-color: white">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;23,025</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><i>Operating Activities</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Cash used in operating activities of $17.0 million during the
three months ended March 31, 2022 was primarily due to a net loss of $14.0 million and changes in operating assets and liabilities of
$5.3 million, which was partially offset by non-cash adjustment related to stock-based compensation expense of $2.2 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Cash used in operating activities of $11.3 million during the
three months ended March 31, 2021 was primarily due to a net loss of $19.1 million, which was partially offset by changes in operating
assets and liabilities of $4.6 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><i>Financing Activities</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Cash provided by financing activities of $83,000 during the three
months ended March 31, 2022 was primarily due to proceeds from the sale of common stock under our employee stock purchase plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Cash provided by financing activities of $34.3 million during
the three months ended March 31, 2021 was due to proceeds from the issuance and sale of common stock, net of costs, of approximately $33.5
million and the proceeds from the exercise of warrants of approximately $5.9 million during the three months ended March 31, 2021. The
cash provided was partially offset by the payment of $5.2 million of convertible debt principal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify"><span id="a_003"></span>ITEM 3. QUANTITATIVE AND QUALITATIVE
DISCLOSURES ABOUT MARKET RISK</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">We are a smaller reporting company, as defined by Rule 12b-2
of the Exchange Act and are not required to provide the information required under this item.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify"><span id="a_004"></span>ITEM 4. CONTROLS AND PROCEDURES</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify">Evaluation of Disclosure Controls
and Procedures</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt">Our disclosure controls and procedures are designed to ensure
that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, communicated to
our management to allow timely decisions regarding required disclosure, summarized and reported within the time periods specified in the
SEC&#8217;s rules and forms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt">Under the supervision and with the participation of our management,
including the Chief Executive Officer (&#8220;CEO&#8221;) and Chief Financial Officer (&#8220;CFO&#8221;), we conducted an evaluation of
the effectiveness of our disclosure controls and procedures, as such term is defined under Rules 13a-15(e) and 15d-15(e) under the Exchange
Act, as of March 31, 2022. Based on this evaluation, our CEO and CFO concluded that our disclosure controls and procedures were effective
as of March 31, 2022 at the reasonable assurance level.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify">Changes in Internal Control over
Financial Reporting</p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.95pt 0 5pt">There were no material changes to our internal control over
financial reporting during the three months ended March 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.95pt 0 5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.05pt; text-align: justify"></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.05pt; text-align: justify"></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.05pt; text-align: justify"></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.05pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">28</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.95pt 0 5pt">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 28.35pt 0 27.4pt; text-align: center">PART II.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"><b><span id="a_005"></span>ITEM 1. LEGAL PROCEEDINGS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt">We are not currently party to, and none of our property is currently
the subject of, any material legal proceedings. We may be a party to certain litigation that is either judged to be not material or that
arises in the ordinary course of business from time to time. We intend to vigorously defend our interests in these matters. We expect
that the resolution of these matters will not have a material adverse effect on our business, financial condition or results of operations.
However, due to the uncertainties inherent in litigation, no assurance can be given as to the outcome of these proceedings.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0 5pt; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0 5pt; text-align: justify"><span id="a_006"></span>ITEM 1A. RISK FACTORS</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: left"><span style="font-weight: normal"><i>We operate
in a dynamic and rapidly changing environment that involves numerous risks and uncertainties. Certain factors may have a material adverse
effect on our business, prospects, financial condition and results of operations, and you should carefully consider them. Accordingly,
in evaluating our business, we encourage you to consider the following discussion of risk factors, in its entirety, in addition to other
information contained in this Quarterly Report on Form 10-Q and our other public filings with the SEC. Other events that we do not currently
anticipate or that we currently deem immaterial may also affect our business, prospects, financial condition and results of operations.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b>Risk Factor Summary</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Below is a summary of the principal factors that make an investment
in our securities speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks
summarized in this risk factor summary, and other risks that we face, can be found below and should be carefully considered, together
with all of the other information appearing in or incorporated by reference into this Quarterly Report on Form 10-Q and our other public
filings with the SEC before making investment decisions regarding the <span style="background-color: white">common stock</span>. Other
events that we do not currently anticipate or that we currently deem immaterial may also affect our business, prospects, financial condition
and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<ul style="margin-top: 0in; list-style-type: disc">

<li style="margin: 0; font-size: 10pt">We are a clinical-stage company, we have a very limited operating history, are not currently profitable,
do not expect to become profitable in the near future and may never become profitable.</li>

<li style="margin: 0; font-size: 10pt">We are dependent on the success of one or more of our current product candidates and we cannot
be&#160;certain that any of them will receive regulatory approval or be commercialized.</li>

<li style="margin: 0; font-size: 10pt">If development of our product candidates does not produce favorable results, or encounters challenges,
we and our collaborators, if&#160;any, may be unable to commercialize these products.</li>

<li style="margin: 0; font-size: 10pt">We expect to continue to incur significant research and development expenses, which may make it
difficult for us to attain profitability.</li>

<li style="margin: 0; font-size: 10pt">Given our lack of current cash flow, we may need to raise additional capital; however, it may be
unavailable&#160;to us or, even if capital is obtained, may cause dilution or place significant restrictions on our ability to&#160;operate
our business. If we fail to raise the necessary additional capital, we may be unable to complete the development and commercialization
of our product candidates, or continue our development programs.</li>

<li style="margin: 0; font-size: 10pt">Our product candidates may cause undesirable side effects that could delay or prevent their regulatory
approval&#160;or commercialization or have other significant adverse implications on our business, financial condition and&#160;results
of operations.</li>

<li style="margin: 0; font-size: 10pt">Delays in the commencement or completion of clinical trials could result in increased costs to
us and delay&#160;our ability to establish strategic collaborations.</li>

<li style="margin: 0; font-size: 10pt">The COVID-19 pandemic, and any other pandemic, epidemic or outbreak of an infectious disease may
materially and adversely affect our business and operations.</li>

<li style="margin: 0; font-size: 10pt">Results of earlier clinical trials may not be predictive of the results of later-stage clinical
trials.</li>

<li style="margin: 0; font-size: 10pt">We intend to rely on third parties to conduct our preclinical studies and clinical trials and perform
other tasks.&#160;If these third parties do not successfully carry out their contractual duties, meet expected deadlines, or comply with&#160;regulatory
requirements, we may not be able to obtain regulatory approval for or commercialize our product&#160;candidates and our business, financial
condition and results of operations could be substantially harmed.</li>

<li style="margin: 0; font-size: 10pt">Our product candidates are subject to extensive regulation under the U.S. Food and Drug Administration
(&#8220;FDA&#8221;), the European Medicines Agency (the &#8220;EMA&#8221;) or comparable foreign authorities, which can be costly and
time consuming, cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates.</li>

<li style="margin: 0; font-size: 10pt">If our competitors have product candidates that are approved faster, marketed more effectively,
are better&#160;tolerated, have a more favorable safety profile or are demonstrated to be more effective than ours, our&#160;commercial
opportunity may be reduced or eliminated.</li>

</ul>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.05pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">29</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->




<ul style="margin-top: 0in; list-style-type: disc">

<li style="margin: 0; font-size: 10pt">We rely completely on third parties to manufacture our preclinical and clinical drug supplies,
and our&#160;business, financial condition and results of operations could be harmed if those third parties fail to provide us&#160;with
sufficient quantities of drug product, or fail to do so at acceptable quality levels or prices.</li>

<li style="margin: 0; font-size: 10pt">The commercial success of our product candidates depends upon their market acceptance among physicians,&#160;patients,
healthcare payors and the medical community.</li>

<li style="margin: 0; font-size: 10pt">If we fail to retain current members of our senior management and scientific personnel, or to attract
and&#160;keep additional key personnel, we may be unable to successfully develop or commercialize our product&#160;candidates.</li>

<li style="margin: 0; font-size: 10pt">We may not be successful in obtaining or maintaining necessary rights to our product candidates
through&#160;acquisitions and in-licenses.</li>

<li style="margin: 0; font-size: 10pt">If we fail to comply with our obligations in the agreements under which we in-license intellectual
property and other rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we
could lose intellectual property rights that are important to our business.</li>

<li style="margin: 0; font-size: 10pt">We may not be able to protect our proprietary or licensed technology in the marketplace.</li>

<li style="margin: 0; font-size: 10pt">The market price of our common stock is expected to be volatile.</li>

</ul>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"><b>Risk Factors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt">The risk factors set forth below with an asterisk (*) next to the
title are new risk factors or risk factors containing material changes from the risk factors previously disclosed in Item 1A of our Annual
Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC on March 4, 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify"><b>Risks Related to the Company</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>*We are a clinical-stage company, we have a very limited
operating history, are not currently profitable, do not expect&#160;to become profitable in the near future and may never become profitable.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">We are a clinical-stage biopharmaceutical company. Since our
incorporation, we have focused primarily on the development and acquisition of clinical-stage therapeutic candidates. All of our therapeutic
candidates are in the clinical development stage and none of our pipeline therapeutic candidates have been approved for marketing or are
being marketed or commercialized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">As a result, we have no meaningful historical operations upon
which to evaluate our business and prospects and have not yet demonstrated an ability to obtain marketing approval for any of our product
candidates or successfully overcome the risks and uncertainties frequently encountered by companies in the biopharmaceutical industry.
We also have generated minimal revenues from collaboration and licensing agreements and no revenues from product sales to date and continue
to incur significant research and development and other expenses. As a result, we have not been profitable and have incurred significant
operating losses in every reporting period since our inception. We have incurred an accumulated deficit of $155.2 million from our inception
through March 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">For the foreseeable future, we expect to continue to incur
losses, which will increase significantly from historical levels as we expand our drug development activities, seek partnering
and/or regulatory approvals for our product candidates and begin to commercialize them if they are approved by the FDA, the EMA or
comparable foreign authorities. Even if we succeed in developing and commercializing one or more product candidates, we may never
become profitable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>We are dependent on the success
of one or more of our current product candidates and we cannot be&#160;certain that any of them will receive regulatory approval or be
commercialized.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">We have spent significant time, money
and effort on the licensing and development of our core assets, SLS-002, SLS-005 and SLS-006 and our other earlier-stage assets, SLS-004,
SLS-007, SLS-008, SLS-010 and SLS-012. To date, no pivotal clinical trials designed to provide clinically and statistically significant
proof of efficacy, or to provide sufficient evidence of safety to justify approval, have been completed with any of our pipeline product
candidates. All of our product candidates will require additional development, including clinical trials as well as further preclinical
studies to evaluate their toxicology, carcinogenicity and pharmacokinetics and optimize their formulation, and regulatory clearances before
they can be commercialized. Positive results obtained during early development do not necessarily mean later development will succeed
or that regulatory clearances will be obtained. Our drug development efforts may not lead to commercial drugs, either because our product
candidates may fail to be safe and effective or because we have inadequate financial or other resources to advance our product candidates
through the clinical development and approval processes. If any of our product candidates fail to demonstrate safety or efficacy at any
time or during any phase of development, we would experience potentially significant delays in, or be required to abandon, development
of the product candidate.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.05pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">30</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">We do not anticipate that any of our current product candidates
will be eligible to receive regulatory approval from the FDA, the EMA or comparable foreign authorities and begin commercialization for
a number of years, if ever. Even if we ultimately receive regulatory approval for any of these product candidates, we or our potential
future partners, if any, may be unable to commercialize them successfully for a variety of reasons. These include, for example, the availability
of alternative treatments, lack of cost-effectiveness, the cost of manufacturing the product on a commercial scale and competition with
other drugs. The success of our product candidates may also be limited by the prevalence and severity of any adverse side effects. If
we fail to commercialize one or more of our current product candidates, we may be unable to generate sufficient revenues to attain or
maintain profitability, and our financial condition and stock price may decline.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>If development of our product candidates does not produce
favorable results, or encounters challenges, we and our collaborators, if&#160;any, may be unable to commercialize these products.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">To receive regulatory approval for the commercialization of our
core assets, SLS-002, SLS-005 and SLS-006 and our earlier-stage assets, SLS-004, SLS-007, SLS-008, SLS-010 and SLS-012, or any other product
candidates that we may develop, adequate and well-controlled clinical trials must be conducted to demonstrate safety and efficacy in humans
to the satisfaction of the FDA, the EMA and comparable foreign authorities. In order to support marketing approval, these agencies typically
require successful results in one or more Phase III clinical trials, which our current product candidates have not yet reached and may
never reach. The development process is expensive, can take many years and has an uncertain outcome. Failure can occur at any stage of
the process. We may experience numerous unforeseen events during, or as a result of, the development process that could delay or prevent
commercialization of our current or future product candidates, including the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<ul style="margin-top: 0in; list-style-type: disc">

<li style="margin: 0; font-size: 10pt">clinical trials may produce negative or inconclusive results;</li>

<li style="margin: 0; font-size: 10pt">preclinical studies conducted with product candidates during clinical development to, among other
things, evaluate their toxicology, carcinogenicity and pharmacokinetics and optimize their formulation may produce unfavorable results;</li>

<li style="margin: 0; font-size: 10pt">we or our contract manufacturers may encounter manufacturing challenges or the FDA may raise concerns
regarding Chemistry, Manufacturing, and Controls (CMC) data or GMP compliance, or biocompatibility or drug-device interaction concerns
for our combination product candidates;</li>

<li style="margin: 0; font-size: 10pt">patient recruitment and enrollment in clinical trials may be slower than we anticipate;</li>

<li style="margin: 0; font-size: 10pt">costs of development may be greater than we anticipate;</li>

<li style="margin: 0; font-size: 10pt">our product candidates may cause undesirable side effects that delay or preclude regulatory approval
or limit their commercial use or market acceptance, if approved;</li>

<li style="margin: 0; font-size: 10pt">collaborators who may be responsible for the development of our product candidates may not devote
sufficient resources to these clinical trials or other preclinical studies of these candidates or conduct them in a timely manner; or</li>

<li style="margin: 0; font-size: 10pt">we may face delays in obtaining regulatory approvals to commence one or more clinical trials.</li>

</ul>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Success in early development does not mean that later development
will be successful because, for example, product candidates in later-stage clinical trials may fail to demonstrate sufficient safety and
efficacy despite having progressed through initial clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">We have licensed or acquired all of the intellectual property
related to our product candidates from third parties. All clinical trials, preclinical studies and other analyses performed to date with
respect to our product candidates have been conducted by their original owners. Therefore, as a company, we have limited experience in
conducting clinical trials for our product candidates. Since our experience with our product candidates is limited, we will need to train
our existing personnel and hire additional personnel in order to successfully administer and manage our clinical trials and other studies
as planned, which may result in delays in completing such planned clinical trials and preclinical studies. Moreover, to date our product
candidates have been tested in less than the number of patients that will likely need to be studied to obtain regulatory approval. The
data collected from clinical trials with larger patient populations may not demonstrate sufficient safety and efficacy to support regulatory
approval of these product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">We currently do not have strategic collaborations in place for
clinical development of any of our current product candidates, except for our collaborative agreement with Team Sanfilippo Foundation
(&#34;TSF&#34;), which we assumed in connection with the asset purchase agreement with Bioblast Pharma Ltd. for IV Trehalose, which
is now known as SLS-005. Therefore, in the future, we or any potential future collaborative partner will be responsible for establishing
the targeted endpoints and goals for development of our product candidates. These targeted endpoints and goals may be inadequate to demonstrate
the safety and efficacy levels required for regulatory approvals. Even if we believe data collected during the development of our product
candidates are promising, such data may not be sufficient to support marketing approval by the FDA, the EMA or comparable foreign authorities.
Further, data generated during development can be interpreted in different ways, and the FDA, the EMA or comparable foreign authorities
may interpret such data in different ways than us or our collaborators. Our failure to adequately demonstrate the safety and efficacy
of our product candidates would prevent our receipt of regulatory approval, and ultimately the potential commercialization of these product
candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.05pt; text-align: justify"></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">31</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.95pt 0 5pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Since we do not currently possess the resources necessary to
independently develop and commercialize our product candidates or any other product candidates that we may develop, we may seek to enter
into collaborative agreements to assist in the development and potential future commercialization of some or all of these assets as a
component of our strategic plan. However, our discussions with potential collaborators may not lead to the establishment of collaborations
on acceptable terms, if at all, or it may take longer than expected to establish new collaborations, leading to development and potential
commercialization delays, which would adversely affect our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>We expect to continue to incur significant research and
development expenses, which may make it difficult&#160;for us to attain profitability.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">We expect to expend substantial funds in research and development,
including preclinical studies and clinical trials of our product candidates, and to manufacture and market any product candidates in the
event they are approved for commercial sale. We also may need additional funding to develop or acquire complementary companies, technologies
and assets, as well as for working capital requirements and other operating and general corporate purposes. Moreover, our planned increases
in staffing will dramatically increase our costs in the near and long-term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">However, our spending on current and future research and development
programs and product candidates for specific indications may not yield any commercially viable products. Due to our limited financial
and managerial resources, we must focus on a limited number of research programs and product candidates and on specific indications. Our
resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Because the successful development of our product candidates
is uncertain, we are unable to precisely estimate the actual funds we will require to develop and potentially commercialize them. In addition,
we may not be able to generate sufficient revenue, even if we are able to commercialize any of our product candidates, to become profitable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>*Given our lack of current cash flow, we may need to raise
additional capital; however, it may be unavailable&#160;to us or, even if capital is obtained, may cause dilution or place significant
restrictions on our ability to&#160;operate our business. If we fail to raise the necessary additional capital, we may be unable to complete
the development and commercialization of our product candidates, or continue our development programs.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">As of March 31, 2022, we had a cash balance of approximately
$61.8 million. Since we will be unable to generate sufficient, if any, cash flow to fund our operations for the foreseeable future, we
may need to seek additional equity or debt financing to provide the capital required to maintain or expand our operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">As a result of our recurring losses from operations, there is
uncertainty regarding our ability to maintain liquidity sufficient to operate our business effectively, which raises substantial doubt
about our ability to continue as a going concern. If we are unsuccessful in our efforts to raise outside financing, we may be required
to significantly reduce or cease operations. The report of our independent registered public accounting firm on our audited financial
statements for the year ended December 31, 2021 included a &#8220;going concern&#8221; explanatory paragraph indicating that our recurring
losses from operations raise substantial doubt about our ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">We currently have an effective shelf registration statement on
Form S-3 filed with the SEC. We may use the shelf registration statement on Form S-3 to offer from time to time any combination of debt
securities, common and preferred stock and warrants, and, as of the date hereof, a total of $95.1 million of securities remains available
for issuance pursuant to the shelf registration statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">There can be no assurance that we will be able to raise sufficient
additional capital on acceptable terms or at all. In addition, the impact of the COVID-19 pandemic on the global financial markets may
reduce our ability to access capital, which could negatively affect our liquidity and ability to continue as a going concern. If such
additional financing is not available on satisfactory terms, or is not available in sufficient amounts, we may be required to delay, limit
or eliminate the development of business opportunities and our ability to achieve our business objectives, our competitiveness, and our
business, financial condition and results of operations will be materially adversely affected. In addition, we may be required to grant
rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. Our inability to fund
our business could lead to the loss of your investment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Our future capital requirements will depend on many factors,
including, but not limited to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<ul style="margin-top: 0in; list-style-type: disc">

<li style="margin: 0; font-size: 10pt">the scope, rate of progress, results and cost of our clinical trials, preclinical studies and other
related activities;</li>

<li style="margin: 0; font-size: 10pt">our ability to establish and maintain strategic collaborations, licensing or other arrangements
and the financial terms of such arrangements;</li>

<li style="margin: 0; font-size: 10pt">the timing of, and the costs involved in, obtaining regulatory approvals for any of our current
or future product candidates;</li>

</ul>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">32</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<ul style="margin-top: 0in; list-style-type: disc">

<li style="margin: 0; font-size: 10pt">the number and characteristics of the product candidates we seek to develop or commercialize;</li>

<li style="margin: 0; font-size: 10pt">the cost of manufacturing clinical supplies, and establishing commercial supplies, of our product
candidates;</li>

<li style="margin: 0; font-size: 10pt">the cost of commercialization activities if any of our current or future product candidates are
approved for sale, including marketing, sales and distribution costs;</li>

<li style="margin: 0; font-size: 10pt">the expenses needed to attract and retain skilled personnel;</li>

<li style="margin: 0; font-size: 10pt">the costs associated with being a public company;</li>

<li style="margin: 0; font-size: 10pt">the amount of revenue, if any, received from commercial sales of our product candidates, should
any of our product candidates receive marketing approval; and</li>

<li style="margin: 0; font-size: 10pt">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing possible
patent claims, including litigation costs and the outcome of any such litigation.</li>

</ul>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">If we raise additional capital by issuing equity securities,
the percentage ownership of our existing stockholders may be reduced, and accordingly these stockholders may experience substantial dilution.
We may also issue equity securities that provide for rights, preferences and privileges senior to those of our common stock. Given our
need for cash and that equity issuances are the most common type of fundraising for similarly situated companies, the risk of dilution
is particularly significant for our stockholders. In addition, debt financing may involve agreements that include covenants limiting or
restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends
and may be secured by all or a portion of our assets.&#160;For example, we granted to Lind Global Asset Management V, LLC (&#8220;Lind&#8221;),
one of the holders of the convertible promissory notes we issued in 2021 (the &#8220;Convertible Promissory Notes&#8221;), a first priority
lien on our assets and properties and the Convertible Promissory Notes include restrictive covenants and event of default provisions,
including restrictions on certain sales or other dispositions of company assets, restrictions on entering into certain variable-rate transactions
and a minimum cash requirement. In addition, although the Securities Purchase Agreement we entered into with Lind in November 2021 provides
that we may issue and sell to Lind additional convertible promissory notes, the issuances of such additional notes are subject to the
satisfaction of certain conditions and milestones, which we may not be able to satisfy or achieve.&#160; Our inability to raise capital
when needed may harm our business, financial condition and results of operations, and could cause our stock price to decline or require
that we wind down our operations altogether.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>Our product candidates may cause undesirable side effects
that could delay or prevent their regulatory approval&#160;or commercialization or have other significant adverse implications on our
business, financial condition and&#160;results of operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Undesirable side effects observed in clinical trials or in supportive
preclinical studies with our product candidates could interrupt, delay or halt their development and could result in the denial of regulatory
approval by the FDA, the EMA or comparable foreign authorities for any or all targeted indications or adversely affect the marketability
of any such product candidates that receive regulatory approval. In turn, this could eliminate or limit our ability to commercialize our
product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Our product candidates may exhibit adverse effects in preclinical
toxicology studies and adverse interactions with other drugs. There are also risks associated with additional requirements the FDA, the
EMA or comparable foreign authorities may impose for marketing approval with regard to a particular disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Our product candidates may require a risk management program
that could include patient and healthcare provider education, usage guidelines, appropriate promotional activities, a post-marketing observational
study, and ongoing safety and reporting mechanisms, among other requirements. Prescribing could be limited to physician specialists or
physicians trained in the use of the drug, or could be limited to a more restricted patient population. Any risk management program required
for approval of our product candidates could potentially have an adverse effect on our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Undesirable side effects involving our product candidates may
have other significant adverse implications on our business, financial condition and results of operations. For example:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<ul style="margin-top: 0in; list-style-type: disc">

<li style="margin: 0; font-size: 10pt">we may be unable to obtain additional financing on acceptable terms, if at all;</li>

<li style="margin: 0; font-size: 10pt">our collaborators may terminate any development agreements covering these product candidates;</li>

<li style="margin: 0; font-size: 10pt">if any development agreements are terminated, we may determine not to further develop the affected
product candidates due to resource constraints and may not be able to establish additional collaborations for their further development
on acceptable terms, if at all;</li>

<li style="margin: 0; font-size: 10pt">if we were to later continue the development of these product candidates and receive regulatory
approval, earlier findings may significantly limit their marketability and thus significantly lower our potential future revenues from
their commercialization;</li>

<li style="margin: 0; font-size: 10pt">we may be subject to product liability or stockholder litigation; and</li>

<li style="margin: 0; font-size: 10pt">we may be unable to attract and retain key employees.</li>

</ul>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">33</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">In addition, if any of our product candidates receive marketing
approval and we or others later identify undesirable side effects caused by the product:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<ul style="margin-top: 0in; list-style-type: disc">

<li style="margin: 0; font-size: 10pt">regulatory authorities may withdraw their approval of the product, or we or our partners may decide
to cease marketing and sale of the product voluntarily;</li>

<li style="margin: 0; font-size: 10pt">we may be required to change the way the product is administered, conduct additional clinical trials
or preclinical studies regarding the product, change the labeling of the product, or change the product's manufacturing facilities; and</li>

<li style="margin: 0; font-size: 10pt">our reputation may suffer.</li>

</ul>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Any of these events could prevent us from achieving or maintaining
market acceptance of the affected product and could substantially increase the costs and expenses of commercializing the product, which
in turn could delay or prevent us from generating significant revenues from the sale of the product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>Our efforts to discover product candidates beyond our current
product candidates may not succeed, and any&#160;product candidates we recommend for clinical development may not actually begin clinical
trials.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">We intend to use our technology, including our licensed technology,
knowledge and expertise to develop novel drugs to address some of the world's most widespread and costly central nervous system, respiratory
and other disorders, including orphan indications. We intend to expand our existing pipeline of core assets by advancing drug compounds
from current ongoing discovery programs into clinical development. However, the process of researching and discovering drug compounds
is expensive, time-consuming and unpredictable. Data from our current preclinical programs may not support the clinical development of
our lead compounds or other compounds from these programs, and we may not identify any additional drug compounds suitable for recommendation
for clinical development. Moreover, any drug compounds we recommend for clinical development may not demonstrate, through preclinical
studies, indications of safety and potential efficacy that would support advancement into clinical trials. Such findings would potentially
impede our ability to maintain or expand our clinical development pipeline. Our ability to identify new drug compounds and advance them
into clinical development also depends upon our ability to fund our research and development operations, and we cannot be certain that
additional funding will be available on acceptable terms, or at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>Delays in the commencement or completion of clinical trials
could result in increased costs to us and delay&#160;our ability to establish strategic collaborations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Delays in the commencement or completion of clinical trials could
significantly impact our drug development costs. We do not know whether planned clinical trials will begin on time or be completed on
schedule, if at all. The commencement of clinical trials can be delayed for a variety of reasons, including, but not limited to, delays
related to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<ul style="margin-top: 0in; list-style-type: disc">

<li style="margin: 0; font-size: 10pt">obtaining regulatory approval to commence one or more clinical trials;</li>

<li style="margin: 0; font-size: 10pt">reaching agreement on acceptable terms with prospective third-party contract research organizations
(&#34;CROs&#34;) and clinical trial sites;</li>

<li style="margin: 0; font-size: 10pt">manufacturing sufficient quantities of a product candidate or other materials necessary to conduct
clinical trials;</li>

<li style="margin: 0; font-size: 10pt">obtaining institutional review board approval to conduct one or more clinical trials at a prospective
site;</li>

<li style="margin: 0; font-size: 10pt">recruiting and enrolling patients to participate in one or more clinical trials; and</li>

<li style="margin: 0; font-size: 10pt">the failure of our collaborators to adequately resource our product candidates due to their focus
on other programs or as a result of general market conditions.</li>

</ul>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">In addition, once a clinical trial has begun, it may be suspended
or terminated by us, our collaborators, the institutional review boards or data safety monitoring boards charged with overseeing our clinical
trials, the FDA, the EMA or comparable foreign authorities due to a number of factors, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<ul style="margin-top: 0in; list-style-type: disc">

<li style="margin: 0; font-size: 10pt">failure to conduct the clinical trial in accordance with regulatory requirements or clinical protocols;</li>

<li style="margin: 0; font-size: 10pt">inspection of the clinical trial operations or clinical trial site by the FDA, the EMA or comparable
foreign authorities resulting in the imposition of a clinical hold;</li>

<li style="margin: 0; font-size: 10pt">unforeseen safety issues; or</li>

<li style="margin: 0; font-size: 10pt">lack of adequate funding to continue the clinical trial.</li>

</ul>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">If we experience delays in the completion, or termination, of
any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to commence
product sales and generate product revenues from any of our product candidates will be delayed. In addition, any delays in completing
our clinical trials will increase our costs and slow down our product candidate development and approval process. Delays in completing
our clinical trials could also allow our competitors to obtain marketing approval before we do or shorten the patent protection period
during which we may have the exclusive right to commercialize our product candidates. Any of these occurrences may harm our business,
financial condition and prospects significantly. In addition, many of the factors that cause, or lead to, a delay in the commencement
or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">34</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>The COVID-19 pandemic, and any other pandemic, epidemic
or outbreak of an infectious disease may materially and adversely affect our business and operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">On March 11, 2020, the World Health Organization declared COVID-19
a pandemic. The COVID-19 pandemic is affecting the United States and global economies and may affect our operations and those of third
parties on which we rely, including by causing disruptions in the supply of our product candidates and the conduct of future clinical
trials. In addition, the COVID-19 pandemic may affect the operations of the FDA and other health authorities, which could result in delays
of reviews and approvals, including with respect to our product candidates. Additionally, while the potential economic impact brought
by, and the duration of the COVID-19 pandemic are difficult to assess or predict, the impact of the COVID-19 pandemic on the global financial
markets may reduce our ability to access capital, which could negatively impact our short-term and long-term liquidity. In addition, the
loss of any of our employees as a result of COVID-19 or another pandemic, may have a material adverse effect on our operations. We are
actively monitoring the effect of the global situation on our financial condition, liquidity, operations, suppliers, industry and workforce.
While the spread of COVID-19 may eventually be contained or mitigated, we cannot predict the timing of the vaccine roll-out globally or
the continued efficacy of such vaccines, and we do not yet know how businesses or our partners will operate in a post COVID-19 environment.&#160;The
ultimate impact of the COVID-19 pandemic on our business, operations or the global economy as a whole remains highly uncertain, and a continued
and prolonged public health crisis such as the COVID-19 pandemic could have a material negative impact on our business, financial condition,
and operating results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>Results of earlier clinical trials may not be predictive
of the results of later-stage clinical trials.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">The results of preclinical studies and early clinical trials
of product candidates may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical
trials may fail to show the desired safety and efficacy results despite having progressed through preclinical studies and initial clinical
trials. Many companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to adverse
safety profiles or lack of efficacy, notwithstanding promising results in earlier studies. Similarly, our future clinical trial results
may not be successful for these or other reasons.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">This product candidate development risk is heightened by any
changes in the planned clinical trials compared to the completed clinical trials. As product candidates are developed through preclinical
to early- to late-stage clinical trials towards approval and commercialization, it is customary that various aspects of the development
program, such as manufacturing and methods of administration, are altered along the way in an effort to optimize processes and results.
While these types of changes are common and are intended to optimize the product candidates for late-stage clinical trials, approval and
commercialization, such changes carry the risk that they will not achieve these intended objectives. In addition, nonclinical studies
may be requested or required even after clinical trials have been commenced or completed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Any of these changes could make the results of our planned clinical
trials or other future clinical trials we may initiate less predictable and could cause our product candidates to perform differently,
including causing toxicities, which could delay completion of our clinical trials, delay approval of our product candidates, and/or jeopardize
our ability to commence product sales and generate revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>If we experience delays in the enrollment of patients in
our clinical trials, our receipt of necessary&#160;regulatory approvals could be delayed or prevented.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">We may not be able to initiate or continue clinical trials for
our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as
required by the FDA or other regulatory authorities. In addition, the COVID-19 pandemic may result in a reduction of patient enrollment,
a loss of patient enrollment and other delays affecting our clinical trials.&#160; Patient enrollment, a significant factor in the timing
of clinical trials, is affected by many factors, including the size and nature of the patient population, the proximity of patients to
clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical trials and clinicians' and
patients' perceptions as to the potential advantages of the drug being studied in relation to other available therapies, including any
new drugs that may be approved for the indications we are investigating.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">If we fail to enroll and maintain the number of patients for
which the clinical trial was designed, the statistical power of that clinical trial may be reduced, which would make it harder to demonstrate
that the product candidate being tested in such clinical trial is safe and effective. Additionally, enrollment delays in our clinical
trials may result in increased development costs for our product candidates, which would cause the value of our company to decline and
limit our ability to obtain additional financing. Our inability to enroll a sufficient number of patients for any of our current or future
clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">35</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;We intend to rely on third parties to conduct our
preclinical studies and clinical trials and perform other tasks.&#160;If these third parties do not successfully carry out their contractual
duties, meet expected deadlines, or comply with&#160;regulatory requirements, we may not be able to obtain regulatory approval for or
commercialize our product&#160;candidates and our business, financial condition and results of operations could be substantially harmed.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">We intend to rely upon third-party CROs, medical institutions,
clinical investigators and contract laboratories to monitor and manage data for our ongoing preclinical and clinical programs. Nevertheless,
we maintain responsibility for ensuring that each of our clinical trials and preclinical studies is conducted in accordance with the applicable
protocol, legal, regulatory, and scientific standards and our reliance on these third parties does not relieve us of our regulatory responsibilities.
We and our CROs and other vendors are required to comply with current requirements on good manufacturing practices (&#34;cGMP&#34;),
good clinical practices (&#34;GCP&#34;) and good laboratory practice (&#34;GLP&#34;), which are a collection of laws and regulations
enforced by the FDA, the EMA and comparable foreign authorities for all of our product candidates in clinical development. Regulatory
authorities enforce these regulations through periodic inspections of preclinical study and clinical trial sponsors, principal investigators,
preclinical study and clinical trial sites, and other contractors. If we or any of our CROs or vendors fails to comply with applicable
regulations, the data generated in our preclinical studies and clinical trials may be deemed unreliable and the FDA, the EMA or comparable
foreign authorities may require us to perform additional preclinical studies and clinical trials before approving our marketing applications.
We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical
trials comply with GCP regulations. In addition, our clinical trials must be conducted with products produced consistent with cGMP regulations.
Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the development and regulatory
approval processes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">We may not be able to enter into arrangements with CROs on commercially
reasonable terms, or at all. In addition, our CROs will not be our employees, and except for remedies available to us under our agreements
with such CROs, we will not be able to control whether or not they devote sufficient time and resources to our ongoing preclinical and
clinical programs. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need
to be replaced or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our protocols, regulatory
requirements, or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory
approval for or successfully commercialize our product candidates. CROs may also generate higher costs than anticipated. As a result,
our business, financial condition and results of operations and the commercial prospects for our product candidates could be materially
and adversely affected, our costs could increase, and our ability to generate revenue could be delayed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Switching or adding additional CROs, medical institutions, clinical
investigators or contract laboratories involves additional cost and requires management time and focus. In addition, there is a natural
transition period when a new CRO commences work replacing a previous CRO. As a result, delays occur, which can materially impact our ability
to meet our desired clinical development timelines. There can be no assurance that we will not encounter similar challenges or delays
in the future or that these delays or challenges will not have a material adverse effect on our business, financial condition or results
of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>Our product candidates are subject to extensive regulation
under the FDA, the EMA or comparable foreign&#160;authorities, which can be costly and time consuming, cause unanticipated delays or prevent
the receipt of the&#160;required approvals to commercialize our product candidates.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">The clinical development, manufacturing, labeling, storage, record-keeping,
advertising, promotion, export, marketing and distribution of our product candidates are subject to extensive regulation by the FDA and
other U.S. regulatory agencies, the EMA or comparable authorities in foreign markets. In the U.S., neither we nor our collaborators are
permitted to market our product candidates until we or our collaborators receive approval of a new drug application (&#34;NDA&#34;)
from the FDA or receive similar approvals abroad. The process of obtaining these approvals is expensive, often takes many years, and can
vary substantially based upon the type, complexity and novelty of the product candidates involved. Approval policies or regulations may
change and may be influenced by the results of other similar or competitive products, making it more difficult for us to achieve such
approval in a timely manner or at all. Any guidance that may result from recent FDA advisory panel discussions may make it more expensive
to develop and commercialize such product candidates. In addition, as a company, we have not previously filed NDAs with the FDA or filed
similar applications with other foreign regulatory agencies. This lack of experience may impede our ability to obtain FDA or other foreign
regulatory agency approval in a timely manner, if at all, for our product candidates for which development and commercialization is our
responsibility.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Despite the time and expense invested, regulatory approval is
never guaranteed. The FDA, the EMA or comparable foreign authorities can delay, limit or deny approval of a product candidate for many
reasons, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<ul style="margin-top: 0in; list-style-type: disc">

<li style="margin: 0; font-size: 10pt">a product candidate may not be deemed safe or effective;</li>

<li style="margin: 0; font-size: 10pt">agency officials of the FDA, the EMA or comparable foreign authorities may not find the data from
non-clinical or preclinical studies and clinical trials generated during development to be sufficient;</li>

<li style="margin: 0; font-size: 10pt">the FDA, the EMA or comparable foreign authorities may not approve our third-party manufacturers'
processes or facilities;</li>

<li style="margin: 0; font-size: 10pt">the FDA, the EMA or a comparable foreign authority may change its approval policies or adopt new
regulations; or</li>

<li style="margin: 0; font-size: 10pt">our inability to obtain these approvals would prevent us from commercializing our product candidates.</li>

</ul>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">36</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;We are pursuing the FDA 505(b)(2) NDA pathway for
our lead product candidate, SLS-002, which presents certain additional development and commercialization risks as compared to a conventional
505(b)(1) NDA for an innovator product candidate. We may pursue this pathway for other product candidates as well. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">For our lead product candidate (SLS-002) we are pursuing development
in order to seek potential FDA approval under an abbreviated regulatory pathway called a 505(b)(2) NDA, which permits the filing of an
NDA where at least some of the information required for approval comes from studies that were not conducted by or for the applicant and
for which the applicant has not obtained a right of reference. We may also pursue this pathway for other of our product candidates. Section
505(b)(2), if applicable to us for a particular product candidate, would allow an NDA we submit to the FDA to rely, in part, on data in
the public domain or the FDA's prior conclusions regarding the safety and effectiveness of approved compounds, which could expedite the
development program for a product candidate by potentially decreasing the amount of clinical data that we would need to generate in order
to obtain FDA approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Even if the FDA allows us to rely on the 505(b)(2) regulatory
pathway, there is no assurance that such marketing approval will be obtained in a timely manner, or at all. The FDA may require us to
perform additional nonclinical studies and clinical trials, and conduct other development work, to support any change from the reference
listed drug (including with respect to the route of administration and drug delivery method and device), which presents uncertainty about
the data that may ultimately be necessary and could be time-consuming and substantially delay our application for or potential receipt
of marketing approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Even if we are able to utilize the 505(b)(2) regulatory pathway,
a drug approved via this pathway may be subject to the same post-approval limitations, conditions and requirements as any other drug,
including, for example a Risk Evaluation and Mitigation Strategy (&#34;REMS&#34;), which we anticipate will be required for our lead
product candidate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Also, as has been the experience of others in our industry, our
competitors may file citizens' petitions with the FDA to contest approval of our NDA, which may delay or even prevent the FDA from approving
any NDA that we submit under the 505(b)(2) regulatory pathway. If an FDA decision or action relative to our product candidate, or the
FDA's interpretation of Section 505(b)(2) more generally, is successfully challenged, it could result in delays or even prevent the FDA
from approving a 505(b)(2) application for such product candidate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">In addition, we may face Hatch-Waxman litigation in relation
to our NDAs submitted under the 505(b)(2) regulatory pathway, which may further delay or prevent the approval of our product candidate.
The pharmaceutical industry is highly competitive, and 505(b)(2) NDAs are subject to special requirements designed to protect the patent
rights of sponsors of previously approved drugs that are referenced in a 505(b)(2) NDA. If the previously approved drugs referenced in
an applicant's 505(b)(2) NDA are protected by patent(s) listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations
publication, or the Orange Book, the 505(b)(2) applicant is required to make a claim after filing its NDA that each such patent is invalid,
unenforceable or will not be infringed. The patent holder may thereafter bring suit for patent infringement, which will trigger a mandatory
30-month delay (or the shorter of dismissal of the lawsuit or expiration of the patent(s)) in approval of the 505(b)(2) NDA application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">If the FDA determines that our 505(b)(2) regulatory pathway is
not viable for SLS-002 or any other applicable product candidate for any reason, we would need to reconsider our plans and might not be
able to commercialize any such product candidate in a cost-efficient manner, or at all. If we were to pursue approval under the 505(b)(1)
NDA pathway, we would be subject to more extensive requirements and risks such as conducting additional clinical trials, providing additional
data and information or meeting additional standards for marketing approval. As a result, the time and financial resources required to
obtain marketing approval for our product candidates would likely increase substantially and further complications and risks associated
with our product candidates may arise. Also, new competing products may reach the market faster than ours, which may materially and adversely
affect our competitive position, business and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>Even if our product candidates receive regulatory approval
in the U.S., we may never receive approval or&#160;commercialize our products outside of the U.S.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">In order to market any products outside of the U.S., we must
establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Approval procedures
vary among countries and can involve additional product testing and additional administrative review periods. The time required to obtain
approval in other countries might differ from that required to obtain FDA approval. The regulatory approval process in other countries
may include all of the risks detailed above regarding FDA approval in the U.S. as well as other risks. Regulatory approval in one country
does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may have a negative
effect on the regulatory process in others. Failure to obtain regulatory approval in other countries or any delay seeking or obtaining
such approval would impair our ability to develop foreign markets for our product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">37</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>Even if any of our product candidates receive regulatory
approval, our product candidates may still face future&#160;development and regulatory difficulties.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">If any of our product candidates receive regulatory approval,
the FDA, the EMA or comparable foreign authorities may still impose significant restrictions on the indicated uses or marketing of the
product candidates or impose ongoing requirements for potentially costly post-approval studies and trials. In addition, regulatory agencies
subject a product, our manufacturer and the manufacturer's facilities to continual review and periodic inspections. If a regulatory agency
discovers previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or problems with
the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, our collaborators or us,
including requiring withdrawal of the product from the market. Our product candidates will also be subject to ongoing FDA, EMA or comparable
foreign authorities' requirements for the labeling, packaging, storage, advertising, promotion, record-keeping and submission of safety
and other post-market information on the drug. If our product candidates fail to comply with applicable regulatory requirements, a regulatory
agency may:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<ul style="margin-top: 0in; list-style-type: disc">

<li style="margin: 0; font-size: 10pt">issue warning letters or other notices of possible violations;</li>

<li style="margin: 0; font-size: 10pt">impose civil or criminal penalties or fines or seek disgorgement of revenue or profits;</li>

<li style="margin: 0; font-size: 10pt">suspend any ongoing clinical trials;</li>

<li style="margin: 0; font-size: 10pt">refuse to approve pending applications or supplements to approved applications filed by us or our
collaborators;</li>

<li style="margin: 0; font-size: 10pt">withdraw any regulatory approvals;</li>

<li style="margin: 0; font-size: 10pt">impose restrictions on operations, including costly new manufacturing requirements, or shut down
our manufacturing operations; or</li>

<li style="margin: 0; font-size: 10pt">seize or detain products or require a product recall.</li>

</ul>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>The FDA, the EMA and comparable foreign authorities actively
enforce the laws and regulations prohibiting the&#160;promotion of off-label uses.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">The FDA, the EMA and comparable foreign authorities strictly
regulate the promotional claims that may be made about prescription products, such as our product candidates, if approved. In particular,
a product may not be promoted for uses that are not approved by the FDA, the EMA or comparable foreign authorities as reflected in the
product's approved labeling. If we receive marketing approval for our product candidates for our proposed indications, physicians may
nevertheless use our products for their patients in a manner that is inconsistent with the approved label, if the physicians personally
believe in their professional medical judgment that our products could be used in such manner. However, if we are found to have promoted
our products for any off-label uses, the federal government could levy civil, criminal or administrative penalties, and seek fines against
us. Such enforcement has become more common in the industry. The FDA, the EMA or comparable foreign authorities could also request that
we enter into a consent decree or a corporate integrity agreement, or seek a permanent injunction against us under which specified promotional
conduct is monitored, changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we
could become subject to significant liability, which would materially adversely affect our business, financial condition and results of
operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>If our competitors have product candidates that are approved
faster, marketed more effectively, are better&#160;tolerated, have a more favorable safety profile or are demonstrated to be more effective
than ours, our&#160;commercial opportunity may be reduced or eliminated.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">The biopharmaceutical industry is characterized by rapidly advancing
technologies, intense competition and a strong emphasis on proprietary products. While we believe that our technology, knowledge, experience
and scientific resources provide us with competitive advantages, we face potential competition from many different sources, including
commercial biopharmaceutical enterprises, academic institutions, government agencies and private and public research institutions. Any
product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become
available in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Many of our competitors have significantly greater financial
resources and expertise in research and development, manufacturing, preclinical studies, clinical trials, regulatory approvals and marketing
approved products than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative
arrangements with large and established companies. Our competitors may succeed in developing technologies and therapies that are more
effective, better tolerated or less costly than any which we are developing, or that would render our product candidates obsolete and
noncompetitive. Even if we obtain regulatory approval for any of our product candidates, our competitors may succeed in obtaining regulatory
approvals for their products earlier than we do. We will also face competition from these third parties in recruiting and retaining qualified
scientific and management personnel, in establishing clinical trial sites and patient registration for clinical trials, and in acquiring
and in-licensing technologies and products complementary to our programs or advantageous to our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">38</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">The key competitive factors affecting the success of each of
our product candidates, if approved, are likely to be its efficacy, safety, tolerability, frequency and route of administration, convenience
and price, the level of branded and generic competition and the availability of coverage and reimbursement from government and other third-party
payors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">The pharmaceutical market for the treatment of major depressive
disorder includes selective serotonin reuptake inhibitors (&#34;SSRIs&#34;), serotonin and norepinephrine reuptake inhibitors (&#34;SNRIs&#34;)
and atypical antipsychotics. A number of these marketed antidepressants will be generic, and would be key competitors to SLS-002. These
products include Forest Laboratory's Lexapro/Cipralex (escitalopram) and Viibryd (vilazodone), Pfizer, Inc.'s Zoloft (sertraline), Effexor
(venlafaxine) and Pristiq (desvenlafaxine), GlaxoSmithKline plc's Paxil/Seroxat (paroxetine), Eli Lilly and Company's Prozac (fluoxetine)
and Cymbalta (duloxetine), AstraZeneca plc's Seroquel (quetiapine) and Bristol-Myers Squibb Company's Abilify (aripiprazole), among others.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Patients with treatment-resistant depression often require treatment
with several antidepressants, such as an SSRI or SNRI, combined with an &#34;adjunct&#34; therapy such as an antipsychotic compound,
such as AstraZeneca plc's Seroquel (quetiapine) and Bristol-Myers Squibb Company's Abilify (aripiprazole), or mood stabilizers, such as
Janssen Pharmaceutica's Topamax (topiramate). In addition, Janssen's Spravato (intranasal esketamine), which has been approved for treatment-resistant
depression and for depressive systems in adults with major depressive disorder with suicidal thoughts or actions, targets the NMDA receptor
and is expected to have a faster onset of therapeutic effect as compared to currently available therapies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Current treatments for Parkinson's Disease (&#34;PD&#34;) are
intended to improve the symptoms of patients. The cornerstone of PD therapy is levodopa, as it is the most effective therapy for reducing
symptoms of PD. There are other drug therapies in development that will target the disease, such as gene and stem cell therapy and A2A
receptor agonists.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>We, or any future collaborators, may not be able to obtain
orphan drug designation or orphan drug exclusivity&#160;for our product candidates.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Regulatory authorities in some jurisdictions, including the United
States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may
designate a product as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient
population of fewer than 200,000 individuals annually in the United States. In the United States and Europe, obtaining orphan drug approval
may allow us to obtain financial incentives, such as an extended period of exclusivity during which only we are allowed to market the
orphan drug. While we have received orphan drug designation for SLS-005 in Sanfilippo Syndrome and in spinocerebellar ataxia type 3 and
in oculopharyngeal muscular dystrophy and we plan to seek orphan drug designation from the FDA for SLS-008 for the treatment of a pediatric
indication, we, or any future collaborators, may not be granted orphan drug designations for our product candidates in the U.S. or in
other jurisdictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Even if we, or any future collaborators, obtain orphan drug designation
for a product candidate, we, or they, may not be able to obtain orphan drug exclusivity for that product candidate. Generally, a product
with orphan drug designation only becomes entitled to orphan drug exclusivity if it receives the first marketing approval for the indication
for which it has such designation, in which case the FDA or the EMA will be precluded from approving another marketing application for
the same drug for that indication for the applicable exclusivity period. The applicable exclusivity period is seven years in the United
States and ten years in Europe. The European exclusivity period can be reduced to six years if a drug no longer meets the criteria for
orphan drug designation or if the drug is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity
may be lost if the FDA or the EMA determines that the request for designation was materially defective or if the manufacturer is unable
to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Even if we, or any future collaborators, obtain orphan drug exclusivity
for a product, that exclusivity may not effectively protect the product from competition because FDA has taken the position that, under
certain circumstances, another drug with the same active chemical and pharmacological characteristics, or moiety, can be approved for
the same condition. Specifically, the FDA's regulations provide that it can approve another drug with the same active moiety for the same
condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major
contribution to patient care.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>The active ingredient of our lead product candidate, SLS-002,
ketamine hydrochloride, is recognized as having the potential for abuse, misuse and diversion and, as a result, is and will be subject
to extensive federal and state laws and regulations governing controlled substances and the entities involved in their research, manufacturing,
sale and distribution, and possession. In addition, we anticipate that if we obtain marketing approval for SLS-002 it will be the subject
of an FDA Risk Evaluation and Mitigation Strategy (REMS).</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Ketamine is listed by the Drug Enforcement Administration (&#34;DEA&#34;)
as a Schedule&#160;III controlled substance under the Controlled Substances Act. The DEA classifies substances as Schedule&#160;I, II,
III, IV or V controlled substances, with Schedule&#160;I controlled substances considered to present the highest risk of substance abuse
and Schedule&#160;V controlled substances the lowest risk. Scheduled controlled substances are subject to DEA regulations relating to
supply, procurement, manufacturing, storage,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">39</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;distribution and physician prescription procedures.
In addition to federal scheduling, some drugs may be subject to state-level controlled substance laws and regulations and in some cases
more broadly applicable or more extensive requirements than those determined by the DEA and FDA. Federal and state-level controlled substance
laws impose a broad range of registration and licensure requirements along with requirements for systems and controls intended to provide
security and reduce the risk of diversion and misuse, and to identify suspicious activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Compliance with these laws can be expensive and time consuming.
Failure to follow these requirements can lead to significant civil and/or criminal penalties and possibly even lead to a revocation of
a DEA registration and state-level licenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">If SLS-002 receives marketing approval from the FDA or other
regulatory authority, we may be required to implement REMS to address the potential for abuse and misuse of our product candidate. As
a result, our product candidate may only be available through a restricted or limited distribution system to which only certain prescribing
healthcare professionals may have access for their patients or healthcare professionals may be limited in their prescribing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Furthermore, product candidates containing controlled substances
may generate public controversy. As a result, these products may be at risk of having their sale and distribution and marketing approvals
further restricted or in extreme cases withdrawn in the event that regulators were to assess that the benefits of a product no longer
outweigh emerging risks. Political pressures or adverse publicity could lead to delays in, and increased expenses for, and limit or restrict,
the commercialization of our product or product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>We are subject to a multitude of manufacturing risks, any
of which could substantially increase our costs and&#160;limit supply of our product candidates.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">The process of manufacturing our product candidates is complex,
highly regulated, and subject to several risks. For example, the process of manufacturing our product candidates is extremely susceptible
to product loss due to contamination, equipment failure or improper installation or operation of equipment, or vendor or operator error.
Even minor deviations from normal manufacturing processes for any of our product candidates could result in reduced production yields,
product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our product candidates or
in the manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended
period of time to investigate and remedy the contamination. In addition, the manufacturing facilities in which our product candidates
are made could be adversely affected by equipment failures, labor shortages, natural disasters, public health crises, pandemics and epidemics,
such as the COVID-19 pandemic, power failures and numerous other factors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">In addition, any adverse developments affecting manufacturing
operations for our product candidates may result in shipment delays, inventory shortages, lot failures, withdrawals or recalls or other
interruptions in the supply of our product candidates. We also may need to take inventory write-offs and incur other charges and expenses
for product candidates that fail to meet specifications, undertake costly remediation efforts or seek costlier manufacturing alternatives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>We rely completely on third parties to manufacture our
preclinical and clinical drug supplies, and our&#160;business, financial condition and results of operations could be harmed if those
third parties fail to provide us&#160;with sufficient quantities of drug product, or fail to do so at acceptable quality levels or prices.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">We do not currently have, nor do we plan to acquire, the infrastructure
or capability internally to manufacture our preclinical and clinical drug supplies for use in our clinical trials, and we lack the resources
and the capability to manufacture any of our product candidates on a clinical or commercial scale. We rely on our manufacturers to purchase
from third-party suppliers the materials necessary to produce our product candidates for our clinical trials. There are a limited number
of suppliers for raw materials that we use to manufacture our product candidates, and there may be a need to identify alternate suppliers
to prevent a possible disruption of the manufacture of the materials necessary to produce our product candidates for our clinical trials,
and, if approved, ultimately for commercial sale. We do not have any control over the process or timing of the acquisition of these raw
materials by our manufacturers. Although we generally do not begin a clinical trial unless we believe we have a sufficient supply of a
product candidate to complete such clinical trial, any significant delay or discontinuity in the supply of a product candidate, or the
raw material components thereof, for an ongoing clinical trial due to the need to replace a third-party manufacturer could considerably
delay completion of our clinical trials, product testing and potential regulatory approval of our product candidates, which could harm
our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>Product candidates that are considered combination products
for FDA purposes, such as the SLS-002 drug-device combination product consisting of ketamine hydrocholoride and a USP aqueous spray solution
in a bi-dose nasal delivery device, may face additional challenges, risks and delays in the product development and regulatory approval
process.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">SLS-002 is delivered by an intranasal delivery device and considered
a drug-device combination product (the device having been developed by a third party is subject to a license agreement). When evaluating
products that utilize a specific drug delivery system or device, the FDA will evaluate the characteristics of that delivery system and
its functionality, as well as the potential</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">40</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">for undesirable interactions between the drug and the delivery
system, including the potential to negatively impact the safety or effectiveness of the drug. The FDA review process can be more complicated
for combination products, and may result in delays, particularly if novel delivery systems are involved. Additionally, quality or design
concerns with the delivery system could delay or prevent regulatory approval and commercialization of our product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>We and our contract manufacturers are subject to significant
regulation with respect to manufacturing our&#160;product candidates. The manufacturing facilities on which we rely may not continue to
meet regulatory&#160;requirements.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">All entities involved in the preparation of therapeutics for
clinical trials or commercial sale, including our contract manufacturers for our product candidates, are subject to extensive regulation.
Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical trials must be manufactured in
accordance with cGMP. These regulations govern manufacturing processes and procedures and the implementation and operation of quality
systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes
can lead to the introduction of contaminants or to inadvertent changes in the properties or stability of our product candidates that may
not be detectable in final product testing. We or our contract manufacturers must supply all necessary documentation in support of an
NDA or marketing authorization application (&#34;MAA&#34;) on a timely basis and must adhere to GLP and cGMP regulations enforced by
the FDA, the EMA or comparable foreign authorities through their facilities inspection program. Some of our contract manufacturers may
not have produced a commercially approved pharmaceutical product and therefore may not have obtained the requisite regulatory authority
approvals to do so. The facilities and quality systems of some or all of our third-party contractors must pass a pre-approval inspection
for compliance with the applicable regulations as a condition of regulatory approval of our product candidates or any of our other potential
products. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation
of our product candidates or any of our other potential products or the associated quality systems for compliance with the regulations
applicable to the activities being conducted. Although we plan to oversee the contract manufacturers, we cannot control the manufacturing
process of, and are completely dependent on, our contract manufacturing partners for compliance with the regulatory requirements. If these
facilities do not pass a pre-approval plant inspection, regulatory approval of the products may not be granted or may be substantially
delayed until any violations are corrected to the satisfaction of the regulatory authority, if ever.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">The regulatory authorities also may, at any time following approval
of a product for sale, audit the manufacturing facilities of our third-party contractors. If any such inspection or audit identifies a
failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent
of such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly or time consuming
for us or a third party to implement, and that may include the temporary or permanent suspension of a clinical trial or commercial sales
or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract
could materially harm our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">If we or any of our third-party manufacturers fail to maintain
regulatory compliance, the FDA, the EMA or comparable foreign authorities can impose regulatory sanctions including, among other things,
refusal to approve a pending application for a product candidate, withdrawal of an approval or suspension of production. As a result,
our business, financial condition and results of operations may be materially and adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Additionally, if supply from one manufacturer is interrupted,
an alternative manufacturer would need to be qualified through an NDA supplement or MAA variation, or equivalent foreign regulatory filing,
which could result in further delay. The regulatory agencies may also require additional studies or trials if a new manufacturer is relied
upon for commercial production. Switching manufacturers may involve substantial costs and is likely to result in a delay in our desired
clinical and commercial timelines.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">These factors could cause us to incur higher costs and could
cause the delay or termination of clinical trials, regulatory submissions, required approvals, or commercialization of our product candidates.
Furthermore, if our suppliers fail to meet contractual requirements and we are unable to secure one or more replacement suppliers capable
of production at a substantially equivalent cost, our clinical trials may be delayed or we could lose potential revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>Any collaboration arrangement that we may enter into in
the future may not be successful, which could&#160;adversely affect our ability to develop and commercialize our current and potential
future product&#160;candidates.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">We may seek collaboration arrangements with biopharmaceutical
companies for the development or commercialization of our current and potential future product candidates. To the extent that we decide
to enter into collaboration agreements, we will face significant competition in seeking appropriate collaborators. Moreover, collaboration
arrangements are complex and time consuming to negotiate, execute and implement. We may not be successful in our efforts to establish
and implement collaborations or other alternative arrangements should we choose to enter into such arrangements, and the terms of the
arrangements may not be favorable to us. If and when we collaborate with a third party for development and commercialization of a product
candidate, we can expect to relinquish some or all of the control over the future success of that product candidate to the third party.
The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborators generally
have significant discretion in determining the efforts and resources that they will apply to these collaborations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">41</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Disagreements between parties to a collaboration arrangement
can lead to delays in developing or commercializing the applicable product candidate and can be difficult to resolve in a mutually beneficial
manner. In some cases, collaborations with biopharmaceutical companies and other third parties are terminated or allowed to expire by
the other party. Any such termination or expiration would adversely affect our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>If we are unable to develop our own commercial organization
or enter into agreements with third parties to sell&#160;and market our product candidates, we may be unable to generate significant revenues.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">We do not have a sales and marketing organization, and we have
no experience as a company in the sales, marketing and distribution of pharmaceutical products. If any of our product candidates are approved
for commercialization, we may be required to develop our sales, marketing and distribution capabilities, or make arrangements with a third
party to perform sales and marketing services. Developing a sales force for any resulting product or any product resulting from any of
our other product candidates is expensive and time consuming and could delay any product launch. We may be unable to establish and manage
an effective sales force in a timely or cost-effective manner, if at all, and any sales force we do establish may not be capable of generating
sufficient demand for our product candidates. To the extent that we enter into arrangements with collaborators or other third parties
to perform sales and marketing services, our product revenues are likely to be lower than if we marketed and sold our product candidates
independently. If we are unable to establish adequate sales and marketing capabilities, independently or with others, we may not be able
to generate significant revenues and may not become profitable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>The commercial success of our product candidates depends
upon their market acceptance among physicians,&#160;patients, healthcare payors and the medical community.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Even if our product candidates obtain regulatory approval, our
products, if any, may not gain market acceptance among physicians, patients, healthcare payors and the medical community. The degree of
market acceptance of any of our approved product candidates will depend on a number of factors, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<ul style="margin-top: 0in; list-style-type: disc">

<li style="margin: 0; font-size: 10pt">the effectiveness of our approved product candidates as compared to currently available products;</li>

<li style="margin: 0; font-size: 10pt">patient willingness to adopt our approved product candidates in place of current therapies;</li>

<li style="margin: 0; font-size: 10pt">our ability to provide acceptable evidence of safety and efficacy;</li>

<li style="margin: 0; font-size: 10pt">relative convenience and ease of administration;</li>

<li style="margin: 0; font-size: 10pt">the prevalence and severity of any adverse side effects;</li>

<li style="margin: 0; font-size: 10pt">restrictions on use in combination with other products;</li>

<li style="margin: 0; font-size: 10pt">availability of alternative treatments;</li>

<li style="margin: 0; font-size: 10pt">pricing and cost-effectiveness assuming either competitive or potential premium pricing requirements,
based on the profile of our product candidates and target markets;</li>

<li style="margin: 0; font-size: 10pt">effectiveness of us or our partners' sales and marketing strategy;</li>

<li style="margin: 0; font-size: 10pt">our ability to obtain sufficient third-party coverage or reimbursement; and</li>

<li style="margin: 0; font-size: 10pt">potential product liability claims.</li>

</ul>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">In addition, the potential market opportunity for our product
candidates is difficult to precisely estimate. Our estimates of the potential market opportunity for our product candidates include several
key assumptions based on our industry knowledge, industry publications, third-party research reports and other surveys. Independent sources
have not verified all of our assumptions. If any of these assumptions proves to be inaccurate, then the actual market for our product
candidates could be smaller than our estimates of the potential market opportunity. If the actual market for our product candidates is
smaller than we expect, our product revenue may be limited, it may be harder than expected to raise funds and it may be more difficult
for us to achieve or maintain profitability. If we fail to achieve market acceptance of our product candidates in the U.S. and abroad,
our revenue will be limited and it will be more difficult to achieve profitability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>If we fail to obtain and sustain an adequate level of reimbursement
for our potential products by third-party&#160;payors, potential future sales would be materially adversely affected.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">There will be no viable commercial market for our product candidates,
if approved, without reimbursement from third-party payors. Reimbursement policies may be affected by future healthcare reform measures.
We cannot be certain that reimbursement will be available for our current product candidates or any other product candidate we may develop.
Additionally, even if there is a viable commercial market, if the level of reimbursement is below our expectations, our anticipated revenue
and gross margins will be adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">42</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;Third-party payors, such as government or private
healthcare insurers, carefully review and increasingly question and challenge the coverage of and the prices charged for drugs. Reimbursement
rates from private health insurance companies vary depending on the company, the insurance plan and other factors. Reimbursement rates
may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services.
There is a current trend in the U.S. healthcare industry toward cost containment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Large public and private payors, managed care organizations,
group purchasing organizations and similar organizations are exerting increasing influence on decisions regarding the use of, and reimbursement
levels for, particular treatments. Such third-party payors, including Medicare, may question the coverage of, and challenge the prices
charged for, medical products and services, and many third-party payors limit coverage of or reimbursement for newly approved healthcare
products. In particular, third-party payors may limit the covered indications. Cost-control initiatives could decrease the price we might
establish for products, which could result in product revenues being lower than anticipated. We believe our drugs will be priced significantly
higher than existing generic drugs and consistent with current branded drugs. If we are unable to show a significant benefit relative
to existing generic drugs, Medicare, Medicaid and private payors may not be willing to provide reimbursement for our drugs, which would
significantly reduce the likelihood of our products gaining market acceptance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">We expect that private insurers will consider the efficacy, cost-effectiveness,
safety and tolerability of our potential products in determining whether to approve reimbursement for such products and at what level.
Obtaining these approvals can be a time consuming and expensive process. Our business, financial condition and results of operations would
be materially adversely affected if we do not receive approval for reimbursement of our potential products from private insurers on a
timely or satisfactory basis. Limitations on coverage could also be imposed at the local Medicare carrier level or by fiscal intermediaries.
Medicare Part D, which provides a pharmacy benefit to Medicare patients as discussed below, does not require participating prescription
drug plans to cover all drugs within a class of products. Our business, financial condition and results of operations could be materially
adversely affected if Part D prescription drug plans were to limit access to, or deny or limit reimbursement of, our product candidates
or other potential products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Reimbursement systems in international markets vary significantly
by country and by region, and reimbursement approvals must be obtained on a country-by-country basis. In many countries, the product cannot
be commercially launched until reimbursement is approved. In some foreign markets, prescription pharmaceutical pricing remains subject
to continuing governmental control even after initial approval is granted. The negotiation process in some countries can exceed 12 months.
To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness
of our products to other available therapies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">If the prices for our potential products are reduced or if governmental
and other third-party payors do not provide adequate coverage and reimbursement of our drugs, our future revenue, cash flows and prospects
for profitability will suffer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>Current and future legislation may increase the difficulty
and cost of commercializing our product candidates&#160;and may affect the prices we may obtain if our product candidates are approved
for commercialization.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">In the U.S. and some foreign jurisdictions, there have been a
number of adopted and proposed legislative and regulatory changes regarding the healthcare system that could prevent or delay regulatory
approval of our product candidates, restrict or regulate post-marketing activities and affect our ability to profitably sell any of our
product candidates for which we obtain regulatory approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">In the U.S., the Medicare Prescription Drug, Improvement, and
Modernization Act of 2003 (&#34;MMA&#34;) changed the way Medicare covers and pays for pharmaceutical products. Cost reduction initiatives
and other provisions of this legislation could limit the coverage and reimbursement rate that we receive for any of our approved products.
While the MMA only applies to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment
limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from the MMA may result in
a similar reduction in payments from private payors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">In March 2010, the Patient Protection and Affordable Care Act,
as amended by the Health Care and Education Reconciliation Act of 2010 (collectively the &#34;PPACA&#34;), was enacted. The PPACA was
intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against healthcare
fraud and abuse, add new transparency requirements for healthcare and health insurance industries, impose new taxes and fees on the health
industry and impose additional health policy reforms. The PPACA increased manufacturers' rebate liability under the Medicaid Drug Rebate
Program by increasing the minimum rebate amount for both branded and generic drugs and revised the definition of &#34;average manufacturer
price&#34;, which may also increase the amount of Medicaid drug rebates manufacturers are required to pay to states. The legislation
also expanded Medicaid drug rebates and created an alternative rebate formula for certain new formulations of certain existing products
that is intended to increase the rebates due on those drugs. The Centers for Medicare &amp; Medicaid Services, which administers the Medicaid
Drug Rebate Program, also has proposed to expand Medicaid rebates to the utilization that occurs in the territories of the U.S., such
as Puerto Rico and the Virgin Islands. Further, beginning in 2011, the PPACA</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">43</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">imposed a significant annual fee on companies that manufacture
or import branded prescription drug products and required manufacturers to provide a 50% discount off the negotiated price of prescriptions
filled by beneficiaries in the Medicare Part D coverage gap, referred to as the &#34;donut hole.&#34; Legislative and regulatory proposals
have been introduced at both the state and federal level to expand post-approval requirements and restrict sales and promotional activities
for pharmaceutical products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">There have been public announcements by members of the U.S. Congress
regarding plans to repeal and replace or amend and expand the PPACA and Medicare. For example, on December 22, 2017 the Tax Cuts and Jobs
Act of 2017 was signed into law, which, among other things, eliminated the individual mandate requiring most Americans (other than those
who qualify for a hardship exemption) to carry a minimum level of health coverage, effective January 1, 2019. We are not sure whether
additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the
impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S.
Congress of the FDA's approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent
product labeling and post-marketing approval testing and other requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">In addition to the PPACA, there will continue to be proposals
by legislators at both the federal and state levels, regulators and third-party payers to reduce costs while expanding individual healthcare
benefits. Certain of these changes could impose additional limitations on the prices we will be able to charge for our current and future
solutions or the amounts of reimbursement available for our current and future solutions from governmental agencies or third-party payers.
While in general it is difficult to predict specifically what effects the PPACA or any future healthcare reform legislation or policies
will have on our business, current and future healthcare reform legislation and policies could have a material adverse effect on our business
and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">In Europe, the United Kingdom withdrew from the European Union
on January 31, 2020 and began a transition period that ended on December 31, 2020. Although the ultimate effects of Brexit have yet to
be seen, Brexit has created additional uncertainties that may ultimately result in new regulatory costs and challenges for companies and
increased restrictions on imports and exports throughout Europe, which could adversely affect our ability to conduct and expand our operations
in Europe and which may have an adverse effect on our business, financial condition and results of operations. Additionally, Brexit may
increase the possibility that other countries may decide to leave the EU in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>Changes in government funding for the FDA and other government
agencies could hinder their ability to hire and&#160;retain key leadership and other personnel, properly administer drug innovation, or
prevent our product&#160;candidates from being developed or commercialized, which could negatively impact our business, financial&#160;condition
and results of operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">The ability of the FDA to review and approve new products can
be affected by a variety of factors, including budget and funding levels, ability to hire and retain key personnel, and statutory, regulatory
and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of
other agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">In December 2016, the 21<sup>st</sup>&#160;Century Cures Act
was signed into law. This new legislation is designed to advance medical innovation and empower the FDA with the authority to directly
hire positions related to drug and device development and review. However, government proposals to reduce or eliminate budgetary deficits
may include reduced allocations to the FDA and other related government agencies. These budgetary pressures may result in a reduced ability
by the FDA to perform their respective roles, including the related impact to academic institutions and research laboratories whose funding
is fully or partially dependent on both the level and timing of funding from government sources.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Disruptions at the FDA and other agencies may also slow the time
necessary for our product candidates to be reviewed or approved by necessary government agencies, which could adversely affect our business,
financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>We are subject to &#34;fraud and abuse&#34; and similar
laws and regulations, and a failure to comply with such&#160;regulations or prevail in any litigation related to noncompliance could harm
our business, financial condition&#160;and results of operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">In the U.S., we are subject to various federal and state healthcare
&#34;fraud and abuse&#34; laws, including anti-kickback laws, false claims laws and other laws intended, among other things, to reduce
fraud and abuse in federal and state healthcare programs. The federal Anti-Kickback Statute makes it illegal for any person, including
a prescription drug manufacturer, or a party acting on its behalf, to knowingly and willfully solicit, receive, offer or pay any remuneration
that is intended to induce the referral of business, including the purchase, order or prescription of a particular drug, or other good
or service for which payment in whole or in part may be made under a federal healthcare program, such as Medicare or Medicaid. Although
we seek to structure our business arrangements in compliance with all applicable requirements, these laws are broadly written, and it
is often difficult to determine precisely how the law will be applied in specific circumstances. Accordingly, it is possible that our
practices may be challenged under the federal Anti-Kickback Statute.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">44</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">The federal False Claims Act prohibits anyone from, among other
things, knowingly presenting or causing to be presented for payment to the government, including the federal healthcare programs, claims
for reimbursed drugs or services that are false or fraudulent, claims for items or services that were not provided as claimed, or claims
for medically unnecessary items or services. Under the Health Insurance Portability and Accountability Act of 1996, we are prohibited
from knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private payors, or knowingly and
willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in
connection with the delivery of or payment for healthcare benefits, items or services to obtain money or property of any healthcare benefit
program. Violations of fraud and abuse laws may be punishable by criminal or civil sanctions, including penalties, fines or exclusion
or suspension from federal and state healthcare programs such as Medicare and Medicaid and debarment from contracting with the U.S. government.
In addition, private individuals have the ability to bring actions on behalf of the government under the federal False Claims Act as well
as under the false claims laws of several states.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Many states have adopted laws similar to the federal Anti-Kickback
Statute, some of which apply to the referral of patients for healthcare services reimbursed by any source, not just governmental payors.
In addition, some states have passed laws that require pharmaceutical companies to comply with the April 2003 Office of Inspector General
Compliance Program Guidance for Pharmaceutical Manufacturers or the Pharmaceutical Research and Manufacturers of America's Code on Interactions
with Healthcare Professionals. Several states also impose other marketing restrictions or require pharmaceutical companies to make marketing
or price disclosures to the state. There are ambiguities as to what is required to comply with these state requirements and if we fail
to comply with an applicable state law requirement, we could be subject to penalties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Neither the government nor the courts have provided definitive
guidance on the application of fraud and abuse laws to our business. Law enforcement authorities are increasingly focused on enforcing
these laws, and it is possible that some of our practices may be challenged under these laws. Efforts to ensure that our business arrangements
with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. If we are found in violation
of one of these laws, we could be subject to significant civil, criminal and administrative penalties, damages, fines, exclusion from
governmental funded federal or state healthcare programs and the curtailment or restructuring of our operations. If this occurs, our business,
financial condition and results of operations may be materially adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>If we face allegations of noncompliance with the law and
encounter sanctions, our reputation, revenues and&#160;liquidity may suffer, and any of our product candidates that are ultimately approved
for commercialization&#160;could be subject to restrictions or withdrawal from the market.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Any government investigation of alleged violations of law could
require us to expend significant time and resources in response, and could generate negative publicity. Any failure to comply with ongoing
regulatory requirements may significantly and adversely affect our ability to generate revenues from any of our product candidates that
are ultimately approved for commercialization. If regulatory sanctions are applied or if regulatory approval is withdrawn, our business,
financial condition and results of operations will be adversely affected. Additionally, if we are unable to generate revenues from product
sales, our potential for achieving profitability will be diminished and our need to raise capital to fund our operations will increase.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>*If we fail to retain current members of our senior management
and scientific personnel, or to attract and&#160;keep additional key personnel, we may be unable to successfully develop or commercialize
our product&#160;candidates.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Our success depends on our continued ability to attract, retain
and motivate highly qualified management and scientific personnel. As of April 29, 2022, we have 16 employees. Our organization will rely
primarily on outsourcing research, development and clinical trial activities, and manufacturing operations, as well as other functions
critical to our business. We believe this approach enhances our ability to focus on our core product opportunities, allocate resources
efficiently to different projects and allocate internal resources more effectively. We have filled several key open positions and are
currently recruiting for a few remaining positions. However, competition for qualified personnel is intense. We may not be successful
in attracting qualified personnel to fulfill our current or future needs and there is no guarantee that any of these individuals will
join us on a full-time employment basis, or at all. In the event we are unable to fill critical open employment positions, we may need
to delay our operational activities and goals, including the development of our product candidates, and may have difficulty in meeting
our obligations as a public company. In addition, we may experience employee turnover as a result of the ongoing &#8220;great resignation&#8221;
occurring throughout the U.S. economy, which has impacted job market dynamics. New hires require training and take time before they achieve
full productivity. New employees may not become as productive as we expect, and we may be unable to hire or retain sufficient numbers
of qualified individuals. In the event we are unable to fill critical open employment positions, we may need to delay our operational
activities and goals, including the development of our product candidates, and may have difficulty in meeting our obligations as a public
company.&#160;We do not maintain &#34;key person&#34; insurance on any of our employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">45</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">In addition, competitors and others are likely in the future
to attempt to recruit our employees. The loss of the services of any of our key personnel, the inability to attract or retain highly qualified
personnel in the future or delays in hiring such personnel, particularly senior management and other technical personnel, could materially
and adversely affect our business, financial condition and results of operations. In addition, the replacement of key personnel likely
would involve significant time and costs, and may significantly delay or prevent the achievement of our business objectives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">From time to time, our management seeks the advice and guidance
of certain scientific advisors and consultants regarding clinical and regulatory development programs and other customary matters. These
scientific advisors and consultants are not our employees and may have commitments to, or consulting or advisory contracts with, other
entities that may limit their availability to us. In addition, our scientific advisors may have arrangements with other companies to assist
those companies in developing products or technologies that may compete with us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>We will need to increase the size of our organization and
may not successfully manage our growth.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">We are a clinical-stage biopharmaceutical company with a small
number of planned employees, and our management system currently in place is not likely to be adequate to support our future growth plans.
Our ability to grow and to manage our growth effectively will require us to hire, train, retain, manage and motivate additional employees
and to implement and improve our operational, financial and management systems. These demands also may require the hiring of additional
senior management personnel or the development of additional expertise by our senior management personnel. Hiring a significant number
of additional employees, particularly those at the management level, would increase our expenses significantly. Moreover, if we fail to
expand and enhance our operational, financial and management systems in conjunction with our potential future growth, it could have a
material adverse effect on our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>Our management's lack of public company experience could
put us at greater risk of incurring fines or&#160;regulatory actions for failure to comply with federal securities laws and could put
us at a competitive&#160;disadvantage, and could require our management to devote additional time and resources to ensure&#160;compliance
with applicable corporate governance requirements.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Our executive officers do not have prior experience as executive
officers in managing and operating a public company, which could have an adverse effect on their ability to quickly respond to problems
or adequately address issues and matters applicable to public companies. Any failure to comply with federal securities laws, rules or
regulations could subject us to fines or regulatory actions, which may materially adversely affect our business, financial condition and
results of operations. Further, since our executive officers do not have prior experience as executive officers managing and operating
a public company, we may need to dedicate additional time and resources to comply with legally mandated corporate governance policies
relative to our competitors whose management teams have more public company experience.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>We are exposed to product liability, non-clinical and clinical
liability risks which could place a substantial&#160;financial burden upon us, should lawsuits be filed against us.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Our business exposes us to potential product liability and other
liability risks that are inherent in the testing, manufacturing and marketing of pharmaceutical formulations and products. In addition,
the use in our clinical trials of pharmaceutical products and the subsequent sale of these products by us or our potential collaborators
may cause us to bear a portion of or all product liability risks. A successful liability claim or series of claims brought against us
could have a material adverse effect on our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">We currently carry product liability insurance for our clinical
development activities. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated
adverse effects. A successful product liability claim or series of claims brought against us could cause our stock price to decline and,
if judgments exceed our insurance coverage, could adversely affect our results of operations and business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>Our research and development activities involve the use
of hazardous materials, which subject us to&#160;regulation, related costs and delays and potential liabilities.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Our research and development activities involve the controlled
use of hazardous materials and chemicals, and we will need to develop additional safety procedures for the handling and disposing of hazardous
materials. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous
environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne
pathogens and the handling of biohazardous materials. Additional federal, state and local laws and regulations affecting our operations
may be adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate any of these
laws or regulations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">46</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;<b><i>We rely significantly on information technology
and any failure, inadequacy, interruption or security lapse&#160;of that technology, including any cybersecurity incidents, could harm
our ability to operate our business&#160;effectively.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Despite the implementation of security measures, our internal
computer systems and those of third parties with which we contract are vulnerable to damage from cyber-attacks, computer viruses, unauthorized
access, natural disasters, terrorism, war and telecommunication and electrical failures. System failures, accidents or security breaches
could cause interruptions in our operations, and could result in a material disruption of our drug development and clinical activities
and business operations, in addition to possibly requiring substantial expenditures of resources to remedy. The loss of drug development
or clinical trial data could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce
the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or
inappropriate disclosure of confidential or proprietary information, we could incur liability and our development programs and the development
of our product candidates could be delayed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>Our employees and consultants may engage in misconduct
or other improper activities, including&#160;noncompliance with regulatory standards and requirements.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">We are exposed to the risk of employee or consultant fraud or
other misconduct. Misconduct by our employees or consultants could include intentional failures to comply with FDA regulations, provide
accurate information to the FDA, comply with manufacturing standards, comply with federal and state healthcare fraud and abuse laws and
regulations, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing
and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks,
self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing
and promotion, sales commissions, customer incentive programs and other business arrangements. Employee and consultant misconduct also
could involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and
serious harm to our reputation. It is not always possible to identify and deter such misconduct, and the precautions we take to detect
and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental
investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions
are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a material
adverse effect on our business, financial condition and results of operations, and result in the imposition of significant fines or other
sanctions against us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>Business disruptions such as natural disasters could seriously
harm our future revenues and financial&#160;condition and increase our costs and expenses.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">We and our suppliers may experience a disruption in our and
their business as a result of natural disasters. A significant natural or man-made disaster, such as an earthquake, power outages,
hurricane, flood or fire, drought and other extreme weather events and changing weather patterns, which are increasing in frequency
due to the impacts of climate change, could severely damage or destroy our headquarters or facilities or the facilities of our
manufacturers or suppliers, which could have a material and adverse effect on our business, financial condition and results of
operations. In addition, terrorist acts or acts of war targeted at the U.S., and specifically the greater New York, New York region,
could cause damage or disruption to us, our employees, facilities, partners and suppliers, which could have a material adverse
effect on our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>We may engage in strategic transactions that could impact
our liquidity, increase our expenses and present&#160;significant distractions to our management.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">From time to time, we may consider strategic transactions, such
as acquisitions of companies, asset purchases and out-licensing or in-licensing of products, product candidates or technologies. Additional
potential transactions that we may consider include a variety of different business arrangements, including spin-offs, strategic partnerships,
joint ventures, restructurings, divestitures, business combinations and investments. Any such transaction may require us to incur non-recurring
or other charges, may increase our near- and long-term expenditures and may pose significant integration challenges or disrupt our management
or business, which could adversely affect our business, financial condition and results of operations. For example, these transactions
may entail numerous operational and financial risks, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<ul style="margin-top: 0in; list-style-type: disc">

<li style="margin: 0; font-size: 10pt">exposure to unknown liabilities;</li>

<li style="margin: 0; font-size: 10pt">disruption of our business and diversion of our management's time and attention in order to develop
acquired products, product candidates or technologies;</li>

<li style="margin: 0; font-size: 10pt">incurrence of substantial debt or dilutive issuances of equity securities to pay for any of these
transactions;</li>

<li style="margin: 0; font-size: 10pt">higher-than-expected transaction and integration costs;</li>

<li style="margin: 0; font-size: 10pt">write-downs of assets or goodwill or impairment charges;</li>

<li style="margin: 0; font-size: 10pt">increased amortization expenses;</li>
</ul>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">47</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<ul style="margin-top: 0in; list-style-type: disc">
<li style="margin: 0; font-size: 10pt">difficulty and cost in combining the operations and personnel of any acquired businesses or product
lines with our operations and personnel;</li>

<li style="margin: 0; font-size: 10pt">impairment of relationships with key suppliers or customers of any acquired businesses or product
lines due to changes in management and ownership; and</li>

<li style="margin: 0; font-size: 10pt">inability to retain key employees of any acquired businesses.</li>

</ul>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Accordingly, although there can be no assurance that we will
undertake or successfully complete any transactions of the nature described above, any transactions that we do complete may be subject
to the foregoing or other risks, and could have a material adverse effect on our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>Compliance with global privacy and data security requirements
could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to
comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business,
financial condition or results of operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">The regulatory framework for the collection, use, safeguarding,
sharing, transfer and other processing of information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable
future. Globally, virtually every jurisdiction in which we operate has established its own data security and privacy frameworks with which
we must comply. For example, the collection, use, disclosure, transfer, or other processing of personal data regarding individuals in
the European Union, including personal health data, is subject to the EU General Data Protection Regulation (the &#8220;GDPR&#8221;),
which took effect across all member states of the European Economic Area (the &#8220;EEA&#8221;) in May 2018. The GDPR is wide-ranging
in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health
and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals
regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing
notification of data breaches, and taking certain measures when engaging third-party processors. In addition, the GDPR also imposes strict
rules on the transfer of personal data to countries outside the European Union, including the United States and, as a result, increases
the scrutiny that clinical trial sites located in the EEA should apply to transfers of personal data from such sites to countries that
are considered to lack an adequate level of data protection, such as the United States. The GDPR also permits data protection authorities
to require destruction of improperly gathered or used personal information and/or impose substantial fines for violations of the GDPR,
which can be up to 4% of global revenues or &#8364;20 million, whichever is greater, and it also confers a private right of action on data
subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for
damages resulting from violations of the GDPR. In addition, the GDPR provides that EU member states may make their own further laws and
regulations limiting the processing of personal data, including genetic, biometric or health data.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Similar actions are either in place or under way in the United
States. There are a broad variety of data protection laws that are applicable to our activities, and a wide range of enforcement agencies
at both the state and federal levels that can review companies for privacy and data security concerns based on general consumer protection
laws. The Federal Trade Commission and state Attorneys General all are aggressive in reviewing privacy and data security protections for
consumers. New laws also are being considered at both the state and federal levels. For example, the California Consumer Privacy Act,
which went into effect on January 1, 2020, is creating similar risks and obligations as those created by the GDPR, though the California
Consumer Privacy Act does exempt certain clinical trial data. Many other states are considering similar legislation. A broad range of
legislative measures also have been introduced at the federal level. Accordingly, failure to comply with federal and state laws (both
those currently in effect and future legislation) regarding privacy and security of personal information could expose us to fines and
penalties under such laws. There also is the threat of consumer class actions related to these laws and the overall protection of personal
data.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Given the breadth and depth of changes in data protection obligations,
preparing for and complying with these requirements is rigorous and time intensive and requires significant resources and a review of
our technologies, systems and practices, as well as those of any third-party collaborators, service providers, contractors or consultants
that process or transfer personal data collected in the European Union. The GDPR and other changes in laws or regulations associated with
the enhanced protection of certain types of sensitive data, such as healthcare data or other personal information from our clinical trials,
could require us to change our business practices and put in place additional compliance mechanisms, may interrupt or delay our development,
regulatory and commercialization activities and increase our cost of doing business, and could lead to government enforcement actions,
private litigation and significant fines and penalties against us and could have a material adverse effect on our business, financial
condition or results of operations. Similarly, failure to comply with federal and state laws regarding privacy and security of personal
information could expose us to fines and penalties under such laws. Even if we are not determined to have violated these laws, government
investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could
harm our reputation and our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">48</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>We are subject to certain U.S. and foreign anti-corruption,
anti-money laundering, export control, sanctions, and other trade laws and regulations. If we fail to comply with these laws, we could
be subject to civil or criminal liabilities, other remedial measures and legal expenses, be precluded from developing, manufacturing and
selling certain products outside the United States or be required to develop and implement costly compliance programs, which could adversely
affect our business, results of operations and financial condition.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Our operations are subject to anti-corruption laws, including
the U.S. Foreign Corrupt Practices Act (the &#8220;FCPA&#8221;), the U.K. Bribery Act 2010 (the &#8220;Bribery Act&#8221;) and other anti-corruption
laws that apply in countries where we do business and may do business in the future. The FCPA, the Bribery Act and these other laws generally
prohibit us, our officers, and our employees and intermediaries from bribing, being bribed or making other prohibited payments to government
officials or other persons to obtain or retain business or gain some other business advantage. Compliance with the FCPA, in particular,
is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular
challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other
hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have
been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">We may in the future operate in jurisdictions that pose a high
risk of potential FCPA or Bribery Act violations, and we may participate in collaborations and relationships with third parties whose
actions could potentially subject us to liability under the FCPA, the Bribery Act or local anti-corruption laws. In addition, we cannot
predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner
in which existing laws might be administered or interpreted. If we expand our operations outside of the United States, we will need to
dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">We are also subject to other laws and regulations governing our
international operations, including regulations administered by the governments of the United States, the United Kingdom and authorities
in the European Union, including applicable export control regulations, economic sanctions on countries and persons, customs requirements
and currency exchange regulations (collectively referred to as &#8220;Trade Control Laws&#8221;). In addition, various laws, regulations
and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals,
of information classified for national security purposes, as well as certain products and technical data relating to those products. If
we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and
these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States,
which could limit our growth potential and increase our development costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">There is no assurance that we will be completely effective in
ensuring our compliance with all applicable anti-corruption laws, including the FCPA, the Bribery Act or other legal requirements, including
Trade Control Laws. If we are not in compliance with the FCPA, the Bribery Act and other anti-corruption laws or Trade Control Laws, we
may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could
have an adverse impact on our business, financial condition, results of operations and liquidity. The Securities and Exchange Commission
also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions. Any
investigation of any potential violations of the FCPA, the Bribery Act, other anti-corruption laws or Trade Control Laws by U.S., United
Kingdom or other authorities could also have an adverse impact on our reputation, our business, results of operations and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>Governments outside the United States tend to impose strict
price controls, which may adversely affect our revenue, if any.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">In some countries, particularly member states of the European
Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental
authorities can take considerable time after the receipt of marketing approval for a product. In addition, there can be considerable pressure
by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic
and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has
been obtained. Reference pricing used by various European Union member states and parallel distribution, or arbitrage between low-priced
and high-priced member states, can further reduce prices. In some countries, we, or our future collaborators, may be required to conduct
a clinical trial or other studies that compare the cost-effectiveness of our product candidates to other available therapies in order
to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further
pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of any product
candidate approved for marketing is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business
could be materially harmed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">49</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>*Investors&#8217; expectations of our performance relating
to environmental, social and governance factors may impose additional costs and expose us to new risks.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">There is an increasing focus from certain investors, employees,
regulators and other stakeholders concerning corporate responsibility, specifically related to environmental, social and governance, or
ESG, factors. Some investors and investor advocacy groups may use these factors to guide investment strategies and, in some cases, investors
may choose not to invest in our company if they believe our policies relating to corporate responsibility are inadequate. Third-party
providers of corporate responsibility ratings and reports on companies have increased to meet growing investor demand for measurement
of corporate responsibility performance, and a variety of organizations currently measure the performance of companies on such ESG topics,
and the results of these assessments are widely publicized. Investors, particularly institutional investors, use these ratings to benchmark
companies against their peers and if we are perceived as lagging with respect to ESG initiatives, certain investors may engage with us
to improve ESG disclosures or performance and may also make voting decisions, or take other actions, to hold us and our board of directors
accountable. In addition, the criteria by which our corporate responsibility practices are assessed may change, which could result in
greater expectations of us and cause us to undertake costly initiatives to satisfy such new criteria. If we elect not to or are unable
to satisfy such new criteria, investors may conclude that our policies with respect to corporate responsibility are inadequate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">We may face reputational damage in the event our corporate responsibility
initiatives or objectives do not meet the standards set by our investors, stockholders, lawmakers, listing exchanges or other constituencies,
or if we are unable to achieve an acceptable ESG or sustainability rating from third-party rating services. A low ESG or sustainability
rating by a third-party rating service could also result in the exclusion of our common stock from consideration by certain investors
who may elect to invest with our competition instead. Ongoing focus on corporate responsibility matters by investors and other parties
as described above may impose additional costs or expose us to new risks. Any failure or perceived failure by us in this regard could
have a material adverse effect on our reputation and on our business, share price, financial condition, or results of operations, including
the sustainability of our business over time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">In addition, the SEC has announced proposed rules that, among
other matters, will establish a framework for reporting of climate-related risks. To the extent the proposed rules impose additional reporting
obligations, we could face increased costs. Separately, the SEC has also announced that it is scrutinizing existing climate-change related
disclosures in public filings, increasing the potential for enforcement if the SEC were to allege our existing climate disclosures are
misleading or deficient.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b>Risks Related to Our Intellectual Property</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>We may not be successful in obtaining or maintaining necessary
rights to our product candidates through&#160;acquisitions and in-licenses.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Because several of our programs require the use of proprietary
rights held by third parties, the growth of our business will likely depend in part on our ability to maintain and exploit these proprietary
rights. In addition, we may need to acquire or in-license additional intellectual property in the future. We may be unable to acquire
or in-license any compositions, methods of use, processes or other intellectual property rights from third parties that we identify as
necessary for our product candidates. We face competition with regard to acquiring and in-licensing third-party intellectual property
rights, including from a number of more established companies. These established companies may have a competitive advantage over us due
to their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive
us to be a competitor may be unwilling to assign or license intellectual property rights to us. We also may be unable to acquire or in-license
third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">We may enter into collaboration agreements with U.S. and foreign
academic institutions to accelerate development of our current or future preclinical product candidates. Typically, these agreements include
an option for the company to negotiate a license to the institution's intellectual property rights resulting from the collaboration. Even
with such an option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us.
If we are unable to license rights from a collaborating institution, the institution may offer the intellectual property rights to other
parties, potentially blocking our ability to pursue our desired program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">If we are unable to successfully obtain required third-party
intellectual property rights or maintain our existing intellectual property rights, we may need to abandon development of the related
program and our business, financial condition and results of operations could be materially and adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">50</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>If we fail to comply with our obligations in the agreements
under which we in-license intellectual property&#160;and other rights from third parties or otherwise experience disruptions to our business
relationships with&#160;our licensors, we could lose intellectual property rights that are important to our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Our license agreement with Ligand Pharmaceuticals
Incorporated, Neurogen Corporation and CyDex Pharmaceuticals, Inc. (the &#34;Ligand License Agreement&#34;), our license agreement
with the Regents of the University of California (the &#34;UC Regents License Agreement&#34;), our license agreement with Duke
University (the &#34;Duke License Agreement) and our license agreement with iX Biopharma Ltd. (the &#8220;iX License
Agreement&#8221;, together with the Ligand License Agreement, the UC Regents License Agreement and the Duke License Agreement, the
&#8220;License Agreements&#8221;) are important to our business and we expect to enter into additional license agreements in the
future. The License Agreements impose, and we expect that future license agreements will impose, various milestone payments,
royalties and other obligations on us. If we fail to comply with our obligations under these agreements, or if we file for
bankruptcy, we may be required to make certain payments to the licensor, we may lose the exclusivity of our license, or the licensor
may have the right to terminate the license, in which event we would not be able to develop or market products covered by the
license. Additionally, the milestone and other payments associated with these licenses could materially and adversely affect our
business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Pursuant to the terms of the Ligand License Agreement, the licensors
each have the right to terminate the Ligand License Agreement with respect to the programs licensed by such licensor under certain circumstances,
including, but not limited to: (i) if we do not pay an amount that is not disputed in good faith, (ii) if we willfully breach the Ligand
License Agreement in a manner for which legal remedies would not be expected to make such licensor whole, or (iii) if we file or have
filed against us a petition in bankruptcy or make an assignment for the benefit of creditors. In the event the Ligand License Agreement
is terminated by a licensor, all licenses granted to us by such licensor will terminate immediately. Further, pursuant to the terms of
the UC Regents License Agreement, the licensor has the right to terminate the UC Regents License Agreement or reduce our license to a
nonexclusive license if we fail to achieve certain milestones within a specified timeframe. Similarly, pursuant to the terms of the Duke
License Agreement and the iX License Agreement, each licensor has the right to terminate the Duke License Agreement or the iX License
Agreement, as applicable, if we fail to achieve certain milestones within a specified timeframe.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">In some cases, patent prosecution of our licensed technology
may be controlled solely by the licensor. If our licensor fails to obtain and maintain patent or other protection for the proprietary
intellectual property we in-license, then we could lose our rights to the intellectual property or our exclusivity with respect to those
rights, and our competitors could market competing products using the intellectual property. In certain cases, we may control the prosecution
of patents resulting from licensed technology. In the event we breach any of our obligations related to such prosecution, we may incur
significant liability to our licensing partners. Licensing of intellectual property is of critical importance to our business and involves
complex legal, business and scientific issues. Disputes may arise regarding intellectual property subject to a licensing agreement, including,
but not limited to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<ul style="margin-top: 0in; list-style-type: disc">

<li style="margin: 0; font-size: 10pt">the scope of rights granted under the license agreement and other interpretation-related issues;</li>

<li style="margin: 0; font-size: 10pt">the extent to which our technology and processes infringe on intellectual property of the licensor
that is not subject to the licensing agreement;</li>

<li style="margin: 0; font-size: 10pt">the sublicensing of patent and other rights;</li>

<li style="margin: 0; font-size: 10pt">our diligence obligations under the license agreement and what activities satisfy those diligence
obligations;</li>

<li style="margin: 0; font-size: 10pt">the ownership of inventions and know-how resulting from the joint creation or use of intellectual
property by us, our licensors and our collaborators; and</li>

<li style="margin: 0; font-size: 10pt">the priority of invention of patented technology.</li>

</ul>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">If disputes over intellectual property and other rights that
we have in-licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable
to successfully develop and commercialize the affected product candidates. If we fail to comply with any such obligations to our licensor,
such licensor may terminate its licenses to us, in which case we would not be able to market products covered by these licenses. The loss
of our licenses would have a material adverse effect on our business.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">51</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>*We are required to make certain cash payments and may be
required to pay milestones and royalties pursuant to certain commercial agreements, which could adversely affect the overall profitability
for us of any products that we may seek to commercialize.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Under the terms of the Ligand License Agreement, we may be obligated
to pay the licensor under the Ligand License Agreement up to an aggregate of approximately $126.7 million in development, regulatory and
sales milestones. Similarly, under the terms of the iX License Agreement, we may be obligated to pay the licensor under the iX License
Agreement up to an aggregate of approximately $239 million in development, regulatory and sales milestones. We will also be required to
pay royalties on future worldwide net product sales. We will also be required to pay up to an aggregate of approximately $17 million in
development and regulatory milestones and royalties on any net sales of SLS-005 pursuant to our asset purchase agreement with Bioblast
Pharma Ltd. These cash, milestone and royalty payments could adversely affect the overall profitability for us of any products that we
may seek to commercialize.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>We may not be able to protect our proprietary or licensed
technology in the marketplace.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">We depend on our ability to protect our proprietary or licensed
technology. We rely on trade secret, patent, copyright and trademark laws, and confidentiality, licensing and other agreements with employees
and third parties, all of which offer only limited protection. Our success depends in large part on our ability and any licensor's or
licensee's ability to obtain and maintain patent protection in the U.S. and other countries with respect to our proprietary or licensed
technology and products. We currently in-license some of our intellectual property rights to develop our product candidates and may in-license
additional intellectual property rights in the future. We cannot be certain that patent enforcement activities by our current or future
licensors have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents
or other intellectual property rights. We also cannot be certain that our current or future licensors will allocate sufficient resources
or prioritize their or our enforcement of such patents. Even if we are not a party to these legal actions, an adverse outcome could prevent
us from continuing to license intellectual property that we may need to operate our business, which would have a material adverse effect
on our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Although we believe we will be able to obtain, through prosecution
of patent applications covering our owned technology and technology licensed from others, adequate patent protection for our proprietary
drug technology, including those related to our in-licensed intellectual property, if we are compelled to spend significant time and money
protecting or enforcing our licensed patents and future patents we may own, designing around patents held by others or licensing or acquiring,
potentially for large fees, patents or other proprietary rights held by others, our business, financial condition and results of operations
may be materially and adversely affected. If we are unable to effectively protect the intellectual property that we own or in-license,
other companies may be able to offer the same or similar products for sale, which could materially adversely affect our business, financial
condition and results of operations. The patents of others from whom we may license technology, and any future patents we may own, may
be challenged, narrowed, invalidated or circumvented, which could limit our ability to stop competitors from marketing the same or similar
products or limit the length of term of patent protection that we may have for our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>Obtaining and maintaining patent protection depends on
compliance with various procedural, document&#160;submission, fee payment and other requirements imposed by governmental patent agencies,
and our patent&#160;protection for licensed patents, pending patent applications and potential future patent applications and patents&#160;could
be reduced or eliminated for non-compliance with these requirements.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Periodic maintenance fees, renewal fees, annuity fees and various
other governmental fees on patents and/or patent applications will be due to be paid to the U.S. Patent and Trademark Office (&#34;USPTO&#34;)
and various governmental patent agencies outside of the U.S. in several stages over the lifetime of the applicable patent and/or patent
application. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary,
fee payment and other similar provisions during the patent application process. In many cases, an inadvertent lapse can be cured by payment
of a late fee or by other means in accordance with the applicable rules. However, there are situations in which noncompliance can result
in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.
If this occurs with respect to our in-licensed patents or patent applications we may file in the future, our competitors might be able
to use our technologies, which would have a material adverse effect on our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">52</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">The patent positions of pharmaceutical products are often complex
and uncertain. The breadth of claims allowed in pharmaceutical patents in the U.S. and many jurisdictions outside of the U.S. is not consistent.
For example, in many jurisdictions, the support standards for pharmaceutical patents are becoming increasingly strict. Some countries
prohibit method of treatment claims in patents. Changes in either the patent laws or interpretations of patent laws in the U.S. and other
countries may diminish the value of our licensed or owned intellectual property or create uncertainty. In addition, publication of information
related to our current product candidates and potential products may prevent us from obtaining or enforcing patents relating to these
product candidates and potential products, including without limitation composition-of-matter patents, which are generally believed to
offer the strongest patent protection.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Patents that we currently license and patents that we may own
or license in the future do not necessarily ensure the protection of our licensed or owned intellectual property for a number of reasons,
including, without limitation, the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<ul style="margin-top: 0in; list-style-type: disc">

<li style="margin: 0; font-size: 10pt">the patents may not be broad or strong enough to prevent competition from other products that are
identical or similar to our product candidates;</li>

<li style="margin: 0; font-size: 10pt">there can be no assurance that the term of a patent can be extended under the provisions of patent
term extensions afforded by U.S. law or similar provisions in foreign countries, where available;</li>

<li style="margin: 0; font-size: 10pt">the issued patents and patents that we may obtain or license in the future may not prevent generic
entry into the market for our product candidates;</li>

<li style="margin: 0; font-size: 10pt">we, or third parties from whom we in-license or may license patents, may be required to disclaim
part of the term of one or more patents;</li>

<li style="margin: 0; font-size: 10pt">there may be prior art of which we are not aware that may affect the validity or enforceability
of a patent claim;</li>

<li style="margin: 0; font-size: 10pt">there may be prior art of which we are aware, which we do not believe affects the validity or enforceability
of a patent claim, but which, nonetheless, ultimately may be found to affect the validity or enforceability of a patent claim;</li>

<li style="margin: 0; font-size: 10pt">there may be other patents issued to others that will affect our freedom to operate;</li>

<li style="margin: 0; font-size: 10pt">if the patents are challenged, a court could determine that they are invalid or unenforceable;</li>

<li style="margin: 0; font-size: 10pt">there might be a significant change in the law that governs patentability, validity and infringement
of our licensed patents or any future patents we may own that adversely affects the scope of our patent rights;</li>

<li style="margin: 0; font-size: 10pt">a court could determine that a competitor's technology or product does not infringe our licensed
patents or any future patents we may own; and</li>

<li style="margin: 0; font-size: 10pt">the patents could irretrievably lapse due to failure to pay fees or otherwise comply with regulations
or could be subject to compulsory licensing.</li>

</ul>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">If we encounter delays in our development or clinical trials,
the period of time during which we could market our potential products under patent protection would be reduced.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Our competitors may be able to circumvent our licensed patents
or future patents we may own by developing similar or alternative technologies or products in a non-infringing manner. Our competitors
may seek to market generic versions of any approved products by submitting abbreviated new drug applications to the FDA in which our competitors
claim that our licensed patents or any future patents we may own are invalid, unenforceable or not infringed. Alternatively, our competitors
may seek approval to market their own products similar to or otherwise competitive with our products. In these circumstances, we may need
to defend or assert our licensed patents or any future patents we may own, including by filing lawsuits alleging patent infringement.
In any of these types of proceedings, a court or other agency with jurisdiction may find our licensed patents or any future patents we
may own invalid or unenforceable. We may also fail to identify patentable aspects of our research and development before it is too late
to obtain patent protection. Even if we own or in-license valid and enforceable patents, these patents still may not provide protection
against competing products or processes sufficient to achieve our business objectives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">The issuance of a patent is not conclusive as to its inventorship,
scope, ownership, priority, validity or enforceability. In this regard, third parties may challenge our licensed patents or any future
patents we may own in the courts or patent offices in the U.S. and abroad. Such challenges may result in loss of exclusivity or freedom
to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to
stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection
of our technology and potential products. In addition, given the amount of time required for the development, testing and regulatory review
of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are
commercialized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">53</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>We may infringe the intellectual property rights of others,
which may prevent or delay our drug development&#160;efforts and prevent us from commercializing or increase the costs of commercializing
our products.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Our commercial success depends significantly on our ability to
operate without infringing the patents and other intellectual property rights of third parties. For example, there could be issued patents
of which we are not aware that our current or potential future product candidates infringe. There also could be patents that we believe
we do not infringe, but that we may ultimately be found to infringe.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Moreover, patent applications are in some cases maintained in
secrecy until patents are issued. The publication of discoveries in the scientific or patent literature frequently occurs substantially
later than the date on which the underlying discoveries were made and patent applications were filed. Because patents can take many years
to issue, there may be currently pending applications of which we are unaware that may later result in issued patents that our product
candidates or potential products infringe. For example, pending applications may exist that claim or can be amended to claim subject matter
that our product candidates or potential products infringe. Competitors may file continuing patent applications claiming priority to already
issued patents in the form of continuation, divisional, or continuation-in-part applications, in order to maintain the pendency of a patent
family and attempt to cover our product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Third parties may assert that we are employing their proprietary
technology without authorization and may sue us for patent or other intellectual property infringement. These lawsuits are costly and
could adversely affect our business, financial condition and results of operations and divert the attention of managerial and scientific
personnel. If we are sued for patent infringement, we would need to demonstrate that our product candidates, potential products or methods
either do not infringe the claims of the relevant patent or that the patent claims are invalid, and we may not be able to do this. Proving
invalidity is difficult. For example, in the U.S., proving invalidity requires a showing of clear and convincing evidence to overcome
the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs
and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could have
a material adverse effect on us. In addition, we may not have sufficient resources to bring these actions to a successful conclusion.
If a court holds that any third-party patents are valid, enforceable and cover our products or their use, the holders of any of these
patents may be able to block our ability to commercialize our products unless we acquire or obtain a license under the applicable patents
or until the patents expire.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">We may not be able to enter into licensing arrangements or make
other arrangements at a reasonable cost or on reasonable terms. Any inability to secure licenses or alternative technology could result
in delays in the introduction of our products or lead to prohibition of the manufacture or sale of products by us. Even if we are able
to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could
be forced, including by court order, to cease commercializing the infringing technology or product. In addition, in any such proceeding
or litigation, we could be found liable for monetary damages, including treble damages and attorneys' fees, if we are found to have willfully
infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of
our business operations, which could materially and adversely affect our business, financial condition and results of operations. Any
claims by third parties that we have misappropriated their confidential information or trade secrets could have a similar material and
adverse effect on our business, financial condition and results of operations. In addition, any uncertainties resulting from the initiation
and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>Any claims or lawsuits relating to infringement of intellectual
property rights brought by or against us will be&#160;costly and time consuming and may adversely affect our business, financial condition
and results of operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">We may be required to initiate litigation to enforce or defend
our licensed and owned intellectual property. Lawsuits to protect our intellectual property rights can be very time consuming and costly.
There is a substantial amount of litigation involving patent and other intellectual property rights in the biopharmaceutical industry
generally. Such litigation or proceedings could substantially increase our operating expenses and reduce the resources available for development
activities or any future sales, marketing or distribution activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">In any infringement litigation, any award of monetary damages
we receive may not be commercially valuable. Furthermore, because of the substantial amount of discovery required in connection with intellectual
property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. Moreover,
there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which
typically last for years before they are resolved. Further, any claims we assert against a perceived infringer could provoke these parties
to assert counterclaims against us alleging that we have infringed their patents. Some of our competitors may be able to sustain the costs
of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from
the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete
in the marketplace.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">54</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">In addition, our licensed patents and patent applications, and
patents and patent applications that we may apply for, own or license in the future, could face other challenges, such as interference
proceedings, opposition proceedings, re-examination proceedings and other forms of post-grant review. Any of these challenges, if successful,
could result in the invalidation of, or in a narrowing of the scope of, any of our licensed patents and patent applications and patents
and patent applications that we may apply for, own or license in the future subject to challenge. Any of these challenges, regardless
of their success, would likely be time consuming and expensive to defend and resolve and would divert our management and scientific personnel's
time and attention.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>Changes in U.S. patent law could diminish the value of
patents in general, thereby impairing our ability to&#160;protect our products.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">As is the case with other biopharmaceutical companies, our success
is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry
involves both technological and legal complexity and is costly, time-consuming and inherently uncertain. For example, the U.S. previously
enacted and is currently implementing wide-ranging patent reform legislation. Specifically, on September 16, 2011, the Leahy-Smith America
Invents Act (the &#34;Leahy-Smith Act&#34;) was signed into law and included a number of significant changes to U.S. patent law, and
many of the provisions became effective in March 2013. However, it may take the courts years to interpret the provisions of the Leahy-Smith
Act, and the implementation of the statute could increase the uncertainties and costs surrounding the prosecution of our licensed and
future patent applications and the enforcement or defense of our licensed and future patents, all of which could have a material adverse
effect on our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">In addition, the U.S. Supreme Court has ruled on several patent
cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent
owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination
of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the
federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability
to obtain new patents or to enforce patents that we might obtain in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>We may not be able to protect our intellectual property
rights throughout the world.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Filing, prosecuting and defending patents on product candidates
throughout the world would be prohibitively expensive. Competitors may use our licensed and owned technologies in jurisdictions where
we have not licensed or obtained patent protection to develop their own products and, further, may export otherwise infringing products
to territories where we may obtain or license patent protection, but where patent enforcement is not as strong as that in the U.S. These
products may compete with our products in jurisdictions where we do not have any issued or licensed patents and any future patent claims
or other intellectual property rights may not be effective or sufficient to prevent them from so competing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Many companies have encountered significant problems in protecting
and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing
countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals,
which could make it difficult for us to stop the infringement of our licensed patents and future patents we may own, or marketing of competing
products in violation of our proprietary rights generally. Further, the laws of some foreign countries do not protect proprietary rights
to the same extent or in the same manner as the laws of the U.S. As a result, we may encounter significant problems in protecting and
defending our licensed and owned intellectual property both in the U.S. and abroad. For example, China currently affords less protection
to a company's intellectual property than some other jurisdictions. As such, the lack of strong patent and other intellectual property
protection in China may significantly increase our vulnerability regarding unauthorized disclosure or use of our intellectual property
and undermine our competitive position. Proceedings to enforce our future patent rights, if any, in foreign jurisdictions could result
in substantial cost and divert our efforts and attention from other aspects of our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>We may be unable to adequately prevent disclosure of trade
secrets and other proprietary information.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">In order to protect our proprietary and licensed technology and
processes, we rely in part on confidentiality agreements with our corporate partners, employees, consultants, manufacturers, outside scientific
collaborators and sponsored researchers and other advisors. These agreements may not effectively prevent disclosure of our confidential
information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others
may independently discover our trade secrets and proprietary information. Failure to obtain or maintain trade secret protection could
adversely affect our competitive business position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">55</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>If our trademarks and trade names are not adequately protected,
then we may not be able to build name recognition in our markets of interest and our business may be adversely affected</i></b>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">We intend to use registered or unregistered trademarks or trade
names to brand and market ourselves and our products. Our trademarks or trade names may be challenged, infringed, circumvented or declared
generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which
we need to build name recognition among potential partners or customers in our markets of interest, and it may be difficult and costly
to register, maintain and/or protect our rights to these trademarks and trade names in jurisdictions in and outside of the United States.
At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly
leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other
registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the
long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete
effectively, and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks,
trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion
of resources and could adversely affect our financial condition or results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>We may be subject to claims that our employees, consultants
or independent contractors have wrongfully&#160;used or disclosed confidential information of third parties.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">We expect to employ individuals who were previously employed
at other biopharmaceutical companies. Although we have no knowledge of any such claims against us, we may be subject to claims that we
or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of
our employees' former employers or other third parties. Litigation may be necessary to defend against these claims. There is no guarantee
of success in defending these claims, and even if we are successful, litigation could result in substantial cost and be a distraction
to our management and other employees. To date, none of our employees have been subject to such claims.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>We may be subject to claims challenging the inventorship
of our licensed patents, any future patents we may&#160;own and other intellectual property.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Although we are not currently experiencing any claims challenging
the inventorship of our licensed patents or our licensed or owned intellectual property, we may in the future be subject to claims that
former employees, collaborators or other third parties have an interest in our licensed patents or other licensed or owned intellectual
property as an inventor or co-inventor. For example, we may have inventorship disputes arising from conflicting obligations of consultants
or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims
challenging inventorship. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual
property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material
adverse effect on our business, financial condition and results of operations. Even if we are successful in defending against such claims,
litigation could result in substantial costs and be a distraction to management and other employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>If we do not obtain additional protection under the Hatch-Waxman
Amendments and similar foreign&#160;legislation extending the terms of our licensed patents and any future patents we may own, our&#160;business,
financial condition and results of operations may be materially and adversely affected.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Depending upon the timing, duration and specifics of FDA regulatory
approval for our product candidates, one or more of our licensed U.S. patents or future U.S. patents that we may license or own may be
eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as
the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent
term lost during drug development and the FDA regulatory review process. This period is generally one-half the time between the effective
date of an investigational new drug application (&#34;IND&#34;) (falling after issuance of the patent), and the submission date of an
NDA, plus the time between the submission date of an NDA and the approval of that application. Patent term restorations, however, cannot
extend the remaining term of a patent beyond a total of 14 years from the date of product approval by the FDA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">The application for patent term extension is subject to approval
by the USPTO, in conjunction with the FDA. It takes at least six months to obtain approval of the application for patent term extension.
We may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration
of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent
protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration or the term of any
such extension is less than we request, the period during which we will have the right to exclusively market our product will be shortened
and our competitors may obtain earlier approval of competing products, and our ability to generate revenues could be materially adversely
affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">56</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b>Risks Related to Owning Our Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>*The market price of our common stock has been and will
likely continue to be volatile.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">The trading price of our common stock has been and is likely
to continue to be volatile. For example, from January 3, 2022 to March 31, 2022, our closing stock price ranged from $0.84 to $1.71 per
share. Our stock price could be subject to wide fluctuations in response to a variety of factors, including the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<ul style="margin-top: 0in; list-style-type: disc">

<li style="margin: 0; font-size: 10pt">results from, and any delays in, planned clinical trials for our product candidates, or any other
future product candidates, and the results of trials of competitors or those of other companies in our market sector;</li>

<li style="margin: 0; font-size: 10pt">any delay in filing an NDA for any of our product candidates and any adverse development or perceived
adverse development with respect to the FDA's review of that NDA;</li>

<li style="margin: 0; font-size: 10pt">significant lawsuits, including patent or stockholder litigation;</li>

<li style="margin: 0; font-size: 10pt">inability to obtain additional funding;</li>

<li style="margin: 0; font-size: 10pt">failure to successfully develop and commercialize our product candidates;</li>

<li style="margin: 0; font-size: 10pt">changes in laws or regulations applicable to our product candidates;</li>

<li style="margin: 0; font-size: 10pt">inability to obtain adequate product supply for our product candidates, or the inability to do
so at acceptable prices;</li>

<li style="margin: 0; font-size: 10pt">unanticipated serious safety concerns related to any of our product candidates;</li>

<li style="margin: 0; font-size: 10pt">adverse regulatory decisions;</li>

<li style="margin: 0; font-size: 10pt">introduction of new products or technologies by our competitors;</li>

<li style="margin: 0; font-size: 10pt">failure to meet or exceed drug development or financial projections we provide to the public;</li>

<li style="margin: 0; font-size: 10pt">failure to meet or exceed the estimates and projections of the investment community;</li>

<li style="margin: 0; font-size: 10pt">the perception of the biopharmaceutical industry by the public, legislatures, regulators and the
investment community;</li>

<li style="margin: 0; font-size: 10pt">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments
by us or our competitors;</li>

<li style="margin: 0; font-size: 10pt">disputes or other developments relating to proprietary rights, including patents, litigation matters
and our ability to obtain patent protection for our licensed and owned technologies;</li>

<li style="margin: 0; font-size: 10pt">additions or departures of key scientific or management personnel;</li>

<li style="margin: 0; font-size: 10pt">changes in the market valuations of similar companies;</li>

<li style="margin: 0; font-size: 10pt">general economic and market conditions and overall fluctuations in the U.S. equity market;</li>

<li style="margin: 0; font-size: 10pt">public health crises, pandemics and epidemics, such as the COVID-19 pandemic;</li>

<li style="margin: 0; font-size: 10pt">sales of our common stock by us or our stockholders in the future; and</li>

<li style="margin: 0; font-size: 10pt">the trading volume of our common stock.</li>

</ul>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">In addition, the stock market in general, and small biopharmaceutical
companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to
the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock,
regardless of our actual operating performance. Further, a decline in the financial markets and related factors beyond our control may
cause our stock price to decline rapidly and unexpectedly.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>*If we fail to comply with the continued listing requirements
of the Nasdaq Capital Market, our common stock may be delisted and the price of our common stock and our ability to access the capital
markets could be negatively impacted.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">We must continue to satisfy the Nasdaq Capital Market's continued
listing requirements, including, among other things, a minimum closing bid price requirement of $1.00 per share for 30 consecutive business
days. If a company fails for 30 consecutive business days to meet the $1.00 minimum closing bid price requirement, The Nasdaq Stock Market
LLC (&#34;Nasdaq&#34;) will send a deficiency notice to the company, advising that it has been afforded a &#34;compliance period&#34;
of 180 calendar days to regain compliance with the applicable requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">A delisting of our common stock from the Nasdaq Capital Market
could materially reduce the liquidity of our common stock and result in a corresponding material reduction in the price of our common
stock. In addition, delisting could harm our ability to raise capital through alternative financing sources on terms acceptable to us,
or at all, and may result in the potential loss of confidence by investors and employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">57</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">On April 22, 2022, we received written notice from Nasdaq indicating
that, for the last thirty consecutive business days, the bid price for our common stock had closed below the minimum $1.00 per share requirement
for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A),
we were provided an initial period of 180 calendar days, or until October 19, 2022, to regain compliance. The written notice states that
the Nasdaq Staff will provide written notification that we have achieved compliance with Rule 5550(a)(2) if at any time before October
19, 2022, the bid price of our common stock closes at $1.00 per share or more for a minimum of ten consecutive business days. There is
no guarantee that we will regain compliance by October 19, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">In addition, we have previously received similar notices from
Nasdaq that our bid price of our common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq
Capital Market under Nasdaq Listing Rule 5550(a)(2). Even though we regained compliance with the Nasdaq Capital Market's minimum market
value of listed securities requirement and minimum closing bid price requirement, there is no guarantee that we will remain in compliance
with such listing requirements or other listing requirements in the future. Any failure to maintain compliance with continued listing
requirements of the Nasdaq Capital Market could result in delisting of our common stock from the Nasdaq Capital Market and negatively
impact our company and holders of our common stock, including by reducing the willingness of investors to hold our common stock because
of the resulting decreased price, liquidity and trading of our common stock, limited availability of price quotations and reduced news
and analyst coverage. Delisting may adversely impact the perception of our financial condition, cause reputational harm with investors,
our employees and parties conducting business with us and limit our access to debt and equity financing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>We will incur significant costs as a result of operating
as a public company and our management will be required to devote substantial time to new compliance initiatives.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and
Consumer Protection Act of 2010 (the &#34;Dodd-Frank Act&#34;) as well as rules subsequently implemented by the SEC and Nasdaq have
imposed various requirements on public companies. There are significant corporate governance and executive compensation related provisions
in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas. Stockholder activism, the current
political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations
and disclosure obligations, which may lead to additional compliance costs and impact (in ways we cannot currently anticipate) the manner
in which we operate our business. Our management and other personnel will need to devote a substantial amount of time to these compliance
initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities
more time-consuming and costly. For example, we expect these rules and regulations to make it more difficult and more expensive for us
to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain our current levels of
such insurance coverage.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">As a publicly traded company, we will incur legal, accounting
and other expenses associated with the SEC reporting requirements applicable to a company whose securities are registered under the Exchange
Act, as well as corporate governance requirements, including those under the Sarbanes-Oxley Act, the Dodd-Frank Act and other rules implemented
by the SEC and Nasdaq. The expenses incurred by public companies generally to meet SEC reporting, finance and accounting and corporate
governance requirements have been increasing in recent years as a result of changes in rules and regulations and the adoption of new rules
and regulations applicable to public companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>*Sales of a substantial number of shares of our common
stock in the public market by our existing stockholders, future issuances of our common stock or&#160;rights to purchase our common stock,
could cause our stock&#160;price to fall.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Sales of a substantial number of shares of our common stock by
our existing stockholders in the public market, or the perception that these sales might occur, could depress the market price of our
common stock and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict
the effect that such sales may have on the prevailing market price of our common stock. As of March 31, 2022, we have outstanding warrants
to purchase an aggregate of approximately 2.6 million shares of our common stock, which, if exercised, would further increase the number
of shares of our common stock outstanding and the number of shares eligible for resale in the public market. A<span style="background-color: white">s
of </span>March 31, 2022<span style="background-color: white">, 18,900,558 shares of our common stock were reserved for issuance under
our equity incentive plans, of which 10,299,170 shares of our common stock were subject to options outstanding at such date at a weighted-average
exercise price of $2.27 per share,&#160;5,518,648 shares of our common stock were reserved for future issuance pursuant to our Amended
and Restated 2012 Stock Long Term Incentive Plan, 646,465 shares of our common stock were reserved for future issuance pursuant to our
2019 Inducement Plan and 2,436,275 shares of our common stock were reserved for issuance pursuant to our 2020 Employee Stock Purchase
Plan. To the extent outstanding options are exercised, our existing stockholders may incur dilution. </span>Furthermore, at any time following
nine-months from the date of issuance of the Convertible Promissory Notes, from time to time and before the maturity date of such Convertible
Promissory Note, each holder thereof will have the option to convert any portion of the then-outstanding principal amount of such holder&#8217;s
Convertible Promissory Note into shares of our common stock at a price per share of $6.00, subject to adjustment for stock splits, reverse
stock splits, stock dividends and similar transactions. We may also elect to make amortization payments on the Convertible Promissory
Notes in shares of our common stock. Any issuances of shares of</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">58</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">our common stock pursuant to the Convertible Promissory Notes will result
in dilution to our then-existing stockholders and increase the number of shares eligible for resale in the public market. Sales of substantial
numbers of such shares in the public market could depress the market price of our common stock. In addition, pursuant to the asset purchase
agreement, as amended, with Phoenixus AG f/k/a Vyera Pharmaceuticals AG and Turing Pharmaceuticals AG (&#8220;Vyera&#8221;), we will (i)
issue to Vyera on or before July 11, 2022 500,000 shares of common stock; and (ii) issue to Vyera on or before January 11, 2023 an additional
number of shares of common stock equal to $1.0 million divided by the volume weighted average closing price of our common stock for the
ten consecutive trading days ending on the fifth trading day prior to the applicable date of issuance of the shares of common stock. Such
issuances of shares of our common stock to Vyera will result in dilution to our then-existing stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>The Financing Warrants contain price-based adjustment provisions
which, if triggered, may cause substantial&#160;additional dilution to our stockholders.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">On October 16, 2018, we entered into a Securities Purchase Agreement
with the investors listed on the Schedule of Buyers attached thereto, as amended, pursuant to which, among other things, we issued warrants
to purchase shares of our common stock (the &#34;Financing Warrants&#34;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">The outstanding Financing Warrants contain price-based adjustment
provisions, pursuant to which the exercise price of the Financing Warrants may be adjusted downward in the event of certain dilutive issuances
by us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">If the Financing Warrants are exercised, additional shares of
our common stock will be issued, which will result in dilution to our then-existing stockholders and increase the number of shares eligible
for resale in the public market. As of March 31, 2022, the Financing Warrants were exercisable for approximately 0.3 million shares of
our common stock at an exercise price of $0.2957 per share of common stock. Sales of substantial numbers of such shares in the public
market could depress the market price of our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>Anti-takeover provisions in our governing documents and
under Nevada law could make an&#160;acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove
our management.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Provisions in our articles of incorporation and bylaws may delay
or prevent an acquisition or a change in management. These provisions include a classified board of directors and the ability of the board
of directors to issue preferred stock without stockholder approval. Although we believe these provisions collectively will provide for
an opportunity to receive higher bids by requiring potential acquirers to negotiate with our board of directors, they would apply even
if the offer may be considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by
our stockholders to replace or remove then current management by making it more difficult for stockholders to replace members of the board
of directors, which is responsible for appointing the members of management.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Certain provisions of Nevada corporate law deter hostile takeovers.
Specifically, Nevada Revised Statutes (&#34;NRS&#34;) 78.411 through 78.444 prohibit a publicly held Nevada corporation from engaging
in a &#34;combination&#34; with an &#34;interested stockholder&#34; for a period of two years following the date the person first
became an interested stockholder, unless (with certain exceptions) the &#34;combination&#34; or the transaction by which the person
became an interested stockholder is approved in a prescribed manner. Generally, a &#34;combination&#34; includes a merger, asset or
stock sale, or certain other transactions resulting in a financial benefit to the interested stockholder. Generally, an &#34;interested
stockholder&#34; is a person who, together with affiliates and associates, beneficially owns or within two years prior to becoming an
&#34;interested stockholder&#34; did own, 10% or more of a corporation's voting power. While these statutes permit a corporation to
opt out of these protective provisions in its articles of incorporation, our articles of incorporation do not include any such opt-out
provision.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Nevada's &#34;acquisition of controlling interest&#34; statutes,
NRS 78.378 through 78.3793, contain provisions governing the acquisition of a controlling interest in certain Nevada corporations. These
&#34;control share&#34; laws provide generally that any person that acquires a &#34;controlling interest&#34; in certain Nevada corporations
may be denied voting rights, unless a majority of the disinterested stockholders of the corporation elects to restore such voting rights.
These statutes provide that a person acquires a &#34;controlling interest&#34; whenever a person acquires shares of a subject corporation
that, but for the application of these provisions of the NRS, would enable that person to exercise (1) one-fifth or more, but less than
one-third, (2) one-third or more, but less than a majority or (3) a majority or more, of all of the voting power of the corporation in
the election of directors. Once an acquirer crosses one of these thresholds, shares that it acquired in the transaction taking it over
the threshold and within the 90 days immediately preceding the date when the acquiring person acquired or offered to acquire a controlling
interest become &#34;control shares&#34; to which the voting restrictions described above apply. While these statutes permit a corporation
to opt out of these protective provisions in its articles of incorporation or bylaws, our articles of incorporation and bylaws do not
include any such opt-out provision.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Further, NRS 78.139 also provides that directors may resist a
change or potential change in control of the corporation if the board of directors determines that the change or potential change is opposed
to or not in the best interest of the corporation upon consideration of any relevant facts, circumstances, contingencies or constituencies
pursuant to NRS 78.138(4).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">59</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>Our net operating loss carryforwards and certain other
tax attributes may be subject to limitations.&#160;The net operating loss carryforwards and certain other tax attributes of us&#160;may
also be subject to limitations as a result of certain prior ownership changes.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">In general, a corporation that undergoes an &#34;ownership change&#34;
as defined in Section 382 of the United States Internal Revenue Code of 1986, as amended, is subject to limitations on its ability to
utilize its pre-change net operating loss carryforwards to offset future taxable income. In general, an ownership change occurs if the
aggregate stock ownership of certain stockholders, generally stockholders beneficially owning five percent or more of a corporation's
common stock, applying certain look-through and aggregation rules, increases by more than 50 percentage points over such stockholders'
lowest percentage ownership during the testing period, generally three years. We may have experienced ownership changes in the past and
may experience ownership changes in the future. It is possible that our net operating loss carryforwards and certain other tax attributes
may also be subject to limitation as a result of ownership changes in the past. Consequently, even if we achieve profitability, we may
not be able to utilize a material portion of our net operating loss carryforwards and certain other tax attributes, which could have a
material adverse effect on cash flow and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>We are a &#8220;smaller reporting company&#8221; and the
reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">We are a smaller reporting company, as defined in Rule 12b-2
under the Exchange Act, and we will remain a smaller reporting company until the fiscal year following the determination that our voting
and non-voting common stock held by non-affiliates is more than $250 million measured on the last business day of our second fiscal quarter,
or our annual revenues are less than $100 million during the most recently completed fiscal year and our voting and non-voting common
stock held by non-affiliates is more than $700 million measured on the last business day of our second fiscal quarter. Smaller reporting
companies are permitted to rely on exemptions from certain disclosure requirements that are applicable to other public companies, including
not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting,
reduced disclosure obligations regarding executive compensation and not being required to provide disclosures regarding quantitative and
qualitative disclosures about market risk in our Annual Reports on Form 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">We have elected to take advantage of certain of these exemptions
in the past and may continue to choose to take advantage of some, but not all, of them in the future. We cannot predict whether investors
will find our common stock less attractive if we rely on certain or all of these exemptions. If some investors find our common stock less
attractive as a result, there may be a less active trading market for our common stock, which may result in additional stock price volatility.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>We may never pay dividends on our common stock so any returns&#160;would
be limited to the appreciation of our stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">We currently anticipate that we will retain future earnings for
the development, operation and expansion of our business and do not anticipate we will declare or pay any cash dividends for the foreseeable
future. Any return to stockholders will therefore be limited to the appreciation of their stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b>General Risk Factors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>An active trading market for our common stock may not be
sustained, and you may not&#160;be able to resell your common stock at a desired market price.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">If no active trading market for our common stock is sustained,
you may be unable to sell your shares when you wish to sell them or at a price that you consider attractive or satisfactory. The lack
of an active market may also adversely affect our ability to raise capital by selling securities in the future or impair our ability to
acquire or in-license other product candidates, businesses or technologies using our shares as consideration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>Our internal control over financial reporting may not meet
the standards required by&#160;Section 404 of the Sarbanes-Oxley Act, and failure to achieve and maintain effective internal control over&#160;financial
reporting in accordance with Section 404 of the Sarbanes-Oxley Act, could have a material adverse effect&#160;on our business and share
price.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Our management is required to report on the effectiveness of
our internal control over financial reporting. The rules governing the standards that must be met for our management to assess our internal
control over financial reporting are complex and require significant documentation, testing and possible remediation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">60</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">In connection with the implementation of the necessary procedures
and practices related to internal control over financial reporting, we may identify deficiencies or material weaknesses that we may not
be able to remediate in time to meet the deadline imposed by the Sarbanes-Oxley Act for compliance with the requirements of Section 404.
In addition, we may encounter problems or delays in completing the implementation of any requested improvements and, when required, receiving
a favorable attestation in connection with the attestation provided by our independent registered public accounting firm. Failure to achieve
and maintain an effective internal control environment could have a material adverse effect on our business, financial condition and results
of operations and could limit our ability to report our financial results accurately and in a timely manner.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>If securities or industry analysts do not publish research,
or publish inaccurate or unfavorable research, about our business, our stock price and trading volume could decline.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">The trading market for our common stock depends, in part, on
the research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who cover
us downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline. In addition,
if our operating results fail to meet the forecast of analysts, our stock price would likely decline. If one or more of these analysts
cease coverage of us or fail to publish reports on us regularly, demand for our common stock could decrease, which might cause our stock
price and trading volume to decline.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>*The impact of the Russian invasion of Ukraine on the global
economy, energy supplies and raw materials is uncertain, but may prove to negatively impact our business and operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">The short and long-term implications of Russia&#8217;s invasion
of Ukraine are difficult to predict at this time. We continue to monitor any adverse impact that the outbreak of war in Ukraine and the
subsequent institution of sanctions against Russia by the United States and several European and Asian countries may have on the global
economy in general, on our business and operations and on the businesses and operations of our suppliers and other third parties with
which we conduct business. For example, a prolonged conflict may result in increased inflation, escalating energy prices and constrained
availability, and thus increasing costs, of raw materials. We will continue to monitor this fluid situation and develop contingency plans
as necessary to address any disruptions to our business operations as they develop. To the extent the war in Ukraine may adversely affect
our business as discussed above, it may also have the effect of heightening many of the other risks described herein. Such risks include,
but are not limited to, adverse effects on macroeconomic conditions, including inflation; disruptions to our technology infrastructure,
including through cyberattack, ransom attack, or cyber-intrusion; adverse changes in international trade policies and relations; disruptions
in global supply chains; and constraints, volatility, or disruption in the capital markets, any of which could negatively affect our business
and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><span style="font-weight: normal">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify"><span id="a_007"></span>ITEM 2. UNREGISTERED SALES OF EQUITY
SECURITIES AND USE OF PROCEEDS</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify"><span id="a_008"></span>ITEM 3. DEFAULTS UPON SENIOR SECURITIES</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 5.45pt 0 0 5pt; text-align: justify">Not applicable.</p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0.4pt 0 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify"><span id="a_009"></span>ITEM 4. MINE SAFETY DISCLOSURES</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 5.5pt 0 0 5pt; text-align: justify">Not applicable.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 6.5pt 0 0 5pt; text-align: justify"><span id="a_010"></span>ITEM 5. OTHER INFORMATION</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6.5pt 0 0 5pt; text-align: justify">Not applicable.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b><span id="a_011"></span>ITEM 6. EXHIBITS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<table cellspacing="1" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; text-align: center; width: 7%"><span style="font-size: 7.5pt"><b>EXHIBITS<br />
NO.</b></span></td>
    <td style="padding: 0.75pt; width: 1%"></td>
    <td style="padding: 0.75pt; width: 92%"><span style="font-size: 7.5pt"><b>DESCRIPTION</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000069/exhibit21agreementandplano.htm">2.1</a>*</span></td>
    <td style="padding: 0.75pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Agreement and Plan of Merger and Reorganization, dated July 30, 2018, by and among the
    Company, Arch Merger Sub, Inc. and Seelos Therapeutics, Inc. (incorporated herein by reference to Exhibit 2.1 to the Company's
    Current Report on Form 8-K filed with the Securities and Exchange Commission on July 30, 2018).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000092/ex21to8-kon10x16x18.htm">2.2</a></span></td>
    <td style="padding: 0.75pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Amendment No. 1 Agreement and Plan of Merger and Reorganization, dated October 16, 2018, by
    and among the Company, Arch Merger Sub, Inc. and Seelos Therapeutics, Inc. (incorporated herein by reference to Exhibit 2.1 to the
    Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on October 17, 2018).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 64 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">61</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


  <table cellspacing="1" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt; width: 7%"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000119312518349990/d602430dex21.htm">2.</a><a href="http://www.sec.gov/Archives/edgar/data/1017491/000119312518349990/d602430dex21.htm">3</a></span></td>
    <td style="padding: 0.75pt; width: 1%"></td>
    <td style="padding: 0.75pt; width: 92%"><span style="font-size: 10pt">Amendment No. 2 Agreement and Plan of Merger and Reorganization, dated
    December 14, 2018, by and among the Company, Arch Merger Sub, Inc. and Seelos Therapeutics, Inc. (incorporated herein by reference
    to Exhibit 2.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on December 14,
    2018).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000114036119001204/ex2_1.htm">2.4</a></span></td>
    <td style="padding: 0.75pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Amendment No. 3 Agreement and Plan of Merger and Reorganization, dated January 16, 2019, by
    and among the Company, Arch Merger Sub, Inc. and Seelos Therapeutics, Inc. (incorporated herein by reference to Exhibit 2.1 to the
    Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 16, 2019).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000113626119000068/exh2-1.htm">2.5</a>*</span></td>
    <td style="padding: 0.75pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Asset Purchase Agreement, dated February 15, 2019, by and between the Company and Bioblast Pharma Ltd. (incorporated herein by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 19, 2019).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/0001005477-97-000778.txt">3.1</a></span></td>
    <td style="padding: 0.75pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Amended and Restated Articles of Incorporation of the Company (incorporated herein by reference to Exhibit 2.1 to the Company's Registration Statement on Form 10-SB filed with the Securities and Exchange Commission on March 14, 1997).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000095013603000741/file002.txt">3.2</a></span></td>
    <td style="padding: 0.75pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Certificate of Amendment to Articles of Incorporation of the Company,
    dated June 22, 2000 (incorporated herein by reference to Exhibit 3.2 to the Company's Annual Report on Form 10-K filed with the
    Securities and Exchange Commission on March 31, 2003).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000114420406010273/v037542_ex3-4.htm">3.3</a></span></td>
    <td style="padding: 0.75pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Certificate of Amendment to Articles of Incorporation of the Company,
    dated June 14, 2005 (incorporated herein by reference to Exhibit 3.4 to the Company's Annual Report on Form 10-K filed with the
    Securities and Exchange Commission on March 16, 2006).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000114420410017441/v178249_ex3-6.htm">3.4</a></span></td>
    <td style="padding: 0.75pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Certificate of Amendment to Amended and Restated Articles of Incorporation of the Company, dated March 3, 2010 (incorporated herein by reference to Exhibit 3.6 to the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2010).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000114420410017441/v178249_ex3-7.htm">3.5</a></span></td>
    <td style="padding: 0.75pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Certificate of Correction to Certificate of Amendment to Amended and Restated Articles of Incorporation of the Company, dated March 3, 2010 (incorporated herein by reference to Exhibit 3.7 to the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2010).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000114420411016743/v215636_ex3-1.htm">3.6</a></span></td>
    <td style="padding: 0.75pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Certificate of Designation for Series D Junior-Participating Cumulative Preferred Stock (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-A12G filed with the Securities and Exchange Commission on March 24, 2011).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000114420410034002/v188471_ex3-1.htm">3.7</a></span></td>
    <td style="padding: 0.75pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Certificate of Change filed with the Nevada Secretary of State (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 17, 2010).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
<tr style="vertical-align: top">
    <td style="padding: 0.75pt; width: 7%"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000114420410048909/v196361_ex3-1.htm">3.8</a></span></td>
    <td style="padding: 0.75pt; width: 1%"></td>
    <td style="padding: 0.75pt; width: 92%"><span style="font-size: 10pt">Certificate of Amendment to Amended and Restated Articles of Incorporation of the Company, dated September 10, 2010 (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 10, 2010).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000119312513224446/d539505dex31.htm">3.9</a></span></td>
    <td style="padding: 0.75pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Certificate of Withdrawal of Series D Junior Participating Cumulative
    Preferred Stock, dated May 15, 2013 (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K
    filed with the Securities and Exchange Commission on May 16, 2013).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000101749116000227/exhibit31to8-konreversesto.htm">3.10</a></span></td>
    <td style="padding: 0.75pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Certificate of Change filed with the Nevada Secretary of State (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on October 25, 2016).</span></td></tr>
   </table>



<!-- Field: Page; Sequence: 66 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">62</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->


<table cellspacing="1" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>

  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt; width: 7%"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000101749117000091/apri63017ex310.htm">3.11</a></span></td>
    <td style="padding: 0.75pt; width: 1%"></td>
    <td style="padding: 0.75pt; width: 92%"><span style="font-size: 10pt">Certificate of Amendment filed with the Nevada Secretary of State (incorporated herein by reference to Exhibit 3.10 to the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 2, 2017).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000075/apri63018ex312.htm">3.12</a></span></td>
    <td style="padding: 0.75pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Certificate of Amendment filed with the Nevada Secretary of State (incorporated herein by reference to Exhibit 3.12 to the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 9, 2018).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000114036119001465/ex3_1.htm">3.13</a></span></td>
    <td style="padding: 0.75pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Certificate of Amendment related to the Share Increase Amendment, filed January 23, 2019 (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 24, 2019 at 8:05 Eastern Time).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000114036119001465/ex3_2.htm">3.14</a></span></td>
    <td style="padding: 0.75pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Certificate of Amendment related to the Name Change, filed January 23, 2019 (incorporated herein by reference to Exhibit 3.2 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 24, 2019 at 8:05 Eastern Time).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000114036119001465/ex3_3.htm">3.15</a></span></td>
    <td style="padding: 0.75pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Amended and Restated Bylaws, dated January 24, 2019 (incorporated herein by reference to Exhibit 3.3 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 24, 2019 at 8:05 Eastern Time).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000113626120000114/exh3-16.htm">3.16</a></span></td>
    <td style="padding: 0.75pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Certificate of Correction to Certificate of Amended and Restated Articles of Incorporation of the Company, dated March 25, 2020 (incorporated herein by reference to Exhibit 3.16 to the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 7, 2020).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000113626120000124/exh3-1.htm">3.17</a></span></td>
    <td style="padding: 0.75pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Certificate of Amendment to the Amended and Restated Articles of Incorporation of Seelos Therapeutics, Inc., filed May 18, 2020 (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 19, 2020).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000113626120000131/exh3-1.htm">3.18</a></span></td>
    <td style="padding: 0.75pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Certificate of Correction to Certificate of Amended and Restated Articles of Incorporation of the Company, filed May 20, 2020 (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 21, 2020).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/0001017491/000113626121000080/exh3-1.htm">3.19</a></span></td>
    <td style="padding: 0.75pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Certificate of Amendment to the Amended and Restated Articles of Incorporation
of the Company, filed May 21, 2021 (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed
with the Securities and Exchange Commission on May 21, 2021).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000114420411016740/v215638_ex4-1.htm">4.1</a></span></td>
    <td style="padding: 0.75pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Form of Common Stock Certificate (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on March 24, 2011).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000119312514375645/d806711dex42.htm">4.2</a></span></td>
    <td style="padding: 0.75pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Form of Warrant issued to the lenders under the Loan and Security Agreement, dated as of October 17, 2014, by and among the Company, NexMed (U.S.A.), Inc., NexMed Holdings, Inc. and Apricus Pharmaceuticals USA, Inc., as borrowers, Oxford Finance LLC, as collateral agent, and the lenders party thereto from time to time including Oxford Finance LLC and Silicon Valley Bank (incorporated herein by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on October 20, 2014).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"></td></tr></table>

<!-- Field: Page; Sequence: 67 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">63</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->


<table cellspacing="1" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt; width: 7%"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000119312516428442/d224777dex41.htm">4.3</a></span></td>
    <td style="padding: 0.75pt; width: 1%"></td>
    <td style="padding: 0.75pt; width: 92%"><span style="font-size: 10pt">Form of Warrant issued to Sarissa Capital Domestic Fund LP and Sarissa Capital Offshore Master Fund LP (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 13, 2016).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000119312516428442/d224777dex42.htm">4.4</a></span></td>
    <td style="padding: 0.75pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Form of Warrant issued to other purchasers (incorporated herein by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 13, 2016).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000119312516722474/d444660dex41.htm">4.5</a></span></td>
    <td style="padding: 0.75pt">&#160;</td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Form of Warrant (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 28, 2016).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000101749117000048/exhibit49formofwarrant.htm">4.6</a></span></td>
    <td style="padding: 0.75pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Form of Warrant (incorporated herein by reference to Exhibit 4.9 of Amendment No. 1 to Company's Registration Statement on Form S-1 (File No. 333-217036) filed with the Securities and Exchange Commission on April 17, 2017).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000101749117000063/exhibit41formofwarrantamen.htm">4.7</a></span></td>
    <td style="padding: 0.75pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Form of Warrant Amendment (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on April 21, 2017).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000034/ex412amendmenttowarranttop.htm">4.8</a></span></td>
    <td style="padding: 0.75pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Amendment to Warrant to Purchase Common Stock (incorporated herein by reference to Exhibit 4.12 of Amendment No. 1 to the Company's Registration Statement on Form S-3 (File No. 333-223353) filed with the Securities and Exchange Commission on March 22, 2018).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000050/exhibit41to8-kon3x29x18.htm">4.9</a></span></td>
    <td style="padding: 0.75pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Amendment to Warrant to Purchase Common Stock, dated as of March 27, 2018
    (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange
    Commission on March 29, 2018).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000050/exhibit42to8-kon3x29x18.htm">4.10</a></span></td>
    <td style="padding: 0.75pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Form of Warrant (incorporated herein by reference to Exhibit 4.2 to the
    Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on March 29, 2018).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000050/exhibit43to8-kon3x29x18.htm">4.11</a></span></td>
    <td style="padding: 0.75pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Form of Placement Agent Warrant (incorporated herein by reference to
    Exhibit 4.3 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on March 29,
    2018).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000065/exhibit41to8-kjune2018warr.htm">4.12</a></span></td>
    <td style="padding: 0.75pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Amendment to Warrant to Purchase Common Stock, dated as of June 22, 2018,
    by and between the Company and Sarissa Offshore (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on
    Form 8-K filed with the Securities and Exchange Commission on June 22, 2018).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000085/ex41to8-konsept2018pipe.htm">4.13</a></span></td>
    <td style="padding: 0.75pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Form of Warrant (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 21, 2018).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000085/ex42to8-konsept2018pipe.htm">4.14</a></span></td>
    <td style="padding: 0.75pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Form of Wainwright Warrant (incorporated herein by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 21, 2018).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000092/ex41to8-kon10x16x18.htm">4.15</a></span></td>
    <td style="padding: 0.75pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Form of Investor Warrants (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on October 17, 2018).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
 <tr style="vertical-align: top">
    <td style="padding: 0.75pt; width: 7%"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000092/ex42to8-kon10x16x18.htm">4.16</a></span></td>
    <td style="padding: 0.75pt; width: 1%"></td>
    <td style="padding: 0.75pt; width: 92%"><span style="font-size: 10pt">Registration Rights Agreement, dated October 16, 2018, by and among the Company and certain investors named therein (incorporated herein by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on October 17, 2018).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000113626119000038/exh4-1.htm">4.17</a></span></td>
    <td style="padding: 0.75pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Form of Series A Warrant, issued to investors on January 31, 2019 (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on February 6, 2019).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"></td></tr></table>

<!-- Field: Page; Sequence: 68 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">64</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->


<table cellspacing="1" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt; width: 7%"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000113626119000232/exh4-1.htm">4.18</a></span></td>
    <td style="padding: 0.75pt; width: 1%"></td>
    <td style="padding: 0.75pt; width: 92%"><span style="font-size: 10pt">Form of Warrant, issued to investors on August 27, 2019 (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on August 27, 2019).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000113626120000167/exh4-1.htm">4.19</a></span></td>
    <td style="padding: 0.75pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Form of Warrant, issued to investors on September 9, 2020 (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 9, 2020).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000113626121000248/exh4-1.htm">4.20</a></span></td>
    <td style="padding: 0.75pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Form of Convertible Promissory Note due November 13, 2024 (incorporated
herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission at 7:27
a.m. Eastern Time on November 24, 2021).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
   <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000113626122000156/exh4-22.htm">4.21</a></span></td>
    <td style="padding: 0.75pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Amendment to Convertible Promissory Note, by and between Seelos Therapeutics,
Inc. and Lind Global Asset Management V, LLC, dated December 10, 2021 (incorporated herein by reference to Exhibit 4.22 to the Company's
Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 4, 2022).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000113626122000035/exh10-1.htm">10.1</a>#</span></td>
    <td style="padding: 0.75pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Amended and Restated Employment Agreement by and between Seelos Therapeutics, Inc. and Raj Mehra, Ph.D., dated as of January 10, 2022 (incorporated herein by reference to Exhibit 10.1
to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 10, 2022).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="exh31-1.htm">31.1</a></span></td>
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Certification of Principal Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></td></tr>
 <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="exh31-2.htm">31.2</a></span> <span style="font-size: 10pt"></span></td>
    <td style="padding: 0.75pt; font-size: 11pt">&#160;</td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Certification of Principal Financial Officer, pursuant to Section 302 of the
    Sarbanes-Oxley Act of 2002.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"></td>
    <td colspan="2" style="padding: 0.75pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="exh32-1.htm">32.1</a> (1)</span></td>
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Certification of Principal Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
<tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="exh32-2.htm">32.2</a> (1)</span></td>
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Certification of Principal Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
<tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt">101.INS</span></td>
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt">101.SCH</span></td>
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Schema.</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt">101.CAL</span></td>
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt">101.DEF</span></td>
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt">101.LAB</span></td>
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td colspan="2" style="padding: 0.75pt; font-size: 11pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt">101.PRE</span></td>
    <td style="padding: 0.75pt; font-size: 11pt"></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt">104</span></td>
    <td style="padding: 0.75pt; font-size: 11pt">&#160;</td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in">(1)&#160;&#160;&#160;&#160;Furnished, not filed.<br /> <br />

* &#160;&#160;&#160;All schedules and exhibits to the agreement have been
omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the
Securities and Exchange Commission upon request.<br /><br />

# &#160;&#160;&#160; Indicates management compensatory plan or arrangement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"></p>

<!-- Field: Page; Sequence: 69 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">65</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 4.6pt 0 0 5pt; text-align: left"><span id="a_012"></span>SIGNATURES</p>

<p style="font: 10pt/103% Times New Roman, Times, Serif; margin: 9.5pt 1.15pt 0 5pt; text-indent: 24pt">Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.</p>

<p style="font: 13pt Times New Roman, Times, Serif; margin: 0.15pt 0 0"></p>

<table cellspacing="1" cellpadding="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt; width: 56%"></td>
    <td style="padding: 0.75pt; width: 44%; font-size: 12pt"><span style="font-size: 10pt">Seelos Therapeutics, Inc.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&#160;</td>
    <td style="padding: 0.75pt; font-size: 12pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"></td>
    <td style="padding: 0.75pt"></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt; font-size: 12pt"><span style="font-size: 10pt">Date: May 10, 2022</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding: 0.75pt; font-size: 12pt"><span style="font-size: 10pt">/s/ Raj Mehra, Ph.D.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"></td>
    <td style="padding: 0.75pt; font-size: 12pt"><span style="font-size: 10pt">Raj Mehra, Ph.D.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"></td>
    <td style="padding: 0.75pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">President, Chief Executive Officer and</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Chairman of the Board </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>(Principal Executive Officer)</i></p></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&#160;</td>
    <td style="padding: 0.75pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt; font-size: 12pt"><span style="font-size: 10pt">Date: May 10, 2022</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding: 0.75pt; font-size: 12pt"><span style="font-size: 10pt">/s/ Michael Golembiewski</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"></td>
    <td style="padding: 0.75pt; font-size: 12pt"><span style="font-size: 10pt">Michael Golembiewski</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"></td>
    <td style="padding: 0.75pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Chief Financial Officer</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>(Principal Financial and Accounting Officer)</i></p></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&#160;</td>
    <td style="padding: 0.75pt">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="padding: 0.75pt">&#160;</td>
    <td style="padding: 0.75pt">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="padding: 0.75pt">&#160;</td>
    <td style="padding: 0.75pt">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 67.8pt 0 4in; text-align: center; text-indent: 0.5in"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 70 -->
    <div style="border-bottom: Black thin solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">66</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>2
<FILENAME>seel-20220331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 9qhZs7xRiXhun8uBa3xcSamK+bPtzJ566ZkhumN0HcnajykiANXCZiwiSkim0WEF -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:SEEL="http://seelostx.com/20220331" elementFormDefault="qualified" targetNamespace="http://seelostx.com/20220331">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://seelostx.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss" id="StatementsOfOperationsAndComprehensiveLoss">
	  <link:definition>00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLossParenthetical" id="StatementsOfOperationsAndComprehensiveLossParenthetical">
	  <link:definition>00000005 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit" id="StatementsOfChangesInStockholdersEquityDeficit">
	  <link:definition>00000006 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000007 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/OrganizationAndDescriptionOfBusiness" id="OrganizationAndDescriptionOfBusiness">
	  <link:definition>00000008 - Disclosure - 1. Organization and Description of Business</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/LiquidityAndGoingConcern" id="LiquidityAndGoingConcern">
	  <link:definition>00000009 - Disclosure - 2. Liquidity and Going Concern</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/SignificantAccountingPolicies" id="SignificantAccountingPolicies">
	  <link:definition>00000010 - Disclosure - 3. Significant Accounting Policies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/FairValueMeasurement" id="FairValueMeasurement">
	  <link:definition>00000011 - Disclosure - 4. Fair Value Measurement</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/PrepaidExpensesAndOtherCurrentAssets" id="PrepaidExpensesAndOtherCurrentAssets">
	  <link:definition>00000012 - Disclosure - 5. Prepaid Expenses and Other Current Assets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/CommonStockOfferings" id="CommonStockOfferings">
	  <link:definition>00000013 - Disclosure - 6. Common Stock Offerings</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/LicenseAgreements" id="LicenseAgreements">
	  <link:definition>00000014 - Disclosure - 7. License Agreements</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/AccruedExpenses" id="AccruedExpenses">
	  <link:definition>00000015 - Disclosure - 8. Accrued Expenses</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/Debt" id="Debt">
	  <link:definition>00000016 - Disclosure - 9. Debt</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/StockholdersEquity" id="StockholdersEquity">
	  <link:definition>00000017 - Disclosure - 10. Stockholders&#8217; Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/Stock-basedCompensation" id="Stock-basedCompensation">
	  <link:definition>00000018 - Disclosure - 11. Stock-based Compensation</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000019 - Disclosure - 12. Commitments and Contingencies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000020 - Disclosure - 13. Subsequent Events</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/SignificantAccountingPoliciesPolicies" id="SignificantAccountingPoliciesPolicies">
	  <link:definition>00000021 - Disclosure - 3. Significant Accounting Policies (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/SignificantAccountingPoliciesTables" id="SignificantAccountingPoliciesTables">
	  <link:definition>00000022 - Disclosure - 3. Significant Accounting Policies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/FairValueMeasurementTables" id="FairValueMeasurementTables">
	  <link:definition>00000023 - Disclosure - 4. Fair Value Measurement (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" id="PrepaidExpensesAndOtherCurrentAssetsTables">
	  <link:definition>00000024 - Disclosure - 5. Prepaid Expenses and Other Current Assets (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/AccruedExpensesTables" id="AccruedExpensesTables">
	  <link:definition>00000025 - Disclosure - 8. Accrued Expenses (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
	  <link:definition>00000026 - Disclosure - 10. Stockholders&#8217; Equity (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
	  <link:definition>00000027 - Disclosure - 11. Stock-based Compensation (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
	  <link:definition>00000028 - Disclosure - 12. Commitments and Contingencies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative" id="LiquidityAndGoingConcernDetailsNarrative">
	  <link:definition>00000029 - Disclosure - 2. Liquidity and Going Concern (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" id="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails">
	  <link:definition>00000030 - Disclosure - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails" id="ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails">
	  <link:definition>00000031 - Disclosure - Schedule of Fair Value Hierarchy Assets and Liabilities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails" id="SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails">
	  <link:definition>00000032 - Disclosure - Summary of Fair Value Measurements Convertible Notes Valuation Assumptions (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/SummaryOfFairValueMeasurementsWarrantValuationAssumptionsDetails" id="SummaryOfFairValueMeasurementsWarrantValuationAssumptionsDetails">
	  <link:definition>00000033 - Disclosure - Summary of Fair Value Measurements Warrant Valuation Assumptions (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/ScheduleOfFairValueLevel3ReconciliationDetails" id="ScheduleOfFairValueLevel3ReconciliationDetails">
	  <link:definition>00000034 - Disclosure - Schedule of Fair Value Level 3 Reconciliation (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/FairValueMeasurementDetailsNarrative" id="FairValueMeasurementDetailsNarrative">
	  <link:definition>00000035 - Disclosure - 4. Fair Value Measurement (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
	  <link:definition>00000036 - Disclosure - Schedule of Prepaid Expenses and Other Current Assets (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/CommonStockOfferingsDetailsNarrative" id="CommonStockOfferingsDetailsNarrative">
	  <link:definition>00000037 - Disclosure - 6. Common Stock Offerings (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/LicenseAgreementsDetailsNarrative" id="LicenseAgreementsDetailsNarrative">
	  <link:definition>00000038 - Disclosure - 7. License Agreements (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/ScheduleOfAccruedLiabilitiesDetails" id="ScheduleOfAccruedLiabilitiesDetails">
	  <link:definition>00000039 - Disclosure - Schedule of Accrued Liabilities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/DebtDetailsNarrative" id="DebtDetailsNarrative">
	  <link:definition>00000040 - Disclosure - 9. Debt (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/SummaryOfWarrantActivityDetails" id="SummaryOfWarrantActivityDetails">
	  <link:definition>00000041 - Disclosure - Summary of Warrant Activity (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
	  <link:definition>00000042 - Disclosure - 10. Stockholders&#8217; Equity (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/ScheduleOfValuationAssumptionsForStockOptionsDetails" id="ScheduleOfValuationAssumptionsForStockOptionsDetails">
	  <link:definition>00000043 - Disclosure - Schedule of Valuation Assumptions for Stock Options (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/SummaryOfStockOptionActivityDetails" id="SummaryOfStockOptionActivityDetails">
	  <link:definition>00000044 - Disclosure - Summary of Stock Option Activity (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/ScheduleOfStock-basedCompensationExpenseDetails" id="ScheduleOfStock-basedCompensationExpenseDetails">
	  <link:definition>00000045 - Disclosure - Schedule of Stock-Based Compensation Expense (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/Stock-basedCompensationDetailsNarrative" id="Stock-basedCompensationDetailsNarrative">
	  <link:definition>00000046 - Disclosure - 11. Stock-based Compensation (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/ScheduleOfFutureMinimumOperatingLeasePaymentsDetails" id="ScheduleOfFutureMinimumOperatingLeasePaymentsDetails">
	  <link:definition>00000047 - Disclosure - Schedule of future minimum operating lease payments (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000048 - Disclosure - 12. Commitments and Contingencies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://seelostx.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
	  <link:definition>00000049 - Disclosure - 13. Subsequent Events (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="seel-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="seel-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="seel-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="seel-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
    <element id="SEEL_May242021Member" name="May242021Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_January282021Member" name="January282021Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_IXLicenseAgreementMember" name="IXLicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_WegLicenseAgreementMember" name="WegLicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_November2021LindSecuritiesPurchaseAgreementMember" name="November2021LindSecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_FirstAnniversaryOfNovember2021LindSecuritiesPurchaseAgreementMember" name="FirstAnniversaryOfNovember2021LindSecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_August232022ThruMaturityNovember2021LindSecuritiesPurchaseAgreementMember" name="August232022ThruMaturityNovember2021LindSecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_AmortizeNovember2021LindSecuritiesPurchaseAgreementMember" name="AmortizeNovember2021LindSecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_December2021SPAsMember" name="December2021SPAsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_LindSecuritiesPurchaseAgreementMember" name="LindSecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_December17SPAsMember" name="December17SPAsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_September2020WarrantsMember" name="September2020WarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_August2019WarrantsMember" name="August2019WarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_August232019Member" name="August232019Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_SeriesAWarrantsMember" name="SeriesAWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_WarrantDerivativeFinancialInstrumentsMember" name="WarrantDerivativeFinancialInstrumentsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_InducementPlanof2019Member" name="InducementPlanof2019Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_IncentiveStockOptionMember" name="IncentiveStockOptionMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_NonQualifiedStockOptionsToEmployeesMember" name="NonQualifiedStockOptionsToEmployeesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_NonQualifiedStockOptionsToNonEmployeeDirectorsMember" name="NonQualifiedStockOptionsToNonEmployeeDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_PSUtoExecutivesMember" name="PSUtoExecutivesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_March2019LeaseMember" name="March2019LeaseMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_March2021LeaseMember" name="March2021LeaseMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_AssetsfromVyeraPharmaceuticalsMember" name="AssetsfromVyeraPharmaceuticalsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_LicensesPayable" name="LicensesPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_GainLossInFairValueOfConvertibleNotes" name="GainLossInFairValueOfConvertibleNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_ReclassOfWarrantLiabilitiesRelatedToSeriesWarrantsExercisedForCash" name="ReclassOfWarrantLiabilitiesRelatedToSeriesWarrantsExercisedForCash" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes" name="OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_FinancingAvailableUnderFormS3ShelfRegistrationStatement" name="FinancingAvailableUnderFormS3ShelfRegistrationStatement" nillable="true" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_NonrefundableCashPayment" name="NonrefundableCashPayment" nillable="true" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_PrepaidClinicalCosts" name="PrepaidClinicalCosts" nillable="true" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_Issuanceofcommonstockforlicenseacquiredshares" name="Issuanceofcommonstockforlicenseacquiredshares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_MinimumStockValueOfSharesIssued" name="MinimumStockValueOfSharesIssued" nillable="true" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_InitialStockValuationShortfallFrom5.5MillionValue" name="InitialStockValuationShortfallFrom5.5MillionValue" nillable="true" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_OutsideResearchAndDevelopmentServicesCurrent" name="OutsideResearchAndDevelopmentServicesCurrent" nillable="true" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_ClassOfWarrantOrRightOutstandingWeightedAverageRemaingContractualLife" name="ClassOfWarrantOrRightOutstandingWeightedAverageRemaingContractualLife" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_NumberofWarrantsIssuedDuringPeriod" name="NumberofWarrantsIssuedDuringPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_ClassOfWarrantOrRightIssuedExercisePriceOfWarrantsOrRights" name="ClassOfWarrantOrRightIssuedExercisePriceOfWarrantsOrRights" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_NumberofWarrantsExercisedDuringPeriod" name="NumberofWarrantsExercisedDuringPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_ClassOfWarrantOrRightExercisedExercisePriceOfWarrantsOrRights" name="ClassOfWarrantOrRightExercisedExercisePriceOfWarrantsOrRights" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_NumberofWarrantsCancelledDuringPeriod" name="NumberofWarrantsCancelledDuringPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_ClassOfWarrantOrRightCancelledExercisePriceOfWarrantsOrRights" name="ClassOfWarrantOrRightCancelledExercisePriceOfWarrantsOrRights" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_ClassOfWarrantOrRightOutstandingEndOfPeriodWeightedAverageRemaingContractualLife" name="ClassOfWarrantOrRightOutstandingEndOfPeriodWeightedAverageRemaingContractualLife" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_WarrantsExercisable" name="WarrantsExercisable" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights1" name="ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights1" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_ClassOfWarrantOrRightExercisableWeightedAverageRemaingContractualLife" name="ClassOfWarrantOrRightExercisableWeightedAverageRemaingContractualLife" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceDiscountOfCommonStockPercent" name="SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceDiscountOfCommonStockPercent" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_SharebasedPaymentArrangementNonvestedAndCanceledAwardExcludingOptionCostNotYetRecognizedAmount" name="SharebasedPaymentArrangementNonvestedAndCanceledAwardExcludingOptionCostNotYetRecognizedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SEEL_CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement" name="CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement" nillable="true" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>3
<FILENAME>seel-20220331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://seelostx.com/role/Cover" xlink:href="seel-20220331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/BalanceSheets" xlink:href="seel-20220331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/BalanceSheetsParenthetical" xlink:href="seel-20220331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="seel-20220331.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLossParenthetical" xlink:href="seel-20220331.xsd#StatementsOfOperationsAndComprehensiveLossParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:href="seel-20220331.xsd#StatementsOfChangesInStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/StatementsOfCashFlows" xlink:href="seel-20220331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/OrganizationAndDescriptionOfBusiness" xlink:href="seel-20220331.xsd#OrganizationAndDescriptionOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/LiquidityAndGoingConcern" xlink:href="seel-20220331.xsd#LiquidityAndGoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/SignificantAccountingPolicies" xlink:href="seel-20220331.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/FairValueMeasurement" xlink:href="seel-20220331.xsd#FairValueMeasurement" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="seel-20220331.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/CommonStockOfferings" xlink:href="seel-20220331.xsd#CommonStockOfferings" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/LicenseAgreements" xlink:href="seel-20220331.xsd#LicenseAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/AccruedExpenses" xlink:href="seel-20220331.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/Debt" xlink:href="seel-20220331.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/StockholdersEquity" xlink:href="seel-20220331.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/Stock-basedCompensation" xlink:href="seel-20220331.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/CommitmentsAndContingencies" xlink:href="seel-20220331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/SubsequentEvents" xlink:href="seel-20220331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/SignificantAccountingPoliciesPolicies" xlink:href="seel-20220331.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/SignificantAccountingPoliciesTables" xlink:href="seel-20220331.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/FairValueMeasurementTables" xlink:href="seel-20220331.xsd#FairValueMeasurementTables" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="seel-20220331.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/AccruedExpensesTables" xlink:href="seel-20220331.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/StockholdersEquityTables" xlink:href="seel-20220331.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/Stock-basedCompensationTables" xlink:href="seel-20220331.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/CommitmentsAndContingenciesTables" xlink:href="seel-20220331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative" xlink:href="seel-20220331.xsd#LiquidityAndGoingConcernDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="seel-20220331.xsd#ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails" xlink:href="seel-20220331.xsd#ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails" xlink:href="seel-20220331.xsd#SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/SummaryOfFairValueMeasurementsWarrantValuationAssumptionsDetails" xlink:href="seel-20220331.xsd#SummaryOfFairValueMeasurementsWarrantValuationAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/ScheduleOfFairValueLevel3ReconciliationDetails" xlink:href="seel-20220331.xsd#ScheduleOfFairValueLevel3ReconciliationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/FairValueMeasurementDetailsNarrative" xlink:href="seel-20220331.xsd#FairValueMeasurementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="seel-20220331.xsd#ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/CommonStockOfferingsDetailsNarrative" xlink:href="seel-20220331.xsd#CommonStockOfferingsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/LicenseAgreementsDetailsNarrative" xlink:href="seel-20220331.xsd#LicenseAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/ScheduleOfAccruedLiabilitiesDetails" xlink:href="seel-20220331.xsd#ScheduleOfAccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/DebtDetailsNarrative" xlink:href="seel-20220331.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/SummaryOfWarrantActivityDetails" xlink:href="seel-20220331.xsd#SummaryOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/StockholdersEquityDetailsNarrative" xlink:href="seel-20220331.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/ScheduleOfValuationAssumptionsForStockOptionsDetails" xlink:href="seel-20220331.xsd#ScheduleOfValuationAssumptionsForStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/SummaryOfStockOptionActivityDetails" xlink:href="seel-20220331.xsd#SummaryOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:href="seel-20220331.xsd#ScheduleOfStock-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="seel-20220331.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/ScheduleOfFutureMinimumOperatingLeasePaymentsDetails" xlink:href="seel-20220331.xsd#ScheduleOfFutureMinimumOperatingLeasePaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="seel-20220331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/SubsequentEventsDetailsNarrative" xlink:href="seel-20220331.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_LicensesPayable" xlink:label="loc_SEELLicensesPayable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_SEELLicensesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleSubordinatedDebtCurrent" xlink:label="loc_us-gaapConvertibleSubordinatedDebtCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapConvertibleSubordinatedDebtCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDerivativeLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleSubordinatedDebtNoncurrent" xlink:label="loc_us-gaapConvertibleSubordinatedDebtNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapConvertibleSubordinatedDebtNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeDomesticDeposits" xlink:label="loc_us-gaapInterestIncomeDomesticDeposits" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeDomesticDeposits" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLossParenthetical" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Changes in Stockholders&apos; Equity (Deficit)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaapProceedsFromStockPlans" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockPlans" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/OrganizationAndDescriptionOfBusiness" xlink:title="00000008 - Disclosure - 1. Organization and Description of Business" />
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/LiquidityAndGoingConcern" xlink:title="00000009 - Disclosure - 2. Liquidity and Going Concern" />
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/SignificantAccountingPolicies" xlink:title="00000010 - Disclosure - 3. Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/FairValueMeasurement" xlink:title="00000011 - Disclosure - 4. Fair Value Measurement" />
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="00000012 - Disclosure - 5. Prepaid Expenses and Other Current Assets" />
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/CommonStockOfferings" xlink:title="00000013 - Disclosure - 6. Common Stock Offerings" />
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/LicenseAgreements" xlink:title="00000014 - Disclosure - 7. License Agreements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/AccruedExpenses" xlink:title="00000015 - Disclosure - 8. Accrued Expenses" />
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/Debt" xlink:title="00000016 - Disclosure - 9. Debt" />
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/StockholdersEquity" xlink:title="00000017 - Disclosure - 10. Stockholders&#8217; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/Stock-basedCompensation" xlink:title="00000018 - Disclosure - 11. Stock-based Compensation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/CommitmentsAndContingencies" xlink:title="00000019 - Disclosure - 12. Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/SubsequentEvents" xlink:title="00000020 - Disclosure - 13. Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000021 - Disclosure - 3. Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/SignificantAccountingPoliciesTables" xlink:title="00000022 - Disclosure - 3. Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/FairValueMeasurementTables" xlink:title="00000023 - Disclosure - 4. Fair Value Measurement (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="00000024 - Disclosure - 5. Prepaid Expenses and Other Current Assets (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/AccruedExpensesTables" xlink:title="00000025 - Disclosure - 8. Accrued Expenses (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/StockholdersEquityTables" xlink:title="00000026 - Disclosure - 10. Stockholders&#8217; Equity (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/Stock-basedCompensationTables" xlink:title="00000027 - Disclosure - 11. Stock-based Compensation (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/CommitmentsAndContingenciesTables" xlink:title="00000028 - Disclosure - 12. Commitments and Contingencies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative" xlink:title="00000029 - Disclosure - 2. Liquidity and Going Concern (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="00000030 - Disclosure - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails" xlink:title="00000031 - Disclosure - Schedule of Fair Value Hierarchy Assets and Liabilities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails" xlink:title="00000032 - Disclosure - Summary of Fair Value Measurements Convertible Notes Valuation Assumptions (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/SummaryOfFairValueMeasurementsWarrantValuationAssumptionsDetails" xlink:title="00000033 - Disclosure - Summary of Fair Value Measurements Warrant Valuation Assumptions (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/ScheduleOfFairValueLevel3ReconciliationDetails" xlink:title="00000034 - Disclosure - Schedule of Fair Value Level 3 Reconciliation (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/FairValueMeasurementDetailsNarrative" xlink:title="00000035 - Disclosure - 4. Fair Value Measurement (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="00000036 - Disclosure - Schedule of Prepaid Expenses and Other Current Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_PrepaidClinicalCosts" xlink:label="loc_SEELPrepaidClinicalCosts" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_SEELPrepaidClinicalCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/CommonStockOfferingsDetailsNarrative" xlink:title="00000037 - Disclosure - 6. Common Stock Offerings (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/LicenseAgreementsDetailsNarrative" xlink:title="00000038 - Disclosure - 7. License Agreements (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/ScheduleOfAccruedLiabilitiesDetails" xlink:title="00000039 - Disclosure - Schedule of Accrued Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/DebtDetailsNarrative" xlink:title="00000040 - Disclosure - 9. Debt (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/SummaryOfWarrantActivityDetails" xlink:title="00000041 - Disclosure - Summary of Warrant Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000042 - Disclosure - 10. Stockholders&#8217; Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/ScheduleOfValuationAssumptionsForStockOptionsDetails" xlink:title="00000043 - Disclosure - Schedule of Valuation Assumptions for Stock Options (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/SummaryOfStockOptionActivityDetails" xlink:title="00000044 - Disclosure - Summary of Stock Option Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="00000045 - Disclosure - Schedule of Stock-Based Compensation Expense (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000046 - Disclosure - 11. Stock-based Compensation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/ScheduleOfFutureMinimumOperatingLeasePaymentsDetails" xlink:title="00000047 - Disclosure - Schedule of future minimum operating lease payments (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeaseLiability" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000048 - Disclosure - 12. Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://seelostx.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000049 - Disclosure - 13. Subsequent Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>seel-20220331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://seelostx.com/role/Cover" xlink:href="seel-20220331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/BalanceSheets" xlink:href="seel-20220331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/BalanceSheetsParenthetical" xlink:href="seel-20220331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="seel-20220331.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLossParenthetical" xlink:href="seel-20220331.xsd#StatementsOfOperationsAndComprehensiveLossParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:href="seel-20220331.xsd#StatementsOfChangesInStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/StatementsOfCashFlows" xlink:href="seel-20220331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/OrganizationAndDescriptionOfBusiness" xlink:href="seel-20220331.xsd#OrganizationAndDescriptionOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/LiquidityAndGoingConcern" xlink:href="seel-20220331.xsd#LiquidityAndGoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/SignificantAccountingPolicies" xlink:href="seel-20220331.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/FairValueMeasurement" xlink:href="seel-20220331.xsd#FairValueMeasurement" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="seel-20220331.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/CommonStockOfferings" xlink:href="seel-20220331.xsd#CommonStockOfferings" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/LicenseAgreements" xlink:href="seel-20220331.xsd#LicenseAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/AccruedExpenses" xlink:href="seel-20220331.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/Debt" xlink:href="seel-20220331.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/StockholdersEquity" xlink:href="seel-20220331.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/Stock-basedCompensation" xlink:href="seel-20220331.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/CommitmentsAndContingencies" xlink:href="seel-20220331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/SubsequentEvents" xlink:href="seel-20220331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/SignificantAccountingPoliciesPolicies" xlink:href="seel-20220331.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/SignificantAccountingPoliciesTables" xlink:href="seel-20220331.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/FairValueMeasurementTables" xlink:href="seel-20220331.xsd#FairValueMeasurementTables" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="seel-20220331.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/AccruedExpensesTables" xlink:href="seel-20220331.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/StockholdersEquityTables" xlink:href="seel-20220331.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/Stock-basedCompensationTables" xlink:href="seel-20220331.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/CommitmentsAndContingenciesTables" xlink:href="seel-20220331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative" xlink:href="seel-20220331.xsd#LiquidityAndGoingConcernDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="seel-20220331.xsd#ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails" xlink:href="seel-20220331.xsd#ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails" xlink:href="seel-20220331.xsd#SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/SummaryOfFairValueMeasurementsWarrantValuationAssumptionsDetails" xlink:href="seel-20220331.xsd#SummaryOfFairValueMeasurementsWarrantValuationAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/ScheduleOfFairValueLevel3ReconciliationDetails" xlink:href="seel-20220331.xsd#ScheduleOfFairValueLevel3ReconciliationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/FairValueMeasurementDetailsNarrative" xlink:href="seel-20220331.xsd#FairValueMeasurementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="seel-20220331.xsd#ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/CommonStockOfferingsDetailsNarrative" xlink:href="seel-20220331.xsd#CommonStockOfferingsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/LicenseAgreementsDetailsNarrative" xlink:href="seel-20220331.xsd#LicenseAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/ScheduleOfAccruedLiabilitiesDetails" xlink:href="seel-20220331.xsd#ScheduleOfAccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/DebtDetailsNarrative" xlink:href="seel-20220331.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/SummaryOfWarrantActivityDetails" xlink:href="seel-20220331.xsd#SummaryOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/StockholdersEquityDetailsNarrative" xlink:href="seel-20220331.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/ScheduleOfValuationAssumptionsForStockOptionsDetails" xlink:href="seel-20220331.xsd#ScheduleOfValuationAssumptionsForStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/SummaryOfStockOptionActivityDetails" xlink:href="seel-20220331.xsd#SummaryOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:href="seel-20220331.xsd#ScheduleOfStock-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="seel-20220331.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/ScheduleOfFutureMinimumOperatingLeasePaymentsDetails" xlink:href="seel-20220331.xsd#ScheduleOfFutureMinimumOperatingLeasePaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="seel-20220331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/SubsequentEventsDetailsNarrative" xlink:href="seel-20220331.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss" />
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLossParenthetical" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Changes in Stockholders&apos; Equity (Deficit)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/OrganizationAndDescriptionOfBusiness" xlink:title="00000008 - Disclosure - 1. Organization and Description of Business" />
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/LiquidityAndGoingConcern" xlink:title="00000009 - Disclosure - 2. Liquidity and Going Concern" />
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/SignificantAccountingPolicies" xlink:title="00000010 - Disclosure - 3. Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/FairValueMeasurement" xlink:title="00000011 - Disclosure - 4. Fair Value Measurement" />
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="00000012 - Disclosure - 5. Prepaid Expenses and Other Current Assets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/CommonStockOfferings" xlink:title="00000013 - Disclosure - 6. Common Stock Offerings" />
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/LicenseAgreements" xlink:title="00000014 - Disclosure - 7. License Agreements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/AccruedExpenses" xlink:title="00000015 - Disclosure - 8. Accrued Expenses" />
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/Debt" xlink:title="00000016 - Disclosure - 9. Debt" />
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/StockholdersEquity" xlink:title="00000017 - Disclosure - 10. Stockholders&#8217; Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/Stock-basedCompensation" xlink:title="00000018 - Disclosure - 11. Stock-based Compensation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/CommitmentsAndContingencies" xlink:title="00000019 - Disclosure - 12. Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/SubsequentEvents" xlink:title="00000020 - Disclosure - 13. Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000021 - Disclosure - 3. Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/SignificantAccountingPoliciesTables" xlink:title="00000022 - Disclosure - 3. Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/FairValueMeasurementTables" xlink:title="00000023 - Disclosure - 4. Fair Value Measurement (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaapFairValueByLiabilityClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="loc_us-gaapFairValueByLiabilityClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember" xlink:label="loc_us-gaapLongTermDebtMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_us-gaapLongTermDebtMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="00000024 - Disclosure - 5. Prepaid Expenses and Other Current Assets (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/AccruedExpensesTables" xlink:title="00000025 - Disclosure - 8. Accrued Expenses (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/StockholdersEquityTables" xlink:title="00000026 - Disclosure - 10. Stockholders&#8217; Equity (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/Stock-basedCompensationTables" xlink:title="00000027 - Disclosure - 11. Stock-based Compensation (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/CommitmentsAndContingenciesTables" xlink:title="00000028 - Disclosure - 12. Commitments and Contingencies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative" xlink:title="00000029 - Disclosure - 2. Liquidity and Going Concern (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_May242021Member" xlink:label="loc_SEELMay242021Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SEELMay242021Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_January282021Member" xlink:label="loc_SEELJanuary282021Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SEELJanuary282021Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCash_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes" xlink:label="loc_SEELOfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SEELOfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_FinancingAvailableUnderFormS3ShelfRegistrationStatement" xlink:label="loc_SEELFinancingAvailableUnderFormS3ShelfRegistrationStatement_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SEELFinancingAvailableUnderFormS3ShelfRegistrationStatement_60" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="00000030 - Disclosure - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaapConvertibleDebtSecuritiesMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapConvertibleDebtSecuritiesMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_110" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails" xlink:title="00000031 - Disclosure - Schedule of Fair Value Hierarchy Assets and Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaapFairValueByLiabilityClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByLiabilityClassAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember" xlink:label="loc_us-gaapLongTermDebtMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_us-gaapLongTermDebtMember_50" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_us-gaapWarrantMember_90" xlink:type="arc" order="93" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="loc_us-gaapDerivativeFinancialInstrumentsLiabilitiesMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_us-gaapDerivativeFinancialInstrumentsLiabilitiesMember_220" xlink:type="arc" order="223" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapAssetsAbstract_300" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_300" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_300" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaapLiabilitiesAbstract_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapLiabilitiesAbstract_300" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAbstract_300" xlink:to="loc_us-gaapDerivativeLiabilities_300" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails" xlink:title="00000032 - Disclosure - Summary of Fair Value Measurements Convertible Notes Valuation Assumptions (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaapFairValueByLiabilityClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="loc_us-gaapFairValueByLiabilityClassAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember" xlink:label="loc_us-gaapLongTermDebtMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_us-gaapLongTermDebtMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_100" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/SummaryOfFairValueMeasurementsWarrantValuationAssumptionsDetails" xlink:title="00000033 - Disclosure - Summary of Fair Value Measurements Warrant Valuation Assumptions (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaapFairValueByLiabilityClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByLiabilityClassAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_30" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/ScheduleOfFairValueLevel3ReconciliationDetails" xlink:title="00000034 - Disclosure - Schedule of Fair Value Level 3 Reconciliation (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaapFairValueByLiabilityClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByLiabilityClassAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember" xlink:label="loc_us-gaapLongTermDebtMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_us-gaapLongTermDebtMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="loc_us-gaapDerivativeFinancialInstrumentsLiabilitiesMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_us-gaapDerivativeFinancialInstrumentsLiabilitiesMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_140" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/FairValueMeasurementDetailsNarrative" xlink:title="00000035 - Disclosure - 4. Fair Value Measurement (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsLineItems" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsTable" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_IXLicenseAgreementMember" xlink:label="loc_SEELIXLicenseAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="loc_SEELIXLicenseAgreementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_NonrefundableCashPayment" xlink:label="loc_SEELNonrefundableCashPayment_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsLineItems" xlink:to="loc_SEELNonrefundableCashPayment_30" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="00000036 - Disclosure - Schedule of Prepaid Expenses and Other Current Assets (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/CommonStockOfferingsDetailsNarrative" xlink:title="00000037 - Disclosure - 6. Common Stock Offerings (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_May242021Member" xlink:label="loc_SEELMay242021Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SEELMay242021Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_January282021Member" xlink:label="loc_SEELJanuary282021Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SEELJanuary282021Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_IXLicenseAgreementMember" xlink:label="loc_SEELIXLicenseAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="loc_SEELIXLicenseAgreementMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes" xlink:label="loc_SEELOfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_SEELOfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_NonrefundableCashPayment" xlink:label="loc_SEELNonrefundableCashPayment_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_SEELNonrefundableCashPayment_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_Issuanceofcommonstockforlicenseacquiredshares" xlink:label="loc_SEELIssuanceofcommonstockforlicenseacquiredshares_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_SEELIssuanceofcommonstockforlicenseacquiredshares_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_MinimumStockValueOfSharesIssued" xlink:label="loc_SEELMinimumStockValueOfSharesIssued_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_SEELMinimumStockValueOfSharesIssued_80" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_InitialStockValuationShortfallFrom5.5MillionValue" xlink:label="loc_SEELInitialStockValuationShortfallFrom5.5MillionValue_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_SEELInitialStockValuationShortfallFrom5.5MillionValue_80" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/LicenseAgreementsDetailsNarrative" xlink:title="00000038 - Disclosure - 7. License Agreements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsLineItems" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsTable" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_WegLicenseAgreementMember" xlink:label="loc_SEELWegLicenseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="loc_SEELWegLicenseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDescription" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDescription_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsLineItems" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDescription_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_NonrefundableCashPayment" xlink:label="loc_SEELNonrefundableCashPayment_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsLineItems" xlink:to="loc_SEELNonrefundableCashPayment_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaapAssetAcquisitionContingentConsiderationLiabilityCurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsLineItems" xlink:to="loc_us-gaapAssetAcquisitionContingentConsiderationLiabilityCurrent_60" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/ScheduleOfAccruedLiabilitiesDetails" xlink:title="00000039 - Disclosure - Schedule of Accrued Liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/DebtDetailsNarrative" xlink:title="00000040 - Disclosure - 9. Debt (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_November2021LindSecuritiesPurchaseAgreementMember" xlink:label="loc_SEELNovember2021LindSecuritiesPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SEELNovember2021LindSecuritiesPurchaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_FirstAnniversaryOfNovember2021LindSecuritiesPurchaseAgreementMember" xlink:label="loc_SEELFirstAnniversaryOfNovember2021LindSecuritiesPurchaseAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SEELFirstAnniversaryOfNovember2021LindSecuritiesPurchaseAgreementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_August232022ThruMaturityNovember2021LindSecuritiesPurchaseAgreementMember" xlink:label="loc_SEELAugust232022ThruMaturityNovember2021LindSecuritiesPurchaseAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SEELAugust232022ThruMaturityNovember2021LindSecuritiesPurchaseAgreementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_AmortizeNovember2021LindSecuritiesPurchaseAgreementMember" xlink:label="loc_SEELAmortizeNovember2021LindSecuritiesPurchaseAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SEELAmortizeNovember2021LindSecuritiesPurchaseAgreementMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_December2021SPAsMember" xlink:label="loc_SEELDecember2021SPAsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SEELDecember2021SPAsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_LindSecuritiesPurchaseAgreementMember" xlink:label="loc_SEELLindSecuritiesPurchaseAgreementMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SEELLindSecuritiesPurchaseAgreementMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_December17SPAsMember" xlink:label="loc_SEELDecember17SPAsMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SEELDecember17SPAsMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtDescription" xlink:label="loc_us-gaapLongTermDebtDescription_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapLongTermDebtDescription_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromConvertibleDebt_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleSubordinatedDebt" xlink:label="loc_us-gaapConvertibleSubordinatedDebt_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleSubordinatedDebt_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_GainLossInFairValueOfConvertibleNotes" xlink:label="loc_SEELGainLossInFairValueOfConvertibleNotes_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_SEELGainLossInFairValueOfConvertibleNotes_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue" xlink:label="loc_us-gaapLongTermDebtFairValue_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapLongTermDebtFairValue_140" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable_140" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaapRepaymentsOfConvertibleDebt_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapRepaymentsOfConvertibleDebt_140" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_140" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapLongTermDebt_140" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/SummaryOfWarrantActivityDetails" xlink:title="00000041 - Disclosure - Summary of Warrant Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapOffsettingAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_WarrantDerivativeFinancialInstrumentsMember" xlink:label="loc_SEELWarrantDerivativeFinancialInstrumentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_SEELWarrantDerivativeFinancialInstrumentsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_ClassOfWarrantOrRightOutstandingWeightedAverageRemaingContractualLife" xlink:label="loc_SEELClassOfWarrantOrRightOutstandingWeightedAverageRemaingContractualLife_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_SEELClassOfWarrantOrRightOutstandingWeightedAverageRemaingContractualLife_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_NumberofWarrantsIssuedDuringPeriod" xlink:label="loc_SEELNumberofWarrantsIssuedDuringPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_SEELNumberofWarrantsIssuedDuringPeriod_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_ClassOfWarrantOrRightIssuedExercisePriceOfWarrantsOrRights" xlink:label="loc_SEELClassOfWarrantOrRightIssuedExercisePriceOfWarrantsOrRights_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_SEELClassOfWarrantOrRightIssuedExercisePriceOfWarrantsOrRights_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_NumberofWarrantsExercisedDuringPeriod" xlink:label="loc_SEELNumberofWarrantsExercisedDuringPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_SEELNumberofWarrantsExercisedDuringPeriod_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_ClassOfWarrantOrRightExercisedExercisePriceOfWarrantsOrRights" xlink:label="loc_SEELClassOfWarrantOrRightExercisedExercisePriceOfWarrantsOrRights_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_SEELClassOfWarrantOrRightExercisedExercisePriceOfWarrantsOrRights_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_NumberofWarrantsCancelledDuringPeriod" xlink:label="loc_SEELNumberofWarrantsCancelledDuringPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_SEELNumberofWarrantsCancelledDuringPeriod_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_ClassOfWarrantOrRightCancelledExercisePriceOfWarrantsOrRights" xlink:label="loc_SEELClassOfWarrantOrRightCancelledExercisePriceOfWarrantsOrRights_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_SEELClassOfWarrantOrRightCancelledExercisePriceOfWarrantsOrRights_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_ClassOfWarrantOrRightOutstandingEndOfPeriodWeightedAverageRemaingContractualLife" xlink:label="loc_SEELClassOfWarrantOrRightOutstandingEndOfPeriodWeightedAverageRemaingContractualLife_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_SEELClassOfWarrantOrRightOutstandingEndOfPeriodWeightedAverageRemaingContractualLife_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_WarrantsExercisable" xlink:label="loc_SEELWarrantsExercisable_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_SEELWarrantsExercisable_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights1" xlink:label="loc_SEELClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_SEELClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights1_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_ClassOfWarrantOrRightExercisableWeightedAverageRemaingContractualLife" xlink:label="loc_SEELClassOfWarrantOrRightExercisableWeightedAverageRemaingContractualLife_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_SEELClassOfWarrantOrRightExercisableWeightedAverageRemaingContractualLife_40" xlink:type="arc" order="14" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000042 - Disclosure - 10. Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_September2020WarrantsMember" xlink:label="loc_SEELSeptember2020WarrantsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_SEELSeptember2020WarrantsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_August2019WarrantsMember" xlink:label="loc_SEELAugust2019WarrantsMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_SEELAugust2019WarrantsMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_SeriesAWarrantsMember" xlink:label="loc_SEELSeriesAWarrantsMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_SEELSeriesAWarrantsMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_September2020WarrantsMember" xlink:label="loc_SEELSeptember2020WarrantsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SEELSeptember2020WarrantsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_August232019Member" xlink:label="loc_SEELAugust232019Member_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SEELAugust232019Member_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_August2019WarrantsMember" xlink:label="loc_SEELAugust2019WarrantsMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SEELAugust2019WarrantsMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_220" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_220" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_220" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_220" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaapCommonStockVotingRights_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapCommonStockVotingRights_220" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:label="loc_us-gaapClassOfWarrantOrRightReasonForIssuingToNonemployees_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightReasonForIssuingToNonemployees_220" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_220" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_220" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_220" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_NumberofWarrantsExercisedDuringPeriod" xlink:label="loc_SEELNumberofWarrantsExercisedDuringPeriod_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_SEELNumberofWarrantsExercisedDuringPeriod_220" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises_220" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_WarrantsExercisable" xlink:label="loc_SEELWarrantsExercisable_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_SEELWarrantsExercisable_220" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/ScheduleOfValuationAssumptionsForStockOptionsDetails" xlink:title="00000043 - Disclosure - Schedule of Valuation Assumptions for Stock Options (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_70" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/SummaryOfStockOptionActivityDetails" xlink:title="00000044 - Disclosure - Summary of Stock Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_50" xlink:type="arc" order="19" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="00000045 - Disclosure - Schedule of Stock-Based Compensation Expense (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapShareBasedCompensation_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000046 - Disclosure - 11. Stock-based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_EmployeeStockPurchasePlanMember" xlink:label="loc_SEELEmployeeStockPurchasePlanMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SEELEmployeeStockPurchasePlanMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_InducementPlanof2019Member" xlink:label="loc_SEELInducementPlanof2019Member_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SEELInducementPlanof2019Member_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_IncentiveStockOptionMember" xlink:label="loc_SEELIncentiveStockOptionMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SEELIncentiveStockOptionMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_NonQualifiedStockOptionsToEmployeesMember" xlink:label="loc_SEELNonQualifiedStockOptionsToEmployeesMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SEELNonQualifiedStockOptionsToEmployeesMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_NonQualifiedStockOptionsToNonEmployeeDirectorsMember" xlink:label="loc_SEELNonQualifiedStockOptionsToNonEmployeeDirectorsMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SEELNonQualifiedStockOptionsToNonEmployeeDirectorsMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaapPerformanceSharesMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapPerformanceSharesMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_PSUtoExecutivesMember" xlink:label="loc_SEELPSUtoExecutivesMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SEELPSUtoExecutivesMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_180" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_180" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_180" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_180" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_180" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_180" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceDiscountOfCommonStockPercent" xlink:label="loc_SEELSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceDiscountOfCommonStockPercent_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SEELSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceDiscountOfCommonStockPercent_180" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation_180" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_180" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_180" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_180" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_180" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_180" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_180" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_180" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_180" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_180" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_180" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_180" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_180" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_180" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_SharebasedPaymentArrangementNonvestedAndCanceledAwardExcludingOptionCostNotYetRecognizedAmount" xlink:label="loc_SEELSharebasedPaymentArrangementNonvestedAndCanceledAwardExcludingOptionCostNotYetRecognizedAmount_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SEELSharebasedPaymentArrangementNonvestedAndCanceledAwardExcludingOptionCostNotYetRecognizedAmount_180" xlink:type="arc" order="21" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/ScheduleOfFutureMinimumOperatingLeasePaymentsDetails" xlink:title="00000047 - Disclosure - Schedule of future minimum operating lease payments (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000048 - Disclosure - 12. Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaapLesseeLeaseDescriptionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaapLesseeLeaseDescriptionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapLesseeLeaseDescriptionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaapLeaseContractualTermAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_us-gaapLeaseContractualTermAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaapLeaseContractualTermDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLeaseContractualTermAxis" xlink:to="loc_us-gaapLeaseContractualTermDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaapLeaseContractualTermDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLeaseContractualTermAxis" xlink:to="loc_us-gaapLeaseContractualTermDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_March2019LeaseMember" xlink:label="loc_SEELMarch2019LeaseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_SEELMarch2019LeaseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_March2021LeaseMember" xlink:label="loc_SEELMarch2021LeaseMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_SEELMarch2021LeaseMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaapLesseeOperatingLeaseDescription_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDescription_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaapLesseeOperatingLeaseOptionToExtend_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseOptionToExtend_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense_80" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://seelostx.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000049 - Disclosure - 13. Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_AssetsfromVyeraPharmaceuticalsMember" xlink:label="loc_SEELAssetsfromVyeraPharmaceuticalsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="loc_SEELAssetsfromVyeraPharmaceuticalsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDescription" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDescription_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDescription_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventDescription" xlink:label="loc_us-gaapSubsequentEventDescription_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventDescription_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement" xlink:label="loc_SEELCashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_SEELCashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" xlink:type="arc" order="3" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>seel-20220331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_May242021Member" xlink:label="SEEL_May242021Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_May242021Member" xlink:to="SEEL_May242021Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_May242021Member_lbl" xml:lang="en-US">May 242021 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_January282021Member" xlink:label="SEEL_January282021Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_January282021Member" xlink:to="SEEL_January282021Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_January282021Member_lbl" xml:lang="en-US">January 282021 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_lbl" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_IXLicenseAgreementMember" xlink:label="SEEL_IXLicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_IXLicenseAgreementMember" xlink:to="SEEL_IXLicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_IXLicenseAgreementMember_lbl" xml:lang="en-US">I X License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xml:lang="en-US">Liability Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember" xlink:label="us-gaap_LongTermDebtMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMember" xlink:to="us-gaap_LongTermDebtMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMember_lbl" xml:lang="en-US">Long-Term Debt [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_lbl" xml:lang="en-US">Derivative Financial Instruments, Liabilities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_WegLicenseAgreementMember" xlink:label="SEEL_WegLicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_WegLicenseAgreementMember" xlink:to="SEEL_WegLicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_WegLicenseAgreementMember_lbl" xml:lang="en-US">Weg License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_November2021LindSecuritiesPurchaseAgreementMember" xlink:label="SEEL_November2021LindSecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_November2021LindSecuritiesPurchaseAgreementMember" xlink:to="SEEL_November2021LindSecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_November2021LindSecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">November 2021 Lind Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_FirstAnniversaryOfNovember2021LindSecuritiesPurchaseAgreementMember" xlink:label="SEEL_FirstAnniversaryOfNovember2021LindSecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_FirstAnniversaryOfNovember2021LindSecuritiesPurchaseAgreementMember" xlink:to="SEEL_FirstAnniversaryOfNovember2021LindSecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_FirstAnniversaryOfNovember2021LindSecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">First Anniversary Of November 2021 Lind Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_August232022ThruMaturityNovember2021LindSecuritiesPurchaseAgreementMember" xlink:label="SEEL_August232022ThruMaturityNovember2021LindSecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_August232022ThruMaturityNovember2021LindSecuritiesPurchaseAgreementMember" xlink:to="SEEL_August232022ThruMaturityNovember2021LindSecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_August232022ThruMaturityNovember2021LindSecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">August 232022 Thru Maturity November 2021 Lind Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_AmortizeNovember2021LindSecuritiesPurchaseAgreementMember" xlink:label="SEEL_AmortizeNovember2021LindSecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_AmortizeNovember2021LindSecuritiesPurchaseAgreementMember" xlink:to="SEEL_AmortizeNovember2021LindSecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_AmortizeNovember2021LindSecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Amortize November 2021 Lind Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_December2021SPAsMember" xlink:label="SEEL_December2021SPAsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_December2021SPAsMember" xlink:to="SEEL_December2021SPAsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_December2021SPAsMember_lbl" xml:lang="en-US">December 2021 S P As [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_LindSecuritiesPurchaseAgreementMember" xlink:label="SEEL_LindSecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_LindSecuritiesPurchaseAgreementMember" xlink:to="SEEL_LindSecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_LindSecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Lind Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_December17SPAsMember" xlink:label="SEEL_December17SPAsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_December17SPAsMember" xlink:to="SEEL_December17SPAsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_December17SPAsMember_lbl" xml:lang="en-US">December 17 S P As [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_September2020WarrantsMember" xlink:label="SEEL_September2020WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_September2020WarrantsMember" xlink:to="SEEL_September2020WarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_September2020WarrantsMember_lbl" xml:lang="en-US">September 2020 Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_August2019WarrantsMember" xlink:label="SEEL_August2019WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_August2019WarrantsMember" xlink:to="SEEL_August2019WarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_August2019WarrantsMember_lbl" xml:lang="en-US">August 2019 Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_August232019Member" xlink:label="SEEL_August232019Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_August232019Member" xlink:to="SEEL_August232019Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_August232019Member_lbl" xml:lang="en-US">August 232019 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_SeriesAWarrantsMember" xlink:label="SEEL_SeriesAWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_SeriesAWarrantsMember" xlink:to="SEEL_SeriesAWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_SeriesAWarrantsMember_lbl" xml:lang="en-US">Series A Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_WarrantDerivativeFinancialInstrumentsMember" xlink:label="SEEL_WarrantDerivativeFinancialInstrumentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_WarrantDerivativeFinancialInstrumentsMember" xlink:to="SEEL_WarrantDerivativeFinancialInstrumentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_WarrantDerivativeFinancialInstrumentsMember_lbl" xml:lang="en-US">Warrant Derivative Financial Instruments [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_EmployeeStockPurchasePlanMember" xlink:label="SEEL_EmployeeStockPurchasePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_EmployeeStockPurchasePlanMember" xlink:to="SEEL_EmployeeStockPurchasePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_InducementPlanof2019Member" xlink:label="SEEL_InducementPlanof2019Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_InducementPlanof2019Member" xlink:to="SEEL_InducementPlanof2019Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_InducementPlanof2019Member_lbl" xml:lang="en-US">Inducement Planof 2019 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_IncentiveStockOptionMember" xlink:label="SEEL_IncentiveStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_IncentiveStockOptionMember" xlink:to="SEEL_IncentiveStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_IncentiveStockOptionMember_lbl" xml:lang="en-US">Incentive Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_NonQualifiedStockOptionsToEmployeesMember" xlink:label="SEEL_NonQualifiedStockOptionsToEmployeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_NonQualifiedStockOptionsToEmployeesMember" xlink:to="SEEL_NonQualifiedStockOptionsToEmployeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_NonQualifiedStockOptionsToEmployeesMember_lbl" xml:lang="en-US">Non Qualified Stock Options To Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_NonQualifiedStockOptionsToNonEmployeeDirectorsMember" xlink:label="SEEL_NonQualifiedStockOptionsToNonEmployeeDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_NonQualifiedStockOptionsToNonEmployeeDirectorsMember" xlink:to="SEEL_NonQualifiedStockOptionsToNonEmployeeDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_NonQualifiedStockOptionsToNonEmployeeDirectorsMember_lbl" xml:lang="en-US">Non Qualified Stock Options To Non Employee Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PerformanceSharesMember_lbl" xml:lang="en-US">Performance Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_PSUtoExecutivesMember" xlink:label="SEEL_PSUtoExecutivesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_PSUtoExecutivesMember" xlink:to="SEEL_PSUtoExecutivesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_PSUtoExecutivesMember_lbl" xml:lang="en-US">P S Uto Executives [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_March2019LeaseMember" xlink:label="SEEL_March2019LeaseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_March2019LeaseMember" xlink:to="SEEL_March2019LeaseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_March2019LeaseMember_lbl" xml:lang="en-US">March 2019 Lease [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_March2021LeaseMember" xlink:label="SEEL_March2021LeaseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_March2021LeaseMember" xlink:to="SEEL_March2021LeaseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_March2021LeaseMember_lbl" xml:lang="en-US">March 2021 Lease [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_AssetsfromVyeraPharmaceuticalsMember" xlink:label="SEEL_AssetsfromVyeraPharmaceuticalsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_AssetsfromVyeraPharmaceuticalsMember" xlink:to="SEEL_AssetsfromVyeraPharmaceuticalsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_AssetsfromVyeraPharmaceuticalsMember_lbl" xml:lang="en-US">Assetsfrom Vyera Pharmaceuticals [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_LicensesPayable" xlink:label="SEEL_LicensesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_LicensesPayable" xlink:to="SEEL_LicensesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_LicensesPayable_lbl" xml:lang="en-US">Licenses payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleSubordinatedDebtCurrent" xlink:label="us-gaap_ConvertibleSubordinatedDebtCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleSubordinatedDebtCurrent" xlink:to="us-gaap_ConvertibleSubordinatedDebtCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleSubordinatedDebtCurrent_lbl" xml:lang="en-US">Short-term portion of convertible notes payable, at fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilities_lbl" xml:lang="en-US">Derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xml:lang="en-US">Warrant liabilities, at fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleSubordinatedDebtNoncurrent" xlink:label="us-gaap_ConvertibleSubordinatedDebtNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleSubordinatedDebtNoncurrent" xlink:to="us-gaap_ConvertibleSubordinatedDebtNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleSubordinatedDebtNoncurrent_lbl" xml:lang="en-US">Convertible notes payable, at fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (note 12)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value, 240,000,000 shares authorized, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 105,590,773 and 105,500,445 issued and outstanding as of &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;March 31, 2022 and December 31, 2021, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in-capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, per value (in usd per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, authorized (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, issued (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, outstanding (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, authorized (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, issued (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, outstanding (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeDomesticDeposits" xlink:label="us-gaap_InterestIncomeDomesticDeposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeDomesticDeposits" xlink:to="us-gaap_InterestIncomeDomesticDeposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeDomesticDeposits_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_GainLossInFairValueOfConvertibleNotes" xlink:label="SEEL_GainLossInFairValueOfConvertibleNotes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_GainLossInFairValueOfConvertibleNotes" xlink:to="SEEL_GainLossInFairValueOfConvertibleNotes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_GainLossInFairValueOfConvertibleNotes_lbl" xml:lang="en-US">Change in fair value of convertible notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss and comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Earnings Per Share, Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_2_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Issuance of common stock, options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_lbl" xml:lang="en-US">Warrants exercised for cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_lbl" xml:lang="en-US">Issuance of common stock, ESPP</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Ownership Plan</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_3_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding, Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Change in fair value of warrant liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_GainLossInFairValueOfConvertibleNotes" xlink:to="SEEL_GainLossInFairValueOfConvertibleNotes_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SEEL_GainLossInFairValueOfConvertibleNotes_2_lbl" xml:lang="en-US">Change in fair value of convertible notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLossOnDerivative" xlink:to="us-gaap_DerivativeLossOnDerivative_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DerivativeLossOnDerivative_lbl" xml:lang="en-US">Derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" xml:lang="en-US">Licenses payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Payment of convertible note</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xml:lang="en-US">Proceeds from sales of common stock under ESPP</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease) in cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Cash paid for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_ReclassOfWarrantLiabilitiesRelatedToSeriesWarrantsExercisedForCash" xlink:label="SEEL_ReclassOfWarrantLiabilitiesRelatedToSeriesWarrantsExercisedForCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ReclassOfWarrantLiabilitiesRelatedToSeriesWarrantsExercisedForCash" xlink:to="SEEL_ReclassOfWarrantLiabilitiesRelatedToSeriesWarrantsExercisedForCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_ReclassOfWarrantLiabilitiesRelatedToSeriesWarrantsExercisedForCash_lbl" xml:lang="en-US">Reclass of warrant liabilities related to Series A warrants exercised for cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="us-gaap_CapitalLeaseObligationsIncurred" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsIncurred" xlink:to="us-gaap_CapitalLeaseObligationsIncurred_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsIncurred_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">1. Organization and Description of Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">2. Liquidity and Going Concern</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">3. Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">4. Fair Value Measurement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">5. Prepaid Expenses and Other Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US">6. Common Stock Offerings</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xml:lang="en-US">Research and Development [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xml:lang="en-US">7. License Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">8. Accrued Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">9. Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">10. Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">11. Stock-based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">12. Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">13. Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value Hierarchy Assets and Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Summary of Fair Value Measurements Warrant Valuation Assumptions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value Level 3 Reconciliation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Summary of Warrant Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Valuation Assumptions for Stock Options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xml:lang="en-US">Summary of Stock Option Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of future minimum operating lease payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Accumlated deficit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Number of shares of common stock issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Cash received from stock sale</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes" xlink:label="SEEL_OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes" xlink:to="SEEL_OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes_lbl" xml:lang="en-US">Offering proceeds used to partially repay certain convertible promissory notes</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_FinancingAvailableUnderFormS3ShelfRegistrationStatement" xlink:label="SEEL_FinancingAvailableUnderFormS3ShelfRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_FinancingAvailableUnderFormS3ShelfRegistrationStatement" xlink:to="SEEL_FinancingAvailableUnderFormS3ShelfRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_FinancingAvailableUnderFormS3ShelfRegistrationStatement_lbl" xml:lang="en-US">[custom:FinancingAvailableUnderFormS3ShelfRegistrationStatement-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive securities excluded</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsAbstract_2_lbl" xml:lang="en-US">Assets [Abstract]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US">Liabilities [Abstract]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativeLiabilities_2_lbl" xml:lang="en-US">Warrant liabilities, at fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_lbl" xml:lang="en-US">Dividend yield (in percent)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_2_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_lbl" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_lbl" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_NonrefundableCashPayment" xlink:label="SEEL_NonrefundableCashPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_NonrefundableCashPayment" xlink:to="SEEL_NonrefundableCashPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_NonrefundableCashPayment_lbl" xml:lang="en-US">[custom:NonrefundableCashPayment]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_PrepaidClinicalCosts" xlink:label="SEEL_PrepaidClinicalCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_PrepaidClinicalCosts" xlink:to="SEEL_PrepaidClinicalCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_PrepaidClinicalCosts_lbl" xml:lang="en-US">Prepaid clinical costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and Development Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_Issuanceofcommonstockforlicenseacquiredshares" xlink:label="SEEL_Issuanceofcommonstockforlicenseacquiredshares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_Issuanceofcommonstockforlicenseacquiredshares" xlink:to="SEEL_Issuanceofcommonstockforlicenseacquiredshares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_Issuanceofcommonstockforlicenseacquiredshares_lbl" xml:lang="en-US">[custom:Issuanceofcommonstockforlicenseacquiredshares]</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_MinimumStockValueOfSharesIssued" xlink:label="SEEL_MinimumStockValueOfSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_MinimumStockValueOfSharesIssued" xlink:to="SEEL_MinimumStockValueOfSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_MinimumStockValueOfSharesIssued_lbl" xml:lang="en-US">[custom:MinimumStockValueOfSharesIssued]</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_InitialStockValuationShortfallFrom5.5MillionValue" xlink:label="SEEL_InitialStockValuationShortfallFrom5.5MillionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_InitialStockValuationShortfallFrom5.5MillionValue" xlink:to="SEEL_InitialStockValuationShortfallFrom5.5MillionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_InitialStockValuationShortfallFrom5.5MillionValue_lbl" xml:lang="en-US">[custom:InitialStockValuationShortfallFrom5.5MillionValue]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDescription" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDescription" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDescription_lbl" xml:lang="en-US">Business Combination, Separately Recognized Transactions, Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_lbl" xml:lang="en-US">Asset Acquisition, Contingent Consideration, Liability, Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Professional fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Personnel related</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_OutsideResearchAndDevelopmentServicesCurrent" xlink:label="SEEL_OutsideResearchAndDevelopmentServicesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_OutsideResearchAndDevelopmentServicesCurrent" xlink:to="SEEL_OutsideResearchAndDevelopmentServicesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_OutsideResearchAndDevelopmentServicesCurrent_lbl" xml:lang="en-US">Outside research and development services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedInsuranceCurrent" xlink:label="us-gaap_AccruedInsuranceCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedInsuranceCurrent" xlink:to="us-gaap_AccruedInsuranceCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedInsuranceCurrent_lbl" xml:lang="en-US">Insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160; Accrued expenses, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Schedule of Short-Term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtDescription" xlink:label="us-gaap_LongTermDebtDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtDescription" xlink:to="us-gaap_LongTermDebtDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtDescription_lbl" xml:lang="en-US">Long-Term Debt, Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleSubordinatedDebt" xlink:label="us-gaap_ConvertibleSubordinatedDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleSubordinatedDebt" xlink:to="us-gaap_ConvertibleSubordinatedDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleSubordinatedDebt_lbl" xml:lang="en-US">Convertible Subordinated Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_GainLossInFairValueOfConvertibleNotes" xlink:to="SEEL_GainLossInFairValueOfConvertibleNotes_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SEEL_GainLossInFairValueOfConvertibleNotes_3_lbl" xml:lang="en-US">[custom:GainLossInFairValueOfConvertibleNotes]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue" xlink:label="us-gaap_LongTermDebtFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtFairValue" xlink:to="us-gaap_LongTermDebtFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtFairValue_lbl" xml:lang="en-US">Long-Term Debt, Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US">Convertible Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US">Repayments of Convertible Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Long-Term Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsTable" xlink:label="us-gaap_OffsettingAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsTable" xlink:to="us-gaap_OffsettingAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsTable_lbl" xml:lang="en-US">Offsetting Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="us-gaap_OffsettingAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsLineItems" xlink:to="us-gaap_OffsettingAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsLineItems_lbl" xml:lang="en-US">Offsetting Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Outstanding as of December 31, 2021</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Outstanding as of December 31, 2020, weighted-average exercise price (in usd per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_ClassOfWarrantOrRightOutstandingWeightedAverageRemaingContractualLife" xlink:label="SEEL_ClassOfWarrantOrRightOutstandingWeightedAverageRemaingContractualLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ClassOfWarrantOrRightOutstandingWeightedAverageRemaingContractualLife" xlink:to="SEEL_ClassOfWarrantOrRightOutstandingWeightedAverageRemaingContractualLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_ClassOfWarrantOrRightOutstandingWeightedAverageRemaingContractualLife_lbl" xml:lang="en-US">Warrants outstanding as of December 31, 2020, weighted-average remaing contractual life (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_NumberofWarrantsIssuedDuringPeriod" xlink:label="SEEL_NumberofWarrantsIssuedDuringPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_NumberofWarrantsIssuedDuringPeriod" xlink:to="SEEL_NumberofWarrantsIssuedDuringPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_NumberofWarrantsIssuedDuringPeriod_lbl" xml:lang="en-US">Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_ClassOfWarrantOrRightIssuedExercisePriceOfWarrantsOrRights" xlink:label="SEEL_ClassOfWarrantOrRightIssuedExercisePriceOfWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ClassOfWarrantOrRightIssuedExercisePriceOfWarrantsOrRights" xlink:to="SEEL_ClassOfWarrantOrRightIssuedExercisePriceOfWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_ClassOfWarrantOrRightIssuedExercisePriceOfWarrantsOrRights_lbl" xml:lang="en-US">Issued, warrant exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_NumberofWarrantsExercisedDuringPeriod" xlink:label="SEEL_NumberofWarrantsExercisedDuringPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_NumberofWarrantsExercisedDuringPeriod" xlink:to="SEEL_NumberofWarrantsExercisedDuringPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_NumberofWarrantsExercisedDuringPeriod_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_ClassOfWarrantOrRightExercisedExercisePriceOfWarrantsOrRights" xlink:label="SEEL_ClassOfWarrantOrRightExercisedExercisePriceOfWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ClassOfWarrantOrRightExercisedExercisePriceOfWarrantsOrRights" xlink:to="SEEL_ClassOfWarrantOrRightExercisedExercisePriceOfWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_ClassOfWarrantOrRightExercisedExercisePriceOfWarrantsOrRights_lbl" xml:lang="en-US">Exercised, exercise price of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_NumberofWarrantsCancelledDuringPeriod" xlink:label="SEEL_NumberofWarrantsCancelledDuringPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_NumberofWarrantsCancelledDuringPeriod" xlink:to="SEEL_NumberofWarrantsCancelledDuringPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_NumberofWarrantsCancelledDuringPeriod_lbl" xml:lang="en-US">Cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_ClassOfWarrantOrRightCancelledExercisePriceOfWarrantsOrRights" xlink:label="SEEL_ClassOfWarrantOrRightCancelledExercisePriceOfWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ClassOfWarrantOrRightCancelledExercisePriceOfWarrantsOrRights" xlink:to="SEEL_ClassOfWarrantOrRightCancelledExercisePriceOfWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_ClassOfWarrantOrRightCancelledExercisePriceOfWarrantsOrRights_lbl" xml:lang="en-US">Cancelled, exercise price of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xml:lang="en-US">Outstanding as of March 31, 2022</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Outstanding as of June 30, 2021, weighted-average exercise price (in usd per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_ClassOfWarrantOrRightOutstandingEndOfPeriodWeightedAverageRemaingContractualLife" xlink:label="SEEL_ClassOfWarrantOrRightOutstandingEndOfPeriodWeightedAverageRemaingContractualLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ClassOfWarrantOrRightOutstandingEndOfPeriodWeightedAverageRemaingContractualLife" xlink:to="SEEL_ClassOfWarrantOrRightOutstandingEndOfPeriodWeightedAverageRemaingContractualLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_ClassOfWarrantOrRightOutstandingEndOfPeriodWeightedAverageRemaingContractualLife_lbl" xml:lang="en-US">Warrants outstanding as of June 30, 2021, weighted-average remaing contractual life (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_WarrantsExercisable" xlink:label="SEEL_WarrantsExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_WarrantsExercisable" xlink:to="SEEL_WarrantsExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_WarrantsExercisable_lbl" xml:lang="en-US">Warrants exercisable as of March 31, 2022</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights1" xlink:label="SEEL_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights1" xlink:to="SEEL_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercisable, weighted-average exercise price (in usd per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_ClassOfWarrantOrRightExercisableWeightedAverageRemaingContractualLife" xlink:label="SEEL_ClassOfWarrantOrRightExercisableWeightedAverageRemaingContractualLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_ClassOfWarrantOrRightExercisableWeightedAverageRemaingContractualLife" xlink:to="SEEL_ClassOfWarrantOrRightExercisableWeightedAverageRemaingContractualLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_ClassOfWarrantOrRightExercisableWeightedAverageRemaingContractualLife_lbl" xml:lang="en-US">Warrants exercisable as of June 30, 2021, weighted-average remaing contractual life (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockVotingRights_lbl" xml:lang="en-US">Common stock voting right</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:label="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:to="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees_lbl" xml:lang="en-US">Warrant description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xml:lang="en-US">Date on which warrants became exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_NumberofWarrantsExercisedDuringPeriod" xlink:to="SEEL_NumberofWarrantsExercisedDuringPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SEEL_NumberofWarrantsExercisedDuringPeriod_2_lbl" xml:lang="en-US">Number of warrants exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_WarrantsExercisable" xlink:to="SEEL_WarrantsExercisable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SEEL_WarrantsExercisable_2_lbl" xml:lang="en-US">Warrants exercisable as of June 30, 2021</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_lbl" xml:lang="en-US">Volatility, minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Volatility, minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Volatility, maximum</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2_lbl" xml:lang="en-US">Expected term (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding as of December 31, 2020</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Outstanding, beginning of period (USD per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted in period (USD per share)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercised in period (USD per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Cancelled (USD per share)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Outstanding as of March 31, 2022</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Outstanding, end of period (USD per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Outstanding - weighted-average remaining contractual life (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Total aggregate intrinsic value shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Vested and expected to vest, end of period (shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Vested and expected to vest stock, end of period (USD per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted-average remaining contractual life (in years) of vested and expected to vest stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Total aggregate intrinsic value of vested or expected to vest stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Exercisable, end of period (shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercisable, end of period (USD per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted-average remaining contractual life (in years) of exercisable stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Total aggregate intrinsic value of exercisable stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xml:lang="en-US">Description of share-based compensation arrangement by share-based payment award</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceDiscountOfCommonStockPercent" xlink:label="SEEL_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceDiscountOfCommonStockPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceDiscountOfCommonStockPercent" xlink:to="SEEL_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceDiscountOfCommonStockPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceDiscountOfCommonStockPercent_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price Discount of Common Stock, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Options granted in period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted-average exercise price per share granted in period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Term of option grant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Vesting percentage on the first anniversary</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_SharebasedPaymentArrangementNonvestedAndCanceledAwardExcludingOptionCostNotYetRecognizedAmount" xlink:label="SEEL_SharebasedPaymentArrangementNonvestedAndCanceledAwardExcludingOptionCostNotYetRecognizedAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_SharebasedPaymentArrangementNonvestedAndCanceledAwardExcludingOptionCostNotYetRecognizedAmount" xlink:to="SEEL_SharebasedPaymentArrangementNonvestedAndCanceledAwardExcludingOptionCostNotYetRecognizedAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_SharebasedPaymentArrangementNonvestedAndCanceledAwardExcludingOptionCostNotYetRecognizedAmount_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested and Canceled Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">Remaining Period Ended December 31, 2022</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less present value discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xml:lang="en-US">Operating lease description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xml:lang="en-US">Option to extend</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Operating lease liabilities - current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating Lease, Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventDescription" xlink:label="us-gaap_SubsequentEventDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventDescription" xlink:to="us-gaap_SubsequentEventDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventDescription_lbl" xml:lang="en-US">Subsequent Event, Description</link:label>
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement" xlink:label="SEEL_CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SEEL_CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement" xlink:to="SEEL_CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SEEL_CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement_lbl" xml:lang="en-US">[custom:CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLossOnDerivative" xlink:to="us-gaap_DerivativeLossOnDerivative_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLossOnDerivative_2_lbl" xml:lang="en-US">Derivative, Loss on Derivative</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_2_lbl" xml:lang="en-US">Repayments of Notes Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_4_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_3_lbl" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>seel-20220331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://seelostx.com/role/Cover" xlink:href="seel-20220331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/BalanceSheets" xlink:href="seel-20220331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/BalanceSheetsParenthetical" xlink:href="seel-20220331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="seel-20220331.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLossParenthetical" xlink:href="seel-20220331.xsd#StatementsOfOperationsAndComprehensiveLossParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:href="seel-20220331.xsd#StatementsOfChangesInStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/StatementsOfCashFlows" xlink:href="seel-20220331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/OrganizationAndDescriptionOfBusiness" xlink:href="seel-20220331.xsd#OrganizationAndDescriptionOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/LiquidityAndGoingConcern" xlink:href="seel-20220331.xsd#LiquidityAndGoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/SignificantAccountingPolicies" xlink:href="seel-20220331.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/FairValueMeasurement" xlink:href="seel-20220331.xsd#FairValueMeasurement" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="seel-20220331.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/CommonStockOfferings" xlink:href="seel-20220331.xsd#CommonStockOfferings" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/LicenseAgreements" xlink:href="seel-20220331.xsd#LicenseAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/AccruedExpenses" xlink:href="seel-20220331.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/Debt" xlink:href="seel-20220331.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/StockholdersEquity" xlink:href="seel-20220331.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/Stock-basedCompensation" xlink:href="seel-20220331.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/CommitmentsAndContingencies" xlink:href="seel-20220331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/SubsequentEvents" xlink:href="seel-20220331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/SignificantAccountingPoliciesPolicies" xlink:href="seel-20220331.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/SignificantAccountingPoliciesTables" xlink:href="seel-20220331.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/FairValueMeasurementTables" xlink:href="seel-20220331.xsd#FairValueMeasurementTables" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="seel-20220331.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/AccruedExpensesTables" xlink:href="seel-20220331.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/StockholdersEquityTables" xlink:href="seel-20220331.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/Stock-basedCompensationTables" xlink:href="seel-20220331.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/CommitmentsAndContingenciesTables" xlink:href="seel-20220331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative" xlink:href="seel-20220331.xsd#LiquidityAndGoingConcernDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="seel-20220331.xsd#ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails" xlink:href="seel-20220331.xsd#ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails" xlink:href="seel-20220331.xsd#SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/SummaryOfFairValueMeasurementsWarrantValuationAssumptionsDetails" xlink:href="seel-20220331.xsd#SummaryOfFairValueMeasurementsWarrantValuationAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/ScheduleOfFairValueLevel3ReconciliationDetails" xlink:href="seel-20220331.xsd#ScheduleOfFairValueLevel3ReconciliationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/FairValueMeasurementDetailsNarrative" xlink:href="seel-20220331.xsd#FairValueMeasurementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="seel-20220331.xsd#ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/CommonStockOfferingsDetailsNarrative" xlink:href="seel-20220331.xsd#CommonStockOfferingsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/LicenseAgreementsDetailsNarrative" xlink:href="seel-20220331.xsd#LicenseAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/ScheduleOfAccruedLiabilitiesDetails" xlink:href="seel-20220331.xsd#ScheduleOfAccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/DebtDetailsNarrative" xlink:href="seel-20220331.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/SummaryOfWarrantActivityDetails" xlink:href="seel-20220331.xsd#SummaryOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/StockholdersEquityDetailsNarrative" xlink:href="seel-20220331.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/ScheduleOfValuationAssumptionsForStockOptionsDetails" xlink:href="seel-20220331.xsd#ScheduleOfValuationAssumptionsForStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/SummaryOfStockOptionActivityDetails" xlink:href="seel-20220331.xsd#SummaryOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:href="seel-20220331.xsd#ScheduleOfStock-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="seel-20220331.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/ScheduleOfFutureMinimumOperatingLeasePaymentsDetails" xlink:href="seel-20220331.xsd#ScheduleOfFutureMinimumOperatingLeasePaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="seel-20220331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://seelostx.com/role/SubsequentEventsDetailsNarrative" xlink:href="seel-20220331.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_LicensesPayable" xlink:label="loc_SEELLicensesPayable" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_SEELLicensesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleSubordinatedDebtCurrent" xlink:label="loc_us-gaapConvertibleSubordinatedDebtCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapConvertibleSubordinatedDebtCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDerivativeLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleSubordinatedDebtNoncurrent" xlink:label="loc_us-gaapConvertibleSubordinatedDebtNoncurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapConvertibleSubordinatedDebtNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeDomesticDeposits" xlink:label="loc_us-gaapInterestIncomeDomesticDeposits" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeDomesticDeposits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_GainLossInFairValueOfConvertibleNotes" xlink:label="loc_SEELGainLossInFairValueOfConvertibleNotes" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_SEELGainLossInFairValueOfConvertibleNotes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLossParenthetical" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Changes in Stockholders&apos; Equity (Deficit)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_GainLossInFairValueOfConvertibleNotes" xlink:label="loc_SEELGainLossInFairValueOfConvertibleNotes" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_SEELGainLossInFairValueOfConvertibleNotes" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="loc_us-gaapDerivativeLossOnDerivative" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDerivativeLossOnDerivative" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccruedLiabilities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaapProceedsFromStockPlans" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapProceedsFromStockPlans" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaapIncomeTaxesPaid" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_ReclassOfWarrantLiabilitiesRelatedToSeriesWarrantsExercisedForCash" xlink:label="loc_SEELReclassOfWarrantLiabilitiesRelatedToSeriesWarrantsExercisedForCash" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_SEELReclassOfWarrantLiabilitiesRelatedToSeriesWarrantsExercisedForCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="loc_us-gaapCapitalLeaseObligationsIncurred" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapCapitalLeaseObligationsIncurred" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/OrganizationAndDescriptionOfBusiness" xlink:title="00000008 - Disclosure - 1. Organization and Description of Business">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/LiquidityAndGoingConcern" xlink:title="00000009 - Disclosure - 2. Liquidity and Going Concern">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/SignificantAccountingPolicies" xlink:title="00000010 - Disclosure - 3. Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/FairValueMeasurement" xlink:title="00000011 - Disclosure - 4. Fair Value Measurement">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="00000012 - Disclosure - 5. Prepaid Expenses and Other Current Assets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="loc_us-gaapOtherCurrentAssetsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherCurrentAssetsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/CommonStockOfferings" xlink:title="00000013 - Disclosure - 6. Common Stock Offerings">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaapBusinessCombinationDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapBusinessCombinationDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/LicenseAgreements" xlink:title="00000014 - Disclosure - 7. License Agreements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="loc_us-gaapResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/AccruedExpenses" xlink:title="00000015 - Disclosure - 8. Accrued Expenses">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/Debt" xlink:title="00000016 - Disclosure - 9. Debt">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/StockholdersEquity" xlink:title="00000017 - Disclosure - 10. Stockholders&#8217; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/Stock-basedCompensation" xlink:title="00000018 - Disclosure - 11. Stock-based Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/CommitmentsAndContingencies" xlink:title="00000019 - Disclosure - 12. Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/SubsequentEvents" xlink:title="00000020 - Disclosure - 13. Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000021 - Disclosure - 3. Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/SignificantAccountingPoliciesTables" xlink:title="00000022 - Disclosure - 3. Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/FairValueMeasurementTables" xlink:title="00000023 - Disclosure - 4. Fair Value Measurement (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaapFairValueByLiabilityClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="loc_us-gaapFairValueByLiabilityClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember" xlink:label="loc_us-gaapLongTermDebtMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_us-gaapLongTermDebtMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="00000024 - Disclosure - 5. Prepaid Expenses and Other Current Assets (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/AccruedExpensesTables" xlink:title="00000025 - Disclosure - 8. Accrued Expenses (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/StockholdersEquityTables" xlink:title="00000026 - Disclosure - 10. Stockholders&#8217; Equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/Stock-basedCompensationTables" xlink:title="00000027 - Disclosure - 11. Stock-based Compensation (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfStockOptionsRollForwardTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfStockOptionsRollForwardTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/CommitmentsAndContingenciesTables" xlink:title="00000028 - Disclosure - 12. Commitments and Contingencies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative" xlink:title="00000029 - Disclosure - 2. Liquidity and Going Concern (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_May242021Member" xlink:label="loc_SEELMay242021Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SEELMay242021Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_January282021Member" xlink:label="loc_SEELJanuary282021Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SEELJanuary282021Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes" xlink:label="loc_SEELOfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SEELOfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_FinancingAvailableUnderFormS3ShelfRegistrationStatement" xlink:label="loc_SEELFinancingAvailableUnderFormS3ShelfRegistrationStatement" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SEELFinancingAvailableUnderFormS3ShelfRegistrationStatement" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="00000030 - Disclosure - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaapConvertibleDebtSecuritiesMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapConvertibleDebtSecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails" xlink:title="00000031 - Disclosure - Schedule of Fair Value Hierarchy Assets and Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaapFairValueByLiabilityClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByLiabilityClassAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember" xlink:label="loc_us-gaapLongTermDebtMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_us-gaapLongTermDebtMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="loc_us-gaapDerivativeFinancialInstrumentsLiabilitiesMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_us-gaapDerivativeFinancialInstrumentsLiabilitiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaapLiabilitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAbstract" xlink:to="loc_us-gaapDerivativeLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails" xlink:title="00000032 - Disclosure - Summary of Fair Value Measurements Convertible Notes Valuation Assumptions (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaapFairValueByLiabilityClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="loc_us-gaapFairValueByLiabilityClassAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember" xlink:label="loc_us-gaapLongTermDebtMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_us-gaapLongTermDebtMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/SummaryOfFairValueMeasurementsWarrantValuationAssumptionsDetails" xlink:title="00000033 - Disclosure - Summary of Fair Value Measurements Warrant Valuation Assumptions (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaapFairValueByLiabilityClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByLiabilityClassAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/ScheduleOfFairValueLevel3ReconciliationDetails" xlink:title="00000034 - Disclosure - Schedule of Fair Value Level 3 Reconciliation (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaapFairValueByLiabilityClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByLiabilityClassAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember" xlink:label="loc_us-gaapLongTermDebtMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_us-gaapLongTermDebtMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="loc_us-gaapDerivativeFinancialInstrumentsLiabilitiesMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_us-gaapDerivativeFinancialInstrumentsLiabilitiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/FairValueMeasurementDetailsNarrative" xlink:title="00000035 - Disclosure - 4. Fair Value Measurement (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsTable" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsTable" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_IXLicenseAgreementMember" xlink:label="loc_SEELIXLicenseAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="loc_SEELIXLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_NonrefundableCashPayment" xlink:label="loc_SEELNonrefundableCashPayment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsLineItems" xlink:to="loc_SEELNonrefundableCashPayment" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="00000036 - Disclosure - Schedule of Prepaid Expenses and Other Current Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_PrepaidClinicalCosts" xlink:label="loc_SEELPrepaidClinicalCosts" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_SEELPrepaidClinicalCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/CommonStockOfferingsDetailsNarrative" xlink:title="00000037 - Disclosure - 6. Common Stock Offerings (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_May242021Member" xlink:label="loc_SEELMay242021Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SEELMay242021Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_January282021Member" xlink:label="loc_SEELJanuary282021Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SEELJanuary282021Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_IXLicenseAgreementMember" xlink:label="loc_SEELIXLicenseAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="loc_SEELIXLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes" xlink:label="loc_SEELOfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_SEELOfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_NonrefundableCashPayment" xlink:label="loc_SEELNonrefundableCashPayment" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_SEELNonrefundableCashPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_Issuanceofcommonstockforlicenseacquiredshares" xlink:label="loc_SEELIssuanceofcommonstockforlicenseacquiredshares" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_SEELIssuanceofcommonstockforlicenseacquiredshares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_MinimumStockValueOfSharesIssued" xlink:label="loc_SEELMinimumStockValueOfSharesIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_SEELMinimumStockValueOfSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_InitialStockValuationShortfallFrom5.5MillionValue" xlink:label="loc_SEELInitialStockValuationShortfallFrom5.5MillionValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_SEELInitialStockValuationShortfallFrom5.5MillionValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/LicenseAgreementsDetailsNarrative" xlink:title="00000038 - Disclosure - 7. License Agreements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsTable" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsTable" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_WegLicenseAgreementMember" xlink:label="loc_SEELWegLicenseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="loc_SEELWegLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDescription" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDescription" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsLineItems" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_NonrefundableCashPayment" xlink:label="loc_SEELNonrefundableCashPayment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsLineItems" xlink:to="loc_SEELNonrefundableCashPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaapAssetAcquisitionContingentConsiderationLiabilityCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsLineItems" xlink:to="loc_us-gaapAssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/ScheduleOfAccruedLiabilitiesDetails" xlink:title="00000039 - Disclosure - Schedule of Accrued Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_OutsideResearchAndDevelopmentServicesCurrent" xlink:label="loc_SEELOutsideResearchAndDevelopmentServicesCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_SEELOutsideResearchAndDevelopmentServicesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedInsuranceCurrent" xlink:label="loc_us-gaapAccruedInsuranceCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedInsuranceCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/DebtDetailsNarrative" xlink:title="00000040 - Disclosure - 9. Debt (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_November2021LindSecuritiesPurchaseAgreementMember" xlink:label="loc_SEELNovember2021LindSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SEELNovember2021LindSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_FirstAnniversaryOfNovember2021LindSecuritiesPurchaseAgreementMember" xlink:label="loc_SEELFirstAnniversaryOfNovember2021LindSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SEELFirstAnniversaryOfNovember2021LindSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_August232022ThruMaturityNovember2021LindSecuritiesPurchaseAgreementMember" xlink:label="loc_SEELAugust232022ThruMaturityNovember2021LindSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SEELAugust232022ThruMaturityNovember2021LindSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_AmortizeNovember2021LindSecuritiesPurchaseAgreementMember" xlink:label="loc_SEELAmortizeNovember2021LindSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SEELAmortizeNovember2021LindSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_December2021SPAsMember" xlink:label="loc_SEELDecember2021SPAsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SEELDecember2021SPAsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_LindSecuritiesPurchaseAgreementMember" xlink:label="loc_SEELLindSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SEELLindSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_December17SPAsMember" xlink:label="loc_SEELDecember17SPAsMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SEELDecember17SPAsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtDescription" xlink:label="loc_us-gaapLongTermDebtDescription" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapLongTermDebtDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleSubordinatedDebt" xlink:label="loc_us-gaapConvertibleSubordinatedDebt" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleSubordinatedDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_GainLossInFairValueOfConvertibleNotes" xlink:label="loc_SEELGainLossInFairValueOfConvertibleNotes" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_SEELGainLossInFairValueOfConvertibleNotes" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue" xlink:label="loc_us-gaapLongTermDebtFairValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapLongTermDebtFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaapRepaymentsOfConvertibleDebt" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapRepaymentsOfConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapLongTermDebt" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/SummaryOfWarrantActivityDetails" xlink:title="00000041 - Disclosure - Summary of Warrant Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapOffsettingAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapOffsettingAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_WarrantDerivativeFinancialInstrumentsMember" xlink:label="loc_SEELWarrantDerivativeFinancialInstrumentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_SEELWarrantDerivativeFinancialInstrumentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_ClassOfWarrantOrRightOutstandingWeightedAverageRemaingContractualLife" xlink:label="loc_SEELClassOfWarrantOrRightOutstandingWeightedAverageRemaingContractualLife" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_SEELClassOfWarrantOrRightOutstandingWeightedAverageRemaingContractualLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_NumberofWarrantsIssuedDuringPeriod" xlink:label="loc_SEELNumberofWarrantsIssuedDuringPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_SEELNumberofWarrantsIssuedDuringPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_ClassOfWarrantOrRightIssuedExercisePriceOfWarrantsOrRights" xlink:label="loc_SEELClassOfWarrantOrRightIssuedExercisePriceOfWarrantsOrRights" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_SEELClassOfWarrantOrRightIssuedExercisePriceOfWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_NumberofWarrantsExercisedDuringPeriod" xlink:label="loc_SEELNumberofWarrantsExercisedDuringPeriod" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_SEELNumberofWarrantsExercisedDuringPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_ClassOfWarrantOrRightExercisedExercisePriceOfWarrantsOrRights" xlink:label="loc_SEELClassOfWarrantOrRightExercisedExercisePriceOfWarrantsOrRights" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_SEELClassOfWarrantOrRightExercisedExercisePriceOfWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_NumberofWarrantsCancelledDuringPeriod" xlink:label="loc_SEELNumberofWarrantsCancelledDuringPeriod" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_SEELNumberofWarrantsCancelledDuringPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_ClassOfWarrantOrRightCancelledExercisePriceOfWarrantsOrRights" xlink:label="loc_SEELClassOfWarrantOrRightCancelledExercisePriceOfWarrantsOrRights" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_SEELClassOfWarrantOrRightCancelledExercisePriceOfWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_ClassOfWarrantOrRightOutstandingEndOfPeriodWeightedAverageRemaingContractualLife" xlink:label="loc_SEELClassOfWarrantOrRightOutstandingEndOfPeriodWeightedAverageRemaingContractualLife" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_SEELClassOfWarrantOrRightOutstandingEndOfPeriodWeightedAverageRemaingContractualLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_WarrantsExercisable" xlink:label="loc_SEELWarrantsExercisable" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_SEELWarrantsExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights1" xlink:label="loc_SEELClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_SEELClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_ClassOfWarrantOrRightExercisableWeightedAverageRemaingContractualLife" xlink:label="loc_SEELClassOfWarrantOrRightExercisableWeightedAverageRemaingContractualLife" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_SEELClassOfWarrantOrRightExercisableWeightedAverageRemaingContractualLife" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000042 - Disclosure - 10. Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_September2020WarrantsMember" xlink:label="loc_SEELSeptember2020WarrantsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_SEELSeptember2020WarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_August2019WarrantsMember" xlink:label="loc_SEELAugust2019WarrantsMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_SEELAugust2019WarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_SeriesAWarrantsMember" xlink:label="loc_SEELSeriesAWarrantsMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_SEELSeriesAWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_September2020WarrantsMember" xlink:label="loc_SEELSeptember2020WarrantsMember_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SEELSeptember2020WarrantsMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_August232019Member" xlink:label="loc_SEELAugust232019Member" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SEELAugust232019Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_August2019WarrantsMember" xlink:label="loc_SEELAugust2019WarrantsMember_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SEELAugust2019WarrantsMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaapCommonStockVotingRights" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapCommonStockVotingRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:label="loc_us-gaapClassOfWarrantOrRightReasonForIssuingToNonemployees" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_NumberofWarrantsExercisedDuringPeriod" xlink:label="loc_SEELNumberofWarrantsExercisedDuringPeriod" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_SEELNumberofWarrantsExercisedDuringPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_WarrantsExercisable" xlink:label="loc_SEELWarrantsExercisable" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_SEELWarrantsExercisable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/ScheduleOfValuationAssumptionsForStockOptionsDetails" xlink:title="00000043 - Disclosure - Schedule of Valuation Assumptions for Stock Options (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/SummaryOfStockOptionActivityDetails" xlink:title="00000044 - Disclosure - Summary of Stock Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="00000045 - Disclosure - Schedule of Stock-Based Compensation Expense (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000046 - Disclosure - 11. Stock-based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_EmployeeStockPurchasePlanMember" xlink:label="loc_SEELEmployeeStockPurchasePlanMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SEELEmployeeStockPurchasePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_InducementPlanof2019Member" xlink:label="loc_SEELInducementPlanof2019Member" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SEELInducementPlanof2019Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_IncentiveStockOptionMember" xlink:label="loc_SEELIncentiveStockOptionMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SEELIncentiveStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_NonQualifiedStockOptionsToEmployeesMember" xlink:label="loc_SEELNonQualifiedStockOptionsToEmployeesMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SEELNonQualifiedStockOptionsToEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_NonQualifiedStockOptionsToNonEmployeeDirectorsMember" xlink:label="loc_SEELNonQualifiedStockOptionsToNonEmployeeDirectorsMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SEELNonQualifiedStockOptionsToNonEmployeeDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaapPerformanceSharesMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapPerformanceSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_PSUtoExecutivesMember" xlink:label="loc_SEELPSUtoExecutivesMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SEELPSUtoExecutivesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceDiscountOfCommonStockPercent" xlink:label="loc_SEELSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceDiscountOfCommonStockPercent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SEELSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceDiscountOfCommonStockPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_SharebasedPaymentArrangementNonvestedAndCanceledAwardExcludingOptionCostNotYetRecognizedAmount" xlink:label="loc_SEELSharebasedPaymentArrangementNonvestedAndCanceledAwardExcludingOptionCostNotYetRecognizedAmount" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SEELSharebasedPaymentArrangementNonvestedAndCanceledAwardExcludingOptionCostNotYetRecognizedAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/ScheduleOfFutureMinimumOperatingLeasePaymentsDetails" xlink:title="00000047 - Disclosure - Schedule of future minimum operating lease payments (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000048 - Disclosure - 12. Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaapLesseeLeaseDescriptionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeLeaseDescriptionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaapLesseeLeaseDescriptionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_us-gaapLesseeLeaseDescriptionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaapLeaseContractualTermAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_us-gaapLeaseContractualTermAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaapLeaseContractualTermDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseContractualTermAxis" xlink:to="loc_us-gaapLeaseContractualTermDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_March2019LeaseMember" xlink:label="loc_SEELMarch2019LeaseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_SEELMarch2019LeaseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_March2021LeaseMember" xlink:label="loc_SEELMarch2021LeaseMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_SEELMarch2021LeaseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaapLesseeOperatingLeaseDescription" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaapLesseeOperatingLeaseOptionToExtend" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseOptionToExtend" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://seelostx.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000049 - Disclosure - 13. Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_AssetsfromVyeraPharmaceuticalsMember" xlink:label="loc_SEELAssetsfromVyeraPharmaceuticalsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="loc_SEELAssetsfromVyeraPharmaceuticalsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDescription" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDescription" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventDescription" xlink:label="loc_us-gaapSubsequentEventDescription" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="seel-20220331.xsd#SEEL_CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement" xlink:label="loc_SEELCashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_SEELCashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>exh31-1.htm
<DESCRIPTION>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-right: 0; margin-left: 0"><B>EXHIBIT 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"><B>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">I, Raj Mehra, Ph.D., certify that:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="width: 97%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">I have reviewed this Quarterly Report on Form 10-Q of Seelos Therapeutics, Inc.;&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="width: 97%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="width: 97%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="width: 97%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)), and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">(a) &nbsp; &nbsp;</FONT></TD>
    <TD STYLE="width: 93%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">(b) &nbsp; &nbsp;</FONT></TD>
    <TD STYLE="width: 93%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">(c) &nbsp; &nbsp;</FONT></TD>
    <TD STYLE="width: 93%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">(d) &nbsp; &nbsp;</FONT></TD>
    <TD STYLE="width: 93%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD STYLE="width: 97%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">(a) &nbsp; &nbsp;</FONT></TD>
    <TD STYLE="width: 93%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">(b) &nbsp; &nbsp;</FONT></TD>
    <TD STYLE="width: 93%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="1" CELLPADDING="0" STYLE="width: 35%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; padding: 0.75pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; padding: 0.75pt"><FONT STYLE="font-size: 10pt">Date: May 10,
    2022</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; padding: 0.75pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 12pt Times New Roman, Times, Serif; padding: 0.75pt"><FONT STYLE="font-size: 10pt">/s/ Raj Mehra, Ph.D.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; padding: 0.75pt"><FONT STYLE="font-size: 10pt">Raj Mehra, Ph.D.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; padding: 0.75pt"><FONT STYLE="font-size: 10pt">Chief Executive Officer and President</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</P>













<HR SIZE="2" ALIGN="CENTER" STYLE="width: 100%">

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>exh32-1.htm
<DESCRIPTION>CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-right: 0; margin-left: 0"><B>EXHIBIT 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"><B>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER<BR>
PURSUANT TO<BR>
18 U.S.C. SECTION 1350,<BR>
AS ADOPTED PURSUANT TO<BR>
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">I, Raj Mehra, Ph.D., certify, pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Seelos
Therapeutics, Inc. on Form 10-Q for the quarter ended March 31, 2022 fully complies with the requirements of Section 13(a)
or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents
in all material respects the financial condition and results of operations of Seelos Therapeutics, Inc.</P>

<TABLE CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 70%">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding: 0.75pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%; padding: 0.75pt">&nbsp;</TD>
    <TD STYLE="width: 10%; padding: 0.75pt">&nbsp;</TD>
    <TD STYLE="width: 39%; padding: 0.75pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.75pt"><FONT STYLE="font-size: 10pt">Date: May 10,
    2022</FONT></TD>
    <TD STYLE="padding: 0.75pt"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; padding: 0.75pt"><FONT STYLE="font-size: 10pt">/s/ Raj Mehra, Ph.D.</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; padding: 0.75pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.75pt"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0.75pt"><FONT STYLE="font-size: 10pt">Raj Mehra, Ph.D.&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; padding: 0.75pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.75pt"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0.75pt"><FONT STYLE="font-size: 10pt">Chief Executive Officer and President</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</P>


<HR SIZE="2" ALIGN="CENTER" STYLE="width: 100%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>9
<FILENAME>exh31-2.htm
<DESCRIPTION>CERTIFICATION OF CHIEF FINANCIAL OFFICER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-right: 0; margin-left: 0"><B>EXHIBIT 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"><B>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">I, Michael Golembiewski, certify that:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="width: 97%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">I have reviewed this Quarterly Report on Form 10-Q of Seelos Therapeutics, Inc.;&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="width: 97%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="width: 97%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="width: 97%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)), and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">(a) &nbsp; &nbsp;</FONT></TD>
    <TD STYLE="width: 93%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">(b) &nbsp; &nbsp;</FONT></TD>
    <TD STYLE="width: 93%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">(c) &nbsp; &nbsp;</FONT></TD>
    <TD STYLE="width: 93%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">(d) &nbsp; &nbsp;</FONT></TD>
    <TD STYLE="width: 93%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD STYLE="width: 97%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">(a) &nbsp; &nbsp;</FONT></TD>
    <TD STYLE="width: 93%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">(b) &nbsp; &nbsp;</FONT></TD>
    <TD STYLE="width: 93%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="1" CELLPADDING="0" STYLE="width: 35%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; padding: 0.75pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; padding: 0.75pt"><FONT STYLE="font-size: 10pt">Date: May 10,
    2022</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; padding: 0.75pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 12pt Times New Roman, Times, Serif; padding: 0.75pt"><FONT STYLE="font-size: 10pt">/s/ Michael Golembiewski</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; padding: 0.75pt"><FONT STYLE="font-size: 10pt">Michael Golembiewski</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; padding: 0.75pt"><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</P>













<HR SIZE="2" ALIGN="CENTER" STYLE="width: 100%">

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>10
<FILENAME>exh32-2.htm
<DESCRIPTION>CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-right: 0; margin-left: 0"><B>EXHIBIT 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"><B>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER<BR>
PURSUANT TO<BR>
18 U.S.C. SECTION 1350,<BR>
AS ADOPTED PURSUANT TO<BR>
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">I, Michael Golembiewski, certify, pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Seelos Therapeutics,
Inc. on Form 10-Q for the quarter ended March 31, 2022 fully complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents in all material respects the
financial condition and results of operations of Seelos Therapeutics, Inc.</P>

<TABLE CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 70%">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding: 0.75pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 53%; padding: 0.75pt">&nbsp;</TD>
    <TD STYLE="width: 8%; padding: 0.75pt">&nbsp;</TD>
    <TD STYLE="width: 39%; padding: 0.75pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.75pt"><FONT STYLE="font-size: 10pt">Date: May 10,
    2022</FONT></TD>
    <TD STYLE="padding: 0.75pt"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; padding: 0.75pt"><FONT STYLE="font-size: 10pt">/s/ Michael Golembiewski</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; padding: 0.75pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.75pt"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0.75pt"><FONT STYLE="font-size: 10pt">Michael Golembiewski&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; padding: 0.75pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.75pt"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="padding: 0.75pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</P>


<HR SIZE="2" ALIGN="CENTER" STYLE="width: 100%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332068654632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Apr. 28, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-22245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SEELOS THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001017491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0449967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">300 Park Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">2nd Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New
York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(646)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">293-2100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per
    share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SEEL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,090,773<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332071045352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 61,772<span></span>
</td>
<td class="nump">$ 78,734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">8,895<span></span>
</td>
<td class="nump">4,727<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">70,667<span></span>
</td>
<td class="nump">83,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">70,693<span></span>
</td>
<td class="nump">83,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,127<span></span>
</td>
<td class="nump">1,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">3,549<span></span>
</td>
<td class="nump">3,728<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_LicensesPayable', window );">Licenses payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleSubordinatedDebtCurrent', window );">Short-term portion of convertible notes payable, at fair value</a></td>
<td class="nump">4,238<span></span>
</td>
<td class="nump">1,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Warrant liabilities, at fair value</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">424<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">10,130<span></span>
</td>
<td class="nump">8,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleSubordinatedDebtNoncurrent', window );">Convertible notes payable, at fair value</a></td>
<td class="nump">14,926<span></span>
</td>
<td class="nump">17,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">25,056<span></span>
</td>
<td class="nump">26,177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 240,000,000 shares authorized, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 105,590,773 and 105,500,445 issued and outstanding as of &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;March 31, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in-capital</a></td>
<td class="nump">200,743<span></span>
</td>
<td class="nump">198,428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(155,211)<span></span>
</td>
<td class="num">(141,210)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">45,637<span></span>
</td>
<td class="nump">57,323<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 70,693<span></span>
</td>
<td class="nump">$ 83,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_LicensesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_LicensesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleSubordinatedDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of convertible subordinated debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. This form of debt can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder, and places a lender in a lien position behind debt having a higher priority of repayment upon liquidation of the entity's assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleSubordinatedDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleSubordinatedDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of convertible subordinated debt as of the balance sheet date that is scheduled to be repaid after one year or beyond the normal operating cycle if longer. This form of debt can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder, and places a lender in a lien position behind debt having a higher priority of repayment in liquidation of the entity's assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleSubordinatedDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332068604728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, per value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">240,000,000<span></span>
</td>
<td class="nump">240,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">105,590,773<span></span>
</td>
<td class="nump">105,500,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">105,590,773<span></span>
</td>
<td class="nump">105,500,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332068535928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 10,009<span></span>
</td>
<td class="nump">$ 14,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">4,001<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expense</a></td>
<td class="nump">14,010<span></span>
</td>
<td class="nump">16,612<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(14,010)<span></span>
</td>
<td class="num">(16,612)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeDomesticDeposits', window );">Interest income</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(990)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_GainLossInFairValueOfConvertibleNotes', window );">Change in fair value of convertible notes</a></td>
<td class="num">(244)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Change in fair value of warrant liabilities</a></td>
<td class="nump">234<span></span>
</td>
<td class="num">(1,533)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">9<span></span>
</td>
<td class="num">(2,504)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (14,001)<span></span>
</td>
<td class="num">$ (19,116)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_GainLossInFairValueOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_GainLossInFairValueOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeDomesticDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest earned on deposits in United States money market accounts and other United States interest earning accounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeDomesticDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332068659096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings Per Share, Basic</a></td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings Per Share, Diluted</a></td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Number of Shares Outstanding, Basic</a></td>
<td class="nump">105,529,772<span></span>
</td>
<td class="nump">69,053,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Number of Shares Outstanding, Diluted</a></td>
<td class="nump">105,529,772<span></span>
</td>
<td class="nump">69,053,332<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332070127544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2020</a></td>
<td class="nump">$ 54<span></span>
</td>
<td class="nump">$ 77,680<span></span>
</td>
<td class="num">$ (75,162)<span></span>
</td>
<td class="nump">$ 2,572<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding, Beginning Balance at Dec. 31, 2020</a></td>
<td class="nump">54,535,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">705<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock Issued During Period, Shares, Conversion of Convertible Securities</a></td>
<td class="nump">6,146,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">33,463<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">33,481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock, options exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">17,530,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments', window );">Warrants exercised for cash</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">7,017<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,023<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2021</a></td>
<td class="nump">$ 78<span></span>
</td>
<td class="nump">118,960<span></span>
</td>
<td class="num">(94,278)<span></span>
</td>
<td class="nump">24,760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</a></td>
<td class="nump">29,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan', window );">Issuance of common stock, ESPP</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan', window );">Stock Issued During Period, Shares, Employee Stock Ownership Plan</a></td>
<td class="nump">40,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(19,116)<span></span>
</td>
<td class="num">(19,116)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding, Ending Balance at Mar. 31, 2021</a></td>
<td class="nump">78,283,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2020</a></td>
<td class="nump">$ 54<span></span>
</td>
<td class="nump">77,680<span></span>
</td>
<td class="num">(75,162)<span></span>
</td>
<td class="nump">2,572<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding, Beginning Balance at Dec. 31, 2020</a></td>
<td class="nump">54,535,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2021</a></td>
<td class="nump">$ 105<span></span>
</td>
<td class="nump">198,428<span></span>
</td>
<td class="num">(141,210)<span></span>
</td>
<td class="nump">$ 57,323<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding, Ending Balance at Dec. 31, 2021</a></td>
<td class="nump">105,500,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,500,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,232<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock, options exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2022</a></td>
<td class="nump">$ 105<span></span>
</td>
<td class="nump">200,743<span></span>
</td>
<td class="num">(155,211)<span></span>
</td>
<td class="nump">$ 45,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</a></td>
<td class="nump">6,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan', window );">Issuance of common stock, ESPP</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan', window );">Stock Issued During Period, Shares, Employee Stock Ownership Plan</a></td>
<td class="nump">84,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (14,001)<span></span>
</td>
<td class="num">$ (14,001)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding, Ending Balance at Mar. 31, 2022</a></td>
<td class="nump">105,590,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,590,773<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 25<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109244457&amp;loc=d3e16649-113920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of stock issued during the period upon the conversion of convertible securities, net of adjustments (for example, to additional paid in capital) including the write-off of an equity component recognized to record the convertible debt instrument as two separate components - a debt component and an equity component. This item is meant to disclose the value of shares issued on conversion of convertible securities that were recorded as two separate (debt and equity) components.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock issued during the period as a result of employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 25<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109244457&amp;loc=d3e16649-113920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332069962584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (14,001)<span></span>
</td>
<td class="num">$ (19,116)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">2,232<span></span>
</td>
<td class="nump">705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="num">(234)<span></span>
</td>
<td class="nump">1,533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_GainLossInFairValueOfConvertibleNotes', window );">Change in fair value of convertible notes payable</a></td>
<td class="nump">244<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">986<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(4,168)<span></span>
</td>
<td class="num">(777)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">434<span></span>
</td>
<td class="num">(259)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(178)<span></span>
</td>
<td class="num">(199)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLossOnDerivative', window );">Derivative liability</a></td>
<td class="num">(1,174)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Licenses payable</a></td>
<td class="num">(200)<span></span>
</td>
<td class="nump">5,875<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(17,045)<span></span>
</td>
<td class="num">(11,252)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows provided by financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payment of convertible note</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(5,167)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">33,481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from sales of common stock under ESPP</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">34,277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash</a></td>
<td class="num">(16,962)<span></span>
</td>
<td class="nump">23,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash, beginning of period</a></td>
<td class="nump">78,734<span></span>
</td>
<td class="nump">15,662<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash, end of period</a></td>
<td class="nump">61,772<span></span>
</td>
<td class="nump">38,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_ReclassOfWarrantLiabilitiesRelatedToSeriesWarrantsExercisedForCash', window );">Reclass of warrant liabilities related to Series A warrants exercised for cash</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsIncurred', window );">Right-of-use assets obtained in exchange for operating lease liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_GainLossInFairValueOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_GainLossInFairValueOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_ReclassOfWarrantLiabilitiesRelatedToSeriesWarrantsExercisedForCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_ReclassOfWarrantLiabilitiesRelatedToSeriesWarrantsExercisedForCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in lease obligation from new lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLossOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLossOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332073035880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>1. Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">1. Organization and Description of Business</a></td>
<td class="text"><p id="xdx_809_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z7EGwvIUIQ98" style="font: 11pt Times New Roman, Times, Serif; margin: 0 142.6pt 0 5pt; text-align: justify; text-indent: 0in"><span style="font-size: 10pt; letter-spacing: -0.8pt"><b/></span><b><span style="font: 7pt Times New Roman, Times, Serif; letter-spacing: -0.8pt">
</span><span style="font-size: 10pt">1. Organization and Description of Business</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 142.6pt 0 5pt; text-align: justify; text-indent: 0in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 5pt">Seelos Therapeutics, Inc. (together with its subsidiaries,
the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company focused on achieving efficient development of products that address
significant unmet needs in Central Nervous System (&#8220;CNS&#8221;) disorders and other rare disorders. The Company&#8217;s lead programs
are SLS-002 for the potential treatment of acute suicidal ideation and behavior in patients with major depressive disorder (&#8220;ASIB
in MDD&#8221;) and SLS-005 for the potential treatment of Amyotrophic Lateral Sclerosis (&#8220;ALS&#8221;) and Spinocerebellar Ataxia
(&#8220;SCA&#8221;). SLS-005 for the potential treatment of Sanfilippo Syndrome currently requires additional natural history data, which
is being considered. Additionally, the Company is developing several preclinical programs, most of which have well-defined mechanisms
of action, including: SLS-004, SLS-006, SLS-007 for the potential treatment of Parkinson&#8217;s Disease (&#8220;PD&#8221;) and SLS-008,
which is being developed for the potential treatment of an undisclosed indication, but may also be targeted at chronic inflammation in
asthma and orphan indications such as pediatric esophagitis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 5pt"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 142.6pt 0 5pt; text-align: justify; text-indent: 0in"><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332072919688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>2. Liquidity and Going Concern<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">2. Liquidity and Going Concern</a></td>
<td class="text"><p id="xdx_800_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zUlIFHdf9E01" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify">2.
Liquidity and Going Concern</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 6.85pt 0 5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt">The accompanying condensed consolidated unaudited financial statements
have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and
settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects
on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty
related to its ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt">The Company has generated limited revenues, has incurred operating
losses since inception, and expects to continue to incur significant operating losses for the foreseeable future and may never become
profitable. As of March 31, 2022, the Company had $<span id="xdx_904_eus-gaap--Cash_iI_pn5n6_c20220331_zQZBKEv6Qhy9" title="Cash">61.8</span> million in cash and an accumulated deficit of $<span id="xdx_904_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_pn5n6_c20220331_zaykptp0g0i7" title="Accumlated deficit">155.2</span> million. The Company has historically
funded its operations through the issuance of convertible notes (see Note 9), the sale of common stock (see Note 6) and exercises of
warrants (see Note 10).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">On May 24, 2021, the Company completed an underwritten
public offering, pursuant to which the Company sold <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20210501__20210531__us-gaap--StatementClassOfStockAxis__custom--May242021Member_z6pU7T7uL1nb" title="Number of shares of common stock issued">22,258,066</span>
shares of its common stock, at a price to the public of $<span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_pp2p0_uUSDPShares_c20210524__us-gaap--StatementClassOfStockAxis__custom--May242021Member_zPIih6iQzU53" title="Shares Issued, Price Per Share">3.10</span>
per share, which included the exercise in full by the underwriter of its option to purchase up to 2,903,226 additional shares of
common stock. The net proceeds to the Company from the offering were approximately $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20210501__20210531__us-gaap--StatementClassOfStockAxis__custom--May242021Member_znvCOQEUOEA3" title="Cash received from stock sale">64.5</span>
million, after deducting underwriting discounts and commissions and other offering costs. The Company used
$<span id="xdx_90B_ecustom--OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes_pn5n6_c20210501__20210531__us-gaap--StatementClassOfStockAxis__custom--May242021Member_z3cGiDLwmfm4" title="Offering proceeds used to partially repay certain convertible promissory notes">7.3</span>
million of the net proceeds from the offering for the partial repayment of certain outstanding convertible promissory notes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">On January 28, 2021, the Company completed an underwritten
public offering, pursuant to which the Company sold <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20210101__20210131__us-gaap--StatementClassOfStockAxis__custom--January282021Member_zSk5mfKSduR5" title="Number of shares of common stock issued">17,530,488</span>
shares of its common stock, at a price to the public of $<span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_pp2p0_uUSDPShares_c20210128__us-gaap--StatementClassOfStockAxis__custom--January282021Member_zeNhjQ7tklc2" title="Shares Issued, Price Per Share">2.05</span>
per share, which included the exercise in full by the underwriter of its option to purchase up to 2,286,585 additional shares of
common stock. The net proceeds to the Company from the offering were approximately $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20210101__20210131__us-gaap--StatementClassOfStockAxis__custom--January282021Member_zXbrplIummQc" title="Cash received from stock sale">33.5</span>
million, after deducting underwriting discounts, commissions and other offering costs. The
Company used $<span id="xdx_903_ecustom--OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes_pn5n6_c20210101__20210131__us-gaap--StatementClassOfStockAxis__custom--January282021Member_zeWIkGFTOzUa" title="Offering proceeds used to partially repay certain convertible promissory notes">3.8</span>
million of the net proceeds from the offering for the partial repayment of certain outstanding convertible promissory notes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">The Company currently has an effective shelf registration statement
on Form S-3 filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;). The Company may use the shelf registration statement
on Form S-3 to offer from time to time any combination of debt securities, common and preferred stock and warrants. As of March 31, 2022,
the Company had approximately $<span id="xdx_90B_ecustom--FinancingAvailableUnderFormS3ShelfRegistrationStatement_iI_pn5n6_c20220331_zpgalEltyrXk">95.1</span> million available under its Form S-3 shelf registration statement. The Company also has the ability
to raise funds through other means, such as through the filing of a registration statement on Form S-1 or in private placements. The rules
and regulations of the SEC or any other regulatory agencies may restrict the Company&#8217;s ability to conduct certain types of financing
activities or may affect the timing of and amounts it can raise by undertaking such activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">The Company evaluated whether there
are any conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern
within one year beyond the filing of this Quarterly Report on Form 10-Q. Based on such evaluation and the Company&#8217;s current plans
(including the ongoing clinical programs for SLS-002, SLS-005, and other product candidates), which are subject to change, management
believes that the Company&#8217;s existing cash and cash equivalents as of March 31, 2022 are not sufficient to satisfy its operating
cash needs for the year after the filing of this Quarterly Report on Form 10-Q.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify">The Company&#8217;s future liquidity and capital
funding requirements will depend on numerous factors, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23pt"/><td style="width: 18pt"><span style="font-size: 10pt; letter-spacing: -0.7pt">&#8226;</span></td><td><span style="font-size: 10pt">its ability to raise additional funds to finance its operations;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23pt"/><td style="width: 18pt"><span style="font-size: 10pt; letter-spacing: -0.7pt">&#8226;</span></td><td><span style="font-size: 10pt">its ability to maintain compliance with the listing requirements of the Nasdaq Capital Market;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23pt"/><td style="width: 18pt"><span style="font-size: 10pt; letter-spacing: -0.7pt">&#8226;</span></td><td><span style="font-size: 10pt">the outcome, costs and timing of clinical trial results for the Company&#8217;s current or future product
candidates;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23pt"/><td style="width: 18pt"><span style="font-size: 10pt; letter-spacing: -0.7pt">&#8226;</span></td><td><span style="font-size: 10pt">potential litigation expenses;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23pt"/><td style="width: 18pt"><span style="font-size: 10pt; letter-spacing: -0.7pt">&#8226;</span></td><td><span style="font-size: 10pt">the emergence and effect of competing or complementary products or product candidates;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23pt"/><td style="width: 18pt"><span style="font-size: 10pt; letter-spacing: -0.7pt">&#8226;</span></td><td style="padding-right: 5.85pt"><span style="font-size: 10pt">its ability to maintain, expand and defend the scope of its intellectual
property portfolio, including the amount and timing of any payments the Company may be required to make, or that it may receive, in connection
with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23pt"/><td style="width: 18pt"><span style="font-size: 10pt; letter-spacing: -0.7pt">&#8226;</span></td><td style="padding-right: 5.85pt"><span style="font-size: 10pt">its ability to retain its current employees and the need and ability to
hire additional management and scientific and medical personnel;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23pt"/><td style="width: 18pt"><span style="font-size: 10pt; letter-spacing: -0.7pt">&#8226;</span></td><td><span style="font-size: 10pt">the terms and timing of any collaborative, licensing or other arrangements that it has or may establish;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23pt"/><td style="width: 18pt"><span style="font-size: 10pt; letter-spacing: -0.7pt">&#8226;</span></td><td><span style="font-size: 10pt">the trading price of its common stock; and</span></td></tr></table>


<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23pt"/><td style="width: 18pt"><span style="font-size: 10pt; letter-spacing: -0.7pt">&#8226;</span></td><td><span style="font-size: 10pt">its ability to increase the number of authorized shares outstanding to facilitate future financing events.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 11.85pt 0 5pt; text-align: justify"><span style="background-color: white">The
Company may raise substantial additional funds, and if it does so, it may do so through one or more of the following: issuance of additional
debt or equity and/or the completion of a licensing or other commercial transaction for one or more of the Company&#8217;s product candidates.
If the Company is unable to maintain sufficient financial resources, its business, financial condition and results of operations will
be materially and adversely affected. This could affect future development and business activities and potential future clinical studies
and/or other future ventures. Failure to obtain additional equity or debt financing will have a material, adverse impact on the Company&#8217;s
business operations. There can be no assurance that the Company will be able to obtain the needed financing on acceptable terms or at
all. Additionally, equity or convertible debt financings will likely have a dilutive effect on the holdings of the Company&#8217;s existing
stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 11.85pt 0 5pt"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 11.85pt 0 5pt; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -URI https://asc.fasb.org/subtopic&amp;trid=51888271<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332072975256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>3. Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">3. Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--SignificantAccountingPoliciesTextBlock_zuGSr9jROLy8" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: left">3. Significant Accounting Policies</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: left">&#160;</p>

<p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zp2emxigUS7i" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify; text-indent: -0.5pt"><b><i>Basis of Presentation
</i></b></p>

<p style="font: 13.5pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify; text-indent: -0.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 5pt">The accompanying unaudited interim condensed consolidated financial
statements should be read in conjunction with the audited financial statements and notes thereto as of and for the year ended December
31, 2021 included in the Company&#8217;s Annual Report on Form 10-K (the &#8220;Annual Report&#8221;) filed with the SEC on March 4, 2022.
The accompanying financial statements have been prepared by the Company in accordance with United States generally accepted accounting
principles (&#8220;U.S. GAAP&#8221;) for interim financial information and in accordance with the instructions to Form 10-Q and Article
10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in
accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, the accompanying unaudited condensed consolidated
financial statements for the periods presented reflect all adjustments, consisting of only normal, recurring adjustments, necessary to
fairly state the Company&#8217;s financial position, results of operations and cash flows. The December 31, 2021 condensed consolidated
balance sheet was derived from audited financial statements, but it does not include all U.S. GAAP disclosures. The unaudited condensed
consolidated financial statements for the interim periods are not necessarily indicative of results for the full year. The preparation
of these unaudited condensed consolidated financial statements requires the Company to make estimates and judgments that affect the amounts
reported in the financial statements and the accompanying notes. The Company&#8217;s actual results may differ from these estimates under
different assumptions or conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>



<p id="xdx_848_eus-gaap--UseOfEstimates_zsG5uQdUXm5h" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify; text-indent: -0.5pt"><b><i>Use of Estimates</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt">The preparation of financial statements in conformity with U.S. GAAP requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets
and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant
estimates in the Company&#8217;s financial statements relate to the valuation of warrants, valuation of convertible notes payable, and
the valuation of stock options. These estimates and assumptions are based on current facts, historical experience and various other factors
believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values
of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially
and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s
future results of operations will be affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"><span style="font-weight: normal">&#160;</span></p>

<p id="xdx_840_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zjtmXpmZ5WGe" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: left"><i>Fair Value Measurements</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">The Company
follows the accounting guidance in the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;)
Topic 820, Fair Value Measurements and Disclosures (&#8220;ASC 820&#8221;), for its fair value measurements of financial assets and liabilities
measured at fair value on a recurring basis. Under this accounting guidance, fair value is defined as an exit price, representing the
amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at
the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants
would use in pricing an asset or a liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">The accounting
guidance requires fair value measurements be classified and disclosed in one of the following three categories:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">Level 1: Quoted
prices in active markets for identical assets or liabilities. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">Level 2: Observable
inputs other than Level 1 prices, for similar assets or liabilities that are directly or indirectly observable in the marketplace.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">Level 3: Unobservable
inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing
models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires
significant judgment or estimation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">The fair value
hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring
fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is
significant to the fair value measurement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify; text-indent: -0.5pt"><b><i>Fair Value Option</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">As permitted
under FASB ASC Topic 825, Financial Instruments (&#8220;ASC 825&#8221;), the Company elected the fair value option to account for its
November 2021 and December 2021 convertible notes (collectively, the &#8220;2021 Convertible Notes&#8221;). In accordance with ASC 825,
the Company records these convertible notes at fair value with changes in fair value recorded in the Consolidated Statement of Operations
and Comprehensive Loss. As a result of applying the fair value option, direct costs and fees related to the convertible notes were expensed
as incurred and were not deferred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"/>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify">&#160;</p>

<p id="xdx_84B_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zylUSVrXTDr3" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"><i>Stock-based Compensation</i></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="font-weight: normal"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"><span style="font-weight: normal">The Company
expenses stock-based compensation to employees, non-employees and board members over the requisite service period based on the estimated
grant-date fair value of the awards and forfeitures rates. The Company accounts for forfeitures as they occur. Stock-based awards with
graded-vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion
of the award. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions
used in calculating the fair value of stock-based awards represent management&#8217;s best estimates and involve inherent uncertainties
and the application of management&#8217;s judgment. All stock-based compensation costs are recorded in general and administrative or research
and development costs in the statements of operations based upon the underlying individual&#8217;s role at the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="font-weight: normal">Performance
share awards are initially valued based on the Company&#8217;s closing stock price on the date of grant. The number of performance share
awards that vest will be determined based on the achievement of specified performance milestones by the end of the performance period.
Compensation expense for performance awards is recognized over the service period and will vary based on remeasurement during the performance
period. If achievement of the performance milestone is not probable of achievement during the performance period, compensation expense
is reversed.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="font-weight: normal"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_zJOg7I8WZ1Vg" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>Net Loss Per Share</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Basic loss per share is computed by dividing net loss applicable
to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share
includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, warrants, performance-based
restricted stock unit awards and stock options that would result in the issuance of incremental shares of common stock. In computing the
basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both
calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>




<p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zKQMCpo58Tdj" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">The following potentially dilutive securities outstanding for
the three months ended March 31, 2022 and 2021 have been excluded from the computation of diluted weighted average shares outstanding,
as they would be anti-dilutive (in thousands):</p>

<p id="xdx_8BF_z66xDxRI5f8d" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; display: none">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: middle"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center"/>
    <td colspan="4" style="font-weight: bold; vertical-align: middle; text-align: center">Three Months</td></tr>
  <tr>
    <td style="vertical-align: middle"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center"/>
    <td colspan="4" style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center">Ended March
    31,</td></tr>
  <tr>
    <td style="vertical-align: middle; width: 62%"/>
    <td style="vertical-align: bottom; text-align: right; width: 2%"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center; width: 2%"/>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; width: 15%">2022</td>
    <td style="vertical-align: bottom; text-align: right; width: 2%"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center; width: 2%"/>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; width: 15%">2021</td></tr>
  <tr style="vertical-align: middle">
    <td>Outstanding stock options</td>
    <td/>
    <td style="text-align: right"/>
    <td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zCScnnyODifk" style="text-align: right; border-top-color: Black; border-top-width: 1pt" title="Outstanding stock options">10,299</td>
    <td/>
    <td style="text-align: right"/>
    <td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zsdriRbP2xd" style="text-align: right; border-top-color: Black; border-top-width: 1pt" title="Outstanding stock options">7,204</td></tr>
  <tr style="vertical-align: middle">
    <td>Restricted stock units</td>
    <td/>
    <td style="text-align: right"/>
    <td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zrW6jSAzEgae" style="text-align: right" title="Restricted stock units"><span style="-sec-ix-hidden: xdx2ixbrl0405">-</span></td>
    <td/>
    <td style="text-align: right"/>
    <td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zqlk7NWOoQwk" style="text-align: right" title="Restricted stock units">2,400</td></tr>
  <tr style="vertical-align: middle">
    <td>Outstanding warrants</td>
    <td/>
    <td style="text-align: right"/>
    <td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zIvMtG3p7Qs6" style="text-align: right" title="Outstanding warrants">2,635</td>
    <td/>
    <td style="text-align: right"/>
    <td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zQSQ9Fb0Dxvj" style="text-align: right" title="Outstanding Warrants">3,920</td></tr>
  <tr style="vertical-align: middle">
    <td>Convertible debt</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_z5VuN4C7Qug9" style="text-align: right">3,704</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zUWQoM64cIZd" style="text-align: right">5,326</td></tr>
  <tr>
    <td style="vertical-align: middle"/>
    <td style="vertical-align: middle; text-align: right"/>
    <td style="vertical-align: middle; text-align: right"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="vertical-align: middle; text-align: right"/>
    <td style="vertical-align: middle; text-align: right"/>
    <td style="vertical-align: bottom; text-align: right"/></tr>
  <tr>
    <td style="vertical-align: middle"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="vertical-align: middle; text-align: right"/>
    <td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_i01_pin3_c20220101__20220331_zIrNJ5WBdVL7" style="border-top: Black 1pt solid; border-bottom: Black 2pt double; vertical-align: middle; text-align: right" title="Antidilutive securities excluded">16,638</td>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="vertical-align: middle; text-align: right"/>
    <td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_i01_pin3_c20210101__20210331_zKMlPxi5SVke" style="border-top: Black 1pt solid; border-bottom: Black 2pt double; vertical-align: middle; text-align: right" title="Antidilutive securities excluded">18,850</td></tr>
  </table>

<p id="xdx_8A9_zKZPpjg80Pv8" style="font: 9pt Sans-Serif; margin: 0 0 0 4.5pt; color: Red"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Amounts in the table reflect the common stock equivalents of
the noted instruments.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: left">&#160;</p>

<p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zrTAZ4Okgtok" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left">Recent Accounting Pronouncements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: justify"><span style="font-weight: normal"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">In August 2020, the FASB issued Accounting Standards Update
(&#8220;ASU&#8221;) No. 2020-06: Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging
&#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an
Entity&#8217;s Own Equity (&#8220;ASU 2020-06&#8221;). This standard simplifies the accounting for convertible debt instruments by
removing the separation models for convertible debt with a cash conversion feature, as well as convertible instruments with a
beneficial conversion feature. As a result, entities will account for a convertible debt instrument wholly as debt, unless certain
other conditions are met. The elimination of these models will reduce non-cash interest expense for entities that have issued a
convertible instrument that was within the scope of those models before the adoption of ASU 2020-06. Additionally, ASU 2020-06
requires the application of the if-converted method for calculating diluted earnings per share and precludes the use of the treasury
stock method for certain debt instruments. The provisions of ASU 2020-06 are applicable for the Company beginning after January 1,
2024, with early adoption permitted, and an entity should adopt the provisions at the beginning of its annual fiscal year. The
Company does not expect the adoption of ASU 2020-06 to have an impact on its consolidated financial statements and related
disclosures.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: justify"/>

<p id="xdx_850_z7BVrm2KkeWk" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="font-weight: normal">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"/>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332072868488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>4. Fair Value Measurement<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">4. Fair Value Measurement</a></td>
<td class="text"><p id="xdx_808_eus-gaap--FairValueDisclosuresTextBlock_ztlU5aWE8O6h" style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>4. Fair Value Measurement</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">The
following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring
basis and indicate the level of the fair value hierarchy utilized to determine such fair values. There were
<span id="xdx_90B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_do_c20220101__20220331_zjJpAFcFuyTb">no</span>
transfers between fair value measurement levels during the three months ended March 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p id="xdx_899_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zmwG4olT1Kz1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">The Company&#8217;s financial assets and liabilities measured at fair value
at March 31, 2022 and December 31, 2021 are as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; background-color: white"><span id="xdx_8BE_zLdsggSUjfL6" style="display: none">Schedule of Fair Value Hierarchy Assets and Liabilities</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; background-color: white"/>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: middle; background-color: white">
    <td style="font-weight: bold; width: 44%"/>
    <td style="font-weight: bold; text-align: right; width: 2%"/>
    <td style="font-weight: bold; text-align: right; width: 2%"/>
    <td style="font-weight: bold; text-align: center; width: 10%"/>
    <td style="font-weight: bold; text-align: right; width: 2%"/>
    <td style="font-weight: bold; text-align: right; width: 2%"/>
    <td style="font-weight: bold; text-align: center; width: 10%"/>
    <td style="font-weight: bold; text-align: right; width: 2%"/>
    <td style="font-weight: bold; text-align: right; width: 2%"/>
    <td style="font-weight: bold; text-align: center; width: 10%"/>
    <td style="font-weight: bold; text-align: right; width: 2%"/>
    <td style="font-weight: bold; text-align: right; width: 2%"/>
    <td style="font-weight: bold; text-align: center; width: 10%"/></tr>
</table>


<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td colspan="10" style="font-weight: bold; vertical-align: middle; text-align: center; background-color: white">Fair Value Measurements</td></tr>
  <tr>
    <td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td colspan="10" style="font-weight: bold; vertical-align: middle; text-align: center; background-color: white">as of March 31, 2022</td></tr>
  <tr>
    <td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: right; background-color: white; width: 44%"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white; width: 2%"/>
    <td style="vertical-align: bottom; text-align: right; width: 2%"/>
    <td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 10%">(Level 1)</td>
    <td style="vertical-align: middle; text-align: right; background-color: white; width: 2%"/>
    <td style="vertical-align: bottom; text-align: right; width: 2%"/>
    <td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 10%">(Level 2)</td>
    <td style="vertical-align: middle; text-align: right; background-color: white; width: 2%"/>
    <td style="vertical-align: bottom; text-align: right; width: 2%"/>
    <td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 10%">(Level 3)</td>
    <td style="vertical-align: middle; text-align: right; background-color: white; width: 2%"/>
    <td style="vertical-align: bottom; text-align: right; width: 2%"/>
    <td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 10%">Total</td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="font-weight: bold"><span id="xdx_900_eus-gaap--AssetsAbstract_iB_c20220101__20220331_ziSTSyBoNVWc">Assets</span>:</td>
    <td style="font-weight: bold; text-align: right"/>
    <td style="font-weight: bold; text-align: center"/>
    <td style="font-weight: bold; text-align: center"/>
    <td style="text-align: right"/>
    <td style="font-weight: bold; text-align: center"/>
    <td style="font-weight: bold; text-align: center"/>
    <td style="text-align: right"/>
    <td style="font-weight: bold; text-align: center"/>
    <td style="font-weight: bold; text-align: center"/>
    <td style="text-align: right"/>
    <td style="font-weight: bold; text-align: center"/>
    <td style="font-weight: bold; text-align: center"/></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt">Cash</td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_980_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zMqtLMj6TFSi" style="border-bottom: Black 2pt double; text-align: right" title="Cash">61,772</td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_988_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zz24VxuSoM5a" style="border-bottom: Black 2pt double; text-align: right" title="Cash"><span style="-sec-ix-hidden: xdx2ixbrl0429">-</span></td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_98C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zaL1DaIgI1v5" style="border-bottom: Black 2pt double; text-align: right" title="Cash"><span style="-sec-ix-hidden: xdx2ixbrl0431">-</span></td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_986_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20220331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zFAa9NtOhvN6" style="border-bottom: Black 2pt double; text-align: right" title="Cash">61,772</td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="font-weight: bold"><span id="xdx_90D_eus-gaap--LiabilitiesAbstract_iB_c20220101__20220331_zSJ30OFb8PIk">Liabilities</span>:</td>
    <td style="font-weight: bold; text-align: right"/>
    <td style="font-weight: bold; text-align: right"/>
    <td style="font-weight: bold; text-align: center"/>
    <td style="font-weight: bold; text-align: right"/>
    <td style="font-weight: bold; text-align: right"/>
    <td style="font-weight: bold; text-align: center"/>
    <td style="font-weight: bold; text-align: right"/>
    <td style="font-weight: bold; text-align: right"/>
    <td style="font-weight: bold; text-align: center"/>
    <td style="font-weight: bold; text-align: right"/>
    <td style="font-weight: bold; text-align: right"/>
    <td style="font-weight: bold; text-align: center"/></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt">Convertible notes payable, at fair value</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_980_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zjsKM8XNM0Fg" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0435">-</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_986_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zdXWGeQSnKdk" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0436">-</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_98C_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_z9av2YuWif5f" style="text-align: right">19,164</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_981_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zA9bPAF27hee" style="text-align: right">19,164</td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt">Warrant liabilities, at fair value</td>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td id="xdx_988_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zAX0BuuWs5Zi" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant liabilities, at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0440">-</span></td>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td id="xdx_98D_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zDx7tAT4Cpg3" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant liabilities, at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0442">-</span></td>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td id="xdx_989_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zRHvxSJNbD8c" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant liabilities, at fair value">190</td>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td id="xdx_987_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zGE4pbeM8qeg" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant liabilities, at fair value">190</td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_98C_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zflU3SniAtPg" style="border-bottom: Black 2pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0447">-</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_98F_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z6tMvCVtLyXf" style="border-bottom: Black 2pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0448">-</span></td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_984_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zQlhU1IQidSc" style="border-bottom: Black 2pt double; text-align: right">19,354</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_987_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zcBb6lxtsIDc" style="border-bottom: Black 2pt double; text-align: right">19,354</td></tr>

  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; background-color: white"/>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: middle; background-color: white">
    <td style="font-weight: bold; width: 44%"/>
    <td style="font-weight: bold; text-align: right; width: 2%"/>
    <td style="font-weight: bold; text-align: right; width: 2%"/>
    <td style="font-weight: bold; text-align: center; width: 10%"/>
    <td style="font-weight: bold; text-align: right; width: 2%"/>
    <td style="font-weight: bold; text-align: right; width: 2%"/>
    <td style="font-weight: bold; text-align: center; width: 10%"/>
    <td style="font-weight: bold; text-align: right; width: 2%"/>
    <td style="font-weight: bold; text-align: right; width: 2%"/>
    <td style="font-weight: bold; text-align: center; width: 10%"/>
    <td style="font-weight: bold; text-align: right; width: 2%"/>
    <td style="font-weight: bold; text-align: right; width: 2%"/>
    <td style="font-weight: bold; text-align: center; width: 10%"/></tr>
</table>


<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td colspan="10" style="font-weight: bold; vertical-align: middle; text-align: center; background-color: white">Fair Value Measurements</td></tr>
  <tr>
    <td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td colspan="10" style="font-weight: bold; vertical-align: middle; text-align: center; background-color: white">as of December 31, 2021</td></tr>
  <tr>
    <td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: right; background-color: white; width: 44%"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white; width: 1%"/>
    <td style="vertical-align: bottom; text-align: right; width: 1%"/>
    <td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 12%">(Level 1)</td>
    <td style="vertical-align: middle; text-align: right; background-color: white; width: 1%"/>
    <td style="vertical-align: bottom; text-align: right; width: 1%"/>
    <td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 12%">(Level 2)</td>
    <td style="vertical-align: middle; text-align: right; background-color: white; width: 1%"/>
    <td style="vertical-align: bottom; text-align: right; width: 1%"/>
    <td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 12%">(Level 3)</td>
    <td style="vertical-align: middle; text-align: right; background-color: white; width: 1%"/>
    <td style="vertical-align: bottom; text-align: right; width: 1%"/>
    <td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 12%">Total</td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="font-weight: bold"><span id="xdx_90C_eus-gaap--AssetsAbstract_iB_c20210101__20211231_z1NdZhfsyYU6">Assets</span>:</td>
    <td style="font-weight: bold; text-align: right"/>
    <td style="font-weight: bold; text-align: center"/>
    <td style="font-weight: bold; text-align: center"/>
    <td style="text-align: right"/>
    <td style="font-weight: bold; text-align: center"/>
    <td style="font-weight: bold; text-align: center"/>
    <td style="text-align: right"/>
    <td style="font-weight: bold; text-align: center"/>
    <td style="font-weight: bold; text-align: center"/>
    <td style="text-align: right"/>
    <td style="font-weight: bold; text-align: center"/>
    <td style="font-weight: bold; text-align: center"/></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt">Cash</td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_980_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zphNLgkyaaSg" style="border-bottom: Black 2pt double; text-align: right">78,734</td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_98E_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zTrI2Jcn3cac" style="border-bottom: Black 2pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0453">-</span></td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_984_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z0vhW9igOboi" style="border-bottom: Black 2pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0454">-</span></td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_981_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zZ0sFf2PIsVd" style="border-bottom: Black 2pt double; text-align: right">78,734</td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="font-weight: bold"><span id="xdx_90E_eus-gaap--LiabilitiesAbstract_iB_c20210101__20211231_zqbnatmsvCN5">Liabilities</span>:</td>
    <td style="font-weight: bold; text-align: right"/>
    <td style="font-weight: bold; text-align: right"/>
    <td style="font-weight: bold; text-align: center"/>
    <td style="font-weight: bold; text-align: right"/>
    <td style="font-weight: bold; text-align: right"/>
    <td style="font-weight: bold; text-align: center"/>
    <td style="font-weight: bold; text-align: right"/>
    <td style="font-weight: bold; text-align: right"/>
    <td style="font-weight: bold; text-align: center"/>
    <td style="font-weight: bold; text-align: right"/>
    <td style="font-weight: bold; text-align: right"/>
    <td style="font-weight: bold; text-align: center"/></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt">Convertible notes payable, at fair value</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_982_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_z1Dji7GN6VXc" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0457">-</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_986_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zZc1eDPalm1i" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0458">-</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_98E_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_z6iymzVEu8el" style="text-align: right">18,920</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_984_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zMlyQogvhvz5" style="text-align: right">18,920</td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt">Derivative liability, at fair value</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td id="xdx_982_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zB0e9XsEXIV7" style="text-align: right">1,174</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td id="xdx_98C_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_z3vyQwT75uk1" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0462">-</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td id="xdx_98B_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zBPGwAQ3cEei" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0463">-</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td id="xdx_98A_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zai4h0Tys5Ud" style="text-align: right">1,174</td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt">Warrant liabilities, at fair value</td>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td id="xdx_984_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zZKHP2KXgNKf" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0465">-</span></td>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td id="xdx_98B_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zpHSbRNVJiJi" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0466">-</span></td>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td id="xdx_98F_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_z2rtoturi0K1" style="border-bottom: Black 1pt solid; text-align: right">424</td>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td id="xdx_982_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zW1Y23DafrH3" style="border-bottom: Black 1pt solid; text-align: right">424</td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_986_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zkxlXzVGYAY6" style="border-bottom: Black 2pt double; text-align: right">1,174</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_987_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zYs6Is3hVU9l" style="border-bottom: Black 2pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0470">-</span></td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_980_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zDyahd65sJWd" style="border-bottom: Black 2pt double; text-align: right">19,344</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_988_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zwS6h5ca1G24" style="border-bottom: Black 2pt double; text-align: right">20,518</td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0"/>

<p style="font: 9pt Sans-Serif; margin: 0 0 0 4.5pt; background-color: white; color: Red"/>



<p style="margin-top: 0; margin-bottom: 0"/>

<p style="font: 9pt Sans-Serif; margin: 0 0 0 4.5pt; background-color: white; color: Red"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="font-weight: normal">&#160;</span></p>


<p id="xdx_8AD_zWf1Uyzwva4e" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="background-color: white">The fair
value of the Company&#8217;s money market funds is based on quoted active market prices for the funds and is determined using the market
approach.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company measures the 2021 Convertible Notes
and warrant liabilities <span style="background-color: white">at fair value based on significant inputs not observable in the market,
which causes them to be classified as a Level&#160;3 measurement within the fair value hierarchy.&#160;</span>These valuations use assumptions
and estimates the Company believes would be made by a market participant in making the same valuation. The Company assesses these assumptions
and estimates on&#160;an&#160;on-going&#160;basis as additional data impacting the assumptions and estimates are obtained. Changes in
the fair value of the convertible notes payable and warrant liabilities related to updated assumptions and estimates are recognized within
the Consolidated Statements of Operations and Comprehensive Loss.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The fair value of the convertible notes payable and warrant
liabilities may change significantly as additional data is obtained, impacting the Company&#8217;s assumptions regarding probabilities
of outcomes used to estimate the fair value of the liabilities. The estimates of fair value may not be indicative of the amounts that
could be realized in a current market exchange. Accordingly, the use of different market assumptions and/or different valuation techniques
may have a material effect on the estimated fair value amounts, and such changes could materially impact the Company&#8217;s results
of operations in future periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>Derivative Liability</i></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The derivative liability represents the fair value of the &#8220;Shortfall
Amount&#8221; provision provided for in the license agreement with iX Biopharma Europe Limited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">At issuance, the fair value of the embedded derivative was estimated
by using a Monte Carlo simulation model. As of December 31, 2021, the Company determined it was probable it would settle the Shortfall
Amount in cash and estimated the fair value based on a probability weighted market approach. The Company paid the Shortfall Amount of
$<span id="xdx_902_ecustom--NonrefundableCashPayment_pn5n6_c20220101__20220131__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_zGsQjw9Csvmh">1.2</span> million in cash in January 2022.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>2021 Convertible Notes</i></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zobZdwvz86B2" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The
2021 Convertible Notes are valued using a Monte Carlo simulation model. The following assumptions were used in determining the fair
value of the 2021 Convertible Notes as of March 31, 2022 and December 31, 2021:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_8B1_ziFuTHcOTBZ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none">Summary of Fair Value Measurements Convertible Notes Valuation
Assumptions</p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 56%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: center; width: 19%">Three Months Ended</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: right; width: 1%">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: right; width: 2%">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: center; width: 19%">Year Ended</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">March 31, 2022</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">December 31, 2021</td></tr>
  <tr style="vertical-align: middle">
    <td style="background-color: white">Risk-free interest rate</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="font-size: 9pt; text-align: center"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_uPure_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_z5HpRHX11Yob">2.45</span>%</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: center; border-top-color: Black; border-top-width: 1pt; background-color: white"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_uPure_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MinimumMember_zZeGHvgGJ9s4">0.90</span>% - <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_uPure_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MaximumMember_z37XKizL0Gw7">0.95</span>%</td></tr>
  <tr style="vertical-align: middle">
    <td style="background-color: white">Volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="font-size: 9pt; text-align: center"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pin2_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zacDLrQ4GKdg">105</span>%</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: center; background-color: white"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pin2_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MinimumMember_zg5wBGRG8c44">113</span>% - <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pin2_uPure_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MaximumMember_zErzf8T2zyUi">114</span>%</td></tr>
  <tr style="vertical-align: middle">
    <td style="background-color: white">Dividend yield</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="font-size: 9pt; text-align: center"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zW1WNfLtpRW5"><span style="-sec-ix-hidden: xdx2ixbrl0482">-</span></span>%</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center; background-color: white"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_ziWfoJRwIme7"><span style="-sec-ix-hidden: xdx2ixbrl0483">-</span></span>%</td></tr>
  <tr style="vertical-align: middle">
    <td style="background-color: white">Contractual term (years)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zWmphv1myut4" style="font-size: 9pt; text-align: center">2.7</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zmlt9elrKnbd" style="vertical-align: bottom; text-align: center; background-color: white">3.0</td></tr>
  <tr style="vertical-align: middle">
    <td style="background-color: white">Stock price</td>
    <td>&#160;</td>
    <td style="text-align: right">$</td>
    <td style="font-size: 9pt; text-align: center"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_uUSDPShares_c20220331__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_z3skXZj1r90j">0.84</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td style="vertical-align: bottom; text-align: center; background-color: white"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_uUSDPShares_c20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MinimumMember_zljLj7MQFzwe">1.74</span> - <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_uUSDPShares_c20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MaximumMember_z3kkv8fM9Zpa">1.95</span></td></tr>
  </table>

<p id="xdx_8AF_zrGUII808ble" style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"/>







<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0; text-align: left"/>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>Warrant Liabilities</i></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The common stock warrant liabilities were recorded at fair value using
the Black-Scholes option pricing model. &#160;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"/>

<p id="xdx_899_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zO2vSCDX6qTh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-weight: normal"><span style="background-color: white">The
following assumptions were used in determining the fair value of the warrant liabilities valued using the Black-Scholes option
pricing model for the three months ended March 31, 2022 and 2021.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-weight: normal"><span style="background-color: white">&#160;</span></span></p>

<p id="xdx_8BD_zAZ6sU0ZV6p3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal"><span style="display: none; background-color: white">Summary
of Fair Value Measurements Warrant Valuation Assumptions</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">&#160;</span></p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
  <tr style="vertical-align: middle">
    <td style="width: 55%">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: right; width: 1%">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: right; width: 1%">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: center; width: 19%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 20%">&#160;</td></tr>
  <tr style="vertical-align: middle">
    <td/>
    <td style="font-size: 9pt; font-weight: bold; text-align: right"/>
    <td style="font-size: 9pt; font-weight: bold; text-align: right"/>
    <td colspan="4" style="font-size: 9pt; font-weight: bold; text-align: center">Three Months  Ended March  31,</td></tr>
  <tr style="vertical-align: middle">
    <td/>
    <td style="font-size: 9pt; font-weight: bold; text-align: right"/>
    <td style="text-align: right"/>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">2022</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><b>2021</b></td></tr>
  <tr style="vertical-align: middle">
    <td>Risk-free interest rate</td>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_uPure_c20220101__20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zOk0436sECG2" style="text-align: center; border-top-color: Black; border-top-width: 1pt">1.96%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_uPure_c20210101__20210331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zQXop3eyrI2k" style="text-align: center; border-top-color: Black; border-top-width: 1pt">0.32%</td>
    </tr>
  <tr style="vertical-align: middle">
    <td>Volatility</td>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pin2_uPure_c20220101__20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zFQkpDdm9Xka" style="text-align: center">103.30%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pin2_uPure_c20210101__20210331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_z8fdFMccT2S2" style="text-align: center">120.91%</td>
    </tr>
  <tr style="vertical-align: middle">
    <td><p style="margin-top: 0; margin-bottom: 0">Dividend yield</p></td>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td style="text-align: center"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20220101__20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zz7ilyPOnhdg" title="Dividend yield (in percent)"><span style="-sec-ix-hidden: xdx2ixbrl0496">-</span></span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20210101__20210331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zSAF5OZBaWde" title="Dividend yield (in percent)"><span style="-sec-ix-hidden: xdx2ixbrl0498">-</span></span>%</td>
    </tr>
  <tr style="vertical-align: middle">
    <td>Expected term (years)</td>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zcrDiuC8yDRb" style="text-align: center">1.82</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zAFqHOxghGpf" style="text-align: center">2.82</td>
    </tr>
  <tr style="vertical-align: middle">
    <td>Weighted-average fair value</td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220101__20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zEZJzyd9xHx3" style="text-align: center">0.63</td>
    <td>&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20210101__20210331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zr76QnsGRBn5" style="text-align: center">4.76</td>
    </tr>
  </table>

<p style="font: bold 9pt Sans-Serif; margin: 0 0 0 6pt; text-align: left; color: Red"/>

<p id="xdx_8A1_zU3M9zd0geK3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left">&#160;</p>






<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_895_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zCPml5pFNX89" style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">The
following table is a reconciliation for the common stock warrant liabilities and convertible notes measured at
fair value using Level 3 unobservable inputs (in thousands):&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="font-weight: normal; background-color: white"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-weight: normal; background-color: white">&#160;</span></p>

<p id="xdx_8BF_z141aSNXGWG7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="display: none; font-weight: normal; background-color: white; font-style: normal">Schedule of Fair Value Level 3 Reconciliation</span></p>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify">&#160;</p>



<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: right; width: 65%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; width: 7%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; width: 6%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; width: 13%"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt"><b>Warrant</b></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt"><b>Derivative</b></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt"><b>Convertible notes,</b></span></td></tr>
  <tr>
    <td style="vertical-align: middle"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; vertical-align: bottom; text-align: center"><span style="font-size: 9pt">liabilities</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; vertical-align: bottom; text-align: center"><span style="font-size: 9pt">liability</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; vertical-align: bottom; text-align: center"><span style="font-size: 9pt">at
    fair value</span></td></tr>
  <tr style="vertical-align: middle">
    <td style="font-weight: bold"><span style="font-size: 9pt">Balance as of December 31, 2020</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">$</span></td>
    <td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zZ5N7YCQckUf" style="text-align: right"><span style="font-size: 9pt">1,062</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td></tr>
  <tr style="vertical-align: middle">
    <td><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;Warrant liability reclassified to stockholders' equity</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"><span id="xdx_90B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zy3q2RQ3tfl9">(1,155)</span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td></tr>
  <tr style="vertical-align: middle">
    <td><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;Issuance of convertible notes, at fair value</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span id="xdx_903_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2l9ITqAdDS3">19,150</span></span></td></tr>
  <tr style="vertical-align: middle">
    <td><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;Issuance of derivative liability</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span id="xdx_909_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zeSjkKoJkkxe">805</span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td></tr>
  <tr style="vertical-align: middle">
    <td><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;Change in fair value measurement of derivative liability</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span id="xdx_90E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zsnriOmehMg3">369</span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td></tr>
  <tr style="vertical-align: middle">
    <td><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;Change in fair value measurement of convertible notes</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span id="xdx_900_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z1bOcwLgc6ni">(230)</span></span></td></tr>
  <tr style="vertical-align: middle">
    <td><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;Change in fair value measurement of warrant liability</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right; background-color: white"><span style="font-size: 9pt"><span id="xdx_90A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z9ZMDiklTg95">517</span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td></tr>
  <tr>
    <td style="font-weight: bold; vertical-align: middle"><span style="font-size: 9pt">Balance as of December 31, 2021</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt">$</span></td>
    <td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zZOckZD8d9d6" style="vertical-align: middle; text-align: right"><span style="font-size: 9pt">424</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt">$</span></td>
    <td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zqO3PH8nHf3a" style="vertical-align: middle; text-align: right"><span style="font-size: 9pt">&#160;1,174</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt">$</span></td>
    <td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zzTtUmRpTS0k" style="vertical-align: middle; text-align: right"><span style="font-size: 9pt">&#160;18,920</span></td></tr>
  <tr style="vertical-align: middle">
    <td><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;Settlement of derivative liability</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span id="xdx_905_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_i01N_pn3n3_di_c20220101__20220331__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwCetRrRSAH2">(1,174)</span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td></tr>
  <tr style="vertical-align: middle">
    <td><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;Change in fair value measurement of convertible notes</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span id="xdx_90E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_i01_pn3n3_c20220101__20220331__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zhaQF9ZHYUVb">244</span></span></td></tr>
  <tr style="vertical-align: middle">
    <td><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;Change in fair value measurement of warrant liability</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right; background-color: white"><span style="font-size: 9pt"><span id="xdx_908_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_i01_pn3n3_c20220101__20220331__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zLeLqN2kvjGc">(234)</span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td></tr>
  <tr>
    <td style="font-weight: bold; vertical-align: middle"><span style="font-size: 9pt">Balance as of March 31, 2022</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt">$</span></td>
    <td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zBuArDbAc7Ek" style="border-bottom: Black 3pt double; vertical-align: middle; text-align: right"><span style="font-size: 9pt">190</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt">$</span></td>
    <td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_z1bamG3QqGxf" style="border-bottom: Black 3pt double; vertical-align: middle; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0519">&#160;</span>-</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt">$</span></td>
    <td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_z07O5qVN9v76" style="border-bottom: Black 3pt double; vertical-align: middle; text-align: right"><span style="font-size: 9pt">&#160;19,164</span></td></tr>
  </table>

<p id="xdx_8A9_zTkGNxX2rtf6" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify">&#160;</p>
<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><span style="background-color: white">For the three months ended
March 31, 2022 and the year ended December 31, 2021, the changes in fair value of the convertible notes, derivative liability and
warrant liability primarily resulted from the volatility of the Company&#8217;s common stock. </span></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332072919688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>5. Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">5. Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p id="xdx_807_eus-gaap--OtherCurrentAssetsTextBlock_zxTYFBXSMjbi" style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>5. Prepaid Expenses and Other Current Assets</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_894_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_z2quCZanxsAd" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Prepaid expenses and other current assets are comprised of the following
(in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_8BB_zFwXqZpjjEH5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none">Schedule of Prepaid Expenses and Other Current Assets</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 85%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: middle">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">&#160;</td>
    <td id="xdx_492_20220331_zUJOJOzjr6L3" style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">&#160;</td>
    <td id="xdx_495_20211231_z0xE0sLPmIEi" style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: middle">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">March 31,</td>
    <td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">December 31,</td></tr>
  <tr>
    <td style="vertical-align: middle">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">2022</td>
    <td style="vertical-align: middle">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">2021</td></tr>
  <tr id="xdx_403_eus-gaap--PrepaidInsurance_iI_pn3n3_maPEAOAzj4M_zj6iYj33ahr1" style="vertical-align: middle">
    <td style="width: 66%">Prepaid insurance</td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; text-align: right; width: 1%">$</td>
    <td style="text-align: right; background-color: white; width: 15%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;787</td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; text-align: right; width: 1%">$</td>
    <td style="text-align: right; width: 15%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;59</td></tr>
  <tr id="xdx_407_ecustom--PrepaidClinicalCosts_iI_pn3n3_maPEAOAzj4M_zosvL0eg1Rc9" style="vertical-align: middle">
    <td>Prepaid clinical costs</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: right; background-color: white">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;7,694</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: right">&#160;</td>
    <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;4,481</td></tr>
  <tr id="xdx_405_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3n3_maPEAOAzj4M_zDuzsVMSYJ83">
    <td style="vertical-align: middle">Other</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: middle; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: middle; text-align: right; background-color: white">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;414</td>
    <td style="vertical-align: middle">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: top; text-align: right">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: middle; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;187</td></tr>
  <tr id="xdx_401_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i01TI_pn3n3_maACzKPF_maACzYR4_mtPEAOAzj4M_zuIdy9vqOoKd" style="vertical-align: middle">
    <td style="padding-left: 24px; text-align: left">Prepaid expenses and other current assets</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2pt double; vertical-align: top; text-align: right">$</td>
    <td style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 1pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;8,895</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2pt double; vertical-align: top; text-align: right">$</td>
    <td style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 1pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;4,727</td></tr>
  </table>
<p id="xdx_8A9_z5E5zcgHzLMl" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"/>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332073027448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>6. Common Stock Offerings<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">6. Common Stock Offerings</a></td>
<td class="text"><p id="xdx_808_eus-gaap--BusinessCombinationDisclosureTextBlock_zWRxfvxCmEWd" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">6. Common Stock Offerings</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Public Offerings</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On May 24, 2021, the Company completed an underwritten public
offering, pursuant to which the Company sold <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--May242021Member_zPVRgA5RMaM1" title="Number of shares of common stock issued">22,258,066</span> shares of its common stock, at a price to the public of $<span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_pp2p0_uUSDPShares_c20210524__us-gaap--StatementClassOfStockAxis__custom--May242021Member_zkYUNTkLxcd1" title="Shares Issued, Price Per Share">3.10</span> per share, which
included the exercise in full by the underwriter of its option to purchase up to 2,903,226 additional shares of common stock. The net
proceeds to the Company from the offering were approximately $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--May242021Member_zhylCscaQiz" title="Cash received from stock sale">64.5</span> million, after deducting underwriting discounts, commissions and
other offering expenses. The Company used $<span id="xdx_90E_ecustom--OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes_pn5n6_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--May242021Member_zbSSnmJkeCOh" title="Offering proceeds used to partially repay certain convertible promissory notes">7.3</span> million of the net proceeds from the offering for the partial repayment
of certain outstanding convertible promissory notes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On January 28, 2021, the Company completed an underwritten public
offering, pursuant to which the Company sold <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--January282021Member_ziiVbkN1rM35">17,530,488
</span>shares of its common stock, at a price to the public of $<span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_pp2p0_uUSDPShares_c20210128__us-gaap--StatementClassOfStockAxis__custom--January282021Member_zhwuTBDaRzq1">2.05
</span>per share, which included the exercise in full by the underwriter of its option to purchase up to 2,286,585 additional shares
of common stock. The net proceeds to the Company from the offering were approximately $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--January282021Member_z86SClZKrcwl">33.5
</span>million, after deducting underwriting discounts, commissions and other offering expenses. The Company used $<span id="xdx_907_ecustom--OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes_pn5n6_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--January282021Member_z7HAPFqbneJ7">3.8
</span>million of the net proceeds from the offering for the partial repayment of certain outstanding convertible promissory notes.&#160;</p>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Stock Purchase Agreement with iX Biopharma Europe Limited</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On November 24, 2021, the Company entered in an exclusive license agreement
and stock purchase agreement (the &#8220;iXBEL Stock Purchase Agreement&#8221;) with iX Biopharma Europe Limited (&#8220;iXBEL&#8221;).
As consideration for the license under the license agreement, the Company paid iXBEL an upfront fee of $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20211101__20211130__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_zbhykfLuIVV3">9.0</span> million, comprised of $<span id="xdx_904_ecustom--NonrefundableCashPayment_pn5n6_c20211101__20211130__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_zmPI9QRGhjX2">3.5</span>
million in cash and <span id="xdx_901_ecustom--Issuanceofcommonstockforlicenseacquiredshares_pip0_c20211101__20211130__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_zW4EhQQTZYA3">2,570,266</span> restricted shares of the Company&#8217;s common stock. Pursuant to the iXBEL Stock Purchase Agreement, the
Company agreed to reimburse iXBEL for the difference in value (the &#8220;Shortfall Amount&#8221;) in the event the aggregate value of
the <span id="xdx_901_ecustom--Issuanceofcommonstockforlicenseacquiredshares_pip0_c20211101__20211130__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_znU54BEBumsl">2,570,266</span> shares of the Company&#8217;s common stock at the time of registration and issuance was less than $<span id="xdx_90D_ecustom--MinimumStockValueOfSharesIssued_pn5n6_c20211101__20211130__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_zpmu58Wkjku9">5.5</span> million. The initial
fair value of this Shortfall Amount was $<span id="xdx_909_ecustom--InitialStockValuationShortfallFrom5.5MillionValue_pn5n6_c20211101__20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_z326PtoKuTtb">0.8</span> million and in January 2022, the Company settled the Shortfall Amount by the payment of $<span id="xdx_906_ecustom--NonrefundableCashPayment_pn5n6_c20220101__20220131__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_zwDR1YtqtHq3">1.2</span>
million in cash to iXBEL. The change in fair value of the Shortfall Amount is included in Change in fair value of derivative liability
on the Condensed Consolidated Statement of Operations and Comprehensive Loss (see Note 4).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4946-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332072864168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>7. License Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">7. License Agreements</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_zdB1HoTH1FWd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>7. License Agreements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Specific information pertaining to each of the Company&#8217;s
significant license agreements is discussed in its audited financial statements included in the Annual Report for the years ended December
31, 2021 and 2020, including their nature and purpose, the significant rights and obligations of the parties, and specific accounting
policy elections. The following represents updates for the three months ended March 31, 2022, if applicable, to the Company&#8217;s significant
license agreements:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Acquisition of Assets from Phoenixus AG f/k/a Vyera Pharmaceuticals,
AG and Turing Pharmaceuticals AG (&#8220;Vyera&#8221;)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">See Note 13 for a subsequent event related to the Vyera Purchase
Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Acquisition of License from Stuart
Weg, MD</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_907_eus-gaap--BusinessCombinationSeparatelyRecognizedTransactionsDescription_c20190801__20190831__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--WegLicenseAgreementMember_zlZ8kLOosFO2">On
August 29, 2019, the Company entered into an amended and restated exclusive license agreement with Stuart Weg, M.D. (the &#8220;Weg License
Agreement&#8221;), pursuant to which the Company was granted an exclusive worldwide license to certain intellectual property and regulatory
materials related to SLS-002. Under the terms of the Weg License Agreement, the Company paid an upfront license fee of $75,000 upon execution
of the agreement. The Company agreed to pay additional consideration to Dr. Weg as follows: (i) $0.1 million on January 2, 2020, (ii)
$0.125 million on January 2, 2021, and (iii) in the event the FDA has not approved an NDA for a product containing ketamine in any dosage
on or before December 31, 2021, $</span><span id="xdx_905_ecustom--NonrefundableCashPayment_pn5n6_c20220101__20220131__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--WegLicenseAgreementMember_zGva1W1wyXU">0.2
</span>million
on January 2, 2022. The Company paid the required $<span id="xdx_90E_ecustom--NonrefundableCashPayment_pn5n6_c20200101__20200131__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--WegLicenseAgreementMember_zL51DBdLIJ7i">0.1
</span>million
on January 2, 2020,  $<span id="xdx_90A_ecustom--NonrefundableCashPayment_pp3n6_c20210101__20210131__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--WegLicenseAgreementMember_zMzcpsO2NU67">0.125
</span>million
on January 2, 2021 and $<span id="xdx_901_ecustom--NonrefundableCashPayment_pn5n6_c20220101__20220131__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--WegLicenseAgreementMember_zh1yTMG0Ikdc">0.2
</span>million
on January 2, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">The remaining potential regulatory and commercial milestones
are not yet considered probable, and <span id="xdx_900_eus-gaap--AssetAcquisitionContingentConsiderationLiabilityCurrent_iI_pip0_do_c20220331__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--WegLicenseAgreementMember_z7ouc9W71hJb">no</span> other milestone payments have been accrued at March 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify"/>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 730<br> -URI https://asc.fasb.org/subtopic&amp;trid=2197926<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332072989304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>8. Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">8. Accrued Expenses</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zIsKhPRNio92" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>8. Accrued Expenses</b></p>

<p id="xdx_89B_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zLbnzvITG1p5" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Accrued expenses are comprised of the following (in
thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin-right: 0; margin-left: 0"><span><span id="xdx_8BD_z6KWwFfJHuHk">Schedule of Accrued Liabilities</span></span></p>




<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_49A_20220331_zwICjhlV6239" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_490_20211231_zmD5DtFUaTSf" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><b>March 31,</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><b>December 31,</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 64%">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 2%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 15%; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 2%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 15%; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td></tr>
  <tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCzZt1_ziFqceZp8kCd" style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Professional fees</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">190&#160;</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">181&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCzZt1_zct9paxXbfkh" style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Personnel related</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">332&#160;</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,303&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--OutsideResearchAndDevelopmentServicesCurrent_iI_pn3n3_zFJGLg2nsUn5" style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Outside research and development services</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">2,387&#160;</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">2,219&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AccruedInsuranceCurrent_iI_pn3n3_zfpu6qZ5A2Kg" style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Insurance</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">580&#160;</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-<span style="-sec-ix-hidden: xdx2ixbrl0581">&#160;</span></span></td></tr>
  <tr id="xdx_40B_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzZt1_zVwREZNxc5Fc" style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Other</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">60&#160;</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">25&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzZt1_ztGJO0fQsEb3" style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;&#160;&#160;&#160; Accrued expenses, net</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">3,549&#160;</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">3,728&#160;</span></td></tr>
  </table>

<p id="xdx_8A6_zJtCCx3fxOm9" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify"><b><i>&#160;</i></b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332073034216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>9. Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">9. Debt</a></td>
<td class="text"><p id="xdx_808_eus-gaap--DebtDisclosureTextBlock_zLtfGH8Xgij3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>9. Debt</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"/><p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>Convertible Notes</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>November 2021 and December 2021 Convertible Notes and Private Placement</i></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_904_eus-gaap--LongTermDebtDescription_c20211101__20211130__us-gaap--DebtInstrumentAxis__custom--November2021LindSecuritiesPurchaseAgreementMember_zfcTsRffSNl3">On November 23, 2021, the Company entered into a Securities Purchase Agreement
(the &#8220;2021 Lind Securities Purchase Agreement&#8221;) with Lind Global Asset Management V, LLC (&#8220;Lind V&#8221;) pursuant
to which, among other things, on November 23, 2021 (the &#8220;Closing Date&#8221;), the Company issued and sold to Lind V, in a private
placement transaction (the &#8220;Private Placement&#8221;), in exchange for the payment by Lind V of $20.0 million, (i) a convertible
promissory note (the &#8220;2021 Note&#8221;) in an aggregate principal amount of $22.0 million (the &#8220;Principal Amount&#8221;),
which will bear no interest until the first anniversary of the issuance of the 2021 Note and will thereafter bear interest at a rate
of 5% per annum, and mature on November 23, 2024 (the &#8220;Maturity Date&#8221;), and (ii) 534,759 shares of Company common stock.</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_904_eus-gaap--LongTermDebtDescription_c20221101__20221130__us-gaap--DebtInstrumentAxis__custom--FirstAnniversaryOfNovember2021LindSecuritiesPurchaseAgreementMember_zEV0cSbbk5d6">At the first anniversary of the Closing Date, the Company shall
have the option, at its sole discretion, to issue to Lind V a convertible promissory note (the &#8220;Second Note&#8221;) in the principal
amount of $11.0 million in exchange for the payment by Lind V of $10.0 million. At the earlier of (i) the two-year anniversary of the
Closing Date, or (ii) the successful readout for SLS-005 in ALS, and subject to the mutual agreement of the Company and Lind V, the Company
shall issue to Lind V a convertible promissory note (the &#8220;Third Note&#8221;) in the principal amount of $11.0 million in exchange
for the payment by Lind V of $10.0 million. In the event of the filing of a new drug application with the U.S. Food &amp; Drug Administration
for either SLS-002 or SLS-005, and subject to the mutual agreement of the Company and Lind V, the Company shall issue to Lind V a convertible
promissory note (the &#8220;Fourth Note&#8221;) in the principal amount of $11.0 million in exchange for the payment by Lind V of $10.0
million. The Second Note, the Third Note and the Fourth Note, if issued, would be in substantially the same form as the 2021 Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_90C_eus-gaap--LongTermDebtDescription_c20220823__20241123__us-gaap--DebtInstrumentAxis__custom--August232022ThruMaturityNovember2021LindSecuritiesPurchaseAgreementMember_zE0qTVToKwsc">At any time following August 23, 2022, from time to time and before the
Maturity Date, Lind V shall have the option to convert any portion of the then-outstanding Principal Amount of the 2021 Note into shares
of Common Stock at a price per share of $6.00, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar
transactions (the &#8220;Conversion Price&#8221;). At any time prior August 23, 2022, the Company shall have the right to prepay, in whole
or in part (exercisable by the Company at any time or from time to time during such period), up to an aggregate of $14.7 million of the
outstanding Principal Amount of the 2021 Note with no penalty. If the Company does not prepay any amounts of the 2021 Note prior to August
23, 2022 then, commencing August 23, 2022, the Company shall have the right to prepay, in whole or in part (exercisable by the Company
at any time or from time to time prior to the Maturity Date), up to the full remaining Principal Amount of the 2021 Note with no penalty;
however, if the Company exercises such prepayment right, Lind V will have the option to convert up to thirty-three and one-third percent
(33 1/3%) of the amount that the Company elects to prepay at the Conversion Price. If the Company prepays any amounts of the 2021 Note
prior to August 23, 2022 then, commencing November 23, 2022, the Company shall not have the right to prepay any amounts of the 2021 Note
between August 23, 2022 to November 23, 2022 and, commencing November 23, 2022, the Company shall have the right to prepay, in whole or
in part (exercisable by the Company at any time or from time to time prior to the Maturity Date) up to the full remaining Principal Amount
of the 2021 Note with no penalty; however, if the Company exercises such prepayment right, Lind V will have the option to convert up to
thirty-three and one-third percent (33 1/3%) of the amount that the Company elects to prepay at the Conversion Price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Subject to certain exceptions, the Company will be required to direct proceeds
from any subsequent debt financings (including subordinated debt, convertible debt or mandatorily redeemable preferred stock but other
than purchase money debt or capital lease obligations or other indebtedness incurred in the ordinary course of business) to repay the
2021 Notes, unless waived by Lind V in advance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_90A_eus-gaap--LongTermDebtDescription_c20221123__20241124__us-gaap--DebtInstrumentAxis__custom--AmortizeNovember2021LindSecuritiesPurchaseAgreementMember_zJDYkPnrmip5">Beginning on November 23, 2022, the 2021 Note will amortize in twenty-four
monthly installments equal to the quotient of (i) the then-outstanding Principal Amount of the 2021 Note, divided by (ii) the number of
months remaining until the Maturity Date. All amortization payments shall be payable, at the Company&#8217;s sole option, in cash, shares
of Common Stock or a combination of both. In addition, commencing on the last business day of the first month following November 23, 2022,
the Company will pay, on a monthly basis, all interest that has accrued and remains unpaid on the then-outstanding Principal Amount of
the 2021 Note. Any portion of an amortization payment or interest payment that is paid in shares of Common Stock shall be priced at 90%
of the average of the five lowest daily volume weighted average prices of the Common Stock during the 20 trading days prior to the date
of issuance of the shares. If, after the first amortization payment, the Company elects to make any amortization payments in cash, the
Company shall pay a 5% premium on each cash payment. In conjunction with the 2021 Lind Securities Purchase Agreement and the 2021 Note,
on the Closing Date, the Company and Lind V entered into a security agreement, which provides Lind V with a first priority lien on the
Company&#8217;s assets and properties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_90F_eus-gaap--LongTermDebtDescription_c20211201__20211231__us-gaap--DebtInstrumentAxis__custom--December2021SPAsMember_zJXT89faIVld">On December 2, 2021, the Company entered into two separate securities purchase
agreements with certain accredited investors on substantially the same terms as the 2021 Lind Securities Purchase Agreement, pursuant
to which the Company sold, in private placement transactions, in exchange for the payment by the accredited investors of an aggregate
of $201,534, (i) convertible promissory notes in an aggregate principal amount of $221,688, which will bear no interest and mature on
December 2, 2024, and (ii) an aggregate of 5,388 shares of its common stock. These notes have substantially the same terms as the 2021
Note.</span></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">During the year ended December 31, 2021, the Company received
aggregate gross proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromConvertibleDebt_pn5n6_c20211201__20211231__us-gaap--DebtInstrumentAxis__custom--December2021SPAsMember_zwqXfHkzQ9i7">20.2</span>
million from the convertible note offerings. The Company elected to account for these notes under the fair value option. At time of
issuance, the Company recorded a liability of $<span id="xdx_90F_eus-gaap--ConvertibleSubordinatedDebt_iI_pn5n6_c20211202__us-gaap--DebtInstrumentAxis__custom--December2021SPAsMember_z9w6y8VcH4hc">19.2</span>
million, which was determined to be the fair value at time of issuance. As of December 31, 2021, the Company recognized a $<span id="xdx_90A_ecustom--GainLossInFairValueOfConvertibleNotes_pn5n6_c20211201__20211231__us-gaap--DebtInstrumentAxis__custom--December2021SPAsMember_zRSD8v8CC3y9">0.2</span>
million gain on change in fair value of convertible notes, recognizing a total convertible note liability of $<span id="xdx_907_eus-gaap--ConvertibleSubordinatedDebt_iI_pn5n6_c20211231__us-gaap--DebtInstrumentAxis__custom--December2021SPAsMember_zVMjFwqdvbzl">18.9</span>
million. During the three months ended March 31, 2022, the Company recognized a
$<span id="xdx_90C_ecustom--GainLossInFairValueOfConvertibleNotes_pn5n6_c20220101__20220331__us-gaap--DebtInstrumentAxis__custom--December2021SPAsMember_zq7yOD8Ou9V3">0.2</span> million loss on change in fair value of convertible notes, recognizing a total convertible note liability of $<span id="xdx_90B_eus-gaap--LongTermDebtFairValue_iI_pn5n6_c20220331__us-gaap--DebtInstrumentAxis__custom--December2021SPAsMember_zxYdvSHkg5w4">19.2</span> million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of March 31, 2022, the principal contractual balance
of the convertible notes totaled $<span id="xdx_907_eus-gaap--ConvertibleNotesPayable_iI_pn5n6_c20220331__us-gaap--DebtInstrumentAxis__custom--December2021SPAsMember_zUMGnrQcH5Hh">22.2</span> million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>December 2020 Convertible Note and Private Placement</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 20pt; text-indent: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><span id="xdx_901_eus-gaap--LongTermDebtDescription_c20201201__20201231__us-gaap--DebtInstrumentAxis__custom--LindSecuritiesPurchaseAgreementMember_zM4f5isFyqNg">On
December 11, 2020, the Company entered into a Securities Purchase Agreement (the &#8220;2020 Lind Securities Purchase
Agreement&#8221;) with Lind Global Asset Management II, LLC (the &#8220;Investor&#8221;) pursuant to which, among other things, on
December 11, 2020, the Company issued and sold to the Investor, in a private placement transaction, in exchange for the payment by
the Investor of $10,000,000, (1) a convertible promissory note (the &#8220;2020 Note&#8221;) in an aggregate principal amount of
$12,000,000 (the &#8220;Principal Amount&#8221;), which did not bear interest and was to mature on December 11, 2022 (the
&#8220;Maturity Date&#8221;), and (2) 975,000 shares of the Company&#8217;s common stock. At any time following June 11, 2021, and
from time to time before the Maturity Date, the Investor had the option to convert any portion of the then-outstanding Principal
Amount of the Note into shares of common stock at a price per share of $1.60, subject to adjustment for stock splits, reverse stock
splits, stock dividends and similar transactions. Prior to June 11, 2021, the Company had the right to prepay up to sixty-six and
two-thirds percent (66 2/3%) of the then-outstanding Principal Amount of the 2020 Note with no penalty. Subject to certain
exceptions, the Company was required to direct proceeds from any subsequent debt financings (including subordinated debt,
convertible debt or mandatorily redeemable preferred stock but other than purchase money debt or capital lease obligations or other
indebtedness incurred in the ordinary course of business) to repay the 2020 Note, unless waived by the Investor in advance. The 2020
Note began amortizing in June 2021 and was to amortize in eighteen monthly installments equal to the quotient of (i) the
then-outstanding Principal Amount of the 2020 Note, divided by (ii) the number of months remaining until the Maturity Date. All
amortization payments were to be payable solely in cash, plus a 2% premium. During the first half of 2021, the Company made certain
repayments on the outstanding principal balance of the convertible notes. On June 14, 2021, the Company and the Investor entered
into an Acknowledgment and Termination Agreement, pursuant to which the Company agreed to issue to the Investor an aggregate of
406,250 additional shares of its common stock (the &#8220;Lind Shares&#8221;) and to pay the Investor the remaining principal amount
of $790,804 (the &#8220;Final Payment&#8221;) in full satisfaction of the Company&#8217;s  remaining obligations to the Investor
under the 2020 Note. The Company issued the Lind Shares and made the Final Payment to the Investor, and the 2020 Lind Securities
Purchase Agreement and the 2020 Note terminated, effective June 15, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_902_eus-gaap--LongTermDebtDescription_c20201201__20201231__us-gaap--DebtInstrumentAxis__custom--December17SPAsMember_zNaztLWBB4i4">On December 17, 2020, the Company entered into three separate securities
purchase agreements with certain accredited investors on substantially the same terms as the Lind Securities Purchase Agreement (the &#8220;December
17 SPAs&#8221;), pursuant to which the Company sold, in private placement transactions, in exchange for the payment by the accredited
investors of an aggregate of $1,138,023, (1) convertible promissory notes (the &#8220;December 17 Notes&#8221;) in an aggregate principal
amount of $1,365,628, which did not bear interest and were to mature on December 17, 2022, and (2) an aggregate of 110,956 shares of its
common stock. On December 18, 2020, the Company entered into an additional securities purchase agreement with
an accredited investor on substantially the same terms as the Lind Securities Purchase Agreement (the &#8220;December 18 SPA&#8221; and,
together with the December 17 SPAs, the "Subsequent Securities Purchase Agreements"), pursuant to which the Company sold, in
a private placement transaction, in exchange for the payment by the accredited investor of $269,373, (1) a convertible promissory note
in an aggregate principal amount of $323,247, which did not bear interest and was to mature on December 18, 2022 (the &#8220;December
18 Note&#8221; and, together with the December 17 Notes, the &#8220;Subsequent Notes&#8221;), and (2) 26,263 shares of the Company&#8217;s
common stock. The Subsequent Securities Purchase Agreements had substantially the same terms as the Lind Securities Purchase Agreement,
and the Subsequent Notes had substantially the same terms as the Note. During the first half of 2021, the Company made certain repayments
on the outstanding principal balance of the convertible notes. On July 7, 2021, the Company and the holder of the December 18 Note (the
&#8220;December 18 Note Holder&#8221;) entered into an Acknowledgement and Termination Agreement, pursuant to which: (i) the December
18 Note Holder agreed to return to the Company $42,777 in cash (the &#8220;Repayment&#8221;) previously paid by the Company to the December
18 Note Holder as a payment against the Company&#8217;s obligations under the December 18 Note, and (ii) the Company agreed to issue to
the December 18 Note Holder an aggregate of 43,664 additional shares of its common stock (the &#8220;December 18 Note Shares&#8221;) in
full satisfaction of the Company&#8217;s remaining obligations to the December 18 Note Holder under the December 18 Note. The December 18 Note Holder
paid the Company the Repayment and the Company issued the December Note Shares, and the December 18 SPA and the December 18 Note terminated,
effective July 7, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company received aggregate net proceeds of $10.9 million from
the convertible note offering, net of $0.5 million of issuance costs. The total gross proceeds were allocated to the convertible notes
and common stock issued under the agreements based on their relative fair values. Due to the principal payments made during the year,
the Company remeasured the beneficial conversion feature discount at each payment date and recorded a loss on extinguishment of debt
of approximately $1.0 million during the year ended December 31, 2021 as well as a reduction in additional paid-in capital of $1.5 million
as of December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">During the year ended December 31, 2021,
the Company paid approximately $<span id="xdx_905_eus-gaap--RepaymentsOfConvertibleDebt_pn5n6_c20211201__20211231__us-gaap--DebtInstrumentAxis__custom--December17SPAsMember_zBKJoERIgJc5">13.6</span> million in principal payments on the outstanding convertible notes and issued an aggregate of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pip0_c20211201__20211231__us-gaap--DebtInstrumentAxis__custom--December17SPAsMember_z4zmjDAAiCB7">475,315</span>
shares of its common stock upon conversion of the convertible notes, and <span id="xdx_90F_eus-gaap--LongTermDebt_iI_dn_c20211231__us-gaap--DebtInstrumentAxis__custom--December17SPAsMember_z5ixQC4kG0Q3">none</span> of the 2020 convertible notes remain outstanding as of December
31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 0; background-color: white">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332071161864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>10. Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">10. Stockholders&#8217; Equity</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zxvBJE321Eaa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>10. Stockholders&#8217; Equity</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Preferred Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company is authorized to issue <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_pip0_c20220331_zofzEj2Uaoak" title="Preferred stock, authorized (in shares)">10,000,000</span> shares of preferred
stock, par value $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pip0_c20220331_zs7lLNcS5yD2" title="Preferred stock, per value (in usd per share)">0.001</span>. <span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20220331_zZaGp0Oct1Ej" title="Preferred stock, outstanding (in shares)"><span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20211231_zfGV5eNrFRGl" title="Preferred stock, outstanding (in shares)">No</span></span> shares of preferred stock were outstanding as of March 31, 2022 or December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company has authorized <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_pp0p0_c20220331_zQX2U7gbKoAc" title="Common stock, authorized (in shares)"><span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_pp0p0_c20211231_zcwqnL9otRod">240,000,000</span></span> shares of common stock as of March 31, 2022 and December 31, 2021. <span id="xdx_908_eus-gaap--CommonStockVotingRights_c20220101__20220331_zrNC2Xv2lvob" title="Common stock voting right">Each share of common stock is entitled to
one voting right</span>. Common stock owners are entitled to dividends when funds are legally available and declared by the Board of
Directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify; text-indent: -0.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify; text-indent: -0.5pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>September 2020 Warrants</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20200901__20200930__us-gaap--ClassOfWarrantOrRightAxis__custom--September2020WarrantsMember_zKPp0HrdPCD2" title="Warrant description"> On September 4, 2020, the Company entered into a securities purchase agreement
with certain institutional investors pursuant to which the Company issued and sold an aggregate of 8,865,000 shares of common stock in
a registered direct offering and issued warrants to purchase up to 6,648,750 shares of common stock in a concurrent private placement
(the &#8220;September 2020 Warrants&#8221;). The September 2020 Warrants are initially exercisable for
<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20200901__20200930__us-gaap--StatementClassOfStockAxis__custom--September2020WarrantsMember_zx2PxpEuEDol" title="Number of shares of common stock issued">6,648,750</span> shares of common stock at an exercise price per share equal to $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20200904__us-gaap--ClassOfWarrantOrRightAxis__custom--September2020WarrantsMember_zVxOUsZ4SiWb">0.84</span>. The September 2020 Warrants became exercisable beginning
on <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20210101__20210930__us-gaap--ClassOfWarrantOrRightAxis__custom--September2020WarrantsMember_z0AFn5jPTCFb" title="Date on which warrants became exercisable">March 9, 2021</span> and will expire on March 9, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">During the three months ended March 31, 2022 and 2021, September 2020
Warrants were exercised for <span id="xdx_900_ecustom--NumberofWarrantsExercisedDuringPeriod_pip0_uShares_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--September2020WarrantsMember_z89QZtTqhhT3">0</span> and <span id="xdx_900_ecustom--NumberofWarrantsExercisedDuringPeriod_pn5n6_uShares_c20210101__20210331__us-gaap--ClassOfWarrantOrRightAxis__custom--September2020WarrantsMember_z6S3SLFSX7ok" title="Number of warrants exercised">4.7</span>
million shares of common stock, respectively, for approximately $<span id="xdx_904_eus-gaap--ProceedsFromWarrantExercises_pp0p0_uUSD_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--September2020WarrantsMember_zX5GqS2Y2ra8">0</span> and $<span id="xdx_90F_eus-gaap--ProceedsFromWarrantExercises_pn5n6_uUSD_c20210101__20210331__us-gaap--ClassOfWarrantOrRightAxis__custom--September2020WarrantsMember_zLEyWQ58N3Dd" title="Proceeds from exercise of warrants">3.9</span>
million, respectively. As of March 31, 2022, September 2020 Warrants exercisable for <span id="xdx_901_ecustom--WarrantsExercisable_iI_pip0_c20220331__us-gaap--StatementClassOfStockAxis__custom--September2020WarrantsMember_z5BldYmwOLN4" title="Warrants exercisable as of March 31, 2022">1.0 million</span>
shares of common stock remain outstanding at an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--September2020WarrantsMember_zjMomzuXBcq8">0.84 </span>per
share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>August 2019 Warrants</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20190801__20190831__us-gaap--ClassOfWarrantOrRightAxis__custom--August2019WarrantsMember_z4gydDtfCY6a" title="Warrant description">On August 23, 2019, the Company entered into a securities
purchase agreement with certain institutional investors pursuant to which the Company issued and sold an aggregate of <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20190801__20190831__us-gaap--StatementClassOfStockAxis__custom--August232019Member_zhtMha9qEnSe" title="Number of shares of common stock issued">4,475,000</span> shares
of common stock in a registered direct offering and issued warrants to purchase up to 2,237,500 shares of common stock in a concurrent
private placement (the &#8220;August 2019 Warrants&#8221;). The August 2019 Warrants were initially exercisable for 2,237,500 shares of
common stock at an exercise price per share equal to $1.78. The August 2019 Warrants became exercisable beginning on <span id="xdx_903_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--August2019WarrantsMember_zEZJfToIzTLf" title="Date on which warrants became exercisable">February 27, 2020</span>
and will expire on August 28, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">During the three months ended March 31, 2022 and 2021, August 2019
Warrants for <span id="xdx_903_ecustom--NumberofWarrantsExercisedDuringPeriod_pip0_uShares_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--August2019WarrantsMember_zxOn2jkWOai5">0</span> and <span id="xdx_901_ecustom--NumberofWarrantsExercisedDuringPeriod_pin6_uShares_c20210101__20210331__us-gaap--ClassOfWarrantOrRightAxis__custom--August2019WarrantsMember_z7sq2VrYAiU4" title="Number of warrants exercised">1.0</span>
million shares of common stock were exercised for approximately $<span id="xdx_90E_eus-gaap--ProceedsFromWarrantExercises_pip0_uUSD_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--August2019WarrantsMember_zKPDOYffFBM6">0</span> and $<span id="xdx_906_eus-gaap--ProceedsFromWarrantExercises_pin6_uUSD_c20210101__20210331__us-gaap--ClassOfWarrantOrRightAxis__custom--August2019WarrantsMember_zt8cfvIKzRyc" title="Proceeds from exercise of warrants">1.8</span>
million, respectively. As of March 31, 2022, August 2019 Warrants exercisable for <span id="xdx_906_ecustom--WarrantsExercisable_iI_pip0_c20220331__us-gaap--StatementClassOfStockAxis__custom--August2019WarrantsMember_zaOf3Z0WsHpa" title="Warrants exercisable as of June 30, 2021">900,000</span>
shares of common stock remain outstanding at an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--August2019WarrantsMember_zPuFwVKpImsg">1.78 </span>per
share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Series A Warrants</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20210101__20210930__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zEpmqsmW0VWe" title="Warrant description">
On January 24, 2019, STI and the Company closed a private placement with certain accredited investors pursuant to which, among other
things, the Company issued warrants representing the right to acquire 1,463,519 shares of common stock (the &#8220;Series A
Warrants&#8221;). The Series A Warrants were initially exercisable for 1,463,519 shares of common stock at an exercise price per
share equal to $4.15, which was adjusted several times pursuant to the terms thereof to 3,629,023 shares of common stock at an
exercise price per share equal to $0.2957 per share. The most recent adjustment to the exercise price (from $0.60 to $0.2957 per
share) occurred during the three months ended September 30, 2020 as a result of the announcement of the registered direct offering
of 8,865,000 shares of common stock in September 2020. The Series A Warrants were immediately exercisable upon issuance and will expire
on January 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt">During the three months ended March 31, 2022 and 2021,
Series A Warrants for <span id="xdx_901_ecustom--NumberofWarrantsExercisedDuringPeriod_pip0_uShares_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zc2QaF5zrXrj" style="background-color: White">0 </span><span style="background-color: White">and <span id="xdx_90D_ecustom--NumberofWarrantsExercisedDuringPeriod_pn5n6_uShares_c20210101__20210331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zMIEgJBHlSb6">0.5
million </span></span><span style="background-color: White">shares of common stock, respectively, were exercised for approximately
$<span id="xdx_903_eus-gaap--ProceedsFromWarrantExercises_pip0_uUSD_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zHamcJ2uo7e8">0 </span></span><span style="background-color: White">and
$<span id="xdx_906_eus-gaap--ProceedsFromWarrantExercises_pn5n6_uUSD_c20210101__20210331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zMLeTA3ZyDXa">0.1 </span></span><span style="background-color: White">million,
respectively. As of March 31, 2022, Series A Warrants exercisable for <span id="xdx_906_ecustom--WarrantsExercisable_iI_pn5n6_uShares_c20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_z8ygjdaLViFj">0.3 </span></span><span style="background-color: White">million
shares of common stock remain outstanding at an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_z3YW3fGFwEAk">0.2957 </span></span><span style="background-color: White">per
share</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify">&#160;</p>

<p id="xdx_891_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zJmTqFB9NdR" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt">A summary of warrant activity during the three months ended March 31, 2022 is as follows (share amounts in thousands):</p>

<p id="xdx_8B7_zAzfrCVOkjad" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; display: none">Summary of Warrant Activity</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt">&#160;</p>

<p style="font: 9pt Sans-Serif; margin: 0 0 0 5pt; color: Red"><b>&#160;</b></p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: middle; width: 52%"/>
    <td style="vertical-align: middle; width: 1%"/>
    <td style="font-weight: bold; vertical-align: middle; width: 12%"/>
    <td style="font-weight: bold; vertical-align: middle; width: 1%"/>
    <td style="vertical-align: bottom; text-align: right; width: 1%"/>
    <td style="vertical-align: bottom; text-align: right; width: 14%"/>
    <td style="vertical-align: bottom; text-align: right; width: 1%"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center; width: 18%">Weighted-</td></tr>
  <tr>
    <td style="vertical-align: middle"/>
    <td style="vertical-align: middle"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Weighted-</td>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Average</td></tr>
  <tr>
    <td style="vertical-align: middle"/>
    <td style="vertical-align: middle"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Average</td>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Remaining</td></tr>
  <tr>
    <td style="vertical-align: middle"/>
    <td style="vertical-align: middle"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Exercise</td>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Contractual Life</td></tr>
  <tr>
    <td style="vertical-align: middle"/>
    <td style="vertical-align: middle"/>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: bottom; text-align: center">Warrants</td>
    <td style="font-weight: bold; vertical-align: bottom; text-align: center"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center">Price</td>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center">(in years)</td></tr>
  <tr style="vertical-align: middle">
    <td>Outstanding as of December 31, 2021</td>
    <td/>
    <td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pin3_c20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zVsegwJaPjd9" style="text-align: right; border-top-color: Black; border-top-width: 1pt" title="Outstanding as of December 31, 2021">2,635</td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pp2p0_uUSDPShares_c20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zk5wu7yMDzS4" style="text-align: right" title="Outstanding as of December 31, 2020, weighted-average exercise price (in usd per share)">4.29</td>
    <td style="text-align: right"/>
    <td id="xdx_98A_ecustom--ClassOfWarrantOrRightOutstandingWeightedAverageRemaingContractualLife_dtY_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zBqZIHnvaY05" style="text-align: right" title="Warrants outstanding as of December 31, 2020, weighted-average remaing contractual life (in years)">2.4</td></tr>
  <tr style="vertical-align: middle">
    <td style="text-align: left">Issued</td>
    <td style="text-align: left"/>
    <td id="xdx_98A_ecustom--NumberofWarrantsIssuedDuringPeriod_i01_pin3_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zkbEChDK2uW6" style="text-align: right" title="Issued"><span style="-sec-ix-hidden: xdx2ixbrl0670">-</span></td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_984_ecustom--ClassOfWarrantOrRightIssuedExercisePriceOfWarrantsOrRights_i01_pp0p0_uUSDPShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zFkmle9m8kN3" style="text-align: right" title="Issued, warrant exercise price"><span style="-sec-ix-hidden: xdx2ixbrl0672">-</span></td>
    <td style="text-align: right"/>
    <td style="text-align: right"/></tr>
  <tr style="vertical-align: middle">
    <td style="text-align: left">Exercised</td>
    <td style="text-align: left"/>
    <td id="xdx_98C_ecustom--NumberofWarrantsExercisedDuringPeriod_i01_pin3_uShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zi5sOrJmTFnk" style="text-align: right" title="Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0674">-</span></td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_989_ecustom--ClassOfWarrantOrRightExercisedExercisePriceOfWarrantsOrRights_i01_pp2p0_uUSDPShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zfLLDTtuHlrf" style="text-align: right" title="Exercised, exercise price of warrants"><span style="-sec-ix-hidden: xdx2ixbrl0676">-</span></td>
    <td style="text-align: right"/>
    <td style="text-align: right"/></tr>
  <tr style="vertical-align: middle">
    <td style="text-align: left">Cancelled</td>
    <td style="text-align: left"/>
    <td id="xdx_98F_ecustom--NumberofWarrantsCancelledDuringPeriod_i01_pin3_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zGfA4SCT2qse" style="text-align: right" title="Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0678">-</span></td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_98D_ecustom--ClassOfWarrantOrRightCancelledExercisePriceOfWarrantsOrRights_i01_pp0p0_uUSDPShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zgm33G3iBXg3" style="text-align: right" title="Cancelled, exercise price of warrants"><span style="-sec-ix-hidden: xdx2ixbrl0680">-</span></td>
    <td style="text-align: right"/>
    <td style="text-align: right"/></tr>
  <tr style="vertical-align: middle">
    <td>Outstanding as of March 31, 2022</td>
    <td/>
    <td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_pin3_c20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zBwytxpqO65h" style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right" title="Outstanding as of March 31, 2022">2,635</td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_pp2p0_uUSDPShares_c20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zKOF7jshxCng" style="text-align: right" title="Outstanding as of June 30, 2021, weighted-average exercise price (in usd per share)">4.29</td>
    <td style="text-align: right"/>
    <td id="xdx_98A_ecustom--ClassOfWarrantOrRightOutstandingEndOfPeriodWeightedAverageRemaingContractualLife_dtY_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zGziPPGfTX45" style="text-align: right" title="Warrants outstanding as of June 30, 2021, weighted-average remaing contractual life (in years)">2.2</td></tr>
  <tr style="vertical-align: middle">
    <td>Exercisable as of March 31, 2022</td>
    <td/>
    <td id="xdx_986_ecustom--WarrantsExercisable_iI_pin3_uShares_c20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zwWZsRDjN16d" style="border-bottom: Black 2pt double; text-align: right" title="Warrants exercisable as of March 31, 2022">2,635</td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_980_ecustom--ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights1_iI_pp2p0_uUSDPShares_c20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_ziAsCKdFiqkc" style="text-align: right" title="Exercisable, weighted-average exercise price (in usd per share)">4.29</td>
    <td style="text-align: right"/>
    <td id="xdx_98F_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageRemaingContractualLife_dtY_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zGBpwIuIP0Ue" style="text-align: right" title="Warrants exercisable as of June 30, 2021, weighted-average remaing contractual life (in years)">2.2</td></tr>
  </table>
<p id="xdx_8AA_zJWRWtXJbfXh" style="font: 9pt Sans-Serif; margin: 0 0 0 5pt; color: Red"><b>&#160;</b></p>

<p style="font: 9pt Sans-Serif; margin: 0 0 0 5pt; color: Red"><b>&#160;</b></p>

<p style="font: 9pt Sans-Serif; margin: 0 0 0 5pt; color: Red"/>

<p style="font: 10pt/103% Times New Roman, Times, Serif; margin: 0">The Series A Warrants were recognized as a liability at
their fair value upon issuance. The warrant liability is remeasured to the then fair value prior to their exercise or at period end for
warrants that are unexercised and the gain or loss recognized in earnings during the period.</p>

<p style="font: 10pt/103% Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/103% Times New Roman, Times, Serif; margin: 0 1.3pt 0 5pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332073013928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>11. Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">11. Stock-based Compensation</a></td>
<td class="text"><p id="xdx_803_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zPxW4MSS64y6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>11. Stock-based Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zT8H60SUTzZ8">The
Company has the Seelos Therapeutics, Inc. Amended and Restated 2012 Stock Long Term Incentive Plan (the &#8220;2012 Plan&#8221;), which
provides for the issuance of incentive and non-incentive stock options, restricted and unrestricted stock awards, stock unit awards and
stock appreciation rights. Options and restricted stock units granted generally vest over a period of one to four years and have a maximum
term of ten years from the date of grant. The 2012 Plan provides that an additional number of shares will automatically be added annually
to the shares authorized for issuance under the 2012 Plan on January 1st of each year commencing on January 1, 2020 and ending on (and
including) January 1, 2029. The number of shares added each year will be equal to the lesser of (a) 4% of the number of shares of common
stock issued and outstanding on a fully-diluted basis as of the close of business on the immediately preceding December 31, and (b) a
number of shares of common stock set by the Company&#8217;s board of directors on or prior to each such January 1. On January 1, 2022,
in accordance with the foregoing, an aggregate of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pn5n6_c20220101__20220131__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4ao9xz93Cyi">4,713,637</span> shares of common stock were added to shares authorized for issuance under
the 2012 Plan. As of March 31, 2022, an aggregate of </span><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pip0_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zdQ2Sv48gtEa">15,817,818
shares of common stock were authorized under the 2012 Plan, of which </span><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pin6_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjKFhUvns2bc">5.5
million shares of common stock were available for future grants. No further awards may be issued under the Seelos Therapeutics, Inc. 2016
Equity Incentive Plan (the "2016 Plan").</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span/></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20200501__20200531__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zUp64cWhap45">On May 15, 2020, the
Company&#8217;s stockholders approved the Company's 2020 Employee Stock Purchase Plan (the "ESPP"),
whereby qualified employees are allowed to purchase limited amounts of the Company&#8217;s common stock at the lesser of
<span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pip2_dp_uPure_c20200501__20200531__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zoJp2tYn9H46">85</span>% of the market price at the beginning or end of the offering period. The
stockholders have authorized an initial amount of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pn5n6_c20200515__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zkHegzw9MvS3">1.0</span> million shares for purchase by employees under the ESPP. The ESPP provides
that an additional number of shares will automatically be added annually to the shares authorized for issuance under the ESPP on
January 1st of each year commencing on January 1, 2021 and ending on (and including) January 1, 2030, which amount shall be equal to
the lesser of (i) 1% of the number of shares of the Company's common stock issued and outstanding on the immediately preceding
December 31, and (ii) a number of shares of common stock set by the Company&#8217;s Board of Directors or the Compensation
Committee of the Board of Directors (the &#8220;Compensation Committee&#8221;) of the Company on
or prior to each such January 1. On January 1, 2022, the Company added <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pn5n6_c20220101__20220131__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zGH7iOhmSb3k">1,055,004</span> shares for purchase by employees under the ESPP.
During the three months ended March 31, 2022, the Company sold <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_pip0_c20220101__20220331__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zJcZe4FXSN0g">84,078</span> shares of common
stock under the ESPP. The compensation costs are calculated as the fair value of the <span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceDiscountOfCommonStockPercent_pip2_dp_uPure_c20220101__20220331__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zFStwj24HRXj" title="Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price Discount of Common Stock, Percent">15</span>% discount from market price and were
approximately $<span id="xdx_903_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220331__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_z1KoSrVpTl92">17,000</span> for the three months ended March 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><span style="background-color: white"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220101__20220331__us-gaap--AwardTypeAxis__custom--InducementPlanof2019Member_zawA1s8R4qkl" title="Description of share-based compensation arrangement by share-based payment award">On July 28, 2019, the Compensation Committee of the Board of Directors (the &#8220;Compensation
Committee&#8221;) of the Company adopted the Seelos Therapeutics, Inc. 2019 Inducement Plan (the &#8220;2019 Inducement Plan&#8221;),
which became effective on August 12, 2019. The 2019 Inducement Plan provides for the grant of equity-based awards in the form of stock
options, stock appreciation rights, restricted stock, unrestricted stock, stock units, including restricted stock units, performance units
and cash awards, solely to prospective employees of the Company or an affiliate of the Company provided that certain criteria are met.
Awards under the 2019 Inducement Plan may only be granted to an individual, as a material inducement to such individual to enter into
employment with the Company, who (i) has not previously been an employee or director of the Company or (ii) is rehired following a bona
fide period of non-employment with the Company. The maximum number of shares available for grant under the 2019 Inducement Plan is <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pip0_c20220331__us-gaap--AwardTypeAxis__custom--InducementPlanof2019Member_zvhJBfnRuq66">1,000,000</span>
shares of the Company&#8217;s common stock. The 2019 Inducement Plan is administered by the Compensation Committee and expires on August 12, 2029.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Stock options</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">During the three months ended March 31, 2022, the Company granted
<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0p0_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__custom--IncentiveStockOptionMember_zVVs6dAihFWk" title="Options granted in period">560,605</span> incentive stock options and <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0p0_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__custom--NonQualifiedStockOptionsToEmployeesMember_znr2Krc0UUKa" title="Options granted in period">2,299,395</span> non-qualified stock options to employees with a weighted average exercise price per share
of $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2p0_uUSDPShares_c20220101__20220331__us-gaap--AwardTypeAxis__custom--IncentiveStockOptionMember_zOl2BrWfHUKl" title="Weighted-average exercise price per share granted in period">1.46</span> and a <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_pp0p0_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__custom--IncentiveStockOptionMember_zaImMXrXhdOl" title="Term of option grant">10</span>-year term, subject to the terms and conditions of the 2012 Plan above. The stock options are subject to time vesting
requirements. The stock options granted to employees vest <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pip2_c20220101__20220331__us-gaap--AwardTypeAxis__custom--IncentiveStockOptionMember_zx9Dyvwck5pa" title="Vesting percentage on the first anniversary">25</span>% on the first anniversary of the grant and monthly thereafter over the next
three years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">During the three months ended March 31, 2022, the
Company also granted <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0p0_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__custom--NonQualifiedStockOptionsToNonEmployeeDirectorsMember_z1Zwg0sFYz99">140,000 </span>non-qualified
stock options to non-employee directors with a weighted average exercise price per share of $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2p0_uUSDPShares_c20220101__20220331__us-gaap--AwardTypeAxis__custom--NonQualifiedStockOptionsToNonEmployeeDirectorsMember_zp3VakZFQ9F">1.56 </span>and
a <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_pp0p0_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__custom--NonQualifiedStockOptionsToNonEmployeeDirectorsMember_zFaVzYOqJVUa">10</span>-year
term, subject to the terms and conditions of the 2012 Plan above. The stock options granted to non-employee directors vest monthly over the
<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_pp0p0_dtM_c20220101__20220331__us-gaap--AwardTypeAxis__custom--NonQualifiedStockOptionsToNonEmployeeDirectorsMember_zxzxaNj5aR9k">12</span> months following the grant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The fair value of stock option grants are estimated on the date
of grant using the Black-Scholes option-pricing model. The Company was historically a private company and lacked sufficient company-specific
historical and implied volatility information. Therefore, it estimates its expected stock volatility based on a weighted average blend
of the historical volatility of a publicly traded set of peer companies, as well as its own historical volatility. Additionally, due to
an insufficient history with respect to stock option activity and post-vesting cancellations, the expected term assumption for employee
grants is based on a permitted simplified method, which is based on the vesting period and contractual term for each tranche of awards.
The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect for time periods approximately equal
to the expected term of the award. Expected dividend yield is zero based on the fact that the Company has never paid cash dividends and
does not expect to pay any cash dividends in the foreseeable future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">During the three months ended March 31, 2022, <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pip0_c20220101__20220331_ztCw3kiZyTyi" title="Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period">6,250</span> stock options were exercised
and <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_pip0_do_c20220101__20220331_zkHYkvCv4GW4">no</span> options were  forfeited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zXhvmmQk8jQ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following assumptions were used in determining the fair value
of the stock options granted during the three months ended March 31, 2022 and 2021:</p>

<p id="xdx_8BF_zXfcPsXzw2Jd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; display: none">Schedule of Valuation Assumptions for Stock Options</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 9pt Sans-Serif; margin: 0 0 0 4.5pt; text-align: center; color: Red"><b>&#160;</b></p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: middle">
    <td/>
    <td style="font-size: 9pt; font-weight: bold; text-align: right"/>
    <td style="font-size: 9pt; font-weight: bold; text-align: right"/>
    <td colspan="4" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">Three Months Ended</td></tr>
  <tr style="vertical-align: middle">
    <td style="width: 56%"/>
    <td style="font-size: 9pt; font-weight: bold; text-align: right; width: 1%"/>
    <td style="text-align: right; width: 2%"/>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center; width: 19%">March 31, 2022</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center; width: 19%">March 31, 2021</td></tr>
  <tr style="vertical-align: middle">
    <td>Risk-free interest rate</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: right"/>
    <td style="text-align: right"/>
    <td style="text-align: center; border-top-color: Black; border-top-width: 1pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjtVcCqUpHQ1" title="Risk-free interest rate, minimum">1.5</span>%
    - <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYRJR2d5QdVk" title="Risk-free interest rate, maximum">1.6</span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center; vertical-align: middle"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zzOjUAmjsxFc" title="Risk-free interest rate, minimum">0.5</span>%
    - <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgvlFJ1D99X1" title="Risk-free interest rate, maximum">0.9</span>%</td></tr>
  <tr style="vertical-align: middle">
    <td>Volatility</td>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td style="text-align: center"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip2_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztiOBv52Qkt2" title="Volatility, minimum">113</span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center; vertical-align: middle"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pip2_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zHkgqet06Yf6" title="Volatility, minimum">120</span>%-<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pip2_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zOpmEyP1jL0f" title="Volatility, maximum">125</span>%</td></tr>
  <tr style="vertical-align: middle">
    <td>Dividend yield</td>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td style="text-align: center"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEwBPf3fS8Bg" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0744">-</span></span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zeyq7EuVL3tf" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0746">-</span></span>%</td></tr>
  <tr style="vertical-align: middle">
    <td>Expected term (years)</td>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td style="text-align: center"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zQuqEZf1Nqbg" title="Expected term (in years)">5</span>
    - <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zuyt1YNTp7zd" title="Expected term (in years)">6</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zd2w1SirpE4l" title="Expected term (in years)">5</span>
    - <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zEq8Wb9zgTbh" title="Expected term (in years)">6</span></td></tr>
  <tr style="vertical-align: middle">
    <td>Weighted-average fair value</td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pp2p0_uUSDPShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zSTQ5fbDjrb1" title="Weighted average fair value">1.24
    - <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pp2p0_uUSDPShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zVxJYCH0CCqe">1.27</span></span></td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: middle">$</td>
    <td style="text-align: center; vertical-align: middle"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pp2p0_uUSDPShares_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUyqXX23Gjzl">3.62</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
<p id="xdx_8A8_zYZBcd45wDAk" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_896_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zHoecFH9CL2f" style="font: 10pt Times New Roman, Times, Serif; margin: 0">A summary of stock option activity during the three months ended
March 31, 2022 is as follows (share amounts in thousands):</p>

<p id="xdx_8B1_z61dgi5nD0Y" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; display: none">Summary of Stock Option Activity</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: middle; width: 50%"/>
    <td style="vertical-align: middle; width: 1%"/>
    <td style="font-weight: bold; vertical-align: middle; width: 10%"/>
    <td style="vertical-align: middle; width: 1%"/>
    <td style="vertical-align: bottom; text-align: right; width: 1%"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center; width: 10%"/>
    <td style="vertical-align: middle; width: 1%"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center; width: 14%">Weighted-</td>
    <td style="vertical-align: middle; width: 1%"/>
    <td style="vertical-align: bottom; text-align: right; width: 1%"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center; width: 10%"/></tr>
  <tr>
    <td style="vertical-align: middle"/>
    <td style="vertical-align: middle"/>
    <td style="font-weight: bold; vertical-align: middle"/>
    <td style="vertical-align: middle"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Weighted-</td>
    <td style="vertical-align: middle"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Average</td>
    <td style="vertical-align: middle"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Total</td></tr>
  <tr>
    <td style="vertical-align: middle"/>
    <td style="vertical-align: middle"/>
    <td style="font-weight: bold; vertical-align: middle"/>
    <td style="vertical-align: middle"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Average</td>
    <td style="vertical-align: middle"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Remaining</td>
    <td style="vertical-align: middle"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Aggregate</td></tr>
  <tr>
    <td style="vertical-align: middle"/>
    <td style="vertical-align: middle"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Stock</td>
    <td style="vertical-align: middle"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Exercise</td>
    <td style="vertical-align: middle"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Contractual</td>
    <td style="vertical-align: middle"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Intrinsic</td></tr>
  <tr>
    <td style="vertical-align: middle"/>
    <td style="vertical-align: middle"/>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: bottom; text-align: center">Options</td>
    <td style="vertical-align: middle"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center">Price</td>
    <td style="vertical-align: middle"/>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center">Life (in years)</td>
    <td style="vertical-align: middle"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center">Value</td></tr>
  <tr style="vertical-align: middle">
    <td>Outstanding as of December 31, 2021</td>
    <td/>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pin3_uShares_c20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z8DRlDoteBmd" style="text-align: right" title="Outstanding as of December 31, 2020">7,306</td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2p0_uUSDPShares_c20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNRFCa6nzHZd" style="text-align: right; border-top-color: Black; border-top-width: 1pt" title="Outstanding, beginning of period (USD per share)">2.60</td>
    <td/>
    <td style="text-align: right; border-top-color: Black; border-top-width: 1pt"/>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td style="text-align: right"/></tr>
  <tr style="vertical-align: middle">
    <td>Granted</td>
    <td/>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pin3_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjcI84J2YaBi" style="text-align: right" title="Granted">3,000</td>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2p0_uUSDPShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ziUtgz9WNN99" style="text-align: right" title="Granted in period (USD per share)">1.47</td>
    <td/>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td style="text-align: right"/></tr>
  <tr style="vertical-align: middle">
    <td>Exercised</td>
    <td/>
    <td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pin3_di_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUYz51vmAwA8" style="text-align: right" title="Exercised">(6)</td>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmPS2631gQh6" style="text-align: right" title="Exercised in period (USD per share)">1.06</td>
    <td/>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td style="text-align: right"/></tr>
  <tr style="vertical-align: middle">
    <td style="text-align: left">Cancelled</td>
    <td style="text-align: left"/>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pin3_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zR6cDFUfPZ4f" style="border-bottom: Black 1pt solid; text-align: right" title="Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0774">-</span></td>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_d0_uUSDPShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjgUGQ9a3OD9" style="text-align: right" title="Cancelled (USD per share)">-</td>
    <td/>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td style="text-align: right"/></tr>
  <tr style="vertical-align: middle">
    <td>Outstanding as of March 31, 2022</td>
    <td/>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pin3_uShares_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zuKMgdCfnJY4" style="border-bottom: Black 2pt double; text-align: right" title="Outstanding as of March 31, 2022">10,300</td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pp2p0_uUSDPShares_c20220331_z3GPMX9yPIuc" style="border-bottom: Black 2pt double; text-align: right" title="Outstanding, end of period (USD per share)">2.27</td>
    <td/>
    <td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zne43COO2mHl" style="text-align: right" title="Outstanding - weighted-average remaining contractual life (in years)">8.7</td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_uUSD_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zFOhlb7tS3V3" style="border-bottom: Black 2pt double; text-align: right" title="Total aggregate intrinsic value shares outstanding">2,894</td></tr>
  <tr style="vertical-align: middle">
    <td>Vested and expected to vest as of March 31, 2022</td>
    <td/>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pin3_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zabB3u9YKS3b" style="border-bottom: Black 2pt double; text-align: right" title="Vested and expected to vest, end of period (shares)">10,300</td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pp2p0_d0_uUSDPShares_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1gIUcwcNnGd" style="border-bottom: Black 2pt double; text-align: right" title="Vested and expected to vest stock, end of period (USD per share)">2.27</td>
    <td/>
    <td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zeDcxxvpPvAk" style="text-align: right" title="Weighted-average remaining contractual life (in years) of vested and expected to vest stock options">8.7</td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_pn3n3_uUSD_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYGOnPpxeAr9" style="border-bottom: Black 2pt double; text-align: right" title="Total aggregate intrinsic value of vested or expected to vest stock options">2,894</td></tr>
  <tr style="vertical-align: middle">
    <td>Exercisable as of March 31, 2022</td>
    <td/>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pin3_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1xJhUmnf5ve" style="border-bottom: Black 2pt double; text-align: right" title="Exercisable, end of period (shares)">3,085</td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pp2p0_d0_uUSDPShares_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zT2olXBumqNh" style="border-bottom: Black 2pt double; text-align: right" title="Exercisable, end of period (USD per share)">3.00</td>
    <td/>
    <td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjVD2HF0t2Be" style="text-align: right" title="Weighted-average remaining contractual life (in years) of exercisable stock options">8.1</td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_uUSD_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQC6bN4xDEB3" style="border-bottom: Black 2pt double; text-align: right" title="Total aggregate intrinsic value of exercisable stock options">2,894</td></tr>
  </table>

<p style="font: 9pt Sans-Serif; margin: 0"/>

<p id="xdx_8AF_zcrDRY3Pdsx" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The intrinsic value of options exercised during the three months ended
March 31, 2022 and 2021 was $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pn5n6_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaEw0FmMIJl3">0.1</span> million and $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zj1hJ44u2uX6">0</span>, respectively. As of March 31, 2022, unrecognized stock-option compensation expense of
$<span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zLYM7LhCg7Tk">10.2</span> million is expected to be realized over a weighted-average period of <span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_pid_dtY_uYears_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQ3ID0rWSzO">2.6</span> years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Performance Stock Award</i></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_pip0_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__us-gaap--PlanNameAxis__custom--PSUtoExecutivesMember_znt4Em1nKwp8">During the year
ended December 31, 2021, the Company&#8217;s Board of Directors awarded a performance stock unit award to the Company&#8217;s Chief Executive
Officer for <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pp0p0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__us-gaap--PlanNameAxis__custom--PSUtoExecutivesMember_zcXiSQnQOTTa">2,400,000</span> shares of common stock, with a grant date fair value of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pp2p0_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__us-gaap--PlanNameAxis__custom--PSUtoExecutivesMember_zlAQCD3CEaqi">4.31</span> per unit. Vesting of this award was subject to the
Company achieving certain performance criteria established at the grant date and the individual fulfilling a service condition (continued
employment). As of December 31, 2021, all performance stock unit awards were unvested and three of the five performance conditions had
been satisfied. The Company recognized stock-based compensation related to this award of $<span id="xdx_904_eus-gaap--ShareBasedCompensation_pn5n6_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__us-gaap--PlanNameAxis__custom--PSUtoExecutivesMember_zIRnh2jKais5">4.9</span> million during the fourth quarter of 2021,
which was recorded in general and administrative expense. During the three months ended March 31, 2022, the Company and its Chief Executive
Officer entered into an agreement to cancel the performance stock unit award for no consideration. In connection with the cancellation
of the award, no replacement awards were granted or authorized. At the time of cancellation, the Company recognized the remaining compensation
expense of the three achieved milestones of $<span id="xdx_902_eus-gaap--ShareBasedCompensation_pn5n6_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__us-gaap--PlanNameAxis__custom--PSUtoExecutivesMember_zHyonyr7eJYh">1.3</span> million. The two remaining milestones were not deemed probable of achievement at the
time of cancellation, and <span id="xdx_907_ecustom--SharebasedPaymentArrangementNonvestedAndCanceledAwardExcludingOptionCostNotYetRecognizedAmount_iI_pn5n6_do_c20220331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__us-gaap--PlanNameAxis__custom--PSUtoExecutivesMember_z1LdYCnnz1ge" title="Share-Based Payment Arrangement, Nonvested and Canceled  Award, Excluding Option, Cost Not yet Recognized, Amount">no</span> compensation cost related to these milestones was recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_89C_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zKedatNYpX1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes the total stock-based compensation
expense resulting from share-based awards recorded in the Company&#8217;s condensed consolidated statements of operations (in thousands):</p>

<p id="xdx_8B8_zeKdjKdluhy2" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; display: none">Schedule of Stock-Based Compensation Expense</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: middle; background-color: white"/>
    <td style="vertical-align: middle; background-color: white"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td colspan="4" style="font-weight: bold; vertical-align: middle; text-align: center; background-color: white">Three Months Ended</td>
    </tr>
  <tr>
    <td style="vertical-align: middle; background-color: white"/>
    <td style="vertical-align: middle; background-color: white"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td colspan="4" style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white">March
    31,</td>
    </tr>
  <tr>
    <td style="vertical-align: middle; background-color: white; width: 64%"/>
    <td style="vertical-align: middle; background-color: white; width: 2%"/>
    <td style="vertical-align: bottom; text-align: right; width: 2%"/>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; background-color: white; width: 14%">2022</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; background-color: white; width: 2%"/>
    <td style="vertical-align: middle; border-top-color: Black; border-top-width: 1pt; background-color: white; width: 2%"/>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; background-color: white; width: 14%">2021</td>
    </tr>
  <tr style="vertical-align: middle">
    <td style="background-color: white">Research and development</td>
    <td style="text-align: right; background-color: white"/>
    <td style="text-align: right">$</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20220101__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zXHbP0LPHD75" style="text-align: right; border-top-color: Black; border-top-width: 1pt" title="Stock-based compensation expense">229</td>
    <td style="text-align: right; background-color: white"/>
    <td style="text-align: right">$</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensation_pn3n3_c20210101__20210331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zumQzKkXYS4" style="text-align: right; border-top-color: Black; border-top-width: 1pt" title="Stock-based compensation expense">136</td>
    </tr>
  <tr style="vertical-align: middle">
    <td style="background-color: white">General and administrative</td>
    <td style="text-align: right; background-color: white"/>
    <td style="text-align: right"/>
    <td id="xdx_981_eus-gaap--ShareBasedCompensation_pn3n3_c20220101__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zrYJ3d2q7vEb" style="border-bottom: Black 1pt solid; text-align: right" title="Stock-based compensation expense">2,003</td>
    <td style="text-align: right; background-color: white"/>
    <td style="text-align: right"/>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensation_pn3n3_c20210101__20210331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zoTjvJL1STs" style="border-bottom: Black 1pt solid; text-align: right" title="Stock-based compensation expense">569</td>
    </tr>
  <tr style="vertical-align: middle">
    <td style="text-align: left; background-color: white"/>
    <td style="text-align: right; background-color: white"/>
    <td style="text-align: right; background-color: white">$</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensation_pn3n3_c20220101__20220331_z581oqWEPrX7" style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 1pt; background-color: white" title="Stock-based compensation expense">2,232</td>
    <td style="text-align: right; background-color: white"/>
    <td style="text-align: right; background-color: white">$</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensation_pn3n3_c20210101__20210331_zkwVMYZ826Tj" style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 1pt" title="Stock-based compensation expense">705</td>
    </tr>
  </table>

<p id="xdx_8AE_z8btxmdDkg6j" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332072974696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>12. Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">12. Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_806_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_znk0rKaHgAr3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>12. Commitments and Contingencies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Leases</i></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> <span id="xdx_901_eus-gaap--LesseeOperatingLeaseDescription_c20220101__20220331__us-gaap--LeaseContractualTermAxis__custom--March2019LeaseMember_zriNh3bpV4uf">In March 2019, the Company entered into a nine-month
office space rental agreement for its headquarters in New York, New York expiring November 2019. In November 2019, the Company renewed
this rental agreement for an additional twelve-months for a base rent of approximately $9,000 per month. In November 2020, the Company
renewed this rental agreement for an additional twelve-months for a base rent of approximately $3,800 per month. In March 2021, the Company
was notified that the counterparty&#8217;s right to occupy the space at 300 Park Avenue, New York, NY was terminated, and the Company
was required to vacate by March 26, 2021. The Company vacated the premises and has advised the counterparty that the counterparty is
in breach of this rental agreement and therefore, the Company has no further obligations thereunder.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_90A_eus-gaap--LesseeOperatingLeaseDescription_c20220101__20220331__us-gaap--LeaseContractualTermAxis__custom--March2021LeaseMember_ziUcNfJIbdQb" title="Operating lease description">In
March 2021, the Company entered into an eighteen-month office space rental agreement for its headquarters at 300 Park Avenue, New
York, NY, expiring July 2022. The rental agreement contains a base rent of approximately $4,000 per month. <span id="xdx_90F_eus-gaap--LesseeOperatingLeaseOptionToExtend_c20220101__20220331__us-gaap--LeaseContractualTermAxis__custom--March2021LeaseMember_zWmTXmfaFl1g" title="Option to extend">This
agreement includes one or more renewal options.</span> At March 31, 2022, the Company has right-of-use
assets of $<span id="xdx_901_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20220331__us-gaap--LeaseContractualTermAxis__custom--March2021LeaseMember_zQC2hitgpqf" title="Operating lease right-of-use asset">26,000</span> and a total lease liability for operating leases of $<span id="xdx_90F_eus-gaap--OperatingLeaseLiability_iI_pp0p0_c20220331__us-gaap--LeaseContractualTermAxis__custom--March2021LeaseMember_ze3OVgtIekhd" title="Operating lease liabilities"><span id="xdx_90D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20220331__us-gaap--LeaseContractualTermAxis__custom--March2021LeaseMember_zVlDaNdhQ1x9" title="Operating lease liabilities - current">26,000</span></span>, of which all
is included in current lease liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span title="Operating lease description">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Upon the commencement of the 300 Park Avenue,
New York, NY office space in March 2021, in exchange for the new operating lease liability, the Company recognized a right-of-use asset
of $<span id="xdx_90D_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20210331__us-gaap--LeaseContractualTermAxis__custom--March2021LeaseMember_zTvUV6UY4vjc">74,000</span>. As March 31, 2022, the weighted-average remaining lease term of the operating lease is <span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_pp0p0_dtY_c20220331_zVN3OsRf62Xa">0.5</span> years, and the weighted-average
discount rate is <span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pp0p0_uPure_c20220331_zN4GUt3lI1R">8.0</span>%.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"/>

<p id="xdx_89B_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_zXhLn9nS7Ama" style="font: 10pt Times New Roman, Times, Serif; margin: 0">At March 31, 2022, future minimum lease payments for operating
leases with non-cancelable terms of more than one year were as follows (in thousands):</p>

<p id="xdx_8BF_z1KRk18BYi8c" style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; display: none">Schedule of future minimum operating lease payments</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 79%"/>
    <td style="width: 2%"/>
    <td style="width: 2%"/>
    <td id="xdx_498_20220331_zXO3vxfsGvva" style="font-weight: bold; text-align: center; width: 17%">Operating</td></tr>
  <tr style="vertical-align: bottom">
    <td/>
    <td/>
    <td/>
    <td style="border-bottom: Black 0.5pt solid; font-weight: bold; text-align: center">Leases</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_maLOLLPz53j_zrpgG7zHWwA3" style="vertical-align: bottom">
    <td>Remaining Period Ended December 31, 2022</td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td style="text-align: right">27</td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_i01TI_pn3n3_mtLOLLPz53j_zQwz4jjjjnJc" style="vertical-align: bottom">
    <td style="text-indent: 10pt">Total</td>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td style="border-top: Black 0.5pt solid; text-align: right">27</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_i01NI_pn3n3_di_maOLLzeMS_zz6HdRwECwrl" style="vertical-align: bottom">
    <td>Less present value discount</td>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td style="text-align: right">(1)</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_mtOLLzeMS_zuijHUAWEMd6" style="vertical-align: bottom">
    <td>Operating lease liabilities</td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td style="border-top: Black 0.5pt solid; border-bottom: Black 2pt double; text-align: right">26</td></tr>
  </table>

<p style="font: 9pt Sans-Serif; margin: 0 5.85pt 0 5pt; text-align: left; color: Red"/>

<p id="xdx_8A6_zLVHyMAiaLE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">For each of the three months ended March 31, 2022 and 2021, rent expense
totaled <span style="background-color: White">$<span id="xdx_902_eus-gaap--OperatingLeaseExpense_pn5n6_c20210101__20210331_zTnyklpw4w2g"><span id="xdx_90B_eus-gaap--OperatingLeaseExpense_pn5n6_c20220101__20220331_z8svIwns85J2">0.1</span>
</span></span><span style="background-color: White">million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="background-color: White">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Contractual Commitments</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company has entered into long-term agreements with certain
manufacturers and suppliers that require it to make contractual payment to these organizations. The Company expects to enter into additional
collaborative research, contract research, manufacturing, and supplier agreements in the future, which may require up-front payments and
long-term commitments of cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Litigation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of March 31, 2022, there was no material litigation against
or involving the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332072975816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>13. Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">13. Subsequent Events</a></td>
<td class="text"><p id="xdx_803_eus-gaap--SubsequentEventsTextBlock_zcuUSist3ril" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>13. Subsequent
Events</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_90F_eus-gaap--BusinessCombinationSeparatelyRecognizedTransactionsDescription_c20220401__20220429__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zT3AHb1H6LVe">On April 8, 2022,
Seelos Corporation (&#8220;STI&#8221;), a wholly-owned subsidiary of the Company, and Phoenixus AG f/k/a Vyera Pharmaceuticals AG (&#8220;Vyera&#8221;),
entered into an amendment (the &#8220;Amendment&#8221;) to the Asset Purchase Agreement by and between STI and Vyera, dated March 6, 2018
(as amended by a first amendment thereto entered into on May 18, 2018, a second amendment thereto entered into on December 31, 2018, a
third amendment thereto entered into on October 15, 2019 and a fourth amendment thereto entered into on February 15, 2021, the &#8220;Vyera
Purchase Agreement&#8221;). Pursuant to the Vyera Purchase Agreement, STI acquired the assets and liabilities of Vyera related to a product
candidate currently referred to as SLS-002 (intranasal ketamine) (the &#8220;Vyera Assets&#8221;) and agreed, among other things, to make
certain development and commercialization milestone payments and royalty payments related to the Vyera Assets (the &#8220;Milestone and
Royalty Payment Obligations&#8221;) and further agreed that in the event that the Company sold, directly or indirectly, all or substantially
all of the Vyera Assets to a third party, then the Company would pay Vyera an amount equal to 4% of the net proceeds actually received
by the Company as an upfront payment in such sale (the &#8220;Change of Control Payment Obligation&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_902_eus-gaap--SubsequentEventDescription_c20220401__20220430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z2aZd5GJHmra">Pursuant
to the Vyera Purchase Agreement, as amended by the Amendment, STI agreed to (i) make a cash payment to Vyera in the aggregate amount
of $<span id="xdx_90C_ecustom--CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement_pn5n6_c20220401__20220430__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zdTkXpwtEtlb">4.0</span>
million on or before April 8, 2022; (ii) issue to Vyera on or before April 11, 2022 <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20220401__20220430__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zfEH9dWjQrk4">500,000</span>
shares of the Company&#8217;s common stock, (the &#8220;Initial Shares&#8221;); (iii) issue to Vyera on or before July 11, 2022 an
additional <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20220701__20220711__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zaysRv0Dcs62">500,000</span>
shares of the Company&#8217;s common stock (as adjusted for stock splits, stock dividends, combinations, recapitalizations and the
like) (the &#8220;July 2022 Shares&#8221;); and (iv) issue to Vyera on or before January 11, 2023 an additional number of shares of
the Company&#8217;s common stock equal to $1.0 million divided by the volume weighted average closing price of the Company&#8217;s
common stock for the ten consecutive trading days ending on the fifth trading day prior to the applicable date of issuance of the
shares of the Company&#8217;s common stock (the &#8220;January 2023 Shares&#8221;, and together with the Cash Payment, the Initial
Shares and the July 2022 Shares, &#8220;Final Payments&#8221;). In consideration for the Final Payments, all of STI&#8217;s
contingent payment obligations under the Vyera Purchase Agreement, including the Milestone and Royalty Payment Obligations and the
Change of Control Payment Obligation, as well as all commercialization covenants of STI under the Vyera Purchase Agreement, will
terminate in full upon the date that all of the Final Payments have been made.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company paid
the $<span id="xdx_901_ecustom--CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement_pn5n6_c20220401__20220430__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z5kGY96KKRRh">4.0</span> million cash payment and issued the <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20220401__20220430__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zDHHdb34L2Mg">500,000</span> Initial Shares to Vyera in April 2022.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332068757688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>3. Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zp2emxigUS7i" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify; text-indent: -0.5pt"><b><i>Basis of Presentation
</i></b></p>

<p style="font: 13.5pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify; text-indent: -0.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 5pt">The accompanying unaudited interim condensed consolidated financial
statements should be read in conjunction with the audited financial statements and notes thereto as of and for the year ended December
31, 2021 included in the Company&#8217;s Annual Report on Form 10-K (the &#8220;Annual Report&#8221;) filed with the SEC on March 4, 2022.
The accompanying financial statements have been prepared by the Company in accordance with United States generally accepted accounting
principles (&#8220;U.S. GAAP&#8221;) for interim financial information and in accordance with the instructions to Form 10-Q and Article
10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in
accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, the accompanying unaudited condensed consolidated
financial statements for the periods presented reflect all adjustments, consisting of only normal, recurring adjustments, necessary to
fairly state the Company&#8217;s financial position, results of operations and cash flows. The December 31, 2021 condensed consolidated
balance sheet was derived from audited financial statements, but it does not include all U.S. GAAP disclosures. The unaudited condensed
consolidated financial statements for the interim periods are not necessarily indicative of results for the full year. The preparation
of these unaudited condensed consolidated financial statements requires the Company to make estimates and judgments that affect the amounts
reported in the financial statements and the accompanying notes. The Company&#8217;s actual results may differ from these estimates under
different assumptions or conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>



<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_848_eus-gaap--UseOfEstimates_zsG5uQdUXm5h" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify; text-indent: -0.5pt"><b><i>Use of Estimates</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt">The preparation of financial statements in conformity with U.S. GAAP requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets
and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant
estimates in the Company&#8217;s financial statements relate to the valuation of warrants, valuation of convertible notes payable, and
the valuation of stock options. These estimates and assumptions are based on current facts, historical experience and various other factors
believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values
of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially
and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s
future results of operations will be affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"><span style="font-weight: normal">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text"><p id="xdx_840_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zjtmXpmZ5WGe" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: left"><i>Fair Value Measurements</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">The Company
follows the accounting guidance in the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;)
Topic 820, Fair Value Measurements and Disclosures (&#8220;ASC 820&#8221;), for its fair value measurements of financial assets and liabilities
measured at fair value on a recurring basis. Under this accounting guidance, fair value is defined as an exit price, representing the
amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at
the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants
would use in pricing an asset or a liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">The accounting
guidance requires fair value measurements be classified and disclosed in one of the following three categories:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">Level 1: Quoted
prices in active markets for identical assets or liabilities. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">Level 2: Observable
inputs other than Level 1 prices, for similar assets or liabilities that are directly or indirectly observable in the marketplace.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">Level 3: Unobservable
inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing
models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires
significant judgment or estimation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">The fair value
hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring
fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is
significant to the fair value measurement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify; text-indent: -0.5pt"><b><i>Fair Value Option</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">As permitted
under FASB ASC Topic 825, Financial Instruments (&#8220;ASC 825&#8221;), the Company elected the fair value option to account for its
November 2021 and December 2021 convertible notes (collectively, the &#8220;2021 Convertible Notes&#8221;). In accordance with ASC 825,
the Company records these convertible notes at fair value with changes in fair value recorded in the Consolidated Statement of Operations
and Comprehensive Loss. As a result of applying the fair value option, direct costs and fees related to the convertible notes were expensed
as incurred and were not deferred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"/>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Compensation</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zylUSVrXTDr3" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"><i>Stock-based Compensation</i></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="font-weight: normal"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"><span style="font-weight: normal">The Company
expenses stock-based compensation to employees, non-employees and board members over the requisite service period based on the estimated
grant-date fair value of the awards and forfeitures rates. The Company accounts for forfeitures as they occur. Stock-based awards with
graded-vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion
of the award. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions
used in calculating the fair value of stock-based awards represent management&#8217;s best estimates and involve inherent uncertainties
and the application of management&#8217;s judgment. All stock-based compensation costs are recorded in general and administrative or research
and development costs in the statements of operations based upon the underlying individual&#8217;s role at the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="font-weight: normal">Performance
share awards are initially valued based on the Company&#8217;s closing stock price on the date of grant. The number of performance share
awards that vest will be determined based on the achievement of specified performance milestones by the end of the performance period.
Compensation expense for performance awards is recognized over the service period and will vary based on remeasurement during the performance
period. If achievement of the performance milestone is not probable of achievement during the performance period, compensation expense
is reversed.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="font-weight: normal"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>&#160;</i></b></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_zJOg7I8WZ1Vg" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>Net Loss Per Share</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Basic loss per share is computed by dividing net loss applicable
to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share
includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, warrants, performance-based
restricted stock unit awards and stock options that would result in the issuance of incremental shares of common stock. In computing the
basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both
calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>




<p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zKQMCpo58Tdj" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">The following potentially dilutive securities outstanding for
the three months ended March 31, 2022 and 2021 have been excluded from the computation of diluted weighted average shares outstanding,
as they would be anti-dilutive (in thousands):</p>

<p id="xdx_8BF_z66xDxRI5f8d" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; display: none">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: middle"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center"/>
    <td colspan="4" style="font-weight: bold; vertical-align: middle; text-align: center">Three Months</td></tr>
  <tr>
    <td style="vertical-align: middle"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center"/>
    <td colspan="4" style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center">Ended March
    31,</td></tr>
  <tr>
    <td style="vertical-align: middle; width: 62%"/>
    <td style="vertical-align: bottom; text-align: right; width: 2%"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center; width: 2%"/>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; width: 15%">2022</td>
    <td style="vertical-align: bottom; text-align: right; width: 2%"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center; width: 2%"/>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; width: 15%">2021</td></tr>
  <tr style="vertical-align: middle">
    <td>Outstanding stock options</td>
    <td/>
    <td style="text-align: right"/>
    <td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zCScnnyODifk" style="text-align: right; border-top-color: Black; border-top-width: 1pt" title="Outstanding stock options">10,299</td>
    <td/>
    <td style="text-align: right"/>
    <td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zsdriRbP2xd" style="text-align: right; border-top-color: Black; border-top-width: 1pt" title="Outstanding stock options">7,204</td></tr>
  <tr style="vertical-align: middle">
    <td>Restricted stock units</td>
    <td/>
    <td style="text-align: right"/>
    <td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zrW6jSAzEgae" style="text-align: right" title="Restricted stock units"><span style="-sec-ix-hidden: xdx2ixbrl0405">-</span></td>
    <td/>
    <td style="text-align: right"/>
    <td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zqlk7NWOoQwk" style="text-align: right" title="Restricted stock units">2,400</td></tr>
  <tr style="vertical-align: middle">
    <td>Outstanding warrants</td>
    <td/>
    <td style="text-align: right"/>
    <td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zIvMtG3p7Qs6" style="text-align: right" title="Outstanding warrants">2,635</td>
    <td/>
    <td style="text-align: right"/>
    <td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zQSQ9Fb0Dxvj" style="text-align: right" title="Outstanding Warrants">3,920</td></tr>
  <tr style="vertical-align: middle">
    <td>Convertible debt</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_z5VuN4C7Qug9" style="text-align: right">3,704</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zUWQoM64cIZd" style="text-align: right">5,326</td></tr>
  <tr>
    <td style="vertical-align: middle"/>
    <td style="vertical-align: middle; text-align: right"/>
    <td style="vertical-align: middle; text-align: right"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="vertical-align: middle; text-align: right"/>
    <td style="vertical-align: middle; text-align: right"/>
    <td style="vertical-align: bottom; text-align: right"/></tr>
  <tr>
    <td style="vertical-align: middle"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="vertical-align: middle; text-align: right"/>
    <td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_i01_pin3_c20220101__20220331_zIrNJ5WBdVL7" style="border-top: Black 1pt solid; border-bottom: Black 2pt double; vertical-align: middle; text-align: right" title="Antidilutive securities excluded">16,638</td>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="vertical-align: middle; text-align: right"/>
    <td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_i01_pin3_c20210101__20210331_zKMlPxi5SVke" style="border-top: Black 1pt solid; border-bottom: Black 2pt double; vertical-align: middle; text-align: right" title="Antidilutive securities excluded">18,850</td></tr>
  </table>

<p id="xdx_8A9_zKZPpjg80Pv8" style="font: 9pt Sans-Serif; margin: 0 0 0 4.5pt; color: Red"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Amounts in the table reflect the common stock equivalents of
the noted instruments.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: left">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zrTAZ4Okgtok" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left">Recent Accounting Pronouncements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: justify"><span style="font-weight: normal"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">In August 2020, the FASB issued Accounting Standards Update
(&#8220;ASU&#8221;) No. 2020-06: Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging
&#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an
Entity&#8217;s Own Equity (&#8220;ASU 2020-06&#8221;). This standard simplifies the accounting for convertible debt instruments by
removing the separation models for convertible debt with a cash conversion feature, as well as convertible instruments with a
beneficial conversion feature. As a result, entities will account for a convertible debt instrument wholly as debt, unless certain
other conditions are met. The elimination of these models will reduce non-cash interest expense for entities that have issued a
convertible instrument that was within the scope of those models before the adoption of ASU 2020-06. Additionally, ASU 2020-06
requires the application of the if-converted method for calculating diluted earnings per share and precludes the use of the treasury
stock method for certain debt instruments. The provisions of ASU 2020-06 are applicable for the Company beginning after January 1,
2024, with early adoption permitted, and an entity should adopt the provisions at the beginning of its annual fiscal year. The
Company does not expect the adoption of ASU 2020-06 to have an impact on its consolidated financial statements and related
disclosures.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: justify"/>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332074602488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>3. Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zKQMCpo58Tdj" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">The following potentially dilutive securities outstanding for
the three months ended March 31, 2022 and 2021 have been excluded from the computation of diluted weighted average shares outstanding,
as they would be anti-dilutive (in thousands):</p>

<p id="xdx_8BF_z66xDxRI5f8d" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; display: none">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: middle"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center"/>
    <td colspan="4" style="font-weight: bold; vertical-align: middle; text-align: center">Three Months</td></tr>
  <tr>
    <td style="vertical-align: middle"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center"/>
    <td colspan="4" style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center">Ended March
    31,</td></tr>
  <tr>
    <td style="vertical-align: middle; width: 62%"/>
    <td style="vertical-align: bottom; text-align: right; width: 2%"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center; width: 2%"/>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; width: 15%">2022</td>
    <td style="vertical-align: bottom; text-align: right; width: 2%"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center; width: 2%"/>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; width: 15%">2021</td></tr>
  <tr style="vertical-align: middle">
    <td>Outstanding stock options</td>
    <td/>
    <td style="text-align: right"/>
    <td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zCScnnyODifk" style="text-align: right; border-top-color: Black; border-top-width: 1pt" title="Outstanding stock options">10,299</td>
    <td/>
    <td style="text-align: right"/>
    <td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zsdriRbP2xd" style="text-align: right; border-top-color: Black; border-top-width: 1pt" title="Outstanding stock options">7,204</td></tr>
  <tr style="vertical-align: middle">
    <td>Restricted stock units</td>
    <td/>
    <td style="text-align: right"/>
    <td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zrW6jSAzEgae" style="text-align: right" title="Restricted stock units"><span style="-sec-ix-hidden: xdx2ixbrl0405">-</span></td>
    <td/>
    <td style="text-align: right"/>
    <td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zqlk7NWOoQwk" style="text-align: right" title="Restricted stock units">2,400</td></tr>
  <tr style="vertical-align: middle">
    <td>Outstanding warrants</td>
    <td/>
    <td style="text-align: right"/>
    <td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zIvMtG3p7Qs6" style="text-align: right" title="Outstanding warrants">2,635</td>
    <td/>
    <td style="text-align: right"/>
    <td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zQSQ9Fb0Dxvj" style="text-align: right" title="Outstanding Warrants">3,920</td></tr>
  <tr style="vertical-align: middle">
    <td>Convertible debt</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_z5VuN4C7Qug9" style="text-align: right">3,704</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zUWQoM64cIZd" style="text-align: right">5,326</td></tr>
  <tr>
    <td style="vertical-align: middle"/>
    <td style="vertical-align: middle; text-align: right"/>
    <td style="vertical-align: middle; text-align: right"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="vertical-align: middle; text-align: right"/>
    <td style="vertical-align: middle; text-align: right"/>
    <td style="vertical-align: bottom; text-align: right"/></tr>
  <tr>
    <td style="vertical-align: middle"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="vertical-align: middle; text-align: right"/>
    <td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_i01_pin3_c20220101__20220331_zIrNJ5WBdVL7" style="border-top: Black 1pt solid; border-bottom: Black 2pt double; vertical-align: middle; text-align: right" title="Antidilutive securities excluded">16,638</td>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="vertical-align: middle; text-align: right"/>
    <td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_i01_pin3_c20210101__20210331_zKMlPxi5SVke" style="border-top: Black 1pt solid; border-bottom: Black 2pt double; vertical-align: middle; text-align: right" title="Antidilutive securities excluded">18,850</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332068520104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>4. Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of Fair Value Hierarchy Assets and Liabilities</a></td>
<td class="text"><p id="xdx_899_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zmwG4olT1Kz1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">The Company&#8217;s financial assets and liabilities measured at fair value
at March 31, 2022 and December 31, 2021 are as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; background-color: white"><span id="xdx_8BE_zLdsggSUjfL6" style="display: none">Schedule of Fair Value Hierarchy Assets and Liabilities</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; background-color: white"/>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: middle; background-color: white">
    <td style="font-weight: bold; width: 44%"/>
    <td style="font-weight: bold; text-align: right; width: 2%"/>
    <td style="font-weight: bold; text-align: right; width: 2%"/>
    <td style="font-weight: bold; text-align: center; width: 10%"/>
    <td style="font-weight: bold; text-align: right; width: 2%"/>
    <td style="font-weight: bold; text-align: right; width: 2%"/>
    <td style="font-weight: bold; text-align: center; width: 10%"/>
    <td style="font-weight: bold; text-align: right; width: 2%"/>
    <td style="font-weight: bold; text-align: right; width: 2%"/>
    <td style="font-weight: bold; text-align: center; width: 10%"/>
    <td style="font-weight: bold; text-align: right; width: 2%"/>
    <td style="font-weight: bold; text-align: right; width: 2%"/>
    <td style="font-weight: bold; text-align: center; width: 10%"/></tr>
</table>


<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td colspan="10" style="font-weight: bold; vertical-align: middle; text-align: center; background-color: white">Fair Value Measurements</td></tr>
  <tr>
    <td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td colspan="10" style="font-weight: bold; vertical-align: middle; text-align: center; background-color: white">as of March 31, 2022</td></tr>
  <tr>
    <td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: right; background-color: white; width: 44%"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white; width: 2%"/>
    <td style="vertical-align: bottom; text-align: right; width: 2%"/>
    <td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 10%">(Level 1)</td>
    <td style="vertical-align: middle; text-align: right; background-color: white; width: 2%"/>
    <td style="vertical-align: bottom; text-align: right; width: 2%"/>
    <td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 10%">(Level 2)</td>
    <td style="vertical-align: middle; text-align: right; background-color: white; width: 2%"/>
    <td style="vertical-align: bottom; text-align: right; width: 2%"/>
    <td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 10%">(Level 3)</td>
    <td style="vertical-align: middle; text-align: right; background-color: white; width: 2%"/>
    <td style="vertical-align: bottom; text-align: right; width: 2%"/>
    <td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 10%">Total</td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="font-weight: bold"><span id="xdx_900_eus-gaap--AssetsAbstract_iB_c20220101__20220331_ziSTSyBoNVWc">Assets</span>:</td>
    <td style="font-weight: bold; text-align: right"/>
    <td style="font-weight: bold; text-align: center"/>
    <td style="font-weight: bold; text-align: center"/>
    <td style="text-align: right"/>
    <td style="font-weight: bold; text-align: center"/>
    <td style="font-weight: bold; text-align: center"/>
    <td style="text-align: right"/>
    <td style="font-weight: bold; text-align: center"/>
    <td style="font-weight: bold; text-align: center"/>
    <td style="text-align: right"/>
    <td style="font-weight: bold; text-align: center"/>
    <td style="font-weight: bold; text-align: center"/></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt">Cash</td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_980_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zMqtLMj6TFSi" style="border-bottom: Black 2pt double; text-align: right" title="Cash">61,772</td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_988_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zz24VxuSoM5a" style="border-bottom: Black 2pt double; text-align: right" title="Cash"><span style="-sec-ix-hidden: xdx2ixbrl0429">-</span></td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_98C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zaL1DaIgI1v5" style="border-bottom: Black 2pt double; text-align: right" title="Cash"><span style="-sec-ix-hidden: xdx2ixbrl0431">-</span></td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_986_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20220331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zFAa9NtOhvN6" style="border-bottom: Black 2pt double; text-align: right" title="Cash">61,772</td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="font-weight: bold"><span id="xdx_90D_eus-gaap--LiabilitiesAbstract_iB_c20220101__20220331_zSJ30OFb8PIk">Liabilities</span>:</td>
    <td style="font-weight: bold; text-align: right"/>
    <td style="font-weight: bold; text-align: right"/>
    <td style="font-weight: bold; text-align: center"/>
    <td style="font-weight: bold; text-align: right"/>
    <td style="font-weight: bold; text-align: right"/>
    <td style="font-weight: bold; text-align: center"/>
    <td style="font-weight: bold; text-align: right"/>
    <td style="font-weight: bold; text-align: right"/>
    <td style="font-weight: bold; text-align: center"/>
    <td style="font-weight: bold; text-align: right"/>
    <td style="font-weight: bold; text-align: right"/>
    <td style="font-weight: bold; text-align: center"/></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt">Convertible notes payable, at fair value</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_980_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zjsKM8XNM0Fg" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0435">-</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_986_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zdXWGeQSnKdk" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0436">-</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_98C_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_z9av2YuWif5f" style="text-align: right">19,164</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_981_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zA9bPAF27hee" style="text-align: right">19,164</td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt">Warrant liabilities, at fair value</td>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td id="xdx_988_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zAX0BuuWs5Zi" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant liabilities, at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0440">-</span></td>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td id="xdx_98D_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zDx7tAT4Cpg3" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant liabilities, at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0442">-</span></td>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td id="xdx_989_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zRHvxSJNbD8c" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant liabilities, at fair value">190</td>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td id="xdx_987_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zGE4pbeM8qeg" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant liabilities, at fair value">190</td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_98C_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zflU3SniAtPg" style="border-bottom: Black 2pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0447">-</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_98F_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z6tMvCVtLyXf" style="border-bottom: Black 2pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0448">-</span></td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_984_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zQlhU1IQidSc" style="border-bottom: Black 2pt double; text-align: right">19,354</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_987_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zcBb6lxtsIDc" style="border-bottom: Black 2pt double; text-align: right">19,354</td></tr>

  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; background-color: white"/>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: middle; background-color: white">
    <td style="font-weight: bold; width: 44%"/>
    <td style="font-weight: bold; text-align: right; width: 2%"/>
    <td style="font-weight: bold; text-align: right; width: 2%"/>
    <td style="font-weight: bold; text-align: center; width: 10%"/>
    <td style="font-weight: bold; text-align: right; width: 2%"/>
    <td style="font-weight: bold; text-align: right; width: 2%"/>
    <td style="font-weight: bold; text-align: center; width: 10%"/>
    <td style="font-weight: bold; text-align: right; width: 2%"/>
    <td style="font-weight: bold; text-align: right; width: 2%"/>
    <td style="font-weight: bold; text-align: center; width: 10%"/>
    <td style="font-weight: bold; text-align: right; width: 2%"/>
    <td style="font-weight: bold; text-align: right; width: 2%"/>
    <td style="font-weight: bold; text-align: center; width: 10%"/></tr>
</table>


<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td colspan="10" style="font-weight: bold; vertical-align: middle; text-align: center; background-color: white">Fair Value Measurements</td></tr>
  <tr>
    <td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td colspan="10" style="font-weight: bold; vertical-align: middle; text-align: center; background-color: white">as of December 31, 2021</td></tr>
  <tr>
    <td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: right; background-color: white; width: 44%"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white; width: 1%"/>
    <td style="vertical-align: bottom; text-align: right; width: 1%"/>
    <td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 12%">(Level 1)</td>
    <td style="vertical-align: middle; text-align: right; background-color: white; width: 1%"/>
    <td style="vertical-align: bottom; text-align: right; width: 1%"/>
    <td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 12%">(Level 2)</td>
    <td style="vertical-align: middle; text-align: right; background-color: white; width: 1%"/>
    <td style="vertical-align: bottom; text-align: right; width: 1%"/>
    <td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 12%">(Level 3)</td>
    <td style="vertical-align: middle; text-align: right; background-color: white; width: 1%"/>
    <td style="vertical-align: bottom; text-align: right; width: 1%"/>
    <td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 12%">Total</td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="font-weight: bold"><span id="xdx_90C_eus-gaap--AssetsAbstract_iB_c20210101__20211231_z1NdZhfsyYU6">Assets</span>:</td>
    <td style="font-weight: bold; text-align: right"/>
    <td style="font-weight: bold; text-align: center"/>
    <td style="font-weight: bold; text-align: center"/>
    <td style="text-align: right"/>
    <td style="font-weight: bold; text-align: center"/>
    <td style="font-weight: bold; text-align: center"/>
    <td style="text-align: right"/>
    <td style="font-weight: bold; text-align: center"/>
    <td style="font-weight: bold; text-align: center"/>
    <td style="text-align: right"/>
    <td style="font-weight: bold; text-align: center"/>
    <td style="font-weight: bold; text-align: center"/></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt">Cash</td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_980_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zphNLgkyaaSg" style="border-bottom: Black 2pt double; text-align: right">78,734</td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_98E_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zTrI2Jcn3cac" style="border-bottom: Black 2pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0453">-</span></td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_984_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z0vhW9igOboi" style="border-bottom: Black 2pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0454">-</span></td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_981_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zZ0sFf2PIsVd" style="border-bottom: Black 2pt double; text-align: right">78,734</td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="font-weight: bold"><span id="xdx_90E_eus-gaap--LiabilitiesAbstract_iB_c20210101__20211231_zqbnatmsvCN5">Liabilities</span>:</td>
    <td style="font-weight: bold; text-align: right"/>
    <td style="font-weight: bold; text-align: right"/>
    <td style="font-weight: bold; text-align: center"/>
    <td style="font-weight: bold; text-align: right"/>
    <td style="font-weight: bold; text-align: right"/>
    <td style="font-weight: bold; text-align: center"/>
    <td style="font-weight: bold; text-align: right"/>
    <td style="font-weight: bold; text-align: right"/>
    <td style="font-weight: bold; text-align: center"/>
    <td style="font-weight: bold; text-align: right"/>
    <td style="font-weight: bold; text-align: right"/>
    <td style="font-weight: bold; text-align: center"/></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt">Convertible notes payable, at fair value</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_982_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_z1Dji7GN6VXc" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0457">-</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_986_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zZc1eDPalm1i" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0458">-</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_98E_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_z6iymzVEu8el" style="text-align: right">18,920</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_984_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zMlyQogvhvz5" style="text-align: right">18,920</td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt">Derivative liability, at fair value</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td id="xdx_982_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zB0e9XsEXIV7" style="text-align: right">1,174</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td id="xdx_98C_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_z3vyQwT75uk1" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0462">-</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td id="xdx_98B_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zBPGwAQ3cEei" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0463">-</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td id="xdx_98A_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zai4h0Tys5Ud" style="text-align: right">1,174</td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt">Warrant liabilities, at fair value</td>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td id="xdx_984_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zZKHP2KXgNKf" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0465">-</span></td>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td id="xdx_98B_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zpHSbRNVJiJi" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0466">-</span></td>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td id="xdx_98F_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_z2rtoturi0K1" style="border-bottom: Black 1pt solid; text-align: right">424</td>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td id="xdx_982_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zW1Y23DafrH3" style="border-bottom: Black 1pt solid; text-align: right">424</td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_986_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zkxlXzVGYAY6" style="border-bottom: Black 2pt double; text-align: right">1,174</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_987_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zYs6Is3hVU9l" style="border-bottom: Black 2pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0470">-</span></td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_980_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zDyahd65sJWd" style="border-bottom: Black 2pt double; text-align: right">19,344</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_988_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zwS6h5ca1G24" style="border-bottom: Black 2pt double; text-align: right">20,518</td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0"/>

<p style="font: 9pt Sans-Serif; margin: 0 0 0 4.5pt; background-color: white; color: Red"/>



<p style="margin-top: 0; margin-bottom: 0"/>

<p style="font: 9pt Sans-Serif; margin: 0 0 0 4.5pt; background-color: white; color: Red"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="font-weight: normal">&#160;</span></p>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Fair Value Level 3 Reconciliation</a></td>
<td class="text"><p id="xdx_895_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zCPml5pFNX89" style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">The
following table is a reconciliation for the common stock warrant liabilities and convertible notes measured at
fair value using Level 3 unobservable inputs (in thousands):&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="font-weight: normal; background-color: white"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-weight: normal; background-color: white">&#160;</span></p>

<p id="xdx_8BF_z141aSNXGWG7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="display: none; font-weight: normal; background-color: white; font-style: normal">Schedule of Fair Value Level 3 Reconciliation</span></p>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify">&#160;</p>



<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: right; width: 65%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; width: 7%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; width: 6%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; width: 13%"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt"><b>Warrant</b></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt"><b>Derivative</b></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt"><b>Convertible notes,</b></span></td></tr>
  <tr>
    <td style="vertical-align: middle"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; vertical-align: bottom; text-align: center"><span style="font-size: 9pt">liabilities</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; vertical-align: bottom; text-align: center"><span style="font-size: 9pt">liability</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; vertical-align: bottom; text-align: center"><span style="font-size: 9pt">at
    fair value</span></td></tr>
  <tr style="vertical-align: middle">
    <td style="font-weight: bold"><span style="font-size: 9pt">Balance as of December 31, 2020</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">$</span></td>
    <td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zZ5N7YCQckUf" style="text-align: right"><span style="font-size: 9pt">1,062</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td></tr>
  <tr style="vertical-align: middle">
    <td><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;Warrant liability reclassified to stockholders' equity</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"><span id="xdx_90B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zy3q2RQ3tfl9">(1,155)</span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td></tr>
  <tr style="vertical-align: middle">
    <td><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;Issuance of convertible notes, at fair value</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span id="xdx_903_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2l9ITqAdDS3">19,150</span></span></td></tr>
  <tr style="vertical-align: middle">
    <td><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;Issuance of derivative liability</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span id="xdx_909_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zeSjkKoJkkxe">805</span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td></tr>
  <tr style="vertical-align: middle">
    <td><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;Change in fair value measurement of derivative liability</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span id="xdx_90E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zsnriOmehMg3">369</span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td></tr>
  <tr style="vertical-align: middle">
    <td><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;Change in fair value measurement of convertible notes</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span id="xdx_900_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z1bOcwLgc6ni">(230)</span></span></td></tr>
  <tr style="vertical-align: middle">
    <td><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;Change in fair value measurement of warrant liability</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right; background-color: white"><span style="font-size: 9pt"><span id="xdx_90A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z9ZMDiklTg95">517</span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td></tr>
  <tr>
    <td style="font-weight: bold; vertical-align: middle"><span style="font-size: 9pt">Balance as of December 31, 2021</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt">$</span></td>
    <td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zZOckZD8d9d6" style="vertical-align: middle; text-align: right"><span style="font-size: 9pt">424</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt">$</span></td>
    <td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zqO3PH8nHf3a" style="vertical-align: middle; text-align: right"><span style="font-size: 9pt">&#160;1,174</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt">$</span></td>
    <td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zzTtUmRpTS0k" style="vertical-align: middle; text-align: right"><span style="font-size: 9pt">&#160;18,920</span></td></tr>
  <tr style="vertical-align: middle">
    <td><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;Settlement of derivative liability</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span id="xdx_905_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_i01N_pn3n3_di_c20220101__20220331__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwCetRrRSAH2">(1,174)</span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td></tr>
  <tr style="vertical-align: middle">
    <td><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;Change in fair value measurement of convertible notes</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span id="xdx_90E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_i01_pn3n3_c20220101__20220331__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zhaQF9ZHYUVb">244</span></span></td></tr>
  <tr style="vertical-align: middle">
    <td><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;Change in fair value measurement of warrant liability</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right; background-color: white"><span style="font-size: 9pt"><span id="xdx_908_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_i01_pn3n3_c20220101__20220331__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zLeLqN2kvjGc">(234)</span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right; background-color: white"><span style="font-size: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td></tr>
  <tr>
    <td style="font-weight: bold; vertical-align: middle"><span style="font-size: 9pt">Balance as of March 31, 2022</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt">$</span></td>
    <td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zBuArDbAc7Ek" style="border-bottom: Black 3pt double; vertical-align: middle; text-align: right"><span style="font-size: 9pt">190</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt">$</span></td>
    <td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_z1bamG3QqGxf" style="border-bottom: Black 3pt double; vertical-align: middle; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0519">&#160;</span>-</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt">$</span></td>
    <td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_z07O5qVN9v76" style="border-bottom: Black 3pt double; vertical-align: middle; text-align: right"><span style="font-size: 9pt">&#160;19,164</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_LongTermDebtMember', window );">Long-Term Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Summary of Fair Value Measurements Warrant Valuation Assumptions</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zobZdwvz86B2" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The
2021 Convertible Notes are valued using a Monte Carlo simulation model. The following assumptions were used in determining the fair
value of the 2021 Convertible Notes as of March 31, 2022 and December 31, 2021:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_8B1_ziFuTHcOTBZ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none">Summary of Fair Value Measurements Convertible Notes Valuation
Assumptions</p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 56%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: center; width: 19%">Three Months Ended</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: right; width: 1%">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: right; width: 2%">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: center; width: 19%">Year Ended</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">March 31, 2022</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">December 31, 2021</td></tr>
  <tr style="vertical-align: middle">
    <td style="background-color: white">Risk-free interest rate</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="font-size: 9pt; text-align: center"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_uPure_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_z5HpRHX11Yob">2.45</span>%</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: right">&#160;</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: center; border-top-color: Black; border-top-width: 1pt; background-color: white"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_uPure_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MinimumMember_zZeGHvgGJ9s4">0.90</span>% - <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_uPure_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MaximumMember_z37XKizL0Gw7">0.95</span>%</td></tr>
  <tr style="vertical-align: middle">
    <td style="background-color: white">Volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="font-size: 9pt; text-align: center"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pin2_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zacDLrQ4GKdg">105</span>%</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right; background-color: white">&#160;</td>
    <td style="text-align: center; background-color: white"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pin2_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MinimumMember_zg5wBGRG8c44">113</span>% - <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pin2_uPure_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MaximumMember_zErzf8T2zyUi">114</span>%</td></tr>
  <tr style="vertical-align: middle">
    <td style="background-color: white">Dividend yield</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="font-size: 9pt; text-align: center"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zW1WNfLtpRW5"><span style="-sec-ix-hidden: xdx2ixbrl0482">-</span></span>%</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center; background-color: white"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_ziWfoJRwIme7"><span style="-sec-ix-hidden: xdx2ixbrl0483">-</span></span>%</td></tr>
  <tr style="vertical-align: middle">
    <td style="background-color: white">Contractual term (years)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zWmphv1myut4" style="font-size: 9pt; text-align: center">2.7</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zmlt9elrKnbd" style="vertical-align: bottom; text-align: center; background-color: white">3.0</td></tr>
  <tr style="vertical-align: middle">
    <td style="background-color: white">Stock price</td>
    <td>&#160;</td>
    <td style="text-align: right">$</td>
    <td style="font-size: 9pt; text-align: center"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_uUSDPShares_c20220331__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_z3skXZj1r90j">0.84</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">$</td>
    <td style="vertical-align: bottom; text-align: center; background-color: white"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_uUSDPShares_c20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MinimumMember_zljLj7MQFzwe">1.74</span> - <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_uUSDPShares_c20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MaximumMember_z3kkv8fM9Zpa">1.95</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Summary of Fair Value Measurements Warrant Valuation Assumptions</a></td>
<td class="text"><p id="xdx_899_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zO2vSCDX6qTh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-weight: normal"><span style="background-color: white">The
following assumptions were used in determining the fair value of the warrant liabilities valued using the Black-Scholes option
pricing model for the three months ended March 31, 2022 and 2021.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-weight: normal"><span style="background-color: white">&#160;</span></span></p>

<p id="xdx_8BD_zAZ6sU0ZV6p3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal"><span style="display: none; background-color: white">Summary
of Fair Value Measurements Warrant Valuation Assumptions</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">&#160;</span></p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
  <tr style="vertical-align: middle">
    <td style="width: 55%">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: right; width: 1%">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: right; width: 1%">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: center; width: 19%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 20%">&#160;</td></tr>
  <tr style="vertical-align: middle">
    <td/>
    <td style="font-size: 9pt; font-weight: bold; text-align: right"/>
    <td style="font-size: 9pt; font-weight: bold; text-align: right"/>
    <td colspan="4" style="font-size: 9pt; font-weight: bold; text-align: center">Three Months  Ended March  31,</td></tr>
  <tr style="vertical-align: middle">
    <td/>
    <td style="font-size: 9pt; font-weight: bold; text-align: right"/>
    <td style="text-align: right"/>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">2022</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><b>2021</b></td></tr>
  <tr style="vertical-align: middle">
    <td>Risk-free interest rate</td>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_uPure_c20220101__20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zOk0436sECG2" style="text-align: center; border-top-color: Black; border-top-width: 1pt">1.96%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_uPure_c20210101__20210331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zQXop3eyrI2k" style="text-align: center; border-top-color: Black; border-top-width: 1pt">0.32%</td>
    </tr>
  <tr style="vertical-align: middle">
    <td>Volatility</td>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pin2_uPure_c20220101__20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zFQkpDdm9Xka" style="text-align: center">103.30%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pin2_uPure_c20210101__20210331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_z8fdFMccT2S2" style="text-align: center">120.91%</td>
    </tr>
  <tr style="vertical-align: middle">
    <td><p style="margin-top: 0; margin-bottom: 0">Dividend yield</p></td>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td style="text-align: center"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20220101__20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zz7ilyPOnhdg" title="Dividend yield (in percent)"><span style="-sec-ix-hidden: xdx2ixbrl0496">-</span></span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20210101__20210331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zSAF5OZBaWde" title="Dividend yield (in percent)"><span style="-sec-ix-hidden: xdx2ixbrl0498">-</span></span>%</td>
    </tr>
  <tr style="vertical-align: middle">
    <td>Expected term (years)</td>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zcrDiuC8yDRb" style="text-align: center">1.82</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zAFqHOxghGpf" style="text-align: center">2.82</td>
    </tr>
  <tr style="vertical-align: middle">
    <td>Weighted-average fair value</td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220101__20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zEZJzyd9xHx3" style="text-align: center">0.63</td>
    <td>&#160;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20210101__20210331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zr76QnsGRBn5" style="text-align: center">4.76</td>
    </tr>
  </table>

<p style="font: bold 9pt Sans-Serif; margin: 0 0 0 6pt; text-align: left; color: Red"/>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_LongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_LongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332072923016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>5. Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p id="xdx_894_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_z2quCZanxsAd" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Prepaid expenses and other current assets are comprised of the following
(in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_8BB_zFwXqZpjjEH5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none">Schedule of Prepaid Expenses and Other Current Assets</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 85%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: middle">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">&#160;</td>
    <td id="xdx_492_20220331_zUJOJOzjr6L3" style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">&#160;</td>
    <td id="xdx_495_20211231_z0xE0sLPmIEi" style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: middle">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">March 31,</td>
    <td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">December 31,</td></tr>
  <tr>
    <td style="vertical-align: middle">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">2022</td>
    <td style="vertical-align: middle">&#160;</td>
    <td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">2021</td></tr>
  <tr id="xdx_403_eus-gaap--PrepaidInsurance_iI_pn3n3_maPEAOAzj4M_zj6iYj33ahr1" style="vertical-align: middle">
    <td style="width: 66%">Prepaid insurance</td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; text-align: right; width: 1%">$</td>
    <td style="text-align: right; background-color: white; width: 15%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;787</td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; text-align: right; width: 1%">$</td>
    <td style="text-align: right; width: 15%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;59</td></tr>
  <tr id="xdx_407_ecustom--PrepaidClinicalCosts_iI_pn3n3_maPEAOAzj4M_zosvL0eg1Rc9" style="vertical-align: middle">
    <td>Prepaid clinical costs</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: right; background-color: white">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;7,694</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: right">&#160;</td>
    <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;4,481</td></tr>
  <tr id="xdx_405_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3n3_maPEAOAzj4M_zDuzsVMSYJ83">
    <td style="vertical-align: middle">Other</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: middle; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: middle; text-align: right; background-color: white">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;414</td>
    <td style="vertical-align: middle">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: top; text-align: right">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: middle; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;187</td></tr>
  <tr id="xdx_401_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i01TI_pn3n3_maACzKPF_maACzYR4_mtPEAOAzj4M_zuIdy9vqOoKd" style="vertical-align: middle">
    <td style="padding-left: 24px; text-align: left">Prepaid expenses and other current assets</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2pt double; vertical-align: top; text-align: right">$</td>
    <td style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 1pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;8,895</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2pt double; vertical-align: top; text-align: right">$</td>
    <td style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 1pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;4,727</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332073013928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>8. Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zLbnzvITG1p5" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Accrued expenses are comprised of the following (in
thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin-right: 0; margin-left: 0"><span><span id="xdx_8BD_z6KWwFfJHuHk">Schedule of Accrued Liabilities</span></span></p>




<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_49A_20220331_zwICjhlV6239" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_490_20211231_zmD5DtFUaTSf" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><b>March 31,</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><b>December 31,</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 64%">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 2%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 15%; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 2%; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 15%; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td></tr>
  <tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCzZt1_ziFqceZp8kCd" style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Professional fees</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">190&#160;</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">181&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCzZt1_zct9paxXbfkh" style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Personnel related</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">332&#160;</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,303&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--OutsideResearchAndDevelopmentServicesCurrent_iI_pn3n3_zFJGLg2nsUn5" style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Outside research and development services</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">2,387&#160;</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">2,219&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AccruedInsuranceCurrent_iI_pn3n3_zfpu6qZ5A2Kg" style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Insurance</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">580&#160;</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-<span style="-sec-ix-hidden: xdx2ixbrl0581">&#160;</span></span></td></tr>
  <tr id="xdx_40B_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzZt1_zVwREZNxc5Fc" style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Other</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">60&#160;</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">25&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzZt1_ztGJO0fQsEb3" style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;&#160;&#160;&#160; Accrued expenses, net</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">3,549&#160;</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">3,728&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332072972744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>10. Stockholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Warrant Activity</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zJmTqFB9NdR" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt">A summary of warrant activity during the three months ended March 31, 2022 is as follows (share amounts in thousands):</p>

<p id="xdx_8B7_zAzfrCVOkjad" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; display: none">Summary of Warrant Activity</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt">&#160;</p>

<p style="font: 9pt Sans-Serif; margin: 0 0 0 5pt; color: Red"><b>&#160;</b></p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: middle; width: 52%"/>
    <td style="vertical-align: middle; width: 1%"/>
    <td style="font-weight: bold; vertical-align: middle; width: 12%"/>
    <td style="font-weight: bold; vertical-align: middle; width: 1%"/>
    <td style="vertical-align: bottom; text-align: right; width: 1%"/>
    <td style="vertical-align: bottom; text-align: right; width: 14%"/>
    <td style="vertical-align: bottom; text-align: right; width: 1%"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center; width: 18%">Weighted-</td></tr>
  <tr>
    <td style="vertical-align: middle"/>
    <td style="vertical-align: middle"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Weighted-</td>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Average</td></tr>
  <tr>
    <td style="vertical-align: middle"/>
    <td style="vertical-align: middle"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Average</td>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Remaining</td></tr>
  <tr>
    <td style="vertical-align: middle"/>
    <td style="vertical-align: middle"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Exercise</td>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Contractual Life</td></tr>
  <tr>
    <td style="vertical-align: middle"/>
    <td style="vertical-align: middle"/>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: bottom; text-align: center">Warrants</td>
    <td style="font-weight: bold; vertical-align: bottom; text-align: center"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center">Price</td>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center">(in years)</td></tr>
  <tr style="vertical-align: middle">
    <td>Outstanding as of December 31, 2021</td>
    <td/>
    <td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pin3_c20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zVsegwJaPjd9" style="text-align: right; border-top-color: Black; border-top-width: 1pt" title="Outstanding as of December 31, 2021">2,635</td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pp2p0_uUSDPShares_c20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zk5wu7yMDzS4" style="text-align: right" title="Outstanding as of December 31, 2020, weighted-average exercise price (in usd per share)">4.29</td>
    <td style="text-align: right"/>
    <td id="xdx_98A_ecustom--ClassOfWarrantOrRightOutstandingWeightedAverageRemaingContractualLife_dtY_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zBqZIHnvaY05" style="text-align: right" title="Warrants outstanding as of December 31, 2020, weighted-average remaing contractual life (in years)">2.4</td></tr>
  <tr style="vertical-align: middle">
    <td style="text-align: left">Issued</td>
    <td style="text-align: left"/>
    <td id="xdx_98A_ecustom--NumberofWarrantsIssuedDuringPeriod_i01_pin3_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zkbEChDK2uW6" style="text-align: right" title="Issued"><span style="-sec-ix-hidden: xdx2ixbrl0670">-</span></td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_984_ecustom--ClassOfWarrantOrRightIssuedExercisePriceOfWarrantsOrRights_i01_pp0p0_uUSDPShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zFkmle9m8kN3" style="text-align: right" title="Issued, warrant exercise price"><span style="-sec-ix-hidden: xdx2ixbrl0672">-</span></td>
    <td style="text-align: right"/>
    <td style="text-align: right"/></tr>
  <tr style="vertical-align: middle">
    <td style="text-align: left">Exercised</td>
    <td style="text-align: left"/>
    <td id="xdx_98C_ecustom--NumberofWarrantsExercisedDuringPeriod_i01_pin3_uShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zi5sOrJmTFnk" style="text-align: right" title="Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0674">-</span></td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_989_ecustom--ClassOfWarrantOrRightExercisedExercisePriceOfWarrantsOrRights_i01_pp2p0_uUSDPShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zfLLDTtuHlrf" style="text-align: right" title="Exercised, exercise price of warrants"><span style="-sec-ix-hidden: xdx2ixbrl0676">-</span></td>
    <td style="text-align: right"/>
    <td style="text-align: right"/></tr>
  <tr style="vertical-align: middle">
    <td style="text-align: left">Cancelled</td>
    <td style="text-align: left"/>
    <td id="xdx_98F_ecustom--NumberofWarrantsCancelledDuringPeriod_i01_pin3_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zGfA4SCT2qse" style="text-align: right" title="Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0678">-</span></td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_98D_ecustom--ClassOfWarrantOrRightCancelledExercisePriceOfWarrantsOrRights_i01_pp0p0_uUSDPShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zgm33G3iBXg3" style="text-align: right" title="Cancelled, exercise price of warrants"><span style="-sec-ix-hidden: xdx2ixbrl0680">-</span></td>
    <td style="text-align: right"/>
    <td style="text-align: right"/></tr>
  <tr style="vertical-align: middle">
    <td>Outstanding as of March 31, 2022</td>
    <td/>
    <td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_pin3_c20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zBwytxpqO65h" style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right" title="Outstanding as of March 31, 2022">2,635</td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_pp2p0_uUSDPShares_c20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zKOF7jshxCng" style="text-align: right" title="Outstanding as of June 30, 2021, weighted-average exercise price (in usd per share)">4.29</td>
    <td style="text-align: right"/>
    <td id="xdx_98A_ecustom--ClassOfWarrantOrRightOutstandingEndOfPeriodWeightedAverageRemaingContractualLife_dtY_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zGziPPGfTX45" style="text-align: right" title="Warrants outstanding as of June 30, 2021, weighted-average remaing contractual life (in years)">2.2</td></tr>
  <tr style="vertical-align: middle">
    <td>Exercisable as of March 31, 2022</td>
    <td/>
    <td id="xdx_986_ecustom--WarrantsExercisable_iI_pin3_uShares_c20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zwWZsRDjN16d" style="border-bottom: Black 2pt double; text-align: right" title="Warrants exercisable as of March 31, 2022">2,635</td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_980_ecustom--ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights1_iI_pp2p0_uUSDPShares_c20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_ziAsCKdFiqkc" style="text-align: right" title="Exercisable, weighted-average exercise price (in usd per share)">4.29</td>
    <td style="text-align: right"/>
    <td id="xdx_98F_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageRemaingContractualLife_dtY_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zGBpwIuIP0Ue" style="text-align: right" title="Warrants exercisable as of June 30, 2021, weighted-average remaing contractual life (in years)">2.2</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332074353864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>11. Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions for Stock Options</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zXhvmmQk8jQ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following assumptions were used in determining the fair value
of the stock options granted during the three months ended March 31, 2022 and 2021:</p>

<p id="xdx_8BF_zXfcPsXzw2Jd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; display: none">Schedule of Valuation Assumptions for Stock Options</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<p style="font: 9pt Sans-Serif; margin: 0 0 0 4.5pt; text-align: center; color: Red"><b>&#160;</b></p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: middle">
    <td/>
    <td style="font-size: 9pt; font-weight: bold; text-align: right"/>
    <td style="font-size: 9pt; font-weight: bold; text-align: right"/>
    <td colspan="4" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">Three Months Ended</td></tr>
  <tr style="vertical-align: middle">
    <td style="width: 56%"/>
    <td style="font-size: 9pt; font-weight: bold; text-align: right; width: 1%"/>
    <td style="text-align: right; width: 2%"/>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center; width: 19%">March 31, 2022</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center; width: 19%">March 31, 2021</td></tr>
  <tr style="vertical-align: middle">
    <td>Risk-free interest rate</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: right"/>
    <td style="text-align: right"/>
    <td style="text-align: center; border-top-color: Black; border-top-width: 1pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjtVcCqUpHQ1" title="Risk-free interest rate, minimum">1.5</span>%
    - <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYRJR2d5QdVk" title="Risk-free interest rate, maximum">1.6</span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center; vertical-align: middle"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zzOjUAmjsxFc" title="Risk-free interest rate, minimum">0.5</span>%
    - <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgvlFJ1D99X1" title="Risk-free interest rate, maximum">0.9</span>%</td></tr>
  <tr style="vertical-align: middle">
    <td>Volatility</td>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td style="text-align: center"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip2_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztiOBv52Qkt2" title="Volatility, minimum">113</span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center; vertical-align: middle"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pip2_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zHkgqet06Yf6" title="Volatility, minimum">120</span>%-<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pip2_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zOpmEyP1jL0f" title="Volatility, maximum">125</span>%</td></tr>
  <tr style="vertical-align: middle">
    <td>Dividend yield</td>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td style="text-align: center"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEwBPf3fS8Bg" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0744">-</span></span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zeyq7EuVL3tf" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0746">-</span></span>%</td></tr>
  <tr style="vertical-align: middle">
    <td>Expected term (years)</td>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td style="text-align: center"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zQuqEZf1Nqbg" title="Expected term (in years)">5</span>
    - <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zuyt1YNTp7zd" title="Expected term (in years)">6</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zd2w1SirpE4l" title="Expected term (in years)">5</span>
    - <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zEq8Wb9zgTbh" title="Expected term (in years)">6</span></td></tr>
  <tr style="vertical-align: middle">
    <td>Weighted-average fair value</td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pp2p0_uUSDPShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zSTQ5fbDjrb1" title="Weighted average fair value">1.24
    - <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pp2p0_uUSDPShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zVxJYCH0CCqe">1.27</span></span></td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: middle">$</td>
    <td style="text-align: center; vertical-align: middle"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pp2p0_uUSDPShares_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUyqXX23Gjzl">3.62</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zHoecFH9CL2f" style="font: 10pt Times New Roman, Times, Serif; margin: 0">A summary of stock option activity during the three months ended
March 31, 2022 is as follows (share amounts in thousands):</p>

<p id="xdx_8B1_z61dgi5nD0Y" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; display: none">Summary of Stock Option Activity</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: middle; width: 50%"/>
    <td style="vertical-align: middle; width: 1%"/>
    <td style="font-weight: bold; vertical-align: middle; width: 10%"/>
    <td style="vertical-align: middle; width: 1%"/>
    <td style="vertical-align: bottom; text-align: right; width: 1%"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center; width: 10%"/>
    <td style="vertical-align: middle; width: 1%"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center; width: 14%">Weighted-</td>
    <td style="vertical-align: middle; width: 1%"/>
    <td style="vertical-align: bottom; text-align: right; width: 1%"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center; width: 10%"/></tr>
  <tr>
    <td style="vertical-align: middle"/>
    <td style="vertical-align: middle"/>
    <td style="font-weight: bold; vertical-align: middle"/>
    <td style="vertical-align: middle"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Weighted-</td>
    <td style="vertical-align: middle"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Average</td>
    <td style="vertical-align: middle"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Total</td></tr>
  <tr>
    <td style="vertical-align: middle"/>
    <td style="vertical-align: middle"/>
    <td style="font-weight: bold; vertical-align: middle"/>
    <td style="vertical-align: middle"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Average</td>
    <td style="vertical-align: middle"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Remaining</td>
    <td style="vertical-align: middle"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Aggregate</td></tr>
  <tr>
    <td style="vertical-align: middle"/>
    <td style="vertical-align: middle"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Stock</td>
    <td style="vertical-align: middle"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Exercise</td>
    <td style="vertical-align: middle"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Contractual</td>
    <td style="vertical-align: middle"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="font-weight: bold; vertical-align: middle; text-align: center">Intrinsic</td></tr>
  <tr>
    <td style="vertical-align: middle"/>
    <td style="vertical-align: middle"/>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: bottom; text-align: center">Options</td>
    <td style="vertical-align: middle"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center">Price</td>
    <td style="vertical-align: middle"/>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center">Life (in years)</td>
    <td style="vertical-align: middle"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center">Value</td></tr>
  <tr style="vertical-align: middle">
    <td>Outstanding as of December 31, 2021</td>
    <td/>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pin3_uShares_c20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z8DRlDoteBmd" style="text-align: right" title="Outstanding as of December 31, 2020">7,306</td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2p0_uUSDPShares_c20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNRFCa6nzHZd" style="text-align: right; border-top-color: Black; border-top-width: 1pt" title="Outstanding, beginning of period (USD per share)">2.60</td>
    <td/>
    <td style="text-align: right; border-top-color: Black; border-top-width: 1pt"/>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td style="text-align: right"/></tr>
  <tr style="vertical-align: middle">
    <td>Granted</td>
    <td/>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pin3_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjcI84J2YaBi" style="text-align: right" title="Granted">3,000</td>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2p0_uUSDPShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ziUtgz9WNN99" style="text-align: right" title="Granted in period (USD per share)">1.47</td>
    <td/>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td style="text-align: right"/></tr>
  <tr style="vertical-align: middle">
    <td>Exercised</td>
    <td/>
    <td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pin3_di_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUYz51vmAwA8" style="text-align: right" title="Exercised">(6)</td>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmPS2631gQh6" style="text-align: right" title="Exercised in period (USD per share)">1.06</td>
    <td/>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td style="text-align: right"/></tr>
  <tr style="vertical-align: middle">
    <td style="text-align: left">Cancelled</td>
    <td style="text-align: left"/>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pin3_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zR6cDFUfPZ4f" style="border-bottom: Black 1pt solid; text-align: right" title="Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0774">-</span></td>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_d0_uUSDPShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjgUGQ9a3OD9" style="text-align: right" title="Cancelled (USD per share)">-</td>
    <td/>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td style="text-align: right"/></tr>
  <tr style="vertical-align: middle">
    <td>Outstanding as of March 31, 2022</td>
    <td/>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pin3_uShares_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zuKMgdCfnJY4" style="border-bottom: Black 2pt double; text-align: right" title="Outstanding as of March 31, 2022">10,300</td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pp2p0_uUSDPShares_c20220331_z3GPMX9yPIuc" style="border-bottom: Black 2pt double; text-align: right" title="Outstanding, end of period (USD per share)">2.27</td>
    <td/>
    <td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zne43COO2mHl" style="text-align: right" title="Outstanding - weighted-average remaining contractual life (in years)">8.7</td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_uUSD_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zFOhlb7tS3V3" style="border-bottom: Black 2pt double; text-align: right" title="Total aggregate intrinsic value shares outstanding">2,894</td></tr>
  <tr style="vertical-align: middle">
    <td>Vested and expected to vest as of March 31, 2022</td>
    <td/>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pin3_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zabB3u9YKS3b" style="border-bottom: Black 2pt double; text-align: right" title="Vested and expected to vest, end of period (shares)">10,300</td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pp2p0_d0_uUSDPShares_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1gIUcwcNnGd" style="border-bottom: Black 2pt double; text-align: right" title="Vested and expected to vest stock, end of period (USD per share)">2.27</td>
    <td/>
    <td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zeDcxxvpPvAk" style="text-align: right" title="Weighted-average remaining contractual life (in years) of vested and expected to vest stock options">8.7</td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_pn3n3_uUSD_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYGOnPpxeAr9" style="border-bottom: Black 2pt double; text-align: right" title="Total aggregate intrinsic value of vested or expected to vest stock options">2,894</td></tr>
  <tr style="vertical-align: middle">
    <td>Exercisable as of March 31, 2022</td>
    <td/>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pin3_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1xJhUmnf5ve" style="border-bottom: Black 2pt double; text-align: right" title="Exercisable, end of period (shares)">3,085</td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pp2p0_d0_uUSDPShares_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zT2olXBumqNh" style="border-bottom: Black 2pt double; text-align: right" title="Exercisable, end of period (USD per share)">3.00</td>
    <td/>
    <td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjVD2HF0t2Be" style="text-align: right" title="Weighted-average remaining contractual life (in years) of exercisable stock options">8.1</td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_uUSD_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQC6bN4xDEB3" style="border-bottom: Black 2pt double; text-align: right" title="Total aggregate intrinsic value of exercisable stock options">2,894</td></tr>
  </table>

<p style="font: 9pt Sans-Serif; margin: 0"/>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zKedatNYpX1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes the total stock-based compensation
expense resulting from share-based awards recorded in the Company&#8217;s condensed consolidated statements of operations (in thousands):</p>

<p id="xdx_8B8_zeKdjKdluhy2" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; display: none">Schedule of Stock-Based Compensation Expense</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: middle; background-color: white"/>
    <td style="vertical-align: middle; background-color: white"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td colspan="4" style="font-weight: bold; vertical-align: middle; text-align: center; background-color: white">Three Months Ended</td>
    </tr>
  <tr>
    <td style="vertical-align: middle; background-color: white"/>
    <td style="vertical-align: middle; background-color: white"/>
    <td style="vertical-align: bottom; text-align: right"/>
    <td colspan="4" style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white">March
    31,</td>
    </tr>
  <tr>
    <td style="vertical-align: middle; background-color: white; width: 64%"/>
    <td style="vertical-align: middle; background-color: white; width: 2%"/>
    <td style="vertical-align: bottom; text-align: right; width: 2%"/>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; background-color: white; width: 14%">2022</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; background-color: white; width: 2%"/>
    <td style="vertical-align: middle; border-top-color: Black; border-top-width: 1pt; background-color: white; width: 2%"/>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; background-color: white; width: 14%">2021</td>
    </tr>
  <tr style="vertical-align: middle">
    <td style="background-color: white">Research and development</td>
    <td style="text-align: right; background-color: white"/>
    <td style="text-align: right">$</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20220101__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zXHbP0LPHD75" style="text-align: right; border-top-color: Black; border-top-width: 1pt" title="Stock-based compensation expense">229</td>
    <td style="text-align: right; background-color: white"/>
    <td style="text-align: right">$</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensation_pn3n3_c20210101__20210331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zumQzKkXYS4" style="text-align: right; border-top-color: Black; border-top-width: 1pt" title="Stock-based compensation expense">136</td>
    </tr>
  <tr style="vertical-align: middle">
    <td style="background-color: white">General and administrative</td>
    <td style="text-align: right; background-color: white"/>
    <td style="text-align: right"/>
    <td id="xdx_981_eus-gaap--ShareBasedCompensation_pn3n3_c20220101__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zrYJ3d2q7vEb" style="border-bottom: Black 1pt solid; text-align: right" title="Stock-based compensation expense">2,003</td>
    <td style="text-align: right; background-color: white"/>
    <td style="text-align: right"/>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensation_pn3n3_c20210101__20210331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zoTjvJL1STs" style="border-bottom: Black 1pt solid; text-align: right" title="Stock-based compensation expense">569</td>
    </tr>
  <tr style="vertical-align: middle">
    <td style="text-align: left; background-color: white"/>
    <td style="text-align: right; background-color: white"/>
    <td style="text-align: right; background-color: white">$</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensation_pn3n3_c20220101__20220331_z581oqWEPrX7" style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 1pt; background-color: white" title="Stock-based compensation expense">2,232</td>
    <td style="text-align: right; background-color: white"/>
    <td style="text-align: right; background-color: white">$</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensation_pn3n3_c20210101__20210331_zkwVMYZ826Tj" style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 1pt" title="Stock-based compensation expense">705</td>
    </tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332072976376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>12. Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of future minimum operating lease payments</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_zXhLn9nS7Ama" style="font: 10pt Times New Roman, Times, Serif; margin: 0">At March 31, 2022, future minimum lease payments for operating
leases with non-cancelable terms of more than one year were as follows (in thousands):</p>

<p id="xdx_8BF_z1KRk18BYi8c" style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; display: none">Schedule of future minimum operating lease payments</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 79%"/>
    <td style="width: 2%"/>
    <td style="width: 2%"/>
    <td id="xdx_498_20220331_zXO3vxfsGvva" style="font-weight: bold; text-align: center; width: 17%">Operating</td></tr>
  <tr style="vertical-align: bottom">
    <td/>
    <td/>
    <td/>
    <td style="border-bottom: Black 0.5pt solid; font-weight: bold; text-align: center">Leases</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_maLOLLPz53j_zrpgG7zHWwA3" style="vertical-align: bottom">
    <td>Remaining Period Ended December 31, 2022</td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td style="text-align: right">27</td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_i01TI_pn3n3_mtLOLLPz53j_zQwz4jjjjnJc" style="vertical-align: bottom">
    <td style="text-indent: 10pt">Total</td>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td style="border-top: Black 0.5pt solid; text-align: right">27</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_i01NI_pn3n3_di_maOLLzeMS_zz6HdRwECwrl" style="vertical-align: bottom">
    <td>Less present value discount</td>
    <td style="text-align: right"/>
    <td style="text-align: right"/>
    <td style="text-align: right">(1)</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_mtOLLzeMS_zuijHUAWEMd6" style="vertical-align: bottom">
    <td>Operating lease liabilities</td>
    <td style="text-align: right"/>
    <td style="text-align: right">$</td>
    <td style="border-top: Black 0.5pt solid; border-bottom: Black 2pt double; text-align: right">26</td></tr>
  </table>

<p style="font: 9pt Sans-Serif; margin: 0 5.85pt 0 5pt; text-align: left; color: Red"/>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332069899928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>2. Liquidity and Going Concern (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>May 24, 2021</div></th>
<th class="th"><div>Jan. 28, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,734<span></span>
</td>
<td class="nump">$ 61,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumlated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 141,210<span></span>
</td>
<td class="nump">155,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Cash received from stock sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_FinancingAvailableUnderFormS3ShelfRegistrationStatement', window );">[custom:FinancingAvailableUnderFormS3ShelfRegistrationStatement-0]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=SEEL_May242021Member', window );">May 242021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares of common stock issued</a></td>
<td class="nump">22,258,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,258,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Cash received from stock sale</a></td>
<td class="nump">$ 64,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes', window );">Offering proceeds used to partially repay certain convertible promissory notes</a></td>
<td class="nump">$ 7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=SEEL_January282021Member', window );">January 282021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,530,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,530,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Cash received from stock sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes', window );">Offering proceeds used to partially repay certain convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_FinancingAvailableUnderFormS3ShelfRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_FinancingAvailableUnderFormS3ShelfRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SEEL_May242021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SEEL_May242021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SEEL_January282021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SEEL_January282021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332069873992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded</a></td>
<td class="nump">16,638,000<span></span>
</td>
<td class="nump">18,850,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded</a></td>
<td class="nump">10,299,000<span></span>
</td>
<td class="nump">7,204,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded</a></td>
<td class="nump">2,635,000<span></span>
</td>
<td class="nump">3,920,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded</a></td>
<td class="nump">3,704,000<span></span>
</td>
<td class="nump">5,326,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332065455848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Fair Value Hierarchy Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="nump">$ 61,772<span></span>
</td>
<td class="nump">$ 78,734<span></span>
</td>
<td class="nump">$ 38,687<span></span>
</td>
<td class="nump">$ 15,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liabilities, at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="nump">61,772<span></span>
</td>
<td class="nump">78,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liabilities, at fair value</a></td>
<td class="nump">19,354<span></span>
</td>
<td class="nump">20,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Long-Term Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liabilities, at fair value</a></td>
<td class="nump">19,164<span></span>
</td>
<td class="nump">18,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liabilities, at fair value</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Derivative Financial Instruments, Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liabilities, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="nump">61,772<span></span>
</td>
<td class="nump">78,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liabilities, at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Long-Term Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liabilities, at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liabilities, at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Derivative Financial Instruments, Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liabilities, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liabilities, at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Long-Term Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liabilities, at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liabilities, at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Derivative Financial Instruments, Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liabilities, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liabilities, at fair value</a></td>
<td class="nump">19,354<span></span>
</td>
<td class="nump">19,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Long-Term Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liabilities, at fair value</a></td>
<td class="nump">19,164<span></span>
</td>
<td class="nump">18,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liabilities, at fair value</a></td>
<td class="nump">$ 190<span></span>
</td>
<td class="nump">$ 424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_LongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_LongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332065655064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Fair Value Measurements Convertible Notes Valuation Assumptions (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_LongTermDebtMember', window );">Long-Term Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</a></td>
<td class="nump">$ 0.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_LongTermDebtMember', window );">Long-Term Debt [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_LongTermDebtMember', window );">Long-Term Debt [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.74<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_LongTermDebtMember', window );">Long-Term Debt [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.95<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="nump">113.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Long-Term Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="nump">245.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="nump">1050000.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Long-Term Debt [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1130000.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Long-Term Debt [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1140000.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_LongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_LongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332068336632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Fair Value Measurements Warrant Valuation Assumptions (Details) - Fair Value, Inputs, Level 3 [Member] - Warrant [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="nump">1.96%<span></span>
</td>
<td class="nump">0.32%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="nump">10330.00%<span></span>
</td>
<td class="nump">12091.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield (in percent)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">1 year 9 months 25 days<span></span>
</td>
<td class="text">2 years 9 months 25 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 0.63<span></span>
</td>
<td class="nump">$ 4.76<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332071132216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Fair Value Level 3 Reconciliation (Details) - Fair Value, Inputs, Level 3 [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</a></td>
<td class="nump">$ 190<span></span>
</td>
<td class="nump">$ 424<span></span>
</td>
<td class="nump">$ 1,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3', window );">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,155)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</a></td>
<td class="num">(234)<span></span>
</td>
<td class="nump">517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Long-Term Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</a></td>
<td class="nump">19,164<span></span>
</td>
<td class="nump">18,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3', window );">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</a></td>
<td class="nump">244<span></span>
</td>
<td class="num">(230)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3', window );">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Derivative Financial Instruments, Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3', window );">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3</a></td>
<td class="nump">1,174<span></span>
</td>
<td class="nump">805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3', window );">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3</a></td>
<td class="num">$ (1,174)<span></span>
</td>
<td class="num">$ (805)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_LongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_LongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332069858280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>4. Fair Value Measurement (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=SEEL_IXLicenseAgreementMember', window );">I X License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_NonrefundableCashPayment', window );">[custom:NonrefundableCashPayment]</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_NonrefundableCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_NonrefundableCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=SEEL_IXLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=SEEL_IXLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332069964600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 787<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_PrepaidClinicalCosts', window );">Prepaid clinical costs</a></td>
<td class="nump">7,694<span></span>
</td>
<td class="nump">4,481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other</a></td>
<td class="nump">414<span></span>
</td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 8,895<span></span>
</td>
<td class="nump">$ 4,727<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_PrepaidClinicalCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_PrepaidClinicalCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332065265224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>6. Common Stock Offerings (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 24, 2021</div></th>
<th class="th"><div>Jan. 28, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Cash received from stock sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,009<span></span>
</td>
<td class="nump">$ 14,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=SEEL_IXLicenseAgreementMember', window );">I X License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_NonrefundableCashPayment', window );">[custom:NonrefundableCashPayment]</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_Issuanceofcommonstockforlicenseacquiredshares', window );">[custom:Issuanceofcommonstockforlicenseacquiredshares]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,570,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_MinimumStockValueOfSharesIssued', window );">[custom:MinimumStockValueOfSharesIssued]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_InitialStockValuationShortfallFrom5.5MillionValue', window );">[custom:InitialStockValuationShortfallFrom5.5MillionValue]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=SEEL_May242021Member', window );">May 242021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,258,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,258,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Cash received from stock sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes', window );">Offering proceeds used to partially repay certain convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=SEEL_January282021Member', window );">January 282021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,530,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,530,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Cash received from stock sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes', window );">Offering proceeds used to partially repay certain convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_InitialStockValuationShortfallFrom5.5MillionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_InitialStockValuationShortfallFrom5.5MillionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_Issuanceofcommonstockforlicenseacquiredshares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_Issuanceofcommonstockforlicenseacquiredshares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_MinimumStockValueOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_MinimumStockValueOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_NonrefundableCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_NonrefundableCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=SEEL_IXLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=SEEL_IXLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SEEL_May242021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SEEL_May242021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SEEL_January282021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SEEL_January282021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332070030248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>7. License Agreements (Details Narrative) - Weg License Agreement [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Aug. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDescription', window );">Business Combination, Separately Recognized Transactions, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On
August 29, 2019, the Company entered into an amended and restated exclusive license agreement with Stuart Weg, M.D. (the &#8220;Weg License
Agreement&#8221;), pursuant to which the Company was granted an exclusive worldwide license to certain intellectual property and regulatory
materials related to SLS-002. Under the terms of the Weg License Agreement, the Company paid an upfront license fee of $75,000 upon execution
of the agreement. The Company agreed to pay additional consideration to Dr. Weg as follows: (i) $0.1 million on January 2, 2020, (ii)
$0.125 million on January 2, 2021, and (iii) in the event the FDA has not approved an NDA for a product containing ketamine in any dosage
on or before December 31, 2021, $<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_NonrefundableCashPayment', window );">[custom:NonrefundableCashPayment]</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent', window );">Asset Acquisition, Contingent Consideration, Liability, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_NonrefundableCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_NonrefundableCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized from contingent consideration in asset acquisition, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 15<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6911878&amp;loc=d3e8732-128492<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of each transaction that is recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=SEEL_WegLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=SEEL_WegLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332068384008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">$ 190<span></span>
</td>
<td class="nump">$ 181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Personnel related</a></td>
<td class="nump">332<span></span>
</td>
<td class="nump">1,303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_OutsideResearchAndDevelopmentServicesCurrent', window );">Outside research and development services</a></td>
<td class="nump">2,387<span></span>
</td>
<td class="nump">2,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedInsuranceCurrent', window );">Insurance</a></td>
<td class="nump">580<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">&#160;&#160;&#160;&#160; Accrued expenses, net</a></td>
<td class="nump">$ 3,549<span></span>
</td>
<td class="nump">$ 3,728<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_OutsideResearchAndDevelopmentServicesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_OutsideResearchAndDevelopmentServicesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedInsuranceCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedInsuranceCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332064960392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>9. Debt (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
<th class="th" colspan="1">27 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Nov. 24, 2024</div></th>
<th class="th"><div>Nov. 23, 2024</div></th>
<th class="th"><div>Dec. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_GainLossInFairValueOfConvertibleNotes', window );">[custom:GainLossInFairValueOfConvertibleNotes]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (244,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=SEEL_November2021LindSecuritiesPurchaseAgreementMember', window );">November 2021 Lind Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtDescription', window );">Long-Term Debt, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On November 23, 2021, the Company entered into a Securities Purchase Agreement
(the &#8220;2021 Lind Securities Purchase Agreement&#8221;) with Lind Global Asset Management V, LLC (&#8220;Lind V&#8221;) pursuant
to which, among other things, on November 23, 2021 (the &#8220;Closing Date&#8221;), the Company issued and sold to Lind V, in a private
placement transaction (the &#8220;Private Placement&#8221;), in exchange for the payment by Lind V of $20.0 million, (i) a convertible
promissory note (the &#8220;2021 Note&#8221;) in an aggregate principal amount of $22.0 million (the &#8220;Principal Amount&#8221;),
which will bear no interest until the first anniversary of the issuance of the 2021 Note and will thereafter bear interest at a rate
of 5% per annum, and mature on November 23, 2024 (the &#8220;Maturity Date&#8221;), and (ii) 534,759 shares of Company common stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=SEEL_FirstAnniversaryOfNovember2021LindSecuritiesPurchaseAgreementMember', window );">First Anniversary Of November 2021 Lind Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtDescription', window );">Long-Term Debt, Description</a></td>
<td class="text">At the first anniversary of the Closing Date, the Company shall
have the option, at its sole discretion, to issue to Lind V a convertible promissory note (the &#8220;Second Note&#8221;) in the principal
amount of $11.0 million in exchange for the payment by Lind V of $10.0 million. At the earlier of (i) the two-year anniversary of the
Closing Date, or (ii) the successful readout for SLS-005 in ALS, and subject to the mutual agreement of the Company and Lind V, the Company
shall issue to Lind V a convertible promissory note (the &#8220;Third Note&#8221;) in the principal amount of $11.0 million in exchange
for the payment by Lind V of $10.0 million. In the event of the filing of a new drug application with the U.S. Food & Drug Administration
for either SLS-002 or SLS-005, and subject to the mutual agreement of the Company and Lind V, the Company shall issue to Lind V a convertible
promissory note (the &#8220;Fourth Note&#8221;) in the principal amount of $11.0 million in exchange for the payment by Lind V of $10.0
million. The Second Note, the Third Note and the Fourth Note, if issued, would be in substantially the same form as the 2021 Note.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=SEEL_August232022ThruMaturityNovember2021LindSecuritiesPurchaseAgreementMember', window );">August 232022 Thru Maturity November 2021 Lind Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtDescription', window );">Long-Term Debt, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">At any time following August 23, 2022, from time to time and before the
Maturity Date, Lind V shall have the option to convert any portion of the then-outstanding Principal Amount of the 2021 Note into shares
of Common Stock at a price per share of $6.00, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar
transactions (the &#8220;Conversion Price&#8221;). At any time prior August 23, 2022, the Company shall have the right to prepay, in whole
or in part (exercisable by the Company at any time or from time to time during such period), up to an aggregate of $14.7 million of the
outstanding Principal Amount of the 2021 Note with no penalty. If the Company does not prepay any amounts of the 2021 Note prior to August
23, 2022 then, commencing August 23, 2022, the Company shall have the right to prepay, in whole or in part (exercisable by the Company
at any time or from time to time prior to the Maturity Date), up to the full remaining Principal Amount of the 2021 Note with no penalty;
however, if the Company exercises such prepayment right, Lind V will have the option to convert up to thirty-three and one-third percent
(33 1/3%) of the amount that the Company elects to prepay at the Conversion Price. If the Company prepays any amounts of the 2021 Note
prior to August 23, 2022 then, commencing November 23, 2022, the Company shall not have the right to prepay any amounts of the 2021 Note
between August 23, 2022 to November 23, 2022 and, commencing November 23, 2022, the Company shall have the right to prepay, in whole or
in part (exercisable by the Company at any time or from time to time prior to the Maturity Date) up to the full remaining Principal Amount
of the 2021 Note with no penalty; however, if the Company exercises such prepayment right, Lind V will have the option to convert up to
thirty-three and one-third percent (33 1/3%) of the amount that the Company elects to prepay at the Conversion Price.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=SEEL_AmortizeNovember2021LindSecuritiesPurchaseAgreementMember', window );">Amortize November 2021 Lind Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtDescription', window );">Long-Term Debt, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Beginning on November 23, 2022, the 2021 Note will amortize in twenty-four
monthly installments equal to the quotient of (i) the then-outstanding Principal Amount of the 2021 Note, divided by (ii) the number of
months remaining until the Maturity Date. All amortization payments shall be payable, at the Company&#8217;s sole option, in cash, shares
of Common Stock or a combination of both. In addition, commencing on the last business day of the first month following November 23, 2022,
the Company will pay, on a monthly basis, all interest that has accrued and remains unpaid on the then-outstanding Principal Amount of
the 2021 Note. Any portion of an amortization payment or interest payment that is paid in shares of Common Stock shall be priced at 90%
of the average of the five lowest daily volume weighted average prices of the Common Stock during the 20 trading days prior to the date
of issuance of the shares. If, after the first amortization payment, the Company elects to make any amortization payments in cash, the
Company shall pay a 5% premium on each cash payment. In conjunction with the 2021 Lind Securities Purchase Agreement and the 2021 Note,
on the Closing Date, the Company and Lind V entered into a security agreement, which provides Lind V with a first priority lien on the
Company&#8217;s assets and properties.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=SEEL_December2021SPAsMember', window );">December 2021 S P As [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtDescription', window );">Long-Term Debt, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On December 2, 2021, the Company entered into two separate securities purchase
agreements with certain accredited investors on substantially the same terms as the 2021 Lind Securities Purchase Agreement, pursuant
to which the Company sold, in private placement transactions, in exchange for the payment by the accredited investors of an aggregate
of $201,534, (i) convertible promissory notes in an aggregate principal amount of $221,688, which will bear no interest and mature on
December 2, 2024, and (ii) an aggregate of 5,388 shares of its common stock. These notes have substantially the same terms as the 2021
Note.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleSubordinatedDebt', window );">Convertible Subordinated Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_GainLossInFairValueOfConvertibleNotes', window );">[custom:GainLossInFairValueOfConvertibleNotes]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-Term Debt, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=SEEL_LindSecuritiesPurchaseAgreementMember', window );">Lind Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtDescription', window );">Long-Term Debt, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On
December 11, 2020, the Company entered into a Securities Purchase Agreement (the &#8220;2020 Lind Securities Purchase
Agreement&#8221;) with Lind Global Asset Management II, LLC (the &#8220;Investor&#8221;) pursuant to which, among other things, on
December 11, 2020, the Company issued and sold to the Investor, in a private placement transaction, in exchange for the payment by
the Investor of $10,000,000, (1) a convertible promissory note (the &#8220;2020 Note&#8221;) in an aggregate principal amount of
$12,000,000 (the &#8220;Principal Amount&#8221;), which did not bear interest and was to mature on December 11, 2022 (the
&#8220;Maturity Date&#8221;), and (2) 975,000 shares of the Company&#8217;s common stock. At any time following June 11, 2021, and
from time to time before the Maturity Date, the Investor had the option to convert any portion of the then-outstanding Principal
Amount of the Note into shares of common stock at a price per share of $1.60, subject to adjustment for stock splits, reverse stock
splits, stock dividends and similar transactions. Prior to June 11, 2021, the Company had the right to prepay up to sixty-six and
two-thirds percent (66 2/3%) of the then-outstanding Principal Amount of the 2020 Note with no penalty. Subject to certain
exceptions, the Company was required to direct proceeds from any subsequent debt financings (including subordinated debt,
convertible debt or mandatorily redeemable preferred stock but other than purchase money debt or capital lease obligations or other
indebtedness incurred in the ordinary course of business) to repay the 2020 Note, unless waived by the Investor in advance. The 2020
Note began amortizing in June 2021 and was to amortize in eighteen monthly installments equal to the quotient of (i) the
then-outstanding Principal Amount of the 2020 Note, divided by (ii) the number of months remaining until the Maturity Date. All
amortization payments were to be payable solely in cash, plus a 2% premium. During the first half of 2021, the Company made certain
repayments on the outstanding principal balance of the convertible notes. On June 14, 2021, the Company and the Investor entered
into an Acknowledgment and Termination Agreement, pursuant to which the Company agreed to issue to the Investor an aggregate of
406,250 additional shares of its common stock (the &#8220;Lind Shares&#8221;) and to pay the Investor the remaining principal amount
of $790,804 (the &#8220;Final Payment&#8221;) in full satisfaction of the Company&#8217;s  remaining obligations to the Investor
under the 2020 Note. The Company issued the Lind Shares and made the Final Payment to the Investor, and the 2020 Lind Securities
Purchase Agreement and the 2020 Note terminated, effective June 15, 2021.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=SEEL_December17SPAsMember', window );">December 17 S P As [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtDescription', window );">Long-Term Debt, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On December 17, 2020, the Company entered into three separate securities
purchase agreements with certain accredited investors on substantially the same terms as the Lind Securities Purchase Agreement (the &#8220;December
17 SPAs&#8221;), pursuant to which the Company sold, in private placement transactions, in exchange for the payment by the accredited
investors of an aggregate of $1,138,023, (1) convertible promissory notes (the &#8220;December 17 Notes&#8221;) in an aggregate principal
amount of $1,365,628, which did not bear interest and were to mature on December 17, 2022, and (2) an aggregate of 110,956 shares of its
common stock. On December 18, 2020, the Company entered into an additional securities purchase agreement with
an accredited investor on substantially the same terms as the Lind Securities Purchase Agreement (the &#8220;December 18 SPA&#8221; and,
together with the December 17 SPAs, the "Subsequent Securities Purchase Agreements"), pursuant to which the Company sold, in
a private placement transaction, in exchange for the payment by the accredited investor of $269,373, (1) a convertible promissory note
in an aggregate principal amount of $323,247, which did not bear interest and was to mature on December 18, 2022 (the &#8220;December
18 Note&#8221; and, together with the December 17 Notes, the &#8220;Subsequent Notes&#8221;), and (2) 26,263 shares of the Company&#8217;s
common stock. The Subsequent Securities Purchase Agreements had substantially the same terms as the Lind Securities Purchase Agreement,
and the Subsequent Notes had substantially the same terms as the Note. During the first half of 2021, the Company made certain repayments
on the outstanding principal balance of the convertible notes. On July 7, 2021, the Company and the holder of the December 18 Note (the
&#8220;December 18 Note Holder&#8221;) entered into an Acknowledgement and Termination Agreement, pursuant to which: (i) the December
18 Note Holder agreed to return to the Company $42,777 in cash (the &#8220;Repayment&#8221;) previously paid by the Company to the December
18 Note Holder as a payment against the Company&#8217;s obligations under the December 18 Note, and (ii) the Company agreed to issue to
the December 18 Note Holder an aggregate of 43,664 additional shares of its common stock (the &#8220;December 18 Note Shares&#8221;) in
full satisfaction of the Company&#8217;s remaining obligations to the December 18 Note Holder under the December 18 Note. The December 18 Note Holder
paid the Company the Repayment and the Company issued the December Note Shares, and the December 18 SPA and the December 18 Note terminated,
effective July 7, 2021.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayments of Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock Issued During Period, Shares, Conversion of Convertible Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">475,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-Term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_GainLossInFairValueOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_GainLossInFairValueOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleSubordinatedDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, the carrying value of convertible subordinated debt, as of the balance sheet date, initially scheduled to be repaid after one year or beyond the normal operating cycle if longer. This form of debt can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder, and places a lender in a lien position behind debt having a higher priority of repayment in liquidation of the entity's assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleSubordinatedDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of long-term debt arrangements, which are debt arrangements that originally require full repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer, and disclosures pertaining to the underlying arrangements, including repayment terms, conversion features, interest rates, restrictions on assets and activities, debt covenants, and other matters important to users of the financial statements. Types of long-term debt arrangements include borrowing under notes payable, bonds payable, debentures, term loans, and other contractual obligations for payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=SEEL_November2021LindSecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=SEEL_November2021LindSecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=SEEL_FirstAnniversaryOfNovember2021LindSecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=SEEL_FirstAnniversaryOfNovember2021LindSecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=SEEL_August232022ThruMaturityNovember2021LindSecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=SEEL_August232022ThruMaturityNovember2021LindSecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=SEEL_AmortizeNovember2021LindSecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=SEEL_AmortizeNovember2021LindSecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=SEEL_December2021SPAsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=SEEL_December2021SPAsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=SEEL_LindSecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=SEEL_LindSecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=SEEL_December17SPAsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=SEEL_December17SPAsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332064841560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Warrant Activity (Details) - Warrant Derivative Financial Instruments [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding as of December 31, 2021 | shares</a></td>
<td class="nump">2,635,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Outstanding as of December 31, 2020, weighted-average exercise price (in usd per share) | $ / shares</a></td>
<td class="nump">$ 4.29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_ClassOfWarrantOrRightOutstandingWeightedAverageRemaingContractualLife', window );">Warrants outstanding as of December 31, 2020, weighted-average remaing contractual life (in years)</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_NumberofWarrantsIssuedDuringPeriod', window );">Issued | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_ClassOfWarrantOrRightIssuedExercisePriceOfWarrantsOrRights', window );">Issued, warrant exercise price | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_NumberofWarrantsExercisedDuringPeriod', window );">Exercised | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_ClassOfWarrantOrRightExercisedExercisePriceOfWarrantsOrRights', window );">Exercised, exercise price of warrants | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_NumberofWarrantsCancelledDuringPeriod', window );">Cancelled | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_ClassOfWarrantOrRightCancelledExercisePriceOfWarrantsOrRights', window );">Cancelled, exercise price of warrants | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding as of March 31, 2022 | shares</a></td>
<td class="nump">2,635,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Outstanding as of June 30, 2021, weighted-average exercise price (in usd per share) | $ / shares</a></td>
<td class="nump">$ 4.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_ClassOfWarrantOrRightOutstandingEndOfPeriodWeightedAverageRemaingContractualLife', window );">Warrants outstanding as of June 30, 2021, weighted-average remaing contractual life (in years)</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_WarrantsExercisable', window );">Warrants exercisable as of March 31, 2022 | shares</a></td>
<td class="nump">2,635,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights1', window );">Exercisable, weighted-average exercise price (in usd per share) | $ / shares</a></td>
<td class="nump">$ 4.29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_ClassOfWarrantOrRightExercisableWeightedAverageRemaingContractualLife', window );">Warrants exercisable as of June 30, 2021, weighted-average remaing contractual life (in years)</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_ClassOfWarrantOrRightCancelledExercisePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_ClassOfWarrantOrRightCancelledExercisePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_ClassOfWarrantOrRightExercisableWeightedAverageRemaingContractualLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_ClassOfWarrantOrRightExercisableWeightedAverageRemaingContractualLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_ClassOfWarrantOrRightExercisedExercisePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_ClassOfWarrantOrRightExercisedExercisePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_ClassOfWarrantOrRightIssuedExercisePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_ClassOfWarrantOrRightIssuedExercisePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_ClassOfWarrantOrRightOutstandingEndOfPeriodWeightedAverageRemaingContractualLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_ClassOfWarrantOrRightOutstandingEndOfPeriodWeightedAverageRemaingContractualLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_ClassOfWarrantOrRightOutstandingWeightedAverageRemaingContractualLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_ClassOfWarrantOrRightOutstandingWeightedAverageRemaingContractualLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_NumberofWarrantsCancelledDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_NumberofWarrantsCancelledDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_NumberofWarrantsExercisedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_NumberofWarrantsExercisedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_NumberofWarrantsIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_NumberofWarrantsIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_WarrantsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_WarrantsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=SEEL_WarrantDerivativeFinancialInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=SEEL_WarrantDerivativeFinancialInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332065656136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>10. Stockholders&#8217; Equity (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Aug. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 04, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, per value (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,000,000<span></span>
</td>
<td class="nump">240,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock voting right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each share of common stock is entitled to
one voting right<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5,868,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=SEEL_September2020WarrantsMember', window );">September 2020 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares of common stock issued</a></td>
<td class="nump">6,648,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_WarrantsExercisable', window );">Warrants exercisable as of June 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=SEEL_August232019Member', window );">August 232019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=SEEL_August2019WarrantsMember', window );">August 2019 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_WarrantsExercisable', window );">Warrants exercisable as of June 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=SEEL_September2020WarrantsMember', window );">September 2020 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Warrant description</a></td>
<td class="text">On September 4, 2020, the Company entered into a securities purchase agreement
with certain institutional investors pursuant to which the Company issued and sold an aggregate of 8,865,000 shares of common stock in
a registered direct offering and issued warrants to purchase up to 6,648,750 shares of common stock in a concurrent private placement
(the &#8220;September 2020 Warrants&#8221;). The September 2020 Warrants are initially exercisable for
6,648,750 shares of common stock at an exercise price per share equal to $0.84. The September 2020 Warrants became exercisable beginning
on March 9, 2021 and will expire on March 9, 2026.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Date on which warrants became exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar.  09,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_NumberofWarrantsExercisedDuringPeriod', window );">Number of warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=SEEL_August2019WarrantsMember', window );">August 2019 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Warrant description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On August 23, 2019, the Company entered into a securities
purchase agreement with certain institutional investors pursuant to which the Company issued and sold an aggregate of 4,475,000 shares
of common stock in a registered direct offering and issued warrants to purchase up to 2,237,500 shares of common stock in a concurrent
private placement (the &#8220;August 2019 Warrants&#8221;). The August 2019 Warrants were initially exercisable for 2,237,500 shares of
common stock at an exercise price per share equal to $1.78. The August 2019 Warrants became exercisable beginning on February 27, 2020
and will expire on August 28, 2023.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Date on which warrants became exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 27,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_NumberofWarrantsExercisedDuringPeriod', window );">Number of warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=SEEL_SeriesAWarrantsMember', window );">Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Warrant description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On January 24, 2019, STI and the Company closed a private placement with certain accredited investors pursuant to which, among other
things, the Company issued warrants representing the right to acquire 1,463,519 shares of common stock (the &#8220;Series A
Warrants&#8221;). The Series A Warrants were initially exercisable for 1,463,519 shares of common stock at an exercise price per
share equal to $4.15, which was adjusted several times pursuant to the terms thereof to 3,629,023 shares of common stock at an
exercise price per share equal to $0.2957 per share. The most recent adjustment to the exercise price (from $0.60 to $0.2957 per
share) occurred during the three months ended September 30, 2020 as a result of the announcement of the registered direct offering
of 8,865,000 shares of common stock in September 2020. The Series A Warrants were immediately exercisable upon issuance and will expire
on January 31, 2024.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_NumberofWarrantsExercisedDuringPeriod', window );">Number of warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_WarrantsExercisable', window );">Warrants exercisable as of June 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_NumberofWarrantsExercisedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_NumberofWarrantsExercisedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_WarrantsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_WarrantsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of reason for issuing warrant or right.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SEEL_September2020WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SEEL_September2020WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SEEL_August232019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SEEL_August232019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SEEL_August2019WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SEEL_August2019WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=SEEL_September2020WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=SEEL_September2020WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=SEEL_August2019WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=SEEL_August2019WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=SEEL_SeriesAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=SEEL_SeriesAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332069767224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Valuation Assumptions for Stock Options (Details) - Share-Based Payment Arrangement, Option [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">150.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">160.00%<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility, minimum</a></td>
<td class="nump">113.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value</a></td>
<td class="nump">$ 1.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value</a></td>
<td class="nump">$ 1.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332068745832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Stock Option Activity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="num">(6,250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, end of period (USD per share) | $ / shares</a></td>
<td class="nump">$ 2.27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding as of December 31, 2020</a></td>
<td class="nump">7,306,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning of period (USD per share) | $ / shares</a></td>
<td class="nump">$ 2.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted in period (USD per share) | $ / shares</a></td>
<td class="nump">$ 1.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="num">(6,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised in period (USD per share) | $ / shares</a></td>
<td class="nump">$ 1.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled (USD per share) | $ / shares</a></td>
<td class="nump">$ (0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding as of March 31, 2022</a></td>
<td class="nump">10,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding - weighted-average remaining contractual life (in years)</a></td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Total aggregate intrinsic value shares outstanding | $</a></td>
<td class="nump">$ 2,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest, end of period (shares)</a></td>
<td class="nump">10,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest stock, end of period (USD per share) | $ / shares</a></td>
<td class="nump">$ 2.27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual life (in years) of vested and expected to vest stock options</a></td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Total aggregate intrinsic value of vested or expected to vest stock options | $</a></td>
<td class="nump">$ 2,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, end of period (shares)</a></td>
<td class="nump">3,085,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, end of period (USD per share) | $ / shares</a></td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual life (in years) of exercisable stock options</a></td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Total aggregate intrinsic value of exercisable stock options | $</a></td>
<td class="nump">$ 2,894<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332064932088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,232<span></span>
</td>
<td class="nump">$ 705<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">229<span></span>
</td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,003<span></span>
</td>
<td class="nump">$ 569<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332069443896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>11. Stock-based Compensation (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 15, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-Based Payment Arrangement, Noncash Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,232,000<span></span>
</td>
<td class="nump">$ 705,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Description of share-based compensation arrangement by share-based payment award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
Company has the Seelos Therapeutics, Inc. Amended and Restated 2012 Stock Long Term Incentive Plan (the &#8220;2012 Plan&#8221;), which
provides for the issuance of incentive and non-incentive stock options, restricted and unrestricted stock awards, stock unit awards and
stock appreciation rights. Options and restricted stock units granted generally vest over a period of one to four years and have a maximum
term of ten years from the date of grant. The 2012 Plan provides that an additional number of shares will automatically be added annually
to the shares authorized for issuance under the 2012 Plan on January 1st of each year commencing on January 1, 2020 and ending on (and
including) January 1, 2029. The number of shares added each year will be equal to the lesser of (a) 4% of the number of shares of common
stock issued and outstanding on a fully-diluted basis as of the close of business on the immediately preceding December 31, and (b) a
number of shares of common stock set by the Company&#8217;s board of directors on or prior to each such January 1. On January 1, 2022,
in accordance with the foregoing, an aggregate of 4,713,637 shares of common stock were added to shares authorized for issuance under
the 2012 Plan. As of March 31, 2022, an aggregate of<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</a></td>
<td class="nump">4,713,637,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,817,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price per share granted in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=SEEL_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Description of share-based compensation arrangement by share-based payment award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On May 15, 2020, the
Company&#8217;s stockholders approved the Company's 2020 Employee Stock Purchase Plan (the "ESPP"),
whereby qualified employees are allowed to purchase limited amounts of the Company&#8217;s common stock at the lesser of
85% of the market price at the beginning or end of the offering period. The
stockholders have authorized an initial amount of 1.0 million shares for purchase by employees under the ESPP. The ESPP provides
that an additional number of shares will automatically be added annually to the shares authorized for issuance under the ESPP on
January 1st of each year commencing on January 1, 2021 and ending on (and including) January 1, 2030, which amount shall be equal to
the lesser of (i) 1% of the number of shares of the Company's common stock issued and outstanding on the immediately preceding
December 31, and (ii) a number of shares of common stock set by the Company&#8217;s Board of Directors or the Compensation
Committee of the Board of Directors (the &#8220;Compensation Committee&#8221;) of the Company on
or prior to each such January 1. On January 1, 2022, the Company added 1,055,004 shares for purchase by employees under the ESPP.
During the three months ended March 31, 2022, the Company sold 84,078 shares of common
stock under the ESPP. The compensation costs are calculated as the fair value of the 15% discount from market price and were
approximately $17,000 for the three months ended March 31, 2022.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</a></td>
<td class="nump">1,055,004,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Stock Issued During Period, Shares, Employee Stock Purchase Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceDiscountOfCommonStockPercent', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price Discount of Common Stock, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-Based Payment Arrangement, Noncash Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=SEEL_InducementPlanof2019Member', window );">Inducement Planof 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Description of share-based compensation arrangement by share-based payment award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On July 28, 2019, the Compensation Committee of the Board of Directors (the &#8220;Compensation
Committee&#8221;) of the Company adopted the Seelos Therapeutics, Inc. 2019 Inducement Plan (the &#8220;2019 Inducement Plan&#8221;),
which became effective on August 12, 2019. The 2019 Inducement Plan provides for the grant of equity-based awards in the form of stock
options, stock appreciation rights, restricted stock, unrestricted stock, stock units, including restricted stock units, performance units
and cash awards, solely to prospective employees of the Company or an affiliate of the Company provided that certain criteria are met.
Awards under the 2019 Inducement Plan may only be granted to an individual, as a material inducement to such individual to enter into
employment with the Company, who (i) has not previously been an employee or director of the Company or (ii) is rehired following a bona
fide period of non-employment with the Company. The maximum number of shares available for grant under the 2019 Inducement Plan is 1,000,000
shares of the Company&#8217;s common stock. The 2019 Inducement Plan is administered by the Compensation Committee and expires on August 12, 2029.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=SEEL_IncentiveStockOptionMember', window );">Incentive Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">560,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price per share granted in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of option grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage on the first anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=SEEL_NonQualifiedStockOptionsToEmployeesMember', window );">Non Qualified Stock Options To Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,299,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=SEEL_NonQualifiedStockOptionsToNonEmployeeDirectorsMember', window );">Non Qualified Stock Options To Non Employee Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price per share granted in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of option grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares [Member] | P S Uto Executives [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-Based Payment Arrangement, Noncash Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">During the year
ended December 31, 2021, the Company&#8217;s Board of Directors awarded a performance stock unit award to the Company&#8217;s Chief Executive
Officer for 2,400,000 shares of common stock, with a grant date fair value of $4.31 per unit. Vesting of this award was subject to the
Company achieving certain performance criteria established at the grant date and the individual fulfilling a service condition (continued
employment). As of December 31, 2021, all performance stock unit awards were unvested and three of the five performance conditions had
been satisfied. The Company recognized stock-based compensation related to this award of $4.9 million during the fourth quarter of 2021,
which was recorded in general and administrative expense. During the three months ended March 31, 2022, the Company and its Chief Executive
Officer entered into an agreement to cancel the performance stock unit award for no consideration. In connection with the cancellation
of the award, no replacement awards were granted or authorized. At the time of cancellation, the Company recognized the remaining compensation
expense of the three achieved milestones of $1.3 million. The two remaining milestones were not deemed probable of achievement at the
time of cancellation, and no compensation cost related to these milestones was recognized.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_SharebasedPaymentArrangementNonvestedAndCanceledAwardExcludingOptionCostNotYetRecognizedAmount', window );">Share-Based Payment Arrangement, Nonvested and Canceled Award, Excluding Option, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceDiscountOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceDiscountOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_SharebasedPaymentArrangementNonvestedAndCanceledAwardExcludingOptionCostNotYetRecognizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_SharebasedPaymentArrangementNonvestedAndCanceledAwardExcludingOptionCostNotYetRecognizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SEEL_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SEEL_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SEEL_InducementPlanof2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SEEL_InducementPlanof2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SEEL_IncentiveStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SEEL_IncentiveStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SEEL_NonQualifiedStockOptionsToEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SEEL_NonQualifiedStockOptionsToEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SEEL_NonQualifiedStockOptionsToNonEmployeeDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SEEL_NonQualifiedStockOptionsToNonEmployeeDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=SEEL_PSUtoExecutivesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=SEEL_PSUtoExecutivesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332068497944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of future minimum operating lease payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remaining Period Ended December 31, 2022</a></td>
<td class="nump">$ 27<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less present value discount</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 26<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332069419384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>12. Commitments and Contingencies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities - current</a></td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating Lease, Weighted Average Remaining Lease Term</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating Lease, Weighted Average Discount Rate, Percent</a></td>
<td class="nump">800.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating Lease, Expense</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=SEEL_March2019LeaseMember', window );">March 2019 Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Operating lease description</a></td>
<td class="text">In March 2019, the Company entered into a nine-month
office space rental agreement for its headquarters in New York, New York expiring November 2019. In November 2019, the Company renewed
this rental agreement for an additional twelve-months for a base rent of approximately $9,000 per month. In November 2020, the Company
renewed this rental agreement for an additional twelve-months for a base rent of approximately $3,800 per month. In March 2021, the Company
was notified that the counterparty&#8217;s right to occupy the space at 300 Park Avenue, New York, NY was terminated, and the Company
was required to vacate by March 26, 2021. The Company vacated the premises and has advised the counterparty that the counterparty is
in breach of this rental agreement and therefore, the Company has no further obligations thereunder.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=SEEL_March2021LeaseMember', window );">March 2021 Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Operating lease description</a></td>
<td class="text">In
March 2021, the Company entered into an eighteen-month office space rental agreement for its headquarters at 300 Park Avenue, New
York, NY, expiring July 2022. The rental agreement contains a base rent of approximately $4,000 per month. This
agreement includes one or more renewal options. At March 31, 2022, the Company has right-of-use
assets of $26,000 and a total lease liability for operating leases of $26,000, of which all
is included in current lease liabilities.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Option to extend</a></td>
<td class="text">This
agreement includes one or more renewal options.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="nump">$ 74,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities - current</a></td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=SEEL_March2019LeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=SEEL_March2019LeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=SEEL_March2021LeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=SEEL_March2021LeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140332065544120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>13. Subsequent Events (Details Narrative) - Subsequent Event [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 11, 2022</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDescription', window );">Business Combination, Separately Recognized Transactions, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On April 8, 2022,
Seelos Corporation (&#8220;STI&#8221;), a wholly-owned subsidiary of the Company, and Phoenixus AG f/k/a Vyera Pharmaceuticals AG (&#8220;Vyera&#8221;),
entered into an amendment (the &#8220;Amendment&#8221;) to the Asset Purchase Agreement by and between STI and Vyera, dated March 6, 2018
(as amended by a first amendment thereto entered into on May 18, 2018, a second amendment thereto entered into on December 31, 2018, a
third amendment thereto entered into on October 15, 2019 and a fourth amendment thereto entered into on February 15, 2021, the &#8220;Vyera
Purchase Agreement&#8221;). Pursuant to the Vyera Purchase Agreement, STI acquired the assets and liabilities of Vyera related to a product
candidate currently referred to as SLS-002 (intranasal ketamine) (the &#8220;Vyera Assets&#8221;) and agreed, among other things, to make
certain development and commercialization milestone payments and royalty payments related to the Vyera Assets (the &#8220;Milestone and
Royalty Payment Obligations&#8221;) and further agreed that in the event that the Company sold, directly or indirectly, all or substantially
all of the Vyera Assets to a third party, then the Company would pay Vyera an amount equal to 4% of the net proceeds actually received
by the Company as an upfront payment in such sale (the &#8220;Change of Control Payment Obligation&#8221;).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventDescription', window );">Subsequent Event, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Pursuant
to the Vyera Purchase Agreement, as amended by the Amendment, STI agreed to (i) make a cash payment to Vyera in the aggregate amount
of $4.0
million on or before April 8, 2022; (ii) issue to Vyera on or before April 11, 2022 500,000
shares of the Company&#8217;s common stock, (the &#8220;Initial Shares&#8221;); (iii) issue to Vyera on or before July 11, 2022 an
additional 500,000
shares of the Company&#8217;s common stock (as adjusted for stock splits, stock dividends, combinations, recapitalizations and the
like) (the &#8220;July 2022 Shares&#8221;); and (iv) issue to Vyera on or before January 11, 2023 an additional number of shares of
the Company&#8217;s common stock equal to $1.0 million divided by the volume weighted average closing price of the Company&#8217;s
common stock for the ten consecutive trading days ending on the fifth trading day prior to the applicable date of issuance of the
shares of the Company&#8217;s common stock (the &#8220;January 2023 Shares&#8221;, and together with the Cash Payment, the Initial
Shares and the July 2022 Shares, &#8220;Final Payments&#8221;). In consideration for the Final Payments, all of STI&#8217;s
contingent payment obligations under the Vyera Purchase Agreement, including the Milestone and Royalty Payment Obligations and the
Change of Control Payment Obligation, as well as all commercialization covenants of STI under the Vyera Purchase Agreement, will
terminate in full upon the date that all of the Final Payments have been made.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Assetsfrom Vyera Pharmaceuticals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SEEL_CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement', window );">[custom:CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SEEL_CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SEEL_CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SEEL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of each transaction that is recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the event or transaction that occurred between the balance sheet date and the date the financial statements are issued or available to be issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=SEEL_AssetsfromVyeraPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=SEEL_AssetsfromVyeraPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>body10-q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:SEEL="http://seelostx.com/20220331"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="seel-20220331.xsd" xlink:type="simple"/>
    <context id="From2022-01-01to2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-04-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
        </entity>
        <period>
            <instant>2022-04-28</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="From2021-05-012021-05-31_custom_May242021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SEEL:May242021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-05-24_custom_May242021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SEEL:May242021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-24</instant>
        </period>
    </context>
    <context id="From2021-01-012021-01-31_custom_January282021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SEEL:January282021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-01-28_custom_January282021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SEEL:January282021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-28</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_ConvertibleDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_ConvertibleDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-01-31_custom_IXLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:IXLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_LongTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_WarrantMember654115578">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_LongTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_LongTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_LongTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_LongTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_LongTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_LongTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_LongTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_LongTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember_us-gaap_LongTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_LongTermDebtMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_LongTermDebtMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_LongTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_LongTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_LongTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_LongTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_LongTermDebtMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_LongTermDebtMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_LongTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_LongTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_May242021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SEEL:May242021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_January282021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SEEL:January282021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-11-012021-11-30_custom_IXLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:IXLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="From2021-11-012021-12-31_custom_IXLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:IXLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2019-08-012019-08-31_custom_WegLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:WegLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-01-31_custom_WegLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:WegLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-01-31_custom_WegLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:WegLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-01-31_custom_WegLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:WegLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_WegLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:WegLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2021-11-012021-11-30_custom_November2021LindSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SEEL:November2021LindSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="From2022-11-012022-11-30_custom_FirstAnniversaryOfNovember2021LindSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SEEL:FirstAnniversaryOfNovember2021LindSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="From2022-08-232024-11-23_custom_August232022ThruMaturityNovember2021LindSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SEEL:August232022ThruMaturityNovember2021LindSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-23</startDate>
            <endDate>2024-11-23</endDate>
        </period>
    </context>
    <context id="From2022-11-232024-11-24_custom_AmortizeNovember2021LindSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SEEL:AmortizeNovember2021LindSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-23</startDate>
            <endDate>2024-11-24</endDate>
        </period>
    </context>
    <context id="From2021-12-012021-12-31_custom_December2021SPAsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SEEL:December2021SPAsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-02_custom_December2021SPAsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SEEL:December2021SPAsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-02</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_December2021SPAsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SEEL:December2021SPAsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_December2021SPAsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SEEL:December2021SPAsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_December2021SPAsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SEEL:December2021SPAsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2020-12-012020-12-31_custom_LindSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SEEL:LindSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-12-012020-12-31_custom_December17SPAsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SEEL:December17SPAsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-12-012021-12-31_custom_December17SPAsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SEEL:December17SPAsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_December17SPAsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SEEL:December17SPAsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2020-09-012020-09-30_custom_September2020WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SEEL:September2020WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-09-012020-09-30_custom_September2020WarrantsMember654121703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SEEL:September2020WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-09-04_custom_September2020WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SEEL:September2020WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-04</instant>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_custom_September2020WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SEEL:September2020WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_September2020WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SEEL:September2020WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_September2020WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SEEL:September2020WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_September2020WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SEEL:September2020WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_September2020WarrantsMember654121843">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SEEL:September2020WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2019-08-012019-08-31_custom_August2019WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SEEL:August2019WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="From2019-08-012019-08-31_custom_August232019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SEEL:August232019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_August2019WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SEEL:August2019WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_August2019WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SEEL:August2019WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_August2019WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SEEL:August2019WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_August2019WarrantsMember654121984">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SEEL:August2019WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_custom_SeriesAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SEEL:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_SeriesAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SEEL:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_SeriesAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SEEL:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_SeriesAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SEEL:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_WarrantDerivativeFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">SEEL:WarrantDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_WarrantDerivativeFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">SEEL:WarrantDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_WarrantDerivativeFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">SEEL:WarrantDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember654123531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-01-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2020-05-012020-05-31_custom_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SEEL:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-05-15_custom_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SEEL:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-15</instant>
        </period>
    </context>
    <context id="From2022-01-012022-01-31_custom_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SEEL:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SEEL:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_InducementPlanof2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SEEL:InducementPlanof2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_InducementPlanof2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SEEL:InducementPlanof2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_IncentiveStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SEEL:IncentiveStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_NonQualifiedStockOptionsToEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SEEL:NonQualifiedStockOptionsToEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_NonQualifiedStockOptionsToNonEmployeeDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SEEL:NonQualifiedStockOptionsToNonEmployeeDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_EmployeeStockOptionMember654123812">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_PerformanceSharesMember_custom_PSUtoExecutivesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SEEL:PSUtoExecutivesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_PerformanceSharesMember_custom_PSUtoExecutivesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SEEL:PSUtoExecutivesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_PerformanceSharesMember_custom_PSUtoExecutivesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SEEL:PSUtoExecutivesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_March2019LeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">SEEL:March2019LeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_March2021LeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">SEEL:March2021LeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_March2021LeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">SEEL:March2021LeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_March2021LeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">SEEL:March2021LeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="From2022-04-012022-04-29_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-04-30_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-04-30_custom_AssetsfromVyeraPharmaceuticalsMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:AssetsfromVyeraPharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-07-11_custom_AssetsfromVyeraPharmaceuticalsMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:AssetsfromVyeraPharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-11</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Years">
        <measure>utr:Y</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-01-01to2022-03-31">0001017491</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-01-01to2022-03-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="From2022-01-01to2022-03-31">2022</dei:DocumentFiscalYearFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2022-01-01to2022-03-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="From2022-01-01to2022-03-31">Q1</dei:DocumentFiscalPeriodFocus>
    <SEEL:LicensesPayable
      contextRef="AsOf2022-03-31"
      id="xdx2ixbrl0074"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2022-03-31"
      id="xdx2ixbrl0080"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2022-03-31"
      id="xdx2ixbrl0098"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0099"
      unitRef="USD"
      xsi:nil="true"/>
    <SEEL:GainLossInFairValueOfConvertibleNotes
      contextRef="From2021-01-012021-03-31"
      id="xdx2ixbrl0173"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0198"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0200"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0203"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0205"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0209"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0211"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0215"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0216"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0232"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0234"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0237"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0239"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0243"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0245"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0251"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0257"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0261"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0262"
      unitRef="USD"
      xsi:nil="true"/>
    <SEEL:GainLossInFairValueOfConvertibleNotes
      contextRef="From2021-01-012021-03-31"
      id="xdx2ixbrl0288"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0290"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLossOnDerivative
      contextRef="From2021-01-012021-03-31"
      id="xdx2ixbrl0306"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0317"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0320"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0323"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0350"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="From2021-01-012021-03-31"
      id="xdx2ixbrl0351"
      unitRef="USD"
      xsi:nil="true"/>
    <SEEL:ReclassOfWarrantLiabilitiesRelatedToSeriesWarrantsExercisedForCash
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0356"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CapitalLeaseObligationsIncurred
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0359"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl0405"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0429"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0431"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_LongTermDebtMember"
      id="xdx2ixbrl0435"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_LongTermDebtMember"
      id="xdx2ixbrl0436"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember"
      id="xdx2ixbrl0440"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember"
      id="xdx2ixbrl0442"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0447"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0448"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0453"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0454"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_LongTermDebtMember"
      id="xdx2ixbrl0457"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_LongTermDebtMember"
      id="xdx2ixbrl0458"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"
      id="xdx2ixbrl0462"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"
      id="xdx2ixbrl0463"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember"
      id="xdx2ixbrl0465"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember"
      id="xdx2ixbrl0466"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0470"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_LongTermDebtMember"
      id="xdx2ixbrl0482"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_LongTermDebtMember"
      id="xdx2ixbrl0483"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-01-012022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      id="xdx2ixbrl0496"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-01-012021-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      id="xdx2ixbrl0498"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"
      id="xdx2ixbrl0519"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccruedInsuranceCurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0581"
      unitRef="USD"
      xsi:nil="true"/>
    <SEEL:NumberofWarrantsIssuedDuringPeriod
      contextRef="From2022-01-012022-03-31_custom_WarrantDerivativeFinancialInstrumentsMember"
      id="xdx2ixbrl0670"
      unitRef="Shares"
      xsi:nil="true"/>
    <SEEL:ClassOfWarrantOrRightIssuedExercisePriceOfWarrantsOrRights
      contextRef="From2022-01-012022-03-31_custom_WarrantDerivativeFinancialInstrumentsMember"
      id="xdx2ixbrl0672"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <SEEL:NumberofWarrantsExercisedDuringPeriod
      contextRef="From2022-01-012022-03-31_custom_WarrantDerivativeFinancialInstrumentsMember"
      id="xdx2ixbrl0674"
      unitRef="Shares"
      xsi:nil="true"/>
    <SEEL:ClassOfWarrantOrRightExercisedExercisePriceOfWarrantsOrRights
      contextRef="From2022-01-012022-03-31_custom_WarrantDerivativeFinancialInstrumentsMember"
      id="xdx2ixbrl0676"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <SEEL:NumberofWarrantsCancelledDuringPeriod
      contextRef="From2022-01-012022-03-31_custom_WarrantDerivativeFinancialInstrumentsMember"
      id="xdx2ixbrl0678"
      unitRef="Shares"
      xsi:nil="true"/>
    <SEEL:ClassOfWarrantOrRightCancelledExercisePriceOfWarrantsOrRights
      contextRef="From2022-01-012022-03-31_custom_WarrantDerivativeFinancialInstrumentsMember"
      id="xdx2ixbrl0680"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember654123531"
      id="xdx2ixbrl0744"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-01-012021-03-31_us-gaap_EmployeeStockOptionMember654123812"
      id="xdx2ixbrl0746"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember654123531"
      id="xdx2ixbrl0774"
      unitRef="Shares"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2022-01-01to2022-03-31">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2022-01-01to2022-03-31">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2022-01-01to2022-03-31">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2022-01-01to2022-03-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2022-01-01to2022-03-31">000-22245</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2022-01-01to2022-03-31">SEELOS THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-01-01to2022-03-31">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-01-01to2022-03-31">87-0449967</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-01-01to2022-03-31">300 Park Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-01-01to2022-03-31">2nd Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-01-01to2022-03-31">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-01-01to2022-03-31">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-01-01to2022-03-31">10022</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-01-01to2022-03-31">(646)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-01-01to2022-03-31">293-2100</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2022-01-01to2022-03-31">Common Stock, par value $0.001 per     share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-01-01to2022-03-31">SEEL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-01-01to2022-03-31">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2022-01-01to2022-03-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2022-01-01to2022-03-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2022-01-01to2022-03-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2022-01-01to2022-03-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-01-01to2022-03-31">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-01-01to2022-03-31">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2022-01-01to2022-03-31">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2022-04-28" decimals="INF" unitRef="Shares">106090773</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Cash contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">61772000</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">78734000</us-gaap:Cash>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">8895000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">4727000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">70667000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">83461000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">26000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">39000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">70693000</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">83500000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">2127000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">1693000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">3549000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">3728000</us-gaap:AccruedLiabilitiesCurrent>
    <SEEL:LicensesPayable contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">200000</SEEL:LicensesPayable>
    <us-gaap:ConvertibleSubordinatedDebtCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">4238000</us-gaap:ConvertibleSubordinatedDebtCurrent>
    <us-gaap:ConvertibleSubordinatedDebtCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">1030000</us-gaap:ConvertibleSubordinatedDebtCurrent>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">1174000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">190000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">424000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">26000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">38000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">10130000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">8287000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleSubordinatedDebtNoncurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">14926000</us-gaap:ConvertibleSubordinatedDebtNoncurrent>
    <us-gaap:ConvertibleSubordinatedDebtNoncurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">17890000</us-gaap:ConvertibleSubordinatedDebtNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">25056000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">26177000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-03-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2022-03-31" decimals="-3" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2021-12-31" decimals="-3" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2022-03-31" decimals="-3" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="-3" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-03-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-03-31" decimals="0" unitRef="Shares">240000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-03-31" decimals="0" unitRef="Shares">240000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">105590773</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-03-31" decimals="0" unitRef="Shares">105590773</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-12-31" decimals="0" unitRef="Shares">105500445</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="0" unitRef="Shares">105500445</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">105000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">105000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">200743000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">198428000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">155211000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">141210000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">45637000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">57323000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">70693000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">83500000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">10009000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">14112000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">4001000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">2500000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">14010000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">16612000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-14010000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">-16612000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeDomesticDeposits
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">26000</us-gaap:InterestIncomeDomesticDeposits>
    <us-gaap:InterestIncomeDomesticDeposits
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">19000</us-gaap:InterestIncomeDomesticDeposits>
    <us-gaap:InterestExpense
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">7000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">990000</us-gaap:InterestExpense>
    <SEEL:GainLossInFairValueOfConvertibleNotes
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-244000</SEEL:GainLossInFairValueOfConvertibleNotes>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">234000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">-1533000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">9000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">-2504000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-14001000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">-19116000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-01to2022-03-31"
      decimals="INF"
      unitRef="USDPShares">-0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-01to2022-03-31"
      decimals="INF"
      unitRef="USDPShares">-0.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-01-012021-03-31"
      decimals="INF"
      unitRef="USDPShares">-0.28</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2021-01-012021-03-31"
      decimals="INF"
      unitRef="USDPShares">-0.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-01to2022-03-31"
      decimals="INF"
      unitRef="Shares">105529772</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-01-01to2022-03-31"
      decimals="INF"
      unitRef="Shares">105529772</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-01-012021-03-31"
      decimals="INF"
      unitRef="Shares">69053332</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2021-01-012021-03-31"
      decimals="INF"
      unitRef="Shares">69053332</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="Shares">105500445</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">105000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">198428000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-141210000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">57323000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">2232000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">2232000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="Shares">6250</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">8000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">8000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="Shares">84078</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">75000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">75000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-14001000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-14001000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="Shares">105590773</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">105000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">200743000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-155211000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">45637000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="Shares">54535891</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">54000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">77680000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-75162000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">2572000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">705000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">705000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="Shares">29999</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">65000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">65000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="Shares">40518</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">30000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">30000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="Shares">6146125</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">6000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">7017000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">7023000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="Shares">17530488</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">18000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">33463000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">33481000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-19116000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">-19116000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="Shares">78283021</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">78000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">118960000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-94278000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">24760000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-14001000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">-19116000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">2232000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">705000</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-234000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">1533000</us-gaap:FairValueAdjustmentOfWarrants>
    <SEEL:GainLossInFairValueOfConvertibleNotes
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-244000</SEEL:GainLossInFairValueOfConvertibleNotes>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">986000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-4168000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">-777000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">434000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">-259000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-178000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">-199000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:DerivativeLossOnDerivative
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">1174000</us-gaap:DerivativeLossOnDerivative>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-200000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">5875000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-17045000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">-11252000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">5167000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">33481000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">5868000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">8000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">65000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">75000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">30000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">83000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">34277000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-16962000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">23025000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">78734000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">15662000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">61772000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">38687000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InterestPaidNet
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">4000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">4000</us-gaap:InterestPaidNet>
    <SEEL:ReclassOfWarrantLiabilitiesRelatedToSeriesWarrantsExercisedForCash
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">1155000</SEEL:ReclassOfWarrantLiabilitiesRelatedToSeriesWarrantsExercisedForCash>
    <us-gaap:CapitalLeaseObligationsIncurred
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">74000</us-gaap:CapitalLeaseObligationsIncurred>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_809_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z7EGwvIUIQ98" style="font: 11pt Times New Roman, Times, Serif; margin: 0 142.6pt 0 5pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-size: 10pt; letter-spacing: -0.8pt"&gt;&lt;b/&gt;&lt;/span&gt;&lt;b&gt;&lt;span style="font: 7pt Times New Roman, Times, Serif; letter-spacing: -0.8pt"&gt;
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;1. Organization and Description of Business&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 142.6pt 0 5pt; text-align: justify; text-indent: 0in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 5pt"&gt;Seelos Therapeutics, Inc. (together with its subsidiaries,
the &#x201c;Company&#x201d;) is a clinical-stage biopharmaceutical company focused on achieving efficient development of products that address
significant unmet needs in Central Nervous System (&#x201c;CNS&#x201d;) disorders and other rare disorders. The Company&#x2019;s lead programs
are SLS-002 for the potential treatment of acute suicidal ideation and behavior in patients with major depressive disorder (&#x201c;ASIB
in MDD&#x201d;) and SLS-005 for the potential treatment of Amyotrophic Lateral Sclerosis (&#x201c;ALS&#x201d;) and Spinocerebellar Ataxia
(&#x201c;SCA&#x201d;). SLS-005 for the potential treatment of Sanfilippo Syndrome currently requires additional natural history data, which
is being considered. Additionally, the Company is developing several preclinical programs, most of which have well-defined mechanisms
of action, including: SLS-004, SLS-006, SLS-007 for the potential treatment of Parkinson&#x2019;s Disease (&#x201c;PD&#x201d;) and SLS-008,
which is being developed for the potential treatment of an undisclosed indication, but may also be targeted at chronic inflammation in
asthma and orphan indications such as pediatric esophagitis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 5pt"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 142.6pt 0 5pt; text-align: justify; text-indent: 0in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_800_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zUlIFHdf9E01" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify"&gt;2.
Liquidity and Going Concern&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 6.85pt 0 5pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"&gt;The accompanying condensed consolidated unaudited financial statements
have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and
settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects
on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty
related to its ability to continue as a going concern.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"&gt;The Company has generated limited revenues, has incurred operating
losses since inception, and expects to continue to incur significant operating losses for the foreseeable future and may never become
profitable. As of March 31, 2022, the Company had $&lt;span id="xdx_904_eus-gaap--Cash_iI_pn5n6_c20220331_zQZBKEv6Qhy9" title="Cash"&gt;61.8&lt;/span&gt; million in cash and an accumulated deficit of $&lt;span id="xdx_904_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_pn5n6_c20220331_zaykptp0g0i7" title="Accumlated deficit"&gt;155.2&lt;/span&gt; million. The Company has historically
funded its operations through the issuance of convertible notes (see Note 9), the sale of common stock (see Note 6) and exercises of
warrants (see Note 10).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;On May 24, 2021, the Company completed an underwritten
public offering, pursuant to which the Company sold &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20210501__20210531__us-gaap--StatementClassOfStockAxis__custom--May242021Member_z6pU7T7uL1nb" title="Number of shares of common stock issued"&gt;22,258,066&lt;/span&gt;
shares of its common stock, at a price to the public of $&lt;span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_pp2p0_uUSDPShares_c20210524__us-gaap--StatementClassOfStockAxis__custom--May242021Member_zPIih6iQzU53" title="Shares Issued, Price Per Share"&gt;3.10&lt;/span&gt;
per share, which included the exercise in full by the underwriter of its option to purchase up to 2,903,226 additional shares of
common stock. The net proceeds to the Company from the offering were approximately $&lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20210501__20210531__us-gaap--StatementClassOfStockAxis__custom--May242021Member_znvCOQEUOEA3" title="Cash received from stock sale"&gt;64.5&lt;/span&gt;
million, after deducting underwriting discounts and commissions and other offering costs. The Company used
$&lt;span id="xdx_90B_ecustom--OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes_pn5n6_c20210501__20210531__us-gaap--StatementClassOfStockAxis__custom--May242021Member_z3cGiDLwmfm4" title="Offering proceeds used to partially repay certain convertible promissory notes"&gt;7.3&lt;/span&gt;
million of the net proceeds from the offering for the partial repayment of certain outstanding convertible promissory notes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;On January 28, 2021, the Company completed an underwritten
public offering, pursuant to which the Company sold &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20210101__20210131__us-gaap--StatementClassOfStockAxis__custom--January282021Member_zSk5mfKSduR5" title="Number of shares of common stock issued"&gt;17,530,488&lt;/span&gt;
shares of its common stock, at a price to the public of $&lt;span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_pp2p0_uUSDPShares_c20210128__us-gaap--StatementClassOfStockAxis__custom--January282021Member_zeNhjQ7tklc2" title="Shares Issued, Price Per Share"&gt;2.05&lt;/span&gt;
per share, which included the exercise in full by the underwriter of its option to purchase up to 2,286,585 additional shares of
common stock. The net proceeds to the Company from the offering were approximately $&lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20210101__20210131__us-gaap--StatementClassOfStockAxis__custom--January282021Member_zXbrplIummQc" title="Cash received from stock sale"&gt;33.5&lt;/span&gt;
million, after deducting underwriting discounts, commissions and other offering costs. The
Company used $&lt;span id="xdx_903_ecustom--OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes_pn5n6_c20210101__20210131__us-gaap--StatementClassOfStockAxis__custom--January282021Member_zeWIkGFTOzUa" title="Offering proceeds used to partially repay certain convertible promissory notes"&gt;3.8&lt;/span&gt;
million of the net proceeds from the offering for the partial repayment of certain outstanding convertible promissory notes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;The Company currently has an effective shelf registration statement
on Form S-3 filed with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;). The Company may use the shelf registration statement
on Form S-3 to offer from time to time any combination of debt securities, common and preferred stock and warrants. As of March 31, 2022,
the Company had approximately $&lt;span id="xdx_90B_ecustom--FinancingAvailableUnderFormS3ShelfRegistrationStatement_iI_pn5n6_c20220331_zpgalEltyrXk"&gt;95.1&lt;/span&gt; million available under its Form S-3 shelf registration statement. The Company also has the ability
to raise funds through other means, such as through the filing of a registration statement on Form S-1 or in private placements. The rules
and regulations of the SEC or any other regulatory agencies may restrict the Company&#x2019;s ability to conduct certain types of financing
activities or may affect the timing of and amounts it can raise by undertaking such activities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;The Company evaluated whether there
are any conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern
within one year beyond the filing of this Quarterly Report on Form 10-Q. Based on such evaluation and the Company&#x2019;s current plans
(including the ongoing clinical programs for SLS-002, SLS-005, and other product candidates), which are subject to change, management
believes that the Company&#x2019;s existing cash and cash equivalents as of March 31, 2022 are not sufficient to satisfy its operating
cash needs for the year after the filing of this Quarterly Report on Form 10-Q.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify"&gt;The Company&#x2019;s future liquidity and capital
funding requirements will depend on numerous factors, including:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-size: 10pt; letter-spacing: -0.7pt"&gt;&#x2022;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;its ability to raise additional funds to finance its operations;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-size: 10pt; letter-spacing: -0.7pt"&gt;&#x2022;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;its ability to maintain compliance with the listing requirements of the Nasdaq Capital Market;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-size: 10pt; letter-spacing: -0.7pt"&gt;&#x2022;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;the outcome, costs and timing of clinical trial results for the Company&#x2019;s current or future product
candidates;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-size: 10pt; letter-spacing: -0.7pt"&gt;&#x2022;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;potential litigation expenses;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-size: 10pt; letter-spacing: -0.7pt"&gt;&#x2022;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;the emergence and effect of competing or complementary products or product candidates;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-size: 10pt; letter-spacing: -0.7pt"&gt;&#x2022;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-right: 5.85pt"&gt;&lt;span style="font-size: 10pt"&gt;its ability to maintain, expand and defend the scope of its intellectual
property portfolio, including the amount and timing of any payments the Company may be required to make, or that it may receive, in connection
with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-size: 10pt; letter-spacing: -0.7pt"&gt;&#x2022;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-right: 5.85pt"&gt;&lt;span style="font-size: 10pt"&gt;its ability to retain its current employees and the need and ability to
hire additional management and scientific and medical personnel;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-size: 10pt; letter-spacing: -0.7pt"&gt;&#x2022;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;the terms and timing of any collaborative, licensing or other arrangements that it has or may establish;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-size: 10pt; letter-spacing: -0.7pt"&gt;&#x2022;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;the trading price of its common stock; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-size: 10pt; letter-spacing: -0.7pt"&gt;&#x2022;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;its ability to increase the number of authorized shares outstanding to facilitate future financing events.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 11.85pt 0 5pt; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The
Company may raise substantial additional funds, and if it does so, it may do so through one or more of the following: issuance of additional
debt or equity and/or the completion of a licensing or other commercial transaction for one or more of the Company&#x2019;s product candidates.
If the Company is unable to maintain sufficient financial resources, its business, financial condition and results of operations will
be materially and adversely affected. This could affect future development and business activities and potential future clinical studies
and/or other future ventures. Failure to obtain additional equity or debt financing will have a material, adverse impact on the Company&#x2019;s
business operations. There can be no assurance that the Company will be able to obtain the needed financing on acceptable terms or at
all. Additionally, equity or convertible debt financings will likely have a dilutive effect on the holdings of the Company&#x2019;s existing
stockholders.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 11.85pt 0 5pt"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 11.85pt 0 5pt; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;&#160;&lt;/p&gt;

</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:Cash contextRef="AsOf2022-03-31" decimals="-5" unitRef="USD">61800000</us-gaap:Cash>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-03-31" decimals="-5" unitRef="USD">155200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-05-012021-05-31_custom_May242021Member"
      decimals="INF"
      unitRef="Shares">22258066</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2021-05-24_custom_May242021Member"
      decimals="2"
      unitRef="USDPShares">3.10</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-05-012021-05-31_custom_May242021Member"
      decimals="-5"
      unitRef="USD">64500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <SEEL:OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes
      contextRef="From2021-05-012021-05-31_custom_May242021Member"
      decimals="-5"
      unitRef="USD">7300000</SEEL:OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-01-31_custom_January282021Member"
      decimals="INF"
      unitRef="Shares">17530488</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2021-01-28_custom_January282021Member"
      decimals="2"
      unitRef="USDPShares">2.05</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-01-31_custom_January282021Member"
      decimals="-5"
      unitRef="USD">33500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <SEEL:OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes
      contextRef="From2021-01-012021-01-31_custom_January282021Member"
      decimals="-5"
      unitRef="USD">3800000</SEEL:OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes>
    <SEEL:FinancingAvailableUnderFormS3ShelfRegistrationStatement contextRef="AsOf2022-03-31" decimals="-5" unitRef="USD">95100000</SEEL:FinancingAvailableUnderFormS3ShelfRegistrationStatement>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_80D_eus-gaap--SignificantAccountingPoliciesTextBlock_zuGSr9jROLy8" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: left"&gt;3. Significant Accounting Policies&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zp2emxigUS7i" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify; text-indent: -0.5pt"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation
&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 13.5pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify; text-indent: -0.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 5pt"&gt;The accompanying unaudited interim condensed consolidated financial
statements should be read in conjunction with the audited financial statements and notes thereto as of and for the year ended December
31, 2021 included in the Company&#x2019;s Annual Report on Form 10-K (the &#x201c;Annual Report&#x201d;) filed with the SEC on March 4, 2022.
The accompanying financial statements have been prepared by the Company in accordance with United States generally accepted accounting
principles (&#x201c;U.S. GAAP&#x201d;) for interim financial information and in accordance with the instructions to Form 10-Q and Article
10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in
accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, the accompanying unaudited condensed consolidated
financial statements for the periods presented reflect all adjustments, consisting of only normal, recurring adjustments, necessary to
fairly state the Company&#x2019;s financial position, results of operations and cash flows. The December 31, 2021 condensed consolidated
balance sheet was derived from audited financial statements, but it does not include all U.S. GAAP disclosures. The unaudited condensed
consolidated financial statements for the interim periods are not necessarily indicative of results for the full year. The preparation
of these unaudited condensed consolidated financial statements requires the Company to make estimates and judgments that affect the amounts
reported in the financial statements and the accompanying notes. The Company&#x2019;s actual results may differ from these estimates under
different assumptions or conditions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;



&lt;p id="xdx_848_eus-gaap--UseOfEstimates_zsG5uQdUXm5h" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify; text-indent: -0.5pt"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"&gt;The preparation of financial statements in conformity with U.S. GAAP requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets
and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant
estimates in the Company&#x2019;s financial statements relate to the valuation of warrants, valuation of convertible notes payable, and
the valuation of stock options. These estimates and assumptions are based on current facts, historical experience and various other factors
believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values
of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially
and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#x2019;s
future results of operations will be affected.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zjtmXpmZ5WGe" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: left"&gt;&lt;i&gt;Fair Value Measurements&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"&gt;&lt;span style="font-weight: normal"&gt;The Company
follows the accounting guidance in the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;)
Topic 820, Fair Value Measurements and Disclosures (&#x201c;ASC 820&#x201d;), for its fair value measurements of financial assets and liabilities
measured at fair value on a recurring basis. Under this accounting guidance, fair value is defined as an exit price, representing the
amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at
the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants
would use in pricing an asset or a liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"&gt;&lt;span style="font-weight: normal"&gt;The accounting
guidance requires fair value measurements be classified and disclosed in one of the following three categories:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"&gt;&lt;span style="font-weight: normal"&gt;Level 1: Quoted
prices in active markets for identical assets or liabilities. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"&gt;&lt;span style="font-weight: normal"&gt;Level 2: Observable
inputs other than Level 1 prices, for similar assets or liabilities that are directly or indirectly observable in the marketplace.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"&gt;&lt;span style="font-weight: normal"&gt;Level 3: Unobservable
inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing
models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires
significant judgment or estimation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"&gt;&lt;span style="font-weight: normal"&gt;The fair value
hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring
fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is
significant to the fair value measurement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify; text-indent: -0.5pt"&gt;&lt;b&gt;&lt;i&gt;Fair Value Option&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"&gt;&lt;span style="font-weight: normal"&gt;As permitted
under FASB ASC Topic 825, Financial Instruments (&#x201c;ASC 825&#x201d;), the Company elected the fair value option to account for its
November 2021 and December 2021 convertible notes (collectively, the &#x201c;2021 Convertible Notes&#x201d;). In accordance with ASC 825,
the Company records these convertible notes at fair value with changes in fair value recorded in the Consolidated Statement of Operations
and Comprehensive Loss. As a result of applying the fair value option, direct costs and fees related to the convertible notes were expensed
as incurred and were not deferred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"&gt;&lt;span style="font-weight: normal"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"/&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zylUSVrXTDr3" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"&gt;&lt;i&gt;Stock-based Compensation&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"&gt;&lt;span style="font-weight: normal"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;The Company
expenses stock-based compensation to employees, non-employees and board members over the requisite service period based on the estimated
grant-date fair value of the awards and forfeitures rates. The Company accounts for forfeitures as they occur. Stock-based awards with
graded-vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion
of the award. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions
used in calculating the fair value of stock-based awards represent management&#x2019;s best estimates and involve inherent uncertainties
and the application of management&#x2019;s judgment. All stock-based compensation costs are recorded in general and administrative or research
and development costs in the statements of operations based upon the underlying individual&#x2019;s role at the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"&gt;&lt;span style="font-weight: normal"&gt;Performance
share awards are initially valued based on the Company&#x2019;s closing stock price on the date of grant. The number of performance share
awards that vest will be determined based on the achievement of specified performance milestones by the end of the performance period.
Compensation expense for performance awards is recognized over the service period and will vary based on remeasurement during the performance
period. If achievement of the performance milestone is not probable of achievement during the performance period, compensation expense
is reversed.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"&gt;&lt;span style="font-weight: normal"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_zJOg7I8WZ1Vg" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;&lt;b&gt;&lt;i&gt;Net Loss Per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;Basic loss per share is computed by dividing net loss applicable
to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share
includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, warrants, performance-based
restricted stock unit awards and stock options that would result in the issuance of incremental shares of common stock. In computing the
basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both
calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;&#160;&lt;/p&gt;




&lt;p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zKQMCpo58Tdj" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;The following potentially dilutive securities outstanding for
the three months ended March 31, 2022 and 2021 have been excluded from the computation of diluted weighted average shares outstanding,
as they would be anti-dilutive (in thousands):&lt;/p&gt;

&lt;p id="xdx_8BF_z66xDxRI5f8d" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; display: none"&gt;Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"/&gt;
    &lt;td colspan="4" style="font-weight: bold; vertical-align: middle; text-align: center"&gt;Three Months&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"/&gt;
    &lt;td colspan="4" style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center"&gt;Ended March
    31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle; width: 62%"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right; width: 2%"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center; width: 2%"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; width: 15%"&gt;2022&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right; width: 2%"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center; width: 2%"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; width: 15%"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Outstanding stock options&lt;/td&gt;
    &lt;td/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zCScnnyODifk" style="text-align: right; border-top-color: Black; border-top-width: 1pt" title="Outstanding stock options"&gt;10,299&lt;/td&gt;
    &lt;td/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zsdriRbP2xd" style="text-align: right; border-top-color: Black; border-top-width: 1pt" title="Outstanding stock options"&gt;7,204&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Restricted stock units&lt;/td&gt;
    &lt;td/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zrW6jSAzEgae" style="text-align: right" title="Restricted stock units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0405"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zqlk7NWOoQwk" style="text-align: right" title="Restricted stock units"&gt;2,400&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Outstanding warrants&lt;/td&gt;
    &lt;td/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zIvMtG3p7Qs6" style="text-align: right" title="Outstanding warrants"&gt;2,635&lt;/td&gt;
    &lt;td/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zQSQ9Fb0Dxvj" style="text-align: right" title="Outstanding Warrants"&gt;3,920&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Convertible debt&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_z5VuN4C7Qug9" style="text-align: right"&gt;3,704&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zUWQoM64cIZd" style="text-align: right"&gt;5,326&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="vertical-align: middle; text-align: right"/&gt;
    &lt;td style="vertical-align: middle; text-align: right"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="vertical-align: middle; text-align: right"/&gt;
    &lt;td style="vertical-align: middle; text-align: right"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="vertical-align: middle; text-align: right"/&gt;
    &lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_i01_pin3_c20220101__20220331_zIrNJ5WBdVL7" style="border-top: Black 1pt solid; border-bottom: Black 2pt double; vertical-align: middle; text-align: right" title="Antidilutive securities excluded"&gt;16,638&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="vertical-align: middle; text-align: right"/&gt;
    &lt;td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_i01_pin3_c20210101__20210331_zKMlPxi5SVke" style="border-top: Black 1pt solid; border-bottom: Black 2pt double; vertical-align: middle; text-align: right" title="Antidilutive securities excluded"&gt;18,850&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zKZPpjg80Pv8" style="font: 9pt Sans-Serif; margin: 0 0 0 4.5pt; color: Red"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;Amounts in the table reflect the common stock equivalents of
the noted instruments.&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zrTAZ4Okgtok" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"&gt;Recent Accounting Pronouncements&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: justify"&gt;&lt;span style="font-weight: normal"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;In August 2020, the FASB issued Accounting Standards Update
(&#x201c;ASU&#x201d;) No. 2020-06: Debt &#x2013; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging
&#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an
Entity&#x2019;s Own Equity (&#x201c;ASU 2020-06&#x201d;). This standard simplifies the accounting for convertible debt instruments by
removing the separation models for convertible debt with a cash conversion feature, as well as convertible instruments with a
beneficial conversion feature. As a result, entities will account for a convertible debt instrument wholly as debt, unless certain
other conditions are met. The elimination of these models will reduce non-cash interest expense for entities that have issued a
convertible instrument that was within the scope of those models before the adoption of ASU 2020-06. Additionally, ASU 2020-06
requires the application of the if-converted method for calculating diluted earnings per share and precludes the use of the treasury
stock method for certain debt instruments. The provisions of ASU 2020-06 are applicable for the Company beginning after January 1,
2024, with early adoption permitted, and an entity should adopt the provisions at the beginning of its annual fiscal year. The
Company does not expect the adoption of ASU 2020-06 to have an impact on its consolidated financial statements and related
disclosures.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: justify"/&gt;

&lt;p id="xdx_850_z7BVrm2KkeWk" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"/&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zp2emxigUS7i" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify; text-indent: -0.5pt"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation
&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 13.5pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify; text-indent: -0.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 5pt"&gt;The accompanying unaudited interim condensed consolidated financial
statements should be read in conjunction with the audited financial statements and notes thereto as of and for the year ended December
31, 2021 included in the Company&#x2019;s Annual Report on Form 10-K (the &#x201c;Annual Report&#x201d;) filed with the SEC on March 4, 2022.
The accompanying financial statements have been prepared by the Company in accordance with United States generally accepted accounting
principles (&#x201c;U.S. GAAP&#x201d;) for interim financial information and in accordance with the instructions to Form 10-Q and Article
10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in
accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, the accompanying unaudited condensed consolidated
financial statements for the periods presented reflect all adjustments, consisting of only normal, recurring adjustments, necessary to
fairly state the Company&#x2019;s financial position, results of operations and cash flows. The December 31, 2021 condensed consolidated
balance sheet was derived from audited financial statements, but it does not include all U.S. GAAP disclosures. The unaudited condensed
consolidated financial statements for the interim periods are not necessarily indicative of results for the full year. The preparation
of these unaudited condensed consolidated financial statements requires the Company to make estimates and judgments that affect the amounts
reported in the financial statements and the accompanying notes. The Company&#x2019;s actual results may differ from these estimates under
different assumptions or conditions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;



</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_848_eus-gaap--UseOfEstimates_zsG5uQdUXm5h" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify; text-indent: -0.5pt"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"&gt;The preparation of financial statements in conformity with U.S. GAAP requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets
and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant
estimates in the Company&#x2019;s financial statements relate to the valuation of warrants, valuation of convertible notes payable, and
the valuation of stock options. These estimates and assumptions are based on current facts, historical experience and various other factors
believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values
of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially
and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#x2019;s
future results of operations will be affected.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_840_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zjtmXpmZ5WGe" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: left"&gt;&lt;i&gt;Fair Value Measurements&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"&gt;&lt;span style="font-weight: normal"&gt;The Company
follows the accounting guidance in the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;)
Topic 820, Fair Value Measurements and Disclosures (&#x201c;ASC 820&#x201d;), for its fair value measurements of financial assets and liabilities
measured at fair value on a recurring basis. Under this accounting guidance, fair value is defined as an exit price, representing the
amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at
the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants
would use in pricing an asset or a liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"&gt;&lt;span style="font-weight: normal"&gt;The accounting
guidance requires fair value measurements be classified and disclosed in one of the following three categories:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"&gt;&lt;span style="font-weight: normal"&gt;Level 1: Quoted
prices in active markets for identical assets or liabilities. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"&gt;&lt;span style="font-weight: normal"&gt;Level 2: Observable
inputs other than Level 1 prices, for similar assets or liabilities that are directly or indirectly observable in the marketplace.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"&gt;&lt;span style="font-weight: normal"&gt;Level 3: Unobservable
inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing
models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires
significant judgment or estimation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"&gt;&lt;span style="font-weight: normal"&gt;The fair value
hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring
fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is
significant to the fair value measurement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify; text-indent: -0.5pt"&gt;&lt;b&gt;&lt;i&gt;Fair Value Option&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"&gt;&lt;span style="font-weight: normal"&gt;As permitted
under FASB ASC Topic 825, Financial Instruments (&#x201c;ASC 825&#x201d;), the Company elected the fair value option to account for its
November 2021 and December 2021 convertible notes (collectively, the &#x201c;2021 Convertible Notes&#x201d;). In accordance with ASC 825,
the Company records these convertible notes at fair value with changes in fair value recorded in the Consolidated Statement of Operations
and Comprehensive Loss. As a result of applying the fair value option, direct costs and fees related to the convertible notes were expensed
as incurred and were not deferred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"&gt;&lt;span style="font-weight: normal"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"/&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_84B_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zylUSVrXTDr3" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"&gt;&lt;i&gt;Stock-based Compensation&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"&gt;&lt;span style="font-weight: normal"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;The Company
expenses stock-based compensation to employees, non-employees and board members over the requisite service period based on the estimated
grant-date fair value of the awards and forfeitures rates. The Company accounts for forfeitures as they occur. Stock-based awards with
graded-vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion
of the award. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions
used in calculating the fair value of stock-based awards represent management&#x2019;s best estimates and involve inherent uncertainties
and the application of management&#x2019;s judgment. All stock-based compensation costs are recorded in general and administrative or research
and development costs in the statements of operations based upon the underlying individual&#x2019;s role at the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"&gt;&lt;span style="font-weight: normal"&gt;Performance
share awards are initially valued based on the Company&#x2019;s closing stock price on the date of grant. The number of performance share
awards that vest will be determined based on the achievement of specified performance milestones by the end of the performance period.
Compensation expense for performance awards is recognized over the service period and will vary based on remeasurement during the performance
period. If achievement of the performance milestone is not probable of achievement during the performance period, compensation expense
is reversed.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"&gt;&lt;span style="font-weight: normal"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_zJOg7I8WZ1Vg" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;&lt;b&gt;&lt;i&gt;Net Loss Per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;Basic loss per share is computed by dividing net loss applicable
to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share
includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, warrants, performance-based
restricted stock unit awards and stock options that would result in the issuance of incremental shares of common stock. In computing the
basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both
calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;&#160;&lt;/p&gt;




&lt;p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zKQMCpo58Tdj" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;The following potentially dilutive securities outstanding for
the three months ended March 31, 2022 and 2021 have been excluded from the computation of diluted weighted average shares outstanding,
as they would be anti-dilutive (in thousands):&lt;/p&gt;

&lt;p id="xdx_8BF_z66xDxRI5f8d" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; display: none"&gt;Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"/&gt;
    &lt;td colspan="4" style="font-weight: bold; vertical-align: middle; text-align: center"&gt;Three Months&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"/&gt;
    &lt;td colspan="4" style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center"&gt;Ended March
    31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle; width: 62%"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right; width: 2%"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center; width: 2%"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; width: 15%"&gt;2022&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right; width: 2%"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center; width: 2%"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; width: 15%"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Outstanding stock options&lt;/td&gt;
    &lt;td/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zCScnnyODifk" style="text-align: right; border-top-color: Black; border-top-width: 1pt" title="Outstanding stock options"&gt;10,299&lt;/td&gt;
    &lt;td/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zsdriRbP2xd" style="text-align: right; border-top-color: Black; border-top-width: 1pt" title="Outstanding stock options"&gt;7,204&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Restricted stock units&lt;/td&gt;
    &lt;td/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zrW6jSAzEgae" style="text-align: right" title="Restricted stock units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0405"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zqlk7NWOoQwk" style="text-align: right" title="Restricted stock units"&gt;2,400&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Outstanding warrants&lt;/td&gt;
    &lt;td/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zIvMtG3p7Qs6" style="text-align: right" title="Outstanding warrants"&gt;2,635&lt;/td&gt;
    &lt;td/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zQSQ9Fb0Dxvj" style="text-align: right" title="Outstanding Warrants"&gt;3,920&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Convertible debt&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_z5VuN4C7Qug9" style="text-align: right"&gt;3,704&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zUWQoM64cIZd" style="text-align: right"&gt;5,326&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="vertical-align: middle; text-align: right"/&gt;
    &lt;td style="vertical-align: middle; text-align: right"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="vertical-align: middle; text-align: right"/&gt;
    &lt;td style="vertical-align: middle; text-align: right"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="vertical-align: middle; text-align: right"/&gt;
    &lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_i01_pin3_c20220101__20220331_zIrNJ5WBdVL7" style="border-top: Black 1pt solid; border-bottom: Black 2pt double; vertical-align: middle; text-align: right" title="Antidilutive securities excluded"&gt;16,638&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="vertical-align: middle; text-align: right"/&gt;
    &lt;td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_i01_pin3_c20210101__20210331_zKMlPxi5SVke" style="border-top: Black 1pt solid; border-bottom: Black 2pt double; vertical-align: middle; text-align: right" title="Antidilutive securities excluded"&gt;18,850&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zKZPpjg80Pv8" style="font: 9pt Sans-Serif; margin: 0 0 0 4.5pt; color: Red"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;Amounts in the table reflect the common stock equivalents of
the noted instruments.&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: left"&gt;&#160;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zKQMCpo58Tdj" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;The following potentially dilutive securities outstanding for
the three months ended March 31, 2022 and 2021 have been excluded from the computation of diluted weighted average shares outstanding,
as they would be anti-dilutive (in thousands):&lt;/p&gt;

&lt;p id="xdx_8BF_z66xDxRI5f8d" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; display: none"&gt;Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"/&gt;
    &lt;td colspan="4" style="font-weight: bold; vertical-align: middle; text-align: center"&gt;Three Months&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"/&gt;
    &lt;td colspan="4" style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center"&gt;Ended March
    31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle; width: 62%"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right; width: 2%"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center; width: 2%"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; width: 15%"&gt;2022&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right; width: 2%"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center; width: 2%"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; width: 15%"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Outstanding stock options&lt;/td&gt;
    &lt;td/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zCScnnyODifk" style="text-align: right; border-top-color: Black; border-top-width: 1pt" title="Outstanding stock options"&gt;10,299&lt;/td&gt;
    &lt;td/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zsdriRbP2xd" style="text-align: right; border-top-color: Black; border-top-width: 1pt" title="Outstanding stock options"&gt;7,204&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Restricted stock units&lt;/td&gt;
    &lt;td/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zrW6jSAzEgae" style="text-align: right" title="Restricted stock units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0405"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zqlk7NWOoQwk" style="text-align: right" title="Restricted stock units"&gt;2,400&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Outstanding warrants&lt;/td&gt;
    &lt;td/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zIvMtG3p7Qs6" style="text-align: right" title="Outstanding warrants"&gt;2,635&lt;/td&gt;
    &lt;td/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zQSQ9Fb0Dxvj" style="text-align: right" title="Outstanding Warrants"&gt;3,920&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Convertible debt&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_z5VuN4C7Qug9" style="text-align: right"&gt;3,704&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zUWQoM64cIZd" style="text-align: right"&gt;5,326&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="vertical-align: middle; text-align: right"/&gt;
    &lt;td style="vertical-align: middle; text-align: right"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="vertical-align: middle; text-align: right"/&gt;
    &lt;td style="vertical-align: middle; text-align: right"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="vertical-align: middle; text-align: right"/&gt;
    &lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_i01_pin3_c20220101__20220331_zIrNJ5WBdVL7" style="border-top: Black 1pt solid; border-bottom: Black 2pt double; vertical-align: middle; text-align: right" title="Antidilutive securities excluded"&gt;16,638&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="vertical-align: middle; text-align: right"/&gt;
    &lt;td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_i01_pin3_c20210101__20210331_zKMlPxi5SVke" style="border-top: Black 1pt solid; border-bottom: Black 2pt double; vertical-align: middle; text-align: right" title="Antidilutive securities excluded"&gt;18,850&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">10299000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">7204000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">2400000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-03-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">2635000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-03-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">3920000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-03-31_us-gaap_ConvertibleDebtSecuritiesMember"
      decimals="INF"
      unitRef="Shares">3704000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-03-31_us-gaap_ConvertibleDebtSecuritiesMember"
      decimals="INF"
      unitRef="Shares">5326000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-01to2022-03-31"
      decimals="INF"
      unitRef="Shares">16638000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-03-31"
      decimals="INF"
      unitRef="Shares">18850000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zrTAZ4Okgtok" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"&gt;Recent Accounting Pronouncements&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: justify"&gt;&lt;span style="font-weight: normal"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;In August 2020, the FASB issued Accounting Standards Update
(&#x201c;ASU&#x201d;) No. 2020-06: Debt &#x2013; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging
&#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an
Entity&#x2019;s Own Equity (&#x201c;ASU 2020-06&#x201d;). This standard simplifies the accounting for convertible debt instruments by
removing the separation models for convertible debt with a cash conversion feature, as well as convertible instruments with a
beneficial conversion feature. As a result, entities will account for a convertible debt instrument wholly as debt, unless certain
other conditions are met. The elimination of these models will reduce non-cash interest expense for entities that have issued a
convertible instrument that was within the scope of those models before the adoption of ASU 2020-06. Additionally, ASU 2020-06
requires the application of the if-converted method for calculating diluted earnings per share and precludes the use of the treasury
stock method for certain debt instruments. The provisions of ASU 2020-06 are applicable for the Company beginning after January 1,
2024, with early adoption permitted, and an entity should adopt the provisions at the beginning of its annual fiscal year. The
Company does not expect the adoption of ASU 2020-06 to have an impact on its consolidated financial statements and related
disclosures.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: justify"/&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_808_eus-gaap--FairValueDisclosuresTextBlock_ztlU5aWE8O6h" style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;4. Fair Value Measurement&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"&gt;The
following tables present information about the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring
basis and indicate the level of the fair value hierarchy utilized to determine such fair values. There were
&lt;span id="xdx_90B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_do_c20220101__20220331_zjJpAFcFuyTb"&gt;no&lt;/span&gt;
transfers between fair value measurement levels during the three months ended March 31, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zmwG4olT1Kz1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"&gt;The Company&#x2019;s financial assets and liabilities measured at fair value
at March 31, 2022 and December 31, 2021 are as follows (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; background-color: white"&gt;&lt;span id="xdx_8BE_zLdsggSUjfL6" style="display: none"&gt;Schedule of Fair Value Hierarchy Assets and Liabilities&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; background-color: white"/&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="vertical-align: middle; background-color: white"&gt;
    &lt;td style="font-weight: bold; width: 44%"/&gt;
    &lt;td style="font-weight: bold; text-align: right; width: 2%"/&gt;
    &lt;td style="font-weight: bold; text-align: right; width: 2%"/&gt;
    &lt;td style="font-weight: bold; text-align: center; width: 10%"/&gt;
    &lt;td style="font-weight: bold; text-align: right; width: 2%"/&gt;
    &lt;td style="font-weight: bold; text-align: right; width: 2%"/&gt;
    &lt;td style="font-weight: bold; text-align: center; width: 10%"/&gt;
    &lt;td style="font-weight: bold; text-align: right; width: 2%"/&gt;
    &lt;td style="font-weight: bold; text-align: right; width: 2%"/&gt;
    &lt;td style="font-weight: bold; text-align: center; width: 10%"/&gt;
    &lt;td style="font-weight: bold; text-align: right; width: 2%"/&gt;
    &lt;td style="font-weight: bold; text-align: right; width: 2%"/&gt;
    &lt;td style="font-weight: bold; text-align: center; width: 10%"/&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td colspan="10" style="font-weight: bold; vertical-align: middle; text-align: center; background-color: white"&gt;Fair Value Measurements&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td colspan="10" style="font-weight: bold; vertical-align: middle; text-align: center; background-color: white"&gt;as of March 31, 2022&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: right; background-color: white; width: 44%"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white; width: 2%"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right; width: 2%"/&gt;
    &lt;td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 10%"&gt;(Level 1)&lt;/td&gt;
    &lt;td style="vertical-align: middle; text-align: right; background-color: white; width: 2%"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right; width: 2%"/&gt;
    &lt;td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 10%"&gt;(Level 2)&lt;/td&gt;
    &lt;td style="vertical-align: middle; text-align: right; background-color: white; width: 2%"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right; width: 2%"/&gt;
    &lt;td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 10%"&gt;(Level 3)&lt;/td&gt;
    &lt;td style="vertical-align: middle; text-align: right; background-color: white; width: 2%"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right; width: 2%"/&gt;
    &lt;td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 10%"&gt;Total&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle; background-color: white"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_900_eus-gaap--AssetsAbstract_iB_c20220101__20220331_ziSTSyBoNVWc"&gt;Assets&lt;/span&gt;:&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle; background-color: white"&gt;
    &lt;td style="text-indent: 10pt"&gt;Cash&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zMqtLMj6TFSi" style="border-bottom: Black 2pt double; text-align: right" title="Cash"&gt;61,772&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zz24VxuSoM5a" style="border-bottom: Black 2pt double; text-align: right" title="Cash"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0429"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zaL1DaIgI1v5" style="border-bottom: Black 2pt double; text-align: right" title="Cash"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0431"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20220331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zFAa9NtOhvN6" style="border-bottom: Black 2pt double; text-align: right" title="Cash"&gt;61,772&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle; background-color: white"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_90D_eus-gaap--LiabilitiesAbstract_iB_c20220101__20220331_zSJ30OFb8PIk"&gt;Liabilities&lt;/span&gt;:&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;
    &lt;td style="font-weight: bold; text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;
    &lt;td style="font-weight: bold; text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;
    &lt;td style="font-weight: bold; text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle; background-color: white"&gt;
    &lt;td style="text-indent: 10pt"&gt;Convertible notes payable, at fair value&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zjsKM8XNM0Fg" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0435"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zdXWGeQSnKdk" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0436"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_z9av2YuWif5f" style="text-align: right"&gt;19,164&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zA9bPAF27hee" style="text-align: right"&gt;19,164&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle; background-color: white"&gt;
    &lt;td style="text-indent: 10pt"&gt;Warrant liabilities, at fair value&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_988_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zAX0BuuWs5Zi" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant liabilities, at fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0440"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_98D_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zDx7tAT4Cpg3" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant liabilities, at fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0442"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_989_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zRHvxSJNbD8c" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant liabilities, at fair value"&gt;190&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_987_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zGE4pbeM8qeg" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant liabilities, at fair value"&gt;190&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle; background-color: white"&gt;
    &lt;td style="text-indent: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zflU3SniAtPg" style="border-bottom: Black 2pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0447"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z6tMvCVtLyXf" style="border-bottom: Black 2pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0448"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zQlhU1IQidSc" style="border-bottom: Black 2pt double; text-align: right"&gt;19,354&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zcBb6lxtsIDc" style="border-bottom: Black 2pt double; text-align: right"&gt;19,354&lt;/td&gt;&lt;/tr&gt;

  &lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;


&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; background-color: white"/&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="vertical-align: middle; background-color: white"&gt;
    &lt;td style="font-weight: bold; width: 44%"/&gt;
    &lt;td style="font-weight: bold; text-align: right; width: 2%"/&gt;
    &lt;td style="font-weight: bold; text-align: right; width: 2%"/&gt;
    &lt;td style="font-weight: bold; text-align: center; width: 10%"/&gt;
    &lt;td style="font-weight: bold; text-align: right; width: 2%"/&gt;
    &lt;td style="font-weight: bold; text-align: right; width: 2%"/&gt;
    &lt;td style="font-weight: bold; text-align: center; width: 10%"/&gt;
    &lt;td style="font-weight: bold; text-align: right; width: 2%"/&gt;
    &lt;td style="font-weight: bold; text-align: right; width: 2%"/&gt;
    &lt;td style="font-weight: bold; text-align: center; width: 10%"/&gt;
    &lt;td style="font-weight: bold; text-align: right; width: 2%"/&gt;
    &lt;td style="font-weight: bold; text-align: right; width: 2%"/&gt;
    &lt;td style="font-weight: bold; text-align: center; width: 10%"/&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td colspan="10" style="font-weight: bold; vertical-align: middle; text-align: center; background-color: white"&gt;Fair Value Measurements&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td colspan="10" style="font-weight: bold; vertical-align: middle; text-align: center; background-color: white"&gt;as of December 31, 2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: right; background-color: white; width: 44%"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white; width: 1%"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right; width: 1%"/&gt;
    &lt;td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 12%"&gt;(Level 1)&lt;/td&gt;
    &lt;td style="vertical-align: middle; text-align: right; background-color: white; width: 1%"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right; width: 1%"/&gt;
    &lt;td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 12%"&gt;(Level 2)&lt;/td&gt;
    &lt;td style="vertical-align: middle; text-align: right; background-color: white; width: 1%"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right; width: 1%"/&gt;
    &lt;td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 12%"&gt;(Level 3)&lt;/td&gt;
    &lt;td style="vertical-align: middle; text-align: right; background-color: white; width: 1%"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right; width: 1%"/&gt;
    &lt;td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 12%"&gt;Total&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle; background-color: white"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_90C_eus-gaap--AssetsAbstract_iB_c20210101__20211231_z1NdZhfsyYU6"&gt;Assets&lt;/span&gt;:&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle; background-color: white"&gt;
    &lt;td style="text-indent: 10pt"&gt;Cash&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zphNLgkyaaSg" style="border-bottom: Black 2pt double; text-align: right"&gt;78,734&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zTrI2Jcn3cac" style="border-bottom: Black 2pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0453"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z0vhW9igOboi" style="border-bottom: Black 2pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0454"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zZ0sFf2PIsVd" style="border-bottom: Black 2pt double; text-align: right"&gt;78,734&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle; background-color: white"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_90E_eus-gaap--LiabilitiesAbstract_iB_c20210101__20211231_zqbnatmsvCN5"&gt;Liabilities&lt;/span&gt;:&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;
    &lt;td style="font-weight: bold; text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;
    &lt;td style="font-weight: bold; text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;
    &lt;td style="font-weight: bold; text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle; background-color: white"&gt;
    &lt;td style="text-indent: 10pt"&gt;Convertible notes payable, at fair value&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_z1Dji7GN6VXc" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0457"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zZc1eDPalm1i" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0458"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_z6iymzVEu8el" style="text-align: right"&gt;18,920&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zMlyQogvhvz5" style="text-align: right"&gt;18,920&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle; background-color: white"&gt;
    &lt;td style="text-indent: 10pt"&gt;Derivative liability, at fair value&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zB0e9XsEXIV7" style="text-align: right"&gt;1,174&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_z3vyQwT75uk1" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0462"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zBPGwAQ3cEei" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0463"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zai4h0Tys5Ud" style="text-align: right"&gt;1,174&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle; background-color: white"&gt;
    &lt;td style="text-indent: 10pt"&gt;Warrant liabilities, at fair value&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_984_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zZKHP2KXgNKf" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0465"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_98B_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zpHSbRNVJiJi" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0466"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_98F_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_z2rtoturi0K1" style="border-bottom: Black 1pt solid; text-align: right"&gt;424&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_982_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zW1Y23DafrH3" style="border-bottom: Black 1pt solid; text-align: right"&gt;424&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle; background-color: white"&gt;
    &lt;td style="text-indent: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zkxlXzVGYAY6" style="border-bottom: Black 2pt double; text-align: right"&gt;1,174&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zYs6Is3hVU9l" style="border-bottom: Black 2pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0470"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zDyahd65sJWd" style="border-bottom: Black 2pt double; text-align: right"&gt;19,344&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zwS6h5ca1G24" style="border-bottom: Black 2pt double; text-align: right"&gt;20,518&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"/&gt;

&lt;p style="font: 9pt Sans-Serif; margin: 0 0 0 4.5pt; background-color: white; color: Red"/&gt;



&lt;p style="margin-top: 0; margin-bottom: 0"/&gt;

&lt;p style="font: 9pt Sans-Serif; margin: 0 0 0 4.5pt; background-color: white; color: Red"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p id="xdx_8AD_zWf1Uyzwva4e" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"&gt;&lt;span style="background-color: white"&gt;The fair
value of the Company&#x2019;s money market funds is based on quoted active market prices for the funds and is determined using the market
approach.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;The Company measures the 2021 Convertible Notes
and warrant liabilities &lt;span style="background-color: white"&gt;at fair value based on significant inputs not observable in the market,
which causes them to be classified as a Level&#160;3 measurement within the fair value hierarchy.&#160;&lt;/span&gt;These valuations use assumptions
and estimates the Company believes would be made by a market participant in making the same valuation. The Company assesses these assumptions
and estimates on&#160;an&#160;on-going&#160;basis as additional data impacting the assumptions and estimates are obtained. Changes in
the fair value of the convertible notes payable and warrant liabilities related to updated assumptions and estimates are recognized within
the Consolidated Statements of Operations and Comprehensive Loss.&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The fair value of the convertible notes payable and warrant
liabilities may change significantly as additional data is obtained, impacting the Company&#x2019;s assumptions regarding probabilities
of outcomes used to estimate the fair value of the liabilities. The estimates of fair value may not be indicative of the amounts that
could be realized in a current market exchange. Accordingly, the use of different market assumptions and/or different valuation techniques
may have a material effect on the estimated fair value amounts, and such changes could materially impact the Company&#x2019;s results
of operations in future periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Derivative Liability&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The derivative liability represents the fair value of the &#x201c;Shortfall
Amount&#x201d; provision provided for in the license agreement with iX Biopharma Europe Limited.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;At issuance, the fair value of the embedded derivative was estimated
by using a Monte Carlo simulation model. As of December 31, 2021, the Company determined it was probable it would settle the Shortfall
Amount in cash and estimated the fair value based on a probability weighted market approach. The Company paid the Shortfall Amount of
$&lt;span id="xdx_902_ecustom--NonrefundableCashPayment_pn5n6_c20220101__20220131__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_zGsQjw9Csvmh"&gt;1.2&lt;/span&gt; million in cash in January 2022.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;2021 Convertible Notes&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zobZdwvz86B2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The
2021 Convertible Notes are valued using a Monte Carlo simulation model. The following assumptions were used in determining the fair
value of the 2021 Convertible Notes as of March 31, 2022 and December 31, 2021:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_8B1_ziFuTHcOTBZ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none"&gt;Summary of Fair Value Measurements Convertible Notes Valuation
Assumptions&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 56%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; text-align: center; width: 19%"&gt;Three Months Ended&lt;/td&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; text-align: right; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; text-align: right; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; text-align: center; width: 19%"&gt;Year Ended&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center"&gt;March 31, 2022&lt;/td&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td style="background-color: white"&gt;Risk-free interest rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 9pt; text-align: center"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_uPure_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_z5HpRHX11Yob"&gt;2.45&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; border-top-color: Black; border-top-width: 1pt; background-color: white"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_uPure_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MinimumMember_zZeGHvgGJ9s4"&gt;0.90&lt;/span&gt;% - &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_uPure_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MaximumMember_z37XKizL0Gw7"&gt;0.95&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td style="background-color: white"&gt;Volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 9pt; text-align: center"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pin2_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zacDLrQ4GKdg"&gt;105&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; background-color: white"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pin2_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MinimumMember_zg5wBGRG8c44"&gt;113&lt;/span&gt;% - &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pin2_uPure_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MaximumMember_zErzf8T2zyUi"&gt;114&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td style="background-color: white"&gt;Dividend yield&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 9pt; text-align: center"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zW1WNfLtpRW5"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0482"&gt;-&lt;/span&gt;&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; background-color: white"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_ziWfoJRwIme7"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0483"&gt;-&lt;/span&gt;&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td style="background-color: white"&gt;Contractual term (years)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zWmphv1myut4" style="font-size: 9pt; text-align: center"&gt;2.7&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zmlt9elrKnbd" style="vertical-align: bottom; text-align: center; background-color: white"&gt;3.0&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td style="background-color: white"&gt;Stock price&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 9pt; text-align: center"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_uUSDPShares_c20220331__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_z3skXZj1r90j"&gt;0.84&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; background-color: white"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_uUSDPShares_c20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MinimumMember_zljLj7MQFzwe"&gt;1.74&lt;/span&gt; - &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_uUSDPShares_c20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MaximumMember_z3kkv8fM9Zpa"&gt;1.95&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zrGUII808ble" style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"/&gt;







&lt;p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0; text-align: left"/&gt;

&lt;p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Warrant Liabilities&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The common stock warrant liabilities were recorded at fair value using
the Black-Scholes option pricing model. &#160;&lt;/p&gt;

&lt;p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p id="xdx_899_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zO2vSCDX6qTh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;span style="font-weight: normal"&gt;&lt;span style="background-color: white"&gt;The
following assumptions were used in determining the fair value of the warrant liabilities valued using the Black-Scholes option
pricing model for the three months ended March 31, 2022 and 2021.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;span style="font-weight: normal"&gt;&lt;span style="background-color: white"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8BD_zAZ6sU0ZV6p3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"&gt;&lt;span style="font-weight: normal"&gt;&lt;span style="display: none; background-color: white"&gt;Summary
of Fair Value Measurements Warrant Valuation Assumptions&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td style="width: 55%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; text-align: right; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; text-align: right; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; text-align: center; width: 19%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 20%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td/&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; text-align: right"/&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; text-align: right"/&gt;
    &lt;td colspan="4" style="font-size: 9pt; font-weight: bold; text-align: center"&gt;Three Months  Ended March  31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td/&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Risk-free interest rate&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_uPure_c20220101__20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zOk0436sECG2" style="text-align: center; border-top-color: Black; border-top-width: 1pt"&gt;1.96%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_uPure_c20210101__20210331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zQXop3eyrI2k" style="text-align: center; border-top-color: Black; border-top-width: 1pt"&gt;0.32%&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pin2_uPure_c20220101__20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zFQkpDdm9Xka" style="text-align: center"&gt;103.30%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pin2_uPure_c20210101__20210331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_z8fdFMccT2S2" style="text-align: center"&gt;120.91%&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20220101__20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zz7ilyPOnhdg" title="Dividend yield (in percent)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0496"&gt;-&lt;/span&gt;&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20210101__20210331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zSAF5OZBaWde" title="Dividend yield (in percent)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0498"&gt;-&lt;/span&gt;&lt;/span&gt;%&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Expected term (years)&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zcrDiuC8yDRb" style="text-align: center"&gt;1.82&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zAFqHOxghGpf" style="text-align: center"&gt;2.82&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Weighted-average fair value&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220101__20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zEZJzyd9xHx3" style="text-align: center"&gt;0.63&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20210101__20210331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zr76QnsGRBn5" style="text-align: center"&gt;4.76&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: bold 9pt Sans-Serif; margin: 0 0 0 6pt; text-align: left; color: Red"/&gt;

&lt;p id="xdx_8A1_zU3M9zd0geK3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"&gt;&#160;&lt;/p&gt;






&lt;p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zCPml5pFNX89" style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"&gt;The
following table is a reconciliation for the common stock warrant liabilities and convertible notes measured at
fair value using Level 3 unobservable inputs (in thousands):&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"&gt;&lt;span style="font-weight: normal; background-color: white"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;span style="font-weight: normal; background-color: white"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8BF_z141aSNXGWG7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"&gt;&lt;span style="display: none; font-weight: normal; background-color: white; font-style: normal"&gt;Schedule of Fair Value Level 3 Reconciliation&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: right; width: 65%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; width: 1%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; width: 2%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; width: 7%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; width: 2%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; width: 6%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; width: 2%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; width: 13%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="font-size: 9pt"&gt;&lt;b&gt;Warrant&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="font-size: 9pt"&gt;&lt;b&gt;Derivative&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="font-size: 9pt"&gt;&lt;b&gt;Convertible notes,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-size: 9pt"&gt;liabilities&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-size: 9pt"&gt;liability&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-size: 9pt"&gt;at
    fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 9pt"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zZ5N7YCQckUf" style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;1,062&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;Warrant liability reclassified to stockholders' equity&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_90B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zy3q2RQ3tfl9"&gt;(1,155)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;Issuance of convertible notes, at fair value&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span id="xdx_903_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2l9ITqAdDS3"&gt;19,150&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;Issuance of derivative liability&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span id="xdx_909_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zeSjkKoJkkxe"&gt;805&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;Change in fair value measurement of derivative liability&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span id="xdx_90E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zsnriOmehMg3"&gt;369&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;Change in fair value measurement of convertible notes&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span id="xdx_900_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z1bOcwLgc6ni"&gt;(230)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;Change in fair value measurement of warrant liability&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_90A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z9ZMDiklTg95"&gt;517&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="font-weight: bold; vertical-align: middle"&gt;&lt;span style="font-size: 9pt"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: middle; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zZOckZD8d9d6" style="vertical-align: middle; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;424&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: middle; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zqO3PH8nHf3a" style="vertical-align: middle; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;1,174&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: middle; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zzTtUmRpTS0k" style="vertical-align: middle; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;18,920&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;Settlement of derivative liability&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span id="xdx_905_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_i01N_pn3n3_di_c20220101__20220331__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwCetRrRSAH2"&gt;(1,174)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;Change in fair value measurement of convertible notes&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span id="xdx_90E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_i01_pn3n3_c20220101__20220331__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zhaQF9ZHYUVb"&gt;244&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;Change in fair value measurement of warrant liability&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_908_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_i01_pn3n3_c20220101__20220331__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zLeLqN2kvjGc"&gt;(234)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="font-weight: bold; vertical-align: middle"&gt;&lt;span style="font-size: 9pt"&gt;Balance as of March 31, 2022&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: middle; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zBuArDbAc7Ek" style="border-bottom: Black 3pt double; vertical-align: middle; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;190&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: middle; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_z1bamG3QqGxf" style="border-bottom: Black 3pt double; vertical-align: middle; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0519"&gt;&#160;&lt;/span&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: middle; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_z07O5qVN9v76" style="border-bottom: Black 3pt double; vertical-align: middle; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;19,164&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zTkGNxX2rtf6" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="background-color: white"&gt;For the three months ended
March 31, 2022 and the year ended December 31, 2021, the changes in fair value of the convertible notes, derivative liability and
warrant liability primarily resulted from the volatility of the Company&#x2019;s common stock. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_899_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zmwG4olT1Kz1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"&gt;The Company&#x2019;s financial assets and liabilities measured at fair value
at March 31, 2022 and December 31, 2021 are as follows (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; background-color: white"&gt;&lt;span id="xdx_8BE_zLdsggSUjfL6" style="display: none"&gt;Schedule of Fair Value Hierarchy Assets and Liabilities&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; background-color: white"/&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="vertical-align: middle; background-color: white"&gt;
    &lt;td style="font-weight: bold; width: 44%"/&gt;
    &lt;td style="font-weight: bold; text-align: right; width: 2%"/&gt;
    &lt;td style="font-weight: bold; text-align: right; width: 2%"/&gt;
    &lt;td style="font-weight: bold; text-align: center; width: 10%"/&gt;
    &lt;td style="font-weight: bold; text-align: right; width: 2%"/&gt;
    &lt;td style="font-weight: bold; text-align: right; width: 2%"/&gt;
    &lt;td style="font-weight: bold; text-align: center; width: 10%"/&gt;
    &lt;td style="font-weight: bold; text-align: right; width: 2%"/&gt;
    &lt;td style="font-weight: bold; text-align: right; width: 2%"/&gt;
    &lt;td style="font-weight: bold; text-align: center; width: 10%"/&gt;
    &lt;td style="font-weight: bold; text-align: right; width: 2%"/&gt;
    &lt;td style="font-weight: bold; text-align: right; width: 2%"/&gt;
    &lt;td style="font-weight: bold; text-align: center; width: 10%"/&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td colspan="10" style="font-weight: bold; vertical-align: middle; text-align: center; background-color: white"&gt;Fair Value Measurements&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td colspan="10" style="font-weight: bold; vertical-align: middle; text-align: center; background-color: white"&gt;as of March 31, 2022&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: right; background-color: white; width: 44%"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white; width: 2%"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right; width: 2%"/&gt;
    &lt;td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 10%"&gt;(Level 1)&lt;/td&gt;
    &lt;td style="vertical-align: middle; text-align: right; background-color: white; width: 2%"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right; width: 2%"/&gt;
    &lt;td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 10%"&gt;(Level 2)&lt;/td&gt;
    &lt;td style="vertical-align: middle; text-align: right; background-color: white; width: 2%"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right; width: 2%"/&gt;
    &lt;td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 10%"&gt;(Level 3)&lt;/td&gt;
    &lt;td style="vertical-align: middle; text-align: right; background-color: white; width: 2%"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right; width: 2%"/&gt;
    &lt;td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 10%"&gt;Total&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle; background-color: white"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_900_eus-gaap--AssetsAbstract_iB_c20220101__20220331_ziSTSyBoNVWc"&gt;Assets&lt;/span&gt;:&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle; background-color: white"&gt;
    &lt;td style="text-indent: 10pt"&gt;Cash&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zMqtLMj6TFSi" style="border-bottom: Black 2pt double; text-align: right" title="Cash"&gt;61,772&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zz24VxuSoM5a" style="border-bottom: Black 2pt double; text-align: right" title="Cash"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0429"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zaL1DaIgI1v5" style="border-bottom: Black 2pt double; text-align: right" title="Cash"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0431"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20220331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zFAa9NtOhvN6" style="border-bottom: Black 2pt double; text-align: right" title="Cash"&gt;61,772&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle; background-color: white"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_90D_eus-gaap--LiabilitiesAbstract_iB_c20220101__20220331_zSJ30OFb8PIk"&gt;Liabilities&lt;/span&gt;:&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;
    &lt;td style="font-weight: bold; text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;
    &lt;td style="font-weight: bold; text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;
    &lt;td style="font-weight: bold; text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle; background-color: white"&gt;
    &lt;td style="text-indent: 10pt"&gt;Convertible notes payable, at fair value&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zjsKM8XNM0Fg" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0435"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zdXWGeQSnKdk" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0436"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_z9av2YuWif5f" style="text-align: right"&gt;19,164&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zA9bPAF27hee" style="text-align: right"&gt;19,164&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle; background-color: white"&gt;
    &lt;td style="text-indent: 10pt"&gt;Warrant liabilities, at fair value&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_988_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zAX0BuuWs5Zi" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant liabilities, at fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0440"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_98D_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zDx7tAT4Cpg3" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant liabilities, at fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0442"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_989_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zRHvxSJNbD8c" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant liabilities, at fair value"&gt;190&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_987_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zGE4pbeM8qeg" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant liabilities, at fair value"&gt;190&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle; background-color: white"&gt;
    &lt;td style="text-indent: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zflU3SniAtPg" style="border-bottom: Black 2pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0447"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z6tMvCVtLyXf" style="border-bottom: Black 2pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0448"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zQlhU1IQidSc" style="border-bottom: Black 2pt double; text-align: right"&gt;19,354&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zcBb6lxtsIDc" style="border-bottom: Black 2pt double; text-align: right"&gt;19,354&lt;/td&gt;&lt;/tr&gt;

  &lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;


&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; background-color: white"/&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="vertical-align: middle; background-color: white"&gt;
    &lt;td style="font-weight: bold; width: 44%"/&gt;
    &lt;td style="font-weight: bold; text-align: right; width: 2%"/&gt;
    &lt;td style="font-weight: bold; text-align: right; width: 2%"/&gt;
    &lt;td style="font-weight: bold; text-align: center; width: 10%"/&gt;
    &lt;td style="font-weight: bold; text-align: right; width: 2%"/&gt;
    &lt;td style="font-weight: bold; text-align: right; width: 2%"/&gt;
    &lt;td style="font-weight: bold; text-align: center; width: 10%"/&gt;
    &lt;td style="font-weight: bold; text-align: right; width: 2%"/&gt;
    &lt;td style="font-weight: bold; text-align: right; width: 2%"/&gt;
    &lt;td style="font-weight: bold; text-align: center; width: 10%"/&gt;
    &lt;td style="font-weight: bold; text-align: right; width: 2%"/&gt;
    &lt;td style="font-weight: bold; text-align: right; width: 2%"/&gt;
    &lt;td style="font-weight: bold; text-align: center; width: 10%"/&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td colspan="10" style="font-weight: bold; vertical-align: middle; text-align: center; background-color: white"&gt;Fair Value Measurements&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td colspan="10" style="font-weight: bold; vertical-align: middle; text-align: center; background-color: white"&gt;as of December 31, 2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: right; background-color: white; width: 44%"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white; width: 1%"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right; width: 1%"/&gt;
    &lt;td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 12%"&gt;(Level 1)&lt;/td&gt;
    &lt;td style="vertical-align: middle; text-align: right; background-color: white; width: 1%"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right; width: 1%"/&gt;
    &lt;td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 12%"&gt;(Level 2)&lt;/td&gt;
    &lt;td style="vertical-align: middle; text-align: right; background-color: white; width: 1%"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right; width: 1%"/&gt;
    &lt;td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 12%"&gt;(Level 3)&lt;/td&gt;
    &lt;td style="vertical-align: middle; text-align: right; background-color: white; width: 1%"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right; width: 1%"/&gt;
    &lt;td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 12%"&gt;Total&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle; background-color: white"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_90C_eus-gaap--AssetsAbstract_iB_c20210101__20211231_z1NdZhfsyYU6"&gt;Assets&lt;/span&gt;:&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle; background-color: white"&gt;
    &lt;td style="text-indent: 10pt"&gt;Cash&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zphNLgkyaaSg" style="border-bottom: Black 2pt double; text-align: right"&gt;78,734&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zTrI2Jcn3cac" style="border-bottom: Black 2pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0453"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z0vhW9igOboi" style="border-bottom: Black 2pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0454"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zZ0sFf2PIsVd" style="border-bottom: Black 2pt double; text-align: right"&gt;78,734&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle; background-color: white"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_90E_eus-gaap--LiabilitiesAbstract_iB_c20210101__20211231_zqbnatmsvCN5"&gt;Liabilities&lt;/span&gt;:&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;
    &lt;td style="font-weight: bold; text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;
    &lt;td style="font-weight: bold; text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;
    &lt;td style="font-weight: bold; text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: right"/&gt;
    &lt;td style="font-weight: bold; text-align: center"/&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle; background-color: white"&gt;
    &lt;td style="text-indent: 10pt"&gt;Convertible notes payable, at fair value&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_z1Dji7GN6VXc" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0457"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zZc1eDPalm1i" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0458"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_z6iymzVEu8el" style="text-align: right"&gt;18,920&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zMlyQogvhvz5" style="text-align: right"&gt;18,920&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle; background-color: white"&gt;
    &lt;td style="text-indent: 10pt"&gt;Derivative liability, at fair value&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zB0e9XsEXIV7" style="text-align: right"&gt;1,174&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_z3vyQwT75uk1" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0462"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zBPGwAQ3cEei" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0463"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zai4h0Tys5Ud" style="text-align: right"&gt;1,174&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle; background-color: white"&gt;
    &lt;td style="text-indent: 10pt"&gt;Warrant liabilities, at fair value&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_984_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zZKHP2KXgNKf" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0465"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_98B_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zpHSbRNVJiJi" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0466"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_98F_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_z2rtoturi0K1" style="border-bottom: Black 1pt solid; text-align: right"&gt;424&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_982_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zW1Y23DafrH3" style="border-bottom: Black 1pt solid; text-align: right"&gt;424&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle; background-color: white"&gt;
    &lt;td style="text-indent: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zkxlXzVGYAY6" style="border-bottom: Black 2pt double; text-align: right"&gt;1,174&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zYs6Is3hVU9l" style="border-bottom: Black 2pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0470"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zDyahd65sJWd" style="border-bottom: Black 2pt double; text-align: right"&gt;19,344&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zwS6h5ca1G24" style="border-bottom: Black 2pt double; text-align: right"&gt;20,518&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"/&gt;

&lt;p style="font: 9pt Sans-Serif; margin: 0 0 0 4.5pt; background-color: white; color: Red"/&gt;



&lt;p style="margin-top: 0; margin-bottom: 0"/&gt;

&lt;p style="font: 9pt Sans-Serif; margin: 0 0 0 4.5pt; background-color: white; color: Red"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      unitRef="USD">61772000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2022-03-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      unitRef="USD">61772000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_LongTermDebtMember"
      decimals="-3"
      unitRef="USD">19164000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2022-03-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_LongTermDebtMember"
      decimals="-3"
      unitRef="USD">19164000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember"
      decimals="-3"
      unitRef="USD">190000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2022-03-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember"
      decimals="-3"
      unitRef="USD">190000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      unitRef="USD">19354000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2022-03-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      unitRef="USD">19354000</us-gaap:DerivativeLiabilities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      unitRef="USD">78734000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2021-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      unitRef="USD">78734000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_LongTermDebtMember"
      decimals="-3"
      unitRef="USD">18920000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2021-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_LongTermDebtMember"
      decimals="-3"
      unitRef="USD">18920000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"
      decimals="-3"
      unitRef="USD">1174000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2021-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"
      decimals="-3"
      unitRef="USD">1174000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember"
      decimals="-3"
      unitRef="USD">424000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2021-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember"
      decimals="-3"
      unitRef="USD">424000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      unitRef="USD">1174000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      unitRef="USD">19344000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2021-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      unitRef="USD">20518000</us-gaap:DerivativeLiabilities>
    <SEEL:NonrefundableCashPayment
      contextRef="From2022-01-012022-01-31_custom_IXLicenseAgreementMember"
      decimals="-5"
      unitRef="USD">1200000</SEEL:NonrefundableCashPayment>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="From2022-01-012022-03-31_us-gaap_LongTermDebtMember">&lt;p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zobZdwvz86B2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The
2021 Convertible Notes are valued using a Monte Carlo simulation model. The following assumptions were used in determining the fair
value of the 2021 Convertible Notes as of March 31, 2022 and December 31, 2021:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_8B1_ziFuTHcOTBZ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none"&gt;Summary of Fair Value Measurements Convertible Notes Valuation
Assumptions&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 56%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; text-align: center; width: 19%"&gt;Three Months Ended&lt;/td&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; text-align: right; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; text-align: right; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; text-align: center; width: 19%"&gt;Year Ended&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center"&gt;March 31, 2022&lt;/td&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td style="background-color: white"&gt;Risk-free interest rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 9pt; text-align: center"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_uPure_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_z5HpRHX11Yob"&gt;2.45&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; border-top-color: Black; border-top-width: 1pt; background-color: white"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_uPure_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MinimumMember_zZeGHvgGJ9s4"&gt;0.90&lt;/span&gt;% - &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_uPure_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MaximumMember_z37XKizL0Gw7"&gt;0.95&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td style="background-color: white"&gt;Volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 9pt; text-align: center"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pin2_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zacDLrQ4GKdg"&gt;105&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; background-color: white"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pin2_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MinimumMember_zg5wBGRG8c44"&gt;113&lt;/span&gt;% - &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pin2_uPure_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MaximumMember_zErzf8T2zyUi"&gt;114&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td style="background-color: white"&gt;Dividend yield&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 9pt; text-align: center"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zW1WNfLtpRW5"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0482"&gt;-&lt;/span&gt;&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; background-color: white"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_ziWfoJRwIme7"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0483"&gt;-&lt;/span&gt;&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td style="background-color: white"&gt;Contractual term (years)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zWmphv1myut4" style="font-size: 9pt; text-align: center"&gt;2.7&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zmlt9elrKnbd" style="vertical-align: bottom; text-align: center; background-color: white"&gt;3.0&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td style="background-color: white"&gt;Stock price&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td style="font-size: 9pt; text-align: center"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_uUSDPShares_c20220331__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_z3skXZj1r90j"&gt;0.84&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; background-color: white"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_uUSDPShares_c20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MinimumMember_zljLj7MQFzwe"&gt;1.74&lt;/span&gt; - &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_uUSDPShares_c20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MaximumMember_z3kkv8fM9Zpa"&gt;1.95&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember_us-gaap_LongTermDebtMember"
      decimals="INF"
      unitRef="Pure">2.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_LongTermDebtMember_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_LongTermDebtMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">0.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember_us-gaap_LongTermDebtMember"
      decimals="INF"
      unitRef="Pure">10500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_LongTermDebtMember_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">11300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_LongTermDebtMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">11400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-01-012022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_LongTermDebtMember">P2Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_LongTermDebtMember">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2022-03-31_us-gaap_LongTermDebtMember"
      decimals="2"
      unitRef="USDPShares">0.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2021-12-31_us-gaap_LongTermDebtMember_srt_MinimumMember"
      decimals="2"
      unitRef="USDPShares">1.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2021-12-31_us-gaap_LongTermDebtMember_srt_MaximumMember"
      decimals="2"
      unitRef="USDPShares">1.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="From2022-01-012022-03-31_us-gaap_WarrantMember654115578">&lt;p id="xdx_899_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zO2vSCDX6qTh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;span style="font-weight: normal"&gt;&lt;span style="background-color: white"&gt;The
following assumptions were used in determining the fair value of the warrant liabilities valued using the Black-Scholes option
pricing model for the three months ended March 31, 2022 and 2021.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;span style="font-weight: normal"&gt;&lt;span style="background-color: white"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8BD_zAZ6sU0ZV6p3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"&gt;&lt;span style="font-weight: normal"&gt;&lt;span style="display: none; background-color: white"&gt;Summary
of Fair Value Measurements Warrant Valuation Assumptions&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td style="width: 55%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; text-align: right; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; text-align: right; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; text-align: center; width: 19%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 20%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td/&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; text-align: right"/&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; text-align: right"/&gt;
    &lt;td colspan="4" style="font-size: 9pt; font-weight: bold; text-align: center"&gt;Three Months  Ended March  31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td/&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Risk-free interest rate&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_uPure_c20220101__20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zOk0436sECG2" style="text-align: center; border-top-color: Black; border-top-width: 1pt"&gt;1.96%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_uPure_c20210101__20210331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zQXop3eyrI2k" style="text-align: center; border-top-color: Black; border-top-width: 1pt"&gt;0.32%&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pin2_uPure_c20220101__20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zFQkpDdm9Xka" style="text-align: center"&gt;103.30%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pin2_uPure_c20210101__20210331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_z8fdFMccT2S2" style="text-align: center"&gt;120.91%&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20220101__20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zz7ilyPOnhdg" title="Dividend yield (in percent)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0496"&gt;-&lt;/span&gt;&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20210101__20210331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zSAF5OZBaWde" title="Dividend yield (in percent)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0498"&gt;-&lt;/span&gt;&lt;/span&gt;%&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Expected term (years)&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zcrDiuC8yDRb" style="text-align: center"&gt;1.82&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zAFqHOxghGpf" style="text-align: center"&gt;2.82&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Weighted-average fair value&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220101__20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zEZJzyd9xHx3" style="text-align: center"&gt;0.63&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20210101__20210331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zr76QnsGRBn5" style="text-align: center"&gt;4.76&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: bold 9pt Sans-Serif; margin: 0 0 0 6pt; text-align: left; color: Red"/&gt;

</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-01-012022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">0.0196</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-01-012021-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">0.0032</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-01-012022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">103.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-01-012021-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">120.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-01-012022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">P1Y9M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-01-012021-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">P2Y9M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">0.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-01-012021-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">4.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_895_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zCPml5pFNX89" style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"&gt;The
following table is a reconciliation for the common stock warrant liabilities and convertible notes measured at
fair value using Level 3 unobservable inputs (in thousands):&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"&gt;&lt;span style="font-weight: normal; background-color: white"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;span style="font-weight: normal; background-color: white"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8BF_z141aSNXGWG7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"&gt;&lt;span style="display: none; font-weight: normal; background-color: white; font-style: normal"&gt;Schedule of Fair Value Level 3 Reconciliation&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: right; width: 65%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; width: 1%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; width: 2%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; width: 7%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; width: 2%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; width: 6%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; width: 2%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; width: 13%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="font-size: 9pt"&gt;&lt;b&gt;Warrant&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="font-size: 9pt"&gt;&lt;b&gt;Derivative&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="font-size: 9pt"&gt;&lt;b&gt;Convertible notes,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-size: 9pt"&gt;liabilities&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-size: 9pt"&gt;liability&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-size: 9pt"&gt;at
    fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-size: 9pt"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zZ5N7YCQckUf" style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;1,062&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;Warrant liability reclassified to stockholders' equity&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_90B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zy3q2RQ3tfl9"&gt;(1,155)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;Issuance of convertible notes, at fair value&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span id="xdx_903_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2l9ITqAdDS3"&gt;19,150&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;Issuance of derivative liability&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span id="xdx_909_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zeSjkKoJkkxe"&gt;805&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;Change in fair value measurement of derivative liability&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span id="xdx_90E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zsnriOmehMg3"&gt;369&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;Change in fair value measurement of convertible notes&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span id="xdx_900_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z1bOcwLgc6ni"&gt;(230)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;Change in fair value measurement of warrant liability&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_90A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z9ZMDiklTg95"&gt;517&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="font-weight: bold; vertical-align: middle"&gt;&lt;span style="font-size: 9pt"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: middle; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zZOckZD8d9d6" style="vertical-align: middle; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;424&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: middle; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zqO3PH8nHf3a" style="vertical-align: middle; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;1,174&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: middle; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zzTtUmRpTS0k" style="vertical-align: middle; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;18,920&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;Settlement of derivative liability&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span id="xdx_905_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_i01N_pn3n3_di_c20220101__20220331__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwCetRrRSAH2"&gt;(1,174)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;Change in fair value measurement of convertible notes&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span id="xdx_90E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_i01_pn3n3_c20220101__20220331__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zhaQF9ZHYUVb"&gt;244&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;Change in fair value measurement of warrant liability&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_908_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_i01_pn3n3_c20220101__20220331__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zLeLqN2kvjGc"&gt;(234)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right; background-color: white"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="font-weight: bold; vertical-align: middle"&gt;&lt;span style="font-size: 9pt"&gt;Balance as of March 31, 2022&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: middle; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zBuArDbAc7Ek" style="border-bottom: Black 3pt double; vertical-align: middle; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;190&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: middle; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_z1bamG3QqGxf" style="border-bottom: Black 3pt double; vertical-align: middle; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0519"&gt;&#160;&lt;/span&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: middle; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20220331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_z07O5qVN9v76" style="border-bottom: Black 3pt double; vertical-align: middle; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;19,164&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="-3"
      unitRef="USD">1062000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      unitRef="USD">-1155000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
      contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_LongTermDebtMember"
      decimals="-3"
      unitRef="USD">19150000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
      contextRef="From2021-01-012021-12-31_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      unitRef="USD">805000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="From2021-01-012021-12-31_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      unitRef="USD">369000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_LongTermDebtMember"
      decimals="-3"
      unitRef="USD">-230000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      unitRef="USD">517000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="-3"
      unitRef="USD">424000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"
      decimals="-3"
      unitRef="USD">1174000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_LongTermDebtMember"
      decimals="-3"
      unitRef="USD">18920000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
      contextRef="From2022-01-012022-03-31_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      unitRef="USD">1174000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="From2022-01-012022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_LongTermDebtMember"
      decimals="-3"
      unitRef="USD">244000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="From2022-01-012022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="-3"
      unitRef="USD">-234000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="-3"
      unitRef="USD">190000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_LongTermDebtMember"
      decimals="-3"
      unitRef="USD">19164000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_807_eus-gaap--OtherCurrentAssetsTextBlock_zxTYFBXSMjbi" style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;5. Prepaid Expenses and Other Current Assets&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_z2quCZanxsAd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Prepaid expenses and other current assets are comprised of the following
(in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_8BB_zFwXqZpjjEH5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none"&gt;Schedule of Prepaid Expenses and Other Current Assets&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 85%; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_492_20220331_zUJOJOzjr6L3" style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_495_20211231_z0xE0sLPmIEi" style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center"&gt;March 31,&lt;/td&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center"&gt;December 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center"&gt;2022&lt;/td&gt;
    &lt;td style="vertical-align: middle"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PrepaidInsurance_iI_pn3n3_maPEAOAzj4M_zj6iYj33ahr1" style="vertical-align: middle"&gt;
    &lt;td style="width: 66%"&gt;Prepaid insurance&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: right; width: 1%"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white; width: 15%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;787&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: right; width: 1%"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right; width: 15%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;59&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--PrepaidClinicalCosts_iI_pn3n3_maPEAOAzj4M_zosvL0eg1Rc9" style="vertical-align: middle"&gt;
    &lt;td&gt;Prepaid clinical costs&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;7,694&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;4,481&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3n3_maPEAOAzj4M_zDuzsVMSYJ83"&gt;
    &lt;td style="vertical-align: middle"&gt;Other&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: middle; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: middle; text-align: right; background-color: white"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;414&lt;/td&gt;
    &lt;td style="vertical-align: middle"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: top; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: middle; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;187&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i01TI_pn3n3_maACzKPF_maACzYR4_mtPEAOAzj4M_zuIdy9vqOoKd" style="vertical-align: middle"&gt;
    &lt;td style="padding-left: 24px; text-align: left"&gt;Prepaid expenses and other current assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2pt double; vertical-align: top; text-align: right"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 1pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;8,895&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2pt double; vertical-align: top; text-align: right"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 1pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;4,727&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A9_z5E5zcgHzLMl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"/&gt;

</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_894_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_z2quCZanxsAd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Prepaid expenses and other current assets are comprised of the following
(in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_8BB_zFwXqZpjjEH5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none"&gt;Schedule of Prepaid Expenses and Other Current Assets&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 85%; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_492_20220331_zUJOJOzjr6L3" style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_495_20211231_z0xE0sLPmIEi" style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center"&gt;March 31,&lt;/td&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center"&gt;December 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center"&gt;2022&lt;/td&gt;
    &lt;td style="vertical-align: middle"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PrepaidInsurance_iI_pn3n3_maPEAOAzj4M_zj6iYj33ahr1" style="vertical-align: middle"&gt;
    &lt;td style="width: 66%"&gt;Prepaid insurance&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: right; width: 1%"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white; width: 15%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;787&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: right; width: 1%"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right; width: 15%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;59&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--PrepaidClinicalCosts_iI_pn3n3_maPEAOAzj4M_zosvL0eg1Rc9" style="vertical-align: middle"&gt;
    &lt;td&gt;Prepaid clinical costs&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;7,694&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;4,481&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3n3_maPEAOAzj4M_zDuzsVMSYJ83"&gt;
    &lt;td style="vertical-align: middle"&gt;Other&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: middle; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: middle; text-align: right; background-color: white"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;414&lt;/td&gt;
    &lt;td style="vertical-align: middle"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: top; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: middle; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;187&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i01TI_pn3n3_maACzKPF_maACzYR4_mtPEAOAzj4M_zuIdy9vqOoKd" style="vertical-align: middle"&gt;
    &lt;td style="padding-left: 24px; text-align: left"&gt;Prepaid expenses and other current assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2pt double; vertical-align: top; text-align: right"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 1pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;8,895&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2pt double; vertical-align: top; text-align: right"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 1pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;4,727&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidInsurance contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">787000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">59000</us-gaap:PrepaidInsurance>
    <SEEL:PrepaidClinicalCosts contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">7694000</SEEL:PrepaidClinicalCosts>
    <SEEL:PrepaidClinicalCosts contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">4481000</SEEL:PrepaidClinicalCosts>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">414000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">187000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">8895000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">4727000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_808_eus-gaap--BusinessCombinationDisclosureTextBlock_zWRxfvxCmEWd" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;6. Common Stock Offerings&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Public Offerings&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;On May 24, 2021, the Company completed an underwritten public
offering, pursuant to which the Company sold &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--May242021Member_zPVRgA5RMaM1" title="Number of shares of common stock issued"&gt;22,258,066&lt;/span&gt; shares of its common stock, at a price to the public of $&lt;span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_pp2p0_uUSDPShares_c20210524__us-gaap--StatementClassOfStockAxis__custom--May242021Member_zkYUNTkLxcd1" title="Shares Issued, Price Per Share"&gt;3.10&lt;/span&gt; per share, which
included the exercise in full by the underwriter of its option to purchase up to 2,903,226 additional shares of common stock. The net
proceeds to the Company from the offering were approximately $&lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--May242021Member_zhylCscaQiz" title="Cash received from stock sale"&gt;64.5&lt;/span&gt; million, after deducting underwriting discounts, commissions and
other offering expenses. The Company used $&lt;span id="xdx_90E_ecustom--OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes_pn5n6_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--May242021Member_zbSSnmJkeCOh" title="Offering proceeds used to partially repay certain convertible promissory notes"&gt;7.3&lt;/span&gt; million of the net proceeds from the offering for the partial repayment
of certain outstanding convertible promissory notes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;On January 28, 2021, the Company completed an underwritten public
offering, pursuant to which the Company sold &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--January282021Member_ziiVbkN1rM35"&gt;17,530,488
&lt;/span&gt;shares of its common stock, at a price to the public of $&lt;span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_pp2p0_uUSDPShares_c20210128__us-gaap--StatementClassOfStockAxis__custom--January282021Member_zhwuTBDaRzq1"&gt;2.05
&lt;/span&gt;per share, which included the exercise in full by the underwriter of its option to purchase up to 2,286,585 additional shares
of common stock. The net proceeds to the Company from the offering were approximately $&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--January282021Member_z86SClZKrcwl"&gt;33.5
&lt;/span&gt;million, after deducting underwriting discounts, commissions and other offering expenses. The Company used $&lt;span id="xdx_907_ecustom--OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes_pn5n6_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--January282021Member_z7HAPFqbneJ7"&gt;3.8
&lt;/span&gt;million of the net proceeds from the offering for the partial repayment of certain outstanding convertible promissory notes.&#160;&lt;/p&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Stock Purchase Agreement with iX Biopharma Europe Limited&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;On November 24, 2021, the Company entered in an exclusive license agreement
and stock purchase agreement (the &#x201c;iXBEL Stock Purchase Agreement&#x201d;) with iX Biopharma Europe Limited (&#x201c;iXBEL&#x201d;).
As consideration for the license under the license agreement, the Company paid iXBEL an upfront fee of $&lt;span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20211101__20211130__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_zbhykfLuIVV3"&gt;9.0&lt;/span&gt; million, comprised of $&lt;span id="xdx_904_ecustom--NonrefundableCashPayment_pn5n6_c20211101__20211130__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_zmPI9QRGhjX2"&gt;3.5&lt;/span&gt;
million in cash and &lt;span id="xdx_901_ecustom--Issuanceofcommonstockforlicenseacquiredshares_pip0_c20211101__20211130__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_zW4EhQQTZYA3"&gt;2,570,266&lt;/span&gt; restricted shares of the Company&#x2019;s common stock. Pursuant to the iXBEL Stock Purchase Agreement, the
Company agreed to reimburse iXBEL for the difference in value (the &#x201c;Shortfall Amount&#x201d;) in the event the aggregate value of
the &lt;span id="xdx_901_ecustom--Issuanceofcommonstockforlicenseacquiredshares_pip0_c20211101__20211130__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_znU54BEBumsl"&gt;2,570,266&lt;/span&gt; shares of the Company&#x2019;s common stock at the time of registration and issuance was less than $&lt;span id="xdx_90D_ecustom--MinimumStockValueOfSharesIssued_pn5n6_c20211101__20211130__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_zpmu58Wkjku9"&gt;5.5&lt;/span&gt; million. The initial
fair value of this Shortfall Amount was $&lt;span id="xdx_909_ecustom--InitialStockValuationShortfallFrom5.5MillionValue_pn5n6_c20211101__20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_z326PtoKuTtb"&gt;0.8&lt;/span&gt; million and in January 2022, the Company settled the Shortfall Amount by the payment of $&lt;span id="xdx_906_ecustom--NonrefundableCashPayment_pn5n6_c20220101__20220131__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_zwDR1YtqtHq3"&gt;1.2&lt;/span&gt;
million in cash to iXBEL. The change in fair value of the Shortfall Amount is included in Change in fair value of derivative liability
on the Condensed Consolidated Statement of Operations and Comprehensive Loss (see Note 4).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-12-31_custom_May242021Member"
      decimals="INF"
      unitRef="Shares">22258066</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2021-05-24_custom_May242021Member"
      decimals="2"
      unitRef="USDPShares">3.10</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31_custom_May242021Member"
      decimals="-5"
      unitRef="USD">64500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <SEEL:OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes
      contextRef="From2021-01-012021-12-31_custom_May242021Member"
      decimals="-5"
      unitRef="USD">7300000</SEEL:OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-12-31_custom_January282021Member"
      decimals="INF"
      unitRef="Shares">17530488</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2021-01-28_custom_January282021Member"
      decimals="2"
      unitRef="USDPShares">2.05</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31_custom_January282021Member"
      decimals="-5"
      unitRef="USD">33500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <SEEL:OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes
      contextRef="From2021-01-012021-12-31_custom_January282021Member"
      decimals="-5"
      unitRef="USD">3800000</SEEL:OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-11-012021-11-30_custom_IXLicenseAgreementMember"
      decimals="-5"
      unitRef="USD">9000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <SEEL:NonrefundableCashPayment
      contextRef="From2021-11-012021-11-30_custom_IXLicenseAgreementMember"
      decimals="-5"
      unitRef="USD">3500000</SEEL:NonrefundableCashPayment>
    <SEEL:Issuanceofcommonstockforlicenseacquiredshares
      contextRef="From2021-11-012021-11-30_custom_IXLicenseAgreementMember"
      decimals="INF"
      unitRef="Shares">2570266</SEEL:Issuanceofcommonstockforlicenseacquiredshares>
    <SEEL:Issuanceofcommonstockforlicenseacquiredshares
      contextRef="From2021-11-012021-11-30_custom_IXLicenseAgreementMember"
      decimals="INF"
      unitRef="Shares">2570266</SEEL:Issuanceofcommonstockforlicenseacquiredshares>
    <SEEL:MinimumStockValueOfSharesIssued
      contextRef="From2021-11-012021-11-30_custom_IXLicenseAgreementMember"
      decimals="-5"
      unitRef="USD">5500000</SEEL:MinimumStockValueOfSharesIssued>
    <SEEL:InitialStockValuationShortfallFrom5.5MillionValue
      contextRef="From2021-11-012021-12-31_custom_IXLicenseAgreementMember"
      decimals="-5"
      unitRef="USD">800000</SEEL:InitialStockValuationShortfallFrom5.5MillionValue>
    <SEEL:NonrefundableCashPayment
      contextRef="From2022-01-012022-01-31_custom_IXLicenseAgreementMember"
      decimals="-5"
      unitRef="USD">1200000</SEEL:NonrefundableCashPayment>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_80D_eus-gaap--ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_zdB1HoTH1FWd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;7. License Agreements&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Specific information pertaining to each of the Company&#x2019;s
significant license agreements is discussed in its audited financial statements included in the Annual Report for the years ended December
31, 2021 and 2020, including their nature and purpose, the significant rights and obligations of the parties, and specific accounting
policy elections. The following represents updates for the three months ended March 31, 2022, if applicable, to the Company&#x2019;s significant
license agreements:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Acquisition of Assets from Phoenixus AG f/k/a Vyera Pharmaceuticals,
AG and Turing Pharmaceuticals AG (&#x201c;Vyera&#x201d;)&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;See Note 13 for a subsequent event related to the Vyera Purchase
Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Acquisition of License from Stuart
Weg, MD&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_907_eus-gaap--BusinessCombinationSeparatelyRecognizedTransactionsDescription_c20190801__20190831__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--WegLicenseAgreementMember_zlZ8kLOosFO2"&gt;On
August 29, 2019, the Company entered into an amended and restated exclusive license agreement with Stuart Weg, M.D. (the &#x201c;Weg License
Agreement&#x201d;), pursuant to which the Company was granted an exclusive worldwide license to certain intellectual property and regulatory
materials related to SLS-002. Under the terms of the Weg License Agreement, the Company paid an upfront license fee of $75,000 upon execution
of the agreement. The Company agreed to pay additional consideration to Dr. Weg as follows: (i) $0.1 million on January 2, 2020, (ii)
$0.125 million on January 2, 2021, and (iii) in the event the FDA has not approved an NDA for a product containing ketamine in any dosage
on or before December 31, 2021, $&lt;/span&gt;&lt;span id="xdx_905_ecustom--NonrefundableCashPayment_pn5n6_c20220101__20220131__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--WegLicenseAgreementMember_zGva1W1wyXU"&gt;0.2
&lt;/span&gt;million
on January 2, 2022. The Company paid the required $&lt;span id="xdx_90E_ecustom--NonrefundableCashPayment_pn5n6_c20200101__20200131__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--WegLicenseAgreementMember_zL51DBdLIJ7i"&gt;0.1
&lt;/span&gt;million
on January 2, 2020,  $&lt;span id="xdx_90A_ecustom--NonrefundableCashPayment_pp3n6_c20210101__20210131__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--WegLicenseAgreementMember_zMzcpsO2NU67"&gt;0.125
&lt;/span&gt;million
on January 2, 2021 and $&lt;span id="xdx_901_ecustom--NonrefundableCashPayment_pn5n6_c20220101__20220131__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--WegLicenseAgreementMember_zh1yTMG0Ikdc"&gt;0.2
&lt;/span&gt;million
on January 2, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;The remaining potential regulatory and commercial milestones
are not yet considered probable, and &lt;span id="xdx_900_eus-gaap--AssetAcquisitionContingentConsiderationLiabilityCurrent_iI_pip0_do_c20220331__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--WegLicenseAgreementMember_z7ouc9W71hJb"&gt;no&lt;/span&gt; other milestone payments have been accrued at March 31, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify"/&gt;

</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsDescription contextRef="From2019-08-012019-08-31_custom_WegLicenseAgreementMember">On
August 29, 2019, the Company entered into an amended and restated exclusive license agreement with Stuart Weg, M.D. (the &#x201c;Weg License
Agreement&#x201d;), pursuant to which the Company was granted an exclusive worldwide license to certain intellectual property and regulatory
materials related to SLS-002. Under the terms of the Weg License Agreement, the Company paid an upfront license fee of $75,000 upon execution
of the agreement. The Company agreed to pay additional consideration to Dr. Weg as follows: (i) $0.1 million on January 2, 2020, (ii)
$0.125 million on January 2, 2021, and (iii) in the event the FDA has not approved an NDA for a product containing ketamine in any dosage
on or before December 31, 2021, $</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsDescription>
    <SEEL:NonrefundableCashPayment
      contextRef="From2022-01-012022-01-31_custom_WegLicenseAgreementMember"
      decimals="-5"
      unitRef="USD">200000</SEEL:NonrefundableCashPayment>
    <SEEL:NonrefundableCashPayment
      contextRef="From2020-01-012020-01-31_custom_WegLicenseAgreementMember"
      decimals="-5"
      unitRef="USD">100000</SEEL:NonrefundableCashPayment>
    <SEEL:NonrefundableCashPayment
      contextRef="From2021-01-012021-01-31_custom_WegLicenseAgreementMember"
      decimals="3"
      unitRef="USD">125000</SEEL:NonrefundableCashPayment>
    <SEEL:NonrefundableCashPayment
      contextRef="From2022-01-012022-01-31_custom_WegLicenseAgreementMember"
      decimals="-5"
      unitRef="USD">200000</SEEL:NonrefundableCashPayment>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent
      contextRef="AsOf2022-03-31_custom_WegLicenseAgreementMember"
      decimals="0"
      unitRef="USD">0</us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_80E_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zIsKhPRNio92" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;b&gt;8. Accrued Expenses&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zLbnzvITG1p5" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;Accrued expenses are comprised of the following (in
thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin-right: 0; margin-left: 0"&gt;&lt;span&gt;&lt;span id="xdx_8BD_z6KWwFfJHuHk"&gt;Schedule of Accrued Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;




&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49A_20220331_zwICjhlV6239" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_490_20211231_zmD5DtFUaTSf" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 64%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; width: 15%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; width: 15%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCzZt1_ziFqceZp8kCd" style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCzZt1_zct9paxXbfkh" style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Personnel related&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--OutsideResearchAndDevelopmentServicesCurrent_iI_pn3n3_zFJGLg2nsUn5" style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Outside research and development services&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,387&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AccruedInsuranceCurrent_iI_pn3n3_zfpu6qZ5A2Kg" style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Insurance&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;580&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;span style="-sec-ix-hidden: xdx2ixbrl0581"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzZt1_zVwREZNxc5Fc" style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Other&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzZt1_ztGJO0fQsEb3" style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&#160;&#160;&#160; Accrued expenses, net&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3,549&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zJtCCx3fxOm9" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_89B_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zLbnzvITG1p5" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;Accrued expenses are comprised of the following (in
thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin-right: 0; margin-left: 0"&gt;&lt;span&gt;&lt;span id="xdx_8BD_z6KWwFfJHuHk"&gt;Schedule of Accrued Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;




&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49A_20220331_zwICjhlV6239" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_490_20211231_zmD5DtFUaTSf" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 64%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; width: 15%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; width: 15%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCzZt1_ziFqceZp8kCd" style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCzZt1_zct9paxXbfkh" style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Personnel related&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--OutsideResearchAndDevelopmentServicesCurrent_iI_pn3n3_zFJGLg2nsUn5" style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Outside research and development services&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,387&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AccruedInsuranceCurrent_iI_pn3n3_zfpu6qZ5A2Kg" style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Insurance&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;580&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;span style="-sec-ix-hidden: xdx2ixbrl0581"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzZt1_zVwREZNxc5Fc" style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Other&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzZt1_ztGJO0fQsEb3" style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&#160;&#160;&#160; Accrued expenses, net&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3,549&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">190000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">181000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">332000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">1303000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <SEEL:OutsideResearchAndDevelopmentServicesCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">2387000</SEEL:OutsideResearchAndDevelopmentServicesCurrent>
    <SEEL:OutsideResearchAndDevelopmentServicesCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">2219000</SEEL:OutsideResearchAndDevelopmentServicesCurrent>
    <us-gaap:AccruedInsuranceCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">580000</us-gaap:AccruedInsuranceCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">60000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">25000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">3549000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">3728000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_808_eus-gaap--DebtDisclosureTextBlock_zLtfGH8Xgij3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;9. Debt&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"/&gt;&lt;p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Convertible Notes&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;November 2021 and December 2021 Convertible Notes and Private Placement&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_904_eus-gaap--LongTermDebtDescription_c20211101__20211130__us-gaap--DebtInstrumentAxis__custom--November2021LindSecuritiesPurchaseAgreementMember_zfcTsRffSNl3"&gt;On November 23, 2021, the Company entered into a Securities Purchase Agreement
(the &#x201c;2021 Lind Securities Purchase Agreement&#x201d;) with Lind Global Asset Management V, LLC (&#x201c;Lind V&#x201d;) pursuant
to which, among other things, on November 23, 2021 (the &#x201c;Closing Date&#x201d;), the Company issued and sold to Lind V, in a private
placement transaction (the &#x201c;Private Placement&#x201d;), in exchange for the payment by Lind V of $20.0 million, (i) a convertible
promissory note (the &#x201c;2021 Note&#x201d;) in an aggregate principal amount of $22.0 million (the &#x201c;Principal Amount&#x201d;),
which will bear no interest until the first anniversary of the issuance of the 2021 Note and will thereafter bear interest at a rate
of 5% per annum, and mature on November 23, 2024 (the &#x201c;Maturity Date&#x201d;), and (ii) 534,759 shares of Company common stock.&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_904_eus-gaap--LongTermDebtDescription_c20221101__20221130__us-gaap--DebtInstrumentAxis__custom--FirstAnniversaryOfNovember2021LindSecuritiesPurchaseAgreementMember_zEV0cSbbk5d6"&gt;At the first anniversary of the Closing Date, the Company shall
have the option, at its sole discretion, to issue to Lind V a convertible promissory note (the &#x201c;Second Note&#x201d;) in the principal
amount of $11.0 million in exchange for the payment by Lind V of $10.0 million. At the earlier of (i) the two-year anniversary of the
Closing Date, or (ii) the successful readout for SLS-005 in ALS, and subject to the mutual agreement of the Company and Lind V, the Company
shall issue to Lind V a convertible promissory note (the &#x201c;Third Note&#x201d;) in the principal amount of $11.0 million in exchange
for the payment by Lind V of $10.0 million. In the event of the filing of a new drug application with the U.S. Food &amp;amp; Drug Administration
for either SLS-002 or SLS-005, and subject to the mutual agreement of the Company and Lind V, the Company shall issue to Lind V a convertible
promissory note (the &#x201c;Fourth Note&#x201d;) in the principal amount of $11.0 million in exchange for the payment by Lind V of $10.0
million. The Second Note, the Third Note and the Fourth Note, if issued, would be in substantially the same form as the 2021 Note.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_90C_eus-gaap--LongTermDebtDescription_c20220823__20241123__us-gaap--DebtInstrumentAxis__custom--August232022ThruMaturityNovember2021LindSecuritiesPurchaseAgreementMember_zE0qTVToKwsc"&gt;At any time following August 23, 2022, from time to time and before the
Maturity Date, Lind V shall have the option to convert any portion of the then-outstanding Principal Amount of the 2021 Note into shares
of Common Stock at a price per share of $6.00, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar
transactions (the &#x201c;Conversion Price&#x201d;). At any time prior August 23, 2022, the Company shall have the right to prepay, in whole
or in part (exercisable by the Company at any time or from time to time during such period), up to an aggregate of $14.7 million of the
outstanding Principal Amount of the 2021 Note with no penalty. If the Company does not prepay any amounts of the 2021 Note prior to August
23, 2022 then, commencing August 23, 2022, the Company shall have the right to prepay, in whole or in part (exercisable by the Company
at any time or from time to time prior to the Maturity Date), up to the full remaining Principal Amount of the 2021 Note with no penalty;
however, if the Company exercises such prepayment right, Lind V will have the option to convert up to thirty-three and one-third percent
(33 1/3%) of the amount that the Company elects to prepay at the Conversion Price. If the Company prepays any amounts of the 2021 Note
prior to August 23, 2022 then, commencing November 23, 2022, the Company shall not have the right to prepay any amounts of the 2021 Note
between August 23, 2022 to November 23, 2022 and, commencing November 23, 2022, the Company shall have the right to prepay, in whole or
in part (exercisable by the Company at any time or from time to time prior to the Maturity Date) up to the full remaining Principal Amount
of the 2021 Note with no penalty; however, if the Company exercises such prepayment right, Lind V will have the option to convert up to
thirty-three and one-third percent (33 1/3%) of the amount that the Company elects to prepay at the Conversion Price.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Subject to certain exceptions, the Company will be required to direct proceeds
from any subsequent debt financings (including subordinated debt, convertible debt or mandatorily redeemable preferred stock but other
than purchase money debt or capital lease obligations or other indebtedness incurred in the ordinary course of business) to repay the
2021 Notes, unless waived by Lind V in advance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_90A_eus-gaap--LongTermDebtDescription_c20221123__20241124__us-gaap--DebtInstrumentAxis__custom--AmortizeNovember2021LindSecuritiesPurchaseAgreementMember_zJDYkPnrmip5"&gt;Beginning on November 23, 2022, the 2021 Note will amortize in twenty-four
monthly installments equal to the quotient of (i) the then-outstanding Principal Amount of the 2021 Note, divided by (ii) the number of
months remaining until the Maturity Date. All amortization payments shall be payable, at the Company&#x2019;s sole option, in cash, shares
of Common Stock or a combination of both. In addition, commencing on the last business day of the first month following November 23, 2022,
the Company will pay, on a monthly basis, all interest that has accrued and remains unpaid on the then-outstanding Principal Amount of
the 2021 Note. Any portion of an amortization payment or interest payment that is paid in shares of Common Stock shall be priced at 90%
of the average of the five lowest daily volume weighted average prices of the Common Stock during the 20 trading days prior to the date
of issuance of the shares. If, after the first amortization payment, the Company elects to make any amortization payments in cash, the
Company shall pay a 5% premium on each cash payment. In conjunction with the 2021 Lind Securities Purchase Agreement and the 2021 Note,
on the Closing Date, the Company and Lind V entered into a security agreement, which provides Lind V with a first priority lien on the
Company&#x2019;s assets and properties.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_90F_eus-gaap--LongTermDebtDescription_c20211201__20211231__us-gaap--DebtInstrumentAxis__custom--December2021SPAsMember_zJXT89faIVld"&gt;On December 2, 2021, the Company entered into two separate securities purchase
agreements with certain accredited investors on substantially the same terms as the 2021 Lind Securities Purchase Agreement, pursuant
to which the Company sold, in private placement transactions, in exchange for the payment by the accredited investors of an aggregate
of $201,534, (i) convertible promissory notes in an aggregate principal amount of $221,688, which will bear no interest and mature on
December 2, 2024, and (ii) an aggregate of 5,388 shares of its common stock. These notes have substantially the same terms as the 2021
Note.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;During the year ended December 31, 2021, the Company received
aggregate gross proceeds of $&lt;span id="xdx_903_eus-gaap--ProceedsFromConvertibleDebt_pn5n6_c20211201__20211231__us-gaap--DebtInstrumentAxis__custom--December2021SPAsMember_zwqXfHkzQ9i7"&gt;20.2&lt;/span&gt;
million from the convertible note offerings. The Company elected to account for these notes under the fair value option. At time of
issuance, the Company recorded a liability of $&lt;span id="xdx_90F_eus-gaap--ConvertibleSubordinatedDebt_iI_pn5n6_c20211202__us-gaap--DebtInstrumentAxis__custom--December2021SPAsMember_z9w6y8VcH4hc"&gt;19.2&lt;/span&gt;
million, which was determined to be the fair value at time of issuance. As of December 31, 2021, the Company recognized a $&lt;span id="xdx_90A_ecustom--GainLossInFairValueOfConvertibleNotes_pn5n6_c20211201__20211231__us-gaap--DebtInstrumentAxis__custom--December2021SPAsMember_zRSD8v8CC3y9"&gt;0.2&lt;/span&gt;
million gain on change in fair value of convertible notes, recognizing a total convertible note liability of $&lt;span id="xdx_907_eus-gaap--ConvertibleSubordinatedDebt_iI_pn5n6_c20211231__us-gaap--DebtInstrumentAxis__custom--December2021SPAsMember_zVMjFwqdvbzl"&gt;18.9&lt;/span&gt;
million. During the three months ended March 31, 2022, the Company recognized a
$&lt;span id="xdx_90C_ecustom--GainLossInFairValueOfConvertibleNotes_pn5n6_c20220101__20220331__us-gaap--DebtInstrumentAxis__custom--December2021SPAsMember_zq7yOD8Ou9V3"&gt;0.2&lt;/span&gt; million loss on change in fair value of convertible notes, recognizing a total convertible note liability of $&lt;span id="xdx_90B_eus-gaap--LongTermDebtFairValue_iI_pn5n6_c20220331__us-gaap--DebtInstrumentAxis__custom--December2021SPAsMember_zxYdvSHkg5w4"&gt;19.2&lt;/span&gt; million.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;As of March 31, 2022, the principal contractual balance
of the convertible notes totaled $&lt;span id="xdx_907_eus-gaap--ConvertibleNotesPayable_iI_pn5n6_c20220331__us-gaap--DebtInstrumentAxis__custom--December2021SPAsMember_zUMGnrQcH5Hh"&gt;22.2&lt;/span&gt; million.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;December 2020 Convertible Note and Private Placement&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 20pt; text-indent: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;span id="xdx_901_eus-gaap--LongTermDebtDescription_c20201201__20201231__us-gaap--DebtInstrumentAxis__custom--LindSecuritiesPurchaseAgreementMember_zM4f5isFyqNg"&gt;On
December 11, 2020, the Company entered into a Securities Purchase Agreement (the &#x201c;2020 Lind Securities Purchase
Agreement&#x201d;) with Lind Global Asset Management II, LLC (the &#x201c;Investor&#x201d;) pursuant to which, among other things, on
December 11, 2020, the Company issued and sold to the Investor, in a private placement transaction, in exchange for the payment by
the Investor of $10,000,000, (1) a convertible promissory note (the &#x201c;2020 Note&#x201d;) in an aggregate principal amount of
$12,000,000 (the &#x201c;Principal Amount&#x201d;), which did not bear interest and was to mature on December 11, 2022 (the
&#x201c;Maturity Date&#x201d;), and (2) 975,000 shares of the Company&#x2019;s common stock. At any time following June 11, 2021, and
from time to time before the Maturity Date, the Investor had the option to convert any portion of the then-outstanding Principal
Amount of the Note into shares of common stock at a price per share of $1.60, subject to adjustment for stock splits, reverse stock
splits, stock dividends and similar transactions. Prior to June 11, 2021, the Company had the right to prepay up to sixty-six and
two-thirds percent (66 2/3%) of the then-outstanding Principal Amount of the 2020 Note with no penalty. Subject to certain
exceptions, the Company was required to direct proceeds from any subsequent debt financings (including subordinated debt,
convertible debt or mandatorily redeemable preferred stock but other than purchase money debt or capital lease obligations or other
indebtedness incurred in the ordinary course of business) to repay the 2020 Note, unless waived by the Investor in advance. The 2020
Note began amortizing in June 2021 and was to amortize in eighteen monthly installments equal to the quotient of (i) the
then-outstanding Principal Amount of the 2020 Note, divided by (ii) the number of months remaining until the Maturity Date. All
amortization payments were to be payable solely in cash, plus a 2% premium. During the first half of 2021, the Company made certain
repayments on the outstanding principal balance of the convertible notes. On June 14, 2021, the Company and the Investor entered
into an Acknowledgment and Termination Agreement, pursuant to which the Company agreed to issue to the Investor an aggregate of
406,250 additional shares of its common stock (the &#x201c;Lind Shares&#x201d;) and to pay the Investor the remaining principal amount
of $790,804 (the &#x201c;Final Payment&#x201d;) in full satisfaction of the Company&#x2019;s  remaining obligations to the Investor
under the 2020 Note. The Company issued the Lind Shares and made the Final Payment to the Investor, and the 2020 Lind Securities
Purchase Agreement and the 2020 Note terminated, effective June 15, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_902_eus-gaap--LongTermDebtDescription_c20201201__20201231__us-gaap--DebtInstrumentAxis__custom--December17SPAsMember_zNaztLWBB4i4"&gt;On December 17, 2020, the Company entered into three separate securities
purchase agreements with certain accredited investors on substantially the same terms as the Lind Securities Purchase Agreement (the &#x201c;December
17 SPAs&#x201d;), pursuant to which the Company sold, in private placement transactions, in exchange for the payment by the accredited
investors of an aggregate of $1,138,023, (1) convertible promissory notes (the &#x201c;December 17 Notes&#x201d;) in an aggregate principal
amount of $1,365,628, which did not bear interest and were to mature on December 17, 2022, and (2) an aggregate of 110,956 shares of its
common stock. On December 18, 2020, the Company entered into an additional securities purchase agreement with
an accredited investor on substantially the same terms as the Lind Securities Purchase Agreement (the &#x201c;December 18 SPA&#x201d; and,
together with the December 17 SPAs, the "Subsequent Securities Purchase Agreements"), pursuant to which the Company sold, in
a private placement transaction, in exchange for the payment by the accredited investor of $269,373, (1) a convertible promissory note
in an aggregate principal amount of $323,247, which did not bear interest and was to mature on December 18, 2022 (the &#x201c;December
18 Note&#x201d; and, together with the December 17 Notes, the &#x201c;Subsequent Notes&#x201d;), and (2) 26,263 shares of the Company&#x2019;s
common stock. The Subsequent Securities Purchase Agreements had substantially the same terms as the Lind Securities Purchase Agreement,
and the Subsequent Notes had substantially the same terms as the Note. During the first half of 2021, the Company made certain repayments
on the outstanding principal balance of the convertible notes. On July 7, 2021, the Company and the holder of the December 18 Note (the
&#x201c;December 18 Note Holder&#x201d;) entered into an Acknowledgement and Termination Agreement, pursuant to which: (i) the December
18 Note Holder agreed to return to the Company $42,777 in cash (the &#x201c;Repayment&#x201d;) previously paid by the Company to the December
18 Note Holder as a payment against the Company&#x2019;s obligations under the December 18 Note, and (ii) the Company agreed to issue to
the December 18 Note Holder an aggregate of 43,664 additional shares of its common stock (the &#x201c;December 18 Note Shares&#x201d;) in
full satisfaction of the Company&#x2019;s remaining obligations to the December 18 Note Holder under the December 18 Note. The December 18 Note Holder
paid the Company the Repayment and the Company issued the December Note Shares, and the December 18 SPA and the December 18 Note terminated,
effective July 7, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company received aggregate net proceeds of $10.9 million from
the convertible note offering, net of $0.5 million of issuance costs. The total gross proceeds were allocated to the convertible notes
and common stock issued under the agreements based on their relative fair values. Due to the principal payments made during the year,
the Company remeasured the beneficial conversion feature discount at each payment date and recorded a loss on extinguishment of debt
of approximately $1.0 million during the year ended December 31, 2021 as well as a reduction in additional paid-in capital of $1.5 million
as of December 31, 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"&gt;During the year ended December 31, 2021,
the Company paid approximately $&lt;span id="xdx_905_eus-gaap--RepaymentsOfConvertibleDebt_pn5n6_c20211201__20211231__us-gaap--DebtInstrumentAxis__custom--December17SPAsMember_zBKJoERIgJc5"&gt;13.6&lt;/span&gt; million in principal payments on the outstanding convertible notes and issued an aggregate of &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pip0_c20211201__20211231__us-gaap--DebtInstrumentAxis__custom--December17SPAsMember_z4zmjDAAiCB7"&gt;475,315&lt;/span&gt;
shares of its common stock upon conversion of the convertible notes, and &lt;span id="xdx_90F_eus-gaap--LongTermDebt_iI_dn_c20211231__us-gaap--DebtInstrumentAxis__custom--December17SPAsMember_z5ixQC4kG0Q3"&gt;none&lt;/span&gt; of the 2020 convertible notes remain outstanding as of December
31, 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 0; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 0; background-color: white"&gt;&#160;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LongTermDebtDescription contextRef="From2021-11-012021-11-30_custom_November2021LindSecuritiesPurchaseAgreementMember">On November 23, 2021, the Company entered into a Securities Purchase Agreement
(the &#x201c;2021 Lind Securities Purchase Agreement&#x201d;) with Lind Global Asset Management V, LLC (&#x201c;Lind V&#x201d;) pursuant
to which, among other things, on November 23, 2021 (the &#x201c;Closing Date&#x201d;), the Company issued and sold to Lind V, in a private
placement transaction (the &#x201c;Private Placement&#x201d;), in exchange for the payment by Lind V of $20.0 million, (i) a convertible
promissory note (the &#x201c;2021 Note&#x201d;) in an aggregate principal amount of $22.0 million (the &#x201c;Principal Amount&#x201d;),
which will bear no interest until the first anniversary of the issuance of the 2021 Note and will thereafter bear interest at a rate
of 5% per annum, and mature on November 23, 2024 (the &#x201c;Maturity Date&#x201d;), and (ii) 534,759 shares of Company common stock.</us-gaap:LongTermDebtDescription>
    <us-gaap:LongTermDebtDescription contextRef="From2022-11-012022-11-30_custom_FirstAnniversaryOfNovember2021LindSecuritiesPurchaseAgreementMember">At the first anniversary of the Closing Date, the Company shall
have the option, at its sole discretion, to issue to Lind V a convertible promissory note (the &#x201c;Second Note&#x201d;) in the principal
amount of $11.0 million in exchange for the payment by Lind V of $10.0 million. At the earlier of (i) the two-year anniversary of the
Closing Date, or (ii) the successful readout for SLS-005 in ALS, and subject to the mutual agreement of the Company and Lind V, the Company
shall issue to Lind V a convertible promissory note (the &#x201c;Third Note&#x201d;) in the principal amount of $11.0 million in exchange
for the payment by Lind V of $10.0 million. In the event of the filing of a new drug application with the U.S. Food &amp; Drug Administration
for either SLS-002 or SLS-005, and subject to the mutual agreement of the Company and Lind V, the Company shall issue to Lind V a convertible
promissory note (the &#x201c;Fourth Note&#x201d;) in the principal amount of $11.0 million in exchange for the payment by Lind V of $10.0
million. The Second Note, the Third Note and the Fourth Note, if issued, would be in substantially the same form as the 2021 Note.</us-gaap:LongTermDebtDescription>
    <us-gaap:LongTermDebtDescription contextRef="From2022-08-232024-11-23_custom_August232022ThruMaturityNovember2021LindSecuritiesPurchaseAgreementMember">At any time following August 23, 2022, from time to time and before the
Maturity Date, Lind V shall have the option to convert any portion of the then-outstanding Principal Amount of the 2021 Note into shares
of Common Stock at a price per share of $6.00, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar
transactions (the &#x201c;Conversion Price&#x201d;). At any time prior August 23, 2022, the Company shall have the right to prepay, in whole
or in part (exercisable by the Company at any time or from time to time during such period), up to an aggregate of $14.7 million of the
outstanding Principal Amount of the 2021 Note with no penalty. If the Company does not prepay any amounts of the 2021 Note prior to August
23, 2022 then, commencing August 23, 2022, the Company shall have the right to prepay, in whole or in part (exercisable by the Company
at any time or from time to time prior to the Maturity Date), up to the full remaining Principal Amount of the 2021 Note with no penalty;
however, if the Company exercises such prepayment right, Lind V will have the option to convert up to thirty-three and one-third percent
(33 1/3%) of the amount that the Company elects to prepay at the Conversion Price. If the Company prepays any amounts of the 2021 Note
prior to August 23, 2022 then, commencing November 23, 2022, the Company shall not have the right to prepay any amounts of the 2021 Note
between August 23, 2022 to November 23, 2022 and, commencing November 23, 2022, the Company shall have the right to prepay, in whole or
in part (exercisable by the Company at any time or from time to time prior to the Maturity Date) up to the full remaining Principal Amount
of the 2021 Note with no penalty; however, if the Company exercises such prepayment right, Lind V will have the option to convert up to
thirty-three and one-third percent (33 1/3%) of the amount that the Company elects to prepay at the Conversion Price.</us-gaap:LongTermDebtDescription>
    <us-gaap:LongTermDebtDescription contextRef="From2022-11-232024-11-24_custom_AmortizeNovember2021LindSecuritiesPurchaseAgreementMember">Beginning on November 23, 2022, the 2021 Note will amortize in twenty-four
monthly installments equal to the quotient of (i) the then-outstanding Principal Amount of the 2021 Note, divided by (ii) the number of
months remaining until the Maturity Date. All amortization payments shall be payable, at the Company&#x2019;s sole option, in cash, shares
of Common Stock or a combination of both. In addition, commencing on the last business day of the first month following November 23, 2022,
the Company will pay, on a monthly basis, all interest that has accrued and remains unpaid on the then-outstanding Principal Amount of
the 2021 Note. Any portion of an amortization payment or interest payment that is paid in shares of Common Stock shall be priced at 90%
of the average of the five lowest daily volume weighted average prices of the Common Stock during the 20 trading days prior to the date
of issuance of the shares. If, after the first amortization payment, the Company elects to make any amortization payments in cash, the
Company shall pay a 5% premium on each cash payment. In conjunction with the 2021 Lind Securities Purchase Agreement and the 2021 Note,
on the Closing Date, the Company and Lind V entered into a security agreement, which provides Lind V with a first priority lien on the
Company&#x2019;s assets and properties.</us-gaap:LongTermDebtDescription>
    <us-gaap:LongTermDebtDescription contextRef="From2021-12-012021-12-31_custom_December2021SPAsMember">On December 2, 2021, the Company entered into two separate securities purchase
agreements with certain accredited investors on substantially the same terms as the 2021 Lind Securities Purchase Agreement, pursuant
to which the Company sold, in private placement transactions, in exchange for the payment by the accredited investors of an aggregate
of $201,534, (i) convertible promissory notes in an aggregate principal amount of $221,688, which will bear no interest and mature on
December 2, 2024, and (ii) an aggregate of 5,388 shares of its common stock. These notes have substantially the same terms as the 2021
Note.</us-gaap:LongTermDebtDescription>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2021-12-012021-12-31_custom_December2021SPAsMember"
      decimals="-5"
      unitRef="USD">20200000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ConvertibleSubordinatedDebt
      contextRef="AsOf2021-12-02_custom_December2021SPAsMember"
      decimals="-5"
      unitRef="USD">19200000</us-gaap:ConvertibleSubordinatedDebt>
    <SEEL:GainLossInFairValueOfConvertibleNotes
      contextRef="From2021-12-012021-12-31_custom_December2021SPAsMember"
      decimals="-5"
      unitRef="USD">200000</SEEL:GainLossInFairValueOfConvertibleNotes>
    <us-gaap:ConvertibleSubordinatedDebt
      contextRef="AsOf2021-12-31_custom_December2021SPAsMember"
      decimals="-5"
      unitRef="USD">18900000</us-gaap:ConvertibleSubordinatedDebt>
    <SEEL:GainLossInFairValueOfConvertibleNotes
      contextRef="From2022-01-012022-03-31_custom_December2021SPAsMember"
      decimals="-5"
      unitRef="USD">200000</SEEL:GainLossInFairValueOfConvertibleNotes>
    <us-gaap:LongTermDebtFairValue
      contextRef="AsOf2022-03-31_custom_December2021SPAsMember"
      decimals="-5"
      unitRef="USD">19200000</us-gaap:LongTermDebtFairValue>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2022-03-31_custom_December2021SPAsMember"
      decimals="-5"
      unitRef="USD">22200000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:LongTermDebtDescription contextRef="From2020-12-012020-12-31_custom_LindSecuritiesPurchaseAgreementMember">On
December 11, 2020, the Company entered into a Securities Purchase Agreement (the &#x201c;2020 Lind Securities Purchase
Agreement&#x201d;) with Lind Global Asset Management II, LLC (the &#x201c;Investor&#x201d;) pursuant to which, among other things, on
December 11, 2020, the Company issued and sold to the Investor, in a private placement transaction, in exchange for the payment by
the Investor of $10,000,000, (1) a convertible promissory note (the &#x201c;2020 Note&#x201d;) in an aggregate principal amount of
$12,000,000 (the &#x201c;Principal Amount&#x201d;), which did not bear interest and was to mature on December 11, 2022 (the
&#x201c;Maturity Date&#x201d;), and (2) 975,000 shares of the Company&#x2019;s common stock. At any time following June 11, 2021, and
from time to time before the Maturity Date, the Investor had the option to convert any portion of the then-outstanding Principal
Amount of the Note into shares of common stock at a price per share of $1.60, subject to adjustment for stock splits, reverse stock
splits, stock dividends and similar transactions. Prior to June 11, 2021, the Company had the right to prepay up to sixty-six and
two-thirds percent (66 2/3%) of the then-outstanding Principal Amount of the 2020 Note with no penalty. Subject to certain
exceptions, the Company was required to direct proceeds from any subsequent debt financings (including subordinated debt,
convertible debt or mandatorily redeemable preferred stock but other than purchase money debt or capital lease obligations or other
indebtedness incurred in the ordinary course of business) to repay the 2020 Note, unless waived by the Investor in advance. The 2020
Note began amortizing in June 2021 and was to amortize in eighteen monthly installments equal to the quotient of (i) the
then-outstanding Principal Amount of the 2020 Note, divided by (ii) the number of months remaining until the Maturity Date. All
amortization payments were to be payable solely in cash, plus a 2% premium. During the first half of 2021, the Company made certain
repayments on the outstanding principal balance of the convertible notes. On June 14, 2021, the Company and the Investor entered
into an Acknowledgment and Termination Agreement, pursuant to which the Company agreed to issue to the Investor an aggregate of
406,250 additional shares of its common stock (the &#x201c;Lind Shares&#x201d;) and to pay the Investor the remaining principal amount
of $790,804 (the &#x201c;Final Payment&#x201d;) in full satisfaction of the Company&#x2019;s  remaining obligations to the Investor
under the 2020 Note. The Company issued the Lind Shares and made the Final Payment to the Investor, and the 2020 Lind Securities
Purchase Agreement and the 2020 Note terminated, effective June 15, 2021.</us-gaap:LongTermDebtDescription>
    <us-gaap:LongTermDebtDescription contextRef="From2020-12-012020-12-31_custom_December17SPAsMember">On December 17, 2020, the Company entered into three separate securities
purchase agreements with certain accredited investors on substantially the same terms as the Lind Securities Purchase Agreement (the &#x201c;December
17 SPAs&#x201d;), pursuant to which the Company sold, in private placement transactions, in exchange for the payment by the accredited
investors of an aggregate of $1,138,023, (1) convertible promissory notes (the &#x201c;December 17 Notes&#x201d;) in an aggregate principal
amount of $1,365,628, which did not bear interest and were to mature on December 17, 2022, and (2) an aggregate of 110,956 shares of its
common stock. On December 18, 2020, the Company entered into an additional securities purchase agreement with
an accredited investor on substantially the same terms as the Lind Securities Purchase Agreement (the &#x201c;December 18 SPA&#x201d; and,
together with the December 17 SPAs, the "Subsequent Securities Purchase Agreements"), pursuant to which the Company sold, in
a private placement transaction, in exchange for the payment by the accredited investor of $269,373, (1) a convertible promissory note
in an aggregate principal amount of $323,247, which did not bear interest and was to mature on December 18, 2022 (the &#x201c;December
18 Note&#x201d; and, together with the December 17 Notes, the &#x201c;Subsequent Notes&#x201d;), and (2) 26,263 shares of the Company&#x2019;s
common stock. The Subsequent Securities Purchase Agreements had substantially the same terms as the Lind Securities Purchase Agreement,
and the Subsequent Notes had substantially the same terms as the Note. During the first half of 2021, the Company made certain repayments
on the outstanding principal balance of the convertible notes. On July 7, 2021, the Company and the holder of the December 18 Note (the
&#x201c;December 18 Note Holder&#x201d;) entered into an Acknowledgement and Termination Agreement, pursuant to which: (i) the December
18 Note Holder agreed to return to the Company $42,777 in cash (the &#x201c;Repayment&#x201d;) previously paid by the Company to the December
18 Note Holder as a payment against the Company&#x2019;s obligations under the December 18 Note, and (ii) the Company agreed to issue to
the December 18 Note Holder an aggregate of 43,664 additional shares of its common stock (the &#x201c;December 18 Note Shares&#x201d;) in
full satisfaction of the Company&#x2019;s remaining obligations to the December 18 Note Holder under the December 18 Note. The December 18 Note Holder
paid the Company the Repayment and the Company issued the December Note Shares, and the December 18 SPA and the December 18 Note terminated,
effective July 7, 2021.</us-gaap:LongTermDebtDescription>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="From2021-12-012021-12-31_custom_December17SPAsMember"
      decimals="-5"
      unitRef="USD">13600000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2021-12-012021-12-31_custom_December17SPAsMember"
      decimals="INF"
      unitRef="Shares">475315</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:LongTermDebt
      contextRef="AsOf2021-12-31_custom_December17SPAsMember"
      decimals="0"
      unitRef="USD">0</us-gaap:LongTermDebt>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_80C_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zxvBJE321Eaa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;10. Stockholders&#x2019; Equity&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Preferred Stock&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company is authorized to issue &lt;span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_pip0_c20220331_zofzEj2Uaoak" title="Preferred stock, authorized (in shares)"&gt;10,000,000&lt;/span&gt; shares of preferred
stock, par value $&lt;span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pip0_c20220331_zs7lLNcS5yD2" title="Preferred stock, per value (in usd per share)"&gt;0.001&lt;/span&gt;. &lt;span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20220331_zZaGp0Oct1Ej" title="Preferred stock, outstanding (in shares)"&gt;&lt;span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20211231_zfGV5eNrFRGl" title="Preferred stock, outstanding (in shares)"&gt;No&lt;/span&gt;&lt;/span&gt; shares of preferred stock were outstanding as of March 31, 2022 or December 31, 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Common Stock&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company has authorized &lt;span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_pp0p0_c20220331_zQX2U7gbKoAc" title="Common stock, authorized (in shares)"&gt;&lt;span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_pp0p0_c20211231_zcwqnL9otRod"&gt;240,000,000&lt;/span&gt;&lt;/span&gt; shares of common stock as of March 31, 2022 and December 31, 2021. &lt;span id="xdx_908_eus-gaap--CommonStockVotingRights_c20220101__20220331_zrNC2Xv2lvob" title="Common stock voting right"&gt;Each share of common stock is entitled to
one voting right&lt;/span&gt;. Common stock owners are entitled to dividends when funds are legally available and declared by the Board of
Directors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify; text-indent: -0.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify; text-indent: -0.5pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;September 2020 Warrants&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20200901__20200930__us-gaap--ClassOfWarrantOrRightAxis__custom--September2020WarrantsMember_zKPp0HrdPCD2" title="Warrant description"&gt; On September 4, 2020, the Company entered into a securities purchase agreement
with certain institutional investors pursuant to which the Company issued and sold an aggregate of 8,865,000 shares of common stock in
a registered direct offering and issued warrants to purchase up to 6,648,750 shares of common stock in a concurrent private placement
(the &#x201c;September 2020 Warrants&#x201d;). The September 2020 Warrants are initially exercisable for
&lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20200901__20200930__us-gaap--StatementClassOfStockAxis__custom--September2020WarrantsMember_zx2PxpEuEDol" title="Number of shares of common stock issued"&gt;6,648,750&lt;/span&gt; shares of common stock at an exercise price per share equal to $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20200904__us-gaap--ClassOfWarrantOrRightAxis__custom--September2020WarrantsMember_zVxOUsZ4SiWb"&gt;0.84&lt;/span&gt;. The September 2020 Warrants became exercisable beginning
on &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20210101__20210930__us-gaap--ClassOfWarrantOrRightAxis__custom--September2020WarrantsMember_z0AFn5jPTCFb" title="Date on which warrants became exercisable"&gt;March 9, 2021&lt;/span&gt; and will expire on March 9, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;During the three months ended March 31, 2022 and 2021, September 2020
Warrants were exercised for &lt;span id="xdx_900_ecustom--NumberofWarrantsExercisedDuringPeriod_pip0_uShares_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--September2020WarrantsMember_z89QZtTqhhT3"&gt;0&lt;/span&gt; and &lt;span id="xdx_900_ecustom--NumberofWarrantsExercisedDuringPeriod_pn5n6_uShares_c20210101__20210331__us-gaap--ClassOfWarrantOrRightAxis__custom--September2020WarrantsMember_z6S3SLFSX7ok" title="Number of warrants exercised"&gt;4.7&lt;/span&gt;
million shares of common stock, respectively, for approximately $&lt;span id="xdx_904_eus-gaap--ProceedsFromWarrantExercises_pp0p0_uUSD_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--September2020WarrantsMember_zX5GqS2Y2ra8"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--ProceedsFromWarrantExercises_pn5n6_uUSD_c20210101__20210331__us-gaap--ClassOfWarrantOrRightAxis__custom--September2020WarrantsMember_zLEyWQ58N3Dd" title="Proceeds from exercise of warrants"&gt;3.9&lt;/span&gt;
million, respectively. As of March 31, 2022, September 2020 Warrants exercisable for &lt;span id="xdx_901_ecustom--WarrantsExercisable_iI_pip0_c20220331__us-gaap--StatementClassOfStockAxis__custom--September2020WarrantsMember_z5BldYmwOLN4" title="Warrants exercisable as of March 31, 2022"&gt;1.0 million&lt;/span&gt;
shares of common stock remain outstanding at an exercise price of $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--September2020WarrantsMember_zjMomzuXBcq8"&gt;0.84 &lt;/span&gt;per
share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;August 2019 Warrants&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20190801__20190831__us-gaap--ClassOfWarrantOrRightAxis__custom--August2019WarrantsMember_z4gydDtfCY6a" title="Warrant description"&gt;On August 23, 2019, the Company entered into a securities
purchase agreement with certain institutional investors pursuant to which the Company issued and sold an aggregate of &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20190801__20190831__us-gaap--StatementClassOfStockAxis__custom--August232019Member_zhtMha9qEnSe" title="Number of shares of common stock issued"&gt;4,475,000&lt;/span&gt; shares
of common stock in a registered direct offering and issued warrants to purchase up to 2,237,500 shares of common stock in a concurrent
private placement (the &#x201c;August 2019 Warrants&#x201d;). The August 2019 Warrants were initially exercisable for 2,237,500 shares of
common stock at an exercise price per share equal to $1.78. The August 2019 Warrants became exercisable beginning on &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--August2019WarrantsMember_zEZJfToIzTLf" title="Date on which warrants became exercisable"&gt;February 27, 2020&lt;/span&gt;
and will expire on August 28, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;During the three months ended March 31, 2022 and 2021, August 2019
Warrants for &lt;span id="xdx_903_ecustom--NumberofWarrantsExercisedDuringPeriod_pip0_uShares_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--August2019WarrantsMember_zxOn2jkWOai5"&gt;0&lt;/span&gt; and &lt;span id="xdx_901_ecustom--NumberofWarrantsExercisedDuringPeriod_pin6_uShares_c20210101__20210331__us-gaap--ClassOfWarrantOrRightAxis__custom--August2019WarrantsMember_z7sq2VrYAiU4" title="Number of warrants exercised"&gt;1.0&lt;/span&gt;
million shares of common stock were exercised for approximately $&lt;span id="xdx_90E_eus-gaap--ProceedsFromWarrantExercises_pip0_uUSD_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--August2019WarrantsMember_zKPDOYffFBM6"&gt;0&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--ProceedsFromWarrantExercises_pin6_uUSD_c20210101__20210331__us-gaap--ClassOfWarrantOrRightAxis__custom--August2019WarrantsMember_zt8cfvIKzRyc" title="Proceeds from exercise of warrants"&gt;1.8&lt;/span&gt;
million, respectively. As of March 31, 2022, August 2019 Warrants exercisable for &lt;span id="xdx_906_ecustom--WarrantsExercisable_iI_pip0_c20220331__us-gaap--StatementClassOfStockAxis__custom--August2019WarrantsMember_zaOf3Z0WsHpa" title="Warrants exercisable as of June 30, 2021"&gt;900,000&lt;/span&gt;
shares of common stock remain outstanding at an exercise price of $&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--August2019WarrantsMember_zPuFwVKpImsg"&gt;1.78 &lt;/span&gt;per
share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Series A Warrants&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20210101__20210930__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zEpmqsmW0VWe" title="Warrant description"&gt;
On January 24, 2019, STI and the Company closed a private placement with certain accredited investors pursuant to which, among other
things, the Company issued warrants representing the right to acquire 1,463,519 shares of common stock (the &#x201c;Series A
Warrants&#x201d;). The Series A Warrants were initially exercisable for 1,463,519 shares of common stock at an exercise price per
share equal to $4.15, which was adjusted several times pursuant to the terms thereof to 3,629,023 shares of common stock at an
exercise price per share equal to $0.2957 per share. The most recent adjustment to the exercise price (from $0.60 to $0.2957 per
share) occurred during the three months ended September 30, 2020 as a result of the announcement of the registered direct offering
of 8,865,000 shares of common stock in September 2020. The Series A Warrants were immediately exercisable upon issuance and will expire
on January 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt"&gt;During the three months ended March 31, 2022 and 2021,
Series A Warrants for &lt;span id="xdx_901_ecustom--NumberofWarrantsExercisedDuringPeriod_pip0_uShares_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zc2QaF5zrXrj" style="background-color: White"&gt;0 &lt;/span&gt;&lt;span style="background-color: White"&gt;and &lt;span id="xdx_90D_ecustom--NumberofWarrantsExercisedDuringPeriod_pn5n6_uShares_c20210101__20210331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zMIEgJBHlSb6"&gt;0.5
million &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color: White"&gt;shares of common stock, respectively, were exercised for approximately
$&lt;span id="xdx_903_eus-gaap--ProceedsFromWarrantExercises_pip0_uUSD_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zHamcJ2uo7e8"&gt;0 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color: White"&gt;and
$&lt;span id="xdx_906_eus-gaap--ProceedsFromWarrantExercises_pn5n6_uUSD_c20210101__20210331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zMLeTA3ZyDXa"&gt;0.1 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color: White"&gt;million,
respectively. As of March 31, 2022, Series A Warrants exercisable for &lt;span id="xdx_906_ecustom--WarrantsExercisable_iI_pn5n6_uShares_c20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_z8ygjdaLViFj"&gt;0.3 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color: White"&gt;million
shares of common stock remain outstanding at an exercise price of $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_z3YW3fGFwEAk"&gt;0.2957 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color: White"&gt;per
share&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zJmTqFB9NdR" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"&gt;A summary of warrant activity during the three months ended March 31, 2022 is as follows (share amounts in thousands):&lt;/p&gt;

&lt;p id="xdx_8B7_zAzfrCVOkjad" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; display: none"&gt;Summary of Warrant Activity&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 9pt Sans-Serif; margin: 0 0 0 5pt; color: Red"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle; width: 52%"/&gt;
    &lt;td style="vertical-align: middle; width: 1%"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; width: 12%"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; width: 1%"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right; width: 1%"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right; width: 14%"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right; width: 1%"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center; width: 18%"&gt;Weighted-&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"&gt;Weighted-&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"&gt;Average&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"&gt;Average&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"&gt;Remaining&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"&gt;Exercise&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"&gt;Contractual Life&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: bottom; text-align: center"&gt;Warrants&lt;/td&gt;
    &lt;td style="font-weight: bold; vertical-align: bottom; text-align: center"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center"&gt;Price&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center"&gt;(in years)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Outstanding as of December 31, 2021&lt;/td&gt;
    &lt;td/&gt;
    &lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pin3_c20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zVsegwJaPjd9" style="text-align: right; border-top-color: Black; border-top-width: 1pt" title="Outstanding as of December 31, 2021"&gt;2,635&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pp2p0_uUSDPShares_c20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zk5wu7yMDzS4" style="text-align: right" title="Outstanding as of December 31, 2020, weighted-average exercise price (in usd per share)"&gt;4.29&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_98A_ecustom--ClassOfWarrantOrRightOutstandingWeightedAverageRemaingContractualLife_dtY_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zBqZIHnvaY05" style="text-align: right" title="Warrants outstanding as of December 31, 2020, weighted-average remaing contractual life (in years)"&gt;2.4&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td style="text-align: left"&gt;Issued&lt;/td&gt;
    &lt;td style="text-align: left"/&gt;
    &lt;td id="xdx_98A_ecustom--NumberofWarrantsIssuedDuringPeriod_i01_pin3_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zkbEChDK2uW6" style="text-align: right" title="Issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0670"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--ClassOfWarrantOrRightIssuedExercisePriceOfWarrantsOrRights_i01_pp0p0_uUSDPShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zFkmle9m8kN3" style="text-align: right" title="Issued, warrant exercise price"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0672"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td style="text-align: left"&gt;Exercised&lt;/td&gt;
    &lt;td style="text-align: left"/&gt;
    &lt;td id="xdx_98C_ecustom--NumberofWarrantsExercisedDuringPeriod_i01_pin3_uShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zi5sOrJmTFnk" style="text-align: right" title="Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0674"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--ClassOfWarrantOrRightExercisedExercisePriceOfWarrantsOrRights_i01_pp2p0_uUSDPShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zfLLDTtuHlrf" style="text-align: right" title="Exercised, exercise price of warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0676"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td style="text-align: left"&gt;Cancelled&lt;/td&gt;
    &lt;td style="text-align: left"/&gt;
    &lt;td id="xdx_98F_ecustom--NumberofWarrantsCancelledDuringPeriod_i01_pin3_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zGfA4SCT2qse" style="text-align: right" title="Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0678"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--ClassOfWarrantOrRightCancelledExercisePriceOfWarrantsOrRights_i01_pp0p0_uUSDPShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zgm33G3iBXg3" style="text-align: right" title="Cancelled, exercise price of warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0680"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Outstanding as of March 31, 2022&lt;/td&gt;
    &lt;td/&gt;
    &lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_pin3_c20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zBwytxpqO65h" style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right" title="Outstanding as of March 31, 2022"&gt;2,635&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_pp2p0_uUSDPShares_c20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zKOF7jshxCng" style="text-align: right" title="Outstanding as of June 30, 2021, weighted-average exercise price (in usd per share)"&gt;4.29&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_98A_ecustom--ClassOfWarrantOrRightOutstandingEndOfPeriodWeightedAverageRemaingContractualLife_dtY_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zGziPPGfTX45" style="text-align: right" title="Warrants outstanding as of June 30, 2021, weighted-average remaing contractual life (in years)"&gt;2.2&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Exercisable as of March 31, 2022&lt;/td&gt;
    &lt;td/&gt;
    &lt;td id="xdx_986_ecustom--WarrantsExercisable_iI_pin3_uShares_c20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zwWZsRDjN16d" style="border-bottom: Black 2pt double; text-align: right" title="Warrants exercisable as of March 31, 2022"&gt;2,635&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights1_iI_pp2p0_uUSDPShares_c20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_ziAsCKdFiqkc" style="text-align: right" title="Exercisable, weighted-average exercise price (in usd per share)"&gt;4.29&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_98F_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageRemaingContractualLife_dtY_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zGBpwIuIP0Ue" style="text-align: right" title="Warrants exercisable as of June 30, 2021, weighted-average remaing contractual life (in years)"&gt;2.2&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AA_zJWRWtXJbfXh" style="font: 9pt Sans-Serif; margin: 0 0 0 5pt; color: Red"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 9pt Sans-Serif; margin: 0 0 0 5pt; color: Red"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 9pt Sans-Serif; margin: 0 0 0 5pt; color: Red"/&gt;

&lt;p style="font: 10pt/103% Times New Roman, Times, Serif; margin: 0"&gt;The Series A Warrants were recognized as a liability at
their fair value upon issuance. The warrant liability is remeasured to the then fair value prior to their exercise or at period end for
warrants that are unexercised and the gain or loss recognized in earnings during the period.&lt;/p&gt;

&lt;p style="font: 10pt/103% Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/103% Times New Roman, Times, Serif; margin: 0 1.3pt 0 5pt"&gt;&#160;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-03-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-03-31" decimals="0" unitRef="Shares">240000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="0" unitRef="Shares">240000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockVotingRights contextRef="From2022-01-01to2022-03-31">Each share of common stock is entitled to
one voting right</us-gaap:CommonStockVotingRights>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees contextRef="From2020-09-012020-09-30_custom_September2020WarrantsMember">On September 4, 2020, the Company entered into a securities purchase agreement
with certain institutional investors pursuant to which the Company issued and sold an aggregate of 8,865,000 shares of common stock in
a registered direct offering and issued warrants to purchase up to 6,648,750 shares of common stock in a concurrent private placement
(the &#x201c;September 2020 Warrants&#x201d;). The September 2020 Warrants are initially exercisable for
6,648,750 shares of common stock at an exercise price per share equal to $0.84. The September 2020 Warrants became exercisable beginning
on March 9, 2021 and will expire on March 9, 2026.</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-09-012020-09-30_custom_September2020WarrantsMember654121703"
      decimals="INF"
      unitRef="Shares">6648750</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-09-04_custom_September2020WarrantsMember"
      decimals="INF"
      unitRef="USDPShares">0.84</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable contextRef="From2021-01-012021-09-30_custom_September2020WarrantsMember">2021-03-09</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <SEEL:NumberofWarrantsExercisedDuringPeriod
      contextRef="From2022-01-012022-03-31_custom_September2020WarrantsMember"
      decimals="INF"
      unitRef="Shares">0</SEEL:NumberofWarrantsExercisedDuringPeriod>
    <SEEL:NumberofWarrantsExercisedDuringPeriod
      contextRef="From2021-01-012021-03-31_custom_September2020WarrantsMember"
      decimals="-5"
      unitRef="Shares">4700000</SEEL:NumberofWarrantsExercisedDuringPeriod>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2022-01-012022-03-31_custom_September2020WarrantsMember"
      decimals="0"
      unitRef="USD">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2021-01-012021-03-31_custom_September2020WarrantsMember"
      decimals="-5"
      unitRef="USD">3900000</us-gaap:ProceedsFromWarrantExercises>
    <SEEL:WarrantsExercisable
      contextRef="AsOf2022-03-31_custom_September2020WarrantsMember"
      decimals="INF"
      unitRef="Shares">1.0</SEEL:WarrantsExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-03-31_custom_September2020WarrantsMember654121843"
      decimals="INF"
      unitRef="USDPShares">0.84</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees contextRef="From2019-08-012019-08-31_custom_August2019WarrantsMember">On August 23, 2019, the Company entered into a securities
purchase agreement with certain institutional investors pursuant to which the Company issued and sold an aggregate of 4,475,000 shares
of common stock in a registered direct offering and issued warrants to purchase up to 2,237,500 shares of common stock in a concurrent
private placement (the &#x201c;August 2019 Warrants&#x201d;). The August 2019 Warrants were initially exercisable for 2,237,500 shares of
common stock at an exercise price per share equal to $1.78. The August 2019 Warrants became exercisable beginning on February 27, 2020
and will expire on August 28, 2023.</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2019-08-012019-08-31_custom_August232019Member"
      decimals="INF"
      unitRef="Shares">4475000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable contextRef="From2022-01-012022-03-31_custom_August2019WarrantsMember">2020-02-27</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <SEEL:NumberofWarrantsExercisedDuringPeriod
      contextRef="From2022-01-012022-03-31_custom_August2019WarrantsMember"
      decimals="INF"
      unitRef="Shares">0</SEEL:NumberofWarrantsExercisedDuringPeriod>
    <SEEL:NumberofWarrantsExercisedDuringPeriod
      contextRef="From2021-01-012021-03-31_custom_August2019WarrantsMember"
      decimals="INF"
      unitRef="Shares">1000000.0</SEEL:NumberofWarrantsExercisedDuringPeriod>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2022-01-012022-03-31_custom_August2019WarrantsMember"
      decimals="0"
      unitRef="USD">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2021-01-012021-03-31_custom_August2019WarrantsMember"
      decimals="0"
      unitRef="USD">1800000</us-gaap:ProceedsFromWarrantExercises>
    <SEEL:WarrantsExercisable
      contextRef="AsOf2022-03-31_custom_August2019WarrantsMember"
      decimals="INF"
      unitRef="Shares">900000</SEEL:WarrantsExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-03-31_custom_August2019WarrantsMember654121984"
      decimals="INF"
      unitRef="USDPShares">1.78</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees contextRef="From2021-01-012021-09-30_custom_SeriesAWarrantsMember">On January 24, 2019, STI and the Company closed a private placement with certain accredited investors pursuant to which, among other
things, the Company issued warrants representing the right to acquire 1,463,519 shares of common stock (the &#x201c;Series A
Warrants&#x201d;). The Series A Warrants were initially exercisable for 1,463,519 shares of common stock at an exercise price per
share equal to $4.15, which was adjusted several times pursuant to the terms thereof to 3,629,023 shares of common stock at an
exercise price per share equal to $0.2957 per share. The most recent adjustment to the exercise price (from $0.60 to $0.2957 per
share) occurred during the three months ended September 30, 2020 as a result of the announcement of the registered direct offering
of 8,865,000 shares of common stock in September 2020. The Series A Warrants were immediately exercisable upon issuance and will expire
on January 31, 2024.</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <SEEL:NumberofWarrantsExercisedDuringPeriod
      contextRef="From2022-01-012022-03-31_custom_SeriesAWarrantsMember"
      decimals="INF"
      unitRef="Shares">0</SEEL:NumberofWarrantsExercisedDuringPeriod>
    <SEEL:NumberofWarrantsExercisedDuringPeriod
      contextRef="From2021-01-012021-03-31_custom_SeriesAWarrantsMember"
      decimals="-5"
      unitRef="Shares">500000</SEEL:NumberofWarrantsExercisedDuringPeriod>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2022-01-012022-03-31_custom_SeriesAWarrantsMember"
      decimals="0"
      unitRef="USD">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2021-01-012021-03-31_custom_SeriesAWarrantsMember"
      decimals="-5"
      unitRef="USD">100000</us-gaap:ProceedsFromWarrantExercises>
    <SEEL:WarrantsExercisable
      contextRef="AsOf2022-03-31_custom_SeriesAWarrantsMember"
      decimals="-5"
      unitRef="Shares">300000</SEEL:WarrantsExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-03-31_custom_SeriesAWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">0.2957</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_891_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zJmTqFB9NdR" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"&gt;A summary of warrant activity during the three months ended March 31, 2022 is as follows (share amounts in thousands):&lt;/p&gt;

&lt;p id="xdx_8B7_zAzfrCVOkjad" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; display: none"&gt;Summary of Warrant Activity&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 9pt Sans-Serif; margin: 0 0 0 5pt; color: Red"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle; width: 52%"/&gt;
    &lt;td style="vertical-align: middle; width: 1%"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; width: 12%"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; width: 1%"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right; width: 1%"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right; width: 14%"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right; width: 1%"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center; width: 18%"&gt;Weighted-&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"&gt;Weighted-&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"&gt;Average&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"&gt;Average&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"&gt;Remaining&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"&gt;Exercise&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"&gt;Contractual Life&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: bottom; text-align: center"&gt;Warrants&lt;/td&gt;
    &lt;td style="font-weight: bold; vertical-align: bottom; text-align: center"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center"&gt;Price&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center"&gt;(in years)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Outstanding as of December 31, 2021&lt;/td&gt;
    &lt;td/&gt;
    &lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pin3_c20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zVsegwJaPjd9" style="text-align: right; border-top-color: Black; border-top-width: 1pt" title="Outstanding as of December 31, 2021"&gt;2,635&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pp2p0_uUSDPShares_c20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zk5wu7yMDzS4" style="text-align: right" title="Outstanding as of December 31, 2020, weighted-average exercise price (in usd per share)"&gt;4.29&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_98A_ecustom--ClassOfWarrantOrRightOutstandingWeightedAverageRemaingContractualLife_dtY_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zBqZIHnvaY05" style="text-align: right" title="Warrants outstanding as of December 31, 2020, weighted-average remaing contractual life (in years)"&gt;2.4&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td style="text-align: left"&gt;Issued&lt;/td&gt;
    &lt;td style="text-align: left"/&gt;
    &lt;td id="xdx_98A_ecustom--NumberofWarrantsIssuedDuringPeriod_i01_pin3_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zkbEChDK2uW6" style="text-align: right" title="Issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0670"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--ClassOfWarrantOrRightIssuedExercisePriceOfWarrantsOrRights_i01_pp0p0_uUSDPShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zFkmle9m8kN3" style="text-align: right" title="Issued, warrant exercise price"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0672"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td style="text-align: left"&gt;Exercised&lt;/td&gt;
    &lt;td style="text-align: left"/&gt;
    &lt;td id="xdx_98C_ecustom--NumberofWarrantsExercisedDuringPeriod_i01_pin3_uShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zi5sOrJmTFnk" style="text-align: right" title="Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0674"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--ClassOfWarrantOrRightExercisedExercisePriceOfWarrantsOrRights_i01_pp2p0_uUSDPShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zfLLDTtuHlrf" style="text-align: right" title="Exercised, exercise price of warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0676"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td style="text-align: left"&gt;Cancelled&lt;/td&gt;
    &lt;td style="text-align: left"/&gt;
    &lt;td id="xdx_98F_ecustom--NumberofWarrantsCancelledDuringPeriod_i01_pin3_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zGfA4SCT2qse" style="text-align: right" title="Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0678"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--ClassOfWarrantOrRightCancelledExercisePriceOfWarrantsOrRights_i01_pp0p0_uUSDPShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zgm33G3iBXg3" style="text-align: right" title="Cancelled, exercise price of warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0680"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Outstanding as of March 31, 2022&lt;/td&gt;
    &lt;td/&gt;
    &lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_pin3_c20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zBwytxpqO65h" style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right" title="Outstanding as of March 31, 2022"&gt;2,635&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_pp2p0_uUSDPShares_c20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zKOF7jshxCng" style="text-align: right" title="Outstanding as of June 30, 2021, weighted-average exercise price (in usd per share)"&gt;4.29&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_98A_ecustom--ClassOfWarrantOrRightOutstandingEndOfPeriodWeightedAverageRemaingContractualLife_dtY_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zGziPPGfTX45" style="text-align: right" title="Warrants outstanding as of June 30, 2021, weighted-average remaing contractual life (in years)"&gt;2.2&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Exercisable as of March 31, 2022&lt;/td&gt;
    &lt;td/&gt;
    &lt;td id="xdx_986_ecustom--WarrantsExercisable_iI_pin3_uShares_c20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zwWZsRDjN16d" style="border-bottom: Black 2pt double; text-align: right" title="Warrants exercisable as of March 31, 2022"&gt;2,635&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights1_iI_pp2p0_uUSDPShares_c20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_ziAsCKdFiqkc" style="text-align: right" title="Exercisable, weighted-average exercise price (in usd per share)"&gt;4.29&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_98F_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageRemaingContractualLife_dtY_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zGBpwIuIP0Ue" style="text-align: right" title="Warrants exercisable as of June 30, 2021, weighted-average remaing contractual life (in years)"&gt;2.2&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2021-12-31_custom_WarrantDerivativeFinancialInstrumentsMember"
      decimals="INF"
      unitRef="Shares">2635000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-12-31_custom_WarrantDerivativeFinancialInstrumentsMember"
      decimals="2"
      unitRef="USDPShares">4.29</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <SEEL:ClassOfWarrantOrRightOutstandingWeightedAverageRemaingContractualLife contextRef="From2022-01-012022-03-31_custom_WarrantDerivativeFinancialInstrumentsMember">P2Y4M24D</SEEL:ClassOfWarrantOrRightOutstandingWeightedAverageRemaingContractualLife>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-03-31_custom_WarrantDerivativeFinancialInstrumentsMember"
      decimals="INF"
      unitRef="Shares">2635000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-03-31_custom_WarrantDerivativeFinancialInstrumentsMember"
      decimals="2"
      unitRef="USDPShares">4.29</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <SEEL:ClassOfWarrantOrRightOutstandingEndOfPeriodWeightedAverageRemaingContractualLife contextRef="From2022-01-012022-03-31_custom_WarrantDerivativeFinancialInstrumentsMember">P2Y2M12D</SEEL:ClassOfWarrantOrRightOutstandingEndOfPeriodWeightedAverageRemaingContractualLife>
    <SEEL:WarrantsExercisable
      contextRef="AsOf2022-03-31_custom_WarrantDerivativeFinancialInstrumentsMember"
      decimals="INF"
      unitRef="Shares">2635000</SEEL:WarrantsExercisable>
    <SEEL:ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-03-31_custom_WarrantDerivativeFinancialInstrumentsMember"
      decimals="2"
      unitRef="USDPShares">4.29</SEEL:ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights1>
    <SEEL:ClassOfWarrantOrRightExercisableWeightedAverageRemaingContractualLife contextRef="From2022-01-012022-03-31_custom_WarrantDerivativeFinancialInstrumentsMember">P2Y2M12D</SEEL:ClassOfWarrantOrRightExercisableWeightedAverageRemaingContractualLife>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_803_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zPxW4MSS64y6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;11. Stock-based Compensation&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zT8H60SUTzZ8"&gt;The
Company has the Seelos Therapeutics, Inc. Amended and Restated 2012 Stock Long Term Incentive Plan (the &#x201c;2012 Plan&#x201d;), which
provides for the issuance of incentive and non-incentive stock options, restricted and unrestricted stock awards, stock unit awards and
stock appreciation rights. Options and restricted stock units granted generally vest over a period of one to four years and have a maximum
term of ten years from the date of grant. The 2012 Plan provides that an additional number of shares will automatically be added annually
to the shares authorized for issuance under the 2012 Plan on January 1st of each year commencing on January 1, 2020 and ending on (and
including) January 1, 2029. The number of shares added each year will be equal to the lesser of (a) 4% of the number of shares of common
stock issued and outstanding on a fully-diluted basis as of the close of business on the immediately preceding December 31, and (b) a
number of shares of common stock set by the Company&#x2019;s board of directors on or prior to each such January 1. On January 1, 2022,
in accordance with the foregoing, an aggregate of &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pn5n6_c20220101__20220131__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4ao9xz93Cyi"&gt;4,713,637&lt;/span&gt; shares of common stock were added to shares authorized for issuance under
the 2012 Plan. As of March 31, 2022, an aggregate of &lt;/span&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pip0_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zdQ2Sv48gtEa"&gt;15,817,818
shares of common stock were authorized under the 2012 Plan, of which &lt;/span&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pin6_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjKFhUvns2bc"&gt;5.5
million shares of common stock were available for future grants. No further awards may be issued under the Seelos Therapeutics, Inc. 2016
Equity Incentive Plan (the "2016 Plan").&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span/&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="background-color: white"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20200501__20200531__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zUp64cWhap45"&gt;On May 15, 2020, the
Company&#x2019;s stockholders approved the Company's 2020 Employee Stock Purchase Plan (the "ESPP"),
whereby qualified employees are allowed to purchase limited amounts of the Company&#x2019;s common stock at the lesser of
&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pip2_dp_uPure_c20200501__20200531__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zoJp2tYn9H46"&gt;85&lt;/span&gt;% of the market price at the beginning or end of the offering period. The
stockholders have authorized an initial amount of &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pn5n6_c20200515__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zkHegzw9MvS3"&gt;1.0&lt;/span&gt; million shares for purchase by employees under the ESPP. The ESPP provides
that an additional number of shares will automatically be added annually to the shares authorized for issuance under the ESPP on
January 1st of each year commencing on January 1, 2021 and ending on (and including) January 1, 2030, which amount shall be equal to
the lesser of (i) 1% of the number of shares of the Company's common stock issued and outstanding on the immediately preceding
December 31, and (ii) a number of shares of common stock set by the Company&#x2019;s Board of Directors or the Compensation
Committee of the Board of Directors (the &#x201c;Compensation Committee&#x201d;) of the Company on
or prior to each such January 1. On January 1, 2022, the Company added &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pn5n6_c20220101__20220131__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zGH7iOhmSb3k"&gt;1,055,004&lt;/span&gt; shares for purchase by employees under the ESPP.
During the three months ended March 31, 2022, the Company sold &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_pip0_c20220101__20220331__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zJcZe4FXSN0g"&gt;84,078&lt;/span&gt; shares of common
stock under the ESPP. The compensation costs are calculated as the fair value of the &lt;span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceDiscountOfCommonStockPercent_pip2_dp_uPure_c20220101__20220331__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zFStwj24HRXj" title="Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price Discount of Common Stock, Percent"&gt;15&lt;/span&gt;% discount from market price and were
approximately $&lt;span id="xdx_903_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220331__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_z1KoSrVpTl92"&gt;17,000&lt;/span&gt; for the three months ended March 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;&lt;span style="background-color: white"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220101__20220331__us-gaap--AwardTypeAxis__custom--InducementPlanof2019Member_zawA1s8R4qkl" title="Description of share-based compensation arrangement by share-based payment award"&gt;On July 28, 2019, the Compensation Committee of the Board of Directors (the &#x201c;Compensation
Committee&#x201d;) of the Company adopted the Seelos Therapeutics, Inc. 2019 Inducement Plan (the &#x201c;2019 Inducement Plan&#x201d;),
which became effective on August 12, 2019. The 2019 Inducement Plan provides for the grant of equity-based awards in the form of stock
options, stock appreciation rights, restricted stock, unrestricted stock, stock units, including restricted stock units, performance units
and cash awards, solely to prospective employees of the Company or an affiliate of the Company provided that certain criteria are met.
Awards under the 2019 Inducement Plan may only be granted to an individual, as a material inducement to such individual to enter into
employment with the Company, who (i) has not previously been an employee or director of the Company or (ii) is rehired following a bona
fide period of non-employment with the Company. The maximum number of shares available for grant under the 2019 Inducement Plan is &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pip0_c20220331__us-gaap--AwardTypeAxis__custom--InducementPlanof2019Member_zvhJBfnRuq66"&gt;1,000,000&lt;/span&gt;
shares of the Company&#x2019;s common stock. The 2019 Inducement Plan is administered by the Compensation Committee and expires on August 12, 2029.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Stock options&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;During the three months ended March 31, 2022, the Company granted
&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0p0_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__custom--IncentiveStockOptionMember_zVVs6dAihFWk" title="Options granted in period"&gt;560,605&lt;/span&gt; incentive stock options and &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0p0_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__custom--NonQualifiedStockOptionsToEmployeesMember_znr2Krc0UUKa" title="Options granted in period"&gt;2,299,395&lt;/span&gt; non-qualified stock options to employees with a weighted average exercise price per share
of $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2p0_uUSDPShares_c20220101__20220331__us-gaap--AwardTypeAxis__custom--IncentiveStockOptionMember_zOl2BrWfHUKl" title="Weighted-average exercise price per share granted in period"&gt;1.46&lt;/span&gt; and a &lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_pp0p0_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__custom--IncentiveStockOptionMember_zaImMXrXhdOl" title="Term of option grant"&gt;10&lt;/span&gt;-year term, subject to the terms and conditions of the 2012 Plan above. The stock options are subject to time vesting
requirements. The stock options granted to employees vest &lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pip2_c20220101__20220331__us-gaap--AwardTypeAxis__custom--IncentiveStockOptionMember_zx9Dyvwck5pa" title="Vesting percentage on the first anniversary"&gt;25&lt;/span&gt;% on the first anniversary of the grant and monthly thereafter over the next
three years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;During the three months ended March 31, 2022, the
Company also granted &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0p0_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__custom--NonQualifiedStockOptionsToNonEmployeeDirectorsMember_z1Zwg0sFYz99"&gt;140,000 &lt;/span&gt;non-qualified
stock options to non-employee directors with a weighted average exercise price per share of $&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2p0_uUSDPShares_c20220101__20220331__us-gaap--AwardTypeAxis__custom--NonQualifiedStockOptionsToNonEmployeeDirectorsMember_zp3VakZFQ9F"&gt;1.56 &lt;/span&gt;and
a &lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_pp0p0_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__custom--NonQualifiedStockOptionsToNonEmployeeDirectorsMember_zFaVzYOqJVUa"&gt;10&lt;/span&gt;-year
term, subject to the terms and conditions of the 2012 Plan above. The stock options granted to non-employee directors vest monthly over the
&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_pp0p0_dtM_c20220101__20220331__us-gaap--AwardTypeAxis__custom--NonQualifiedStockOptionsToNonEmployeeDirectorsMember_zxzxaNj5aR9k"&gt;12&lt;/span&gt; months following the grant.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The fair value of stock option grants are estimated on the date
of grant using the Black-Scholes option-pricing model. The Company was historically a private company and lacked sufficient company-specific
historical and implied volatility information. Therefore, it estimates its expected stock volatility based on a weighted average blend
of the historical volatility of a publicly traded set of peer companies, as well as its own historical volatility. Additionally, due to
an insufficient history with respect to stock option activity and post-vesting cancellations, the expected term assumption for employee
grants is based on a permitted simplified method, which is based on the vesting period and contractual term for each tranche of awards.
The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect for time periods approximately equal
to the expected term of the award. Expected dividend yield is zero based on the fact that the Company has never paid cash dividends and
does not expect to pay any cash dividends in the foreseeable future.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;During the three months ended March 31, 2022, &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pip0_c20220101__20220331_ztCw3kiZyTyi" title="Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period"&gt;6,250&lt;/span&gt; stock options were exercised
and &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_pip0_do_c20220101__20220331_zkHYkvCv4GW4"&gt;no&lt;/span&gt; options were  forfeited.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zXhvmmQk8jQ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following assumptions were used in determining the fair value
of the stock options granted during the three months ended March 31, 2022 and 2021:&lt;/p&gt;

&lt;p id="xdx_8BF_zXfcPsXzw2Jd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; display: none"&gt;Schedule of Valuation Assumptions for Stock Options&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 9pt Sans-Serif; margin: 0 0 0 4.5pt; text-align: center; color: Red"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td/&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; text-align: right"/&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; text-align: right"/&gt;
    &lt;td colspan="4" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center"&gt;Three Months Ended&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td style="width: 56%"/&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; text-align: right; width: 1%"/&gt;
    &lt;td style="text-align: right; width: 2%"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center; width: 19%"&gt;March 31, 2022&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center; width: 19%"&gt;March 31, 2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Risk-free interest rate&lt;/td&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: center; border-top-color: Black; border-top-width: 1pt"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjtVcCqUpHQ1" title="Risk-free interest rate, minimum"&gt;1.5&lt;/span&gt;%
    - &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYRJR2d5QdVk" title="Risk-free interest rate, maximum"&gt;1.6&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; vertical-align: middle"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zzOjUAmjsxFc" title="Risk-free interest rate, minimum"&gt;0.5&lt;/span&gt;%
    - &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgvlFJ1D99X1" title="Risk-free interest rate, maximum"&gt;0.9&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip2_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztiOBv52Qkt2" title="Volatility, minimum"&gt;113&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; vertical-align: middle"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pip2_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zHkgqet06Yf6" title="Volatility, minimum"&gt;120&lt;/span&gt;%-&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pip2_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zOpmEyP1jL0f" title="Volatility, maximum"&gt;125&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Dividend yield&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEwBPf3fS8Bg" title="Dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0744"&gt;-&lt;/span&gt;&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zeyq7EuVL3tf" title="Dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0746"&gt;-&lt;/span&gt;&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Expected term (years)&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zQuqEZf1Nqbg" title="Expected term (in years)"&gt;5&lt;/span&gt;
    - &lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zuyt1YNTp7zd" title="Expected term (in years)"&gt;6&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zd2w1SirpE4l" title="Expected term (in years)"&gt;5&lt;/span&gt;
    - &lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zEq8Wb9zgTbh" title="Expected term (in years)"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Weighted-average fair value&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pp2p0_uUSDPShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zSTQ5fbDjrb1" title="Weighted average fair value"&gt;1.24
    - &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pp2p0_uUSDPShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zVxJYCH0CCqe"&gt;1.27&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; vertical-align: middle"&gt;$&lt;/td&gt;
    &lt;td style="text-align: center; vertical-align: middle"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pp2p0_uUSDPShares_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUyqXX23Gjzl"&gt;3.62&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
&lt;p id="xdx_8A8_zYZBcd45wDAk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zHoecFH9CL2f" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;A summary of stock option activity during the three months ended
March 31, 2022 is as follows (share amounts in thousands):&lt;/p&gt;

&lt;p id="xdx_8B1_z61dgi5nD0Y" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; display: none"&gt;Summary of Stock Option Activity&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle; width: 50%"/&gt;
    &lt;td style="vertical-align: middle; width: 1%"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; width: 10%"/&gt;
    &lt;td style="vertical-align: middle; width: 1%"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right; width: 1%"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center; width: 10%"/&gt;
    &lt;td style="vertical-align: middle; width: 1%"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center; width: 14%"&gt;Weighted-&lt;/td&gt;
    &lt;td style="vertical-align: middle; width: 1%"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right; width: 1%"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center; width: 10%"/&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle"/&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"&gt;Weighted-&lt;/td&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"&gt;Average&lt;/td&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"&gt;Total&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle"/&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"&gt;Average&lt;/td&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"&gt;Remaining&lt;/td&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"&gt;Aggregate&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"&gt;Stock&lt;/td&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"&gt;Exercise&lt;/td&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"&gt;Contractual&lt;/td&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"&gt;Intrinsic&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: bottom; text-align: center"&gt;Options&lt;/td&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center"&gt;Price&lt;/td&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center"&gt;Life (in years)&lt;/td&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center"&gt;Value&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Outstanding as of December 31, 2021&lt;/td&gt;
    &lt;td/&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pin3_uShares_c20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z8DRlDoteBmd" style="text-align: right" title="Outstanding as of December 31, 2020"&gt;7,306&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2p0_uUSDPShares_c20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNRFCa6nzHZd" style="text-align: right; border-top-color: Black; border-top-width: 1pt" title="Outstanding, beginning of period (USD per share)"&gt;2.60&lt;/td&gt;
    &lt;td/&gt;
    &lt;td style="text-align: right; border-top-color: Black; border-top-width: 1pt"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Granted&lt;/td&gt;
    &lt;td/&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pin3_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjcI84J2YaBi" style="text-align: right" title="Granted"&gt;3,000&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2p0_uUSDPShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ziUtgz9WNN99" style="text-align: right" title="Granted in period (USD per share)"&gt;1.47&lt;/td&gt;
    &lt;td/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;
    &lt;td/&gt;
    &lt;td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pin3_di_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUYz51vmAwA8" style="text-align: right" title="Exercised"&gt;(6)&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmPS2631gQh6" style="text-align: right" title="Exercised in period (USD per share)"&gt;1.06&lt;/td&gt;
    &lt;td/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td style="text-align: left"&gt;Cancelled&lt;/td&gt;
    &lt;td style="text-align: left"/&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pin3_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zR6cDFUfPZ4f" style="border-bottom: Black 1pt solid; text-align: right" title="Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0774"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_d0_uUSDPShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjgUGQ9a3OD9" style="text-align: right" title="Cancelled (USD per share)"&gt;-&lt;/td&gt;
    &lt;td/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Outstanding as of March 31, 2022&lt;/td&gt;
    &lt;td/&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pin3_uShares_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zuKMgdCfnJY4" style="border-bottom: Black 2pt double; text-align: right" title="Outstanding as of March 31, 2022"&gt;10,300&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pp2p0_uUSDPShares_c20220331_z3GPMX9yPIuc" style="border-bottom: Black 2pt double; text-align: right" title="Outstanding, end of period (USD per share)"&gt;2.27&lt;/td&gt;
    &lt;td/&gt;
    &lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zne43COO2mHl" style="text-align: right" title="Outstanding - weighted-average remaining contractual life (in years)"&gt;8.7&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_uUSD_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zFOhlb7tS3V3" style="border-bottom: Black 2pt double; text-align: right" title="Total aggregate intrinsic value shares outstanding"&gt;2,894&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Vested and expected to vest as of March 31, 2022&lt;/td&gt;
    &lt;td/&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pin3_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zabB3u9YKS3b" style="border-bottom: Black 2pt double; text-align: right" title="Vested and expected to vest, end of period (shares)"&gt;10,300&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pp2p0_d0_uUSDPShares_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1gIUcwcNnGd" style="border-bottom: Black 2pt double; text-align: right" title="Vested and expected to vest stock, end of period (USD per share)"&gt;2.27&lt;/td&gt;
    &lt;td/&gt;
    &lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zeDcxxvpPvAk" style="text-align: right" title="Weighted-average remaining contractual life (in years) of vested and expected to vest stock options"&gt;8.7&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_pn3n3_uUSD_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYGOnPpxeAr9" style="border-bottom: Black 2pt double; text-align: right" title="Total aggregate intrinsic value of vested or expected to vest stock options"&gt;2,894&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Exercisable as of March 31, 2022&lt;/td&gt;
    &lt;td/&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pin3_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1xJhUmnf5ve" style="border-bottom: Black 2pt double; text-align: right" title="Exercisable, end of period (shares)"&gt;3,085&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pp2p0_d0_uUSDPShares_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zT2olXBumqNh" style="border-bottom: Black 2pt double; text-align: right" title="Exercisable, end of period (USD per share)"&gt;3.00&lt;/td&gt;
    &lt;td/&gt;
    &lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjVD2HF0t2Be" style="text-align: right" title="Weighted-average remaining contractual life (in years) of exercisable stock options"&gt;8.1&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_uUSD_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQC6bN4xDEB3" style="border-bottom: Black 2pt double; text-align: right" title="Total aggregate intrinsic value of exercisable stock options"&gt;2,894&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 9pt Sans-Serif; margin: 0"/&gt;

&lt;p id="xdx_8AF_zcrDRY3Pdsx" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The intrinsic value of options exercised during the three months ended
March 31, 2022 and 2021 was $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pn5n6_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaEw0FmMIJl3"&gt;0.1&lt;/span&gt; million and $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zj1hJ44u2uX6"&gt;0&lt;/span&gt;, respectively. As of March 31, 2022, unrecognized stock-option compensation expense of
$&lt;span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zLYM7LhCg7Tk"&gt;10.2&lt;/span&gt; million is expected to be realized over a weighted-average period of &lt;span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_pid_dtY_uYears_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQ3ID0rWSzO"&gt;2.6&lt;/span&gt; years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Performance Stock Award&lt;/i&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_pip0_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__us-gaap--PlanNameAxis__custom--PSUtoExecutivesMember_znt4Em1nKwp8"&gt;During the year
ended December 31, 2021, the Company&#x2019;s Board of Directors awarded a performance stock unit award to the Company&#x2019;s Chief Executive
Officer for &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pp0p0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__us-gaap--PlanNameAxis__custom--PSUtoExecutivesMember_zcXiSQnQOTTa"&gt;2,400,000&lt;/span&gt; shares of common stock, with a grant date fair value of $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pp2p0_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__us-gaap--PlanNameAxis__custom--PSUtoExecutivesMember_zlAQCD3CEaqi"&gt;4.31&lt;/span&gt; per unit. Vesting of this award was subject to the
Company achieving certain performance criteria established at the grant date and the individual fulfilling a service condition (continued
employment). As of December 31, 2021, all performance stock unit awards were unvested and three of the five performance conditions had
been satisfied. The Company recognized stock-based compensation related to this award of $&lt;span id="xdx_904_eus-gaap--ShareBasedCompensation_pn5n6_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__us-gaap--PlanNameAxis__custom--PSUtoExecutivesMember_zIRnh2jKais5"&gt;4.9&lt;/span&gt; million during the fourth quarter of 2021,
which was recorded in general and administrative expense. During the three months ended March 31, 2022, the Company and its Chief Executive
Officer entered into an agreement to cancel the performance stock unit award for no consideration. In connection with the cancellation
of the award, no replacement awards were granted or authorized. At the time of cancellation, the Company recognized the remaining compensation
expense of the three achieved milestones of $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensation_pn5n6_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__us-gaap--PlanNameAxis__custom--PSUtoExecutivesMember_zHyonyr7eJYh"&gt;1.3&lt;/span&gt; million. The two remaining milestones were not deemed probable of achievement at the
time of cancellation, and &lt;span id="xdx_907_ecustom--SharebasedPaymentArrangementNonvestedAndCanceledAwardExcludingOptionCostNotYetRecognizedAmount_iI_pn5n6_do_c20220331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__us-gaap--PlanNameAxis__custom--PSUtoExecutivesMember_z1LdYCnnz1ge" title="Share-Based Payment Arrangement, Nonvested and Canceled  Award, Excluding Option, Cost Not yet Recognized, Amount"&gt;no&lt;/span&gt; compensation cost related to these milestones was recognized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zKedatNYpX1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table summarizes the total stock-based compensation
expense resulting from share-based awards recorded in the Company&#x2019;s condensed consolidated statements of operations (in thousands):&lt;/p&gt;

&lt;p id="xdx_8B8_zeKdjKdluhy2" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; display: none"&gt;Schedule of Stock-Based Compensation Expense&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle; background-color: white"/&gt;
    &lt;td style="vertical-align: middle; background-color: white"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td colspan="4" style="font-weight: bold; vertical-align: middle; text-align: center; background-color: white"&gt;Three Months Ended&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle; background-color: white"/&gt;
    &lt;td style="vertical-align: middle; background-color: white"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td colspan="4" style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white"&gt;March
    31,&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle; background-color: white; width: 64%"/&gt;
    &lt;td style="vertical-align: middle; background-color: white; width: 2%"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right; width: 2%"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; background-color: white; width: 14%"&gt;2022&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; background-color: white; width: 2%"/&gt;
    &lt;td style="vertical-align: middle; border-top-color: Black; border-top-width: 1pt; background-color: white; width: 2%"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; background-color: white; width: 14%"&gt;2021&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td style="background-color: white"&gt;Research and development&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20220101__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zXHbP0LPHD75" style="text-align: right; border-top-color: Black; border-top-width: 1pt" title="Stock-based compensation expense"&gt;229&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensation_pn3n3_c20210101__20210331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zumQzKkXYS4" style="text-align: right; border-top-color: Black; border-top-width: 1pt" title="Stock-based compensation expense"&gt;136&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td style="background-color: white"&gt;General and administrative&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensation_pn3n3_c20220101__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zrYJ3d2q7vEb" style="border-bottom: Black 1pt solid; text-align: right" title="Stock-based compensation expense"&gt;2,003&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensation_pn3n3_c20210101__20210331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zoTjvJL1STs" style="border-bottom: Black 1pt solid; text-align: right" title="Stock-based compensation expense"&gt;569&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td style="text-align: left; background-color: white"/&gt;
    &lt;td style="text-align: right; background-color: white"/&gt;
    &lt;td style="text-align: right; background-color: white"&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ShareBasedCompensation_pn3n3_c20220101__20220331_z581oqWEPrX7" style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 1pt; background-color: white" title="Stock-based compensation expense"&gt;2,232&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"/&gt;
    &lt;td style="text-align: right; background-color: white"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensation_pn3n3_c20210101__20210331_zkwVMYZ826Tj" style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 1pt" title="Stock-based compensation expense"&gt;705&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_z8btxmdDkg6j" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;&#160;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember654123531">The
Company has the Seelos Therapeutics, Inc. Amended and Restated 2012 Stock Long Term Incentive Plan (the &#x201c;2012 Plan&#x201d;), which
provides for the issuance of incentive and non-incentive stock options, restricted and unrestricted stock awards, stock unit awards and
stock appreciation rights. Options and restricted stock units granted generally vest over a period of one to four years and have a maximum
term of ten years from the date of grant. The 2012 Plan provides that an additional number of shares will automatically be added annually
to the shares authorized for issuance under the 2012 Plan on January 1st of each year commencing on January 1, 2020 and ending on (and
including) January 1, 2029. The number of shares added each year will be equal to the lesser of (a) 4% of the number of shares of common
stock issued and outstanding on a fully-diluted basis as of the close of business on the immediately preceding December 31, and (b) a
number of shares of common stock set by the Company&#x2019;s board of directors on or prior to each such January 1. On January 1, 2022,
in accordance with the foregoing, an aggregate of 4,713,637 shares of common stock were added to shares authorized for issuance under
the 2012 Plan. As of March 31, 2022, an aggregate of</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2022-01-012022-01-31_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      unitRef="Shares">4713637000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2022-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">15817818</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2022-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">5500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2020-05-012020-05-31_custom_EmployeeStockPurchasePlanMember">On May 15, 2020, the
Company&#x2019;s stockholders approved the Company's 2020 Employee Stock Purchase Plan (the "ESPP"),
whereby qualified employees are allowed to purchase limited amounts of the Company&#x2019;s common stock at the lesser of
85% of the market price at the beginning or end of the offering period. The
stockholders have authorized an initial amount of 1.0 million shares for purchase by employees under the ESPP. The ESPP provides
that an additional number of shares will automatically be added annually to the shares authorized for issuance under the ESPP on
January 1st of each year commencing on January 1, 2021 and ending on (and including) January 1, 2030, which amount shall be equal to
the lesser of (i) 1% of the number of shares of the Company's common stock issued and outstanding on the immediately preceding
December 31, and (ii) a number of shares of common stock set by the Company&#x2019;s Board of Directors or the Compensation
Committee of the Board of Directors (the &#x201c;Compensation Committee&#x201d;) of the Company on
or prior to each such January 1. On January 1, 2022, the Company added 1,055,004 shares for purchase by employees under the ESPP.
During the three months ended March 31, 2022, the Company sold 84,078 shares of common
stock under the ESPP. The compensation costs are calculated as the fair value of the 15% discount from market price and were
approximately $17,000 for the three months ended March 31, 2022.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="From2020-05-012020-05-31_custom_EmployeeStockPurchasePlanMember"
      decimals="INF"
      unitRef="Pure">0.0085</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2020-05-15_custom_EmployeeStockPurchasePlanMember"
      decimals="-5"
      unitRef="Shares">1000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2022-01-012022-01-31_custom_EmployeeStockPurchasePlanMember"
      decimals="-5"
      unitRef="Shares">1055004000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="From2022-01-012022-03-31_custom_EmployeeStockPurchasePlanMember"
      decimals="INF"
      unitRef="Shares">84078</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <SEEL:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceDiscountOfCommonStockPercent
      contextRef="From2022-01-012022-03-31_custom_EmployeeStockPurchasePlanMember"
      decimals="INF"
      unitRef="Pure">0.0015</SEEL:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceDiscountOfCommonStockPercent>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-03-31_custom_EmployeeStockPurchasePlanMember"
      decimals="0"
      unitRef="USD">17000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2022-01-012022-03-31_custom_InducementPlanof2019Member">On July 28, 2019, the Compensation Committee of the Board of Directors (the &#x201c;Compensation
Committee&#x201d;) of the Company adopted the Seelos Therapeutics, Inc. 2019 Inducement Plan (the &#x201c;2019 Inducement Plan&#x201d;),
which became effective on August 12, 2019. The 2019 Inducement Plan provides for the grant of equity-based awards in the form of stock
options, stock appreciation rights, restricted stock, unrestricted stock, stock units, including restricted stock units, performance units
and cash awards, solely to prospective employees of the Company or an affiliate of the Company provided that certain criteria are met.
Awards under the 2019 Inducement Plan may only be granted to an individual, as a material inducement to such individual to enter into
employment with the Company, who (i) has not previously been an employee or director of the Company or (ii) is rehired following a bona
fide period of non-employment with the Company. The maximum number of shares available for grant under the 2019 Inducement Plan is 1,000,000
shares of the Company&#x2019;s common stock. The 2019 Inducement Plan is administered by the Compensation Committee and expires on August 12, 2029.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2022-03-31_custom_InducementPlanof2019Member"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-012022-03-31_custom_IncentiveStockOptionMember"
      decimals="0"
      unitRef="Shares">560605</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-012022-03-31_custom_NonQualifiedStockOptionsToEmployeesMember"
      decimals="0"
      unitRef="Shares">2299395</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-03-31_custom_IncentiveStockOptionMember"
      decimals="2"
      unitRef="USDPShares">1.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="From2022-01-012022-03-31_custom_IncentiveStockOptionMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="From2022-01-012022-03-31_custom_IncentiveStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-012022-03-31_custom_NonQualifiedStockOptionsToNonEmployeeDirectorsMember"
      decimals="0"
      unitRef="Shares">140000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-03-31_custom_NonQualifiedStockOptionsToNonEmployeeDirectorsMember"
      decimals="2"
      unitRef="USDPShares">1.56</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="From2022-01-012022-03-31_custom_NonQualifiedStockOptionsToNonEmployeeDirectorsMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2022-01-012022-03-31_custom_NonQualifiedStockOptionsToNonEmployeeDirectorsMember">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-01-01to2022-03-31"
      decimals="INF"
      unitRef="Shares">6250</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2022-01-01to2022-03-31"
      decimals="INF"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zXhvmmQk8jQ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following assumptions were used in determining the fair value
of the stock options granted during the three months ended March 31, 2022 and 2021:&lt;/p&gt;

&lt;p id="xdx_8BF_zXfcPsXzw2Jd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; display: none"&gt;Schedule of Valuation Assumptions for Stock Options&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 9pt Sans-Serif; margin: 0 0 0 4.5pt; text-align: center; color: Red"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td/&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; text-align: right"/&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; text-align: right"/&gt;
    &lt;td colspan="4" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center"&gt;Three Months Ended&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td style="width: 56%"/&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; text-align: right; width: 1%"/&gt;
    &lt;td style="text-align: right; width: 2%"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center; width: 19%"&gt;March 31, 2022&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center; width: 19%"&gt;March 31, 2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Risk-free interest rate&lt;/td&gt;
    &lt;td style="font-size: 9pt; font-weight: bold; text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: center; border-top-color: Black; border-top-width: 1pt"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjtVcCqUpHQ1" title="Risk-free interest rate, minimum"&gt;1.5&lt;/span&gt;%
    - &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYRJR2d5QdVk" title="Risk-free interest rate, maximum"&gt;1.6&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; vertical-align: middle"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zzOjUAmjsxFc" title="Risk-free interest rate, minimum"&gt;0.5&lt;/span&gt;%
    - &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgvlFJ1D99X1" title="Risk-free interest rate, maximum"&gt;0.9&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip2_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztiOBv52Qkt2" title="Volatility, minimum"&gt;113&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; vertical-align: middle"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pip2_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zHkgqet06Yf6" title="Volatility, minimum"&gt;120&lt;/span&gt;%-&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pip2_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zOpmEyP1jL0f" title="Volatility, maximum"&gt;125&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Dividend yield&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEwBPf3fS8Bg" title="Dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0744"&gt;-&lt;/span&gt;&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zeyq7EuVL3tf" title="Dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0746"&gt;-&lt;/span&gt;&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Expected term (years)&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zQuqEZf1Nqbg" title="Expected term (in years)"&gt;5&lt;/span&gt;
    - &lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zuyt1YNTp7zd" title="Expected term (in years)"&gt;6&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zd2w1SirpE4l" title="Expected term (in years)"&gt;5&lt;/span&gt;
    - &lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zEq8Wb9zgTbh" title="Expected term (in years)"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Weighted-average fair value&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pp2p0_uUSDPShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zSTQ5fbDjrb1" title="Weighted average fair value"&gt;1.24
    - &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pp2p0_uUSDPShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zVxJYCH0CCqe"&gt;1.27&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; vertical-align: middle"&gt;$&lt;/td&gt;
    &lt;td style="text-align: center; vertical-align: middle"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pp2p0_uUSDPShares_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUyqXX23Gjzl"&gt;3.62&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember654123531"
      decimals="INF"
      unitRef="Pure">1.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember654123531"
      decimals="INF"
      unitRef="Pure">1.6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2021-01-012021-03-31_us-gaap_EmployeeStockOptionMember654123812"
      decimals="INF"
      unitRef="Pure">0.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2021-01-012021-03-31_us-gaap_EmployeeStockOptionMember654123812"
      decimals="INF"
      unitRef="Pure">0.9</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember654123531"
      decimals="INF"
      unitRef="Pure">1.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2021-01-012021-03-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">1.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2021-01-012021-03-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">1.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-01-012021-03-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-01-012021-03-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember"
      decimals="2"
      unitRef="USDPShares">1.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember"
      decimals="2"
      unitRef="USDPShares">1.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-01-012021-03-31_us-gaap_EmployeeStockOptionMember654123812"
      decimals="2"
      unitRef="USDPShares">3.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_896_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zHoecFH9CL2f" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;A summary of stock option activity during the three months ended
March 31, 2022 is as follows (share amounts in thousands):&lt;/p&gt;

&lt;p id="xdx_8B1_z61dgi5nD0Y" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; display: none"&gt;Summary of Stock Option Activity&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle; width: 50%"/&gt;
    &lt;td style="vertical-align: middle; width: 1%"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; width: 10%"/&gt;
    &lt;td style="vertical-align: middle; width: 1%"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right; width: 1%"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center; width: 10%"/&gt;
    &lt;td style="vertical-align: middle; width: 1%"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center; width: 14%"&gt;Weighted-&lt;/td&gt;
    &lt;td style="vertical-align: middle; width: 1%"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right; width: 1%"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center; width: 10%"/&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle"/&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"&gt;Weighted-&lt;/td&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"&gt;Average&lt;/td&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"&gt;Total&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle"/&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"&gt;Average&lt;/td&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"&gt;Remaining&lt;/td&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"&gt;Aggregate&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"&gt;Stock&lt;/td&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"&gt;Exercise&lt;/td&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"&gt;Contractual&lt;/td&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="font-weight: bold; vertical-align: middle; text-align: center"&gt;Intrinsic&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: bottom; text-align: center"&gt;Options&lt;/td&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center"&gt;Price&lt;/td&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center"&gt;Life (in years)&lt;/td&gt;
    &lt;td style="vertical-align: middle"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center"&gt;Value&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Outstanding as of December 31, 2021&lt;/td&gt;
    &lt;td/&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pin3_uShares_c20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z8DRlDoteBmd" style="text-align: right" title="Outstanding as of December 31, 2020"&gt;7,306&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2p0_uUSDPShares_c20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNRFCa6nzHZd" style="text-align: right; border-top-color: Black; border-top-width: 1pt" title="Outstanding, beginning of period (USD per share)"&gt;2.60&lt;/td&gt;
    &lt;td/&gt;
    &lt;td style="text-align: right; border-top-color: Black; border-top-width: 1pt"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Granted&lt;/td&gt;
    &lt;td/&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pin3_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjcI84J2YaBi" style="text-align: right" title="Granted"&gt;3,000&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2p0_uUSDPShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ziUtgz9WNN99" style="text-align: right" title="Granted in period (USD per share)"&gt;1.47&lt;/td&gt;
    &lt;td/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;
    &lt;td/&gt;
    &lt;td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pin3_di_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUYz51vmAwA8" style="text-align: right" title="Exercised"&gt;(6)&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmPS2631gQh6" style="text-align: right" title="Exercised in period (USD per share)"&gt;1.06&lt;/td&gt;
    &lt;td/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td style="text-align: left"&gt;Cancelled&lt;/td&gt;
    &lt;td style="text-align: left"/&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pin3_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zR6cDFUfPZ4f" style="border-bottom: Black 1pt solid; text-align: right" title="Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0774"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_d0_uUSDPShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjgUGQ9a3OD9" style="text-align: right" title="Cancelled (USD per share)"&gt;-&lt;/td&gt;
    &lt;td/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Outstanding as of March 31, 2022&lt;/td&gt;
    &lt;td/&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pin3_uShares_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zuKMgdCfnJY4" style="border-bottom: Black 2pt double; text-align: right" title="Outstanding as of March 31, 2022"&gt;10,300&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pp2p0_uUSDPShares_c20220331_z3GPMX9yPIuc" style="border-bottom: Black 2pt double; text-align: right" title="Outstanding, end of period (USD per share)"&gt;2.27&lt;/td&gt;
    &lt;td/&gt;
    &lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zne43COO2mHl" style="text-align: right" title="Outstanding - weighted-average remaining contractual life (in years)"&gt;8.7&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_uUSD_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zFOhlb7tS3V3" style="border-bottom: Black 2pt double; text-align: right" title="Total aggregate intrinsic value shares outstanding"&gt;2,894&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Vested and expected to vest as of March 31, 2022&lt;/td&gt;
    &lt;td/&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pin3_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zabB3u9YKS3b" style="border-bottom: Black 2pt double; text-align: right" title="Vested and expected to vest, end of period (shares)"&gt;10,300&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pp2p0_d0_uUSDPShares_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1gIUcwcNnGd" style="border-bottom: Black 2pt double; text-align: right" title="Vested and expected to vest stock, end of period (USD per share)"&gt;2.27&lt;/td&gt;
    &lt;td/&gt;
    &lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zeDcxxvpPvAk" style="text-align: right" title="Weighted-average remaining contractual life (in years) of vested and expected to vest stock options"&gt;8.7&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_pn3n3_uUSD_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYGOnPpxeAr9" style="border-bottom: Black 2pt double; text-align: right" title="Total aggregate intrinsic value of vested or expected to vest stock options"&gt;2,894&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td&gt;Exercisable as of March 31, 2022&lt;/td&gt;
    &lt;td/&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pin3_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1xJhUmnf5ve" style="border-bottom: Black 2pt double; text-align: right" title="Exercisable, end of period (shares)"&gt;3,085&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pp2p0_d0_uUSDPShares_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zT2olXBumqNh" style="border-bottom: Black 2pt double; text-align: right" title="Exercisable, end of period (USD per share)"&gt;3.00&lt;/td&gt;
    &lt;td/&gt;
    &lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjVD2HF0t2Be" style="text-align: right" title="Weighted-average remaining contractual life (in years) of exercisable stock options"&gt;8.1&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_uUSD_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQC6bN4xDEB3" style="border-bottom: Black 2pt double; text-align: right" title="Total aggregate intrinsic value of exercisable stock options"&gt;2,894&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 9pt Sans-Serif; margin: 0"/&gt;

</us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">7306000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      unitRef="USDPShares">2.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember654123531"
      decimals="INF"
      unitRef="Shares">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember654123531"
      decimals="2"
      unitRef="USDPShares">1.47</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember654123531"
      decimals="INF"
      unitRef="Shares">6000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember654123531"
      decimals="INF"
      unitRef="USDPShares">1.06</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember654123531"
      decimals="INF"
      unitRef="USDPShares">-0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">10300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-03-31"
      decimals="2"
      unitRef="USDPShares">2.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember654123531">P8Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2022-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="-3"
      unitRef="USD">2894000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2022-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">10300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      unitRef="USDPShares">2.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember654123531">P8Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="AsOf2022-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="-3"
      unitRef="USD">2894000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">3085000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      unitRef="USDPShares">3.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember654123531">P8Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2022-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="-3"
      unitRef="USD">2894000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember654123531"
      decimals="-5"
      unitRef="USD">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="From2021-01-012021-03-31_us-gaap_EmployeeStockOptionMember654123812"
      decimals="0"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="AsOf2022-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      unitRef="USD">10200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember654123531">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward contextRef="From2021-01-012021-12-31_us-gaap_PerformanceSharesMember_custom_PSUtoExecutivesMember">During the year
ended December 31, 2021, the Company&#x2019;s Board of Directors awarded a performance stock unit award to the Company&#x2019;s Chief Executive
Officer for 2,400,000 shares of common stock, with a grant date fair value of $4.31 per unit. Vesting of this award was subject to the
Company achieving certain performance criteria established at the grant date and the individual fulfilling a service condition (continued
employment). As of December 31, 2021, all performance stock unit awards were unvested and three of the five performance conditions had
been satisfied. The Company recognized stock-based compensation related to this award of $4.9 million during the fourth quarter of 2021,
which was recorded in general and administrative expense. During the three months ended March 31, 2022, the Company and its Chief Executive
Officer entered into an agreement to cancel the performance stock unit award for no consideration. In connection with the cancellation
of the award, no replacement awards were granted or authorized. At the time of cancellation, the Company recognized the remaining compensation
expense of the three achieved milestones of $1.3 million. The two remaining milestones were not deemed probable of achievement at the
time of cancellation, and no compensation cost related to these milestones was recognized.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2021-01-012021-12-31_us-gaap_PerformanceSharesMember_custom_PSUtoExecutivesMember"
      decimals="0"
      unitRef="Shares">2400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-01-012021-12-31_us-gaap_PerformanceSharesMember_custom_PSUtoExecutivesMember"
      decimals="2"
      unitRef="USDPShares">4.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-12-31_us-gaap_PerformanceSharesMember_custom_PSUtoExecutivesMember"
      decimals="-5"
      unitRef="USD">4900000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-03-31_us-gaap_PerformanceSharesMember_custom_PSUtoExecutivesMember"
      decimals="-5"
      unitRef="USD">1300000</us-gaap:ShareBasedCompensation>
    <SEEL:SharebasedPaymentArrangementNonvestedAndCanceledAwardExcludingOptionCostNotYetRecognizedAmount
      contextRef="AsOf2022-03-31_us-gaap_PerformanceSharesMember_custom_PSUtoExecutivesMember"
      decimals="-5"
      unitRef="USD">0</SEEL:SharebasedPaymentArrangementNonvestedAndCanceledAwardExcludingOptionCostNotYetRecognizedAmount>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_89C_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zKedatNYpX1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table summarizes the total stock-based compensation
expense resulting from share-based awards recorded in the Company&#x2019;s condensed consolidated statements of operations (in thousands):&lt;/p&gt;

&lt;p id="xdx_8B8_zeKdjKdluhy2" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; display: none"&gt;Schedule of Stock-Based Compensation Expense&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle; background-color: white"/&gt;
    &lt;td style="vertical-align: middle; background-color: white"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td colspan="4" style="font-weight: bold; vertical-align: middle; text-align: center; background-color: white"&gt;Three Months Ended&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle; background-color: white"/&gt;
    &lt;td style="vertical-align: middle; background-color: white"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right"/&gt;
    &lt;td colspan="4" style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white"&gt;March
    31,&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: middle; background-color: white; width: 64%"/&gt;
    &lt;td style="vertical-align: middle; background-color: white; width: 2%"/&gt;
    &lt;td style="vertical-align: bottom; text-align: right; width: 2%"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; background-color: white; width: 14%"&gt;2022&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; background-color: white; width: 2%"/&gt;
    &lt;td style="vertical-align: middle; border-top-color: Black; border-top-width: 1pt; background-color: white; width: 2%"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; background-color: white; width: 14%"&gt;2021&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td style="background-color: white"&gt;Research and development&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20220101__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zXHbP0LPHD75" style="text-align: right; border-top-color: Black; border-top-width: 1pt" title="Stock-based compensation expense"&gt;229&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensation_pn3n3_c20210101__20210331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zumQzKkXYS4" style="text-align: right; border-top-color: Black; border-top-width: 1pt" title="Stock-based compensation expense"&gt;136&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td style="background-color: white"&gt;General and administrative&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensation_pn3n3_c20220101__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zrYJ3d2q7vEb" style="border-bottom: Black 1pt solid; text-align: right" title="Stock-based compensation expense"&gt;2,003&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensation_pn3n3_c20210101__20210331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zoTjvJL1STs" style="border-bottom: Black 1pt solid; text-align: right" title="Stock-based compensation expense"&gt;569&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: middle"&gt;
    &lt;td style="text-align: left; background-color: white"/&gt;
    &lt;td style="text-align: right; background-color: white"/&gt;
    &lt;td style="text-align: right; background-color: white"&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ShareBasedCompensation_pn3n3_c20220101__20220331_z581oqWEPrX7" style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 1pt; background-color: white" title="Stock-based compensation expense"&gt;2,232&lt;/td&gt;
    &lt;td style="text-align: right; background-color: white"/&gt;
    &lt;td style="text-align: right; background-color: white"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensation_pn3n3_c20210101__20210331_zkwVMYZ826Tj" style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 1pt" title="Stock-based compensation expense"&gt;705&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-03-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      unitRef="USD">229000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-03-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      unitRef="USD">136000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-03-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      unitRef="USD">2003000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-03-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      unitRef="USD">569000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-01to2022-03-31"
      decimals="-3"
      unitRef="USD">2232000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-03-31"
      decimals="-3"
      unitRef="USD">705000</us-gaap:ShareBasedCompensation>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_806_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_znk0rKaHgAr3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;12. Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt; &lt;span id="xdx_901_eus-gaap--LesseeOperatingLeaseDescription_c20220101__20220331__us-gaap--LeaseContractualTermAxis__custom--March2019LeaseMember_zriNh3bpV4uf"&gt;In March 2019, the Company entered into a nine-month
office space rental agreement for its headquarters in New York, New York expiring November 2019. In November 2019, the Company renewed
this rental agreement for an additional twelve-months for a base rent of approximately $9,000 per month. In November 2020, the Company
renewed this rental agreement for an additional twelve-months for a base rent of approximately $3,800 per month. In March 2021, the Company
was notified that the counterparty&#x2019;s right to occupy the space at 300 Park Avenue, New York, NY was terminated, and the Company
was required to vacate by March 26, 2021. The Company vacated the premises and has advised the counterparty that the counterparty is
in breach of this rental agreement and therefore, the Company has no further obligations thereunder.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_90A_eus-gaap--LesseeOperatingLeaseDescription_c20220101__20220331__us-gaap--LeaseContractualTermAxis__custom--March2021LeaseMember_ziUcNfJIbdQb" title="Operating lease description"&gt;In
March 2021, the Company entered into an eighteen-month office space rental agreement for its headquarters at 300 Park Avenue, New
York, NY, expiring July 2022. The rental agreement contains a base rent of approximately $4,000 per month. &lt;span id="xdx_90F_eus-gaap--LesseeOperatingLeaseOptionToExtend_c20220101__20220331__us-gaap--LeaseContractualTermAxis__custom--March2021LeaseMember_zWmTXmfaFl1g" title="Option to extend"&gt;This
agreement includes one or more renewal options.&lt;/span&gt; At March 31, 2022, the Company has right-of-use
assets of $&lt;span id="xdx_901_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20220331__us-gaap--LeaseContractualTermAxis__custom--March2021LeaseMember_zQC2hitgpqf" title="Operating lease right-of-use asset"&gt;26,000&lt;/span&gt; and a total lease liability for operating leases of $&lt;span id="xdx_90F_eus-gaap--OperatingLeaseLiability_iI_pp0p0_c20220331__us-gaap--LeaseContractualTermAxis__custom--March2021LeaseMember_ze3OVgtIekhd" title="Operating lease liabilities"&gt;&lt;span id="xdx_90D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20220331__us-gaap--LeaseContractualTermAxis__custom--March2021LeaseMember_zVlDaNdhQ1x9" title="Operating lease liabilities - current"&gt;26,000&lt;/span&gt;&lt;/span&gt;, of which all
is included in current lease liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span title="Operating lease description"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;Upon the commencement of the 300 Park Avenue,
New York, NY office space in March 2021, in exchange for the new operating lease liability, the Company recognized a right-of-use asset
of $&lt;span id="xdx_90D_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20210331__us-gaap--LeaseContractualTermAxis__custom--March2021LeaseMember_zTvUV6UY4vjc"&gt;74,000&lt;/span&gt;. As March 31, 2022, the weighted-average remaining lease term of the operating lease is &lt;span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_pp0p0_dtY_c20220331_zVN3OsRf62Xa"&gt;0.5&lt;/span&gt; years, and the weighted-average
discount rate is &lt;span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pp0p0_uPure_c20220331_zN4GUt3lI1R"&gt;8.0&lt;/span&gt;%.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"/&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_zXhLn9nS7Ama" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;At March 31, 2022, future minimum lease payments for operating
leases with non-cancelable terms of more than one year were as follows (in thousands):&lt;/p&gt;

&lt;p id="xdx_8BF_z1KRk18BYi8c" style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; display: none"&gt;Schedule of future minimum operating lease payments&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 79%"/&gt;
    &lt;td style="width: 2%"/&gt;
    &lt;td style="width: 2%"/&gt;
    &lt;td id="xdx_498_20220331_zXO3vxfsGvva" style="font-weight: bold; text-align: center; width: 17%"&gt;Operating&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td/&gt;
    &lt;td/&gt;
    &lt;td/&gt;
    &lt;td style="border-bottom: Black 0.5pt solid; font-weight: bold; text-align: center"&gt;Leases&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_maLOLLPz53j_zrpgG7zHWwA3" style="vertical-align: bottom"&gt;
    &lt;td&gt;Remaining Period Ended December 31, 2022&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;27&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_i01TI_pn3n3_mtLOLLPz53j_zQwz4jjjjnJc" style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: 10pt"&gt;Total&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="border-top: Black 0.5pt solid; text-align: right"&gt;27&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_i01NI_pn3n3_di_maOLLzeMS_zz6HdRwECwrl" style="vertical-align: bottom"&gt;
    &lt;td&gt;Less present value discount&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;(1)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_mtOLLzeMS_zuijHUAWEMd6" style="vertical-align: bottom"&gt;
    &lt;td&gt;Operating lease liabilities&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td style="border-top: Black 0.5pt solid; border-bottom: Black 2pt double; text-align: right"&gt;26&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 9pt Sans-Serif; margin: 0 5.85pt 0 5pt; text-align: left; color: Red"/&gt;

&lt;p id="xdx_8A6_zLVHyMAiaLE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;For each of the three months ended March 31, 2022 and 2021, rent expense
totaled &lt;span style="background-color: White"&gt;$&lt;span id="xdx_902_eus-gaap--OperatingLeaseExpense_pn5n6_c20210101__20210331_zTnyklpw4w2g"&gt;&lt;span id="xdx_90B_eus-gaap--OperatingLeaseExpense_pn5n6_c20220101__20220331_z8svIwns85J2"&gt;0.1&lt;/span&gt;
&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color: White"&gt;million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="background-color: White"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Contractual Commitments&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company has entered into long-term agreements with certain
manufacturers and suppliers that require it to make contractual payment to these organizations. The Company expects to enter into additional
collaborative research, contract research, manufacturing, and supplier agreements in the future, which may require up-front payments and
long-term commitments of cash.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Litigation&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;As of March 31, 2022, there was no material litigation against
or involving the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseDescription contextRef="From2022-01-012022-03-31_custom_March2019LeaseMember">In March 2019, the Company entered into a nine-month
office space rental agreement for its headquarters in New York, New York expiring November 2019. In November 2019, the Company renewed
this rental agreement for an additional twelve-months for a base rent of approximately $9,000 per month. In November 2020, the Company
renewed this rental agreement for an additional twelve-months for a base rent of approximately $3,800 per month. In March 2021, the Company
was notified that the counterparty&#x2019;s right to occupy the space at 300 Park Avenue, New York, NY was terminated, and the Company
was required to vacate by March 26, 2021. The Company vacated the premises and has advised the counterparty that the counterparty is
in breach of this rental agreement and therefore, the Company has no further obligations thereunder.</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:LesseeOperatingLeaseDescription contextRef="From2022-01-012022-03-31_custom_March2021LeaseMember">In
March 2021, the Company entered into an eighteen-month office space rental agreement for its headquarters at 300 Park Avenue, New
York, NY, expiring July 2022. The rental agreement contains a base rent of approximately $4,000 per month. This
agreement includes one or more renewal options. At March 31, 2022, the Company has right-of-use
assets of $26,000 and a total lease liability for operating leases of $26,000, of which all
is included in current lease liabilities.</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:LesseeOperatingLeaseOptionToExtend contextRef="From2022-01-012022-03-31_custom_March2021LeaseMember">This
agreement includes one or more renewal options.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2022-03-31_custom_March2021LeaseMember"
      decimals="0"
      unitRef="USD">26000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2022-03-31_custom_March2021LeaseMember"
      decimals="0"
      unitRef="USD">26000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2022-03-31_custom_March2021LeaseMember"
      decimals="0"
      unitRef="USD">26000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2021-03-31_custom_March2021LeaseMember"
      decimals="0"
      unitRef="USD">74000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2022-03-31">P0Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2022-03-31" decimals="0" unitRef="Pure">8.0</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_89B_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_zXhLn9nS7Ama" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;At March 31, 2022, future minimum lease payments for operating
leases with non-cancelable terms of more than one year were as follows (in thousands):&lt;/p&gt;

&lt;p id="xdx_8BF_z1KRk18BYi8c" style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; display: none"&gt;Schedule of future minimum operating lease payments&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 79%"/&gt;
    &lt;td style="width: 2%"/&gt;
    &lt;td style="width: 2%"/&gt;
    &lt;td id="xdx_498_20220331_zXO3vxfsGvva" style="font-weight: bold; text-align: center; width: 17%"&gt;Operating&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td/&gt;
    &lt;td/&gt;
    &lt;td/&gt;
    &lt;td style="border-bottom: Black 0.5pt solid; font-weight: bold; text-align: center"&gt;Leases&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_maLOLLPz53j_zrpgG7zHWwA3" style="vertical-align: bottom"&gt;
    &lt;td&gt;Remaining Period Ended December 31, 2022&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;27&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_i01TI_pn3n3_mtLOLLPz53j_zQwz4jjjjnJc" style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: 10pt"&gt;Total&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="border-top: Black 0.5pt solid; text-align: right"&gt;27&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_i01NI_pn3n3_di_maOLLzeMS_zz6HdRwECwrl" style="vertical-align: bottom"&gt;
    &lt;td&gt;Less present value discount&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;(1)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_mtOLLzeMS_zuijHUAWEMd6" style="vertical-align: bottom"&gt;
    &lt;td&gt;Operating lease liabilities&lt;/td&gt;
    &lt;td style="text-align: right"/&gt;
    &lt;td style="text-align: right"&gt;$&lt;/td&gt;
    &lt;td style="border-top: Black 0.5pt solid; border-bottom: Black 2pt double; text-align: right"&gt;26&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 9pt Sans-Serif; margin: 0 5.85pt 0 5pt; text-align: left; color: Red"/&gt;

</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">27000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">27000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">1000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">26000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2021-01-012021-03-31"
      decimals="-5"
      unitRef="USD">100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2022-01-01to2022-03-31"
      decimals="-5"
      unitRef="USD">100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_803_eus-gaap--SubsequentEventsTextBlock_zcuUSist3ril" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;13. Subsequent
Events&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_90F_eus-gaap--BusinessCombinationSeparatelyRecognizedTransactionsDescription_c20220401__20220429__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zT3AHb1H6LVe"&gt;On April 8, 2022,
Seelos Corporation (&#x201c;STI&#x201d;), a wholly-owned subsidiary of the Company, and Phoenixus AG f/k/a Vyera Pharmaceuticals AG (&#x201c;Vyera&#x201d;),
entered into an amendment (the &#x201c;Amendment&#x201d;) to the Asset Purchase Agreement by and between STI and Vyera, dated March 6, 2018
(as amended by a first amendment thereto entered into on May 18, 2018, a second amendment thereto entered into on December 31, 2018, a
third amendment thereto entered into on October 15, 2019 and a fourth amendment thereto entered into on February 15, 2021, the &#x201c;Vyera
Purchase Agreement&#x201d;). Pursuant to the Vyera Purchase Agreement, STI acquired the assets and liabilities of Vyera related to a product
candidate currently referred to as SLS-002 (intranasal ketamine) (the &#x201c;Vyera Assets&#x201d;) and agreed, among other things, to make
certain development and commercialization milestone payments and royalty payments related to the Vyera Assets (the &#x201c;Milestone and
Royalty Payment Obligations&#x201d;) and further agreed that in the event that the Company sold, directly or indirectly, all or substantially
all of the Vyera Assets to a third party, then the Company would pay Vyera an amount equal to 4% of the net proceeds actually received
by the Company as an upfront payment in such sale (the &#x201c;Change of Control Payment Obligation&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_902_eus-gaap--SubsequentEventDescription_c20220401__20220430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z2aZd5GJHmra"&gt;Pursuant
to the Vyera Purchase Agreement, as amended by the Amendment, STI agreed to (i) make a cash payment to Vyera in the aggregate amount
of $&lt;span id="xdx_90C_ecustom--CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement_pn5n6_c20220401__20220430__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zdTkXpwtEtlb"&gt;4.0&lt;/span&gt;
million on or before April 8, 2022; (ii) issue to Vyera on or before April 11, 2022 &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20220401__20220430__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zfEH9dWjQrk4"&gt;500,000&lt;/span&gt;
shares of the Company&#x2019;s common stock, (the &#x201c;Initial Shares&#x201d;); (iii) issue to Vyera on or before July 11, 2022 an
additional &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20220701__20220711__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zaysRv0Dcs62"&gt;500,000&lt;/span&gt;
shares of the Company&#x2019;s common stock (as adjusted for stock splits, stock dividends, combinations, recapitalizations and the
like) (the &#x201c;July 2022 Shares&#x201d;); and (iv) issue to Vyera on or before January 11, 2023 an additional number of shares of
the Company&#x2019;s common stock equal to $1.0 million divided by the volume weighted average closing price of the Company&#x2019;s
common stock for the ten consecutive trading days ending on the fifth trading day prior to the applicable date of issuance of the
shares of the Company&#x2019;s common stock (the &#x201c;January 2023 Shares&#x201d;, and together with the Cash Payment, the Initial
Shares and the July 2022 Shares, &#x201c;Final Payments&#x201d;). In consideration for the Final Payments, all of STI&#x2019;s
contingent payment obligations under the Vyera Purchase Agreement, including the Milestone and Royalty Payment Obligations and the
Change of Control Payment Obligation, as well as all commercialization covenants of STI under the Vyera Purchase Agreement, will
terminate in full upon the date that all of the Final Payments have been made.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company paid
the $&lt;span id="xdx_901_ecustom--CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement_pn5n6_c20220401__20220430__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z5kGY96KKRRh"&gt;4.0&lt;/span&gt; million cash payment and issued the &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20220401__20220430__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zDHHdb34L2Mg"&gt;500,000&lt;/span&gt; Initial Shares to Vyera in April 2022.&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsDescription contextRef="From2022-04-012022-04-29_us-gaap_SubsequentEventMember">On April 8, 2022,
Seelos Corporation (&#x201c;STI&#x201d;), a wholly-owned subsidiary of the Company, and Phoenixus AG f/k/a Vyera Pharmaceuticals AG (&#x201c;Vyera&#x201d;),
entered into an amendment (the &#x201c;Amendment&#x201d;) to the Asset Purchase Agreement by and between STI and Vyera, dated March 6, 2018
(as amended by a first amendment thereto entered into on May 18, 2018, a second amendment thereto entered into on December 31, 2018, a
third amendment thereto entered into on October 15, 2019 and a fourth amendment thereto entered into on February 15, 2021, the &#x201c;Vyera
Purchase Agreement&#x201d;). Pursuant to the Vyera Purchase Agreement, STI acquired the assets and liabilities of Vyera related to a product
candidate currently referred to as SLS-002 (intranasal ketamine) (the &#x201c;Vyera Assets&#x201d;) and agreed, among other things, to make
certain development and commercialization milestone payments and royalty payments related to the Vyera Assets (the &#x201c;Milestone and
Royalty Payment Obligations&#x201d;) and further agreed that in the event that the Company sold, directly or indirectly, all or substantially
all of the Vyera Assets to a third party, then the Company would pay Vyera an amount equal to 4% of the net proceeds actually received
by the Company as an upfront payment in such sale (the &#x201c;Change of Control Payment Obligation&#x201d;).</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsDescription>
    <us-gaap:SubsequentEventDescription contextRef="From2022-04-012022-04-30_us-gaap_SubsequentEventMember">Pursuant
to the Vyera Purchase Agreement, as amended by the Amendment, STI agreed to (i) make a cash payment to Vyera in the aggregate amount
of $4.0
million on or before April 8, 2022; (ii) issue to Vyera on or before April 11, 2022 500,000
shares of the Company&#x2019;s common stock, (the &#x201c;Initial Shares&#x201d;); (iii) issue to Vyera on or before July 11, 2022 an
additional 500,000
shares of the Company&#x2019;s common stock (as adjusted for stock splits, stock dividends, combinations, recapitalizations and the
like) (the &#x201c;July 2022 Shares&#x201d;); and (iv) issue to Vyera on or before January 11, 2023 an additional number of shares of
the Company&#x2019;s common stock equal to $1.0 million divided by the volume weighted average closing price of the Company&#x2019;s
common stock for the ten consecutive trading days ending on the fifth trading day prior to the applicable date of issuance of the
shares of the Company&#x2019;s common stock (the &#x201c;January 2023 Shares&#x201d;, and together with the Cash Payment, the Initial
Shares and the July 2022 Shares, &#x201c;Final Payments&#x201d;). In consideration for the Final Payments, all of STI&#x2019;s
contingent payment obligations under the Vyera Purchase Agreement, including the Milestone and Royalty Payment Obligations and the
Change of Control Payment Obligation, as well as all commercialization covenants of STI under the Vyera Purchase Agreement, will
terminate in full upon the date that all of the Final Payments have been made.</us-gaap:SubsequentEventDescription>
    <SEEL:CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement
      contextRef="From2022-04-012022-04-30_custom_AssetsfromVyeraPharmaceuticalsMember_us-gaap_SubsequentEventMember"
      decimals="-5"
      unitRef="USD">4000000.0</SEEL:CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-04-012022-04-30_custom_AssetsfromVyeraPharmaceuticalsMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Shares">500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-07-012022-07-11_custom_AssetsfromVyeraPharmaceuticalsMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Shares">500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <SEEL:CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement
      contextRef="From2022-04-012022-04-30_custom_AssetsfromVyeraPharmaceuticalsMember_us-gaap_SubsequentEventMember"
      decimals="-5"
      unitRef="USD">4000000.0</SEEL:CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-04-012022-04-30_custom_AssetsfromVyeraPharmaceuticalsMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Shares">500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>61
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M$AS6P%T23\%X($*2H<@AJ9!;$53W.ZX^^85!EO7 P4U\!SD( I@B99?[ _(
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M5I+ABC5DI?G3L\Q?SR^AKH.Y+H6L'@HUKB^2)O-]#C(@$FP%L85^60+<LTJ
M%[,H(G=Y!K>SRKZLT:E9AKJE\;MG&?\HYG*IOZ[?04&MP&GCE"65N:L1K%N-
MNJ7ONV>M%KP5AUQA0+A,+=#!-LU9:X6/1NF932WRF"NHF(DVM*H-I9WRM5'6
MVYYK*)!MNVMW.F[/6A]B60<;;;I7S/YC1GP]3=WNN157BSW.@=G9L\KFVPU2
M6(=#IV8DX@L(M:\Z\'RYW7/<GBB1FFV[N5!*Q.9PQ5G I6X ]Q="J/V)?D"Q
M\]O_#U!+ P04    " #\@:I4Q5D6MC,%   *%   &    'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;*5846_;-A#^*X17%"U@QR0E67*;&&@=#!NP84'3KL^,
M1$=$)5$E*:?=K]]1=B5;I%0'?8A#VG>G[XZ\^^YT_235%YUS;M"WLJCTS2PW
MIGZS7.HTYR735[+F%?RRDZID!K;J<:EKQ5G6*I7%DF*\6I9,5+/-=?O=G=I<
MR\84HN)W"NFF+)GZ_IX7\NEF1F8_OO@@'G-COUANKFOVR.^Y^53?*=@M.RN9
M*'FEA:R0XKN;V3OR9DLCJ]!*_"OXDSY9(^O*@Y1?[.;/[&:&+2)>\-18$PS^
M[?F6%X6U!#B^'HW.NF=:Q=/U#^N_M\Z#,P],\ZTL/HO,Y#>S9(8ROF--83[(
MIS_XT:$68"H+W7ZBIZ,LGJ&TT4:61V5 4(KJ\)]].P;B1(&$(PKTJ$ O50B.
M"D'KZ %9Z]8M,VQSK>034E8:K-E%&YM6&[P1E3W&>Z/@5P%Z9K.550:'PC,$
M*RT+D3$#F_>L8%7*T;TUK-$"?;J_1:]>O$8OD*C0QUPVFE69OEX:P& M+=/C
M\]X?GD='GO<W4U<H('-$,:4>]>VT^BU/.W5RKKX$SSOW:><^;>T%8^XW2O'*
M(*8U^#EA,.@,!JW!<,P@T[DO*@>M5:ME4VN_69$XA@CL3YUWI>(D#L).Z@Q2
MV$$*)R'=*5XSD2'^K;8GK1&<')(FYPHNV+C[!]P'T]$)HB191P/8KE 8T]B/
M.NI01Y.H/TK#B@L 1LZS8[Q:Q0.$KE02A"OBA[CJ(*XF(?Y3<\6,J!Y1P:&2
M(&5+QD+N%@UL6L0^P"L'"ET-T+HBP=H/->Z@QA=$<SR*L2^*ZV" RY5*@@AC
M/[2D@Y9<E(*%8 ^B$$;PJ3Q<=U;7DPZ_2U/95%"Z:O:=/13<Y_3:/0E"AS?'
M%2*G@3D#1W!?=?'/X*F&]SGI+:38O091N![@\TG%-!D!>$(+9!+@7R(]%(N)
M^$V;L W(&UVSE-_,H,/07.WY;(.\-9^X)S%VK4A?V@F==.$^E\HL#%<EJF%E
MFP:Y0ZFL]AQVX!.JI.D]G"-FT(X)A?:L:/P.4[?0T2 9GH@K17 PYDY/+&2:
M66ZY$GMFFYXN5;Y[04Z:><ZI!*X?)!XA(]*S$9FFH\],*7:>[Y>$WN48LL;#
MR'N(B(X![HF(3#/1L,Q/1]]E&J>\>V2"L83MN8A,D]$Y7XX6TR-*EV$()H$3
M3U<LH<D(L9.>B\@T&6U_)05=#B+AV@VQ1RQ.UF-)V',522Z(\L^BF[AW(,*1
M@]$C9IO"$8P]\Y%IZMO*LA0&1BUS:/6@XMG;RZL4\*)7-N*(T-=>Y).6GU,[
M?MW0>3_?,RO%D^W$O9'IEUP6&5?ZY6\))?%;Q+\V3KJ>F^]YD4[SH@TN$(FV
M3YFC%_@*8P+7]WAC82X)\1SC]@_IG"G;;C<&F$C\Q[,Y>OD;6>&WEW\B@J-Y
MM,;S. [:PVSW8#\,(R2TMCU$V\XW1AM8V"K%M.6YYS[I\ GC69IW\UEK&D8N
M7C[ L/!C[)K#^*YKWL[?A;<(4I?/ ??@^O]$Z/Q\3N:Y:=)_EV7"4CUDJ1UZ
M%J):I*P6D+5>H"Y50^,1A\/&UR-'UDDXUF;1GM3I-*E#']B43='.W!G?B51X
M9P;J4O&"1!$E9 C4)Q@22D8J'^UIFT[3]J'RZ0NSZPC;P\?1*ABVV!ZQ* [H
M2)-->^*FEXR0)\6ZO<_/="%R1W+/9.01\XU&RY,7-?8M&:3;HZ@T-!8[T,-7
M,9A1AQ=/AXV1=?ONYD$:(\MVF7,&T*T _+Z34,V/&_LZJ'O]M_D?4$L#!!0
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M7!;*BA?BUT3H\?D=S6.1=A(#<<5HFL28BYL5%Q^B'C@#= WNMCC?$ :27/Q
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M/+#&M4Y\87=I''<<Z)*:]0%L" K[&>HCD_Q(3;?F+UV5FLOE<=QQHW>UZPL
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MV$XZ-WIQ.[M&9W?&.9-;>Y6ND#WKEG>N]6A]77]O+ZE;XP_X9E%>NC=JRO\
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M<>U0+;TMZ:/3?JC=,W%>./!^B* O%8J<CA3M+$1(PC_ ]$YJ0T]H7%UQ9 [
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M?N>OP*@S'6?F))U.DNTHMF=DQ6G3-K%KV6UG.GW D;@[Q"3!$*3.ZJ_OM[L
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MWF>2D%+IX0600\3&Y^. K)='OI.+JH.Z'Y^OQRYS;1#S-4^O-W"3^HNN>V+
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M]F?3 =/517+U8-7*7=[.E;4J=\M4<#B#-N#WA8)[Z@<2T-[F7_\?4$L#!!0
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MG.YC5DL<"\]"VX[VN&B5W+T/?^:Y5;SM!J>:F^D'D[,7U?U4%ZK%K@W&EFJ
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M2PVXI#0 G\\M$%N\H0VJ'ZJ]^1]02P,$%     @ _(&J5/V.!EI1!@  \A
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M:6'BKAT%>JN"^V&3IE,<;E/C6(V#M-1<KL#F2!^-"$55;G3E!BI6DK?5 FZ
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MPMV-=S-H"]XM %4#UW)/S$L,6[RW&%&(;AC$\D*#E)XG7V*A809M0_CY0-7
M=;<A7=<B[0BW/J(0W=J(Y:4*T:V%7&"I,C&#=F!3]RO2=86!K4PQ1#<08EY.
MM)EBJ)9\:EY)G)IBS&YM=F LKQ6H;CG4_,BH_9:6%G5J%O6.FUK'CXOJ]A?J
MS<B)@9QJL:?FU8&54NXT@5#=-:CM;<C2/N1%-B)K=A!KMB'JS$YO0U"MQ+3Y
M7N,YG+68'JC6<FIYF4"U[-)++!-RT,K6^-%N18W1\6Z%6WHK)'WIYY&)E1\E
M(.!+Y>5=]Q73XO >S>% QIOL19%9+&4<9A_7G"VX2 W4[\LXEJ\'Z;LGQ=M,
MX_\ 4$L#!!0    ( /R!JE2Q5G6J[P0  ",@   9    >&PO=V]R:W-H965T
M<R]S:&5E=#,R+GAM;-5:;6_J-A3^*Q;:I$VB)':@T J0RLO5*I6M:G>[#U?[
M8,@!K"8QLPT4Z?[XV4D:TRXD*:L&ZX<V,7Z.GW-\3IX3W.Z6BV>Y!%#H)0PB
MV:LME5I=.XZ<+2&DLL%7$.E/YER$5.E;L7#D2@#U8U 8.,1U+YV0LJC6[\9C
M]Z+?Y6L5L CN!9+K,*1B-X" ;WLU7'L=>&"+I3(#3K^[H@MX!/5U=2_TG9-9
M\5D(D60\0@+FO=H-OAY[;0.(9SPQV,J]:V1<F7+^;&YN_5[--8P@@)DR)JC^
MLX$A!(&QI'G\E1JM96L:X/[UJ_4OL?/:F2F5,.3!'\Q7RUZM4T,^S.DZ4 ]\
M^PND#K6,O1D/9/P;;=.Y;@W-UE+Q, 5K!B&+DK_T)0W$'H"T#@!("B#O +AY
M ."E .\]X/( H)D"FE57:*6 V'4G\3T.W(@JVN\*OD7"S-;6S$4<_1BMX\4B
MDRB/2NA/F<:I_F.2((C/T1?*!'JBP1K0!*A<"] )H20:\F@#0K%I .A7KD#&
MDVB\SS=29]C*7$KTTP@498'\&5V@'Y"#Y)(*D%U':9IF,6>64AHDE,@!2AZ:
M\$@M)1I'/O@Y^%$Q'I," XZ.3Q8D\AJD 2FT.*&B@3Q<1\0E)(?0L#H<Y_E3
M#!_!K'#U<74X+@B&EV6,%]MK'K!WQZ/%Q>\@0C2"J4+?)A!.0?Q98+F966[&
MEKT#EFT"UM$=HU,6,,5TNJ79Z".=< \P6PO!H@4:4,ED'7V-^%2"V%"3GK?1
M:JW,'![--#K)T6]W>AUTJR"412Q;&<M6H?^/)JTO].J:T)"'^HDMTUH0@D:+
MN&C0=(?VY]W373Q\LZ7"K^]7VEX!U='X!<2,24#W@LT@KW(2:IV8FM& 3=]M
M=)I=9Y/CT&7FT.4Q&XJ^H_T-B4.K.=[!!@+D5=GW=D:@?<;[WLE8=DZW[RNM
MFWK^B&V8#Y&/'JC*V_]1(4735%S+%9U!KZ:[!A,=J/51WB/CW]MY$\.K+(97
M)X^AR>2\TBEF1M .J)"H@\)$.[2*^'27)U_C8DM>8JD@6MBUXNP>69H3%K%P
M'58I0[S7"^ S+D1,+$]RMH_@<<IM_QF,&^T#SV!L514?):MFJ^E+Y:VV4HO/
M66NQ%5M\OFH[QO^46]RX:AW8:JNWN%AP<[E:=^KHMU42S H;;C46G[/(8JNR
M^/0R^\0#;5,'8'=(: <E+#'V&J[[8Y''5A/QZ46QK+$8%'.LWED,/\'0VW<T
M*Y:D6"P_6E8?4U%B592<LXH2JZ+DA"I:THR54&OE]5#IJ_81R+<!LI),BB7Y
MF(2JKM7$:C4Y9ZTF5JO)";6Z+*&*J5T6)-01R+<!LL)//E?X=4)]_-L68EL"
M<LXM ;$M 3E92_# Y#/Z(L"XHD +DCJHD"4D2;-5TA$0VQ&0TW<$%7J@$I;8
M;;GZI\1KS^JW]^GZ_2GOQYY5=N^<E=VSRNZ=3-FK%\RXA.15:>;L?2-=7:A/
M5R_C$I;ZG:%*O=BVP&O^A_52O7'Q;$/@M<ZY7JPN>]5U^83U4DSRJDQ?/"O\
M7OM_42_%+#%N%M6+LW?H&8)8Q*?-$LWX.E+):58VFIUHW\3GN._&!_AZB'/&
M1_AZG)Q76_/)\?F$B@6+) I@KI=R&VU=!B(YD4YN%%_%1ZY3KA0/X\LE4!^$
MF: _GW.N7F_, MG_!?3_!E!+ P04    " #\@:I4 ]ZW(I #  "K"@  &0
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M]@7=!*H<C<J-D;F;+I;2T*SBE@E-DZBL ;U?2VF.&_N!:CX=_PU02P,$%
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MV4O5@CGFC&J'Z0O<8B17@O_!&'XH)C1S]T[#PQ7AX-)@IA\;>'1K'EW'HWN
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M"&.17<IE#XIOS%W* U=01)CFFM& "3T WB\YK%#^H!T45Z.37U!+ P04
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MIP,\>C6/GN/1^Y]YM&"*.E0\M[-=T3A\[-]9@P)"F0C!ES(D+3 )6A8YR]9
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MH[RT7B194DF.MI1Q:>^!'5U-QY#0P9DTP'+R^[*,VBVM4Q<!S,8B*D)C:=M
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M&"P$DDU58?%R!Y1OIX[OO'YX(.M2F0]N.JGQ&I:@'NN%T#.W8\E)!4P2SI"
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MKVL>!@6-?01IU>LF=E'/E3'C:A&'RCPT1<4SHBR4C$C @LULV%4LKP2)GB9
M,9XYOQ3N%KQARA>BXB9X1^ A[A/P$'ARGT0Y^/@-#>\17 ,0-FE4T]6..J-4
M)\6F,3$CP.A<"Q6![F4VFZ+J(!CA01;4"#7:7"W<L7?XW!7_)HHPW*+AI:Y2
MZZ<6/,E54X\5)!WF*Y2PX!!;$*# 0#H+L>/O/)[5.QE]W6Y1CE>&;6E5VMVZ
MJ_H5S9F&5'L]5+T.6TT0L$^$[D)6@1 (Y9JC)!($B\ Q:56VFD;.<8BA2B%
MML8&"$BHRYM7<R"W>W9S)69&L+ICM^Q"]@I(59O9G3Q+0*K:QN[9$P:DRSW8
M/L>LXLG>65:V@2H9<@L<#!0J@.JVUNIFE=H@E=QG(#R.XQ'P9P(<+B&Z!X-/
M4HGBW]'W@2U7LM;XV:_@]O8TJYZI)E% ,4./FECKJ$GNG2*1(VL]SKQ6PUIJ
MSN3:...@^-O1395]9TBN/9I,"E-KGPS5YC-60[H#8_C2K+B'MC^9&)X=V_.U
M,0RV_(#EBF#*;?O*S]K7N/.JL8;7/8BX39.9$(%4M8$Q>"=[:+T_XFP-WO&V
MAF-.WNO$5%U$K[N+:&Y_ET^3-,!< ]1B)RT*W]"@Q9V<U6G1ER?<+:K=LTZJ
MJPZCYSWO589+O<&PQM+M0USO7U<_0M7#]![7P\0#,#I!ZR4<?YOKW;RLZB"O
MNPXR-8#XQ6Y5#MM*Q_85$,_KI*,JA+SNVQM/4WAY55WD/<N-#:\*U=Y3WMEX
MMP?;9\,3NOJZUL]?VFC>!W!VQB?K9RYMW-SH6QO&+C<ZSFS=W6#[[F[L.WC+
MU0S\N-BP?D&C/6KN"YJ6B5"/DFQ0>OK/#MVC1\P:B=V/O7YAO7"]8L-^ER]T
MB V@W,'.6^-V!-Z?X#KO+VY"--GLT496CYL0WA$[&P^)MBKZMI6_]6C</GGY
M+0<[U"2XM(&UW46KYBZL,7>I26K)@Z<8NUCUUD)SXH+/S9/MGKBX)Z.?G;A8
M/28NM43P!.E7]6.#I:;Q%!QJ-F15*U*&/[*'8_A)8L#; -3;DU5S;S1BGMG<
M>TQ_QMDQY;BK^*/S;PML4ZQU?EOK37#LW'S/0_1\L#Z %S,LT\P<B[)G2/1@
M'=(<H+N?0YY#/1,)N60\B_) S76,% C7V99IU@0)+%W!V3CH%Y;\L#'X1ZZL
M7LQ%BI0H&4WSK'1F8.!%D8$=%/%0(IOQ=9@!>R*!GR73*%QP-3)#5X/@%OA:
M6"P":N< M7FJ'+W2;2(XQ1M'.6H+-HETZ^<(6:+D66.YS?(X0EP;'MZKQEC-
M;- A!??895!3<@2D#!CL;E%U79!CL)2TBXH<PZV873_5#8%Z^:=:?M;C56I/
MRX\]JN5GM3=$-B(E=U0U_:BY1Z?3K9)UE(-Y,J_LC)RPJZK;HQH*2Q[-D:1M
MRUSQ0)3Z7W;I9=$_,QE2!0P(QV9SR%1>JGI.V&<M,'?0Y@Z*)DNI"CJKL%16
M$;.+V;<XV40B6)1-&<QQB@YE2S7+6JM9*K2#VF6IVKZ-VLX:."/;&SIEVQ/.
MNKO0JT5(E=G0VC+BTC$35AA&N2MYPE(KFG&8*N+QF6-/G/HMP>L0Z;E5$C+#
M.HUQ)+!&SO5-T!V!T=C5]  -KE@Y.(*TKNO*0ANY$*XPSJU+ZD %S!JUV]F2
MT6?;2@NM[KZ<=NB95@B\)"/F<T%_*:6U;JBTKK.4KGI57O>=R"IC&3^B%^95
MK2KO6:XX^E4OP'_**X[O]F S>V'N>&^-H(9V+>TPJXQ4S]$.ZU'HF;95G,A"
M&=]>R"KU['8PS],NLW:VRU1^9[O^Q'9PCH)%06?#K.V0J,A4A.^O#6JW0&U_
M-+1'WJ1'UJ_#5EO:/RZF>$52WSR?"U7/V7!4][Q6/:FO*>%D?Z$:UUSZ=DO6
MN(R(*FCQ5NU[9N6#DZ#R::G0'0,K2Q:"DKMRDE%S1Z"JZM@'=U7JV;FS/.BM
MU-8_K&=W-8%5DW9T9OMCOT==:_5J^OI@#MY@_(\JTHE1D6Y[AHE93ZL;(-W2
M(1M3XBDN7E="JAE@90P>)" CO[O M;;:S:RW]*D4>QH=MJTB*#>/U7L3E5K\
M9+K*JG35>HIT%:@<=V6K2S +E=G7!:WTHM;&V/KP \&6_K;IG*I\5SPZX7U9
MWEIHJJK>U<B"4P%*'Q?96'' %P//'H_'14E14_\O!8^KCEHJ[L,DE\ N&G,W
MKB9IW#MIP5JE<!%\@2/[]CL,9H):):1-QAISFNZ\WVJ564%4(P(-?'LT&OQ$
M%;"U0:,B )_:.UGOS-5WG60WIY2?V %GD21K8H37I>Q+$V@I $J,QGFK]+X1
MVEJ?-[-YR\SF*Z/L2N;]:A3E=X^BOA@E[KS77,QOF3#YHXYIA%]-F/SN"9.Z
MFW&CF*F]X"W=][5+3AKWTAH$5\ZYE>SMF=)@//3=X0ZBC;\??LQ,J75K?XMC
M35:=&E\YL!+I@K[B @T+PKGZ6^;R:?DU&A?TY1&-YV_=E^_<EN?7[LOWZDLR
M*O3J.SL^\72!%X4B,8>MG),QL"A57X.AWF3)FK[P8)ID6;*BETL!<2?%!?#Y
M/ &%U6]P@_++2,[_!U!+ P04    " #\@:I4<6PJWJH#   (#P  &0   'AL
M+W=O<FMS:&5E=',O<VAE970T,2YX;6RU5]MNVS@0_96!T(<&2*.;[3B!;2"W
MHEELT*#!;A^*/M#2R"8JD2Y)V0FP'[]#29;<PJ$O15XD4N+,G#,<\F!&*ZE^
MZ#FB@><B%WKLS8U97/J^3N98,'TF%RCH3R95P0Q-U<S7"X4LK8R*W(^"8. 7
MC MO,JJ^/:K)2)8FYP(?%>BR*)AZN<9<KL9>Z*T_?.&SN;$?_,EHP6;XA.:?
MQ:.BF=]Z27F!0G,I0&$V]J["R^MP: VJ%?]R7.F-,5@J4RE_V,E].O8"BPAS
M3(QUP>BUQ!O,<^N)</QLG'IM3&NX.5Y[_UB1)S)3IO%&YE]Y:N9C;^A!BADK
M<_-%KCYA0ZAO_24RU]435LW:P(.DU$86C3$A*+BHW^RY2<2&0?R:0=081!7N
M.E"%\I89-ADIN0)E5Y,W.ZBH5M8$C@N[*T]&T5].=F;R5.\&R R^,J68,'!E
M$\7-"[R_1<-XKD_@0_OS%A5?,IM)^,@%$PEG.=P+;51)>V4T?'O 8HKJ^\@W
M!,\&\9,&RG4-)7H%2@P/4IBYACN18OJKO4^T6F[1FMMUY'3XP-09Q.$I1$$4
MO0,?])PIU/73X3]N<Q=7_N-7_'_.,HW&<#&#*TTC(O\W+8%[@X7^[@C0:P/T
MJ@"]UP*41ALF4AN!:;M'MYA4Z5W3"N$_V,:G3D_MO5]YM\=S.8D&<3\(@I&_
MW *KW\+J_R&LX!16U7G ] -;HJ+S#?B,*N$:8:%X@O">"RAU"@NRJAB<$)5N
MD[;1J5$--^CTSJ*+[5P&+9>!DTM3U\3B*%(*[<TW@X0J5]$-4])IR'E6TWM!
MIO3)-B9N3%%M"3THZ@,1]2!E+ZZ2/6_IGCM=WVM=8NHL&J<#*Q*7>L$2''ND
M AK5$KT).) -6V3#/9!1BIN+YK=RV54;3N>'H[YH45\X4=\U*-TI=?HX'%P8
M=)=[L!^\T]_S2?6]6I?^KMRZ@QR!?T.<0B?^&Q(8$NP=Z74[.0)?U.&+]L/W
M9_EU!CD"?R=@87S@34Z:F<Q;T72G/3Y,7L).]L)#=>^ODG0U#FK->Q-Q:2#M
MIRYA)Y6A6RL=^K*+TY':L@/06ERBM;B$T2YQ"3LQ#?=4TV8_V#3'(PIK<&!A
M=>H7NN7OKH/U-D5T?D@1==(8NK71D=:W*B(WH$.*R-]H3@I4LZH%TP2H%*;N
M4]JO;9MW53<WW?*Z1Z0:FG&A(<>,3(.S<RH15;==]<3(1=7J3*6AQJD:SJE5
M1647T/],2K.>V !M\SOY'U!+ P04    " #\@:I4MQEGH$((  !S)0  &0
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M&TCS -Y?"*%?+LP+JO/@\']02P,$%     @ _(&J5)ZMH:N6!   D1(  !D
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M511+; Y2P7'+;E(.QS".^[>_G 2!]P.UQZ?TW?_A<,CN%S)>#%9%?B<3"$R
MIR2(5*KB,!#:1C8#XN19GKVP3Q1-GM<Q#K%=%C(NC:!5UGJ@FY*QH*7^5F72
MV(_6Q,"T60$PCJ5V0(%P4(WJ=43C;HV*XR@V!U?AL[G(P'YI^L#NH"'+[T3!
M.%O1 D.%<@BD,@==JX(]"%[H01<<-41X))?5<E"B+:%Q*3+3:%;D2S). L;'
MGVB^$7J+-99EC2G+!0?=((*21*+H/&59A>NIB3<%<"U-&:\ IX&R,8D\%=B#
M#)A5^&0 HN*LI@NT7N2%_"^T0&<UCJH@/+3OK"Q@/@ 9%; $YJ,A9DSP>$'J
M8)1#2,42PJ;=3!^J9! (.//K<_0-.#VM\,GA1NM3;8(MY;0:=D92%M03'T$O
M9K1*A5*ZUW-^R**_DLF[1H-/*'*>F2!!Q4V8 4F"!=%(R]FL KN]2&1:83C
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M>]<*6]MZ8SA=]88$*R>N4DIRF=38C,N"W2$:J@WGP]Z22!53G%)R9GV+@=A
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M7V(#^'V6YV7]!2=H7@,_^S]02P,$%     @ _(&J5*^'Q.1C @  @04  !D
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ME%T>1;J'H5]@Z/\H!BH*/Y62JJ@*3?\DOQVNZ@Z.8KXJ,%^=B#E/JL^V&6(
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MV4?3K5":!30_%T)O!\9 <6<V_@]02P,$%     @ _(&J5,GS\(L@!P  (Q,
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MVWM:Z[(YY+/N?^OT$U!+ 0(4 Q0    ( /R!JE0'04UB@0   +$    0
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M965T,RYX;6Q02P$"% ,4    " #\@:I4S6$$7)P#  "F"P  &
M    @($.%@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @
M_(&J5#C+"JZ\ @  >@<  !@              ("!X!D  'AL+W=O<FMS:&5E
M=',O<VAE970U+GAM;%!+ 0(4 Q0    ( /R!JE28*H_H(@8   4>   8
M          " @=(<  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M    " #\@:I45#$D/R$&  #H&   &               @($J(P  >&PO=V]R
M:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ _(&J5(O7EQ=D!   IPD
M !@              ("!@2D  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+
M 0(4 Q0    ( /R!JE0NXE:3_0@  /D5   8              " @1LN  !X
M;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " #\@:I4!HH>YYP/
M  "S*@  &0              @(%.-P  >&PO=V]R:W-H965T<R]S:&5E=#$P
M+GAM;%!+ 0(4 Q0    ( /R!JE0\-6*K0P@  -D7   9              "
M@2%'  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ _(&J
M5":$D&NJ @  'P8  !D              ("!FT\  'AL+W=O<FMS:&5E=',O
M<VAE970Q,BYX;6Q02P$"% ,4    " #\@:I4#OJ[DC8#  !3!P  &0
M        @(%\4@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0
M   ( /R!JE2<R3(K\P0  +(*   9              " @>E5  !X;"]W;W)K
M<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ _(&J5+D =IVN @  HP4
M !D              ("!$UL  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q0
M2P$"% ,4    " #\@:I4\;"=[ X/  "T-@  &0              @('X70
M>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( /R!JE3]C@9:
M408  /(0   9              " @3UM  !X;"]W;W)K<VAE971S+W-H965T
M,3<N>&UL4$L! A0#%     @ _(&J5'WPU/7B"@  -QL  !D
M ("!Q7,  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " #\
M@:I44#8,!8L%  "3#0  &0              @('>?@  >&PO=V]R:W-H965T
M<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( /R!JE1M'JCBI00  *(*   9
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M970R-"YX;6Q02P$"% ,4    " #\@:I4X;&N*;@"  "D!0  &0
M    @($%I@  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (
M /R!JE0<&TT9O@(   X&   9              " @?2H  !X;"]W;W)K<VAE
M971S+W-H965T,C8N>&UL4$L! A0#%     @ _(&J5#/H+TVE!   *0L  !D
M             ("!Z:L  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"
M% ,4    " #\@:I4W[,>JZ8"  #C!0  &0              @('%L   >&PO
M=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( /R!JE0J4+%R2 0
M *(/   9              " @:*S  !X;"]W;W)K<VAE971S+W-H965T,CDN
M>&UL4$L! A0#%     @ _(&J5-K=;R)# P  =PP  !D              ("!
M(;@  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " #\@:I4
MR-<1NF %  #9)   &0              @(&;NP  >&PO=V]R:W-H965T<R]S
M:&5E=#,Q+GAM;%!+ 0(4 Q0    ( /R!JE2Q5G6J[P0  ",@   9
M      " @3+!  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%
M  @ _(&J5 />MR*0 P  JPH  !D              ("!6,8  'AL+W=O<FMS
M:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " #\@:I4!/@= !T$  !0$@
M&0              @($?R@  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+
M 0(4 Q0    ( /R!JE3%-":KZ (  *D'   9              " @7/.  !X
M;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ _(&J5#@,E=Z2
M @  F 8  !D              ("!DM$  'AL+W=O<FMS:&5E=',O<VAE970S
M-BYX;6Q02P$"% ,4    " #\@:I4'7 9>C$%   F%0  &0
M@(%;U   >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( /R!
MJE2PWDT.:@0   X+   9              " @</9  !X;"]W;W)K<VAE971S
M+W-H965T,S@N>&UL4$L! A0#%     @ _(&J5'^2TH+4 @  UP<  !D
M         ("!9-X  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4
M    " #\@:I4>UEL\700  "81   &0              @(%OX0  >&PO=V]R
M:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( /R!JE1Q;"K>J@,   @/
M   9              " @1KR  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL
M4$L! A0#%     @ _(&J5+<99Z!""   <R4  !D              ("!^_4
M 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " #\@:I4#U)3
M$)\#   ;#@  &0              @(%T_@  >&PO=V]R:W-H965T<R]S:&5E
M=#0S+GAM;%!+ 0(4 Q0    ( /R!JE2>K:&KE@0  )$2   9
M  " @4H" 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @
M_(&J5''KS?_@ @  M0@  !D              ("!%P<! 'AL+W=O<FMS:&5E
M=',O<VAE970T-2YX;6Q02P$"% ,4    " #\@:I4 >P9U#@.   2/@  &0
M            @($N"@$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4
M Q0    ( /R!JE2OA\3D8P(  ($%   9              " @9T8 0!X;"]W
M;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ _(&J5.Q+LE%U!0
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M96QS+RYR96QS4$L! A0#%     @ _(&J5%,>([)P!   #"$   \
M     ( !9BP! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( /R!JE2.83CZ
MO0$  'H=   :              "  0,Q 0!X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    ( /R!JE2<*],/O0$  '<=   3
M  "  ?@R 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     Y #D A@\  .8T
$ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>164</ContextCount>
  <ElementCount>235</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>48</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/BalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLossParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - 1. Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/OrganizationAndDescriptionOfBusiness</Role>
      <ShortName>1. Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - 2. Liquidity and Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/LiquidityAndGoingConcern</Role>
      <ShortName>2. Liquidity and Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - 3. Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/SignificantAccountingPolicies</Role>
      <ShortName>3. Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - 4. Fair Value Measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/FairValueMeasurement</Role>
      <ShortName>4. Fair Value Measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - 5. Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/PrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>5. Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - 6. Common Stock Offerings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/CommonStockOfferings</Role>
      <ShortName>6. Common Stock Offerings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - 7. License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/LicenseAgreements</Role>
      <ShortName>7. License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - 8. Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/AccruedExpenses</Role>
      <ShortName>8. Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - 9. Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/Debt</Role>
      <ShortName>9. Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - 10. Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/StockholdersEquity</Role>
      <ShortName>10. Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - 11. Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/Stock-basedCompensation</Role>
      <ShortName>11. Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - 12. Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/CommitmentsAndContingencies</Role>
      <ShortName>12. Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - 13. Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/SubsequentEvents</Role>
      <ShortName>13. Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - 3. Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>3. Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://seelostx.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - 3. Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>3. Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://seelostx.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - 4. Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/FairValueMeasurementTables</Role>
      <ShortName>4. Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://seelostx.com/role/FairValueMeasurement</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - 5. Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/PrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>5. Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://seelostx.com/role/PrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - 8. Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/AccruedExpensesTables</Role>
      <ShortName>8. Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://seelostx.com/role/AccruedExpenses</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - 10. Stockholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/StockholdersEquityTables</Role>
      <ShortName>10. Stockholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://seelostx.com/role/StockholdersEquity</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - 11. Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/Stock-basedCompensationTables</Role>
      <ShortName>11. Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://seelostx.com/role/Stock-basedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - 12. Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>12. Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://seelostx.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - 2. Liquidity and Going Concern (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative</Role>
      <ShortName>2. Liquidity and Going Concern (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://seelostx.com/role/LiquidityAndGoingConcern</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails</Role>
      <ShortName>Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Schedule of Fair Value Hierarchy Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails</Role>
      <ShortName>Schedule of Fair Value Hierarchy Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Summary of Fair Value Measurements Convertible Notes Valuation Assumptions (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails</Role>
      <ShortName>Summary of Fair Value Measurements Convertible Notes Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Summary of Fair Value Measurements Warrant Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/SummaryOfFairValueMeasurementsWarrantValuationAssumptionsDetails</Role>
      <ShortName>Summary of Fair Value Measurements Warrant Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - Schedule of Fair Value Level 3 Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/ScheduleOfFairValueLevel3ReconciliationDetails</Role>
      <ShortName>Schedule of Fair Value Level 3 Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - 4. Fair Value Measurement (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/FairValueMeasurementDetailsNarrative</Role>
      <ShortName>4. Fair Value Measurement (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://seelostx.com/role/FairValueMeasurementTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Schedule of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Schedule of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - 6. Common Stock Offerings (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/CommonStockOfferingsDetailsNarrative</Role>
      <ShortName>6. Common Stock Offerings (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://seelostx.com/role/CommonStockOfferings</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - 7. License Agreements (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/LicenseAgreementsDetailsNarrative</Role>
      <ShortName>7. License Agreements (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://seelostx.com/role/LicenseAgreements</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - Schedule of Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/ScheduleOfAccruedLiabilitiesDetails</Role>
      <ShortName>Schedule of Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - 9. Debt (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/DebtDetailsNarrative</Role>
      <ShortName>9. Debt (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://seelostx.com/role/Debt</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - Summary of Warrant Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/SummaryOfWarrantActivityDetails</Role>
      <ShortName>Summary of Warrant Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - 10. Stockholders??? Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>10. Stockholders??? Equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://seelostx.com/role/StockholdersEquityTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - Schedule of Valuation Assumptions for Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/ScheduleOfValuationAssumptionsForStockOptionsDetails</Role>
      <ShortName>Schedule of Valuation Assumptions for Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/SummaryOfStockOptionActivityDetails</Role>
      <ShortName>Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - Schedule of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/ScheduleOfStock-basedCompensationExpenseDetails</Role>
      <ShortName>Schedule of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - 11. Stock-based Compensation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/Stock-basedCompensationDetailsNarrative</Role>
      <ShortName>11. Stock-based Compensation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://seelostx.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - Schedule of future minimum operating lease payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/ScheduleOfFutureMinimumOperatingLeasePaymentsDetails</Role>
      <ShortName>Schedule of future minimum operating lease payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - 12. Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>12. Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://seelostx.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="body10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - 13. Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://seelostx.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>13. Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://seelostx.com/role/SubsequentEvents</ParentRole>
      <Position>49</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="body10-q.htm">body10-q.htm</File>
    <File>exh31-1.htm</File>
    <File>exh31-2.htm</File>
    <File>exh32-1.htm</File>
    <File>exh32-2.htm</File>
    <File>seel-20220331.xsd</File>
    <File>seel-20220331_cal.xml</File>
    <File>seel-20220331_def.xml</File>
    <File>seel-20220331_lab.xml</File>
    <File>seel-20220331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="479">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>66
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "body10-q.htm": {
   "axisCustom": 0,
   "axisStandard": 16,
   "contextCount": 164,
   "dts": {
    "calculationLink": {
     "local": [
      "seel-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "seel-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "body10-q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "seel-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "seel-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "seel-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 396,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 56,
    "http://seelostx.com/20220331": 10,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 71
   },
   "keyCustom": 25,
   "keyStandard": 210,
   "memberCustom": 25,
   "memberStandard": 19,
   "nsprefix": "SEEL",
   "nsuri": "http://seelostx.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://seelostx.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - 3. Significant Accounting Policies",
     "role": "http://seelostx.com/role/SignificantAccountingPolicies",
     "shortName": "3. Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - 4. Fair Value Measurement",
     "role": "http://seelostx.com/role/FairValueMeasurement",
     "shortName": "4. Fair Value Measurement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - 5. Prepaid Expenses and Other Current Assets",
     "role": "http://seelostx.com/role/PrepaidExpensesAndOtherCurrentAssets",
     "shortName": "5. Prepaid Expenses and Other Current Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - 6. Common Stock Offerings",
     "role": "http://seelostx.com/role/CommonStockOfferings",
     "shortName": "6. Common Stock Offerings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - 7. License Agreements",
     "role": "http://seelostx.com/role/LicenseAgreements",
     "shortName": "7. License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - 8. Accrued Expenses",
     "role": "http://seelostx.com/role/AccruedExpenses",
     "shortName": "8. Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - 9. Debt",
     "role": "http://seelostx.com/role/Debt",
     "shortName": "9. Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - 10. Stockholders\u2019 Equity",
     "role": "http://seelostx.com/role/StockholdersEquity",
     "shortName": "10. Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - 11. Stock-based Compensation",
     "role": "http://seelostx.com/role/Stock-basedCompensation",
     "shortName": "11. Stock-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - 12. Commitments and Contingencies",
     "role": "http://seelostx.com/role/CommitmentsAndContingencies",
     "shortName": "12. Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://seelostx.com/role/BalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - 13. Subsequent Events",
     "role": "http://seelostx.com/role/SubsequentEvents",
     "shortName": "13. Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - 3. Significant Accounting Policies (Policies)",
     "role": "http://seelostx.com/role/SignificantAccountingPoliciesPolicies",
     "shortName": "3. Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - 3. Significant Accounting Policies (Tables)",
     "role": "http://seelostx.com/role/SignificantAccountingPoliciesTables",
     "shortName": "3. Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - 4. Fair Value Measurement (Tables)",
     "role": "http://seelostx.com/role/FairValueMeasurementTables",
     "shortName": "4. Fair Value Measurement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - 5. Prepaid Expenses and Other Current Assets (Tables)",
     "role": "http://seelostx.com/role/PrepaidExpensesAndOtherCurrentAssetsTables",
     "shortName": "5. Prepaid Expenses and Other Current Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - 8. Accrued Expenses (Tables)",
     "role": "http://seelostx.com/role/AccruedExpensesTables",
     "shortName": "8. Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - 10. Stockholders\u2019 Equity (Tables)",
     "role": "http://seelostx.com/role/StockholdersEquityTables",
     "shortName": "10. Stockholders\u2019 Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - 11. Stock-based Compensation (Tables)",
     "role": "http://seelostx.com/role/Stock-basedCompensationTables",
     "shortName": "11. Stock-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - 12. Commitments and Contingencies (Tables)",
     "role": "http://seelostx.com/role/CommitmentsAndContingenciesTables",
     "shortName": "12. Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - 2. Liquidity and Going Concern (Details Narrative)",
     "role": "http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative",
     "shortName": "2. Liquidity and Going Concern (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "-5",
      "lang": null,
      "name": "SEEL:FinancingAvailableUnderFormS3ShelfRegistrationStatement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://seelostx.com/role/BalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:PreferredStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "role": "http://seelostx.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
     "shortName": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - Schedule of Fair Value Hierarchy Assets and Liabilities (Details)",
     "role": "http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails",
     "shortName": "Schedule of Fair Value Hierarchy Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "AsOf2022-03-31_us-gaap_FairValueMeasurementsRecurringMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "AsOf2022-03-31_us-gaap_LongTermDebtMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - Summary of Fair Value Measurements Convertible Notes Valuation Assumptions (Details)",
     "role": "http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails",
     "shortName": "Summary of Fair Value Measurements Convertible Notes Valuation Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "AsOf2022-03-31_us-gaap_LongTermDebtMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-012022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - Summary of Fair Value Measurements Warrant Valuation Assumptions (Details)",
     "role": "http://seelostx.com/role/SummaryOfFairValueMeasurementsWarrantValuationAssumptionsDetails",
     "shortName": "Summary of Fair Value Measurements Warrant Valuation Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-012022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "AsOf2022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - Schedule of Fair Value Level 3 Reconciliation (Details)",
     "role": "http://seelostx.com/role/ScheduleOfFairValueLevel3ReconciliationDetails",
     "shortName": "Schedule of Fair Value Level 3 Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "AsOf2022-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - 4. Fair Value Measurement (Details Narrative)",
     "role": "http://seelostx.com/role/FairValueMeasurementDetailsNarrative",
     "shortName": "4. Fair Value Measurement (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "role": "http://seelostx.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
     "shortName": "Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2021-01-012021-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000037 - Disclosure - 6. Common Stock Offerings (Details Narrative)",
     "role": "http://seelostx.com/role/CommonStockOfferingsDetailsNarrative",
     "shortName": "6. Common Stock Offerings (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2021-11-012021-11-30_custom_IXLicenseAgreementMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2019-08-012019-08-31_custom_WegLicenseAgreementMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000038 - Disclosure - 7. License Agreements (Details Narrative)",
     "role": "http://seelostx.com/role/LicenseAgreementsDetailsNarrative",
     "shortName": "7. License Agreements (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2019-08-012019-08-31_custom_WegLicenseAgreementMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000039 - Disclosure - Schedule of Accrued Liabilities (Details)",
     "role": "http://seelostx.com/role/ScheduleOfAccruedLiabilitiesDetails",
     "shortName": "Schedule of Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "SEEL:GainLossInFairValueOfConvertibleNotes",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000040 - Disclosure - 9. Debt (Details Narrative)",
     "role": "http://seelostx.com/role/DebtDetailsNarrative",
     "shortName": "9. Debt (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2021-11-012021-11-30_custom_November2021LindSecuritiesPurchaseAgreementMember",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "AsOf2021-12-31_custom_WarrantDerivativeFinancialInstrumentsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000041 - Disclosure - Summary of Warrant Activity (Details)",
     "role": "http://seelostx.com/role/SummaryOfWarrantActivityDetails",
     "shortName": "Summary of Warrant Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "AsOf2021-12-31_custom_WarrantDerivativeFinancialInstrumentsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000042 - Disclosure - 10. Stockholders\u2019 Equity (Details Narrative)",
     "role": "http://seelostx.com/role/StockholdersEquityDetailsNarrative",
     "shortName": "10. Stockholders\u2019 Equity (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "AsOf2021-03-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember654123531",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000043 - Disclosure - Schedule of Valuation Assumptions for Stock Options (Details)",
     "role": "http://seelostx.com/role/ScheduleOfValuationAssumptionsForStockOptionsDetails",
     "shortName": "Schedule of Valuation Assumptions for Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-012022-03-31_us-gaap_EmployeeStockOptionMember654123531",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000044 - Disclosure - Summary of Stock Option Activity (Details)",
     "role": "http://seelostx.com/role/SummaryOfStockOptionActivityDetails",
     "shortName": "Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000045 - Disclosure - Schedule of Stock-Based Compensation Expense (Details)",
     "role": "http://seelostx.com/role/ScheduleOfStock-basedCompensationExpenseDetails",
     "shortName": "Schedule of Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-012022-03-31_us-gaap_ResearchAndDevelopmentExpenseMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000046 - Disclosure - 11. Stock-based Compensation (Details Narrative)",
     "role": "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative",
     "shortName": "11. Stock-based Compensation (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000047 - Disclosure - Schedule of future minimum operating lease payments (Details)",
     "role": "http://seelostx.com/role/ScheduleOfFutureMinimumOperatingLeasePaymentsDetails",
     "shortName": "Schedule of future minimum operating lease payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000048 - Disclosure - 12. Commitments and Contingencies (Details Narrative)",
     "role": "http://seelostx.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "12. Commitments and Contingencies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-04-012022-04-29_us-gaap_SubsequentEventMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000049 - Disclosure - 13. Subsequent Events (Details Narrative)",
     "role": "http://seelostx.com/role/SubsequentEventsDetailsNarrative",
     "shortName": "13. Subsequent Events (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-04-012022-04-29_us-gaap_SubsequentEventMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EarningsPerShareBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)",
     "role": "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLossParenthetical",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EarningsPerShareBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit)",
     "role": "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit",
     "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000007 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://seelostx.com/role/StatementsOfCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - 1. Organization and Description of Business",
     "role": "http://seelostx.com/role/OrganizationAndDescriptionOfBusiness",
     "shortName": "1. Organization and Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - 2. Liquidity and Going Concern",
     "role": "http://seelostx.com/role/LiquidityAndGoingConcern",
     "shortName": "2. Liquidity and Going Concern",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "body10-q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 48,
   "tag": {
    "SEEL_AmortizeNovember2021LindSecuritiesPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortize November 2021 Lind Securities Purchase Agreement [Member]"
       }
      }
     },
     "localname": "AmortizeNovember2021LindSecuritiesPurchaseAgreementMember",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SEEL_AssetsfromVyeraPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assetsfrom Vyera Pharmaceuticals [Member]"
       }
      }
     },
     "localname": "AssetsfromVyeraPharmaceuticalsMember",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SEEL_August2019WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "August 2019 Warrants [Member]"
       }
      }
     },
     "localname": "August2019WarrantsMember",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SEEL_August232019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "August 232019 [Member]"
       }
      }
     },
     "localname": "August232019Member",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SEEL_August232022ThruMaturityNovember2021LindSecuritiesPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "August 232022 Thru Maturity November 2021 Lind Securities Purchase Agreement [Member]"
       }
      }
     },
     "localname": "August232022ThruMaturityNovember2021LindSecuritiesPurchaseAgreementMember",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SEEL_CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement]"
       }
      }
     },
     "localname": "CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SEEL_ClassOfWarrantOrRightCancelledExercisePriceOfWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cancelled, exercise price of warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightCancelledExercisePriceOfWarrantsOrRights",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "SEEL_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable, weighted-average exercise price (in usd per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "SEEL_ClassOfWarrantOrRightExercisableWeightedAverageRemaingContractualLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercisable as of June 30, 2021, weighted-average remaing contractual life (in years)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisableWeightedAverageRemaingContractualLife",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "SEEL_ClassOfWarrantOrRightExercisedExercisePriceOfWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercised, exercise price of warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisedExercisePriceOfWarrantsOrRights",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "SEEL_ClassOfWarrantOrRightIssuedExercisePriceOfWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued, warrant exercise price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssuedExercisePriceOfWarrantsOrRights",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "SEEL_ClassOfWarrantOrRightOutstandingEndOfPeriodWeightedAverageRemaingContractualLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants outstanding as of June 30, 2021, weighted-average remaing contractual life (in years)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstandingEndOfPeriodWeightedAverageRemaingContractualLife",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "SEEL_ClassOfWarrantOrRightOutstandingWeightedAverageRemaingContractualLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants outstanding as of December 31, 2020, weighted-average remaing contractual life (in years)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstandingWeightedAverageRemaingContractualLife",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "SEEL_December17SPAsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "December 17 S P As [Member]"
       }
      }
     },
     "localname": "December17SPAsMember",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SEEL_December2021SPAsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "December 2021 S P As [Member]"
       }
      }
     },
     "localname": "December2021SPAsMember",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SEEL_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SEEL_FinancingAvailableUnderFormS3ShelfRegistrationStatement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:FinancingAvailableUnderFormS3ShelfRegistrationStatement-0]"
       }
      }
     },
     "localname": "FinancingAvailableUnderFormS3ShelfRegistrationStatement",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SEEL_FirstAnniversaryOfNovember2021LindSecuritiesPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "First Anniversary Of November 2021 Lind Securities Purchase Agreement [Member]"
       }
      }
     },
     "localname": "FirstAnniversaryOfNovember2021LindSecuritiesPurchaseAgreementMember",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SEEL_GainLossInFairValueOfConvertibleNotes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of convertible notes",
        "negatedLabel": "Change in fair value of convertible notes payable",
        "verboseLabel": "[custom:GainLossInFairValueOfConvertibleNotes]"
       }
      }
     },
     "localname": "GainLossInFairValueOfConvertibleNotes",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/DebtDetailsNarrative",
      "http://seelostx.com/role/StatementsOfCashFlows",
      "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SEEL_IXLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "I X License Agreement [Member]"
       }
      }
     },
     "localname": "IXLicenseAgreementMember",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/CommonStockOfferingsDetailsNarrative",
      "http://seelostx.com/role/FairValueMeasurementDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SEEL_IncentiveStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Stock Option [Member]"
       }
      }
     },
     "localname": "IncentiveStockOptionMember",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SEEL_InducementPlanof2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inducement Planof 2019 [Member]"
       }
      }
     },
     "localname": "InducementPlanof2019Member",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SEEL_InitialStockValuationShortfallFrom5.5MillionValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:InitialStockValuationShortfallFrom5.5MillionValue]"
       }
      }
     },
     "localname": "InitialStockValuationShortfallFrom5.5MillionValue",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/CommonStockOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SEEL_Issuanceofcommonstockforlicenseacquiredshares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:Issuanceofcommonstockforlicenseacquiredshares]"
       }
      }
     },
     "localname": "Issuanceofcommonstockforlicenseacquiredshares",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/CommonStockOfferingsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "SEEL_January282021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "January 282021 [Member]"
       }
      }
     },
     "localname": "January282021Member",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/CommonStockOfferingsDetailsNarrative",
      "http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SEEL_LicensesPayable": {
     "auth_ref": [],
     "calculation": {
      "http://seelostx.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Licenses payable"
       }
      }
     },
     "localname": "LicensesPayable",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SEEL_LindSecuritiesPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lind Securities Purchase Agreement [Member]"
       }
      }
     },
     "localname": "LindSecuritiesPurchaseAgreementMember",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SEEL_March2019LeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "March 2019 Lease [Member]"
       }
      }
     },
     "localname": "March2019LeaseMember",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SEEL_March2021LeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "March 2021 Lease [Member]"
       }
      }
     },
     "localname": "March2021LeaseMember",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SEEL_May242021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "May 242021 [Member]"
       }
      }
     },
     "localname": "May242021Member",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/CommonStockOfferingsDetailsNarrative",
      "http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SEEL_MinimumStockValueOfSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:MinimumStockValueOfSharesIssued]"
       }
      }
     },
     "localname": "MinimumStockValueOfSharesIssued",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/CommonStockOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SEEL_NonQualifiedStockOptionsToEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Qualified Stock Options To Employees [Member]"
       }
      }
     },
     "localname": "NonQualifiedStockOptionsToEmployeesMember",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SEEL_NonQualifiedStockOptionsToNonEmployeeDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Qualified Stock Options To Non Employee Directors [Member]"
       }
      }
     },
     "localname": "NonQualifiedStockOptionsToNonEmployeeDirectorsMember",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SEEL_NonrefundableCashPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:NonrefundableCashPayment]"
       }
      }
     },
     "localname": "NonrefundableCashPayment",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/CommonStockOfferingsDetailsNarrative",
      "http://seelostx.com/role/FairValueMeasurementDetailsNarrative",
      "http://seelostx.com/role/LicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SEEL_November2021LindSecuritiesPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "November 2021 Lind Securities Purchase Agreement [Member]"
       }
      }
     },
     "localname": "November2021LindSecuritiesPurchaseAgreementMember",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SEEL_NumberofWarrantsCancelledDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cancelled"
       }
      }
     },
     "localname": "NumberofWarrantsCancelledDuringPeriod",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "SEEL_NumberofWarrantsExercisedDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercised",
        "verboseLabel": "Number of warrants exercised"
       }
      }
     },
     "localname": "NumberofWarrantsExercisedDuringPeriod",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/StockholdersEquityDetailsNarrative",
      "http://seelostx.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "SEEL_NumberofWarrantsIssuedDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued"
       }
      }
     },
     "localname": "NumberofWarrantsIssuedDuringPeriod",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "SEEL_OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering proceeds used to partially repay certain convertible promissory notes"
       }
      }
     },
     "localname": "OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/CommonStockOfferingsDetailsNarrative",
      "http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SEEL_OutsideResearchAndDevelopmentServicesCurrent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outside research and development services"
       }
      }
     },
     "localname": "OutsideResearchAndDevelopmentServicesCurrent",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SEEL_PSUtoExecutivesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "P S Uto Executives [Member]"
       }
      }
     },
     "localname": "PSUtoExecutivesMember",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SEEL_PrepaidClinicalCosts": {
     "auth_ref": [],
     "calculation": {
      "http://seelostx.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid clinical costs"
       }
      }
     },
     "localname": "PrepaidClinicalCosts",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SEEL_ReclassOfWarrantLiabilitiesRelatedToSeriesWarrantsExercisedForCash": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclass of warrant liabilities related to Series A warrants exercised for cash"
       }
      }
     },
     "localname": "ReclassOfWarrantLiabilitiesRelatedToSeriesWarrantsExercisedForCash",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SEEL_September2020WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "September 2020 Warrants [Member]"
       }
      }
     },
     "localname": "September2020WarrantsMember",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SEEL_SeriesAWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Warrants [Member]"
       }
      }
     },
     "localname": "SeriesAWarrantsMember",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SEEL_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceDiscountOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price Discount of Common Stock, Percent"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceDiscountOfCommonStockPercent",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "SEEL_SharebasedPaymentArrangementNonvestedAndCanceledAwardExcludingOptionCostNotYetRecognizedAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested and Canceled Award, Excluding Option, Cost Not yet Recognized, Amount"
       }
      }
     },
     "localname": "SharebasedPaymentArrangementNonvestedAndCanceledAwardExcludingOptionCostNotYetRecognizedAmount",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SEEL_WarrantDerivativeFinancialInstrumentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Derivative Financial Instruments [Member]"
       }
      }
     },
     "localname": "WarrantDerivativeFinancialInstrumentsMember",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "SEEL_WarrantsExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercisable as of March 31, 2022",
        "verboseLabel": "Warrants exercisable as of June 30, 2021"
       }
      }
     },
     "localname": "WarrantsExercisable",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/StockholdersEquityDetailsNarrative",
      "http://seelostx.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "SEEL_WegLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weg License Agreement [Member]"
       }
      }
     },
     "localname": "WegLicenseAgreementMember",
     "nsuri": "http://seelostx.com/20220331",
     "presentation": [
      "http://seelostx.com/role/LicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r389",
      "r391",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://seelostx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r131",
      "r132",
      "r133",
      "r134",
      "r150",
      "r183",
      "r209",
      "r210",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r363",
      "r364",
      "r374",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfValuationAssumptionsForStockOptionsDetails",
      "http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r131",
      "r132",
      "r133",
      "r134",
      "r150",
      "r183",
      "r209",
      "r210",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r363",
      "r364",
      "r374",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfValuationAssumptionsForStockOptionsDetails",
      "http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r126",
      "r131",
      "r132",
      "r133",
      "r134",
      "r150",
      "r183",
      "r200",
      "r209",
      "r210",
      "r241",
      "r242",
      "r243",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r363",
      "r364",
      "r374",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfValuationAssumptionsForStockOptionsDetails",
      "http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r126",
      "r131",
      "r132",
      "r133",
      "r134",
      "r150",
      "r183",
      "r200",
      "r209",
      "r210",
      "r241",
      "r242",
      "r243",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r363",
      "r364",
      "r374",
      "r375"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfValuationAssumptionsForStockOptionsDetails",
      "http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "8. Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r23",
      "r329"
     ],
     "calculation": {
      "http://seelostx.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedInsuranceCurrent": {
     "auth_ref": [
      "r27"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Insurance"
       }
      }
     },
     "localname": "AccruedInsuranceCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://seelostx.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://seelostx.com/role/ScheduleOfAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued expenses",
        "totalLabel": "Accrued expenses, net"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/BalanceSheets",
      "http://seelostx.com/role/ScheduleOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://seelostx.com/role/ScheduleOfAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://seelostx.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional paid-in-capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r74",
      "r75",
      "r76",
      "r252",
      "r253",
      "r254",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r212",
      "r257",
      "r258"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r49",
      "r60",
      "r170",
      "r312"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive securities excluded"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r270"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized from contingent consideration in asset acquisition, classified as current.",
        "label": "Asset Acquisition, Contingent Consideration, Liability, Current"
       }
      }
     },
     "localname": "AssetAcquisitionContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/LicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r9",
      "r71",
      "r112",
      "r114",
      "r118",
      "r121",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r272",
      "r274",
      "r302",
      "r327",
      "r329",
      "r345",
      "r355"
     ],
     "calculation": {
      "http://seelostx.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets [Default Label]",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "verboseLabel": "Assets [Abstract]"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/BalanceSheets",
      "http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r22",
      "r71",
      "r121",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r272",
      "r274",
      "r302",
      "r327",
      "r329"
     ],
     "calculation": {
      "http://seelostx.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfValuationAssumptionsForStockOptionsDetails",
      "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative",
      "http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails",
      "http://seelostx.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/CommonStockOfferingsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r269",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "6. Common Stock Offerings"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/CommonStockOfferings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures related to transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination by type of transaction.",
        "label": "Business Combination, Separately Recognized Transactions [Axis]"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/CommonStockOfferingsDetailsNarrative",
      "http://seelostx.com/role/FairValueMeasurementDetailsNarrative",
      "http://seelostx.com/role/LicenseAgreementsDetailsNarrative",
      "http://seelostx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDescription": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A description of each transaction that is recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.",
        "label": "Business Combination, Separately Recognized Transactions, Description"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/LicenseAgreementsDetailsNarrative",
      "http://seelostx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of transaction that is recognized separately from the acquisition of assets and assumptions of liabilities in a business combination by transaction."
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/CommonStockOfferingsDetailsNarrative",
      "http://seelostx.com/role/FairValueMeasurementDetailsNarrative",
      "http://seelostx.com/role/LicenseAgreementsDetailsNarrative",
      "http://seelostx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Combination, Separately Recognized Transactions [Line Items]"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/FairValueMeasurementDetailsNarrative",
      "http://seelostx.com/role/LicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing the disclosures related to transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination by type of transaction.",
        "label": "Business Combination, Separately Recognized Transactions [Table]"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/FairValueMeasurementDetailsNarrative",
      "http://seelostx.com/role/LicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalLeaseObligationsIncurred": {
     "auth_ref": [
      "r64",
      "r65"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in lease obligation from new lease.",
        "label": "Right-of-use assets obtained in exchange for operating lease liabilities"
       }
      }
     },
     "localname": "CapitalLeaseObligationsIncurred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r8",
      "r329",
      "r370",
      "r371"
     ],
     "calculation": {
      "http://seelostx.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/BalanceSheets",
      "http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r8",
      "r62"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash, end of period",
        "periodStartLabel": "Cash, beginning of period",
        "verboseLabel": "Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails",
      "http://seelostx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r55",
      "r303"
     ],
     "calculation": {
      "http://seelostx.com/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Net increase (decrease) in cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r68",
      "r71",
      "r89",
      "r90",
      "r91",
      "r93",
      "r95",
      "r101",
      "r102",
      "r103",
      "r121",
      "r136",
      "r140",
      "r141",
      "r142",
      "r145",
      "r146",
      "r181",
      "r182",
      "r185",
      "r189",
      "r195",
      "r302",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/CommonStockOfferingsDetailsNarrative",
      "http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative",
      "http://seelostx.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format.",
        "label": "Date on which warrants became exercisable"
       }
      }
     },
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r198",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "periodEndLabel": "Outstanding as of June 30, 2021, weighted-average exercise price (in usd per share)",
        "periodStartLabel": "Outstanding as of December 31, 2020, weighted-average exercise price (in usd per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StockholdersEquityDetailsNarrative",
      "http://seelostx.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Outstanding as of March 31, 2022",
        "periodStartLabel": "Outstanding as of December 31, 2021"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of reason for issuing warrant or right.",
        "label": "Warrant description"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightReasonForIssuingToNonemployees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r198",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r30",
      "r349",
      "r360"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and contingencies (note 12)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r128",
      "r129",
      "r130",
      "r135",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "12. Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r74",
      "r75",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value (in usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/BalanceSheetsParenthetical",
      "http://seelostx.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r15",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, outstanding (in shares)",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/BalanceSheetsParenthetical",
      "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r15",
      "r329"
     ],
     "calculation": {
      "http://seelostx.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, $0.001 par value, 240,000,000 shares authorized, \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 105,590,773 and 105,500,445 issued and outstanding as of \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0March 31, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockVotingRights": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
        "label": "Common stock voting right"
       }
      }
     },
     "localname": "CommonStockVotingRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.",
        "label": "Convertible Debt Securities [Member]"
       }
      }
     },
     "localname": "ConvertibleDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleNotesPayable": {
     "auth_ref": [
      "r12",
      "r347",
      "r356",
      "r372"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable"
       }
      }
     },
     "localname": "ConvertibleNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleSubordinatedDebt": {
     "auth_ref": [
      "r12",
      "r347",
      "r357"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, the carrying value of convertible subordinated debt, as of the balance sheet date, initially scheduled to be repaid after one year or beyond the normal operating cycle if longer. This form of debt can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder, and places a lender in a lien position behind debt having a higher priority of repayment in liquidation of the entity's assets.",
        "label": "Convertible Subordinated Debt"
       }
      }
     },
     "localname": "ConvertibleSubordinatedDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleSubordinatedDebtCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://seelostx.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the carrying value of convertible subordinated debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. This form of debt can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder, and places a lender in a lien position behind debt having a higher priority of repayment upon liquidation of the entity's assets.",
        "label": "Short-term portion of convertible notes payable, at fair value"
       }
      }
     },
     "localname": "ConvertibleSubordinatedDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleSubordinatedDebtNoncurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://seelostx.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the carrying value of convertible subordinated debt as of the balance sheet date that is scheduled to be repaid after one year or beyond the normal operating cycle if longer. This form of debt can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder, and places a lender in a lien position behind debt having a higher priority of repayment in liquidation of the entity's assets.",
        "label": "Convertible notes payable, at fair value"
       }
      }
     },
     "localname": "ConvertibleSubordinatedDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r67",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r164",
      "r171",
      "r172",
      "r173",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "9. Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r70",
      "r72",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r154",
      "r160",
      "r161",
      "r162",
      "r163",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r175",
      "r176",
      "r177",
      "r178",
      "r314",
      "r346",
      "r347",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r29",
      "r70",
      "r72",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r154",
      "r160",
      "r161",
      "r162",
      "r163",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r175",
      "r176",
      "r177",
      "r178",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Schedule of Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/PrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect.",
        "label": "Derivative Financial Instruments, Liabilities [Member]"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails",
      "http://seelostx.com/role/ScheduleOfFairValueLevel3ReconciliationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r37",
      "r277",
      "r279",
      "r280",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r33",
      "r36",
      "r37",
      "r301"
     ],
     "calculation": {
      "http://seelostx.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative liability",
        "verboseLabel": "Warrant liabilities, at fair value"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/BalanceSheets",
      "http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://seelostx.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Warrant liabilities, at fair value"
       }
      }
     },
     "localname": "DerivativeLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLossOnDerivative": {
     "auth_ref": [
      "r278"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Loss on Derivative",
        "negatedLabel": "Derivative liability"
       }
      }
     },
     "localname": "DerivativeLossOnDerivative",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r215",
      "r216",
      "r246",
      "r247",
      "r249",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "11. Stock-based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/Stock-basedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r45",
      "r79",
      "r80",
      "r81",
      "r82",
      "r83",
      "r87",
      "r89",
      "r93",
      "r94",
      "r95",
      "r98",
      "r99",
      "r284",
      "r285",
      "r351",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLossParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r45",
      "r79",
      "r80",
      "r81",
      "r82",
      "r83",
      "r89",
      "r93",
      "r94",
      "r95",
      "r98",
      "r99",
      "r284",
      "r285",
      "r351",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLossParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r96",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://seelostx.com/role/ScheduleOfAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Personnel related"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r248"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://seelostx.com/role/ScheduleOfValuationAssumptionsForStockOptionsDetails",
      "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative",
      "http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails",
      "http://seelostx.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r40",
      "r41",
      "r42",
      "r74",
      "r75",
      "r76",
      "r78",
      "r84",
      "r86",
      "r100",
      "r122",
      "r195",
      "r197",
      "r252",
      "r253",
      "r254",
      "r262",
      "r263",
      "r283",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r326",
      "r365",
      "r366",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r60",
      "r180"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Change in fair value of warrant liability"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails",
      "http://seelostx.com/role/ScheduleOfFairValueLevel3ReconciliationDetails",
      "http://seelostx.com/role/SummaryOfFairValueMeasurementsWarrantValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r286",
      "r287",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails",
      "http://seelostx.com/role/ScheduleOfFairValueLevel3ReconciliationDetails",
      "http://seelostx.com/role/SummaryOfFairValueMeasurementsWarrantValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r296",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Schedule of Fair Value Hierarchy Assets and Liabilities"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Summary of Fair Value Measurements Warrant Valuation Assumptions"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r162",
      "r175",
      "r176",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r287",
      "r333",
      "r334",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails",
      "http://seelostx.com/role/ScheduleOfFairValueLevel3ReconciliationDetails",
      "http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails",
      "http://seelostx.com/role/SummaryOfFairValueMeasurementsWarrantValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r295",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/FairValueMeasurementTables",
      "http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails",
      "http://seelostx.com/role/ScheduleOfFairValueLevel3ReconciliationDetails",
      "http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails",
      "http://seelostx.com/role/SummaryOfFairValueMeasurementsWarrantValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r286",
      "r287",
      "r290",
      "r291",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "4. Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/FairValueMeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r162",
      "r201",
      "r202",
      "r207",
      "r208",
      "r287",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r162",
      "r175",
      "r176",
      "r201",
      "r202",
      "r207",
      "r208",
      "r287",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r162",
      "r175",
      "r176",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r287",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails",
      "http://seelostx.com/role/ScheduleOfFairValueLevel3ReconciliationDetails",
      "http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails",
      "http://seelostx.com/role/SummaryOfFairValueMeasurementsWarrantValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/FairValueMeasurementTables",
      "http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails",
      "http://seelostx.com/role/ScheduleOfFairValueLevel3ReconciliationDetails",
      "http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails",
      "http://seelostx.com/role/SummaryOfFairValueMeasurementsWarrantValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/FairValueMeasurementTables",
      "http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r292",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/FairValueMeasurementTables",
      "http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r292",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Schedule of Fair Value Level 3 Reconciliation"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency."
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3": {
     "auth_ref": [
      "r294"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3",
        "negatedLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfFairValueLevel3ReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3": {
     "auth_ref": [
      "r294"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfFairValueLevel3ReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/FairValueMeasurementDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r293"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfFairValueLevel3ReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r292"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfFairValueLevel3ReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r162",
      "r175",
      "r176",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r333",
      "r334",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails",
      "http://seelostx.com/role/ScheduleOfFairValueLevel3ReconciliationDetails",
      "http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails",
      "http://seelostx.com/role/SummaryOfFairValueMeasurementsWarrantValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r295",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r299",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r125",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r57",
      "r63"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "verboseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accrued Liabilities",
        "verboseLabel": "Licenses payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r43",
      "r111",
      "r311",
      "r313",
      "r353"
     ],
     "calculation": {
      "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeDomesticDeposits": {
     "auth_ref": [
      "r352"
     ],
     "calculation": {
      "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest earned on deposits in United States money market accounts and other United States interest earning accounts.",
        "label": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeDomesticDeposits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r54",
      "r56",
      "r63"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of lessee's operating lease.",
        "label": "Operating lease description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r324"
     ],
     "calculation": {
      "http://seelostx.com/role/ScheduleOfFutureMinimumOperatingLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfFutureMinimumOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r324"
     ],
     "calculation": {
      "http://seelostx.com/role/ScheduleOfFutureMinimumOperatingLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Remaining Period Ended December 31, 2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfFutureMinimumOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r324"
     ],
     "calculation": {
      "http://seelostx.com/role/ScheduleOfFutureMinimumOperatingLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less present value discount"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfFutureMinimumOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r26",
      "r71",
      "r115",
      "r121",
      "r136",
      "r137",
      "r138",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r273",
      "r274",
      "r275",
      "r302",
      "r327",
      "r328"
     ],
     "calculation": {
      "http://seelostx.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r20",
      "r71",
      "r121",
      "r302",
      "r329",
      "r348",
      "r359"
     ],
     "calculation": {
      "http://seelostx.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r28",
      "r71",
      "r121",
      "r136",
      "r137",
      "r138",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r273",
      "r274",
      "r275",
      "r302",
      "r327",
      "r328",
      "r329"
     ],
     "calculation": {
      "http://seelostx.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r12",
      "r161",
      "r174",
      "r175",
      "r176",
      "r347",
      "r357"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtDescription": {
     "auth_ref": [
      "r29",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of long-term debt arrangements, which are debt arrangements that originally require full repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer, and disclosures pertaining to the underlying arrangements, including repayment terms, conversion features, interest rates, restrictions on assets and activities, debt covenants, and other matters important to users of the financial statements. Types of long-term debt arrangements include borrowing under notes payable, bonds payable, debentures, term loans, and other contractual obligations for payment.",
        "label": "Long-Term Debt, Description"
       }
      }
     },
     "localname": "LongTermDebtDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-Term Debt, Fair Value"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer.",
        "label": "Long-Term Debt [Member]"
       }
      }
     },
     "localname": "LongTermDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/FairValueMeasurementTables",
      "http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails",
      "http://seelostx.com/role/ScheduleOfFairValueLevel3ReconciliationDetails",
      "http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://seelostx.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r55",
      "r58",
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r38",
      "r39",
      "r42",
      "r44",
      "r61",
      "r71",
      "r77",
      "r79",
      "r80",
      "r81",
      "r82",
      "r85",
      "r86",
      "r92",
      "r112",
      "r113",
      "r116",
      "r117",
      "r119",
      "r121",
      "r136",
      "r137",
      "r138",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r285",
      "r302",
      "r350",
      "r361"
     ],
     "calculation": {
      "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "totalLabel": "Net loss and comprehensive loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfCashFlows",
      "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit",
      "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash investing and financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OffsettingAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Offsetting Assets [Line Items]"
       }
      }
     },
     "localname": "OffsettingAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OffsettingAssetsTable": {
     "auth_ref": [
      "r34",
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements.",
        "label": "Offsetting Assets [Table]"
       }
      }
     },
     "localname": "OffsettingAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/SummaryOfWarrantActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expense"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expense"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r112",
      "r113",
      "r116",
      "r117",
      "r119"
     ],
     "calculation": {
      "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r318"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r317"
     ],
     "calculation": {
      "http://seelostx.com/role/ScheduleOfFutureMinimumOperatingLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating lease liabilities",
        "totalLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://seelostx.com/role/ScheduleOfFutureMinimumOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r317"
     ],
     "calculation": {
      "http://seelostx.com/role/BalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating lease liability",
        "verboseLabel": "Operating lease liabilities - current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/BalanceSheets",
      "http://seelostx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r316"
     ],
     "calculation": {
      "http://seelostx.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/BalanceSheets",
      "http://seelostx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r323",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r322",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r3",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "1. Organization and Description of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/OrganizationAndDescriptionOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://seelostx.com/role/ScheduleOfAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other current assets.",
        "label": "5. Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/PrepaidExpensesAndOtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Change in fair value of warrant liabilities"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r21",
      "r124"
     ],
     "calculation": {
      "http://seelostx.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, per value (in usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/BalanceSheetsParenthetical",
      "http://seelostx.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/BalanceSheetsParenthetical",
      "http://seelostx.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r14",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred stock, issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred stock, outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/BalanceSheetsParenthetical",
      "http://seelostx.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://seelostx.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://seelostx.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets",
        "totalLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/BalanceSheets",
      "http://seelostx.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r5",
      "r123",
      "r124"
     ],
     "calculation": {
      "http://seelostx.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://seelostx.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from issuance of common stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r51",
      "r251"
     ],
     "calculation": {
      "http://seelostx.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from exercise of options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://seelostx.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from sales of common stock under ESPP"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://seelostx.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfCashFlows",
      "http://seelostx.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Repayments of Convertible Debt"
       }
      }
     },
     "localname": "RepaymentsOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://seelostx.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedLabel": "Payment of convertible note"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r261",
      "r343",
      "r376"
     ],
     "calculation": {
      "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development",
        "verboseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/CommonStockOfferingsDetailsNarrative",
      "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.",
        "label": "7. License Agreements"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/LicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r17",
      "r197",
      "r329",
      "r358",
      "r368",
      "r369"
     ],
     "calculation": {
      "http://seelostx.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumlated deficit",
        "negatedLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/BalanceSheets",
      "http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r74",
      "r75",
      "r76",
      "r78",
      "r84",
      "r86",
      "r122",
      "r252",
      "r253",
      "r254",
      "r262",
      "r263",
      "r283",
      "r365",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Shares Issued, Price Per Share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/CommonStockOfferingsDetailsNarrative",
      "http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/AccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r266",
      "r267",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/CommonStockOfferingsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r245",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of future minimum operating lease payments"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r211",
      "r213",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfValuationAssumptionsForStockOptionsDetails",
      "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative",
      "http://seelostx.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Valuation Assumptions for Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-Term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in stock options.",
        "label": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r198",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Summary of Warrant Activity"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfStock-basedCompensationExpenseDetails",
      "http://seelostx.com/role/StatementsOfCashFlows",
      "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "auth_ref": [
      "r214",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.",
        "label": "Description of share-based compensation arrangement by share-based payment award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative",
      "http://seelostx.com/role/SummaryOfFairValueMeasurementsWarrantValuationAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield",
        "verboseLabel": "Dividend yield (in percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfValuationAssumptionsForStockOptionsDetails",
      "http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails",
      "http://seelostx.com/role/SummaryOfFairValueMeasurementsWarrantValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "verboseLabel": "Volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfValuationAssumptionsForStockOptionsDetails",
      "http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails",
      "http://seelostx.com/role/SummaryOfFairValueMeasurementsWarrantValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfValuationAssumptionsForStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfValuationAssumptionsForStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails",
      "http://seelostx.com/role/SummaryOfFairValueMeasurementsWarrantValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfValuationAssumptionsForStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfValuationAssumptionsForStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfValuationAssumptionsForStockOptionsDetails",
      "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative",
      "http://seelostx.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Exercisable, end of period (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Exercisable, end of period (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r235"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "verboseLabel": "Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Granted",
        "verboseLabel": "Options granted in period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative",
      "http://seelostx.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Weighted average fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfValuationAssumptionsForStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r250"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Total aggregate intrinsic value shares outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r220",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding as of March 31, 2022",
        "periodStartLabel": "Outstanding as of December 31, 2020"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r220",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, end of period (USD per share)",
        "periodStartLabel": "Outstanding, beginning of period (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r236"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Total aggregate intrinsic value of vested or expected to vest stock options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Vested and expected to vest, end of period (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Vested and expected to vest stock, end of period (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfValuationAssumptionsForStockOptionsDetails",
      "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative",
      "http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails",
      "http://seelostx.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Exercised in period (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Cancelled (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Granted in period (USD per share)",
        "verboseLabel": "Weighted-average exercise price per share granted in period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative",
      "http://seelostx.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r219",
      "r238",
      "r239",
      "r240",
      "r241",
      "r244",
      "r255",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Stock-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Vesting percentage on the first anniversary"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Term of option grant"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/ScheduleOfValuationAssumptionsForStockOptionsDetails",
      "http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails",
      "http://seelostx.com/role/SummaryOfFairValueMeasurementsWarrantValuationAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r250"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Total aggregate intrinsic value of exercisable stock options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted-average remaining contractual life (in years) of exercisable stock options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Outstanding - weighted-average remaining contractual life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Weighted-average remaining contractual life (in years) of vested and expected to vest stock options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-Term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r66",
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "3. Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/SignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r68",
      "r71",
      "r89",
      "r90",
      "r91",
      "r93",
      "r95",
      "r101",
      "r102",
      "r103",
      "r121",
      "r136",
      "r140",
      "r141",
      "r142",
      "r145",
      "r146",
      "r181",
      "r182",
      "r185",
      "r189",
      "r195",
      "r302",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/CommonStockOfferingsDetailsNarrative",
      "http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative",
      "http://seelostx.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r32",
      "r40",
      "r41",
      "r42",
      "r74",
      "r75",
      "r76",
      "r78",
      "r84",
      "r86",
      "r100",
      "r122",
      "r195",
      "r197",
      "r252",
      "r253",
      "r254",
      "r262",
      "r263",
      "r283",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r326",
      "r365",
      "r366",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative",
      "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r74",
      "r75",
      "r76",
      "r100",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative",
      "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r31",
      "r165",
      "r195",
      "r196",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/DebtDetailsNarrative",
      "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan": {
     "auth_ref": [
      "r14",
      "r15",
      "r195",
      "r197",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Ownership Plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r14",
      "r15",
      "r195",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r195",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Number of shares of common stock issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/CommonStockOfferingsDetailsNarrative",
      "http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative",
      "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit",
      "http://seelostx.com/role/StockholdersEquityDetailsNarrative",
      "http://seelostx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r14",
      "r15",
      "r195",
      "r197",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit",
      "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative",
      "http://seelostx.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of stock issued during the period upon the conversion of convertible securities, net of adjustments (for example, to additional paid in capital) including the write-off of an equity component recognized to record the convertible debt instrument as two separate components - a debt component and an equity component. This item is meant to disclose the value of shares issued on conversion of convertible securities that were recorded as two separate (debt and equity) components.",
        "label": "Warrants exercised for cash"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan": {
     "auth_ref": [
      "r14",
      "r15",
      "r195",
      "r197",
      "r259"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock issued during the period as a result of employee stock ownership plan (ESOP).",
        "label": "Issuance of common stock, ESPP"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r195",
      "r197"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Issuance of common stock, net of issuance costs",
        "verboseLabel": "Cash received from stock sale"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/CommonStockOfferingsDetailsNarrative",
      "http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative",
      "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r32",
      "r195",
      "r197"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Issuance of common stock, options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r15",
      "r18",
      "r19",
      "r71",
      "r120",
      "r121",
      "r302",
      "r329"
     ],
     "calculation": {
      "http://seelostx.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/BalanceSheets",
      "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r69",
      "r182",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r197",
      "r199",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "10. Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventDescription": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the event or transaction that occurred between the balance sheet date and the date the financial statements are issued or available to be issued.",
        "label": "Subsequent Event, Description"
       }
      }
     },
     "localname": "SubsequentEventDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r310",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r310",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r310",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r310",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r330",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "13. Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.",
        "label": "2. Liquidity and Going Concern"
       }
      }
     },
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/LiquidityAndGoingConcern"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/FairValueMeasurementTables",
      "http://seelostx.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails",
      "http://seelostx.com/role/ScheduleOfFairValueLevel3ReconciliationDetails",
      "http://seelostx.com/role/SummaryOfFairValueMeasurementsWarrantValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r88",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLossParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r87",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLossParenthetical"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "40",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=51888271"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "40",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=109244457&loc=d3e16649-113920"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225877-175312"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.4)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "730",
   "Topic": "985",
   "URI": "https://asc.fasb.org/subtopic&trid=2197926"
  },
  "r378": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r379": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r380": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r381": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r382": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r383": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r384": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r385": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r386": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r387": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r388": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r389": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r390": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r391": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r392": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r393": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r394": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r395": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r396": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r397": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r398": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>67
<FILENAME>0001136261-22-000210-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001136261-22-000210-xbrl.zip
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MB-&.JD\Z(JA^&YQS-C)D%1E&31MTL6,$)S=;:"CH&+/*^!Z)VI,J3Y#4QK&
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MA67R0)W9Z>#\/3@T_W1/'ZZ;[4:=^<<8"JH]GX),_'46?R3*ZM,)DR4$QHY
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M:_O'N'!E5A]^\*M:"\3I-M&&KUOTE/A(N\+&XO#4KV_+XH5P_U13=N'PA&R
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MHY\M;M6U(^MJ-PL6.S*E'* !'(PXPM!A!YFR1G*]X_40O M#GL]P1<_B_G>
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MYKS7S7>CN*@.-(ULP<-\D"R(/L*N-"B@Y!;9;I<..]E'+F8J1;]]QR16C">
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MEQ:14_G0E HSX A&I.?ER+VQ!EX2^<KH#.4A2Z2!8PLLU^G0W[!<=%PC68Y
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M!J>^O0QG2G6()[.PTS2?)Z)[+S+(!"-I<*03G"SJ!TD:_FNZ1ZHBHL,T>H4
M/:>I*-H+X0GWR;7I'(<'9!\>OP8^%TU=?K+"8ZM6UC[)ZZ5+04:A@HZ$V()J
M6/O<I 'H(C3S\?9B>'!\>-"<>18:,(Q4(MCN)(UKDV=Z8ALSH3;"GAQD3S$/
M3\\^3Q]Q=@09NK=+\P'D'G#GN!^D9F&CBH'* 9V6%A$W0<(";4 M =UYA089
M;=@;$K61(MG;L1:ON[NSD)XE%C"N/5=:Z>#$N=:+3LK",+$7;>U"?W(0;CT%
M\H-_&L?,N2 K\ D47Y!>K&X&LFA*>J)T39< DO0S.=4N.,O,V"MD9(QZD6QQ
M>5 -H\9>RQ1I9-L<H,<RT(5].'(^7B?\-K_31R?OPIZ_XH;;]LF0NP$W:7X#
MAY?IP\3HP]Z[B?&B*/,=2J;K==<?S:[=RKTK\A]$:F\(#B2,1%)Z8X>X%)R^
MIDCD%1\&MO<J#P^(E8+'H1>.H]<B5SY1ECHMT67;TYHQ;YQNH3?(]+A\521U
MFU ZB$-AJ +QZPM2=Y?K!AJ@,QE=M/3*[_N;R_%\?[.H>H+0+G.Y8\8%$C.%
MB;&!BKCEW:ZZW9T)AFS<].:0/J;_^E N[[[O(M@ G<F01X-7^>FA59+GW<_(
MA':N70YV  MV@SGYE !*VB&Y.NL1Z5C>R2T'@\0*7Y1>VDR;HH7.+],6+^02
M'GFPLN4L*'6[!0SV<8F1)\DI0;+R3K]'*O5WG+S3LC8RQ-[3/@&D3LG4K$(6
M<N6$NPH%D2X$=2222N## ZO&A9N>79 ]33-3555(4"V6J'R;J?N<><QI?S5?
M2PI5;JI594-/\T.OH 7$>B[5HV&.=;+"\>N(8==T:;K3]J 2W)%:1[OI"7&^
MB , R1I'TB#UB)$A8_]TVG7MX;AUS%Q4J[?3)=EW+F%R3^%TW:A%?>M%4$BK
M!]7 :D.T>D!HTW(?\E(58CL%>_,<"S2\=\H$F5;VQS%1FSKX#N"6V'5]\Q/W
M-,T$AG#=_658/7R4\0RQ/9'LH):T"9M'IHT,%RVF' _^Y #.O6$?MDEY"3JY
M6:[^-.E%#\_Y")*W !T>> +K5)"3DQL$>%!%I)<-[3F$%^UN1V35Z=&-5_#0
M565L(2<#">"13BK39]Y0L<@8!NQ"0"ZO)\A0L$6 \!27*:!#S9!I9M@[)G#*
MT.!*-JM(U)9/QA%//X1T!840QN@C9#(O O3.TZ?G8)8I#=HTS@[]9KHW871-
MB>SB( J=!YG@*-**WMH.F6RIL<EE5]?9&)8)@](^=,\DP)O?7"7'J4"=47@H
MLUJ69[,&X-/FAFZ%8NT50/J.U'Q3HOT>24^N3)^K9M:JDH4^4J &ITK55W<O
MB (]S>#9^5*@6P4V4DBP+KN*X\GJIZ"2TEP<BY-'2,P([<6&5MFQ[JIDC:;6
M,%++.U=7&+_/_6"@FU[#1MZ<A^8^"C?[8&=B7!1&=]+#CT&AOQM/[(&V97-
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MZW8K;7^];(%)#F4D%C%4(&>>=+9V.K1#&W'6&/:DA+(W[32D02T1MB@=-QK
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MCG! QHW=CPM_P?,+6YJ,7'CP%;1AT$1? ,X7P'R $9*$C'/ G^>,;>'Q.KV
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M9&OG\O+7%C_G%O-A-?PY>R ..&7??NZ*YF!!H(0\^)]4F=[P[:8FP7_VW0S
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M[DW!'0XM2F9T1P/;9M[V""\$)5/&CXB@7$U$&S):WQP/1_C?!"RR:2%];5$
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M55?1*O@Q^C&8?BYJD__]G[K UWZ8GJ'&VYQ#<-E!W8='/\%F/^H:SV??18(
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M;= 59A11=&UNV-H-HJ\0Z >Q$G(+ZH#+!+>X*^L]8C%C"81V2#E;[+Z,%23
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MNM[HB4>WJI0R-4<('<04OOXL^3=N7E9B^HWUIB.E0YH!VMH'5-W(:=?/3-?
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MY[8]2E#,^'%HBT8TL?/S?=J?" /V'*]D*][K^F&UV+ZYGC[4Y]-[]"./D=_
MK0%+E>#,]BP @@7JYH;=XV@@XGX]"#,RHFB0B09BJ#'R,!&ZCK3N-M<<DJ(\
MD%-7L@E-.:$M"B\0JN-.H(O2M6P,X7%HCO0J<Q<J0BK;ZP@_#S^U6QS1YD+0
M>5^'N>^DH0J\X72E05:+XJP(7T> WG)_0DJ$=7PH$_=PL! *++K3L<;\@+8:
M DB@)\F_P.*D/^)P@P#ZT&B$9*^" 4N,&W.;(\C!SW&!96$AD^N#A$<_Z\L:
M]$=2)QQTGN)T9&- QRJB$=")=&2&(;W1T\<&,:OPH@,1CHCXXET9CH=(=0$X
MH6&03(TOTJ,6P"/101CX@T2).<#E'& 23:-Q4+1')W!H_D$4N../.$8VF(@#
M"FC/'1G>P"#4QO 3M!6B >D[Z/&!;F"]!/AR<#5&)$+0YVZ&:2+$F[C_D2PB
M5QS.@\N\9:U+YP\XC]FME#2L/>EO_\;H08A7Q_"C[[['&P0(@>.1@[B?Q,?M
M,!VE8+>J;)KDK;_%[USY+[M+4V UIS3=)A1F4 D;#--ALD1OC$"W)2GJ&$@"
MB652P4K7QGW,X!^=L:EH: /P$J9\IED34*&,5_3DH,'G_NY\Y\3-C>@M4L(T
M98OK3-B.9L!\?.V'R75T1/?P FE!!0W2=&Q\.(8-AILY1G\XT$9\X$>54 #$
M0,<UW9 P(>!.;/!): #9U]$!"HDS7#*1^>2F^+S7="B>N)%-AV)I-P>_0N 7
M50AE46^\3QNEW8F2.,4EO],E-VSA4RF?C,9D%FI\J5 M10[+C&WZ3E@746$:
MJ8,-?5?L1+4'\1&AW_[T]H;R='S*CC8#%!G7_GH.2I0NA?9KN=ZW]A/;R&1^
MEM@@4E94ES@<L%*H\S7TOV!#Y,@F(X3B7 H+464%G!" FR%&D,E^#F3R*BHJ
M!!A:NG$ RIX&W*M94<O3K];@YE4SA4YW6=3B/]+2B29,5E5B^XS%4HU]'BR6
M>F,+>83$,$-&XQFR\L8&],*TS<RAB"TL:CFX=!9M>R,*K&YND/X=$>9UJ0S&
M=94:U^A?W[>S'7L.RZRC[_C5-GQ-VH97OMJ&KWW;\/]Z>B]ER"WQ;9S>2!LG
M&YJ9BJ68=GZ9!8Z*Q0KU$]#?XO2M?87CT547="HAB&9;Z=Z,JN7NW4 <E2MI
MHD?%K6*%&/#X;^ZM2<*'\HD<(?_O%.DP: U-BJ$L)I3D.)<FTWJ*=,Y\E3V=
MO/^O2=Q\^PPTD&2?@E%OW_;;%Q??OB,O\PUZ2B-O%IQWI:> 9V^W$,<1=1&:
M0Q&GP1D&J2I#W 7<;A5%_6__?OW]J#UQ 42G2:9>)QFL'3]8'8R1*]E=O 6"
M2]D B01^@? HC1['Z%$Y)V+4CT>"]5MK')83)U3E=])0QW5^NI_9)-PJ,S8A
M /O;SWI8A@067DZ "$FB9]FB-_F4:)B9F@:^_:'/.M-+Z9T-AR.P'C8A 4#7
M"0&*(WW>*?6&Q4WR]TV=@ FB.+Z2 <4]'\K]Z5OC]+5=6@\/%9,7.EJFY)40
M'(D9BL?YW [P*QQYAL2?*_1<]P%D)(F!PM^<&##$1;() G.SQH#Q/B!4.E?\
MEP^)_W)1X5](:2">.>43M$EOG)?$AYA K_*=XV,#O5Y5%3*L.2SJ&QG W=P(
M1G 5M <Q)LB<','=L2.X>VX$UW">M+D%*V>D!"U9M@\6\B)[4<.^S3DOV[<V
M/NA@',\3-?8L0HCM P6%4TN[@\.:<CX8MCNEQ":OJX\,+U4"%HH5F')13@H/
MIY9_B,MF:"GJ)4 \:#ZNI7L[;OAZ),!,-K:;\@(Z-6D==Q_D<NN^?59,'&TW
MY^YGZP"?O5T6%M^MEPO%D&%W47<*]EU=F*[LLH*N"QD;V(] W^Z.<18'1V_&
MF;0?*OW\I++C)A1F8R9#?@DHLY2.0?;4U6I;;T]"^?#J_LE)+L3[WMH)Y)AP
MS.F 1=GGZ DYO(\"X^%AL]D^)L"5')1X@NA!ZAK$9;WF#^I5<T"(9\+'>":2
M#4Z<*^!U4&# CPR3?1(F*)<2M2XMYLR'[OA?>MNX'5VK#6$^A;D*E,4,L.!K
M<5-9G9271'V5[_ E-I">*IZ7U]=SS2Q+)NT\,\ML%CC2I#$9" 9TIO=@W)TS
ML_BMR9OUJ_++L^I(7>:#CJ- $_T\&DST"F'VN1$5PO@6:J%4[>C-YQ9O/!XC
M,274[;F ?@>'6\2_8;RC* ='E/211:.7L==T#<X%3FCZ6^ !)Q,.@IO@P';D
M+H(A)_=Z9-0)>)5TYC8O$  X^5[!SP7RZ/ ])/:Z\?4A)09Z%:EH=I(.SC/#
M9A)RY>QDNLA<N$(@_ZT0DFK'YMBA5QS?/2)YK@"!,2QJ21@!_0@I*J2RNJ(Y
M<-/V=%4FL0AT5'L<#.,0^%U3 X<^>CU%56C>$?MK"BZ)9,K9HR,1Z5F(*T1L
M"@YE"[D530(P3U9 $/IPM:MK)'ABIP+"7$@(XTD*^M)85 LD21U4KP&!/<5=
M U)=P&MV'\;>-%Q,H9]!#(.<TQUVR9P% B Z#FM ,J>F@]*77Q5];.+]R!J>
MF&+'VA%<[*2O$)#AR 1.@1\H!@[P0%P=5WER'>1<;F[T$-28?$;(R8S9&QW2
M2/(:0W+T/!?HA&(3((TVYY?LPKKDZ*01\J^#XYV>=C5^J::+N2\M1R>%C,\F
M1P=,HK3#ZI/N:V($(N1<2D-%LZ=M,H&T$.V!0XYX^J49D+M"8WGVE^(801F-
M2B:3F-E<Z0R7SM1@FS^ 0R5N\*ZNG(5DH-G?!Z0EH$:B)P=(!YEV8YM436TB
M907-Z@G)T+J]-:M24QFT[MQ6878NNJUED-8BTC@W:1)]_MF\K>B3+N1H.6E<
MU6*A6HSTC[F(R@$N;,YG)AHE7[HYT[5+^RZ< :AYK=M>K5,JJAG"+Z-;O+GY
M)7X",DI]\$RH2B@(C4:AU(BF*[" W*P$+VV!$><8J-@V$IW26RZB+-PI!\?S
MH ,1FMU92-.<"1F^PEA/V?C,#?GF$'?GJK!CW/4.;WZY_N]=0A&].RD\>TK.
M#GI+%I3)I?7\=KD:2=$@$<5DF3A/['4?3"S\L#T@&4O"Y KZ.<A)/!J>WAOW
M ^G<):=K6EA%&)30S((AD52X"BM67SBUQ@],A-9BA*&ZA6_=H:P,.=+CSA/,
MG;=KF]$/B19$YR9WB([I[19SB1W]E=9,^]0G8CUV163=X=(W?/-M0.S!(,P4
M]C+C*KMR$A?.A=RQ+$Y]^(];LCG2^X)&^A&_DGN5S(GPO;$W>7WK/E=&KNZE
M.P Q13]N)Q#T%,.$E T-+6:8HC')+2TK#A1+EE:>*P\A<.4AQ"5C18#-IE\2
M40#:QKZ$BEU 0Q9[$%C!M9DX!P0=%;)$P.? U9;93!E=M7OD%ODB,.L.KRUD
M4*R;K8M^8UM]3KS7N4QZ>.L7S=;O::/Q@8W:Z!-F8M_RY?!8C%WHY+%N[?MT
MQKQUXW^((MUJTEEMW= 1SJV/;>K.1[6CTJWX_-"Z;+0^K/V:(S&GL6PK0<O6
MIF9<21XT;0.U ^M@VLY'/BWQ=OK[_.7X]D9<R*Y=&(=K8?&23@I9F[R,U1HA
M_K ):YL<MIT1#$]6LE"]K"5'H,([I'>Z3-)[G[Z+9T\5\:KQO!ZDAQ&0V<UT
M")P1^87T"*.)W,0Z<R_0''MT+:W+C):Y#B3,L:Q#:V.QSPB '.(\.VK$0V,3
M'/*BUX"F#31<.PFC[745+F?P2EM@/\ #0UV25<*DMK7[)IK<0$'?-6A"NPC6
MQBM< G=M@QBQ/JP* ;MQKX>6@FLC^MLMN%Q&U-?=W'"7P:\HB/@@R/>JJXAJ
M2+LPC1 >VA/>A8%+& N<8CDG-#D%M^2#*VLG0L@L02[F<>.0@+W44650650V
M,=MAWD>_1"<<=U2E"PZ.(8(_ *GCZ!<C63;HN13 F B=TR#CGVQ*?]/"%]WF
MW'QB=5+@I+&,4^GQA38#,O+RA-A[2/^.J)3U8!V4\"ONRH9@.-)-:XL&"+@N
MZ< OTK0#.*,#)]P#1S3-\9"L C?$MJC=W*"4I)@L^) YB:_ST/$QJG!$=BA;
M UVRJP38%^!SKZXO#C?:5"<X+1#Q)O"7(;,=_5CKXH(>FI6PO;D!E&<HYO-6
M#WPR!:[L0?@;0&[H8Y(,2R@:N8!$U(%^#5D.5!/=;+<1V1BXW=R$FT Q*=<=
M&Z\R;ON&,T%(0@>$5<@>:4V=D\.'ZQR</CU>\%&ZP9O=YO;MW^$D RA0(A]$
MVYS*ANX%3$\$3 YH:1/;+DJ30:&-1(4F:-BKT3Y*DBZ3+ 2R%9RP(0+N)_['
MW204V91ED@: :^BSD9!A!>+KF:HVFVL?Z\#'Y7JSRM099!.=I#ZU=M]*S\K#
MY'JB9)D%?&YG&=E[P)1PD2YF/_/YXEP7;R_!3+(;J@6A$IWPZ;4C<0\)IQ$D
M27GR([>>872FI1L]60$&,YL:8TL[+B"A!4D/)X?GP]_/K[NOY8.[<M[QE,2=
MSH55;!<BS+[I2'3+VBQHU?1(G'JP"9^#G<OQG3E7;N5EWVT3V6>R-%9EFG44
MP"S+G+?(."04X:AW\QKD?T3SS0;/<D&F'WJ<W@]>A\/+Y_K3Y8*].+'MZ^;+
MN5\DI#$VR>6D;1'8$M\UEQT[+]S=E&;0$MB0@5K*?QG*<>"YTT+'[G4OS/OI
MFW L+7)L5R?^@ *$D2I._@6O6/[VTT846"$.(C@&$]BR(:E)YW9JTE+5='Q7
M8WJJL%XAR?V32:L2T@7&Z5*2HFM)^O,R_4J<441H7ZHX,N5_.?MOWV8?'Q'>
M8=W?429DM'OJ>0&9K(5." +X_WTKQP]U\(^C3_]=>PS]->:V4\)M^\!MB\_/
MH]BK5/_*$D@N540N&_V.$/E.+G!U]]I 'XZ;4.+OZ./MSQ/UF)#PV+(/Q2\P
MT>4JW,',GU/G>M &A3L\S:X?PD#V_,(&EUM\E'$)> NI5] ^,J-X )PM!,TC
M"LPK!,M3I)&'XR$R@:7L>T8_6;?=W9>;T>$E[WA2$3@M<$.RD]QL[!DADO+N
M9Y:NUND]+7_Y8TBK/CL9@)#D5L"#JBV5BDBE0SY4]/OJ^$J0*I?2[7,**B([
M63T5T7VL%15%YK[]Y9N-%:9 8K5*F!R,DN^Y7 ?-*^]XAU+YQ2EU>OYTTQP^
MF>^M[N>0=[Q#J?QLE%KGA04HM3B'O,LD=WU>>9<I%?5?U=8QO]=HW*?1FA]
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MHQR;]?9TYP!&E?"INH/1<X$D2B]]8>KD6$JRSB?@],*_JQ5AX([;!<Y]17$
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M2R;TN*1=O#-'U"\'ILN*3IEK9I^ZIN2^4R]:RGVZ8IIKOO7^/@C#K\U^GH)
MXVX0=3FR=L=:?,TQRZ<]U!O@L#>EYIA-D!XL-0?W 9Y*P0).G7PK:@YOQC1J
M/S\Z>OOS>L]A(1?OK2\*^0#ALER#E$E4N.A-":.I%Z6@SW1Q>PM*C0*.:5\8
MD7&\\OK4WK4/T&OW+0YSASVL%O(P[P=!U*5_G?3&?<AX=9)IW:X.2KM=K?B=
M_WS]78'Q\O[OX5]-]W99!A>D#F(3*U+?. ^%&D?!RQ-6,"B+99KID.LCP 6R
M@$RX'AP2.S/D =&2;*6RS!.'5@T.Y9&>AC@V='_!?DL9MX1S%D1]2RC;:UZ?
MK=U_OJK?O4^_>T%V.6K=9K/RIH23K;;DI$VO+9$5]O$Z1[Q/Z^Z[^(@;;W7<
M[N=^#$+(TWBV8)"D2V+ZWWJ8Q7':8704$__SPV9A%V_1A6GJU"](RW_'1M41
M&E7V7&[0*.&;V.VU(N3/6!K9LSPS,&K7=1+FIFUO+MT=;=Z0K17V))L^UKK/
M9RG\Z_F;0KW>)BM6'NEJ%C]B0S1W-H-'MI6:,)I3KOK2Z(=3.<L9V"GD+$,[
MT@.S/8B&J/HLC@F_'#N^77YVF?.H;6JLICF/CD-0(-6YUNK>BM8[9M;KG0!#
M]C#?!U&BM+'^UYO.:>/MZ9O#G:W<6)_FY!9%];Y;&RSIDUI@'U:1.-TJ\R _
M )J;7SQKT=STQ,X5TEPV^/#U]\]__7V^^;A);GI2Z-V07+,]&PIW+?SU]=18
MQAU2^U1BGQ^W7R&#E:V 0]XO;,08N<=__];V6O_N7!UUEJ?WFZ#4KI^E+K3R
ME52C-!IEGOW[)[3YI=8KY*H+$EIT\>GJM[?-\XOD<='9=#YZ5W2VM3U;>*\2
MI_OV9+G6$:8K$A/ULLOPUJ];N\WHWS^/3N._=E9$G3-+^%9FPJR>GQ9][BO@
MD:UV64;_0R:E^5BS,[CGU\_7?[S[^W]W6]L7GQXB*:V3,ZZ 7G8:L]$@2JL\
M9Y5L'OWS=;>3?AEXAY_[VY]6$R 8=\H_E##;>J)UX[N[^N@=4-K 3RD$A'%M
MRK_KJ[#KJ^303[I!E&2QFA*2:]@6Y'(#_?,U_-R(?W??]/?C]NWB;/_I_-)L
MU1WK_9PI8,_@/R\Z*SOHCCFDU8WI__)6P;U/BM4A#Y0H'\2<)K)I; /OK4H2
MI4XXG!GV:6\/X1;$/F5HS+'QZ.MC" [%_!8*4L  >_158\[Y[R_;G>$?FUGO
M9D5?DN)1-OKXM9VS0NSW+:F!.% Q&:Z8]>>$?J@V**<0$_(P,=#!&"9&G4,&
M6=!)@9CIA_F$E\KU),,QP8 SGM??4?RY9OZ%PM6GM,7WT17G[.(\*"VP\,EX
MFEZHKC'YES)E2]^/68H>)^C"W])K%5S)[!/^NX.BGIZE#*WA,(Z^@/!+53!R
M?MS#(@'*C*9'QN?3:A3F4ZW(A)QUS:==VYV8CSZVL2J=:@43:\(H]3$/&?XB
M"===S"Q2\1".(P_WDWJ"V3E1MYL-1_1%/E1XJ@VO/'7AD/:O5)BIFGU^?U/Z
M#HP'1A5F"-1,%G=A&K'Z-_-CP99SNYCMW1GIF6]S<G8Q59J_Q4,-8S7 6FL:
M^Q*&<[TK@D@87T_Y*AT_J5: [#JQ<N%].JM]XGADYK&"<U!%0KNDK71ZF*R+
M:;H=T.HD\X&> )55Q;-3EQX&&UQWRL.JAEV'4(/#491ZIW[YS__9V'!>^2KP
M?@;2[H.R?@X4"K)?_>SL.AL;6H7U_*N9ZCX04J@=&_Q*\X5M6@:G@"R8]V%E
M<^"C\2^6N41AN,3_J@@9I3S65GA>#L9:J%[B2P=3-W]V]F.WXW=?.IB/R=OP
M/L*U-W?LIU[HQ_!/.7R+5NK_\P+VJ&R[X+*!&45WZ6=G2'LL.P1&SLJW9]'M
MF#U_>]FX'[QDBVX>S W<JN_"/<%_K/@2SJ[KO2-%J=4L*$K^Q^[[WF_''>]#
M[O<V<W "_"J8K)8R<WMEJC"#&RA3&I]G0BQ/U%!P?9D*60EP;J!131'1U8J6
MT;5<O?HM S4"5\W2=N(%N%6N#V)MMAZR.:X7C1/-JSE$PZG/%]'1EU2%WIKH
MYL_!Q5^#GOLJ:/8MNB%'"NR]HE??"[$45X\I9:BBY*?@A\1N$B<*%=:P#(")
MLK(+AR5(4=.T#2QRF57D@ZH,J7L;46\C2Q2\%R:8EM>HV$92<0EG.,1)[V.B
M]O%QALG4M=&K.L /!ZU+/^T/_^U-O??V4AQ:R3ROV<QUS$RYGWGJMRA+9N_K
M]LR"9(J22@(PKSSP07P'/NBWR!6BXKZ4'^>KJ<?Y5@^VGH-4[9,_^NFQ^GSI
M33U)O1X?*U5G%?M/F?E!%B.W6L\"_@@.W??>Y8?FE[U%%N!L.%V>SG+4:!9S
M?W1XH^G*WC_ VU-^G0S^%=P2KK1T@P",Q$2S7DJ,ER.</-XU%ZDP\2^BZ&C%
M;Z5OO_4P&S%G"S;,!QBNI,$_#J-0#/3! *V*@2@8^-FX%E.M%#P-!=7(+SH^
M?(S/="^Q]HK8(0X'XG*<+>9,<VJ]IULB4JCR=(*;3N=),X7C>.3^IBSIXNKC
M']L?_]Z\^M1=O<AKWL6EW=F<)?*HBK],DYG1,H\/&=U1FJ;&"0"N^.+G. VN
ME_[(V,OF:',09@HM_O&^?9*<];9;?[DS5<P9K1AG@7,M.T_$A=R:":^5>^[&
M][=:\?R$'&I.3-BYDUO87G0+#V6D,QCH5,7=@L#.3K-8V9OX?O/UQ[0='#?/
MEJ/P^2]=03_,<L+&)2!Z\U2R_JF^*FM]!IN]D_*]5QGVI7X'E#;(!F=D24H5
M++:M+IY(<H'>EFFE>K^6ENK=8OQ_OOYU^3;<"\]W]@>W+,LK,:=Z-#%GP#,3
MQC*4J16U\6I%U'%"-("CV. Z;_)[(9\B19WLNQ2D%QE\>!VYC-Q-I")PL0*[
M5_]\;?Y^]KFY^^O?_F[W5O%SV[\TL\9N;"_&V:W>E3OP>MU9M=WN8L5VLZMX
M2O*[9/B=O:FU&G.+.:9_05/)YMZNE4OUUTG[ZDLO>7UUY<ZJFYOE7=V!=YF[
MN'#KFHE-F-UL89G:E09&$&94KTPNY@<331^?O=FU EI'F4O'F$*:1;$0AND!
M(_-14"!R: YX/W#?GKQ]>_IUJ_WIGZ_QL/]ZY^N;/Z_W\]R&^3MFQ+S#E<E<
MC#B!>C2EA&J5?0/FMG"8(K5OOI$KD-\S4^&F]-R;0AR_+DL<A]@%K-&\,-20
M6M3PX?KKYB?XG_"W[N+44#@#W"[-U'[XA4!95T\$,Z\DQ7A*[N-Z2.1P=B^O
MNR>(>>YOLX*/H=:M%>*"P%<U!$NC^5Y3A^<#NP#Z^*K>G?_S]>OV&^_L^NC@
M.@Z68!8X"PRD)VAO,URA?O-=D4;)%Y_=XO"G;=V:*6$20._Y+$HX6,3E:O$!
M<\R9_^G-Q_T_C]YYVTL<\PR?Y)V)@3DL8/5=5&[@0UT%2YA2,W6[[B9CFO=D
MSK_D#9\I;\%&*-O_?'W[QYO1NWW??7MT.]B-6?KW@_ \KG*85]@3TR0,+0"F
M9WJPU#AL*@GCU0I%;90&])I:%_>G3G:? 117)'6I7BF'>60-_R(<?0Z&UYO7
MK?YD5.77)4:>J,/83:Z.K\-D=^NWUG(7]$@GTJ\R3WT&4M6JYG:+JHNE^[64
M^X[PIMOQB\4(2N/6K2-(,>_=#S- H9.H+:^[G0]N9U4_I%3HB[$P?B&5)(C"
M_@9YODT>@7B=!)*W6H'1LQXN-Z:T$>!6238<!C[^1IF3DJ;I^)0+.G _JT)?
M/W'FY"AN4=QW0_\K9T(6\S>YZT="B18X3<EW,:FOU0HY3$ 9H#H\A*RB0N>:
M>:/U43YQN*>UPLSMU0J6%;ND:A+8&[@CLZYLN-&+8?C<60=#52OYUG6MH@#"
M9$PN5]-V8DQT_J>#Y*>) ZEMI;4!L,><GKHR2KZ[^9?W(*(L6X<SFAW,0HI]
M:C2I%PID@&E+&*E#4KN*@BL-@BL4N:KV(7=><7.>=1)*P4R/KI PIQ77V#&8
MJ<_\\[6;?3SWD[0=^\'MZVC:=2=_5;7"+ULA,:PUL=$VTG_-$C\$$Q*(I8.9
M[$!2YVKHQI3OED, 7L2@L[-,3B;S'C>-@K39VK,BO&.G40*<.O8-$^)M[[_I
M--]LO_TCKQZ=35J;)D]M<P/FH,N?2\<?)[3;[<$/OYR$SOX0R,K9E5M;K9PK
M%40)7,%X&#%4H/,,BPY:C9?G%\?TK^;+YS5L W4)XF"T$5V'"#,(T_4]WXU'
M6OF62\R\__0R4J'_)4N<_==.[\7G%Z[SQPBT./B#"]I85V5D)=.?]>OH"^:%
MV.AD#,H:F+Y'TNT9OD^>VM>?ZB=UYQ**G#NG&7 I-+/W3>I>AV&T.RJ]1B!X
M6"7]3J^O.8RBR,R-RAZ:N]7*,ZQH&+!%@8\[/3].4FM&Q/RT(-5SCC !8N0T
M=WF8&@'D(VSC @^.N8CI:2JBB1=Y^J2;1OAP<XL>WI/<-($RG__\*]6),SQ;
M'D GR-H'5:U,;JT^@CIN>Y*Y1A'1AS_Q1(VWOZMK3RXEG8-U'SM="ZB,![&
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MX_>O9G:"VYK=!ZY:R1O!E<.DV\WA;%%^C'U-07O@%VFA370[AW"I1*N9QQ1
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M\PNQB+E'NORU@A7@M83_3!KZW0CXB2LA"U3N%YG\M8\%3P:X [7\7@;#9[I
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M4/\0BV3J3%&NA.F4-1?.R$9[LMY>$QJ&/Q(OQQ ")>SD3XH Q6T@(8K$CX$
M1$Z$0;C0DGE;9^1DB4/8SR-)ZX+C3[!A,XE$)+&H@P>%'=II1</ #1/RT>+H
M;O?25U? !IU7G$Q5D_S[&;P\5KU =7GP*Q^1D,* \I%D)W5D("7H0=ET9!9J
M2$+8(#;#[ /WN@92F?W**>:*A%$1 SERLB&-B$N<,2M<VS57G@:N/Z"O,ZN
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M+2<95"N49<"Z%L4^XRCK&]E:\,Y@O@<64)"2Q;>[H (@J^#24)R?J8"M48%
MJ"MC\^I4W#B>HZI7*\=YBE$MGRY6X\*1H><$F$B<#<WJP*R#Q1%,LVA _2#J
MX"9PFA3I0"H5"P_'":2F)'2PG"?"O4R"Z-H#,0L;I&MY.0SK!C6'7"VTL376
ME+FZ)4+6VX] Z(1XY_%P,U FQ"M ZIH$DK&>(7 '>7;*"]1EJ>""#1*@: ]1
MY@GDS?^J:289HN^0\L#-1G S7YV"5=/(Y4D:^S3:W)>A4=LQ4RM4]-:=7SGO
MB_**]!N!!BCX4JM6!E&23EZ"ZP@VV$.0T CCU77GXQ D!YR)6(=4M21@^O@T
M5R1=HTK+]AUZ+&+2$CU2KFP1Y*D \[.8UN"U0U=J4($"(]PH+1U!U_&Q) WU
M3JD5JJ'-0#28HD6<#?$6^E=\0*2?3GUV"_<"& OY@8R=.[:2:H6=F:&Y+VS6
M%G+!+)OW6K3XPGH-[>%KAG!LY,,)8[@>)*B'L0\4[(,>['&>'BP&)#I.BR+H
M0#>P'[3(S,.]2]5$R5$R]#^3(]@<:I<P$V5$_,H)7 /@/LX5O OVO>Z\B:Y!
MH+$EG#,=[M.3VOX0F V[0& 2F(,(9JV'MY$<S0Y"BY&50'JN2N _7958KH/!
M0G7@-Y<%CZA_SE//G!GAX[VGGCG%(/**J.X^;MR-QC8Y)04- 54TXKSH]8J(
M-^4EI.P*YY@6R-(K]AA>*4OE<S\K:E;"V9@1,V@W1T!P/6"""&LMFEI1Z3+1
M+JD,+DHYAE70J; D;@OZGN'&R^MTVD6-PMBH=P@<G86?0Q0FY A$CX&GABID
MFU!<X[:[C@=#1Z^&\T [[=+O7\+V&;<O*VQN*,Y8V$K4]=!?RC[M\A&U\U<*
M;F$*J"LF+%&\3'**2;U&2>.GHZD;P\^H@8K[=.LQ:9Z4(WP"8>C-$R*_Y"WY
MJ?%!C*N$Q>^P?F'IJ!QB[6<!*JD@T:1Y*1O,$1&&8@5#H?[/RAE6I>8Y\@6R
MH[I>,3'H]ZYN<0?C35,E28NY5C72W&"R@2Y!#$=Y=P4&84&:8 ^5--]!Y9.A
M2^&;FJH(;EQ4:#O)VM@E6NFB^#!U$< _"_6,Z4PU+A\F'T2@"!C/4EYZXI0?
M5[2N%8+EC$R3 AF$3(WZ>=UY%44>[>9AG/4=NZ.\%?A]=;B?!WYCXRV>/"Z\
M.EDW955N0X<&_# 9:A,(I]DEYZHG5XEF'L!=#EW6F\D+* \[UK,<K.*]IVTR
M-U8(*[\W0+#P,'#X4;4"&CLU>R*]G[1$=%R33W(*;\#]@EG!9F6)00_B.A+Q
MB4=CS(/HF0(=.M"&[X"C(,4+R("O+<Z:R_9M:J"'XZ@?NX.$2@%RGEO0"&'F
M.<,E]R304-<?:OUS-D,EOG0+EC<^8]VQ!P,5KH_M)?*K*+<_EQGPL%1KF-5H
M5DU-O]##JJ.J#,P?BK;,!>\3W-['_EX8ZUA.BM31LUZM<-B.HW9.<[]62,.H
ME30WQ2A/EN@ &O-<2_/7)+0B9]M#J ^8<%?IS&FP.5&"W[??[4:*C5@4)[9>
M 8Q(!7BW"-/KBLS) 7*8(<4-4B7.X#2/Y5@H&F(OH^,"2T<4YASX"4/A2[)V
MP><;P(R4EHK\++M^!RCHL=*+X1A"KE=CD9-R=A'&8X$UHT-(NU/8[YN0TQGM
M>"<67PJWCK&TA=7;? MU3=U;00>($^:/*%@*CO6A/V06BSMCV@OD_01RZ\*V
M)L:MC>)FM!:&SF>[8@XVO&1TSL9Z[Y MV;2!9<O1<?-W;_U4#OY>2,:R;$9&
MSX;+=<K[R+=+2IIFH.\W?YHWYA@JX@+0]LLOM[5[T^4><S21X.,>TXJ;K9NN
MV(J-\+1.L;#H<:U^<W6K1S]ZEHPO?Y&V#L6K>_-=>7IRY4\N=7P6899\YR9T
M)C[O_W1BYP6]XCC'R3ISNZ3=_BYX6>,+7GBY9O#RC5O]JO:[&::T9F!1>+"0
M8T_E7H-?%:C96);];/_\^-?GW+'N$QHVCG-(&6()&MF'$G1VGKT[/'Q^TZ7?
MV8J),SK'QPOL]0,]LP-V!2B*/(+&Y'944!;98&])&*&;R<.I<$X@5\[!NTF+
M G76Y00O,H^:VD4$JE?4PQZ"H'-22AV'/S1HWXY.-*?43QP2YV.]'(:A 5ND
M$SN<,\5Z*DZ% V:(E(C#ENV<7/<G7OT8GUQ>U$[WZ1-*K/QU?IW5 CQ\JU#6
M[\S_GY6]__@/YR(&KAI$B;(FL:ICFKF'L\7 8!2!C3D$P]-YBTX5K*WM!BJ.
M$C"SGNV_/9]@[/<V5\W 7QP#$W\HDSJQ4$%;&CX68R:& 3L>(ZL(?V6(5/2&
MDS-/BA*T1]SP2BI+ @[YLL!;.32_Q@MW]RQF5DQO6M>8IVG>YS173'+WL'*:
MW2)O.A_Z8=15L0)-*W!C9S]UO_BN\^S\8/_N^.*-YJ^99>=.N>5-B>P<\XB*
M:43"ZUZ.Z9:4"X/SF.2C$I7.DZ_*8\>/SS/P:#CVHY_.MTX/YV[8\P-_.(R<
M\U'H@?4WX;*X=_7NP4SHI)-*E]+033/4C"]!/<, .-K.CX]LGIZ\&X5F 4MT
M\\$0^:D;?_;#) K_.T&''K5>?'8ZZ<Z[OPG&:N/X_>%#FH])ND$+S=)5[HNF
M7JM02?'AZ+[OTO?RY!/+?]1/WCW+WWXX'.S!L_R'Z.A['W$&*">86HDI+PV6
M+ZF*,#",H8;)?9$;1E\PT',8#2DFZ>SW(TSRO.\K][T\^209'O63=R\9=AX,
MCWOXDN&!&P.C^S8%3M4P!5'D'(>7?L=/H_B^K]/W\N03UW_43^;'9^&'WBS5
M?1)G=6[*\YH*^W1%;>>7MUC1=2I%)^O,M5_O2C U/,"EZ/H9*JK+JV1T*TM=
M/&@!0J2Q<E,=1%HL^4UW4CT__M640^6EY)+.3XEQY5EQNOODX:%^G//W)1EE
M<I9.<9*S4S/T[-Z>%U#_ID4L-0#5P;Z%N[G@3$JB!H5VHH2WEA0:V)0XS'4=
M)$R^HPA@0,PFY=77? $601/?NETAN"YS7D5EN+R3@#R&"4Q._VL,?'J"K\V6
M/9.LZ8<2=.EV>ZQ^>J&RZ_8F/-5JC#\Q;<P5U91/V>R;%GFOCO&MA8D79!J=
MA:>ZTISZ9P9!P\S./&-9RS==9.5CY:G)78XE=UGW^F6D5B>]QGK,*RRC[.M,
M)"P$]K!@5+#3N))3\Q10R!,;<E45>#3>=\'/TEV@BFP.V"ME&!\>UC4#AZD@
MWB,(3.S:@P@=L#=7B-F,^:JN\YM[A:5 XUVS&7/OQ9LH&?K8LYJP6/4T:''-
M;6?"><\ IE2K.80O?Z'J47CG5J-1K209P5LF9FJZM$MQ?UR#XZ6K" D4#&XT
MPGC1EF%A(Z[7243<6( Z!?0?V#KLB\5;3OV"@17#$9-DX3RQO&L1;:=&]$M4
M2A6R6.(ZD.IE*NO^ NR7,&_TAK/ Y$)VF!@A+/F=C"OT72R_[6(MK>)"<T8/
M%2')E9T$APC;0B+ C[O9 'L9=S7.J]_C^GCI5#RBURG",8'SHSK.J(?]PA >
M *N5U>>\U)^Z.%EU=_(@3JV#172AWU,)%<?_J1B>%^&5K&HYKK:+A@@*@YU%
MRO>99GB4@615;FAJ\W 2!K?-;"SP9@3OT<#2?LA-3E!7@,MQ25"0&K:64ZH[
MA/\B!["/A=*,V/B&,*\0I=,Y4V!9(X@63N1#1A11DZJ_:_Q1I,,F-D3!_W<0
MEYK+D77!/DC?*!KP[/FD8$?<-%6#(2^CU6BVI^Q"$(4*<5.QCEV*X_652+)^
M'_$5-6L@=)HQ!8$.Q04N,O2]6G[&.:U5*SBK6/48PPLO,2M)&IL@OP_W5*UX
MV]&1U1EV4BA5%)YC0289Y&P@%>"PV(,H"%0@6&@CZLN'4,NQ.81GX@9_3O2>
MIY,B?":<F)7 CR7/\F7MA>B9]WK4(XA.[U^#_,G8!=4*(QDPI)M@R#?JSCY#
M 6-5>(V+/PJ0;UU3AN 2MHQSX P4(Q08>-A7A_M26\[]Q9U^!F>-Q;;,=JBZ
MT^595RO'QUQV0(A%4G:@I<MIE*/03RP.-U@+D#&]_/"0T#L1)8T =HG!,(!<
MZ9EQBT6X]+KVU!3]UL:: X8P0S,"'@+CC]Y_]>UM1[?.77.PL?,UX/PN< <0
M5]A/4R&JF-1WV 1OVD.62?N2P[HV3)W2IXD9@D 8@KF#@W/I/4'W*TUB_\TY
M?]3G(;<)&8(!9:]]ODR-"&/Z2$_G)'1^RX 7M]JU_"[F;(%SRREOG#$5#7]@
M%#/-( 3B%/&I%0(5O] ?>*,0F'TWR6_9#&71>2;'_-SN>T$B(H Y8=8[T047
M >77W(LR-(0Z<'] :L!WNZH3;9 > C8./ ;7729@WVVMAAER(9Z8UQ_1Q<T?
M18''3#9-?M;U3:A2@L#/2Z<03UU6VMPQKQ!%1ANI7&;.:.)<UV39L>[\]9A7
MC GU5L.\$0QQ/%O=$G:KE@/YS2XB,+NBH>E-$9?9BKISHOEW^;@,C\D0,WB#
M&01$%Y<5<V\7?U]>*#;V.K[-J";,+D.K5DY/9$B&1;$FU8TN"?5/\!(GA,*S
M&73[O :$.0#KA<HLD*,50!%S7L4*#3ML7")PL#H#PM(TJ*5PH R3/DL*H47D
MZTO%^PDC6 3G>+[;#Z-$-VV!9\2G0MA!R:A["40>(_K#)5HV>8=B UPXUEL@
MU]L%L-VEWBBTWTD7<2CA"R!4=QM;+YW6+AR*3SU864U\!\3;!_T^'FT 0]O;
M>9ET0-DT+BYL>4);5ZV<8Q\_02E^MW]X)CC%-=Q4_9HMA #:IO)!_ 9AL&PT
M&X7OZ*DTM\:F<GZIU*4;;IQ;IA-)'>ISQ&\_WSB_.'\.LCLB#9;&Y$/3SB="
M9 ;.CR:9WA;1D9\ESZFC"%Q8N%*#W$0]P#;)'=\5)R%"M N2%B]>O_U@X_S\
M[/RYWF9Y)5TC,/G #D9<SS!'J>77,K837QWYB-@3J78(((430<P=PHRM(:OY
ME'E]"_>'C, $M;B,KB.W(LBMU)S(L0+4=7:VZUL_H6P?8J-F!MUY9G[5?5FV
M&O@=@G1"5#.\E9IPGFLK@F$SD90].JS\:--KF,)H ]$\'3 68]WS@)D5,#!5
M$Q^#2V^T7H5C6^=';V[OU3=QO4V0?T(7CUER ]/?7I:S4V587DUKBU>[5FRL
MJ-8R6'M*>0@?I!TGL]1U7^L79HJQO(XN.\%TL7> BRO&A4'+F?B*BW+%00^E
MX#-?J]A6REW+H&1#7-PPVLFTM@._$^"AY7UV6Y;/#F_]\1\HDKAN%%DF0=RA
M/I02'M=7%4LGEFX<D4\*M[T31)&WT8E==(RZ<>RK6#?AH496"8+@(=1]?V04
M^F"41 DLC>K)+Z]=FXB&5I!;>I5=^:#?:$M5?!= K 19A$!5<S&*Q"O%*YMB
M*KP]APT^8#N2,>A\@^^2<%L;X)DEP0GL*&;&9L]0=.T,0'QW,XR)7"OJS./Y
MB=OM@O:+_/U9H][>;#F?#]WG#.$D:(+P=!\VDDJ-TLLHB/JT#P@&S5Y ZM<1
M! CEEI*?A%GS970=TJ4!O441'W8&6=(-^";0<4T[+ :%"[%C+L-5D3^)H!P9
MFTR1C\E-DJC+ZB\SU4Z(SJF ID/K%&H!_M_O8Y\?P24<GR8WGP%6K(IKM)["
M"0S\!)1ACRTM'#<IJ/Z1H2^+O(28$@WCS'XR^:*,2\V7N['/R..,RN8<_2IZ
MQ<6KHU]SM>*S&DE'&]SWG&B)O,U;^Y@/#8:AZ"O8.:?P0AB2B35D1YKX1XS?
M,44_HF L.F%&'?;@.;/SC %FM@H1#K,!@B/JCDLP/Y=POQBE;C4X<8OUR9@1
MXFHWGD)<MPYQ-1]WB&NUU+:>4%?.N_<:H/H-^B\&;U$2 C52:PEB7[:"BPP)
MN!.I*492Y9H%6F4Q1O1U7G&Y Q"O>P0"@IK C,*^0O8++)M8J3=**!8_$K9T
M<OKN4+JRD"^[&'5''SR%W5/4M]KR#,BRMF%EV+-+ (43,)A!#'F1\QLL>GBI
M&4U-NQL+!I[8GN1T"Q*#L(RS@&L.:K?;-\UIW.X(.Z01O&<=^('-W,=XEM8L
M--,7-J>E&SH]E,A@-I#>GPNV+(NUFD-PO!F%ZS#^1U,+4,Q1[T!NA<KV-,(M
MBA\$!W<P_>*RCGTV*0@S65^CNT3I)D[HI86I$\A]:6A"P(%A;JD;IA.+\QFF
M5K0*( (7VT_@MIU&P6C_!?[\8/C]([4Z_J3^5BAYU7CL!S%D0QWT<F/B<P2F
M:L,!DQ%;U-&*S@V\ YQS H2-)!WDL,D4]]/EV!BP^C+TN65NJ]'>'(.]/8GA
MRH4,27R8NY/U53N4F\;NY<);+4T&^X;FI=^3$3_Y@PG\P3?,*XX^\AMH7CF<
M1Z.YQX90DF342,3JK>)C[-$%<A+0Z#2+T2S+F_<%(T:U)8\ZQ_OZV$U3;O6%
M<@>V[OH*U>8B#//%^2L=^4#=)XQ"<CCEX*%Z8-P8\S3]D_V5?+1T ;N7?N#!
M;_SR,IT9'7?[P"<#T!,L!S,%)&GB,"8<A=W* _>T9"B8#O4-9+NR;KZ-'@[M
MB('=*0QJ/5",S[[#M2)TJQU,I:/'KS$QY%KHK+@$?I=7F?5!G#FMK?%E2NL6
M LKF*Z*UOV:CMK/5K+6WVD[JI^C X]9<)^].3\ZIC_DY-3)_=W3QYN3PW'EU
M<N9<G!WM7QR_?PU_</9?OSX[>DV]RJN5P^/SH_WS(P>^ _\\.3L\.J/1Y.HP
MT' BB0-R^\3=OB4)%KK_#4^R2XCIM'\#8-(,2IYINVIR#.H.(KR?]X8,+W:'
M"M>CKI ZE2U1 =]D=B-@AD&HC,="M^;^F<2@:..=+ !S)A>@+HM/=+\B:'LT
M ),GV!@"T_ ]D.NCQ'=1.NAOG?K=S_^=Y)(0;&;0]:(..74]A1I^+/8,Q7TD
M^2[)AD!5&<@C-'] /L)0,&>XA^ADB\A^H@L+LIEY'^>[^\G  :'SF9@5*!%@
MK0PB2G)H[N0N[0F"T21\ANSN%"B5_+0F=7Z2EYV=:F9V@WN$#SMLMO@A*J?2
ME8A"S>AVP:EP+)*>41YQ=81\KQ%SY=#&090,,/)#;961-8O6P#Z;L59VH;KF
M% MWJ'O[6#T?="B_8+?KU@;4F&YH-L5(4[V=K?((@>G].,9X[. B[=C^V_.<
M;TSE%\3239_T*7$SIF_1A,:3(C%S \Q.?)U6.C"=%#6-@/GL&S>^<F./WTU9
MFI=1%-1@E4D"FEV&^3G<IKAL,(;NQX-EEL4"D^,%!IFZ)#-3 ITX5.+C%]U0
M$6?E-XT-S[C7KC\@QM+'0;#%4!<4, IJ\#[02_%#Q(L7GT W2J3Y1()Q%Y A
M-HUHX'N)8LW#PB(2FX.'I47UU+VB,WT/3$^?Z1@-L9>!1$D7<PETSR@@C^/W
MK#P08>%GY1*C<#M+O5,@@NH.P=9L%'%KD.KI$EZ[(U9WK[4JQ+<-(T 4N)J^
M\G+@FCH[$WWO?WYP_WD3?-[9W=W;:[6VT1P4K^%CU%/W/3OI3?S.EIM0.[YL
MPT#'^JW6:2P\*3A"T3I/]7R\2V4@[79S P%DJ '_!YZ::"%WF'TF+1(E*^5G
MY9G;.^/?O<!XY1D*I=2D?N6/4LM'L*.!C$+?K<U+MC8U6*C[-7=>6I58.B/F
M,%<+>49PU]AG1<$>4 A ?H780B+L!>Y $M;0_DG2RP%, >3O$%FRHF2VU)<^
M%JR&ESE9<S:N$G*RX4/R]F8#APY!$8T"-4Q&DFD1<.C)=";--[#9JK$,P_@!
M.8U8P+!N-X3SW) ^%"C?4)3D;>P?J2WVG\XOY^2K$)?[B?38>_PE&3?(2_[9
M#G+,RZ$KYA3I)#IG^1RZ5UI-16J#S^R$.0IBS,QLT\G1>:PL3XI;.-$-74]Y
MDLJ4-+;R5!>X3Y27BR$%.W$"O5HF;P*%BI4G40K<.Y8X8R5X3(0:9X08J;N,
M'=-\O/?REA$Z^@)?YF0"Q(Z)M\2=14J-.#'6HJ$ZMH):K=RCANJ4**C5RNHU
MU-H"*JHSIJ%2G]%EX5IOK9XZD]HI)XRL6CW]4^EDD7XFBF6)PLIA+I.B1X"1
M5@J>CL"N1H5UI/FZM(,B=AR92C#I8D:^V;*B,PKSQ3BXHA0@ZM%;5FM&:2LF
MF<>P9-+62AJ9W17W>@K.K3<XUWH*SCVL&K3-,6D)SX+*M@$[A@[$@'Q8/E[>
M*^KS" Q9VS'$>SB0C^8AJ6W<"?KP_3ZY.4<2O)(P%29]PF\F)349D1\0K9X
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M.1\-.E%0XF:#7=IM%^'K\N%EIS3:7).(=R8:'K=!SV/A+0I0Y+ \4KN5I!M
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MOB[APZ 2%2ZI]!H]7; N^IW>7J,B6XV42#F/S=UJY1GJ@ .EZ^U<R8?*9T3
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MFLHET$>8:#8QTVRHV?I^M6)RDCB(QUC9TY7Q9*Z:3;[LTLGWBEHR*^+-&FJ
MH..#W)[![(N:H8V6PPPQ6589;]:V=W<G5&RL2;)48*/G%D+O?-J;HL.BPC&^
MKJU:>W=WAK>>)4?)*EC)*YPQ@QE.'G(N"U:7B+).VY@*WS>MBV*EX$EY]#40
M+094AED'E _8N!Y5B-)M*5JHFF"=5JO6VMJM-;:W9P5'R);A8([H).85SH_M
M>K-!U@T-8+J[<:E+T;-!58_D@1="-]-FG16[L[)R+KT*^>YE0_RU5=MKM&NM
MUK8=S,HG/4D?A1@V#  ZD\8[1<V;-X=Q4G_<QB9)QJ)E>\[C]DKP'3--BCR!
MN,>+D)CL Y^$?V(U6C&CH_<N3 @R?$0BDR/GQJM3K=S(9_1H;#6K,9^@-JR0
M>)L[P/P:M<V9O&(V\;;J8,S<"?&V=K=K6[M;ZR#>=ON)>-?DT<^][YDTY2H<
MC,%/=CL11Z^-H">["8;%^F.-Q1-3S2'G "(9PK\2@DXDJD./O%">WCBT*[-8
M([F8@L+<.5ZSD5[1^B0,'FE;/IG%E4AB$@?6)26!SQFH,J-X-&6-<<]8C?R/
M*@B=W6,ZNCQAC90"[BTO3;:32Q7TB@"-AD IF^(56HWG&VVT[G6#*%(-CPZH
MO_/TX$BQ3^F/>UOUIK&3W2O7#^@F<? :S]:\:7).V&!5)O68-EY#"'BFYPDY
M20FX K'ONSJ>R>1%SA1*F.$L!X1I&,]%JG&N7.QB>,12[ZA_;(JW+V-?GH6)
M8,)E5&C$$)/4'#LVF%>8QT"^L8X:1:$WYLY!9(YJY8-I^GVFJ.D>YG'BF34;
M&Q^L+F^4\B9+U^@+Q!F9#*D38())DG8Z120XMA/ S';K\YIQ#W$:"7/IR4(3
MX_$FB+_<*<>V1LU" =:-HA/>5IRF81HFED?_P#ZJL";.H<S)OEIIFTRJF()O
M\$*$9O$EI2Q!8);>R [EZ;%#YIQB^;!KDD36Y.X[LS?_L=R)"S;IN R'1;*;
ML7FWE-,I3T09QF@4H_:$K558$V KS X2\\:770!-*?AM-1A*PPS"Y<HS;M#@
MS).&$>(TD!@;_,7.(2[BC6$W! YB:GG%EIX7";8-2SCD!)Q0-]"X$K'J!42S
M!#V2"*H<AZR9=YO.MK&BIAT&?H((-H#I4CA\;/I":FR_BN93^"X1MKTBNA8H
MCZ6;.\EYA/\@YT(ZLE.'+;9#+ML9?.?14"S"%\C&!SH_0Y@"JPQ:A>!&R\8!
M0\VH4)F@P%:8#52,J%#<<M &39B)@+"*G;A)J>@"KUY_E6BKS3Z_4L=C<W>B
M?!.L*."0&[*JGYV-1GV']V,7;.7QJM!?QH0D2U3+)L&#I<O(+$B-)6.4^#N?
MMGOQ[3;XC&3_^K3!1K<,1 (7[A3VVX2_O7<3S_W7T:EB[ZC9[]-A+'<8I'%E
M*68[U:RV+*D_T $\U$Z+-:S2_8^[&UKJ7&08Y*0B]G0NRYU+#C.&XE?0R[3S
MX6DSER=RZLJ+<4 VL!B2D-U,0\8/BV)QP2&70>^<4#$I2T\4O2:V7T.JYCQ)
M2HY48G,F79"PVGF)X9, ]>",[4&0O5BT!M9/#^R#:#PC7Z(R$XP,H1<D@?U:
MD2[;45JT>+JJKL:Z,9>AL;Y+%5X4I0*E-92F"9:,$G2'FIAJU#^.RS?0^4B+
M2G0[56":W=QD0.ZJ.V<B-TVY'6K9:KFD_XGJ;J?;*5(U;*F%MEXT4BHOSR!,
M9R+)_,%+;#5JZ826X\ M]J:G")_TQ("32Y!B@J=C6YYC2VAR4ANQ&Z;6+' 5
M<X$H4;@OVJ*^RN0I@*_@E38(@D_G<H-SD7*SJ95L@EI4MK%/6[LHIP*)%E.+
M-N)(IC[1S=++*/:_(@Z"A,JR%%V_GO0]Z<';8 ST<8DRGL=-V*U<7QQKZ"DW
MZU'E9FT]Y68U7JXOB,/E0:PI3H9=QAU&[.'U>R![JA4O GJM:8V2?C/H8-3W
M..;&0Y/]C^V$>^L5GNJD-0I%()X!%CI'*<4H7HAG5[()#!JS$9-4%LUR,J\H
MM<.T;-<7)X7,:=($JCO'/0V_GH7<=M%RZ%CAC]QY'^N*OAI,Q$*$K5G?,=$P
M:8/'[@:<AG&Z&=1L#"K& @"!*IN'^=P89G3)Q#.HPEU*BQW_L_!(.* Q! T3
M5\Z[6M7LUQ>^0W&LO+^'\-V)'@%R.KSW\B7DR!ACI@P'G CL+BZ+$;"SF-O^
MZ?[%LF:]TU$G;VP"=)D'2;A"7'J!T9=)E\*N7%356W>*'5*9CM@"-OERN"F=
M-!\R(=KEP+'C^0%7IVM+FJ=Q&04>?55HQH302#' ORJ$$W]OK2YQ9,E]&"XL
M72O%$&2Q]C73,[OK&,+*"SX/,!6EBR .^UW*1<$M.X(_#DR"PBF(.^PKMN(2
MX+LI";5?Q[$_CM:9J%19<(];/G1!&!N?<+52Q :4!!+IZ3>DW*E\ R5-$_&^
M=9G:Z_W]4Y/6*99_8AMSX@1 "\':? HI#OGF(X%6*\(^[!A:3.%8RD\EVK]1
M1)-?9P=&*56U;I?>8=^&!'.KJI5\FK"/>=TH>0IC'U4KC'&C8]Q*9LJ3#5A&
MZ48E8CQ9:_7ML'C$WA(7+%JJB'7V ]!%J4U02NU/K3T#SF;:Y>6[:T 8.I@*
M^SF,K@/E,1""L<:OK%W(-YP3@6!/8,\S$UUE'LHE$O)R2A&A7"3@R]A/N#.B
M+#3JZ =?-0%+F]WD$^=('<Y:)H(1U3S%CC2 *&4FV&7L!A*",_:8NEM18C,G
M1D5)SM!1=<!$8JHTNC')B"/+EH1&]AWG'!,$KL]<V3YBG0EQ/:;?J"LJNT4>
MKG>'/6-X._0:XUB2ATPFM]3QF.;9.&8."NJ:20+I\@VZS661-K97/B9Y%6?Z
M*?/Z&@1D[ (3JKV\-N<62#6X"A1(>'<B3PJP607)H_ FZM[C3>*+(F56]"#^
MQJN'ST;2>UP-E$#PPQXC=;KQB.8O%XQI@BZ2?:W=V+YS+T' 7BMJN<.S)Q>A
M5I!(M?0Q4]$DX=FW<M7H$?<A.C (WQ5A66#U(AW9R5K8/2E%DA0JW+;],,P(
M6V(\?>;W'"  'H*O4"8.8TF-H>2UFMI=&"L+#26,#(7+S2+&29JAGB,IX!;+
MR73+(K0(%/:'"=/+1%Y;S*B[NR-\(+2R+M!-2\TZC2-N8S,7@7/Q.;3;]99%
MM:N\#V-#GU(/;\8?U+G<7-PBOY0P5@)+F"-3N(-O7L;'[([VKJ!AV7LWE3I7
M?HIWK9ZC-A;["6\#%V3B37W'-_4(;VJU4KRJQ!Z03TR;)2&?=>]Z;];UUA.3
MT'C$0>K5F61WAUJSR/(D!N]<NY3]R9X:2F)%W2Y+7'3]@ 3_@O8(*@1X9T#_
M39ZO,+]KX2UAZY\=FL;EN3Z_^U3/Z0_D#_Q/&FN_8.ZC'/>4LB^QX*]\>N:Q
M/ /GC5&-__FA72"E#<9#9-;\TAD?<N!['BJW90[NJ7AKDRPX5Y9R+_?"9,=S
M6&XK;O+,8MNW.1Z,* 9 $-Q;XA^WVMX%=G%B00N_<+UDM>9](1%^E8@$OR$U
M&>ZXN?7332@KYZY+/LZ[LO#C:]U+(Q72:*BO,+VA\ <]4Q1L^M^MG_@<EMNR
MF[[M>][BYA-5+K5E/]JAQLF?C._Z(,CV 6_B3S,W[F;2>T)/7^X0["52OMW-
M"/R6P]R,)&[VCN]OQ7-1A!_\NE>TAI5NR#I78K.">0Q@8J*3.3>S>?>9[C3.
M^<@F*Z!\&R;._X;;N<PX/ZYJ*NO[V410Z[VG+5M^XS9KS>84A?=IX^;^? ;;
MUV@_GZ(*K7NS-EI[/]V<8<W9J->"E<%)3@,_%$B$JRDJSGU0RVK'N9N?F\"I
MII@_3UNXS,]6;:O1>&@;\!@W4B0!;.<4NES[FK<;Z^-CLW]>1%C*&RUFQ2VI
M?)=\?8IXRW75$HNYU*)NP]\1=Z74I+I/10S86_,!W<IO?L-EV[=KVX] C?O6
MMIU_/FO5MANM>U,"F]OCS'-5138+A7[U.M81_B]ID<,F=<%HMAK:ZF2 E6<M
MUQL/(2M@FJ\@1PDD,$*7P+'+\@2<IS2!IS2![_"9IS2!IS2!;S]-8&E?]:+9
M HO&_LKOQ#ICAW<7_K_UXKZ)S9GB(?A^]N 6D?B'$W&_O\CZTBQJJIR=JPNO
MT!Z[V4-W$6-]6LZ=+*=\K'6]8/$+,V.;;QV8?DL%_*8ORI3[-&W4L9U:-*YW
M?_[OV3\WOMG5[V$[Z&]P=<]H8<^7N+$E$]Y _\$#NI,'16#,V:)NP>-;<DON
M\@RW:GM;"\1*'^?B^&>KMK/[C2^1?[9KS9W&[:;>;&X^I,OXS@TS1-7."HU:
MOM6S;-7:K?:WNCC^V:Q-M?Z_E27JA;;'8_U+W\76SD.ZBT<"JLGPNF%"P!S?
MPU'RS[VMG>]GL?QS>^]V6NLC7+(PXNV=VRVEO736X%I56D2U09@=Q C(@O1[
MD*63/[>V%LA>_E86RS\WV]^%K)W\":+S=DM9/NUWG1?XA "8XINY8[_%LVXU
MO[N[W-S][O2/R9_C_&QIE?I!:=2S?W+>['HO_<J2"%NSD@@?3G'2=[ 5LB$+
M%AU]-QO"/TN+B9;V6$\J!W>+N?Z$ZEY\Y^-#==\>?^)[1'5?2P+QC*P%#1A\
M]E_N8/CR4&,&(W0>]4B+E1:J""Z: WWZ(2'9>M(EFOMZ,AY[DO>;$H>88(MR
MVTPMHVLXWC70,/[7)!(S,*4?>]C#**:&G->7U%B3,-EEF@AF2:#JZM(->MPU
M_<=-J]NRIZ2K!%PU_8Q&-%L0B+):X=[.;D)K<:5U$O5L<@<V!BIWMF=T4OB2
MU?L;T4G=?#+8=7ZOWC"SA&>#L6BW8[>\IX;O?XQ4[#JGNJ?\?C]6#(^LP8']
M&';\7^Z6BZ_@Z42]7J)2@@66#AL) 8..];CC8T;D_&+OZG:]E;>5'Y1&'$J>
M:M;;><-K1"@5]RB2DT4.,T9H;>]@_'3E *#3$^GE0Q]!(^$%;<J*^$_GE__X
MYDKZP!4Z*X<*77A*&XWZUE8^*ZF0Y<:W^X426:L.X:[GO&8&-KTL.,<\IWN^
M;V#/B;21YIDY%5B,:5BEVS%@@R75=^%WT^U@O%6"'UXI!!YG3H9PR'5'WID/
MKB^;AS</[L.6O@_5RC( N(NR'6GZ8)KH(%ICSG\\[@7MAOD7HEZU M/:--<4
M=X.:%CAE5[1FC6;U/29&C[L6! ;:'B;6PR[0\.D&8Z(#1P0F@_C<\H8L]%.-
M(5VME#&N5D$J%"<.'+[11N: (Y@#% XF2\VW/TG=7@_W>X%MSUN:DR@AL2$\
MDRM;2!012G;.5C573[A?7D(KT]WY.EE* .J!/_!YS[ &!M:)_1PF"4G3:@D?
M;C=HR2M!3_[&H%C) 7@<8D]7NJ"K1V2]T_*K62\[D8:)9JT&GI4+KS0^:[52
M*+Q::9'5$IOQ".NLG@I>'G#!RRIJIU8'M22TM]5Z*E^!?V^NMWQE->G?CVPS
MOXER%WM-BY>OW.IF3@U+%.3G,Q&>JRR=?ZIM^,Z7LSKQ,NYGO3'<Q#'>0^Q
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MY-[/&!?/D?C8<W1#]S3OY\X\0)F9)VGF^2+2QY=#87AN,@SD3:>5NF &U)F
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M#[*1<&M5]S*,@J@_T@? '('\0S?B2,)1B*<9KZM=AXDI--H@8G7L*L+]+?B
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M)/'\:S'V6?^5)=+='(N&DVRPDEW*XN$F^8"J!<OTC,>H7_!+YN0"<1C[YLE
MSHIR@>CDBV+Z<;5RTUP0)"HJ.193QP!6#<M+U8@]MJK7$[,,#\(2*V-,WW@(
M8B78;C"%M^<;C49+_V.+'N)_;X^E.DK06C2ZX@";M6J%_[6C/]J5?S0;^9C-
M5MVY8/%%129#_XJZZXX'CFW,!>T?UM^14#VVI@"&)9\4!! \@4OMX<; 1]V1
M]DGJH2SGLL(/0G:?2$P+OBBVDZ&IFJ4O:M^[IXWWT83.6:*I%%3=DDL@5$T1
M1=M):IT?)L%K9(&)2#MR:A@![>PLYKR(W.E?K>@HO:V_L5<ZC;[X7?)*82@4
M[DL8@2J# I;W6=2?Z#,L#'9;9T$ $0I#AC$PP"\AX9H$!LRU[ 9 -]QKDB,O
M5#4VRB.SA5OJG$9H0UQ9V0Z27:4+K)$*1P6R%H-0.V'11D&=EI,D"M^D318V
M#XQ*\E_+)TO?A0GJ]]>=DS(!R'<OS]R  ;RBW*)GX*)(+1M( PHX3]-H<2#M
MP^UPG-612RXAU"@?Y-JH2JX'M(.GFL=JM/N5:M&RN,O'[WI7KE:Z9OBGI]M;
M9.QI7DLU7PFIC\>]$F7=)G$3J,EM 7WE,+0K=]5A=B]Q>OB#G#N./23HN*A7
MO!6P"=?D#[9<S,,H53HMPN:=GLZ2JDG*J W<XG9@LDC"UO &;VEB0>N"@WB*
M.]]_W+G=>%QQYU5J'<).K4(!6P6;K<MA10:S31"$?5^"([.4->.7'M/<Y^3W
M6$;"9+IF#Q5_%ZOOT D-DT;?-&57DQU:4/I!QF@LPYG3S%T1A;SK<;5?6S6:
M_50KXGH4NXAGL6!Z]Z#HVZ Y.%<NQI9H)@Q5DQ"4(D7""!JG1E]47UQ44WA+
M)9N97"[$T-R <$TX(P>&227WS2141TFZ44 .DEZ+\#G^/4\PT)4K>C_0MU&(
ME'?=0+LJ.'D)3XAC_"R=2#QR>^OY8753CM)1IJI" T12LT9ET#'QJ'W>*#PY
MG:EK9PJCT*)T?"MH:L>5ES%CR@/8VBMDJYS&MY,GQ"/!ZH!R,3N^9I3P:4D8
M JQ*,4!\OT=JW^,V,F]<B0'W;8E2#&=-E1B/R]*\F,.AQ0-5DA;?X]#!\@;E
M;%/26<B2I'.UTL!+=&E=WL;7@N@)[I/6E-GO$ 0; NZ$X<F)A&S0O-A,T2AK
MY0JL:.BLP<(=OLQ@]Q/RRC)(,MBJR#"M2LJ"P-,,<I:KZACY!.7;1I2SA3;_
MI->\)N3H8@8MF7RC(1O))M'93FO19A8R(8O=G9*F?7Q\/+XCVILXQZ=3</['
MV-):L 4IZY[C;_0Q,_ZQ@A$2 I*[0#G'7"J:8FG1 (^<!+KXH?&_N8-?PU+4
ML7%T0*!PF'#:1<^X:#%,=!H?3UYGL$DL(\*4[V>AN%]#703.1@F38.XV)PR4
M\>"87L^,JI2BL\J^7&:/(Q/$+!,]1<A!4V*_PGCZ/519EA5'Z(*[4/5-S3-&
M+G']B>4V>+EL.DU924-^Z<G34R9^6 $JM9,)1H<2_ 2L &TM<@2LU0%3V"8@
MW'%QN/3.Y%JM+KJP\TL%L\+(US'5,!>VCH@18'OT!)>NX<F!)IH@;]*%T >@
M^6+9 .S'.WLP5H4T**WS[.#=P7-T);HX].MWI^R9\]&[P=:]'Q%+37T)-D:L
M;&[ *?E<\*UBX<GY/'IFL8,.IIKC7R=/?GGZXIQ.E+1QYJ?&DZ)"E#P#P> I
M(WET L%UICH+8&6DLFC3;.EI<#U7T8.BW])'0V UKYFAO2]2NV?S1[)IRA03
M<N"1#6!J@HS500ZVDHQ;MKXD9G2#S;-41)"#45ZAD P1GT!$]X0(F&W/H)B$
M;T=8[%DP$RRO'<OT<?(P'KXR[F5,U6*X7-=Q<2@-K35!"X:+&Z(?)(IOP"'8
M:XFYG:8,,<^6+0T :BV:?)&6YC&VQK7D*:X+R_]<[%<,>)>XJ<54(><TT?F$
MASKWGU@JFCA[Q^SZ$F+RP]+"0)N9E/I@<YK+M5E"&V)U%F[J$ QMU.DH=(\%
MO>CSQ3QT]A7#>U)_,HSS:(+L.M9F4G51K>OJZJX<7J0TUQA%ETGO^__LO6N3
M&]>1)OR=$?P/%?ONKJ2-:IJ2+V./)S:"IB[F6+(8HFS%[K<"4.@N":C"5 '=
MA'_]F_GDY>2I*H#=E"D+6D;,6.QNH"[GDB<O3S[/J=3W!!PM]:")<WVJLU*V
M>=56FR,C*K2I4L,1GD3)J+ A4CS B2>)=2SS;B2!TG 78T.#PZ6#NQ;,=F#)
M9=^W%#=W@N:S'$SPFIM6FACIVG.5JM.%_P!'B]=S#/C<BA_L":0, &(];?FG
MQ<V/(E?C2J' 3J3=0&*'4:TM_;7)0JV0@ZNTIQ&3L=)^"/$79GI?M5]<YA&T
MTRQ[ ZJ 1)B0VJZ3[;1V[?9:.+CU:_,-MM,E\Z3XBN:L ZV!+9!3]::T(.BG
MO< ?-AJO*(+2\ZC6F**!-8_VIOF!#P\;=+9<>(;5^:99E7^!]\;'JD#4!2@U
M>D?,_X:V+7J]Q8O:=3MU=^,1^@:3E@+T$$#/,0&<R_)>DDT+K#Y=XIL\U9W/
M$R]4%<B?S\8T75;C.Y<,K5^SSU4D;]IO=1L:3V1ROZVK;?&J:IE#B6:E^)PY
MCU+3\*]_\\=O7WV._WY4IAX5)JC<RGI=\JY=>F99<MZ<5$IZ4Z-;_JGI%IMJ
MV'.B@Z*KXLO]Z@D>]L7?BV_[FJ*6CD]<W.SQHX8/[KOB!_H?,&!J:BNSCPH8
M#-@L34]Y+< "^'PLM##@]>:Q+^FT"DE#BO<"C&Z[VG6-H0:O.S.O]W(]K6IP
M]FKJWX;R<NX[* /LS!93!)F75]<G@&!9,691;QKZ7C$R"X%:_?2K33##]'L*
M(Q$WPH;BHEEOE]N(LPFU$]"R-Z7K'C_Z7( 8I=PYX4/U=>*K*!@"$2G9<S7#
MS* C]*QW="Z4WOKWL"?ARL(Q73H,QN068O,/0S'9M1U[ PR 6&M6#4@"61/P
M<Y/M/;$BSA#(:/G>6NWY0Z'5?F;5R%"$TAT2>;[/9I-IF4'/D#D_L46_)+[Z
M]S"$?RT,X>-+@B'\\TGJWY%K)&'&'#OB#HCIP>AV-/^2VGN9"*EI'?L:FI+'
M,.%3 *O9HM6$OV-<L]*?@;"&#-5>V&^11)GUK*2Z/ P4JYAK,@9QS3@F,W9S
MZ 2&E<+@H79E8/H_@5AW;3B1DX<)E<_"><A-KD<H1=6UCW8[YM?&B#I^!7>&
MS '(75@Z8]K8_L_218JXV/,+("VL/&\H)FVZ]MHRGK%1-G%9<=-E?I,23P2'
MI#L]IG,E'8GOW(7%H7>6<>KAS+^76_)_2SY"BB'O1TA8.!^AO,X;20DOJXB?
M#1^&8179H6B+,QL%@O'YEJ!,N.R^!%]G. $KX1.+5"22,9&4?'L\D<%$T[-S
M+HVZ/-99^QWZH5"X!23(^1Y#2H=?.]^J(;>G:19^>]&*T.:O,K7J2]Z&$:^*
M48A :[K27=>#V]?H(".56$@!!=EOCJT0"O"65B9B#E/IZ,D3-QA8S?M8V\X
M"FB:5%K*=#'$C*N^8JYCP<%[?X^X[TFO0OI@T79&-N^*+>/%I#*R\X/[(5;2
MA.,)"'XM/<-.+6]T!8"(TEH5)SG:KC=APR5W^3F=HQU$1_9ZL'+3$J0AOVUP
MUCC\I_A4[);05DAZ-/"[I;1A+P)BZF7((<]P$[3<"I#.OI]2</Y^;WH=++YV
M]HT0R2%9C%M#-')I1Y014X=:':RD0^1DI0L^SEX^[$D;!RG?><^@[OM$[]5<
M4"[M3PJW#WU.7)BY5YX%V2.'IPCDK(]8,K:U#3P \CH0T$K^2JH,8K<MMVT
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MH&/N:,6OC)WH<2W:/*J5NE/","&S0[=1E,*I%I=372T7=^#^B#$5+Y)L1I:
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MH7<(\4+DUIT9X5I0D V.IVI9J;QMQG043BK+?&G-O;DUR0WMI6 ,-]1WXQ7
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MTXWR>1(&*2V;_="[ZYY'NG5@-$YC-0O[_(:<C6)UJ(UKJT*CK$B3TVDIF*#
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MSV'D,_H&]NO\%>*3Y(][R9%7/M)JU>%-T :5?Z>H5RBFT7,1;+K,+>9AVH(
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MRFI# [)BG*(<@I+6Y\!=)60L PZ??-GU.P#'5E*+J%\KZQ7-5))*T9#!BDY
M9=F9X(FEOFY7F<N8S:+&*OONCKQ@>1S5!P!P[U(<D"]YK1CSL;2[RX*PE2TU
MJQ56:U8!9;^#SK/#SJ@BQR52F9F!W&@6N1[]!?H[;"O;Z[#FF99S<Y"46PN
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M8P_+1;>9[M33 *Q[P'@OKL;Q8E1URPSQ]X>^&5:*)2DU-X]J+=BJR6=+X"R
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M<-'JM9X2Z[H>K/8BWT:;@E0AM-\?TO*)@T=OHKM/:O5#'-RDGILQZGQ GUT
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M,XR^L#88V@=#\;Q; >OP@IT]W0EL>>D-_IQ&FYYJ74-<F);S$UHD<?UJKX<
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M,X+JP/'H9<!\:'OZJ8PU2SCO&EJ E>GQG2\UG'81>;;L@SEUD0("P"TKQ*+
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MH1=G;F0>EGCGS&\R,DIGMH9BA!=TI4S> ?F0Q ?Z:9$B=5IX[5)DOUC#:LE
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M+0C/ZK;&)OA]9]N+:S)9=$-==IQC+*(#S>:NT(SC+Z5$:A>G$#$PJU[1;2J
M$%)XB=I+RU?94P7*5>,:7MLVB4:S2S&R^0I"E!((30E3GME&*%?D5 )L^&0J
MFVD?GF3_S&\(>. KH%JQI-]L;B8MR5SD43,#ZJN0[%S7A-H6G7GB!=M-(F8Q
MW^H"MA+F3"624X8" GT!G];:L%2(@[AL%^)_YVU-U<QF(WJXJ2(5BP *-P"N
M'B6B0+5P$@H3X+0$:Z%=KD!<,NXMQTVJM/W"(JACEB0 %;5<,C%J6E#7-5AU
MZ4S/.06)(KN05R61@IUXJN50/DF6]\9Y-L9F=XGNO"6EY!9FX8 QM4($RLV0
MT:;M?(J/K,WUTLS9D#CJ^C8*,Z)-ELH4[V^8+B8T&45$S('"Y<WT;Y&&A1KK
MNDZT4,.6#!67?=F:SKKQ^H%CK8'+6;(G3;NMCJQ7ZV8,&69D0+RJ"NB9U9N/
MS*G@;K]0?,B9"YO0FM=5C@7V5^4HA%P "RPDW"P%,MNW4,B57DGEJDX71N2,
M<D(,2_>\?)ZC3[7]Y5RA%1Z[N)+%D71+C'4=0*(44=[)\_UI_9PCVY3NKRB>
M-'-<<DZC,:YQQM1RJBN)]?F B)4: 6!=+Q;$4D=P#W\Z,^LT3N0OHI'S(DMN
MRA^Y@,KMA74G40E:RG(0$\[I6?,16FI#8LFRO+J+WZ^=;X^4M!KEN 7<@H]6
MFJD@*&CB\BBJ5W-;D6L+;?^=RS_@Z'$:M:RU"+7F):[?)"U5X\"8E;6F%=$X
M9U3GBJJD5-<98FLH\.YN-3 /'[:TQ1=-D$L'V*9JKQI+I[24QPP9V2G62Y%K
MR FR/Z5;"G24=BNBE,-IHSF$EUPG4+RO\)5T53TFT\$35M&"?A=+MG#>@4:E
M>R>NG1:5(V3G2(\PPZ*V0E/\<Y6CE)N*YT$&'!1*S">NF'?YHG$G;R07;;54
MZQ7U=&UR-724ST"B!1W- =)C&& &9 %I+WOY8&RS'6G>"3[(ME<(D!:&0CDN
M8G;IIFD/:8>-84J!R10=#F7&NP2:F@S1;^N(QW)A638ISJ6=D2V3,??&W+B!
M1I':&@?.I:JW2E:=;'Q6'5[TS47:U=''[NQ3LH)(\K"K GF#MCFN@*CQ E4!
M?VAN:BE[?'@$\JF%BA< OIE"/<\Y<>V[;ZZ-(<MP$T^7:+L#D4G7T#89NQK[
M=@8&K(L$FP!K>]A=]&:+H&*( "/<;P,PU"$41T5S5]/:+((2+[UQQPTID(R/
M.'1]G5L4GY[&S E[D9;?Z)K6]%*ME[*UNL"^-)=>RA0""!?/L9Z$$7ON?9W
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M?"6N,1RUR50L.WQL&]2>(O1O* ,U[S?WC@0G"2"*U%RN(E1EX>5K>,#,K5;
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MR#J#JS.['8^#5)RVGRJG8X)O67X]3N*+1"JU$#=8 V/;*&+[S@-E)'.\-PM
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MCY7LBNXOZRVG40S3.7%+IJ4MY06%.DZY*;2Q/"^<N5N]Q9DF%.XDYDS!<J'
MRSFV\0?=2<FZ4R)9:WTB]>R$F@;YB#V-6[G=J/!>H9ZF$1(!U4OII6UQ3HS"
M<P9C+:BU=?![RUC@.&\%U(X?Y4! V/Q@50F*I9%15FE.7\'J/7@U^$)N&+6T
MO%EZ>8V'L_RM539>6^0M+KRQUOG"(4'E?+!07[! TMY+1-O1J?P]F@TO=WZ-
MOIM7&1\?J,\F-N\MCCNG[F@2"B3,C8OD$D,BD86)]%M8SLWWZ!U6OHS.7(F(
M:NE>Z^MV#3H8XGR:9\*'A& N2X),^2)";>/" &^_8R'&'KU$B=_>/"GT^A)5
M]U*AK(E5@_;2^[4N<5%-D\ VH=W9WDK,;9!*I32R.3O(%K9'@ELNYUDY67T+
M3*J?"^B$?**Z?L&TJ>5;\!6^_$5]&>#G9A*]H\,!5,:,DH(+[*.2[ (M_X$3
M?T+*M/P12EJ @=H2ENOA2GNG^91J:HT^);AX5%*0)"OI@X[BC/MZC<':YLK?
M*FFL19'Z6\H54D(5#Z-.2VG_D2I(">SJCKGA1HY)ZSR972?,<6U#&]M;Q#8Y
M$K.@%)5KI*:I1P3WI#[]^);!_*]&YGVHPY&&6A.\SRP[TVL'A'<MUP/WZNVM
MCV^/PV ZGI?- V[\5F"^9)]K91U?''E(=]MENRIL1OPO!?MOSH31HT98OU.
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M)#0#/8EJ>C?-D&=4[7GD&!%L/0,M.YO3V 7.-43B$\I,-D2M;W1I3%"I)DH
MGJ,Y\>,4<!E*%NOM/5QD7&4]2%DCH,)8R69&;JFU/2.VC!F*,V8V,(/U@QGL
M;V &#^+Y?$G+;Z6Q^FP6Z-,UWM&04#)VX@1*%V?Y\-LC>EY/XM[]\:OK?CI%
M*]BQD\ D2Y@D%C]A1!7+M(W^ K\9J[TMJ1FEU*\0D3Q.ULX5@F6 W!XS8B^S
M#G!CX")@X+IM(?QP%YIM_QYE<XC=[$+!:[\/WZ!"T=T>_88[D!G;'89#KZ9!
M(0]G3(_Y0[=S.( O_Z'7.>C!'64NM4MS25+:4W^MJ:<AE.P&H_%\*!5V5 6(
MV$#"@F(^.:&FI"/*@7B4C9>_F4;1XO?#NH8VJ& )1\%I "Q[7&V-N-CG)58N
M3NBW-F%P7HN*/O#CW3TOH5PJ6Q"<@"K_\$ AD* VWUB]2:C,&K'59 ^R"S22
MZ8Q:)FR73:)[E:Z2EGW)Q?_T)YKJ*(V=_F,I[JBX7&8P*\]+%Q,(2:$69<>Z
MC:>&Z(E50FOU!KA9O>A41<U&5%N]\F-58U,7Y1S;/I&, &BA1;Y/-^NAXZ2@
M.H["*S/5'L"#]3YO7D/&!\OSR[D0GBPZAY2L48^+H9E8CES&9AFG9!NBKEQ]
MG,8E@?YBZ11-A1)<A;EQ3Z,1J$X@V<9&P@I0LO 8K7YF^3"I (ZM*+[#FONL
MRJJQ&*D?74AY?E-U6NXCT),DP1-HO"< R=6"5;E&L)@Q_3.18L/$(LA9;U [
ME0<<#(:S2FIH8]'@=@ <&:#(%A,+3R;SS,C:77I5DZ:T[/B+N4(DS$-3#BW;
MAID'T?:03-B*<>06N?\P(8P%5?!,%^XS:"#G.H'5(<F$;10N@+2'T8R7Z=3\
M_I^Y$;8 <F(P5FJ5,DUGA :9I#C"$B,Z<YM$O8^HV82B36@JZ?(I:^MXL/IE
M47J !^KB4CI/OHUS0"=,1&G=4K!\!XU %TU)J%=8=EKB4? MN:FT$E*I*TNJ
M=)_K8>;\"<P6VB,B>1]KLJS\%@X\!XE1JOG$#%\ABVT>AZ'%R'(QKMFWMMP/
MPEDS"<^L/!(Z;< 5-#96R[!(2ZIOS>)D FD21,I,4_K)Y5GA[2>?_NOT[4[O
MR'YZ=6,&^%T;W1/OK"A+ID)T<><&[.(@&>=F/FGTD!ZS*?I34:C06K)<:3(M
M3(5-0*QJ^AB[7SI+W%4:AUR7+9"2!*C09LC.0JX9/)37TQ-6M'7QN_G(* YR
M.P' 2V8$P<Q 4>4%&I70J2:G]),C&#;_0,R9RY5P%VH&V_T$]:XR56)'XFN%
M_3V*82>@Y:X4G'2V1- @1! SL\;)!R)"##2.4!.Y(H(?RD9%<.W-+ZAW2M?2
M8LA@.5_"E6?&DL%.R4!R(]P0VBE&& >]I3 W3\QYW7E&&,?$_&*M,_=_5!@3
M!E-S*H%IIRA@$:/_#'NA8_Q"\Q=\C,HX^M_@A._FGW'YP[KND8J#!)[&=QE1
M1[4%4QJN2FF(@21N^$(HU*,-MS$,)8Y :[>6F7?(#LW+F1<UDJQ+ZZK_6+I-
M@P!<?=>4F1)R,8G%?G%#=J .G,PG-KITGL826W(/@OWZ0Z_3[<+Y##"HA-;*
M;A=A5LCRHFH3(<%[4V*:QE; H]R5B[X5Q$@VQ,8VS)I>N=0(0\RE\S)A))87
M:7OKPX<33B#3GX40#M(N):*V !2$="!#3-"Q,J!#@8,/J036\CJG,Q7ZDYQ5
M1/1S>*Y25+&4)L+?XOGI'9J9F]LZBXW=([,%I8B)2?LU>R3;\FWK(M7'?/R9
MMJ)VXFW2NE&\A6E5Y:44)_XX-0M"G==;=(D#;H$0%A3*1'O%LL3A\Z2@KT4[
M89=Q8\GX!3]N8H)I@U1B4_</\6*8U<AK;\37& 1UN6:#P1VECD,@VBY$$",$
M*,9L>O@]VW'TMNQ(.K@+X-Q,"DJAT-43[^^!\6B;U-X3I_8.-JF]!^@'G07'
MYM"/ \BR4*[%-8>(@^LB!?H/N1508;&R@D*7831C\'<T(\P&\;0@!#@M*-[7
M?-&%',B1NVSD0AHZOQ0'7#IRGHSS:S*T^3ZL7LCJBD 4>(-%QZ"^1G7+&#C^
MVP?^QI>Y.4E[>WO=5]'K5_W7I 6'1IW&[JIJ_,IAK_MJ^/K5[NM7QZ]#K'7E
M2B",S,4$_4JIJI7Q(0T79!C8MGN?C$V/O+!'LE%-ER=AZBK;5F)Y*>/C9]I.
M,)<W&0(2,=3?' FNQ^OE$ TOH>MU7+NQ*TN%M#3<,I&09=BO@J>QO:7FX0E"
MTW6&,H#(I.JF"X@2TS%6-,!63[)VX7.%/]M;NO(G\'I[U"T3<X=4MV%MC)%J
MWTS<3%689L^\!*9(>$IN<L$B8^L%%V_870]NL,2YW=ZZT\%%5+PK<Z'-;1#C
M1>Z&S&#"!IHE-F4G#[LYIMPDQ$T*K97EK/A94T%:52PGS!KJAFX4#(R=.Z+4
M'2%=M=+P5Y^!%&GO=?!?2N*K2U7;* AQZ)<N<)EKU07W,95QA9T?O+U%CK"-
MD6,:UGQ$]5FMA6<"KW$D6L:2U8=E-__..'#CS$CHN&@>V1!Y)"BCC1JXEC%Q
M0CQCO/NA,N2E%+QE#4*+XF9V83*T$>L*<O2_\WP6N9 O^0JP+-<<AX^R:'R#
M3C9$@Z&_P5N[YGZ/.%Z^>O*EI6X:@+S$C#&=SP3)C"X!=WKB!0LK59[<SX$J
ML.!I<RIELLH:OSXOF6$*\. 4-9,^H7%R3IO/\6OK4*R-6K9EC'BVN3^SIE^G
M0AO'#:B*,9"Q$O["\7<MZI7"40%9ZOYW<7)E'":OK =O:O,GR'.JTR[=C:[6
ML$@;[*&SJ#B/C$#M?/H^3FX")(G'8H<\CG?>&R7[+?@5XMAGLP)B+U^(J1_I
MRTZP:X!1G)]=HHH+'OK=7E?Q[JN'.=K]"/*QYLG,.8XP[1+]0*]G #4G@T>=
MO3O!_6,]1TVQS>?P+@4 $B33?2V;^?N/D6RR;[#\RQ,FH<8@(FS<7&I'(G:2
M5SXA 65'NF][3/FSI1N*AV7G@01Z0%NBH!ZT"E5>;MNT/ +EV*$(%L-.J#U?
M.:$MX[+4[:UI#OE&R/TFV55:Y)E7PL$?"RY3<]V/(;$).T:S)MI?\"BOF-E0
M#8<*/G#_L;B&VR;K0P*'0PV>66,5^9HKQ)3^MOI1:C'4$7,%=:Q\7YDU0?IQ
MZECFE^0ZA,5K3CX M2ANCD5CDY)(?()&A,(UEN>Y+NZH*X29AY5$6[=)41@N
ME2(&B=89/D >+HI&*1 5Z(@XB487Z6'5K=.P:/A5)*1%,E'7TG%["_V#A@X@
MW%*S5G\KE X+!HI&$9'?XM-]7B%J/&<;_! IKN:)C\TA@0P-K3Y\%0TSN='3
M3%H-XLQ:>I?B15&KR-3F&AH0? [P")3(L\ M!^4=UAI8%X5^[&X\X"T& IK8
M!:JOO9L4Y2=$CWV>.8IG+DBU[4;+,A]2KV?K H#^,N8,9!.KUK*/[G(1_FO$
M(BH?@)P;RS#DBNS>?2>$@/0K<9=$HX9N26DP^-$]=HEK#G2U6P&2;G4+V8HA
M_QJBJ()=+US;@NZLZM6CRN$DE>$MI50S<X<JNS%\)'GVVULMTU=L%JKA1:5?
M1]5<4G",YO-LZ]G@ME)0+_RT-$)N@_?5+M^U3I*>"9K"U_BJ-Q#X[&5CCL#&
MX6E%."/.L+CD.[L:&H@12G6KE# V SER+EEV!&S3>6%VM4R:TNS<TL-/<DMG
M+TYN00'EVIFR=]H;BX5AWZMI&QHWSB)%E0N(9A[=C 2[X48F0Z,0I+=AG$P+
MR5HW@"(0&N)GJK@3$_9D6RZ)A+@4,P!<#&=/L1?H5# R%_IU<MS>A0*AB> W
M(N9!X%D)!4<N:;'DBLL!;X-Y(&>Y^7VU@D$B;D  .(LH#W<=%07Q<VB)!MK?
MBPN(3W'-+52Y?4>LI5&J_<Z^6?3Q&':C?;O9[D26.F/;%T/H?RR-";D%A]_Z
MBH2(J(_:I4B/7I1F3?R\RG/SBVB<- J86:J_E%/@?^<<3#3\=H%]MB ;E1=_
M@DG,DA_^2NB+O[R!#__57]CE'A &O</PJ-L-]_8.%TT/0_3  5U (!2&;TNK
M\9;E(T129I8/W >(HHXC,/5M2ZY>-^P?'86]@^ZM+U,%*'3UE/X:LUAB53-$
MT\VWX,0E\4Y$9AO43M/^.IG\0[_3/W !UI#4T5ZX9U9A?[#B"E04-#6NCJAS
M"'P=2_:E:!-H =".,KYQGW$('P!V@:0!IW;%/H]!Y>T/]L/!_MZ#CF=[R[SZ
MR+P*HE_HXL"[4%C[X6!W/^P?K/C"UID;^>L&[SB6Q9/]S*=X>PM>B]Q<J&>X
M(83:6MGN")T%>T3;=32Q((%5&Z?C.978\YGP6K3KI(NM1]K>RHP#N,/EW+5J
M^2J#P$F>84X73O%G;)]>@F/\,<<* OJZ>'XI=QMU#<D!8  *^,8^'X58/=0L
MC__4,$@B\Q%V^3$*GH\J!<5LFU%Q&?8J@'DRX$]&;OX_V]'K;$Y%!JZR]EIQ
M./2N__<OA_W>P9]+C/2TS3G EHD+I :/)IT_E9LR)W&_8[2.5YL?_W/.</.1
MU-<$I;$G9XA/YZY]_J_I)^05-&?-IXTQ_D]61M(O@ZOLHW&9&S7,KT17U4S>
MS.W_**XSC6YL[*A]N[>W<+^1^J=UZI0M\,PW^^$-KF(=<16'OV-<Q0,:ZS4=
MH:^/VW2L9/ILQQ91^7+WH)IKOB<(MUPS[>YDH%F/0_D;YBK!!Y96D_)C&[V_
MI7R"BD;Q4M7598O*$KYM[UG;C /C*!%9(R$%<CY?YDF6?I^7P?'?@M&;;V^B
MX+]NC-ED_N UMH(_P[)])4*+AK^^@GNBW_TS?AW_W?OS:Q=M>I6^AF[))2%7
MZ1W$L\&WXK_/C>W>8Z,UV#.70K>KK4.] %B/8!Z9O@X6/I++IOFIN]0O1'PA
MV27?+?0$$DH'QUPPW;5.!5TS-A_!6'PQ.P,V.VT>NQT#P' @(%[RH1B2XT0$
MJ.O[2;CV$<3?W <<>4L%$-IFN33/E:CX:(OJ]U1][';%U3D,5CJ&:QT%@FC?
M>XO-_)7=5,SW8^D6[/D.,9HK>T9GB9S[.2O2BPN(?U++1PK+*'5"$U).?'6-
M*ZNZ7B&;3YE##%%#[T-*,G!30C0L(_,(&S06#R(X%L7&X Y74PG0 T:<\+DY
M&UXF\9SB(3_-D2XYFLTB^"T9T[/<5X]:J_)>->'CKQ-I4=D<JUAPA%QBM"Y)
ME!Q=FXP#' ?M4JQ\-)#DB<]&P]JSBUAUXV?-I]#2^\/3H3(XO\ZNH;USM3F4
M;2F)!^I*!5FYC'1M-N"T=3$JWK-2(U8T*6CC._F,AB#9EB3MG77]"B87(5,7
M!\4:XX<M\\=P!2] )":='S'L=G;K$<.&1<&X08,8_J';Z1_M'?B.;>5R;3 3
M@V6L1"EGNHN9N,X7[+%9HAV@V\,&:TXY"&V)ZU,>Y\.Y)8O=WF*L8W(5Q1%0
M3P2J%6O$Y+&JWAQ),LO&)'7D&M5!L?9D.K,,!IYL(\IX:CSFA%@N)CD@4GQX
MT>-=RT^R)Y]KZX_UJBS3KJ.,0$7.;Y#T Y80V6&P-,4N9A9X&P"X9-=>7JT9
M-Q/T-A\RNP"V&(Z-FY..4K##<]#M9AR"&E#I2@<!1 PU?!)#Y>ZC !5 'V)J
MB5E%!<ZPP[@F>!$^/;_KQ+G170F%X/SA0D##-CWT4.1&"4$\.,BG$)U#2@62
M(X08(R@'^U[$)6$M(;^;>IV>< D+EK\LN<@!2Z)Z;==7!57D#:<XB/@1-L38
M_+0Z^6B$_:RH;Y89OQDHYK"3#*O?B"(4T2.>Q5EK=.0O CQP5,R)U2'PY.!&
M'RPZ,K>>++QE+&I# 77.H3C_&R:[:Z 3&TAL>/(DL5JX14;D^DM+H;M*U44"
MK!2"@U7/\L[^>A@1)VP.J<TS$V%5ZG 7H%2Q-5IPF9= 61:(GH8&76=,_0P
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M^;(.I'.Y14J:3IMRBGP7VS9'+BWF,5CTFA)]W1*L,!"/@JT">CQ=6"S #</
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MK..954&;646#J-A6SK^P&;C=1ST(-(H[6EPVC[R)PCXZGG??_+O?/Q!$_*Z
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M;%WK;TR]6Q.-\];[BW>UD^9%I]F^+RUX[)"PQ6\#^M<#^2W"?P%02P,$%
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M:3P&9Q@%_B$X";WQ.5F%G\$EW*!#\ LBB,(HI)_!KS"(Q6_",QP@"H[#S39
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MSKPER/VO0J,OX%07"D+L@^+8-='4(EZPA98MJ\178DPDJRX4R^:WZ@LJ,F)
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M:-!Q&?&LX(MQ3:O@G6!#4':)U@@B_ID!R!;'=98^/>!\1><)VBF?3- EE=1
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MS?:%O'/!A*R?1H0.?>SK#.?#S)N?%;33$SL"=.1<$T *LTN EA H LB0J0A
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MD7KR$.FD FDD%5?TR:U['&[(^+@].7U\B,M$MKCLBS@;DQ3@FA&I\SL(;BA
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M"<#.Q%B0 ,$1)2S5M%A\*\!/[KS-8Q*'[Y,L4.^RM&0<9\SKP^LDR]L) &)
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M^?@Q,OCVE %P6&&0]5SC8.*O'.Z8N0,I@TO CK_&Z=,'7-XLA37+".\?40<
MSN_7/+8Q?7 %T#UH+ZL4[Q0*(1\MLQR%0?%\:'NV9Q[V!2]3[6EW#<K>"0F>
MH\-^N];_\#O!S%);$( 096&H]1!]D)-+,_3^H\U$X_@=VP83]];0@D::)_YM
MZ'&+1+G;8,O^O/@4Y&2$KVHZ0G5=!3U$S0%!=0D6E2]7ZR3;XFHV_BDE;O\<
MKV])^XP(\;K" +B&I<&VP[2Z).@N8@???A%V>7]["Y7E/!Q,17-S:0!X;FNR
M]3APN$RWQ#]F,5<7RC^&HJ981,OU-!,=>#G [7=I7??)<:GN!KR&,P$ Y_Y6
M>$><"*@6"E". S3G?<@ZE"P:WR?9)U,.-KV*EV-9&O#2 UH2>3#>;P%2?6B+
M?H4C2HAI04KT1Z(5!7:;9R]QA*-WVX]DX7"5-GE4%O050?Z^C2$%R8B"'%])
M&VEH9V@:6 H8_HZ&W@NFE,A+1F0Q?PY]V+(IPCNOA2TZ^D@Z@<Q.3#YD]-1)
M&L8);HWF#]DT7C!_M9Z.4\W:B(KC5+/4"<8?'1G:?ZJSJ1:5&<KKRM@G>':G
ME?R5_CM%A#9T&RE.8?IX?<FR?=A,-7PKA)W.B[2 6S,BJ:13[K[@_#$KL'8?
M7H?RX,[Q-2E0=BYRLZP_Y"A:P*#CDEQ6\$6.:17 A$D;E&,SA&C?59RAJV9/
M*N1HK\2<EVH$YM'YA= ZV-)[4]X#R&*5$5S_8%'M9GF!'\N+N BS35K>YG@5
M;U:JF8!9S^FLS]:,UK3-I 0FH-@B[4V<!#W*PXAHHJA2]<X],E',,1E;+S#_
M7V%J6!W--[\%85V X^<A!AK6>3'"4AL,/P=#E@?.HC-M+PI<\GPUD/)C]8TE
M3K@.8OK4.WL@K\ZLFD8L5]B"F6'=<G:%^:7S$(/UU+8I"=H28B\K),\J4M5Z
M1<'ISC-XA1M2&)GZ<3\ R/M%R :2XI9/9JR;JZ?GE\T*,_3$[2C!YZ@<<&_&
M4$F!F:!*#<DW9 J_&Q*&M$%/U3OW%,88Z=?1.P@&RC%+2$@%FYCHG807.(]?
MV%L>=&UXD^[^6V&\3L$EX<S 19JII:&LT:V1=BFU$[#;2?&U &+SA?$!3JGO
M>?FC-\NP^I$KPX]W>N"]QSWBD$\ H8R\]A]?]_YZ"_6S^GZ?T\'EB!V&6W9(
M#/X'-H69[^,T2,,)#H=H"P+ 8@M#+=BL*07,IM-HZ)K#(>NJ,'HK85D7!(G>
M=WC-+T@4-TOV+4*_]E:+NWV24@^Z_1JE7!;:#-2 L[?-4UUKD7P,\LXIXD$A
MQE'QGG1:?1>!?O1J#JTJFL!"SR7+K,T0Z694 A/N;)'V-QBY'C_X%BOOFL!,
M9R%:77U!;VZ"63147\47(U7@563LRH/DH0*DGH+U]6+A= ,LG@VYS&JAYXMQ
MUE=5C4H@N3?D(JJ:@%6:$WC\HY>=;"*<*.R5:2W 6GHQ2;B<$N'IB50$"2ZZ
M(RG:I!'.85S=M%\B[;W&@KKXW6_1"X:E@R$K=V_ +W&IG?3_:9:,%^)A9'IP
MA\D"/@[)DHS^L$BC]A\$27Z9M+\7&R8;>E?N\G/(3IK<D>7=Y7*)E;L_KD&X
M=!X_#=RZP.D4 1@G]F*V+!#$52GHRZ@JYRNZH6M*]>/,_4D[=*Q?D/"7YUMB
MJ"XSM*6N:V>S-J?K(T9%D/G/!P"7;<4>H<<FTSF96ZV-N5X.M_=\Y*\WW54?
M!%S>?Y@>8;/I.3=7KC;K=<*N- =)?0OZ*EUF^8J=BS;=4+?5=GHI:YA)K5M:
M=JI@QLQA>'L7N 1M=O ]R8I-SG<_ZZ\^9.1KBOO..UOK]\YIBGHR5"L/&W2D
M?#P]WX$H>WJ^$@'#)CDNZ0=!=BJ7)D",*QT U* 7:Q^"S_1C4ZS:D>Q).3[Z
M(X/8.> CB@"BA@R7B1KLC>62*GFG1WTC.WTA9*5; FG4; ^P:]JF P_V^H[?
M]1YF5N>=;SME,#0<BKBWO,O28S:TQ74)[$:!;*=G[\&NP#AA/'Q[=G;"N,CN
M4-[A, F*HKGR*IQ]N\,)_;#^D-V3N2$NZCNQS?[]^RRG'M9IF\E*=<';B9N@
MN4V[?Y'>.3ZM'5WF5P7++DV3PE#."Z>I(GCQ:-%\?AR8\MC1/@B[.'=-=V=N
M'I/XB4U0"S),T6M!JM'?J.5V[\/*A/:Z6:OBG<+#</8H2M]:/<Z6QYL"U]<;
ML\<RB%-^HA)7FWB,A;OCE0G;JX-T!_(F?PK2ZF+Q.;$[2^*(K\?2Z):T-5UP
M\<O*U> 5)$UB,=,\9**R71)]TN80W6&2@L$XS936=%U++)L])K4KG4V Q/+I
M$-'4@'950$IRMU=;730['0_X<_DN49_AF[Z:@_$[32--YH*2.EZ'-ZH-ZSKF
MR1LDUL2<\0(781ZO:U]\MRG("*A//^MHJ_B19E<MB:D7V>:Q7#QFF_+[C*8Q
MH&3,4Y,[#2G [8;Q4,/:>\:VVF#(/1ARE[:G;]!U_-LFCN)RRSC+E%&E[9VI
MU3UMFH^;^&UHD>51H^ T4X\1>"M%CU(:#-.,$!57[%GJ\TH#TL3C/GY*XV4<
M$N?IFV:,?Y;*3F/?((-:<<]*$PP3!\'MLO+L#1+TD82DWIG99&3;33Y,44^O
MXB75H0:\--.A1!X,XRQ =GE&51#308(2I  H,\H4]PPZOHFFC7):!=!4,\6T
M/[Q! MU^P '5HLL7[QRK,T6=TTM6U5YB_ \<5=F@VIFC=A8;HMW>I;I-33))
M$[3SE^Q5)!BN3V-'/P4*+Q6Q8H^04/ 1JHH^8DL=5CKBQ0M1&E*09A#/>8(T
M#M2XTZ73<+II98;>VG]2BX,AK!ECEXS?O*DIAR[%S'><>E51%06]DZW>GSK/
M5H]Q6N^1,7"+\+=-7,06!PF'%N*2DN,,%%DZK 0PQ!T%N\OENA DE,+(S,I!
M0D&0(JC$=/O/!K;*GDELN<5OIPF9M/;;\7]\@\27Q=#-DLP*R#+??Y2]PP4F
M+4I/GU_@%YQD:SI5-T15DY+;-"<V!K23G>@TP!#."F;_. Y7JC[X-&J08F"-
M4;0J90^#;$J<WV?+\E.08_NPN$=Y/H@ZVFP9AP<7!H[>8RWH,O]/]-,12^:'
M%D\YYA],O7.]RD]4T/D-S4D8)*;-4ZV&TUP#9NBMA -J<3"<,V.49)!B&GQF
M6>E "J:=!-.U9:W<E_:A='1I'CYFCC59\J5S:%%@"+T?_B[9__P&U4F@+^$D
M@>;/KEANQ<J%W>ZPZ@"W-TYEDF"XI877W^9\+(%N6K;M,$5 I;0_#FDCF$(4
M*(M,$>C;-X@J>.<,O81=;@W1IBODDB%R@"(QVA)@^""%U:4!%X(41-BVS7.6
M1#@O.#J:?M0^K S0=_O^^D"SVH^Q6RJ#(=]0Q+U3M6_?(+&,W__NSZ<G?_H+
MXF5Y)^G.$):BM'DXM;KAQ;Y LI=8V=NJ57)<TWITWT*=CIN3-$!K>-VK1##$
MG\2,7IH'JG#,7O5%=:;E!;W:]X2A;3E:V_].M-\X5]RW5)"^H6^"4<XA+_+P
MO$-K1V^P.*D&B^HI:[%D[PY!OT;%_'%WMNO*#IWB-&SM%QA&AH%E.+T#.\:\
MUHW8(06 (?(8U+U<&[LRV*9GJQ2@2WPKNTW1?&@AX/BLC=7#2C@L1ALC\2G_
M_*ZDM7<"TXM3^+<-07?Y8C$G5XN[OMZF ]V]S":3!4,T \!^BK-:''%Y2.&P
M:XO-_4F%O$\^&6]'2H7!,LH8I>AEH"ZMO'.)3'GCXF;9N=JTY?\T'EBS5'9Z
M8&V00:T#:U::8/@W"&[O="55IK?$Q3OIWLGXL2 KM,NBC%=D7:;*GM\5<DDN
M.4"11&T),&21PNJ2XB-_O:,1\\Z'YGJ2D"WA*B7#\(9-]#C5%19;ZGJY1&9C
MCO0RF4X1#->&H-5<9!1NEOEGXFY[2-SFX0_ED(7+%>G[E+Z#S)XYT?)R5$E.
MIVGC36U-X(87 X;!X['WUA%0-P@O@YSF@J</(#!K[29\1BVGW\CM3&A]-->K
M@"&@'4[9(Q3TY79$U!#3\TZS#_B3,$'-LY3\:XB%<<".=\.+<?MNTC@CVZ\G
M#2L##%5' I?D&<6=#!FMLKPS^3Y\QM$F(9.:!<$7Q<F&C@#W.-SD[!CFY6?Z
M9@R.Z(MG_)1[E>>KZ\O&W9H9*G(Z?YBMH5K3B\EK >-1LYG6FYQ4%=%%GU@5
MVM6%ZLKXVWQ"=6RE6%4(:,!I%A_"">EJ)1'=I'?4,'HQC^U_?$RSQP+G+_1H
M]55*#",_$WX3+6;A@^8)\.FK\;(0G;B1I&O6B>H XYXS&:9>"1\AH:9Z61PA
MXH)-98C5=H3$^A"K$+5K1#^S.OU_PYBP%:_C%+,D_O-WF%#5@?IKK[%F\MFF
MGM?HMUWC7/DNK1>QB@$Y,$\GLD@C?;L2@0]9FK>:F<4BZRQ@$U;DQ7DG;RBI
MZTY6"SS'G=HTW7Q8V(C^MQCG]";SMD[>1,^77 -Z-V"*!J+Z?$Z"P^<T_FV#
MW7FG1=V'YK#6S3FU#QLK?E5N;6MM_WC/:A7DVXZCBU^<4/5.#FJJH-Z_6;%O
M (!<?H)%B*V'3UK5@4Z?[?QWPGK@N>OTQEF.P]<TDP@ZZ\R*O;OBR+R2YHO*
M^Q9[ 'E'#5>?]RL3C.M,9(C.30XG[:.PN]U+96$UXQQ2@*?O'I:&*;YG&+3!
MT'HP9.WWARHQ":1UU<Y ^<7B^BG%FYP]06<^ASV^/#]$'FFVG-<#"P-(\W$6
M:-8>]1ICP5^/]7_#7+"U>Q]R\2G((]8"_!S4;NTEK(L&!O!I*O'D&Q,VD,)A
M)J@!HA=-9Y9N0)&NV]D3H%6*5B K^4YXJ6#=94GR/LMIRPSU*;M2/ XHMB9J
MAA%3$1!I/P"W9L@0R0MQW+A<K9-LB_$]6?['(9:?I%TD# 8[M$)7\T\I6P[A
M/,[X(LF>[I/7Y\<Q9FHVN0M-7!E 9YO'0MUPPP]ZO^L=]*Y7Y(!<]/VFW.3X
MASB-5YO5';W\E=0Y+TA0NJD?R&:O< ^=T>U5MA_7FZ YY&ZV1\$ 76I_:W3N
MLV2EHQ4OOO=*^[JJ2>=%,Y+E#O/7Y.OSCHLPW*PV+'G,!5[&8:S(0V_2^N44
M3$</ "MY>G.S8I(HXJ*>NHG%X"LRVR>8-_1C!(_E+/H7'_ G]I/TX).=IN/N
M>L'Y8U;@:YU[#L/=NS"R63WBG/I?P33HOX7\'8N"S3-C5K3_L2MH9M"W.1G/
MZP/.JE91BCL=80R@6_Q3R(()#P: TM1Q!>+,I.^@$16[0^+NPP/[N#@F.K05
M#R8X*&#W\D0%Q3/*<8CCE_KT/X\)!:'"OA&AP#AA;O[V[.R$N?K]Y>7U+_6S
M.;=Y%F(<%1_);/HANPUR^N)XLKW#9!YPCG,Z4IUG*6F",B;S#"*](H$JR]EV
M;/<4\)0%NP@?TS<$I?)TI7H/29.;TF5^739:5X6C#5W5E1F9AE;E(_JY=8M"
M7@,9,YLJJ%)5!TJS"9(H*%RENEF?/BU>@CBAT^V/:81S,A5?W9_=/^.$+&F?
M8IJQB*Y"[TLR/:,S:%E;CB[*F3OL:6SC "/+@4'Y_<!W2?YSN"'A?/7=R%*/
MW_H_@3[=/3G-1:^I*SG,FYBJ2U[3UN#=SV8UR\'M2S"WN_9LMFO#C:[IBG?Z
MKM'$C=)ZZ&BBLL&XX,0&]?:LIG*X:T!7LO9LL\6*IEZ8IS_JL@_(W]K-,:&S
M\8)?BZ>UK-&Z6;%S,UR5[MUE)KM;9CHUOW_YAW8%RIP98-_"P;C0U!;I[A/O
M[@W3(]YB,6!F?U,TAVD*.'$=A^9<VLG@I!6\*B<S30M%1Y-?]E7<X>_Y(D^P
M:SL]G',6Q%M+D[N]+0'O.X8"7V^NP?O++D_[C U./YS0MPS(_]!#XB]!PO+-
ME^=!GF\)-1B]9/U@I?C+&;3N&09;]IG)^X E^+?A90:II,O!0P-5Y))$#$P@
M5V/KDD.,N][]^@+GA-QT)2/ DK6]5!!>6-7#['9%?54EV<D>H:!$2SIBOE 7
M]^[%BE.>NQ?KWFWE=P_$F45]4^ N+GY]GV-\E9:8=$!Y%Y3*3P3SU^L___,,
MS6C.%CUAI6"BGRM+=:\YM@XHBT\Z/FZ1]-5'6O^1>!=?P$"6I 0%HC!0C0-1
M(*\K(-!SW&&)HQ^SA!1#(N#654A0U7RP04'?E+.%!7FUKS,P:&UU&!IJ'&@'
MY!7'AHOX)8YP&KF.#.UZ#SXNR)IQ]J@@5OJZ8X+$4A\1H88!*!X\FEOZ<4A+
M/^!\=:+KVIDJ=!X!9FVXGNO/4ALLGY_31!_.3NN'X>/315.<AW&!V=T&-^&[
M5>$!C_*2AIMQ>!=J@^7C<YKHU,=Y]?R6CZ^[/:]S'@INT]B=R5T&-]/%;8R3
M"'T9IVA-B$?*_^IP!Q:>14IX')&E['MX#JK'YHKO66JIJY1?W?H)TPQ3.%J0
MG@J>,/OQ@C1:T[A3]]KT^ YBV)JK6R8)'E.#._Q!<:86F6$,Y4B1 +5*TED2
ML'5*JB/$\2(2XCCB(U1C1A5H+H(H;&%@]AX(FR844FG_%)?/O83 13N);W'7
M.:;#/S)N=4%MIKJ\G 2;H[FD)\*FK A,X)C3.MT),:$Z](G4)WG"I>ADJQ;/
M;U;OOC35'K@/-W8\D-!4+'%>W&S*FR7+VGTV<<\9ZCH$'[9JKBE\6%O1P?NP
MC763^W!3Z1%JJD79IJ27A*HL]:_(C:_2,G/DQ6)5A^G$_<::QX=W];Q"%^X9
MY\:#:;4'[[^*.<WW09S2M\&O4G[SZBJM+W)-W)LCZC\$3Q_=K%.X_^#*#SXF
MC+78X72=+--I[I<O*9ZO4(V(+MIK3)[VP@]Z,'.TX_TMIVZ*GVC>0MV.]ZQ6
M_A..:^\V19SBHCC/5H]QRK/*X'60DWZ@>9OJ-+P,?1"R9;KN@NWXXER..OL:
M+;K=V++ C E[&M#UF;HX))1WA'8EHEV12"P3S'79$>UQ;;@=NU^1P#VC9_R>
MWG$-[JKK!$9,YR77@#*<3#.=9#=%F^'Q U9=]INMML-;\"B;;/KE3:\J,&XY
MKWWS+UU8S<+$\ B1VF?*3\DNPR\W:401TDN^U9?03M,:9)UEF#3!;5)(J@2]
MD]0&G2H)I$K-?\"OWK6\2@G]@U1YT+(OYC+$JD"*L;$KXYTO!F!=JM0/C,:U
MW$QQHZKGG$C&89"P=UAD3)?+.8L7.IA-K) )>>]W$S)5QX>5+ JIL/? P([-
M5-BJ)W:JAVX5/-<IN P69N!BV%!+>R>2-<1>?FVJX&EOM(VS_?*RIALLU!R?
MU2VS,DAT^Y9#(*M\'HNO26?LH%I8O28=0'M-NE[@+L+?-G$1L\7KNZWP7W99
MGFV+\9/'>9B1\DS-=F6 "2\C@>NR+3=[(6))1_3HIO '<-N# C;;[3^YBH_M
M/1UXV?:=3!X,)2U *K??6@RSW%J;L7_N<(&).$W@=4$_$&5KNNZK!@U9!VD5
MX-U7L8/;[:U:BXU[@MY4CSDJUC[T11ZZM,J6_!$N]M[.,LN3.*2U!I0Z.8[X
M6UVR:?W  IRMED89UBRC!FE[#Q*C(:LV9P:5M?=PI:!F]>XC>U**[4E6[W@7
M_'TI61L859S1SQ)\0SB#/ R*V8%4D<J@/1>-KM*8/J#45,L_;3UG>;D,DH3F
M&O_FS3<_Q$E"_BR[^S&V$'>1;JR!NV@WM 08=!P+6QGUAI8'9Z(^X*OM!2["
M/&;7OJ;[%-PJ%/BW?$D#[/DU7RC1NV=,:L947_2/D%"V=Z=A&U+"HN@\2^F[
MSV2R3?ZMB".<MT_3Z3=Y1Y?F]%V2_4SNI>X>7A08Q]@/OS0#N+C"/D*[ E&K
MQ-9)R:I4_[X0ACF9?-WFV9+X-4$9).\Q[NY+=YO0H.24V58&M BLU8##4QN8
M_5WTG31:XOV? MV;8)>K=9)M,;[#[+EV(>^SGF,6>BYI9FV&R#2C$ABRV2+M
M\0WG19:F!%W.->=ZI7E3TD JWUJ[Q_E+'*H(-4+?W9O+(\S:/:T\0-D[T<8B
M[GW(Y440N@G;I9&P75I4Q7@/?%7\;@ZY6 VI?6D/8ZD*LF00[8IZYYD=OBZK
MKJ8Z833-&9,*O/58:5)R?M;$:$#OO(E2 ]K7'2NTD(Z?#.H+M6' CIJ8@7;[
MX/>_._GCV[_T_XFJHIJ3)T<HW?^(\H2G3-@.)$UF>H$?2[L3)3(5/Z='U.#E
M)T7Z\F"&% N0NA,@3.F8:B&J!N:L1\N8:\,I#Y6PVQ1[.L#M?'<R23B$TL'K
M9X+KT.<:T!VIZRQ]J@TQ?U]02CM]U$P/N?6PF5P4#(_T^'H/G!'I'8]@[<S?
MYEF(<53P%Z!3,ATK8Q(D*5"%[5H-MQ<RC-#;IWN5XF!X9<8HV7YD&O53]HT.
MXYIW>@F [C>/61[13U@XTM!+J^&27A;06^]ZJL7!T,N,L?=PIT H4<7(KKGV
M[W:Y89I[FC=+ >6'K)0<+K/2@O/HZ@C,JA,65J7 FLZ8\EPK9'U-9;3YGZ6"
M8.*!#IUI$@,H'W&7SK?!5K-F5TI[&EQDD!4#BR@*AD1Z?+H!A8FC2MX[B^[P
MFM^'+EH!4C-5T6JX9),%]/;I?J4X&%:9,?:/\]<:=.\'W$Q8C+46X=C?>&8:
MQL!01 )*/VAYY\#-<EG@DAY5XC<T=5O+"EFG'Y9T<%O?DV2"8'BB0]?[;-3(
M\CPJ</*'=:VX-NP;:^1]<J@'6\>C:W ;R":$%GRZ!K2+?)X$!1E@?PKHVR;E
M37Y'WQ^A!S[*("4K_2?5E,^HYG0N;6E$:U)MT'%*N#5[_N6^#/)2]P'6$K/L
M_$XE@0(V-[K (5X]XAR=G1PAPHD3F#QLO7C7_%A4OQ:J)U='EN6=L;;F&FEL
M*NA@N&UIR'#"OSU"GZJGEHZ#ZJDE7#]PN*:UL9?G-D5$7Y]#[-+EWN_/*<Y9
MFKRZ\X[5'5X%Y*_TQ'L>A.4F2*[CI?0"W40%.SN9.6E#-#N_DY3J??HQN2E=
MGZE]B[YO,L)Y<EX7"G>5H834QMQHBX.\F,M]/FPHMJP)#OQFZ\6&9D3DSZK)
MFM)&RUU60FL3=OD)C2HP*&N-LW<\E FZ#+F\1L.08^V6EJ7Y#:Z#3-9'5*NB
M8'!R;_QRKI*HR,4[,PE'<:^&/CCT*12]13^M(<H *-6"P;<A4+O4:F1=1L*F
MTJF"H7V!?N/A4,/U(=&V-!@LG<($)7N/NJLK,JVLHN7>MX8LX^,YO6N2),/C
MHT+16WS4&J*,CU(M&,P; K7W-;F6=1D?FTJGBH_V!?J-CT,-U\='V])@L'0*
M$Y3L'1L?#VU3W>V-)K[U>)EJ'_ZRQFS>9?R!W8ZM=DE.(?6;NZWE0^EA:T/,
MW?[OFQ2CL[?\2\H!;2R39KM9\M%UMCWFX76 V6X>VSS6.\]#*P \#NYOU8#]
M:)._^=N+[JSP)8=[U&+.>*\!V5!7(@.#?6I@2@+AG>C@<7JFG16*9>#'[8G*
M!+&_,L1\JRT6FP)A\'<B*Q0;+;0$Z!,0 >JTLX[A!8-QA@GG%T-+/0RWF&0F
MT1\( ,PDYCDYI3M7K%/P?@9*><)8+>V=P=80>]L_5('RL%)!68Z8$I@SQU*3
MK@T'CTU*WDG6,\!(M&MPYY"M8 X@W#6D0\GL 02>$SRC1Z>EV^E&:;?7^;20
MV]?YI*)PF*7%U[_.1Z41>ZT"O3!YE%,%_RR2><@=#HHL?9_E],P&P?J0?<A2
M7&7B'!303"5YCW)VIAI#G[X8.*P=C5TQ7T2179*6U[N5[S8;PN#.M<9O/0H>
MH;I,=%M_A=OM0U9"_K.<REJC*"^"$M.L,3\]Q^%SMS'4&Y)3%>H[W UO ).#
MV)<(VD\&F]%U%ZJ.R!#_B:HW7Z71(PZ#%187U3ZRP<QY>!#,*W<C,'<[D6N+
MQPJ:74'MT1EH'R%@]8D.X=AM*._#BYAS,\CQNX!0A,SR::)6]J;&@MKQA%FB
MA7?;G<PM3[ZP( 2+;%.F[EF^K_RJDS2+*AGK7H6#&8JFMDB?YI5H'S-U)-:!
MQ$KHN[^B8%418C6!V7 S-I:JK4R;<E,4[#;C[%0-T<Y.NV^I<!QL*E/Z66_-
MWF1P)DB;B:/;J<F'MBB*S8KM Q1W<?'K^QSCJ[3$I$/+.S(WKM[8G+J;!E=_
M$-XYLE$G\>&!=1^^IX\SN)=6BV@<+XD*BBL=1%\>/$(KKO9/X.'!9Z\>7E?_
MNCR\W:AN/9S7_4_DX2V#[3V<JWG:_IZT52X_KW%8XNC'+"'%T <A:;O,SCYY
MM7"V,7P8W:7?3NR5CBGR]G X;S0 .-AQQ:IA'?OVJYX]VIC\_]U[ZWC2: #P
MVMS;T<116_L_E7MK)X\M]WY]\\6+^"6.<!HYG2V*E3H^AD'F_QYFBE*#>Q^B
M*R&TC7'B^JMER_Q'L_F/0\RG":JE!W?FJPWH$F1>6_O79K@4*FF&<$"'^D<[
MV0TW_WOVJ?DJE=[#9#^R0R&&=U:<HSB(F<I^33S)V#$.PN'/6?:RNW<@H])#
M]6V?)7W0Y@7$@S;[MI!P'YN?_)FI)R3U')(/*YMI2B_M50(Q_?)<1HY(S?R:
MG*\3FUI'EN?O"7WM!^JH-DTZD_OJJG[E3FUANL;5C] C?HK3E'H]<7D.'WWY
M\?YBPDOHWOV^/2WY/L^*R0]CZ6HZ)'_6--5\$V16S2N=!(NV=1V12>Z?(7%^
M_U(>!+69]T\RMDZ) )0_3M^T@_QTNNH/QW\GMUGAURA.1XRH<Y*1W@7N)_IG
MC5&P'V_J3;KJ!HJ44X-+<;6E^2TG1XJ?Z$/8V@G8>!MF2P3N/XS7IGB-Y -!
M'%0P']7 D\;S00A>3T@?8[;2T<?%=1@AP-!.[[-\B>-RD^]::J99LK0F4,X\
MOJFF7"E)J@'Y?7 6$V=+*N]_K)48[6.T'0P#E(O.U,B3CK@#,;R>,7><X4J7
MA[*&.LPO6P"SO\]GY($\"/!/\.WE==/.RG3MUQ=Z: [X=Y<Q![^,3<7SQ+8S
MQ=(38:=3'T';!XGSJ8Z?II[D6.-X&+ F/%YLUXU7QZKDQ]#3'T\89Z^(E7%:
MQ.&<9R(U]8%:\^S;;#-- ]J5O>IA7VIJUX<?LI(X9?#TE+.O$?0"+U?B!QGY
M$-]Z1.7@/?9'7-"8ET;-&>^,_LG5D4?[Z@_)GX<VZI3N;5LWK"'<G<&]&U=,
M'1%)A)L+#!EZ(7_N3?6Y_Q_^,&UN,@]'+?<%];H"A.O-@?T0_1,%DQ';H9H0
MPU.]O_8]A<&MJEI\==_Q@@CPD'8@IN^8*3<FID,'*SY!:A+5/:YA&Q<T=KV8
MHAS*N TPPMFL@\2B7D(ZV079 \_KFC09FMWM?$D!!E8H\M@"0S=?=B$FRU][
MA!%2H,^Z_2*IYY B@K*9IO3T7B6OQH-5EFG?0WVE6R+JYS%=['U8UWZ@WNEZ
M-\.RZM?HR>,/24O]^Y7M1)A>P76WY3 *R2'M+>S1U%-N(HR  2LL>+%]NFT!
M\8$>@)/T:5JWO<!Q$#)Z%1YH9% TW$P!H%/;:_1SN8DCUMJ _;9Y#.FR>GST
M'N<O9'JCF$4E# ;YMYOE'0ZSIS3^!VE%-K\YSXJRL'M>:]*Z_#RU-4-SR9_=
MFK B.#XZHW6Z1X.:QX!VT8"^K$HKJG;;SX-U3-R9EG^$%JMLD\)Y\GZ:MKHV
M/,<U>2TN_7.F)A(]<^(JP/CD/';-X(W7K^$)KXO=$]Y3;V.TBCZ(/2Y)8TRR
M@264"\;-)C2FEX5Z)T$GG6R7Z9A-<\FZ<E<7"G:5T=?R1+EUY9(!K?%PO8OO
MP-\L%U$44Y4@87+%8E,^9SD-)U/WCDV-!^&+]DTWB8N:JSM\S[6V<?+W+H_0
M[G7M7>U<OD"[^@_?TUWY]X%[M1-??KT>[,-O7Z^SO@1Q0E?6[[.<)8R;N=?Z
MU1VBZZH:;0X/[M;UZAQ98: 3?Z[K1LLL1ZQV&(X]9NO\EG3N<U!]&+]9$NU5
MEK(L@K>8=+O>M6>J\" ^XE@WW"0?<8RUP7+P.4V<P<7KJA&KF[HZKQW=\VLI
M%0#_7JY+_=GL K(FJQN3-)4R8?C8TISZYWXF6R=_51<%Q[/VPM]S&_8QDQ>'
M>'F(%WA4#71'J"Z4^X'@)K3<?;VAP#AA%'][=G;":'Y_>7D]4?RXB(N0[CE;
MC&C.:G7A-HZ;D+J7HRJ]NZ%;.^<?Y6H0HX8[Y\LM^\62X\1=PQ<[RO1:QB]L
M'TCK!<5S_:4-5 <=Q#L=,-^GG,G(7FHFKH*>NBG^H?+H];PO<7B\F\%XXV':
MZJP=1FLV0#7G[8<Q%O9^"PG=<<Z$S2G*IRG_('935,TRR>9)MW!8\X,)+>J=
M;Z4O$)/I'3^RRMWH<%V'_8/>K25+U3L:.HIJHDIBQ]0-K*_K(%S*IKDF<2]=
M18?O:A;6R1+=T.V4=2.(B/>5SQ@MX[PH49"F,1GRBB#?PO#&,1-0L5UX$-+>
M]YBLBH/X\J=IG$F6.)+R87G:M$;-L!G"_@?5GGH+:%:YQVI0>+: )Z2H)@D.
M'\11U7L0;CNT&6=Z+$=>Z>$[^$!+9_#Z"L$1$C"PX^H""KK*?"7QH/=T&+OP
MYB09DUW5AQ05AC3F#$D<M/6^FM@PP-@YPT,#8Q<,CE"# C$8WJ.#U;6?#UG*
MTT4Q$PO6G.+O].K/AZS\+USN+@6)CXCN<^5H_[K!74";JCD'7TO;MV(P$<*E
MM6,^L%7)U5H1X0C1"LFO)=KB$NWJK*^VO=Y8P(,?F2Y5?Z)RJH6^:Q"O(CIH
M&]A)F) B>/WQ0F?V_H%#&3!XM>SHL%"Q]P R>N)&OS$4-TOV[U-/"MME'\1B
M0=8<DZP&Q(+!..>4ULPPGV>UL!MTAWTI]O*W35QNK]*BS#?LX_Q-^8SSA^<@
ME7Z-G[JS!E=_$)XZLE$G<>:!=1^^OX\S>(:0P($@ 0EB4%!)L.PV #B<Z;8"
MC8>=Z\;:&;*;TZ01?TFXFMY<?@Z3#4TLS='*YC9\5:(_P#I/C1X..<_9=)(#
MSG-4Y]W!W=FXQ]2:YY7A=3?^7%=_,$OU:UR0:'"SQO1[0_ITC8GIUW'P&"<D
M,%4M4/#$E!&]\/@^+L(@^2\<J+*?[U.@RY%Z?\/%L7=\:=Z=;3(3NK[4I#.M
M5YF71#%"%SC$[ ZKS:/A<'S@0OEQREX='+\OY!^);'6=<K>DVRBZ4\0#44O3
M;\+FXL<TJJ[)8#K2$5'IU&K/LL"PU&2N-655!;GA[[><ORG+ZJI]6G<?([IT
MIF6A-0%*IS \@6RM[YWD"@L5K:*4=DE4 V21B@I16,%2#[)_6:>21@D51TDE
M'V/_F8>YTS SA,1UNOS!6@WWT4\+O1_CI.+ 9I$ZC+) A?$18CI'2$P^""5A
MKMRH:T,"7*.6?ZKU3##3[1I<PED[G$-H=PTH,ZQL3F!.^FK4\CW),Z1J-:@
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M5^Y NMN(?TS?BX4B7JHZV:WXIVOR;^3/]9_(/VCV7_*7_P=02P,$%     @
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M7LKJ##5./ ; 9!Z3?!Y1#Q!!A6'Z0S4ZSLB&%U5O!,6'Z<LY>5)J>[G,4.M
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MSK8I)V_+GBN7NI3JVQ5Q#21_V&I_5*^_MI:VPUJHXJ+N -HJ"O[U2*U?C7E
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M'A  #               @ $     8F]D>3$P+7$N:'1M4$L! A0#%     @
M_(&J5#5%%S;Y!@  4"@   L              ( !"2," &5X:#,Q+3$N:'1M
M4$L! A0#%     @ _(&J5 .ZO:+J!@  3"@   L              ( !*RH"
M &5X:#,Q+3(N:'1M4$L! A0#%     @ _(&J5*L?BDB2 P  \0L   L
M         ( !/C$" &5X:#,R+3$N:'1M4$L! A0#%     @ _(&J5+Y\!86-
M P  _0L   L              ( !^30" &5X:#,R+3(N:'1M4$L! A0#%
M  @ _(&J5'-)W.D-#@  "H@  !$              ( !KS@" '-E96PM,C R
M,C S,S$N>'-D4$L! A0#%     @ _(&J5 M\,]E*#0  -9<  !4
M     ( !ZT8" '-E96PM,C R,C S,S%?8V%L+GAM;%!+ 0(4 Q0    ( /R!
MJE1Z*>T[^B@  ++\ @ 5              "  6A4 @!S965L+3(P,C(P,S,Q
M7V1E9BYX;6Q02P$"% ,4    " #\@:I4AP7W.7)*  !+< 0 %0
M    @ &5?0( <V5E;"TR,#(R,#,S,5]L86(N>&UL4$L! A0#%     @ _(&J
M5(4IOF$)/   +CH$ !4              ( !.L@" '-E96PM,C R,C S,S%?
=<')E+GAM;%!+!08     "@ * &D"  !V! ,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
